UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934
Filed
by
the Registrant x
Filed
by
a Party other than the Registrant o
Check
the
appropriate box:
|
|
|
x
Preliminary
Proxy Statement
|
|
|
|
o
Confidential,
for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
|
|
|
|
o
Definitive
Proxy Statement
|
|
|
|
o
Definitive
Additional Materials
|
|
|
|
o
Soliciting
Material Under Rule 14a-12
|
HEALTHCARE
ACQUISITION CORP.
(Name
of
Registrant as Specified In Its Charter)
(Name
of
Person(s) Filing Proxy Statement, if other than the
Registrant)
Payment
of Filing Fee (Check the appropriate box):
|
|
|
o
No
fee required.
|
|
|
|
x
Fee
computed on table below per Exchange Act
Rules 14a-6(i)(1) and 0-11.
|
|
|
|
|
|
(1)
Title of each class of securities to which transaction
applies:
Common
Stock of Healthcare Acquisition
Corp.
|
|
|
(2)
Aggregate number of securities to which transaction
applies:
Acquisition
of all of the outstanding securities
of PharmAthene, Inc.
|
|
|
(3)
Per unit price or other underlying value of transaction computed
pursuant
to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):
N/A
|
|
|
(4)
Proposed maximum aggregate value of transaction:
$114,250,000
(including up to a maximum of
$10,000,000 in milestone payments, 12,500,000 shares of common
stock and
$12,500,000 in 8% convertible notes) is being paid for outstanding
capital
stock, options and warrants.
|
|
|
(5)
Total
fee paid:
$12,225.00
|
|
o
Fee
paid previously with preliminary materials.
|
|
|
|
o
Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its
filing.
|
|
|
(1)
Amount Previously Paid:
|
|
|
(2)
Form, Schedule or Registration Statement
No.:
|
|
|
Persons
who are to respond to the collection of information contained
in this form
are not required to respond unless the form displays a currently
valid OMB
control number.
|
HEALTHCARE
ACQUISITION CORP.
2116
Financial Center
666
Walnut Street
Des
Moines, Iowa 50309
To
the
Stockholders of Healthcare Acquisition Corp.:
You
are
cordially invited to attend a special meeting of the stockholders of Healthcare
Acquisition Corp., or HAQ, to be held on ________, 2007. At the meeting you
will
be asked to consider proposals relating to the proposed merger of PAI
Acquisition Corp., referred to in the attached proxy statement as Merger Sub,
a
wholly-owned subsidiary of HAQ, into PharmAthene, Inc., referred to in the
proxy
statement as PharmAthene, resulting in PharmAthene becoming a wholly-owned
subsidiary of HAQ. PharmAthene is a privately-held company engaged in the
biodefense industry, specifically the discovery and development of new human
therapeutics and prophylactics for the treatment and prevention of
morbidity and mortality from exposure to chemical and biological weapons.
The
special meeting will be held at 10:00 a.m., Eastern Time, on _________,
2007, at the offices of _______________________________________ (the “Special
Meeting”). At this important meeting, you will be asked to consider and vote
upon the following proposals:
· the
Merger Proposal-
the
proposed merger with PharmAthene, Inc. (the “Merger”), a Delaware corporation,
pursuant to the Agreement and Plan of Merger, dated as of January 19, 2007,
by
and among HAQ, Merger Sub and PharmAthene, and the transactions contemplated
thereby, whereby PharmAthene will become a wholly-owned subsidiary of HAQ
(“Proposal 1” or the “Merger Proposal”) and the stockholders,
optionholders, warrantholders and noteholders of PharmAthene shall receive
the following consideration:
(i) |
an
aggregate of 12,500,000 shares of HAQ common stock;
|
(ii) |
$12,500,000
in 8% convertible notes issued by HAQ; and
|
(iii) |
up
to $10,000,000 in milestone payments (if certain conditions are
met).
|
· the
Amendment Proposal - the amendment to HAQ’s amended and restated
certificate of incorporation (the “Certificate of Incorporation Amendment”),
to: (i) change HAQ’s name from “Healthcare Acquisition Corp.” to
“PharmAthene, Inc.”; (ii) remove certain provisions containing procedural and
approval requirements applicable to HAQ prior to the consummation of the
business combination that will no longer be operative after the consummation
of
the Merger; and (iii) grant to holders of convertible promissory notes
issued in the Merger the right to designate three members to the Board of
Directors of HAQ for so long as at least 30% of the original face value of
such
notes remain outstanding (“Proposal 2” or the “Amendment
Proposal”);
·
the
Incentive Plan Proposal- the
adoption of the 2007 Long-Term Incentive Plan (the “Incentive Plan”) pursuant to
which HAQ will reserve 3,500,000 shares of common stock for issuance pursuant
to
the Plan (“Proposal 3” or the “Incentive Plan Proposal”); and
· such
other business as may properly come before the meeting or any adjournment or
postponement thereof.
HAQ’s
shares of common stock and warrants are listed on the American Stock Exchange
under the symbols HAQ and HAQ-WT, respectively. If each of the Merger Proposal,
the Amendment Proposal and the Incentive Plan Proposal are approved, the
operations and assets of PharmAthene will become those of HAQ, and HAQ’s name
will be changed to “PharmAthene, Inc.” upon consummation of the
Merger.
After
careful consideration of the terms and conditions of the proposed merger with
PharmAthene, the Certificate of Incorporation Amendment and the adoption of
the
Incentive Plan, the Board of Directors of HAQ has determined that such proposals
and the transactions contemplated thereby are fair to, and in the best interests
of, HAQ and its stockholders. No fairness opinion was sought or obtained by
the
Board of Directors in reaching its determination. HAQ’s initial stockholders,
including all of its directors and officers and their affiliates, who purchased
or received shares of common stock prior to HAQ’s IPO, presently own an
aggregate of approximately 19.3% of the outstanding shares of HAQ common stock,
and all of these stockholders have agreed to vote the shares acquired prior
to
the IPO in accordance with the vote of the majority in interest of all other
HAQ
stockholders on the Merger Proposal. The Board of Directors of HAQ unanimously
recommends that you vote or give instruction to vote: (i) “FOR” the Merger
Proposal; (ii) “FOR” the Amendment Proposal; and (iii) “FOR” the
Incentive Plan Proposal, all as described in Proposals 1, 2 and 3,
respectively, in the attached proxy statement.
Enclosed
is a Notice of Special Meeting and proxy statement containing detailed
information concerning the proposed Merger, the Certificate of Incorporation
Amendment and the Incentive Plan. Whether or not you plan to attend the Special
Meeting, we urge you to read this material carefully. We look forward to seeing
you at the meeting.
Sincerely,
John
Pappajohn
Chairman
of the Board
and
Secretary
Neither
the Securities and Exchange Commission nor any state securities commission
has
determined if the attached proxy statement is truthful or complete. Any
representation to the contrary is a criminal offense.
The
proxy
statement is dated ______________, 2007 and is first being mailed to HAQ
stockholders on or about ____________, 2007.
IF
YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW YOU WISH TO VOTE, YOU
WILL NOT BE ELIGIBLE TO HAVE YOUR SHARES CONVERTED INTO A PRO RATA PORTION
OF
THE TRUST ACCOUNT IN WHICH A SUBSTANTIAL PORTION OF THE NET PROCEEDS OF HAQ’S
INITIAL PUBLIC OFFERING ARE HELD. YOU MUST AFFIRMATIVELY VOTE AGAINST THE MERGER
PROPOSAL AND DEMAND THAT HAQ CONVERT YOUR SHARES INTO CASH NO LATER THAN
THE CLOSE OF THE VOTE ON THE MERGER PROPOSAL TO EXERCISE YOUR CONVERSION RIGHTS.
IN ORDER TO CONVERT YOUR SHARES, YOU MUST ALSO PRESENT OUR STOCK TRANSFER AGENT
WITH YOUR PHYSICAL STOCK CERTIFICATE NO LATER THAN 5:00 PM, NEW YORK CITY TIME,
ON THE BUSINESS DAY PRIOR TO THE DATE OF THE SPECIAL MEETING. SEE “SPECIAL
MEETING OF HAQ STOCKHOLDERS — CONVERSION RIGHTS” FOR MORE SPECIFIC
INSTRUCTIONS.
SEE
ALSO “RISK FACTORS” FOR A DISCUSSION OF VARIOUS FACTORS THAT YOU SHOULD CONSIDER
IN CONNECTION WITH THE MERGER.
2116
Financial Center
666
Walnut Street
Des
Moines, Iowa 50309
NOTICE
OF SPECIAL MEETING OF STOCKHOLDERS
TO
BE HELD ON _________, 2007
TO
THE
STOCKHOLDERS OF HEALTHCARE ACQUISITION CORP.:
NOTICE
IS
HEREBY GIVEN that a special meeting of stockholders (the “Special Meeting”),
including any adjournments or postponements thereof, of Healthcare Acquisition
Corp., a Delaware corporation (“HAQ”), will be held at 10:00 a.m. Eastern
Time, on ________, 2007, at the offices of ______________________________,
at
which you will be asked to consider and vote upon the following:
· the
Merger Proposal-
the
proposed merger with PharmAthene, Inc. (the “Merger”), a Delaware corporation,
pursuant to the Agreement and Plan of Merger, dated as of January 19, 2007,
by
and among HAQ, Merger Sub and PharmAthene, and the transactions contemplated
thereby, whereby PharmAthene will become a wholly-owned subsidiary of HAQ
(“Proposal 1” or the “Merger Proposal”) and the stockholders,
optionholders, warrantholders and noteholders of PharmAthene shall receive
the following consideration:
|
(i) |
an
aggregate of 12,500,000 shares of HAQ common stock;
|
|
(ii) |
$12,500,000
in 8% convertible notes issued by HAQ;
and
|
|
(iii) |
up
to $10,000,000 in milestone payments (if certain conditions are
met).
|
· the
Amendment Proposal - the amendment to HAQ’s amended and restated
certificate of incorporation (the “Certificate of Incorporation Amendment”),
to: (i) change HAQ’s name from “Healthcare Acquisition Corp.” to
“PharmAthene, Inc.”; (ii) remove certain provisions containing procedural and
approval requirements applicable to HAQ prior to the consummation of the
business combination that will no longer be operative after the consummation
of
the Merger; and (iii) grant to holders of convertible promissory notes
issued in the Merger the right to designate three members to the Board of
Directors of HAQ for so long as at least 30% of the original face value of
such
notes remain outstanding (“Proposal 2” or the “Amendment
Proposal”);
·
the
Incentive Plan Proposal- the
adoption of the 2007 Long-Term Incentive Plan (the “Incentive Plan”) pursuant to
which HAQ will reserve 3,500,000 shares of common stock for issuance pursuant
to
the Plan (“Proposal 3” or the “Incentive Plan Proposal”); and
· such
other business as may properly come before the meeting or any adjournment or
postponement thereof.
These
proposals are described in the attached proxy statement which HAQ urges you
to
read in its entirety before voting.
Each
of
the the Amendment Proposal and the Incentive Plan Proposal are conditioned
upon
the approval of the Merger Proposal and, in the event the Merger Proposal does
not receive the necessary vote to approve that proposal, then HAQ will not
complete any of the transactions identified in any of the proposals. If the
Merger Proposal is approved but the Amendment Proposal or Incentive
Plan are not approved, we may still consummate the Merger if PharmAthene
waives these conditions.
The
Board
of Directors of HAQ has fixed the close of business on ____________, 2007,
as
the record date (the “Record Date”) for the determination of stockholders
entitled to notice of and to vote at the Special Meeting and at any adjournment
thereof. A list of the stockholders entitled to vote as of the Record Date
at
the Special Meeting will be open to the examination of any stockholder, for
any
purpose germane to the meeting, during ordinary business hours for a period of
ten calendar days before the Special Meeting at HAQ’s offices at 2116 Financial
Center, 666 Walnut Street, Des Moines, Iowa, 50309 and at the time and place
of
the meeting during the duration of the meeting.
HAQ
will
not transact any other business at the Special Meeting, except for business
properly brought before the Special Meeting, or any adjournment or postponement
thereof, by HAQ’s Board of Directors.
Your
vote is important.
Please
sign, date and return your proxy card as soon as possible to make sure that
your
shares are represented at the Special Meeting. If you are a stockholder of
record of HAQ common stock, you may also cast your vote in person at the Special
Meeting. If your shares are held in an account at a brokerage firm or bank,
you
must instruct your broker or bank on how to vote your shares.
For
purposes of Proposal 1, under our certificate of incorporation, approval of
the Merger Proposal will require (i) the affirmative vote of a majority of
the
shares of HAQ’s common stock issued in our initial public offering completed in
July 2005 (“IPO”) that vote on this proposal at the Special Meeting; and (ii)
not more than 20% of the shares of HAQ’s common stock issued in HAQ’s IPO vote
against the Merger Proposal and elect a cash conversion of their shares. For
purposes of Proposal 2, the affirmative vote of a majority of the shares of
HAQ’s common stock issued and outstanding as of the Record Date is required to
approve the Amendment Proposal. For purposes of Proposal 3, the affirmative
vote of a majority of the shares of HAQ’s common stock that are present in
person or by proxy and entitled to vote at the Special Meeting is required
to
approve the Incentive Plan Proposal. Each
of
the Amendment Proposal and the Incentive Plan Proposal are conditioned upon
the
approval of the Merger Proposal and, in the event the Merger Proposal does
not
receive the necessary vote to approve that proposal, then HAQ will not complete
any of the transactions identified in any of the proposals. If the Merger
Proposal is approved but the Amendment Proposal or Incentive Plan are
not approved, we may still consummate the Merger if these proposals,
which are conditions to the Merger, are waived by the parties. Therefore,
if Proposal 1 is not approved, we will not adopt either the Amendment Proposal
or the Incentive Plan Proposal. If the Merger Proposal is not approved, HAQ
will
have insufficient time and resources to seek another suitable business
combination and will have to commence the winding up, dissolution and
liquidation of HAQ, including the liquidation of the trust account and
distribution of the trust proceeds, in accordance with the terms of HAQ’s
amended and restated certificate of incorporation and the agreement with respect
to the trust as set forth in HAQ’s amended and restated certificate of
incorporation. In order to do so, under Delaware law, HAQ will be required
to
obtain stockholder approval for its plan of dissolution. The funds held in
HAQ’s
trust account may not be distributed except upon HAQ’s dissolution and, unless
and until such approval is obtained from its stockholders, the funds held in
HAQ’s trust account will not be released. Consequently, holders of a majority of
HAQ’s outstanding stock must approve its dissolution in order to receive the
funds held in its trust account and the funds will not be available for any
other corporate purpose.
In
addition, each HAQ stockholder who holds shares of common stock issued in HAQ’s
IPO or purchased following the IPO in the open market has the right to vote
against the Merger Proposal and, at the same time, demand that HAQ convert
such
stockholder’s shares into cash equal to a pro rata portion of the proceeds in
the trust account, including interest, which as of September 30, 2006 is equal
to $7.48 per share. If the holders of 1,880,000 or more shares of HAQ’s common
stock, an amount equal to 20% or more of the total number of shares issued
in
the IPO, vote against the Merger and demand conversion of their shares into
a
pro rata portion of the trust account, then HAQ will not be able to consummate
the Merger. HAQ’s initial stockholders, including all of its directors and
officers and their affiliates, who purchased or received shares of common stock
prior to HAQ’s IPO, presently own an aggregate of approximately 19.3% of the
outstanding shares of HAQ common stock, and all of these stockholders have
agreed to vote the shares acquired prior to the IPO in accordance with the
vote
of the majority in interest of all other HAQ stockholders on the Merger
Proposal.
YOUR
VOTE IS IMPORTANT. WHETHER YOU PLAN TO ATTEND THE SPECIAL MEETING OR NOT, PLEASE
SIGN, DATE AND RETURN THE ENCLOSED PROXY CARD AS SOON AS POSSIBLE IN THE
ENVELOPE PROVIDED. IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW
YOU WISH TO VOTE, SINCE IT IS NOT AN AFFIRMATIVE VOTE IN FAVOR OF A RESPECTIVE
PROPOSAL, IT (I) WILL HAVE THE SAME EFFECT AS A VOTE AGAINST THE MERGER
PROPOSAL BUT WILL NOT HAVE THE EFFECT OF CONVERTING YOUR SHARES INTO A PRO
RATA
PORTION OF THE TRUST ACCOUNT IN WHICH A SUBSTANTIAL PORTION OF THE NET PROCEEDS
OF HAQ’S IPO ARE HELD, UNLESS AN AFFIRMATIVE VOTE AGAINST THE MERGER PROPOSAL IS
MADE AND
AN AFFIRMATIVE ELECTION TO CONVERT SUCH SHARES OF COMMON STOCK IS MADE ON THE
PROXY CARD, (II) WILL BE TREATED AS A VOTE AGAINST THE AMENDMENT PROPOSAL
AND,
(III) WILL
HAVE THE SAME EFFECT AS A VOTE AGAINST THE INCENTIVE PLAN
PROPOSAL.
SEE
THE SECTION ENTITLED “RISK FACTORS” BEGINNING ON PAGE 25 FOR A
DISCUSSION OF VARIOUS FACTORS THAT YOU SHOULD CONSIDER IN CONNECTION WITH THE
MERGER WITH PHARMATHENE SINCE, UPON THE MERGER WITH PHARMATHENE, THE OPERATIONS
AND ASSETS OF HAQ WILL LARGELY BE THOSE OF PHARMATHENE.
The
attached proxy statement incorporates important business and financial
information about HAQ and PharmAthene that is not included in or delivered
with
this document. This information is available without charge to security holders
upon written or oral request. The request should be sent to: Matthew Kinley,
President of HAQ at 2116 Financial Center, 666 Walnut Street, Des Moines, Iowa
50309, or by calling him at (515) 244-5746.
To
obtain
timely delivery of requested materials, security holders must request the
information no later than five days before the date they submit their proxies
or
attend the Special Meeting. The latest date to request the information to be
received timely is ________, 2007.
We
are
soliciting the proxy on behalf of the Board of Directors, and we will pay all
costs of preparing, assembling and mailing the proxy materials. In addition
to
mailing out proxy materials, HAQ’s officers may solicit proxies by telephone or
fax, without receiving any additional compensation for their services. We have
requested brokers, banks and other fiduciaries to forward proxy materials to
the
beneficial owners of our stock.
The
Board
of Directors of HAQ unanimously recommends that you vote “FOR” Proposal 1,
the Merger Proposal, “FOR” Proposal 2, the Amendment Proposal and “FOR”
Proposal 3, the Incentive Plan Proposal.
By
Order
of the Board of Directors,
John
Pappajohn
Chairman
of the Board and
Secretary
March
__,
2007
PROXY
STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS OF
HEALTHCARE
ACQUISITION CORP.
The
Board
of Directors of Healthcare Acquisition Corp., or HAQ, has unanimously approved
an Agreement and Plan of Merger, dated as of January 19, 2007, among HAQ, Merger
Sub and PharmAthene (the “Merger Agreement”) and the Merger contemplated thereby
(the “Merger”), whereby HAQ will acquire all of the outstanding securities held
by the stockholders of PharmAthene and PharmAthene will become a wholly-owned
subsidiary of HAQ. If the Merger Proposal is not approved, then the Merger
will
not be consummated. In such event, it is likely that HAQ will have insufficient
time and resources to pursue an alternative business combination and will be
forced to liquidate the trust. The liquidation will be in accordance with our
existing amended and restated certificate of incorporation and applicable
Delaware law.
If
the
Merger is consummated and you vote your shares in favor of the Merger Proposal,
you will continue to hold the HAQ securities that you currently own. If the
Merger is consummated but you have voted your shares against the Merger Proposal
and have elected a cash conversion instead, your HAQ shares will be cancelled
and you will receive cash equal to a pro rata portion of the trust account,
which, as of September 30, 2006, was equal to approximately $7.48 per share.
The
stockholders (including holders of its options, warrants and notes) of
PharmAthene will receive 12,500,000 shares of HAQ common stock, subject to
possible adjustment, $12,500,000 in 8% convertible notes issued by HAQ and
possible milestone payments of up to $10,000,000 in exchange for their shares
of
capital stock (or applicable options, warrants or notes) of
PharmAthene.
HAQ’s
common stock and warrants are currently listed on the American Stock Exchange
under the symbols HAQ and HAQ-WT, respectively. Upon consummation of the Merger,
PharmAthene will become HAQ’s wholly-owned subsidiary and HAQ’s name will be
changed to “PharmAthene, Inc.” HAQ’s common stock and warrants will
continue to be traded on the American Stock Exchange although we anticipate
seeking to change our trading symbols.
We
believe that, generally, for U.S. federal income tax purposes, the Merger with
PharmAthene will have no direct tax effect on stockholders of HAQ. However,
if
you vote against the Merger Proposal and elect a cash conversion of your shares
of HAQ common stock into your pro-rata portion of the trust account and as
a
result receive cash in exchange for your HAQ shares, there may be certain tax
consequences, such as realizing a loss on your investment in HAQ’s
shares.
WE URGE YOU TO CONSULT YOUR OWN TAX ADVISORS REGARDING YOUR PARTICULAR TAX
CONSEQUENCES.
This
proxy statement provides you with detailed information about the proposed
Merger, the proposed Certificate of Incorporation Amendment, the proposed
Incentive Plan and the Special Meeting. We encourage you to carefully read
this
entire document and the documents incorporated by reference, including the
Merger Agreement, the form of Certificate of Incorporation Amendment and the
proposed Incentive Plan which are attached hereto as Annexes A, B and C,
respectively.
YOU SHOULD ALSO CAREFULLY CONSIDER THE RISK FACTORS BEGINNING ON
PAGE ___
.
The
Merger cannot be consummated unless at least a majority of the shares of HAQ’s
common stock issued in HAQ’s IPO and voting at the Special Meeting (whether in
person or by proxy) approve and adopt the Merger Agreement and less than 20%
of
the shares of HAQ’s common stock issued in HAQ’s IPO vote against the
Merger
Proposal and elect a cash conversion of their shares.
HAQ’s
Board of Directors unanimously approved the Merger Agreement and the proposed
Merger, the Certificate of Incorporation Amendment, adoption of the proposed
Incentive Plan and unanimously recommends that you vote or instruct your vote
to
be cast “FOR” Proposal 1, the Merger Proposal, “FOR” Proposal 2, the
Amendment Proposal, and “FOR” Proposal 3, the Incentive Plan
Proposal.
This
proxy statement incorporates important business and financial information about
HAQ and PharmAthene that is not included in or delivered with this document.
This information is available without charge to security holders upon written
or
oral request. The request should be sent to:
Matthew
Kinley, President
Healthcare
Acquisition Corp.
2116
Financial Center
666
Walnut Street
Des
Moines, Iowa 50309
(515)
244-5746
To
obtain
timely delivery of requested materials, security holders must request the
information no later than five days before the date they submit their proxies
or
attend the Special Meeting. The latest date to request the information to be
received timely is _________, 2007.
We
are
soliciting the enclosed proxy card on behalf of the Board of Directors of HAQ,
and we will pay all costs of preparing, assembling and mailing the proxy
materials. In addition to mailing out proxy materials, our officers may solicit
proxies by telephone or fax, without receiving any additional compensation
for
their services. We have requested brokers, banks and other fiduciaries to
forward proxy materials to the beneficial owners of our stock.
THIS
PROXY STATEMENT IS DATED ________, 2007, AND IS FIRST BEING MAILED TO HAQ
STOCKHOLDERS ON OR ABOUT ____________, 2007.
TABLE
OF CONTENTS
|
|
Page
|
|
SUMMARY
TERM SHEET
|
|
|
1 |
|
QUESTIONS
AND ANSWERS ABOUT THE PROPOSALS
|
|
|
2 |
|
SUMMARY
OF THE PROXY STATEMENT
|
|
|
9 |
|
THE
MERGER PROPOSAL
|
|
|
9
|
|
THE
AGREEMENT AND PLAN OF MERGER
|
|
|
9 |
|
OUR
STOCK OWNERSHIP
|
|
|
10
|
|
DATE,
TIME AND PLACE OF SPECIAL MEETING OF OUR STOCKHOLDERS
|
|
|
11
|
|
RECORD
DATE; VOTING POWER
|
|
|
11 |
|
QUORUM
AND VOTE REQUIRED
|
|
|
11
|
|
PROXIES
|
|
|
11
|
|
TAX
CONSEQUENCES
|
|
|
11
|
|
ACCOUNTING
TREATMENT
|
|
|
11
|
|
RISK
FACTORS
|
|
|
12
|
|
RELATION
OF PROPOSALS
|
|
|
12
|
|
APPROVAL
OF PHARMATHENE’S STOCKHOLDERS
|
|
|
12
|
|
CONVERSION
RIGHTS
|
|
|
12
|
|
APPRAISAL
AND DISSENTERS’ RIGHTS
|
|
|
12
|
|
STOCK
OWNERSHIP
|
|
|
13
|
|
HAQ’S
BOARD OF DIRECTORS’ RECOMMENDATION
|
|
|
14
|
|
REASONS
FOR THE MERGER
|
|
|
14
|
|
INTERESTS
OF HAQ DIRECTORS AND OFFICERS IN THE MERGER
|
|
|
14
|
|
INTERESTS
OF PHARMATHENE DIRECTORS AND OFFICERS IN THE MERGER
|
|
|
15
|
|
INTEREST
OF MAXIM GROUP LLC IN THE MERGER; FEES
|
|
|
15
|
|
INTEREST
OF THE BEAR STEARNS COMPANIES INC., MPM CAPITAL, L.P. AND HEALTHCARE
VENTURES VII, L.P. IN THE MERGER
|
|
|
16
|
|
CONDITIONS
TO THE CONSUMMATION OF THE MERGER
|
|
|
16
|
|
TERMINATION,
AMENDMENT AND WAIVER
|
|
|
17
|
|
REGULATORY
MATTERS
|
|
|
18
|
|
THE
AMENDMENT PROPOSAL
|
|
|
18
|
|
THE
INCENTIVE PLAN PROPOSAL
|
|
|
18 |
|
SELECTED
HISTORICAL FINANCIAL INFORMATION
|
|
|
19 |
|
HEALTHCARE
ACQUISITION CORP. SELECTED FINANCIAL DATA |
|
|
20 |
|
PRO
FORMA CAPITALIZATION OF COMBINED COMPANY
|
|
|
21 |
|
SUMMARY
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL
INFORMATION
|
|
|
22 |
|
MARKET
PRICE INFORMATION AND DIVIDEND DATA FOR HAQ SECURITIES
|
|
|
24 |
|
RISK
FACTORS
|
|
|
25 |
|
RISKS
RELATED TO THE BUSINESS OF PHARMATHENE
|
|
|
25 |
|
LEGAL
AND REGULATORY RISKS OF DEVELOPMENT STAGE BIOTECHNOLOGY
COMPANIES
|
|
|
31 |
|
RISKS
PARTICULAR TO THE MERGER
|
|
|
36 |
|
RISKS
RELATING TO HAQ’S BUSINESS
|
|
|
37 |
|
FORWARD-LOOKING
STATEMENTS
|
|
|
44 |
|
THE
HAQ SPECIAL MEETING OF STOCKHOLDERS
|
|
|
46 |
|
THE
HAQ SPECIAL MEETING
|
|
|
46 |
|
DATE,
TIME AND PLACE
|
|
|
46 |
|
PURPOSE
OF THE SPECIAL MEETING
|
|
|
46 |
|
RECORD
DATE, WHO IS ENTITLED TO VOTE
|
|
|
47 |
|
VOTING
YOUR SHARES
|
|
|
47 |
|
WHO
CAN ANSWER YOUR QUESTIONS ABOUT VOTING YOUR SHARES
|
|
|
47 |
|
NO
ADDITIONAL MATTERS MAY BE PRESENTED AT THE SPECIAL MEETING
|
|
|
47 |
|
REVOKING
YOUR PROXY
|
|
|
48 |
|
QUORUM;
VOTE REQUIRED
|
|
|
48 |
|
ABSTENTIONS
AND BROKER NON-VOTES
|
|
|
48 |
|
CONVERSION
RIGHTS
|
|
|
49 |
|
APPRAISAL
OR DISSENTERS’ RIGHTS
|
|
|
49 |
|
SOLICITATION
COSTS
|
|
|
49 |
|
STOCK
OWNERSHIP
|
|
|
49 |
|
PROPOSAL 1
- THE MERGER PROPOSAL
|
|
|
51
|
|
GENERAL
DESCRIPTION OF THE MERGER
|
|
|
51 |
|
BACKGROUND
OF THE MERGER
|
|
|
51 |
|
INTERESTS
OF HAQ DIRECTORS AND OFFICERS IN THE MERGER
|
|
|
54 |
|
HAQ’S
REASONS FOR THE MERGER AND RECOMMENDATION OF THE HAQ BOARD
|
|
|
55 |
|
SATISFACTION
OF THE 80% REQUIREMENT
|
|
|
55 |
|
UNITED
STATES FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER
|
|
|
56 |
|
REGULATORY
MATTERS
|
|
|
56 |
|
CONSEQUENCES
IF MERGER PROPOSAL IS NOT APPROVED
|
|
|
56 |
|
REQUIRED
VOTE
|
|
|
57 |
|
RECOMMENDATION
|
|
|
57
|
|
THE
AGREEMENT AND PLAN OF MERGER
|
|
|
58 |
|
GENERAL
|
|
|
58 |
|
STOCK
CONSIDERATION
|
|
|
58 |
|
8%
CONVERTIBLE NOTES TO BE ISSUED AND NOTE EXCHANGE AGREEMENT
|
|
|
60 |
|
MILESTONE
PAYMENTS
|
|
|
62 |
|
EFFECT
OF MERGER ON PHARMATHENE OPTIONS AND WARRANTS
|
|
|
62 |
|
REPRESENTATIONS
AND WARRANTIES OF THE PARTIES
|
|
|
63 |
|
COVENANTS
AND AGREEMENTS
|
|
|
65 |
|
OPERATIONS
AFTER THE MERGER
|
|
|
69 |
|
CONDITIONS
TO THE COMPLETION OF THE MERGER
|
|
|
69 |
|
MATERIALITY
AND MATERIAL ADVERSE EFFECT
|
|
|
70 |
|
TERMINATION
|
|
|
70 |
|
INDEMNIFICATION
OF CLAIMS AND ESCROW OF SHARES
|
|
|
71 |
|
REPRESENTATIVE
|
|
|
72 |
|
ASSIGNMENT
|
|
|
72 |
|
FURTHER
ASSURANCES
|
|
|
72 |
|
OTHER
AGREEMENTS RELATED TO THE MERGER
|
|
|
73 |
|
REGISTRATION
RIGHTS AGREEMENT
|
|
|
73 |
|
LOCK-UP
AGREEMENTS
|
|
|
73 |
|
EMPLOYMENT
AGREEMENTS
|
|
|
73 |
|
PROPOSAL 2
- THE AMENDMENT PROPOSAL
|
|
|
74 |
|
GENERAL
|
|
|
74 |
|
REQUIRED
VOTE
|
|
|
76 |
|
RECOMMENDATION
|
|
|
76 |
|
PROPOSAL 3
- THE INCENTIVE PLAN PROPOSAL
|
|
|
77
|
|
BACKGROUND
|
|
|
77 |
|
STOCK
SUBJECT TO THE 2007 INCENTIVE PLAN
|
|
|
77 |
|
ADMINISTRATION
|
|
|
77 |
|
TYPES
OF AWARDS
|
|
|
78 |
|
TRANSFERABILITY
|
|
|
79 |
|
CHANGE
OF CONTROL EVENT
|
|
|
80 |
|
TERMINATION
OF EMPLOYMENT/RELATIONSHIP
|
|
|
80 |
|
DILUTION;
SOLUTION
|
|
|
80 |
|
AMENDMENT
OF THE INCENTIVE PLAN
|
|
|
80 |
|
ACCOUNTING
TREATMENT
|
|
|
80
|
|
TAX
TREATMENT
|
|
|
81 |
|
REQUIRED
VOTE
|
|
|
82
|
|
RECOMMENDATION
|
|
|
82
|
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OF PHARMATHENE
|
|
|
83 |
|
INFORMATION
ABOUT PHARMATHENE |
|
|
97 |
|
INFORMATION
ABOUT HAQ
|
|
|
109 |
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OF HAQ
|
|
|
110 |
|
UNAUDITED
PRO FORMA CONDENSED COMBINED CONSOLIDATED FINANCIAL INFORMATION
AS OF SEPTEMBER 30, 2006
|
|
|
115 |
|
DIRECTORS
AND MANAGEMENT OF HAQ FOLLOWING THE MERGER WITH
PHARMATHENE
|
|
|
122 |
|
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS |
|
|
127 |
|
BENEFICIAL
OWNERSHIP OF SECURITIES
|
|
|
129 |
|
PRICE
RANGE OF SECURITIES AND DIVIDENDS
|
|
|
132 |
|
DESCRIPTION
OF SECURITIES
|
|
|
133 |
|
STOCKHOLDER
PROPOSALS
|
|
|
135 |
|
WHERE
YOU CAN FIND MORE INFORMATION
|
|
|
135 |
|
INDEX
TO FINANCIAL STATEMENTS
|
|
|
FS-1 |
|
ANNEXES
|
|
|
|
|
Annex
A - Agreement and Plan of Merger
|
|
|
|
|
Annex
B - Form of Amendment to the Amended and Restated Certificate of
Incorporation
|
|
|
|
|
Annex
C - Form of 2007 Long-Term Incentive Plan
|
|
|
|
|
SUMMARY
OF THE MATERIAL TERMS OF THE MERGER
This
Summary together with the sections entitled “Questions and Answers About
the Merger and the Special Meeting” and “Summary of the Proxy Statement,”
summarizes certain material information contained in this proxy statement.
You
should carefully read this entire proxy statement for a more complete
understanding of the matters to be considered at the Special Meeting of
stockholders.
|
·
|
Pursuant
to a Merger Agreement, HAQ will acquire all of the outstanding securities
held by the stockholders of PharmAthene (other than those securities
being
cancelled) and PharmAthene will become a wholly-owned subsidiary
of HAQ.
For more information about the Merger, see the section entitled “The
Merger Proposal” beginning on page 51 and the Merger Agreement that is
attached as Annex A to this proxy statement.
|
|
·
|
At
the Special Meeting of stockholders to be held on _________, 2007,
you
will be asked, among other things, to approve the Merger. For more
information about the Special Meeting, see the section entitled “The HAQ
Special Meeting” beginning on page 46.
|
|
·
|
We
are a special purpose acquisition company organized under the laws
of
Delaware on April 25, 2005. We were formed to effect an acquisition,
merger, capital stock exchange, asset acquisition or other similar
business combination with an operating business in the healthcare
industry. For more information about us, see the section entitled
“Information About HAQ” beginning on page 109.
|
|
|
|
|
·
|
PharmAthene
is a privately-held Delaware company engaged in the biodefense industry,
specifically the discovery and development of novel human therapeutics
and
prophylactics for the treatment and prevention of
morbidity and mortality from exposure to biological and chemical
weapons.
For more information about PharmAthene, see the sections entitled
“Unaudited Pro Forma Condensed Combined Financial Statements,”
“Information About PharmAthene,” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations of PharmAthene” beginning
on pages 21, 97, and 83, respectively. Also see
PharmAthene’s financial statements beginning on page F-2.
|
|
·
|
At
the closing of the Merger, stockholders, optionholders, warrantholders
and
noteholders of PharmAthene will receive an aggregate of 12,500,000
shares
of HAQ common stock, subject to possible adjustment as set forth
in the
Merger Agreement; $12,500,000 in 8% convertible notes issued by HAQ
and up
to $10,000,000 in milestone payments (if certain conditions are met).
For
more information about the merger consideration, see the section
entitled
“The Agreement and Plan of Merger” beginning on page 58.
|
|
·
|
At
the closing, the
stockholders (including option holders and warrant holders of PharmAthene)
will place 1,375,000 shares of HAQ common stock to be issued in the
Merger
into escrow which shares will be the sole and exclusive source for
satisfying any indemnification claims. The indemnification obligations
are
subject to the limitation that we incur damages of at least $500,000
prior
to making any claim. Further, the ability to be indemnified is subject
to
a limitation of the shares held in escrow. For more information about
indemnification, see the section entitled “The
Agreement and Plan of Merger — Indemnification of Claims and Escrow of
Shares” beginning on page 71.
|
|
·
|
At
the closing, all series of preferred stock of PharmAthene will be
surrendered for conversion into shares of HAQ common stock, and the
preferred stock will be cancelled. Additionally, a total of 16,118,359
warrants held by the holders of the PharmAthene preferred stock will
be
cancelled, as well as all related agreements previously entered into
by
the holders of the preferred stock and
PharmAthene.
|
|
·
|
After
we complete the Merger with PharmAthene, officers of PharmAthene
will
continue as before the Merger. Our Board will be reconstituted, and
will
be comprised of seven persons, only two of whom will be continuing
Board
members of HAQ. For more information about management, see the section
entitled “Directors and Management of HAQ Following the Merger with
PharmAthene” on page 127.
|
|
|
|
|
·
|
Our
management and Board considered various factors in determining to
merge
with PharmAthene and to approve the Merger Agreement. For more information
about our decision-making process, see the section entitled “HAQ’s Reasons
for the Merger and Recommendation of the HAQ Board” beginning on page 55.
|
|
|
|
|
·
|
Our
merger with PharmAthene involves numerous risks. For more information
about these risks, see the section entitled “Risk Factors” beginning on
page 25.
|
QUESTIONS
AND ANSWERS ABOUT THE PROPOSALS
Why
am I receiving this proxy statement?
HAQ
and
PharmAthene have agreed to a business combination under the terms of an
Agreement and Plan of Merger, dated January 19, 2007, among HAQ, PAI Acquisition
Corp., a newly-formed subsidiary of HAQ (“Merger Sub”) and PharmAthene, Inc.
(“PharmAthene”) pursuant to which Merger Sub will be merged (the “Merger”) with
and into PharmAthene. This agreement is referred to as the Merger Agreement.
A
copy of the Merger Agreement is attached to this proxy statement as Annex A,
which we encourage you to review in its entirety.
In
order
to consummate the Merger, under our amended and restated certificate of
incorporation, a majority of the shares issued in the IPO voting at the meeting
(whether in person or by proxy) must vote to approve and adopt the Merger
Agreement and the transactions contemplated thereby. Also, not more than 20%
of
such shares can elect to convert their shares to cash from the trust account
established with the proceeds of our IPO.
HAQ
will
hold a Special Meeting of its stockholders to obtain this approval. This proxy
statement contains important information about the proposed merger and the
Amendment Proposal and the Incentive Plan Proposal. You should read it
carefully.
Your
vote
is important. We encourage you to vote as soon as possible after carefully
reviewing this proxy statement.
What
is being voted on?
There
are
three proposals on which you are being asked to vote. The first proposal is
to
approve and adopt a Merger Agreement and the transactions contemplated thereby.
As a consequence of the Merger, PharmAthene will become a wholly-owned
subsidiary of HAQ.
The
second proposal is to approve an amendment to HAQ’s amended and restated
certificate of incorporation, subject to consummation of the Merger,
to:
· change
HAQ’s name to “PharmAthene, Inc.” after the Merger;
· remove
certain provisions that will no longer be operative to HAQ as an operating
company upon consummation of the Merger; and
· grant
to the holders of the 8% convertible notes to be issued as part of the
Merger the right to designate three members to the Board of Directors of HAQ
for
so long as at least 30% of the original face value of such notes remain
outstanding.
The
third
proposal is to approve the adoption of the 2007 Long-Term Incentive Plan, or
the
Incentive Plan, pursuant to which 3,500,000 of shares of HAQ common stock will
be reserved for issuance in accordance with the terms of the Incentive Plan
(including approximately 482,800 shares reserved to honor options and
warrants issued by PharmAthene which will be assumed by HAQ pursuant to the
Merger Agreement).
It
is
important for you to note that in the event the Merger Proposal does not receive
the necessary vote to approve such proposal, then HAQ will not consummate that
proposal or the other proposals and HAQ will be forced to liquidate. If the
Incentive Plan Proposal or the Amendment Proposal is not approved, but the
Merger Proposal is approved, HAQ may still consummate the Merger if the
conditions in the Merger Agreement requiring approval of these proposals are
waived.
What
is a quorum?
A
quorum
is the number of shares that must be represented, in person or by proxy, in
order for business to be transacted
at the special meeting.
More
than
one-half of the total number of shares of our common stock outstanding as of
the
record date (a quorum) must be represented, either in person or by proxy, in
order to transact business at the special meeting. Abstentions and broker
non-votes are counted for purposes of determining the presence of a quorum.
If
there is no quorum, a majority of the shares present at the Special Meeting
may
adjourn the Special Meeting to another date.
However,
in order to vote on Proposal 1, more than one-half of the shares of our common
stock purchased in our IPO must be represented (4,700,001 shares), because
only
the holders of those shares may vote on the Merger Proposal.
Why
is HAQ proposing the Merger, the Certificate
of Incorporation Amendment and the adoption of the Incentive
Plan?
HAQ
is a
blank-check company formed specifically as a vehicle for the acquisition of
or
merger with a business whose net assets are at least 80% of the net assets
of
HAQ. In the course of HAQ’s search for a business combination partner, HAQ was
introduced to PharmAthene, a company which the Board of Directors of HAQ
believes has significant growth potential. PharmAthene is in the business of
discovering and developing novel human therapeutics and prophylactics for the
treatment and prevention of morbidity from exposure to biological and chemical
weapons. The Board of Directors of HAQ found PharmAthene to be an attractive
merger partner because of the industry in which it operates, its existing
products, growth prospects and management team, among other factors. As a
result, HAQ believes that the Merger will provide HAQ stockholders with an
opportunity to participate in a company with significant growth potential.
The
Certificate of Incorporation Amendment is being undertaken because upon
consummation of the Merger, (i) management desires the name of the business
to
reflect its operations, (ii) there are provisions in the certificate of
incorporation which will no longer be applicable and, (iii) pursuant to the
terms of the Merger Agreement, HAQ has agreed that, as a consequence of the
Merger, noteholders will have the right to appoint members to the Board of
Directors. The adoption of the Incentive Plan is being undertaken because the
Board of Directors of HAQ deems it beneficial for the combined company going
forward following the Merger to have incentives available to attract and retain
employees and to honor options held by PharmAthene employees which will be
assumed as part of the Merger.
What
vote is required in order to approve the Merger Proposal?
The
approval of the Merger Proposal will require the affirmative vote of a majority
of the votes cast at the Special Meeting of the shares of common stock issued
as
part of HAQ’s IPO. We issued 9,400,000 shares as part of our IPO. In addition,
not more than 20% of such shares (1,880,000 shares) may vote against the Merger
and elect to convert their shares into cash from the trust account.
What
happens if I vote against the Merger?
Each
HAQ
stockholder who holds shares of common stock issued in HAQ’s IPO or purchased
following such offering in the open market has the right to vote against the
Merger Proposal and, at the same time, demand that HAQ convert such
stockholder’s shares into cash equal to a pro rata portion of the trust account.
These shares will be converted into cash only if the Merger is consummated.
Based on the amount of cash held in the trust account as of September 30, 2006,
without taking into account any interest accrued after such date, stockholders
who vote against the Merger Proposal and elect to convert such stockholder’s
shares as described above will be entitled to convert each share of common
stock
that it holds into approximately $7.48 per share. However, if the holders of
1,880,000 or more shares of common stock issued in HAQ’s IPO (an amount equal to
20% or more of the total number of shares issued in the IPO), vote against
the
Merger and demand conversion of their shares into a pro rata portion of the
trust account, then HAQ will not be able to consummate the Merger.
How
is Management of HAQ voting?
HAQ’s
initial stockholders, including all of its directors and officers, who purchased
or received shares of common stock prior to HAQ’s IPO, presently, together with
their affiliates, own an aggregate of approximately 19.3% of the outstanding
shares of HAQ common stock (an aggregate of 2,250,000 shares). All of these
persons have agreed to vote all of these shares which were acquired prior to
the
IPO in accordance with the vote of the majority interest of all other HAQ
stockholders on the Merger Proposal.
What
vote is required in order to approve the Amendment
Proposal?
The
approval of the Amendment Proposal will require the affirmative vote of a
majority of the shares of HAQ’s common stock issued and outstanding as of the
Record Date. The officers and directors of HAQ intend to vote all of their
shares of common stock in favor of this proposal.
What
vote is required in order to approve the Incentive Plan
Proposal?
The
approval of the Incentive Plan Proposal will require the affirmative vote of
a
majority of the votes cast at the Special Meeting. The officers and directors
of
HAQ intend to vote all of their shares of common stock in favor of this
proposal.
If
I am not going to attend the Special Meeting of stockholders in person, should
I
return my proxy card instead?
Yes.
Whether or not you plan to attend the Special Meeting, after carefully reading
and considering the information contained in this proxy statement, please
complete and sign your proxy card. Then return the enclosed proxy card in the
return envelope provided herewith as soon as possible, so that your shares
may
be represented at the Special Meeting.
What
will happen if I abstain from voting or fail to vote?
An
abstention or failure to vote by a HAQ stockholder will not be counted towards
the vote total for the Merger Proposal, and your shares of common stock will
not
be converted into a pro rata portion of the funds in the trust account. An
abstention or failure to vote will have the effect of voting against the
Amendment Proposal. An abstention will have the effect of voting against the
Incentive Plan.
As
long
as a quorum is established at the Special Meeting, a failure to vote will have
no impact upon the approval of the Merger Proposal or the Incentive Plan
Proposal but as the Amendment Proposal requires a majority of all outstanding
shares of common stock, a failure to vote will have the effect of a vote against
such proposal. Failure to vote will not have the effect of converting your
shares into a pro rata portion of the trust account.
If
my shares are held in “street name” by my broker, will my broker vote my shares
for me?
If
you
hold your shares in “street name,” your bank or broker cannot vote your shares
with respect to the Merger Proposal, the Amendment Proposal or the Incentive
Plan Proposal without specific instructions from you, which are sometimes
referred to in this proxy statement as the broker “non-vote” rules. If you
do not provide instructions with your proxy, your bank or broker may deliver
a
proxy card expressly indicating that it is NOT voting your shares; this
indication that a bank or broker is not voting your shares is referred to as
a
“broker non-vote.” Broker non-votes will be counted for the purpose of
determining the existence of a quorum, but will not count for purposes of
determining the number of votes cast at the Special Meeting. Your broker can
vote your shares only
if you
provide instructions on how to vote. You should instruct your broker to vote
your shares in accordance with directions you provide to your
broker.
What
do I do if I want to change my vote?
If
you
wish to change your vote, please send a later-dated, signed proxy card to our
corporate Secretary, John Pappajohn at HAQ prior to the date of the Special
Meeting or attend the Special Meeting and vote in person. You also may revoke
your proxy by sending a notice of revocation to John Pappajohn at the address
of
HAQ’s corporate headquarters, provided such revocation is received prior to the
Special Meeting.
Will
I receive anything in the Merger?
If
the
Merger is consummated and you vote your shares for the Merger Proposal or you
abstain, you will continue to hold the HAQ securities that you currently own.
If
the Merger is consummated but you have voted your shares against the Merger
Proposal and have elected a cash conversion instead, your shares of HAQ common
stock will be cancelled and you will receive cash equal to a pro rata portion
of
the trust account, which, as of September 30, 2006, was equal to approximately
$7.48 per share. Because HAQ is acquiring all of the outstanding securities
of
PharmAthene, the stockholders (and certain optionholders and warrantholders)
and
noteholders of PharmAthene will receive 12.5 million shares of HAQ common stock,
subject to adjustment, 8% convertible notes in the amount of $12,500,000 and
up
to $10,000,000 in milestone payments, as applicable in exchange for their shares
(or applicable options or warrants) of capital stock of PharmAthene and in
replacement of currently outstanding notes.
How
is HAQ paying for the Merger?
HAQ
will
use a portion of the proceeds from its recently completed IPO in order to
finance the Merger with PharmAthene. Primarily, HAQ will be issuing new shares
of its common stock and 8% convertible notes to finance the Merger. Further,
as
described elsewhere in this proxy statement, the PharmAthene stockholders may
also receive milestone payments from future revenues of the post-merger
company.
Are
PharmAthene stockholders or noteholders required to approve the
Merger?
Yes.
All
of the holders of PharmAthene’s preferred stock, and more than 80% of the
holders of the common stock of PharmAthene, have already executed irrevocable
consents approving and adopting the Merger Agreement and the transactions
contemplated thereby. Accordingly, there are no additional approvals required
by
PharmAthene to consummate the Merger. In addition holders of 11,625,000
principal amount of notes have agreed to exchange their old PharmAthene notes
(principal and interest) for the new notes to be issued by
HAQ.
What
will happen in the Merger?
PAI
Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of
HAQ
formed for the purpose of consummating the Merger (which we also refer to as
“Merger Sub”), will merge with and into PharmAthene with PharmAthene being the
surviving corporation. As a consequence of the Merger, the following will occur:
· |
PharmAthene
will be a wholly-owned subsidiary of HAQ;
|
· |
the
stockholders of PharmAthene will receive shares of HAQ common stock;
|
· |
the
option and warrant holders of PharmAthene will receive options and
warrants to purchase shares of HAQ common stock in exchange for their
equity interests in PharmAthene;
|
· |
the
holders of the 8% convertible notes of PharmAthene will exchange
their
notes (principal and interest) for $12,500,000 of 8% convertible
notes
issued by HAQ;
|
· |
at
the closing, all series of preferred stock of PharmAthene will be
surrendered for conversion into shares of HAQ Common Stock, and the
preferred stock will be cancelled. Additionally, a total
of 16,118,359 warrants held by the holders of the PharmAthene
preferred stock will be terminated, as well as all related agreements
previously entered into by the holders of the preferred stock and
PharmAthene;
|
· |
the
Board of HAQ will be restructured and reconstituted to provide that
the
Board will be comprised of seven persons, and the holders of the
8% notes
to be issued to the PharmAthene note holders will have the right
to
appoint up to three directors.
|
Has
HAQ received a valuation or fairness opinion with respect to the Merger
Proposal?
No. Our
Board of Directors has determined that the fair market value of PharmAthene
exceeds 80% of our net assets as was represented in the prospectus relating
to
our IPO and required by our amended and restated certificate of incorporation.
The terms of the merger were determined based upon arm’s-length negotiations
between us and the management of PharmAthene, who had no prior dealings with
us
or our officers or directors. Some of our officers and directors, including
John
Pappajohn, our Chairman, Derace L. Schaffer, M.D., our Chief Executive Officer,
and Matthew Kinley, our President, have extensive industry and deal-making
experience. Further, obtaining a valuation or fairness opinion is not required
under our amended and restated certificate of incorporation. Under the
circumstances, our Board of Directors believed that the aggregate consideration
for the Merger appropriately reflected PharmAthene’s fair market value and that
obtaining a valuation or fairness opinion was unnecessary.
What
will PharmAthene stockholders receive in the Merger?
The
Merger Agreement provides that the holders of PharmAthene capital stock
(including holders of warrants and options) and outstanding noteholders will
receive the following consideration:
· |
an
aggregate of 12,500,000 shares of HAQ common stock subject to adjustment;
|
· |
$12,500,000
of 8% convertible notes will be issued by HAQ; and
|
· |
up
to $10,000,000 in milestone payments may be paid (if certain conditions
are met),
|
The
Merger Agreement provides that the holders of PharmAthene outstanding capital
stock and 8% convertible notes immediately prior to the Merger will initially
own up to approximately 52% of the issued and outstanding shares of HAQ capital
stock after the Merger (not including as outstanding for purposes of the
calculation are shares to be issued upon exercise of HAQ’s outstanding warrants,
excluding securities issuable upon exercise of a purchase option issued to
underwriters in HAQ’s IPO and excluding the 8% convertible notes to be issued in
the Merger). Since HAQ has outstanding warrants to purchase 9.4 million shares
of common stock and a unit purchase option to purchase 225,000
units, each unit consisting of one share of common stock and one
warrant,
holders
of PharmAthene outstanding capital stock will own as much as 36.7% of the
aggregate issued and outstanding shares of HAQ capital stock after taking into
account such securities. The holders of HAQ capital stock immediately prior
to
the Merger will own the balance of the issued and outstanding shares of HAQ
capital stock. Therefore, the holders of HAQ capital stock immediately prior
to
the Merger will experience substantial dilution of their ownership interest
as a
result of the Merger.
Will
fractional shares of HAQ be
paid?
Fractional
shares will not be issued to PharmAthene stockholders in the Merger. In lieu
of
fractional shares, the PharmAthene stockholders will receive cash.
What
will PharmAthene noteholders receive in the Merger?
Pursuant
to a Note Exchange Agreement, the execution of which is a condition precedent
to
consummation of the Merger, current holders of PharmAthene’s $11,800,000 in 8%
convertible notes are required to exchange such notes (all principal and
accrued interest) for the 8% convertible notes of HAQ in the principal
amount of $12,500,000. Pursuant to the Note Exchange Agreement, such holders
will also have the right to designate three nominees to HAQ’s Board
of
Directors, comprised of seven members,
and two
of the three members to each committee of the Board including the corporate
governance and nominating committee and compensation committee.
Do
I have conversion rights in connection with the Merger?
If
you
hold shares of common stock issued in HAQ’s IPO, then you have the right to vote
against the Merger Proposal and demand that HAQ convert your shares of HAQ
common stock into a pro rata portion of the trust account. These rights to
vote
against the Merger and demand conversion of your shares into a pro rata portion
of the trust account are sometimes referred to herein as conversion
rights.
If
I have conversion rights, how do I exercise them?
If
you
wish to exercise your conversion rights, you must vote against the Merger
Proposal and, at the same time, demand that HAQ convert your shares into cash
by
marking the appropriate space on the proxy card. If, notwithstanding your vote,
the Merger is consummated,
then you will be entitled to receive a pro rata share of the trust account
in
which a substantial portion of the net proceeds of HAQ’s IPO are held, including
any interest earned thereon through the date of the Special Meeting. Based
on
the amount of cash held in the trust account as of September 30, 2006, without
taking into account any interest accrued after such date, you will be entitled
to convert each share of HAQ common stock that you hold into approximately
$7.48
per share. If you exercise your conversion rights, then you will be exchanging
your shares of HAQ common stock for cash and will no longer own these shares
of
common stock. You will only be entitled to receive cash for these shares if
you
continue to hold these shares through the closing date of the Merger and then
tender your stock certificate to HAQ. If you convert your shares of common
stock, you will still have the right to exercise the warrants received as part
of the units purchased in the IPO in accordance with the terms thereof. If
the
Merger is not consummated: (i) then your shares will not be converted into
cash
at this time, even if you so elected; and (ii) we will commence the dissolution
process and you will be entitled to distribution upon liquidation. See
“Conversion Rights” at page 49 and the section entitled “Dissolution and
Liquidation if No Business Combination” beginning on
page 111.
What
happens to the funds deposited in the trust account after completion of the
Merger?
Upon
consummation of the Merger, a portion of the funds remaining in the trust
account after payment of amounts, if any, to stockholders requesting and
exercising their conversion rights, will be used to pay expenses associated
with
the Merger and to fund working capital of the combined company. In addition,
approximately $720,000 will be used to pay deferred underwriter’s compensation
from HAQ’s IPO.
Who
will manage HAQ from and after consummation of the Merger with
PharmAthene?
From
and
after consummation of the Merger, HAQ will be managed by the current management
of PharmAthene including David P. Wright as President and Chief Executive
Officer. It is anticipated that the Board of Directors of the combined company
will consist of the following seven board members: John Pappajohn, Derace M.
Schaffer, M.D., James Cavanaugh, Ph.D., Steven St. Peter, M.D. Elizabeth
Czerepak, Joel McCleary and David Wright, each to serve until his or her
successor is elected and qualified or until his or her earlier death,
resignation or removal. Ms. Czerepak and Drs. Cavanaugh and St. Peter are
directors nominated by the holders of 8% convertible notes to be issued by
HAQ
in exchange for the currently-outstanding 8% convertible notes of
PharmAthene.
What
happens if the Merger is not consummated?
If
the
Merger is not consummated, HAQ’s amended and restated certificate of
incorporation will not be further amended pursuant to the Amendment Proposal
and
we will not adopt the Incentive Plan pursuant to the Incentive Plan Proposal.
Further, it is likely that HAQ will be liquidated pursuant to its amended and
restated certificate of incorporation. In the event the Merger is not
consummated, HAQ will probably not have sufficient time and resources to seek
another suitable business combination and HAQ will be forced to dissolve and
liquidate. If a liquidation were to occur by approximately August 3, 2007 (the
last day on which HAQ would be permitted to consummate an acquisition under
its
amended and restated certificate of incorporation), HAQ estimates that
approximately $2,000,000 million in interest would accrue on the amounts that
are held in trust through such date, which would yield a trust balance of
approximately $72,280,000 million or $7.68 per share. This amount, less any
liabilities not indemnified by certain members of HAQ’s Board and not waived by
HAQ’s creditors, would be distributed to the holders of the 9,400,000 shares of
common stock purchased in HAQ’s IPO. HAQ currently estimates that, at the end of
January 2007, there would be approximately $250,000 in Delaware franchise tax
and state income tax claims which are not indemnified and not waived by such
taxing authorities. Thus, HAQ estimates that the total amount available for
distribution upon liquidation would be approximately $72,030,000 million or
$7.66 per share.
When
do you expect the Merger to be completed?
Assuming
the approval of the Merger Proposal, it is currently anticipated that the Merger
and other proposals will be completed as promptly as practicable following
the
Special Meeting of stockholders to be held on __________, 2007.
What
do I need to do now?
HAQ
urges
you to read carefully and consider the information contained in this proxy
statement, including the annexes, and to consider how the merger will affect
you
as a stockholder of HAQ. You should then vote as soon as possible in accordance
with the instructions provided in this proxy statement and on the enclosed
proxy
card.
Do
I need to send in my stock certificates?
Only
HAQ
stockholders who vote against adoption of the Merger Proposal and elect to
have
their shares converted into a pro rata share of the funds in the trust account
must send their physical stock certificate to our stock transfer agent no later
than 5:00 p.m., New York City time, on the business day prior to the date of
the
Special Meeting. HAQ stockholders who vote in favor of the adoption of the
merger proposal, or who otherwise do not elect to have their shares converted
should not submit their stock certificates now or after the Merger, because
their shares will not be converted or exchanged in connection with the
Merger.
What
should I do if I receive more than one set of voting
materials?
You
may
receive more than one set of voting materials, including multiple copies of
this
proxy statement and multiple proxy cards or voting instruction cards, if your
shares are registered in more than one name or are registered in different
accounts. For example, if you hold your shares in more than one brokerage
account, you will receive a separate voting instruction card for each brokerage
account in which you hold shares. Please complete, sign, date and return each
proxy card and voting instruction card that you receive in order to cast a
vote
with respect to all of your HAQ shares.
Who
can help answer my questions?
If
you
have questions about any of the proposals, you may write or call Healthcare
Acquisition Corp. at 2116 Financial Center, 666 Walnut Street, Des Moines,
Iowa
50309, (515) 244-5746, Attention: Matthew Kinley.
This
summary highlights certain information from this proxy statement including
information with respect to each of the proposals, although the Merger is the
primary reason for the calling of the Special Stockholders and the other
proposals are dependent upon the approval of the Merger Proposal. This summary
does not contain all of the information that is important to you. All of the
proposals are described in detail elsewhere in this proxy statement and this
summary discusses the material items of each of the proposals. You should
carefully read this entire proxy statement and the other documents to which
this
proxy statement refers you. See, “Where You Can Find More Information.” on page
135.
The
Merger Proposal (Page 51)
The
Parties
HAQ
HAQ
is a
blank-check company formed specifically as a vehicle for the acquisition of
or
merger with a business whose net assets are at least 80% of the net assets
of
HAQ. The principal executive offices of HAQ are located at 2116 Financial
Center, 666 Walnut Street, Des Moines, Iowa 50309, and its telephone number
is
(515) 244-5746.
PAI
Acquisition
PAI
Acquisition, Inc. or Merger Sub, is a wholly owned subsidiary of HAQ, formed
for
the purpose of merging with and into PharmAthene. The principal executive
offices of Merger Sub are located at 2116 Financial Center, 666 Walnut Street,
Des Moines, Iowa 50309, and its telephone number is (515) 244-5746.
PharmAthene
PharmAthene
is a privately owned, commercial-stage Delaware corporation in the business
of
discovering and developing novel human therapeutics and prophylactics for the
treatment and prevention of morbidity and mortality from exposure to chemical
and biological weapons. Based in Annapolis, Maryland, PharmAthene’s goal is to
become the premier company worldwide specializing in the discovery, development
and commercialization of therapeutic and prophylactic drugs for defense against
bioterrorism and to eventually leverage its biodefense capabilities for
non-biodefense products in broader commercial markets. PharmAthene has two
products under development, Valortim™, a human monoclonal antibody for the
prevention and treatment of anthrax infection, and Protexia®, a bioscavenger for
the treatment of organophosphate nerve agent poisoning. Beyond its initial
focus
in biodefense, PharmAthene intends to identify and develop dual-use technologies
which have application and indications in broader commercial
markets.
PharmAthene
was incorporated on March 13, 2001 under the name PharmAthene, Inc. The
principal executive offices of PharmAthene are located at 175 Admiral Cochrane
Drive, Suite #101, Annapolis, MD 21401, and its telephone number is
(410)
571-8920.
The Agreement
and Plan of Merger (Page 58)
On
January 19, 2007, the parties entered into an Agreement and Plan of Merger
(the
“Merger Agreement”) which provides for a business combination by means of a
merger of Merger Sub with and into PharmAthene in which PharmAthene will be
the
surviving entity and become a wholly-owned subsidiary of HAQ. We will acquire
all of the capital stock of PharmAthene and certain of its securities will
be
terminated. At the closing, and subject to certain adjustments as hereafter
described, the PharmAthene stockholders, optionholders, warrantholders and
noteholders will receive the following in the Merger (the “Merger
Consideration”):
· |
an
aggregate of 12,500,000 shares of HAQ common stock;
|
· |
$12,500,000
in 8% convertible notes issued by HAQ; and
|
· |
up
to $10,000,000 in milestone payments (if certain conditions are met),
|
We
are
also assuming outstanding options and warrants, to acquire shares of
PharmAthene, which will be converted into options and warrants to acquire
482,800 shares of HAQ.
Milestone
payments
may be made to the stockholders of PharmAthene as part of the Merger
Consideration equal to 10% of the actual collections on gross sales of its
product, Valortim, to the U.S. federal government until the earlier of (A)
December 31, 2009, or (B) the point at which total aggregate milestone payments
to the stockholders, optionholders and warrantholders equal $10 million. These
payments will be conditioned upon receipt by PharmAthene of an award,
procurement or other contract (x) on or before December 31, 2007; (y) which
provides for a procurement by the U.S. government of doses or treatments equal
to or greater than 60,000; and (z) with a total contract value of $150 million
or more.
The
12,500,000 shares of HAQ common stock issued as a portion of the Merger
Consideration will only be subject to adjustment to
the
extent that the stockholders of HAQ owning more than 5% of the outstanding
HAQ
Common Stock exercise their conversion rights. The number of shares of HAQ
common stock comprising the stock consideration shall be adjusted upward by
the
product of (x) the number (as a percentage) that is the difference between
the
percentage of HAQ common stock that is converted and 5% and (y) 2.25
million.
Of
the
shares of HAQ common stock to be issued to the PharmAthene stockholders as
a
portion of the Merger Consideration, 1,375,000 shares of HAQ common stock will
be placed in an escrow account for a period of one year from the closing date
of
the Merger as the sole and exclusive source to satisfy any indemnification
claims against PharmAthene under the Merger Agreement.
HAQ,
Merger Sub and PharmAthene plan to consummate the Merger as promptly as
practicable after the Special Meeting, provided that:
· |
HAQ’s
stockholders have approved and adopted the Merger Agreement and the
transactions contemplated thereby;
|
· |
holders
of no more than 19.99% of the shares of the common stock issued in
HAQ’s
IPO vote against the Merger Proposal and demand conversion of their
shares
into cash;
|
· |
at
the closing, all series of preferred stock of PharmAthene are surrendered
for conversion, all warrants held by the holders of the PharmAthene
preferred stock are cancelled, as well as all related agreements
previously entered into by the holders of the preferred stock and
PharmAthene are terminated;
|
· |
all
of the noteholders of PharmAthene surrender their notes for exchange
into
the new 8% convertible notes of
HAQ;
|
· |
all
registration rights, security agreements and any other agreement
related
to the preferred stock and notes of PharmAthene entered into by the
holders of the preferred stock and /or note holders are terminated;
and
|
· |
the
other conditions specified in the Merger Agreement have been satisfied
or
waived.
|
See
the
description of the Merger Agreement in the section entitled “The Agreement and
Plan of Merger” beginning on page 58. The Merger Agreement is included as “Annex
A” to this proxy statement. We encourage you to read the Merger Agreement in its
entirety.
Our
Stock Ownership (Page 49)
On
the
Record Date, our officers and directors owned an aggregate of
2,250,000 shares of our common stock, or approximately 19.3% of our
outstanding shares, that they acquired prior to our IPO. They have agreed to
vote these shares with respect to the Merger Proposal as the holders of a
majority of our IPO shares that are voted at the Special Meeting. Our officers
and directors own no shares that were issued in the IPO.
Date,
Time and Place of Special Meeting of Our Stockholders (Page 46)
The
Special Meeting of our stockholders will be held at 10:00 A.M., local time,
on _________, 2007 at [_].
Record
Date; Who is Entitled to Vote (Page 47)
You
will
be entitled to vote or direct votes to be cast at the Special Meeting if you
owned shares of our common stock at the close of business on ______________,
2007, which is the record date for the Special Meeting. You will have one vote
for each share of our common stock you owned at the close of business on the
record date. On the record date, there were 11,650,000 shares of our common
stock outstanding, of which 9,400,000 shares were IPO shares. The remaining
2,250,000 shares were issued to our founders prior to our IPO.
Quorum
and Vote Required (Page 48)
A
quorum
of our stockholders is necessary to hold a valid stockholders meeting. A quorum
will be present at the Special Meeting if a majority of the shares of our common
stock outstanding as of the record date are presented in person or by proxy.
Abstentions and broker non-votes will count as present for the purposes of
establishing a quorum.
The
approval of the Merger Proposal will require the approval of the holders of
a
majority of the shares of our common stock issued in our IPO present and that
vote on the Merger Proposal at the Special Meeting with respect to the Merger.
Notwithstanding such approval, the Merger will not be completed if the holders
of 20% or more of our IPO shares (1,880,000 or more shares) vote against the
Merger Proposal and exercise their conversion rights.
As
long
as a quorum is established at the Special Meeting, a failure to vote will have
no impact upon the approval of the Merger Proposal or the Incentive Plan
Proposal but as the Amendment Proposal requires a majority of all outstanding
shares of common stock, a failure to vote will have the effect of a vote against
such proposal. Failure to vote will not have the effect of converting your
shares into a pro rata portion of the trust account.
Voting
Your Shares; Proxies (Page 47)
Proxies
may be solicited by mail, telephone or in person.
If
you
grant a proxy, you may still vote your shares in person if you revoke your
proxy
at or before the Special Meeting.
Tax
Consequences (Page 46)
There
will be no tax consequences to our stockholders resulting from the Merger,
except to the extent they exercise their conversion rights.
A
stockholder who exercises conversion rights will generally be required to
recognize capital gain or loss upon the conversion, if such shares were held
as
a capital asset on the date of the Merger. This gain or loss will be measured
by
the difference between the amount of cash received and the stockholder’s tax
basis in the converted shares. The gain or loss will be short-term gain or
loss
if the acquisition closes as scheduled, but may be long-term gain or loss if
the
closing is postponed.
Accounting
Treatment (Page 56)
The
Merger will be accounted for as a reverse acquisition and equity
recapitalization, with HAQ treated as the “acquired” company for financial
reporting purposes. For accounting purposes, the transaction is being treated
as
an acquisition of assets and not a business combination because HAQ did not
meet
the definition of a business under EITF 98-3, Determination Whether a
Nonmonetary Transaction Involves Receipt of Productive Assets or of a Business.
Accordingly, the transaction has been treated as a capital transaction whereby
PharmAthene is issuing stock for the net monetary assets of HAQ, accompanied
by
a recapitalization.
Risk
Factors (Page 25)
Before
you grant your proxy or vote or instruct the vote with respect to the Merger,
you should be aware that the occurrence of the events described in the “Risk
Factors” section and elsewhere in this proxy statement could have a material
adverse effect on us and PharmAthene.
Relation
of Proposals
Each
of
the the Amendment Proposal and the Incentive Plan Proposal are conditioned
upon
the approval of the Merger Proposal and, in the event the Merger Proposal does
not receive the necessary vote to approve that proposal, then HAQ will not
complete any of the transactions identified in any of the proposals. If
the Amendment Proposal and/or Incentive Plan Proposal is not approved but
the Merger Proposal is approved, we may still consummate the Merger if the
conditions in the Merger Agreement requiring the approval of these proposals
are
waived.
Approval
of PharmAthene’s Stockholders
The
approval of the stockholders and noteholders of PharmAthene is required to
consummate the Merger. More than 80% of the holders of PharmAthene’s common
stock, 100% of its preferred stockholders have previously consented to the
Merger and the Merger Agreement and have agreed among themselves to the
allocation of the Merger Consideration. No further approval is required of
PharmAthene securityholders. A form of the Note Exchange Agreement, to be
executed at closing, and a form of the 8% Convertible Notes, to be issued at
closing, have been agreed upon by the PharmAthene noteholders and HAQ. Further,
the stockholders and noteholders of PharmAthene have agreed to a lockup of
their
shares issuable to them in the Merger under which 50% of the shares will be
released after six months and the remaining shares will be released after 12
months. HAQ has agreed to register the shares issuable to the PharmaAthene
stockholders and note holders following the closing pursuant to the terms of
a
Registration Rights Agreement, the form of which is filed as Exhibit 10.1 to
the
Current Report on Form 8-K, filed with the SEC on January 19, 2007.
Conversion
Rights (Page 49)
Pursuant
to HAQ’s existing amended and restated certificate of incorporation, a holder of
shares of HAQ’s common stock issued in its IPO may, if the stockholder votes
against the Merger Proposal, demand that HAQ convert such shares into a pro
rata
portion of the trust account. This demand must be made on the proxy card at
the
same time that the stockholder votes against the Merger Proposal. We issued
a
total of 9,400,000 shares in our IPO and, other than the 2,250,000 shares issued
to our management, we have no other shares of common stock issued and
outstanding. If properly demanded, HAQ will convert each share of common stock
as to which such demand has been made into a pro rata portion of the trust
account in which a substantial portion of the net proceeds of HAQ’s IPO are
held, plus all interest earned thereon. If you exercise your conversion rights,
then you will be exchanging your shares of HAQ common stock for cash and will
no
longer own these shares. Based on the amount of cash held in the trust account
as of September 30, 2006, without taking into account any interest accrued
after
such date, you would be entitled to convert each share of common stock that
you
hold into approximately $7.48 per share. You will only be entitled to receive
cash for these shares if you continue to hold these shares through the closing
date of the Merger and then tender your stock certificate to HAQ. If the Merger
is not consummated, then these shares will not be converted into cash
immediately. If you convert your shares of common stock, you will still have
the
right to exercise the warrants received as part of the units purchased in our
IPO in accordance with the terms thereof. If the Merger is not consummated,
then
your shares will not be converted to cash after the Special Meeting, even if
you
so elected, and your shares will be converted into cash upon liquidation of
the
trust.
The
Merger will not be consummated if the holders of 1,880,000 or more shares of
common stock issued in HAQ’s IPO, an amount equal to 20% or more of such shares,
vote against the Merger Proposal and exercise their conversion
rights.
Appraisal
or Dissenters’ Rights (Page 49)
No
dissenter’s or appraisal rights are available under the Delaware General
Corporation Law for the stockholders of HAQ in connection with the proposals.
The holders of PharmAthene common stock may be entitled to dissenter’s or
appraisal rights under the Delaware General Corporation Law. However, all of
the
holders of PharmAthene’s classes of preferred stock and stockholders
representing 80% of its outstanding common stock have voted in favor of the
Merger Proposal.
Stock
Ownership
The
following table sets forth information as of _________,
2007,
based
on information obtained from the persons named below, with respect to the
beneficial ownership of shares of HAQ’s common stock by (i) each person known by
us to be the owner of more than 5% of our outstanding shares of HAQ’s common
stock, (ii) each director and (iii) all officers and directors as a group.
Except as indicated in the footnotes to the table, the persons named in the
table have sole voting and investment power with respect to all shares of common
stock shown as beneficially owned by them.
Name
and Address of
Beneficial
Owner (1)
|
|
Amount
and Nature of Beneficial Ownership
|
|
Percent
of Class
|
|
John
Pappajohn (2)
|
|
|
882,000
|
|
|
7.57
|
%
|
Derace
L. Schaffer, M.D. (3)
|
|
|
882,000
|
|
|
7.57
|
%
|
Matthew
P. Kinley (4)
|
|
|
441,000
|
|
|
3.79
|
%
|
Edward
B. Berger (5)
|
|
|
22,500
|
|
|
*
|
|
Wayne
A. Schellhammer
|
|
|
22,500
|
|
|
*
|
|
Sapling,
LLC (6)
|
|
|
681,815
|
|
|
5.85
|
%
|
Fir
Tree Recovery Master Fund, LP (6)
|
|
|
335,185
|
|
|
2.88
|
%
|
All
directors and executive officers as a group (5) persons
|
|
|
2,250,000
|
|
|
19.31
|
%
|
* Represents
beneficial ownership of less than 1%.
(1)
Does
not include shares of common stock issuable upon exercise of warrants which
are
beneficially owned by certain of the persons named in the above table but which
are not exercisable until the later of (i) July 28, 2006 or (ii) the
consummation by us of a business combination (including our acquisition of
PharmAthene). Unless otherwise indicated, the business address of each of the
individuals is 2116 Financial Center, 666 Walnut Street, Des Moines, Iowa
50309.
(2)
Does
not include 141,960 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1
above.
(3)
Does
not include 141,960 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1
above.
(4)
Does
not include 70,980 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1
above.
(5)
Does
not include 12,000 warrants purchased by Mr. Berger in open market purchases.
See footnote 1 above.
(6)
Based
on information contained in a Statement on Schedule 13G filed by Sapling LLC
in
August 2005. Sapling may direct the vote and disposition of the 681,815 shares
of common stock, and Fir Tree Recovery may direct the vote and disposition
of
335,185 shares of common stock. The address of both Sapling LLC and Fir Tree
Recovery is 535 Fifth Avenue, 31st Floor, New York, New York 10017.
All
of
the shares of HAQ common stock held by our officers and directors were placed
in
escrow with Continental Stock Transfer & Trust Company, as escrow agent,
until the earliest of (i) July 28, 2008; or (ii) the consummation of a
liquidation, merger, stock exchange or other similar transaction which results
in all of our stockholders having the right to exchange their shares of common
stock for cash, securities or other property subsequent to our acquisition
of
PharmAthene.
During
the escrow period, the holders of these shares are not able to sell or transfer
their securities except to their spouses and children or trusts established
for
their benefit, but will retain all other rights as our stockholders, including,
without limitation, the right to vote their shares of common stock and the
right
to receive cash dividends, if declared. If dividends are declared and payable
in
shares of common stock, such dividends will also be placed in escrow. If we
are
unable to effect a business combination and liquidate, none of these
stockholders will receive any portion of the liquidation proceeds with respect
to common stock owned by them prior to HAQ’s IPO.
Reasons
for the Merger (Page 54)
No
fairness opinion was sought or obtained by our Board of Directors in reaching
its determination. In reaching its decision with respect to the Merger and
the
transactions contemplated thereby, the Board of Directors reviewed various
industry and financial data and the due diligence and evaluation materials
of
PharmAthene. In addition, in reaching its decision to approve the Merger, the
Board of Directors considered a number of factors including, but not limited
to,
the following:
· |
the
experience of PharmAthene’s management, including David P. Wright,
PharmAthene’s Chief Executive Officer, in building and operating
PharmAthene’s business;
|
· |
PharmAthene’s
existing products, which have been awarded U.S. government
contracts;
|
· |
PharmAthene’s
business strategy;
|
· |
PharmAthene’s
financial results, including potential for revenue growth and operating
margins;
|
· |
PharmAthene’s
competitive position;
|
· |
the industry dynamics, including barriers to
entry; |
· |
the
regulatory environment for
PharmAthene;
|
· |
acquisition
opportunities in the industry;
|
· |
the
valuation of comparable companies;
|
· |
the
experience of HAQ’s management, in particular, Mr. Pappajohn and Dr.
Schaffer, in building, consolidating and investing in similar businesses
in the U.S. including relationships HAQ could introduce to PharmAthene
to
potentially enhance its growth; and
|
· |
the
involvement of certain of the stockholders and noteholders of PharmAthene,
whom HAQ believes represent strong long term investors with experience
in
venture transactions and growth
companies.
|
HAQ’s
Board of Directors believes that the above factors
strongly support its determination and recommendation to approve the
Merger.
HAQ’s
Board of Directors’ Recommendation (Pages 56, 75 and 81)
After
careful consideration of the terms and conditions of the Merger Agreement,
HAQ’s
Board of Directors has determined unanimously that the Merger Agreement and
the
transactions contemplated thereby are fair to, and in the best interests of,
HAQ
and its stockholders. Accordingly, HAQ’s Board has unanimously approved
and declared advisable the Merger and unanimously recommends that the
stockholders vote or instruct their vote to be cast “FOR” the Merger
Proposal.
HAQ’s
Board of Directors has determined unanimously that the Amendment Proposal is
fair to, and in the best interest of HAQ and its stockholders. Accordingly,
HAQ’s Board of Directors has unanimously approved and declared advisable the
Amendment Proposal and unanimously recommends that you vote or instruct your
vote to be cast “FOR” the approval of the Amendment Proposal.
HAQ’s
Board of Directors has determined unanimously that the adoption of the Incentive
Plan is fair to, and in the best interests of, HAQ and its stockholders.
Accordingly, HAQ’s Board of Directors has unanimously approved and declared
advisable the adoption of the Incentive Plan and unanimously recommends that
you
vote or instruct your vote to be cast “FOR” the approval of the Incentive Plan
Proposal.
Interests
of HAQ Directors and Officers in the Merger (Page 53)
When
you
consider the recommendation of HAQ’s Board of Directors that you vote in favor
of the Merger Proposal, you should keep in mind that certain of HAQ’s Directors
and officers have interests in the Merger that are different from, or in
addition to, your interests as a stockholder. It is anticipated that after
the
consummation of the Merger, John Pappajohn and Derace L. Shaffer, MD will remain
on the Board. All other current HAQ Directors will resign. If the Merger is
not
approved, HAQ will be required to liquidate, and the warrants owned by certain
of HAQ’s directors and the shares of common stock issued at a price per share of
$0.0111 prior to HAQ’s IPO to and held by HAQ’s executives and directors will be
worthless because HAQ’s executives and directors are not entitled to receive any
of the net proceeds of HAQ’s IPO that may be distributed upon liquidation of
HAQ. Additionally, HAQ’s officers and directors who acquired shares of HAQ
common stock prior to HAQ’s IPO at a price per share of $0.0111 will benefit if
the Merger is approved because they will continue to hold their shares.
The
table
below sets forth the value of the shares and warrants owned by the officers
and
directors of HAQ upon consummation of the Merger and the unrealized profit
from
such securities based on an assumed market price of the common stock and the
warrants of HAQ, as of February 7, 2007, of $7.34 and $1.36,
respectively.
|
|
Common
Shares (a)
|
|
Warrants
(b)
|
|
|
|
Owned
|
|
Amount
Paid
|
|
Current
Value
|
|
Unrealized
Profit
|
|
Owned
|
|
Amount Paid
|
|
Current
Value
|
|
John
Pappajohn
|
|
|
882,000
|
|
|
9,800
|
|
|
|
|
|
|
|
|
141,960 |
|
|
154,414
|
|
|
|
|
Derrace
L. Schaffer, M.D.
|
|
|
882,000
|
|
|
9,800
|
|
|
|
|
|
|
|
|
141,960 |
|
|
154,414
|
|
|
|
|
Matthew
P. Kinley
|
|
|
441,000
|
|
|
4,900
|
|
|
|
|
|
|
|
|
70,980 |
|
|
77,242
|
|
|
|
|
Edward
B. Berger
|
|
|
22,500
|
|
|
250
|
|
|
|
|
|
|
|
|
12,000 |
|
|
12,917
|
|
|
|
|
Wayne
A. Shellhammer
|
|
|
22,500
|
|
|
250
|
|
|
|
|
|
|
|
|
0 |
|
|
-
|
|
|
|
|
(a)
|
The
purchase price per share for these common shares was $0.0111 per
share.
Pursuant to escrow agreements signed by these stockholders, these
shares
may not be sold or pledged until July 28, 2008. Additionally, these
shares
are currently not registered, although after the release from escrow,
these stockholders may demand that HAQ use its best efforts to register
the resale of such shares.
|
|
|
(b)
|
These
warrants were purchased pursuant to the guidelines set forth in SEC
Rule
10b5-1 in connection with a Rule 10b5-1 Plan.
|
Interests
of PharmAthene Directors and Officers in the Merger
You
should understand that some of the current directors and officers of PharmAthene
have interests in the Merger that are different from, or in addition to, your
interests as a stockholder of HAQ. Following the closing of the Merger, a
majority of the members of the Board of Directors of the combined company will
consist of parties initially designated by PharmAthene or its noteholders.
In
particular, David Wright, PharmAthene’s current Chief Executive Officer, is
expected to become HAQ’s Chief Executive Officer and serve on our Board.
Further, David Wright is expected to enter into an employment agreement with
HAQ
in connection with the Merger.
For
so
long as at least 30% of the 8% convertible notes to be issued in the Merger
remain outstanding, the holders of the 8% convertible notes shall have the
right, as a separate class (and notwithstanding the existence of less than
three
such holders at any given time), to (a) elect three members to the Board of
Directors of HAQ and, (b) to the extent they elect to fill such committee
positions, appoint two of the three members of such committees of the Board.
It
is currently contemplated that Elizabeth Czerepak, Steven St. Peter, MD and
James Cavanaugh, Ph.D., who are currently members of the Board of Directors
of
PharmAthene, will be members of the HAQ Board of Directors following the Merger
as representatives of the noteholders.
In
addition, Elizabeth Czerepak, Steven St. Peter, MD and James Cavanaugh, Ph.D.
are employed by funds affiliated with Bear Stearns Health Innoventures
Management, LLC, MPM Capital L.P. and HealthCare Ventures VII, L.P.,
respectively. Funds affiliated with Bear Stearns Health Innoventures Management,
LLC will beneficially own approximately ___% of the outstanding voting shares
of
the combined company (and __% of the HAQ 8% convertible notes), funds affiliated
with MPM Capital L.P. will beneficially own approximately __% of the outstanding
voting securities of the combined company (and __% of the HAQ 8% convertible
notes) and HealthCare Ventures VII, L.P. will beneficially own approximately
__%
of the outstanding voting securities of the combined company (and __% of the
HAQ
8% convertible notes). Accordingly, these funds will have the ability to
exercise substantial influence over the election of members of the HAQ Board
of
Directors and other issues submitted to the stockholders of the combined
company.
Interests
of Maxim Group in the Merger; Fees
Maxim
served as an underwriter in our IPO and agreed to defer $720,000 of its
underwriting discounts and commissions until after the consummation of a
business combination. Maxim has also served as our financial advisor in
connection with negotiating the Merger. The deferred amount payable in
connection with the IPO will be paid out of the trust account established for
the proceeds of the IPO only if we consummate the Merger. Maxim, therefore,
has
an interest in our consummating the Merger that will result in the payment
of
its deferred compensation. Further, Maxim owns an option to purchase 225,000
units (comprised of one share and one warrant) at an exercise price of $10.00
per unit, received as consideration as underwriters in our IPO.
In
addition to receiving its deferred compensation, Maxim will receive fees of
$500,000 only upon completion of the Merger in consideration for its advisory
services to HAQ in connection with the Merger.
Interest
of The Bear Stearns Companies Inc. in the Merger
Bear,
Stearns & Co. Inc. was retained by PharmAthene to advise PharmAthene in
connection with the negotiations of the terms of the Merger. For its services,
Bear, Stearns & Co. Inc. will receive a fee of $1,250,000 upon completion of
the Merger. Bear
Stearns, therefore, has an interest in our consummating the Merger that will
result in the payment of such fee.
The
Bear
Stearns Companies Inc. is the parent company of Bear, Stearns & Co. Inc. and
Bear Stearns Asset Management, Inc., which is the sole manager of Bear Stearns
Health Innoventures Management, LLC. Funds affiliated with Bear Stearns Health
Innoventures Management, LLC will beneficially own approximately ___% of
the
outstanding voting shares of the combined company (and __% of the HAQ 8%
convertible notes) following the Merger. In addition, Elizabeth Czerepak,
a
general partner of Bear Stearns Health Innoventures Management, LLC, is expected
to be a member of the Board of Directors of HAQ following the
Merger.
Conditions
to the Consummation of the Merger
The
obligations of HAQ and PharmAthene to consummate the Merger are subject to
the
satisfaction or waiver of specified conditions before completion of the Merger,
including the following:
The
respective obligations of each of HAQ and PharmAthene to consummate the Merger
are subject to the satisfaction of, or waiver of, the following
conditions:
· the
receipt of HAQ stockholder approval;
· the
receipt of PharmAthene stockholder approval (which has been obtained and is
irrevocable);
· holders
of the outstanding notes of PharmAthene shall have executed the Note Exchange
Agreement;
· the
outstanding classes of preferred stock of PharmAthene, as well as related
warrants and side agreements are terminated in full; and
· the
absence of any order or injunction preventing consummation of the
merger.
Conditions
to HAQ’s obligations:
The
obligation of HAQ to consummate the Merger is further subject to the following
conditions, among others:
· the
representations and warranties made by PharmAthene must be true and correct
in
all material respects;
· PharmAthene
must have performed in all material respects all obligations required to be
performed by it under the terms of the Merger Agreement;
· there
must not have occurred since the date of the Merger Agreement any material
adverse effect on PharmAthene’s financial condition or business;
and
· PharmAthene
shall have delivered to HAQ executed termination agreements from the holders
of
the PharmAthene preferred stock and noteholders whereby the holders of such
securities terminate all rights under any agreements entered into by PharmAthene
and such preferred stockholders and noteholders.
Conditions
to PharmAthene’s obligations:
The
obligation of PharmAthene to consummate the Merger is further subject to the
following conditions, among others:
· the
representations and warranties made by HAQ and Merger Sub must be true and
correct in all respects;
· HAQ
and
Merger Sub must have performed in all material respects all obligations required
to be performed by it under the terms of the Merger Agreement;
· there
must not have occurred since the date of the Merger Agreement any material
adverse effect on the financial condition or business of HAQ or Merger
Sub;
· the
HAQ
certificate of incorporation shall have been amended and restated to provide
for
board designee rights of the 8% convertible noteholders; and
· the
12,500,000 shares of HAQ common stock issuable in the Merger and the shares
into
which the new 8% convertible notes to be issued in the Merger may be converted
shall have been accepted for listing on the American Stock
Exchange.
Termination,
Amendment and Waiver
The
Merger Agreement may be terminated at any time prior to the consummation of
the
Merger, whether before or after receipt of stockholder approval, as
follows:
· by
mutual
written consent of.
· by
either
party if the Merger is not consummated on or before August 3, 2007;
or
· by
either
party if any permanent injunction or other order of a court or other competent
authority preventing the consummation of the Merger shall have become final
and
nonappealable; or
· by
either
party if during any 15-day trading period following the execution of the Merger
Agreement and before its consummation, the average trading price of the
publicly-traded warrants of HAQ is below $0.20 per warrant.
· by
either
party if the other party has breached any of its covenant or representations
and
warranties in any material respect, subject to certain conditions and a right
to
cure, as further described below; or
· by
either
party if any of the conditions to the consummation of the Merger shall have
become incapable of fulfillment; or
· by
PharmAthene if HAQ has not held its Special Meeting of Stockholders to approve
the Merger Proposal within 35 days of the date of approval of the proxy
statement by the SEC; or
· by
PharmAthene if HAQ’s Board of Directors has withdrawn or changed its
recommendation to it stockholders regarding the Merger; or
· by
PharmAthene if more than 20% of the holders of the shares issued in HAQ’s IPO
entitled to vote on the Merger elect to convert such shares into cash from
the
Trust Fund.
If
permitted under applicable law, either HAQ or PharmAthene may waive conditions
for their own respective benefit and consummate the Merger, even though one
or
more of these conditions have not been met. We cannot assure you that all of
the
conditions will be satisfied or waived or that the Merger will
occur.
In
certain instances, more fully described below, either HAQ or PharmAthene may
be
liable for a termination fee of $250,000.
Regulatory
Matters
We
believe the Merger and the transactions contemplated by the Merger Agreement
are
not subject to any federal or state regulatory requirement or approval, except
for filings necessary to effectuate the transactions contemplated by the Merger
Proposal and the Amendment Proposal with the Secretary of State of the State
of
Delaware.
The
Amendment Proposal
HAQ
is
seeking stockholder approval to amend HAQ’s amended and restated certificate of
incorporation. Any amendment will not become effective unless and until the
Merger with PharmAthene is consummated. The material terms of such amendment
are
to: (i) change HAQ’s name from “Healthcare Acquisition Corp.” to
“PharmAthene, Inc.” (ii) remove certain provisions containing procedural and
approval requirements applicable to HAQ prior to the consummation of the
business combination that will no longer be operative after the consummation
of
the Merger and (iii) grant to holders of certain secured,
convertible promissory notes the right to designate three members to the
Board of Directors of HAQ for so long as at least 30% of the original face value
of such notes remain outstanding.
The
Incentive Plan Proposal
HAQ
is
seeking stockholder approval for the adoption of the Incentive Plan which will
provide for the granting of options and/or other stock-based or
stock-denominated awards. The material terms of such plan are:
· 3,500,000
shares of HAQ common stock will be reserved for issuance;
· the
Incentive Plan will be administered by the HAQ Board of Directors, or a
committee thereof, and any particular term of a grant or award shall be at
the
Board’s discretion; and
· the
Incentive Plan will become effective upon the closing of the Merger with
PharmAthene.
HAQ
is
providing the following financial information to assist you in the analysis
of
the financial aspects of the Merger. We are providing the financial information
related to PharmAthene since, for accounting purposes, PharmAthene will be
deemed the acquiror. We derived PharmAthene’s historical information from the
audited consolidated financial statements of PharmAthene as of and for each
of
the years ended December 31, 2005, December 31, 2004, December 31, 2003 and
the
unaudited financial statements for the nine months ended September 30, 2006.
The
information is only a summary and should be read in conjunction with the
historical consolidated financial statements and related notes contained
elsewhere herein. The historical results included below and elsewhere in
this proxy statement are not indicative of the future performance of
PharmAthene.
Selected
Historical Financials Statements of PharmAthene
|
|
Fiscal
Year Ended December 31,
|
|
|
|
2005
|
|
2004
|
|
2003
|
|
Revenues
|
|
$
|
1,098,400
|
|
$
|
1,037,979
|
|
$
|
7,297,332
|
|
Research
and Development
|
|
|
6,351,157
|
|
|
7,843,863
|
|
|
11,324,559
|
|
General
and Administrative
|
|
|
5,009,267
|
|
|
3,327,571
|
|
|
2,510,112
|
|
Acquired
in process Research and Development
|
|
|
12,812,000
|
|
|
—
|
|
|
—
|
|
Operating
Loss
|
|
|
(23,734,591
|
)
|
|
(10,158,653
|
)
|
|
(6,540,413
|
)
|
Net
Loss attributable to common stockholders
|
|
$
|
(29,052,369
|
)
|
$
|
(12,441,644
|
)
|
$
|
(6,919,129
|
)
|
Net
Loss per share:
|
|
|
|
|
|
|
|
|
|
|
Basic
and Diluted
|
|
$
|
(2.69
|
)
|
$
|
(1.16
|
)
|
$
|
(2.03
|
)
|
Weighted
Average Shares
|
|
|
|
|
|
|
|
|
|
|
Outstanding
basic and diluted
|
|
|
10,817,949
|
|
|
10,740,000
|
|
|
3,401,212
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Assets
|
|
$
|
16,280,234
|
|
$
|
24,016,883
|
|
$
|
7,623,015
|
|
Cash
and cash equivalents
|
|
|
7,938,116
|
|
|
21,662,117
|
|
|
6,971,293
|
|
Total
Liabilities
|
|
|
1,441,327
|
|
|
1,639,689
|
|
|
2,699,814
|
|
Total
Stockholders deficit
|
|
|
(48,108,384
|
)
|
|
(19,899,650
|
)
|
|
(10,342,382
|
)
|
Net
cash used in operating activities
|
|
$
|
(9,990,864
|
)
|
$
|
(12,833,092
|
)
|
$
|
(4,314,514
|
)
|
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
Revenues
|
|
$
|
188,032
|
|
Research
and Development
|
|
|
4,745,628
|
|
General
and Administrative
|
|
|
4,665,292
|
|
Acquired
in process Research and Development
|
|
|
389,975
|
|
Operating
Loss
|
|
|
(9,612,863
|
)
|
Net
Loss attributable to common stockholders
|
|
$
|
(14,710,900
|
)
|
Net
Loss per share:
|
|
|
|
|
Basic
and Diluted
|
|
|
|
) |
Weighted
Average Shares
|
|
|
|
|
Outstanding
basic and diluted
|
|
|
11,123,241
|
|
|
|
|
|
|
Total
Assets
|
|
$
|
19,371,340
|
|
Cash
and cash equivalents
|
|
|
6,505,932
|
|
Total
Liabilities
|
|
|
13,537,643
|
|
Total
Stockholders deficit
|
|
|
(61,595,938
|
)
|
Net
cash used in operating activities
|
|
$
|
(8,667,425
|
)
|
HEALTHCARE
ACQUISITION CORP. SELECTED FINANCIAL DATA
HAQ
is
providing the following selected financial information to assist you in your
analysis of the financial aspects of the merger. The following selected
financial and other operating data should be read in conjunction with
“Healthcare Acquisition Corp.’s Management’s Discussion and Analysis of
Financial Condition and Results of Operations” and
its financial
statements and the related notes to those statements included elsewhere in
this
proxy statement. The statement of operations data for the period from April
25,
2005 (inception) through December 31, 2005 and the balance sheet data as
of
December 31, 2005 have been derived from HAQ’s audited financial statements
included elsewhere in this proxy statement. The statement of operations data
for
the period from April 25, 2005 (inception) through September 30, 2006 and
for
the nine months ended September 30, 2006 and the balance sheet data as of
September 30, 2006 have been derived from HAQ’s unaudited financial statements
included elsewhere in this proxy statement. Interim results are not necessarily
indicative of results for the full fiscal year and historical results are
not
necessarily indicative of results to be expected in any future period.
STATEMENTS
OF OPERATIONS
|
|
For
the Nine
Months
Ended
September
30,
2006
|
|
For
the Period from April 25,
2005 (inception)
to
December
31, 2005
|
|
For
the Period from April 25,
2005 (inception) to
September
30, 2006
|
|
|
|
(unaudited)
|
|
|
|
(unaudited)
|
|
Revenues
|
|
|
|
|
|
|
|
Interest
income
|
|
$
|
37,442
|
|
$
|
19,548
|
|
$
|
56,990
|
|
Interest
and dividend income from Trust Fund
|
|
|
1,318,114
|
|
|
566,526
|
|
|
1,884,640
|
|
Total
revenues
|
|
|
1,355,556
|
|
|
586,074
|
|
|
1,941,630
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs
and expenses
|
|
|
|
|
|
|
|
|
|
|
Capital
based taxes
|
|
|
89,238
|
|
|
115,000
|
|
|
204,238
|
|
Management
fees
|
|
|
67,500
|
|
|
37,986
|
|
|
105,486
|
|
Insurance
|
|
|
71,788
|
|
|
37,500
|
|
|
109,288
|
|
Legal
fees
|
|
|
66,705
|
|
|
9,536
|
|
|
76,241
|
|
Travel
|
|
|
68,958
|
|
|
27,741
|
|
|
96,699
|
|
General
and administrative
|
|
|
56,882
|
|
|
30,516
|
|
|
87,398
|
|
Formation
costs
|
|
|
-
|
|
|
2,500
|
|
|
2,500
|
|
Total
expenses
|
|
|
421,071
|
|
|
260,779
|
|
|
681,850
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
before taxes
|
|
|
934,485
|
|
|
325,295
|
|
|
1,259,780
|
|
Provision
for income taxes
|
|
|
145,000
|
|
|
48,000
|
|
|
193,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income
|
|
$
|
789,485
|
|
$
|
277,295
|
|
$
|
1,066,780
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
earnings per share
|
|
$
|
0.07
|
|
$
|
0.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share
|
|
$
|
0.06
|
|
$
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average basic shares outstanding
|
|
|
11,650,000
|
|
|
7,869,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average diluted shares outstanding
|
|
|
13,758,715
|
|
|
8,323,201
|
|
|
|
|
BALANCE
SHEETS
|
|
|
|
|
|
|
|
|
|
September
30, 2006
|
|
December
31, 2005
|
|
Assets
|
|
(unaudited)
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
763,931
|
|
$
|
1,398,181
|
|
Cash
held in trust
|
|
|
70,283,506
|
|
|
68,636,069
|
|
Prepaid
expense
|
|
|
116,168
|
|
|
52,500
|
|
Total
current assets
|
|
$
|
71,163,605
|
|
$
|
70,086,750
|
|
|
|
|
|
|
|
|
|
Liabilities
and stockholders' equity
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
12,477
|
|
$
|
6,996
|
|
Accrued
expenses
|
|
|
82,996
|
|
|
98,996
|
|
State
income tax payable
|
|
|
108,874
|
|
|
48,000
|
|
Capital
based taxes payable
|
|
|
22,693
|
|
|
115,000
|
|
Deferred
revenue
|
|
|
470,865
|
|
|
141,543
|
|
Total
current liabilities
|
|
|
697,905
|
|
|
410,535
|
|
|
|
|
|
|
|
|
|
Common
stock, subject to possible redemption
|
|
|
|
|
|
|
|
1,879,060
shares, at conversion value
|
|
|
13,578,807
|
|
|
13,578,807
|
|
|
|
|
|
|
|
|
|
Stockholders'
equity
|
|
|
|
|
|
|
|
Preferred
stock, $.0001 par value, 1,000,000 shares authorized; none
|
|
|
|
|
|
|
|
issued
and outstanding
|
|
|
-
|
|
|
-
|
|
Common
stock, $.0001 par value, 100,000,000 shares authorized;
|
|
|
|
|
|
|
|
11,650,000
shares issued and outstanding (which includes 1,879,060
|
|
|
|
|
|
|
|
subject
to possible conversion)
|
|
|
1,165
|
|
|
1,165
|
|
Paid-in
capital in excess of par
|
|
|
55,818,948
|
|
|
55,818,948
|
|
Equity
accumulated during the development stage
|
|
|
1,066,780
|
|
|
277,295
|
|
Total
stockholders' equity
|
|
|
56,886,893
|
|
|
56,097,408
|
|
Total
liabilities and stockholders' equity
|
|
$
|
71,163,605
|
|
$
|
70,086,750
|
|
PRO
FORMA CAPITALIZATION OF COMBINED COMPANY
The
following table sets forth our unaudited total capitalization as of September
30, 2006 on an as adjusted basis to give effect to the consummation of the
Merger, including the pro forma capitalization reflecting maximum and minimum
stockholder approval. The following table does not reflect 3,500,000 shares
of
common stock reserved for the proposed new HAQ Incentive Plan.
|
|
|
|
|
|
After
Merger with
|
|
|
|
PharmAthene,
Inc. Actual (unaudited)
|
|
As
Adjusted (unaudited)
|
|
Minimum
Shareholder Approval
|
|
Maximum
Shareholder Approval
|
|
Minority
Interest - Series C convertible redeemable preferred stock of PHTN
Canada,
par value $0.001 per share; unlimited shares authorized
|
|
$
|
2,507,557
|
|
$
|
2,507,557
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series
A convertible redeemable preferred stock, par value $0.001 per share;
authorized 16,442,000 shares
|
|
$
|
18,736,219
|
|
$
|
18,736,219
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series
B convertible redeemable preferred stock, par value $0.001 per share;
authorized 30,448,147 shares
|
|
$
|
31,051,618
|
|
$
|
31,051,618
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series
C convertible redeemable preferred stock, par value $0.001 per share;
authorized 22,799,574 shares
|
|
$
|
14,259,971
|
|
$
|
14,259,971
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants
to purchase Series C convertible redeemable preferred stock, exercisable
at approx. $0.91 per share
|
|
$
|
874,270
|
|
$
|
874,270
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholder’s
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred
stock $0.0001 par value; authorized 1,000,000; none issued and outstanding
|
|
|
|
|
$ |
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock - $0.0001 par value; authorized 100,000,000 shares; 11,650,000
shares issued and outstanding (which includes 1,879,060 subject to
possible conversion)
|
|
|
|
|
$
|
1,165
|
|
$
|
2,135
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock, par value $0.0001 per share; authorized 147,089,104 shares,
12,483,472 shares issued and outstanding
|
|
$
|
12,483
|
|
$
|
12,483
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
paid-in capital
|
|
|
|
|
|
55,818,947
|
|
|
67,440,916
|
|
|
67,440,916
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
other comprehensive loss
|
|
|
389,720
|
|
|
389,720
|
|
|
389,720
|
|
|
389,720
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retained
Earnings (Accumulated Deficit)
|
|
|
(61,998,141
|
)
|
|
(60,931,361
|
)
|
|
(11,603,626
|
)
|
|
5,427,568
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
stockholders’ equity
|
|
$
|
(61,595,938
|
)
|
$
|
(4,709,045
|
)
|
|
56,229,144
|
|
|
73,260,571
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
capitalization
|
|
$
|
5,833,697
|
|
$
|
62,720,590
|
|
|
56,229,144
|
|
|
73,260,571
|
|
SUMMARY
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION
HAQ
is
providing the following summary unaudited pro forma condensed combined financial
information to assist you in your analysis of the financial aspects of the
Merger. The summary unaudited pro forma condensed combined financial information
has been derived from, and should be read in conjunction with, the unaudited
pro
forma condensed combined financial statements and the related notes thereto
included elsewhere in this proxy statement and is intended to provide you
with a
picture of what HAQ’s business might have looked like had the Merger been
completed on January 1, 2005. The condensed consolidated financial information
may have been different had the Merger actually been completed. You should
not
rely on the selected unaudited pro forma condensed combined financial
information as being indicative of the historical results that would have
occurred had the Merger occurred or of the future results that may be achieved
after the Merger. The pro forma adjustments are preliminary, and the summary
unaudited pro forma condensed combined financial information We have included
financial information taking into account the following two scenarios: (i)
no
stockholders of HAQ elect to convert their shares of common stock into a
pro
rata share of the trust account (maximum approval) and (ii) the maximum number
of stockholders of shares of our outstanding common stock elect to convert
their
shares (minimum approval). If stockholders holding 20% or more of the shares
of
common stock issued in the IPO vote against the Merger Proposal and elect
to
convert their shares, HAQ will not complete the Merger.
|
|
Year
Ended
December
31, 2005
|
|
Nine
Months Ended
September
30, 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum
Approval
|
|
Minimum
Approval
|
|
Maximum
Approval
|
|
Minimum
Approval
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
revenues
|
|
$
|
1,098,400
|
|
$
|
1,098,400
|
|
$
|
188,032
|
|
$
|
188,032
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
expenses
|
|
|
25,336,110
|
|
|
25,336,110
|
|
|
10,221,966
|
|
|
10,221,966
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(24,237,710
|
)
|
|
(24,237,710
|
)
|
|
(10,033,934
|
)
|
|
(10,033,934
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income (expense), net
|
|
|
(33,074
|
)
|
|
(33,074
|
)
|
|
736,730
|
|
|
736,730
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
(24,270,784
|
)
|
|
(24,270,784
|
)
|
|
(9,297,204
|
)
|
|
(9,297,204
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro
forma net loss per common shareholder
|
|
$
|
(1.22
|
)
|
$
|
(1.32
|
)
|
$
|
(0.39
|
)
|
$
|
(0.44
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average
shares outstanding
|
|
|
19,886,400
|
|
|
18,320,429
|
|
|
23,667,200
|
|
|
21,348,850
|
|
Selected
Balance Sheet Data as of September 30, 2006:
|
|
|
|
|
|
Maximum
Approval
|
|
Minimum
Approval
|
|
|
|
|
|
|
|
|
|
|
|
Cash,
cash equivalents and short-term investments
|
|
|
|
|
|
|
|
|
75,553,369
|
|
|
58,521,943
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
assets
|
|
|
|
|
|
|
|
|
88,534,945
|
|
|
71,503,519
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’
equity
|
|
|
|
|
|
|
|
|
73,260,571
|
|
|
56,229,144
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
liabilities
|
|
|
|
|
|
|
|
|
15,274,374
|
|
|
15,274,374
|
|
MARKET
PRICE INFORMATION AND DIVIDEND DATA FOR HAQ SECURITIES
HAQ
consummated its IPO on August 3, 2005. In the IPO, HAQ sold 9,000,000 units,
each consisting of one share of HAQ’s common stock and one warrant to purchase
common stock and on August 16, 2005, HAQ consummated the closing of an
additional 400,000 units that was subject to the underwriters over-allotment
option. The units were quoted on the AMEX from the consummation of the IPO
through October 6, 2005 under the symbol HAQ.U. On October 6, 2005, the common
stock and warrants included in the units began trading separately and the
trading in the units ceased on such date. The shares of HAQ common stock and
warrants are currently quoted on the American Stock Exchange under the symbols
“HAQ” and “HAQ.WT”, respectively. The closing price per share of common stock
and per warrant of HAQ on January 19, 2007, the last trading day before the
announcement of the execution of the Merger Agreement, were $7.46 and $1.60
(the
closing price on January 19, 2007), respectively. Each warrant entitles the
holder to purchase from HAQ one share of common stock at an exercise price
of
$6.00 commencing on the later of the consummation of a business combination
(if
consummated) or July 28, 2006. The HAQ warrants will expire at
5:00 p.m., New York City time, on July 27, 2009, or earlier upon
redemption. Prior to August 1, 2005, there was no established public
trading market for HAQ’s securities.
The
following table sets forth, for the calendar quarter indicated, the quarterly
high and low sales prices of HAQ’s common stock, warrants and units as reported
on the American Stock Exchange.
|
|
Common Stock
|
|
Warrants
|
|
Units
|
|
Quarter Ended
|
|
High
|
|
Low
|
|
High
|
|
Low
|
|
High
|
|
Low
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2006
|
|
$
|
7.40
|
|
$
|
7.04
|
|
$
|
1.35
|
|
$
|
0.78
|
|
|
N/A
|
|
|
N/A
|
|
September 30,
2006
|
|
$
|
8.05
|
|
$
|
7.12
|
|
$
|
2.00
|
|
$
|
1.01
|
|
|
N/A
|
|
|
N/A
|
|
June
30, 2006
|
|
$
|
8.45
|
|
$
|
7.50
|
|
$
|
2.40
|
|
$
|
1.524
|
|
|
N/A
|
|
|
N/A
|
|
March 31,
2006
|
|
$
|
9.08
|
|
$
|
6.96
|
|
$
|
2.52
|
|
$
|
1.40
|
|
|
N/A
|
|
|
N/A
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
2005
|
|
$
|
7.20
|
|
$
|
6.75
|
|
$
|
1.75
|
|
$
|
0.985
|
|
|
N/A
|
|
|
N/A
|
|
September 30,
2005
|
|
$
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
|
|
|
|
|
On
February 7, 2007 the closing prices of our common
stock and warrants were $7.34 and $1.36, respectively.
Holders
As
of
February 5, 2007, the Record Date of the Special Meeting, there were 0 holders
of record of units, 6 holders of record of the common stock and 1 holder of
record of the warrants. We estimate that there are 945 beneficial owners of
our
common stock and __ beneficial owners of our warrants.
Dividends
HAQ
has
not paid any cash dividends on its common stock and does not intend to pay
dividends prior to consummation of the Merger. It is the present intention
of
the Board of Directors to retain all earnings, if any, for use in the business
operations and, accordingly, the Board does not anticipate declaring dividends
in the foreseeable future.
You
should carefully consider the following risk factors, together with all of
the
other information included in this proxy statement, before you decide whether
to
vote or instruct your vote to be cast to adopt the Merger Proposal. As HAQ’s
operations will be those of PharmAthene upon consummation of the Merger, a
number of the following risk factors relate to the business and operations
of
PharmAthene and HAQ, as the successor to such business.
Risks
Related to the Business of PharmAthene
It
is expected that PharmAthene will incur net losses and negative cash flow for
the foreseeable future and we cannot guarantee that we will achieve
profitability.
PharmAthene
has incurred significant losses since it commenced operations. For the year
ended December 31, 2005, PharmAthene incurred an operating loss of approximately
$23.4 million. The pro forma combined accumulated deficit of the combined
company is approximately $60.9 million at September 30, 2006. PharmAthene’s
losses to date have resulted principally from research and development costs
related to the development of its product candidates and general and
administrative costs related to its operations.
It
is
expected that the combined company will incur substantial losses for the
foreseeable future as a result of increases in its research and development
costs, including costs associated with conducting preclinical testing, clinical
trials and regulatory compliance activities.
The
combined company’s likelihood for achieving profitability will depend on
numerous factors, including success in:
· developing
and testing new product candidates;
· carrying
out the combined company’s intellectual property strategy;
· establishing
the combined company’s competitive position;
· pursuing
third-party collaborations;
· acquiring
or in-licensing products;
· receiving
regulatory approvals;
· manufacturing
and marketing products; and
· continuing
to receive government funding and identifying new government funding
opportunities.
Many
of
these factors will depend on circumstances beyond the combined company’s
control. We cannot guarantee that we will achieve sufficient revenues for
profitability. Even if we do achieve profitability, we cannot guarantee that
we
can sustain or increase profitability on a quarterly or annual basis in the
future. If revenues grow slower than we anticipate, or if operating expenses
exceed our expectations or cannot be adjusted accordingly, then our business,
results of operations, financial condition and cash flows will be materially
and
adversely affected. Because our strategy might include acquisitions of other
businesses, acquisition expenses and any cash used to make these acquisitions
will reduce our available cash.
PharmAthene
is in various stages of product development and there can be no assurance of
successful commercialization.
In
general, PharmAthene’s research and development programs are at an early stage
of development. To obtain FDA approval for PharmAthene’s biological warfare
defense products under the current FDA regulation, we will be required to
perform two animal models and provide animal and human safety data.
PharmAthene’s other products will be subject to the relevant approval guidelines
under FDA regulatory requirements which include a number of phases of testing
in
humans.
PharmAthene
has not commercialized any products or recognized any revenue from product
sales. Valortim™, PharmAthene’s anthrax treatment, is currently in late
preclinical and early clinical stages of development. PharmAthene expects that
it must conduct significant additional research and development activities
before it will be able to receive final regulatory approval to commercialize
Valortim™. In addition, Protexia, Pharmathene’s nerve agent countermeasure, is
in the pre-clinical stage of development and must also undergo clinical trials
and receive regulatory approval before it can be commercialized.
Other
than the Valortim™ product candidate, the research and development program for
PharmAthene is at an early stage of development. Other drug candidates developed
by the combined company will require significant additional research and
development efforts, including extensive pre-clinical and clinical testing
and
regulatory approval, prior to commercial sale. HAQ cannot be sure the approach
of PharmAthene to drug discovery will be effective or will result in the
development of any drug. HAQ does not expect that any drugs resulting from
the
research and development efforts of PharmAthene will be commercially available
for many years, if at all.
Even
if
PharmAthene receives initially positive pre-clinical or clinical results, such
results do not indicate that similar results will be obtained in the later
stages of drug development, such as additional pre-clinical testing or human
clinical trials.
All
of
PharmAthene’s potential product candidates will be prone to the risks of failure
inherent in pharmaceutical product development, including the possibility that
none of its product candidates will or can:
· be
safe,
non-toxic and effective and otherwise meet applicable regulatory
standards;
· develop
into commercially viable drugs;
· be
manufactured or produced economically and on a large scale;
· be
successfully marketed; and
· achieve
customer acceptance.
Even
if
PharmAthene succeeds in developing and commercializing its product candidates,
it may never generate sufficient or sustainable revenue to enable it to be
profitable.
Furthermore,
even if the product candidates of PharmAthene are successful when tested in
animals, such success would not be a guarantee of the effectiveness and safety
of such product candidates in humans. PharmAthene’s first product, its Dominate
Negative Inhibitor (“DNI”), was demonstrated to be effective in animal testing,
but was determined to be unsafe for humans following clinical trials in human
subjects. The DNI program was subsequently terminated. There can be no
assurances that one or more of PharmAthene’s future product candidates would not
similarly fail to meet safety standards in human testing, even if those product
candidates were found to be effective in animal studies. Nor can there be any
assurances that any such product candidates will prove to be effective in
humans.
Most
of PharmAthene’s immediately foreseeable future revenues are contingent upon
grants and contracts from the U.S. government and collaborative and license
agreements and PharmAthene may not achieve sufficient revenues from these
agreements to attain profitability.
Until
and
unless PharmAthene successfully markets a product, its ability to generate
revenues will largely depend on its ability to enter into additional
collaborative agreements, strategic alliances, research grants, contracts and
license agreements with third parties, including, without limitation, the U.S.
government and branches and agencies thereof, and maintain the agreements it
currently has in place. Substantially all of the revenue of PharmAthene for
the
years ended December 31, 2005, 2004 and 2003, respectively, were derived from
revenues related to grants, contracts and license agreements.
In
addition, PharmAthene’s business plan calls for significant payments from
milestone based collaborative agreements. PharmAthene may not earn significant
milestone payments under its existing collaborative agreements until its
collaborators have advanced products into clinical testing, which may not occur
for many years, if at all.
PharmAthene
has a material agreement with Medarex, Inc., to develop Valortim™, its fully
human monoclonal antibody product designed to protect against and treat
inhalation anthrax. Under the agreement with Medarex, PharmAthene will be
entitled to a variable percentage of profits derived from sales of Valortim™,
depending on the amount of its investment. In addition, PharmAthene has entered
into licensing and research and development agreements with a number of other
parties and collaborators.
PharmAthene
may need additional capital in the future. If additional capital is not
available or not available on acceptable terms, PharmAthene may be forced to
delay or curtail the development of its product
candidates.
PharmAthene’s
requirements for additional capital may be substantial and will depend on many
other factors, including:
· continued
funding by the Department of Defense and other branches and agencies of the
U.S.
Government;
· payments
received under present or future collaborative partner agreements;
· continued
progress of research and development of PharmAthene’s products;
· PharmAthene’s
ability to license compounds or products from others;
· costs
associated with protecting PharmAthene’s intellectual property
rights;
· development
of marketing and sales capabilities; and
· market
acceptance of PharmAthene’s products.
To
the
extent PharmAthene’s capital resources are insufficient to meet future capital
requirements, it will have to raise additional funds to continue the development
of its product candidates. We cannot assure you that funds will be available
on
favorable terms, if at all. To the extent PharmAthene raises additional capital
through the sale of securities, the issuance of those securities could result
in
dilution which may be substantial to the PharmAthene’s stockholders. In
addition, if PharmAthene incurs debt financing, a substantial portion of its
operating cash flow may be dedicated to the payment of principal and interest
on
such indebtedness, thus limiting funds available for PharmAthene’s business
activities. If adequate funds are not available, PharmAthene may be required
to
curtail significantly its development and commercialization
activities.
Biodefense
treatment and drug development is an expensive and uncertain process, and delay
or failure can occur at any stage of the combined company’s development
process.
To
develop biodefense treatment and drug candidates, PharmAthene must provide
the
FDA and foreign regulatory authorities with clinical data that demonstrates
adequate safety and immune response. Because humans are not normally exposed
to
anthrax, nerve agents, smallpox or to other lethal biotoxins or chemical agents,
statistically significant effectiveness of PharmAthene’s biodefense product
candidates cannot be demonstrated in humans, but instead must be demonstrated,
in part, by utilizing animal models before they can be approved for commercial
sale. In addition, because the effectiveness of PharmAthene’s’s biodefense
product candidates cannot be demonstrated in humans, PharmAthene will not know
the long term adverse reactions to its products. Additionally, few facilities
in
the U.S. have the capability of testing animals with anthrax or nerve agent
exposure. PharmAthene may not be able to secure clinical contracts to conduct
the testing in a predictable timeframe or at all.
Even
if PharmAthene completes
the development of its products, if the U.S. government does not purchase
sufficient quantities of its nerve agent countermeasure and anthrax treatment
products, PharmAthene may
be unable to generate sufficient revenues to continue
operations.
Changes
in government budgets and agendas may result in a decreased and de-prioritized
emphasis on procuring the biodefense products PharmAthene will develop.
Government contracts typically contain provisions that permit cancellation
in
the event that funds are unavailable to the governmental agency. Furthermore,
PharmAthene cannot be certain of the timing of any purchases. Additionally,
substantial delays or cancellations of purchases could result from protests
or
challenges from third parties. If the U.S. government fails to purchase
PharmAthene’s products, it may be unable to generate sufficient revenues to
continue operations. Similarly, if PharmAthene develops products that are
approved by the FDA, but the U.S. government does not place sufficient orders
for these products, PharmAthene’s future business will be harmed.
PharmAthene
may fail to obtain contracts to supply the strategic national stockpiles of
anthrax treatments to the U.S. government.
The
U.S.
government has undertaken commitments to help secure improved countermeasures
against bioterrorism, including the stockpiling of treatments and vaccines
for
anthrax through a program known as the Strategic National Stockpile. However,
the process of obtaining government contracts is lengthy and uncertain and
PharmAthene will have to compete for each contract. PharmAthene cannot be
certain that it will be awarded any contracts to supply a government stockpile
of anthrax treatment. It is possible that future awards to provide the U.S.
government with emergency stockpiles of anthrax treatments will be granted
solely to other suppliers. If the U.S. government makes significant future
contract awards for the supply of its emergency stockpile to PharmAthene’s
competitors, PharmAthene’s business will be harmed and it is unlikely that
PharmAthene will ultimately be able to commercialize that particular treatment
or product.
U.S.
government agencies have special contracting requirements, which create
additional risks.
PharmAthene
anticipates that its primary sales will be to the U.S. government. U.S.
government contracts typically contain unfavorable termination provisions and
are subject to audit and modification by the government at its sole discretion,
which will subject PharmAthene to additional risks. These risks include the
ability of the U.S. government to unilaterally:
· suspend
or prevent PharmAthene for a set period of time from receiving new contracts
or
extending existing contracts based on violations or suspected violations of
laws
or regulations;
· terminate
PharmAthene’s contracts;
· reduce
the scope and value of PharmAthene’s contracts;
· audit
and
object to PharmAthene’s contract-related costs and fees, including allocated
indirect costs;
· control
and potentially prohibit the export of PharmAthene’s products; and
· change
certain terms and conditions in PharmAthene’s contracts.
The
U.S.
government will be able to terminate any of its contracts with PharmAthene
either for its convenience or if PharmAthene defaults by failing to perform
in
accordance with the contract schedule and terms. Termination for convenience
provisions would generally enable PharmAthene to recover only PharmAthene’s
costs incurred or committed, and settlement expenses and profit on the work
completed prior to termination. Termination for default provisions do not permit
these recoveries and would make PharmAthene liable for excess costs incurred
by
the U.S. government in procuring undelivered items from another
source.
Delays
in successfully completing PharmAthene’s clinical trials could jeopardize its
ability to obtain regulatory approval or market its product candidates on a
timely basis.
PharmAthene
will not be able to successfully commercialize its products without first
demonstrating adequate evidence of effectiveness in animal models, and in
certain cases, demonstrating safety and immune response in humans through
clinical trials. Any delay or adverse clinical events arising during any of
its
clinical trials could force PharmAthene to abandon a product altogether or
to
conduct additional clinical trials in order to obtain approval from the FDA
or
other regulatory bodies. These clinical trials are lengthy and expensive, and
the outcome is uncertain.
Completion
of PharmAthene’s clinical trials, announcement of results of the trials and
PharmAthene’s ability to obtain regulatory approvals could be delayed for a
variety of reasons, including:
· slower-than-anticipated
enrollment of volunteers in the trials;
· lower-than-anticipated
recruitment or retention rate of volunteers in the trials;
· adverse
events related to the products;
· unsatisfactory
results of any clinical trial;
· mistakes
or delays on the part of third-party investigators that perform PharmAthene’s
clinical trials; or
· different
interpretations of PharmAthene’s preclinical and clinical data, which could
initially lead to inconclusive results.
PharmAthene’s
development costs will substantially increase if it has material delays in
any
clinical trial or if it needs to perform more or larger clinical trials than
planned. If the delays are significant, or if any of PharmAthene’s products do
not prove to be safe or effective or do not receive required regulatory
approvals, PharmAthene’s financial results and the commercial prospects for its
product candidates will be harmed. Furthermore, PharmAthene’s inability to
complete its clinical trials in a timely manner could jeopardize its ability
to
obtain regulatory approval.
PharmAthene
may fail to fully realize the potential of Valortim™ and of its co-development
arrangement with its partner in the development of
Valortim™.
PharmAthene
and its development partner have completed the first Phase I clinical trial
for
Valortim without any reported adverse reactions. However, before it may begin
selling any doses of Valortim, it will need to conduct a more comprehensive
Phase I trial to a significantly larger group of subjects. PharmAthene will
be
required to expend a significant amount to scale up manufacturing capability
through a contract manufacturer in order to conduct the more extensive Phase
I
clinical trial. PharmAthene does not expect to commence this trial until 2008.
If PharmAthene’s contract manufacturer is unable to produce sufficient
quantities at a reasonable cost, then PharmAthene will be unable to commence
the
necessary clinical trials necessary to begin marketing Valortim. Even after
PharmAthene expends the sufficient funds to complete the development of Valortim
and when and if it enters into an agreement to market Valortim to the U.S,
government, it will be required to share any and all profits from the sale
of
products with its partner in accordance with a pre-determined formula.
If
PharmAthene cannot enter into new licensing arrangements, its ability to develop
a diverse product portfolio could be limited.
A
component of PharmAthene’s business strategy will be in-licensing compounds and
products developed by other pharmaceutical and biotechnology companies or
academic research laboratories that may be marketed and developed or improved
upon using PharmAthene’s novel technologies. Competition for promising compounds
or products can be intense. If PharmAthene is not able to identify new licensing
opportunities or enter into other licensing arrangements on acceptable terms,
it
may be unable to develop a diverse portfolio of products.
PharmAthene
will face competition from several companies with greater financial, personnel
and research and development resources.
The
biopharmaceutical industry is characterized by rapid and significant
technological change. PharmAthene’s success will depend on its ability to
develop and apply its technologies in the design and development of its product
candidates and to establish and maintain a market for its product candidates.
There also are many companies, both public and private, including major
pharmaceutical and chemical companies, specialized biotechnology firms,
universities and other research institutions engaged in developing
pharmaceutical and biotechnology products. Many of these companies have
substantially greater financial, technical, research and development, and human
resources than those of PharmAthene. Competitors may develop products or other
technologies that are more effective than any that are being developed by
PharmAthene or may obtain FDA approval for products more rapidly. If PharmAthene
commences commercial sales of products, it still must compete in the
manufacturing and marketing of such products, areas in which it has limited
experience. Many of these companies also have manufacturing facilities and
established marketing capabilities that would enable such companies to market
competing products through existing channels of distribution. PharmAthene’s
commercial opportunities will be reduced or eliminated if its competitors
develop and market products for any of the harmful effects that it targets
that:
· are
more
effective;
· have
fewer or less severe adverse side effects;
· are
more
adaptable to various modes of dosing;
· are
easier to administer; or
· are
less
expensive than the products or product candidates PharmAthene will be
developing.
Even
if
PharmAthene is successful in developing effective products, and obtains FDA
and
other regulatory approvals necessary for commercializing them, its products
may
not compete effectively with other successful products. PharmAthene’s
competitors may succeed in developing and marketing products either that are
more effective than those that it may develop, alone or with its collaborators,
making its products obsolete, or that are marketed before any products that
PharmAthene develops are marketed.
Companies
that are developing products that would compete with PharmAthene’s products
include: VaxGen, Inc., which is developing vaccines against anthrax and
smallpox; Avant Immunotherapeutics, Inc., which has vaccine programs for agents
of biological warfare, including plague and anthrax; Human Genome Sciences,
Inc., Elusys Therapeutics, Inc. and AVANIR Pharmaceuticals, Inc., all of which
are developing monoclonal antibodies as anthrax treatments. Other competitors
of
PharmAthene include: Emergent Biosolutions Inc., Merck & Co., Inc., Bio
Sante Pharmaceuticals, Inc., Dynport Vaccine Company, LLC (“DVC”) and Ligocyte
Pharmaceuticals, Inc.
Political
or social factors may delay or impair PharmAthene’s ability to market its
products.
Products
developed to treat diseases caused by, or to combat the threat of, bioterrorism
will be subject to changing political and social environments. The political
and
social responses to bioterrorism have been unpredictable. Political or social
pressures may delay or cause resistance to bringing PharmAthene’s products to
market or limit pricing of its products, which would harm PharmAthene’s
business.
The
U.S. government’s determination to award any contracts to PharmAthene may be
challenged by an interested party, such as another bidder, at the General
Accounting Office or in federal court.
The
laws
and regulations governing the procurement of goods and services by the U.S.
government provide procedures by which other bidders and other interested
parties may challenge the award of a government contract. In the event that
PharmAthene is awarded a government contract, such protests could be filed
even
if there are not any valid legal grounds on which to base the protest. If any
such protests are filed, the government agency may decide to suspend
PharmAthene’s performance under the contract while such protests are being
considered by the General Accounting Office or the applicable federal court,
thus potentially delaying delivery of goods and services and payment. In
addition, PharmAthene could be forced to expend considerable funds to defend
any
potential award. If a protest is successful, the government may be ordered
to
terminate PharmAthene’s contract at its convenience and reselect bids. The
government could even be directed to award a potential contract to one of the
other bidders.
Failure
to hire and retain key management employees could adversely affect PharmAthene’s
ability to obtain financing, develop its products, conduct clinical trials
or
execute its business strategy.
PharmAthene
will be highly dependent on its senior management and scientific staff. These
individuals have played a critical role in raising capital, negotiating business
development opportunities, developing the product candidates, conducting
clinical trials and manufacturing product candidates for PharmAthene.
PharmAthene will face intense competition for qualified personnel, and the
existence of non-competition agreements between prospective employees and their
former employers may prevent PharmAthene from hiring those individuals or
subject it to suit from their former employers. PharmAthene likely will not
maintain non-compete agreements with any of its employees. If PharmAthene loses
the services of any key members of its senior management or scientific staff,
temporarily or permanently, and it is unable to recruit qualified replacements
where it deems it necessary, PharmAthene may be unable to achieve its business
objectives.
PharmAthene
may have difficulty managing its growth.
PharmAthene
expects to experience growth in the number of its employees and the scope of
its
operations. This future growth could place a significant strain on PharmAthene’s
management and operations. Its ability to manage this growth will depend upon
its ability to broaden its management team and its ability to attract, hire
and
retain skilled employees. PharmAthene’s success will also depend on the ability
of its officers and key employees to continue to implement and improve its
operational and other systems and to hire, train and manage its
employees.
Legal
and Regulatory Risks of Development Stage Biotechnology
Companies
PharmAthene’s
patents and proprietary technology may be subject to challenges by
others.
The
patent position of biotechnology firms generally is highly uncertain and
involves complex legal and factual questions. To date, no consistent policy
has
emerged regarding the breadth of claims allowed in biotechnology patents.
Accordingly, there can be no assurance that patent applications owned or
licensed by PharmAthene will result in patents being issued or that, if issued,
the patents will afford protection against competitors with similar technology.
PharmAthene
is aware of one U.S. patent covering recombinant production of an antibody,
which, it has been argued, covers any reproduction of an antibody, as well
as
another U.S. patent application with claims over pegylated
butyrylcholinesterase. Although PharmAthene believes that neither Valortim,
which is a monoclonal antibody and uses recombinant reproduction of antibodies,
nor Protexia, which uses pegylated butyrylcholinesterase technology, infringes
on any valid claims of such patents, PharmAthene cannot provide any assurances
that if a legal action based on either of these two patents is brought against
PharmAthene or its distributors, licensees or collaborators, such action or
actions would be resolved in PharmAthene’s favor. If such a dispute were
resolved against PharmAthene, in addition to potential damages, the clinical
testing, manufacturing or sale of Valortim and Protexia, as applicable, could
be
enjoined unless, in each case, as applicable a license is obtained. There can
be
no assurances that if a license is required, any such license would be made
available on terms acceptable to PharmAthene.
Any
inability to protect PharmAthene’s intellectual property could harm its
competitive position and adversely affect its
business.
PharmAthene’s
success will depend, in part, on its ability to obtain patents and maintain
adequate protection of other intellectual property for its technologies and
products in the U.S. and other countries. If PharmAthene does not adequately
protect its intellectual property, competitors may be able to use its
technologies and erode or negate its competitive advantages. Further, the laws
of some foreign countries will not protect PharmAthene’s proprietary rights to
the same extent as the laws of the U.S., and PharmAthene may encounter
significant problems in protecting its proprietary rights in these foreign
countries.
The
patent positions of pharmaceutical and biotechnology companies, including
PharmAthene’s patent positions, involve complex legal and factual questions and,
therefore, validity and enforceability cannot be predicted with certainty.
Patents may be challenged, deemed unenforceable, invalidated or circumvented.
PharmAthene will be able to protect its proprietary rights from unauthorized
use
by third parties only to the extent that it covers its proprietary technologies
with valid and enforceable patents or that it effectively maintains such
proprietary technologies as trade secrets. PharmAthene will apply for patents
covering its technologies and product candidates as it deems appropriate.
PharmAthene may fail to apply for patents on important technologies or products
in a timely fashion, or at all, and in any event, the applications PharmAthene
files may be challenged and may not result in issued patents. Any future patents
PharmAthene obtains may not be sufficiently broad to prevent others from
practicing its technologies or from developing competing products. Furthermore,
others may independently develop similar or alternative technologies or design
around PharmAthene’s patented technologies. In addition, if challenged,
PharmAthene’s patents may be declared invalid. Even if valid, PharmAthene’s
patents may fail to provide it with any competitive advantages.
PharmAthene
will rely upon trade secrets protection for its confidential and proprietary
information. PharmAthene has taken measures to protect their proprietary
information; however, these measures may not provide adequate protection to
PharmAthene. The companies have sought to protect their proprietary information
by entering into confidentiality agreements with employees, collaborators and
consultants. Nevertheless, employees, collaborators or consultants may still
disclose the companies’ proprietary information, and PharmAthene may not be able
to meaningfully protect its trade secrets. In addition, others may independently
develop substantially equivalent proprietary information or techniques or
otherwise gain access to PharmAthene’s trade secrets.
If
the technologies of PharmAthene or of its collaborators are alleged or found
to
infringe the patents or proprietary rights of others, PharmAthene may be sued
or
have to license those rights from others on unfavorable
terms.
The
commercial success of PharmAthene will depend significantly on its ability
to
operate without infringing the patents and proprietary rights of third parties.
The technologies of PharmAthene, along with the technologies of its licensors
and collaborators, may infringe the patents or proprietary rights of others.
If
there is an adverse outcome in litigation or an interference to determine
priority or other proceeding in a court or patent office, then PharmAthene,
or
its collaborators and licensors, could be subjected to significant liabilities,
required to license disputed rights from or to other parties and/or required
to
cease using a technology necessary to carry out research, development and
commercialization. PharmAthene is aware of one U.S. patent covering recombinant
production of an antibody, which, it has been argued, covers any reproduction
of
an antibody, as well as another U.S. patent application with claims over
pegylated butyrylcholinesterase. PharmAthene believes that neither Valortim,
which is a monoclonal antibody and uses recombinant reproduction of antibodies,
nor Protexia, which uses pegylated butyrylcholinesterase technology, infringes
on any valid claims of such patents. PharmAthene is not aware of any other
potential infringement claims against it.
The
costs
to establish the validity of patents, to defend against patent infringement
claims of others and to assert infringement claims against others can be
expensive and time consuming, even if the outcome is favorable. An outcome
of
any patent prosecution or litigation that is unfavorable to PharmAthene or
one
of their licensors or collaborators may have a material adverse effect on
PharmAthene. PharmAthene could incur substantial costs if it is required to
defend itself in patent suits brought by third parties, if it participates
in
patent suits brought against or initiated by their licensors or collaborators
or
if it initiates such suits. PharmAthene may not have sufficient funds or
resources in the event of litigation. Additionally, PharmAthene may not prevail
in any such action.
Any
conflicts resulting from third-party patent applications and patents could
significantly reduce the coverage of the patents owned, optioned by or licensed
to PharmAthene or its collaborators and limit the ability of PharmAthene or
that
of its collaborators to obtain meaningful patent protection. If patents are
issued to third parties that contain competitive or conflicting claims,
PharmAthene, its licensors or collaborators may be legally prohibited from
researching, developing or commercializing potential products or be required
to
obtain licenses to these patents or to develop or obtain alternative technology.
PharmAthene, its licensors and/or its collaborators may be legally prohibited
from using patented technology, may not be able to obtain any license to the
patents and technologies of third parties on acceptable terms, if at all, or
may
not be able to obtain or develop alternative technologies.
PharmAthene’s
use of hazardous materials and chemicals require it to comply with regulatory
requirements and expose it to potential liabilities.
PharmAthene’s
research and development involves the controlled use of hazardous materials
and
chemicals. PharmAthene will be subject to federal, state, local and foreign
laws
governing the use, manufacture, storage, handling and disposal of such
materials. PharmAthene will not be able to eliminate the risk of accidental
contamination or injury from these materials. In the event of such an accident,
PharmAthene could be held liable for significant damages or fines, and these
damages could exceed its resources and any applicable insurance coverage. In
addition, PharmAthene may be required to incur significant costs to comply
with
regulatory requirements in the future.
PharmAthene
may become subject to product liability claims, which could reduce demand for
its product candidates or result in damages that exceed its insurance
coverage.
PharmAthene
will face an inherent risk of exposure to product liability suits in connection
with its products being tested in human clinical trials or sold commercially.
PharmAthene may become subject to a product liability suit if any product it
develops causes injury, or if treated individuals subsequently become infected
or otherwise suffer adverse effects from its products. Regardless of merit
or
eventual outcome, product liability claims may result in decreased demand for
a
product, injury to PharmAthene’s reputation, withdrawal of clinical trial
volunteers and loss of revenues.
If
a
product liability claim is brought against PharmAthene, the cost of defending
the claim could be significant and any adverse determination may result in
liabilities in excess of its insurance coverage. Additionally, PharmAthene
will
be applying for indemnification under the Support Anti-terrorism by Fostering
Effective Technologies Act of 2002 which preempts and modifies tort laws so
as
to limit the claims and damages potentially faced by companies who provide
certain “qualified” anti-terrorism products. However, PharmAthene cannot to be
certain that it will be able to obtain or maintain adequate insurance coverage
on acceptable terms, if at all.
Legislation
limiting or restricting liability for medical products used to fight
bioterrorism is new, and PharmAthene cannot be certain that any such protection
will apply to its products.
The
Public Readiness and Emergency Preparedness Act (“Public Readiness Act”) was
signed into law in December 2005 and creates general immunity for manufacturers
of countermeasures, including security countermeasures (as defined in Section
319F-2(c)(1)(B)), when the Secretary of Defense issues a declaration for their
manufacture, administration or use. The declaration is meant to provide general
immunity from all claims under state or federal law for loss arising out of
the
administration or use of a covered countermeasure. Manufacturers are excluded
from this protection in cases of willful misconduct.
Upon
a
declaration by the Secretary of Health and Human Services, a compensation fund
is created to provide “timely, uniform, and adequate compensation to eligible
individuals for covered injuries directly caused by the administration or use
of
a covered countermeasure.” The “covered injuries” to which the program applies
are defined as serious physical injuries or death. Individuals are permitted
to
bring a willful misconduct action against a manufacturer only after they have
exhausted their remedies under the compensation program. A willful misconduct
action could be brought against us if an individual(s) has exhausted their
remedies under the compensation program which thereby could expose us to
liability. PharmAthene may become subject to standard product liability suits
and other third party claims if products it develops which fall outside of
the
Public Readiness Act cause injury or if treated individuals subsequently become
infected or otherwise suffer adverse effects from such products.
PharmAthene
may be subject to claims that it or its employees wrongfully used or disclosed
alleged trade secrets of the employees’ former
employers.
As
is
commonplace in the biotechnology industry, PharmAthene employs individuals
who
were previously employed at other biotechnology or pharmaceutical companies,
including their competitors or potential competitors. Although no claims against
PharmAthene are currently pending, PharmAthene may be subject to claims that
these employees or it have inadvertently or otherwise used or disclosed trade
secrets or other proprietary information of their former employers. Litigation
may be necessary to defend against these claims. Even if PharmAthene is
successful in defending against these claims, litigation could result in
substantial costs and be a distraction to management.
If
PharmAthene experiences delays in obtaining regulatory approvals, or is unable
to obtain or maintain regulatory approvals, it may be unable to commercialize
any products.
PharmAthene
will need to conduct a substantial amount of additional research and development
before any U.S. or foreign regulatory authority will approve any of its
products. In addition, PharmAthene’s product candidates will be subject to
extensive and rigorous domestic government regulation. Results of PharmAthene’s
research and development activities may indicate that its potential products
are
unsafe or ineffective. In this case, regulatory authorities will not approve
them. Even if approved, PharmAthene’s products may not be commercially
successful. If PharmAthene fails to develop and commercialize its products,
it
may be forced to curtail or cease operations.
In
addition, the commencement and rate of completion of clinical trials for
PharmAthene’s products may be delayed by many factors, including:
· lack
of
efficacy during the clinical trials in animals;
· unsatisfactory
results of any clinical trial;
· unforeseen
safety issues;
· slower
than expected rate of patient recruitment; or
· government
or regulatory delays.
· Delays
in
obtaining regulatory approvals may:
· adversely
affect the commercialization of any products that PharmAthene or its
collaborative partners develop;
· impose
costly procedures on PharmAthene or its collaborative partners;
· diminish
any competitive advantages that PharmAthene or its collaborative partners may
attain; and
· adversely
affect PharmAthene’s receipt of revenues or royalties.
The
results from preclinical testing and early clinical trials are often not
predictive of results obtained in later clinical trials. Although a new product
may show promising results in initial clinical trials, it may subsequently
prove
unfeasible or impossible to generate sufficient safety and efficacy data to
obtain necessary regulatory approvals. Data obtained from preclinical and
clinical studies are susceptible to varying interpretations, which may delay,
limit or prevent regulatory approval. In addition, PharmAthene may encounter
regulatory delays or rejections as a result of many factors, including results
that do not support its claims, perceived defects in the design of clinical
trials and changes in regulatory policy during the period of product
development. PharmAthene’s business, financial condition, prospects and results
of operations may be materially adversely affected by any delays in, or
termination of, its clinical trials or a determination by the FDA that the
results of PharmAthene’s trials are inadequate to justify regulatory
approval.
Any
required approvals, once obtained, may be withdrawn. Further, if the companies
fail to comply with applicable FDA and other regulatory requirements at any
stage during the regulatory process, it may encounter difficulties including:
· delays
in
clinical trials or commercialization;
· product
recalls or seizures;
· suspension
of production and/or distribution;
· withdrawals
of previously approved marketing applications; and
· fines,
civil penalties and criminal prosecutions.
PharmAthene’s
collaborative partners may not be able to conduct clinical testing or obtain
necessary approvals from the FDA or other regulatory authorities for any product
candidates. If PharmAthene fails to obtain required governmental approvals,
it
or its collaborative partners will experience delays in, or be precluded from,
marketing products developed through it or, as applicable, their
research.
PharmAthene
and its contract manufacturers will also be required to comply with the
applicable FDA good manufacturing practice regulations. Good manufacturing
practice regulations include requirements relating to quality control and
quality assurance as well as the corresponding maintenance of records and
documentation. Manufacturing facilities are subject to inspection by the FDA.
These facilities must be approved before PharmAthene will be able to use them
in
commercial manufacturing of their products. PharmAthene and its contract
manufacturers may not be able to comply with the applicable good manufacturing
practice requirements and other FDA regulatory requirements. If PharmAthene
and
its contract manufacturers fail to comply, they could be subject to fines or
other sanctions, or be precluded from marketing their products.
PharmAthene
may be required to perform additional clinical trials or change the labeling
of
its products if it or others identify side effects after its products are on
the
market, which could harm sales of the affected
products.
If
PharmAthene or others identify side effects after any of its products are on
the
market, or if manufacturing problems occur:
· regulatory
approval may be withdrawn;
· reformulation
of the affected products, additional clinical trials, or changes in labeling
of
PharmAthene’s products may be required;
· changes
to or re-approvals of PharmAthene’s manufacturing facilities may be
required;
· sales
of
the affected products may drop significantly;
· PharmAthene’s
reputation in the marketplace may suffer; and
· lawsuits,
including class action suits, may be brought against PharmAthene.
Any
of
the above occurrences could harm or prevent sales of the affected products
or
could increase the costs and expenses of commercializing and marketing these
products.
Risks
Particular to the Merger
HAQ
stockholders will experience immediate dilution as a consequence of the issuance
of shares of HAQ common stock as consideration in the Merger. Having a minority
share position may reduce the influence that HAQ’s current stockholders have on
the management of the combined company.
Following
the consummation of the Merger, the influence of HAQ’s current stockholders, in
their capacity as stockholders of the combined company, will be significantly
limited. HAQ’s current stockholders will hold, in the aggregate, at most 48% of
the issued and outstanding shares of the combined company.
Moreover,
following the Merger, funds affiliated with MPM Capital, L.P., HealthCare
Ventures VII, L.P. and Bear Stearns Health Innoventures Management LLC will
beneficially own approximately ___%, ___% and ___%, respectively, (___% in
the
aggregate) of the outstanding voting shares of the combined company and,
therefore, will have the ability to exercise substantial influence over the
election of directors and other issues submitted to the stockholders of the
combined company. Funds affiliated with MPM Capital, L.P., HealthCare Ventures
VII, L.P. and Bear Stearns Health Innoventures Management LLC will
beneficially own approximately ___%, ___% and ___%, respectively, (___% in
the
aggregate) of the outstanding HAQ 8% convertible notes pursuant to the
Merger Agreement. The parties have agreed that the noteholders shall have the
right to elect three designees to serve on the Board of Directors of the
combined company so long as they continue to hold, in the aggregate, at
least 30% of the original face amount of such notes. The concentration of
ownership, as well as the Board designee provision of the Merger Agreement,
may
have the effect of delaying or preventing a change in control of the combined
company even if such a change in control would be in your interest.
HAQ’s
dividend policy may reduce the value of your
investment.
Following
the Merger, HAQ does not intend that it will in the foreseeable future declare
or pay any cash dividend on its shares and anticipates that earnings, if any,
will be used to finance the development and expansion of its business. Any
payment of future dividends and the amounts thereof will be dependent upon
earnings, financial requirements and other factors deemed relevant by its Board
of Directors, including its contractual obligations, if any.
HAQ
may waive one or more conditions to the Merger without resoliciting stockholder
approval for the Merger.
One
or
more conditions to HAQ’s obligation to complete the Merger may be waived in
whole or in part to the extent legally allowable either unilaterally or by
agreement of PharmAthene and HAQ. Depending upon the condition, the Board of
Directors of HAQ, will evaluate the materiality of any such waiver to determine
whether amendment to this proxy statement and re-solicitation of proxies as
necessary. In the event that the Board of Directors of HAQ determines any such
waivers are not significant enough to require re-solicitation of stockholders,
it would have the discretion to complete the Merger without seeking further
stockholder approval.
There
was no independent valuation of PharmAthene undertaken in connection with the
Merger.
HAQ
has
not obtained an independent opinion regarding the valuation of PharmAthene.
Current HAQ stockholders and prospective investors must rely on their own
business and investment background, and their own investigation of PharmAthene,
and the proposed business of the combined company in determining whether to
vote
in favor of the Merger Proposal or invest in HAQ. Although we have knowledge
of
PharmAthene’s business and the industry, it is possible the proposed valuation
of PharmAthene’s business is lower than HAQ could realize upon a sale of the
combined company or its assets. No assurances can be given that you will receive
the value of your investment upon disposition thereof.
HAQ’s
stock price is, and is expected to remain, volatile, which could limit
investors’ ability to sell stock at a profit.
The
volatile price of our stock makes it difficult for investors to predict the
value of their investment, to sell shares at a profit at any given time, or
to
plan purchases and sales in advance. A variety of factors may affect the market
price of our common stock. These include, but are not limited to:
· publicity
regarding actual or potential clinical results relating to products under
development by our competitors or us;
· delay
or
failure in initiating, completing or analyzing pre-clinical or clinical trials
or the unsatisfactory design or results of these trials;
· achievement
or rejection of regulatory approvals by our competitors or us;
· announcements
of technological innovations or new commercial products by our competitors
or
us;
· developments
concerning proprietary rights, including patents;
· developments
concerning our collaborations;
· regulatory
developments in the U.S. and foreign countries;
· economic
or other crises and other external factors;
· period-to-period
fluctuations in our revenues and other results of operations;
· changes
in financial estimates by securities analysts; and
· sales
and
short selling activity of our common stock.
Additionally,
because there is not a high volume of trading in our stock, any information
about PharmAthene in the media may result in significant volatility in our
stock
price.
We
will
not be able to control many of these factors, and we believe that
period-to-period comparisons of our financial results will not necessarily
be
indicative of our future performance.
In
addition, the stock market in general, and the market for biopharmaceutical
and
biotechnology companies in particular, has experienced extreme price and volume
fluctuations that may have been unrelated or disproportionate to the operating
performance of individual companies. These broad market and industry factors
may
seriously harm the market price of our common stock, regardless of our operating
performance.
Risks
Relating to HAQ’s Business
Our
outstanding warrants may have an adverse effect on the market price of common
stock and make it more difficult to effect the
Merger.
In
connection with the IPO, we issued warrants to purchase 9,400,000 shares of
common stock. The sale, or even the possibility of sale, of the shares
underlying the warrants could have an adverse effect on the market price for
our
securities or on our ability to obtain future public financing. If and to the
extent these warrants are exercised, you may experience dilution to your
holdings.
If
our existing stockholders exercise their registration rights, it may have an
adverse effect on the market price of our common
stock.
Our
initial stockholders are entitled to require us to register the resale of their
shares of common stock at any time after the date on which their shares are
released from escrow, which, except in limited circumstances, will not be before
July 29, 2008. If our existing stockholders exercise their registration rights
with respect to all of their shares of common stock, then there will be an
additional 2,250,000 shares of common stock eligible for trading in the public
market. The presence of this additional number of shares of common stock
eligible for trading in the public market may have an adverse effect on the
market price of our common stock.
The
American Stock Exchange may delist our securities from trading which could
limit
investors’ ability to make transactions in our securities and subject us to
additional trading restrictions.
Our
common stock and warrants are listed on the AMEX, a national securities
exchange. We cannot assure you that our securities will continue to be listed
on
the AMEX in the future prior to a business combination. If the AMEX delists
our
securities from trading on its exchange and we are not able to list our
securities on another exchange or to have them quoted on Nasdaq, our securities
could be quoted on the OTC Bulletin Board, or “pink sheets”. As a result, we
could face significant material adverse consequences including:
· a
limited
availability of market quotations for our securities;
· a
determination that our common stock is a “penny stock” which will require
brokers trading in our common stock to adhere to more stringent rules and
possibly resulting in a reduced level of trading activity in the secondary
trading market for our securities;
· a
limited
amount of news and analyst coverage for our company; and
· a
decreased ability to issue additional securities or obtain additional financing
in the future.
The
National Securities Markets Improvement Act of 1996, which is a federal statute,
prevents or preempts the states from regulating the sale of certain securities,
which are referred to as “covered securities”. Since we are listed on the AMEX,
our securities are covered securities. Although the states are preempted from
regulating the sale of our securities, the federal statute does allow the states
to investigate companies if there is a suspicion of fraud, and if there is
a
finding of fraudulent activity, then the states can regulate or bar the sale
of
covered securities in a particular case. While we are not aware of a state
having used these powers to prohibit or restrict the sale of securities issued
by blank check companies generally, certain state securities regulators view
blank check companies unfavorably and might use these powers, or threaten to
use
these powers, to hinder the sale of securities of blank check companies in
their
states.
Failure
to consummate the Merger could negatively impact the market price of HAQ’s
common stock, resulting, ultimately, in the disbursement of the trust proceeds,
causing investors to experience a loss on their
investment.
If
the
Merger is not completed for any reason, HAQ may be subject to a number of
material risks, including:
|
· |
the
market price of HAQ’s common stock may decline to the extent that the
current market price of its common stock reflects a market assumption that
the Merger will be
consummated;
|
|
· |
certain
costs related to the Merger, such as legal and accounting fees,
must be
paid even if the Merger is not completed;
and
|
|
· |
charges
will be made against earnings for transaction-related expenses,
which
could be higher than
expected.
|
Such
decreased market price and added costs and charges of the failed merger may
result, ultimately, in the disbursement of the trust proceeds, causing investors
to experience a loss on their investment. [confirm]
A
stockholder may make a claim against HAQ for taking actions inconsistent with
the IPO prospectus as such stockholder may interpret the requirement that HAQ’s
Board of Directors determine the fair value of acquisition targets based upon
certain standards set forth in HAQ’s IPO prospectus and its existing amended and
restated certificate of incorporation differently than HAQ’s management
interpreted such standards and as a result, HAQ may suffer monetary
losses.
HAQ’s
IPO
prospectus stated and our existing amended and restated certificate of
incorporation states that the fair market value of a business to be acquired
by
HAQ would be determined by its Board of Directors based upon standards generally
accepted by the financial community such as actual and potential sales, earnings
and cash flow and book value. Although, HAQ’s Board considered these factors,
and concluded that the purchase price was fair to HAQ, HAQ did not determine
a
specific valuation of PharmAthene at the time it entered into the Merger
Agreement. Accordingly, a stockholder may make a claim against HAQ that it
failed to comply with the terms of HAQ’s existing amended and restated
certificate of incorporation when evaluating the proposed merger with
PharmAthene.
Although
HAQ would vigorously contest any such claim, it could incur considerable expense
in defending such a claim. If HAQ were not successful, it would be liable for
damages as determined by a court or may have to make payments in connection
with
settling such claim.
If
HAQ is deemed to be an investment company, HAQ may be required to institute
burdensome compliance requirements and its activities may be restricted, which
may make it difficult for it to complete a business
combination.
In
order
not to be regulated as an investment company under the Investment Company Act
of
1940, as amended, or the Investment Company Act, unless HAQ can qualify for
an
exclusion, HAQ must ensure that it is engaged primarily in a business other
than
investing, reinvesting or trading of securities and that its activities do
not
include investing, reinvesting, owning, holding or trading “investment
securities.” HAQ’s business is to identify and consummate a business combination
and thereafter to operate the acquired business or businesses. HAQ invests
the
funds in the trust account only in treasury bills issued by the U.S. having
a
maturity of 180 days or less or money market funds meeting the criteria under
Rule 2a-7 under the Investment Company Act until it uses them to complete a
business combination. By limiting the investment of the funds to these
instruments, HAQ believes that it will not be considered an investment company
under the Investment Company Act. The trust account and the purchase of
government securities for the trust account is intended as a holding place
for
funds pending the earlier to occur of either: (i) the consummation of our
primary business objective, which is a business combination, or (ii) absent
a
business combination, our dissolution, liquidation and distribution of our
assets, including the proceeds held in the trust account, as part of our plan
of
dissolution and liquidation. If we fail to invest the proceeds as described
above or if we cease to be primarily engaged in our business as set forth above
(for instance, if our stockholders do not approve a plan of dissolution and
liquidation and the funds remain in the trust account for an indeterminable
amount of time), we may be considered to be an investment company and thus
be
required to comply with the Investment Company Act.
If
HAQ is
deemed to be an investment company under the Investment Company Act, its
activities may be restricted, including:
·
restrictions
on the nature of its investments; and
·
restrictions
on the issuance of securities.
each
of
which may make it difficult for it to consummate a business combination. HAQ
would also become subject to burdensome regulatory requirements, including
reporting, record keeping, voting, proxy and disclosure requirements and the
costs of meeting these requirements would reduce the funds it has available
outside the trust account to consummate a business combination.
If
20% or more of the holders of HAQ’s common stock issued in HAQ’s IPO decide to
vote against the Merger Proposal and convert their shares to cash, HAQ will
be
forced to abandon the Merger with PharmAthene and will seek to liquidate, in
which event stockholders may receive less than $7.48 per share and the warrants
may expire worthless.
Under
the
terms of HAQ’s certificate of incorporation, if 20% or more of shares issued in
HAQ’s IPO decide to vote against the proposed merger and opt to convert their
shares to cash, HAQ will be required to liquidate. In any liquidation, the
net
proceeds of HAQ’s IPO held in the trust account, plus any interest earned
thereon, will be distributed on a pro rata basis to the holders of HAQ’s common
stock issued in the IPO. If HAQ liquidates its assets, the per-share liquidation
will be the approximately $69 million deposited in the trust account at the
time
of the IPO, plus interest accrued thereon until the date of any liquidation;
as
of September 30, 2006, there was approximately $7.48 per share available in
the
trust account for distribution to stockholders. Furthermore, there will be
no
distribution with respect to HAQ’s outstanding warrants and, accordingly, the
warrants will expire worthless.
If
third parties bring claims against HAQ, the proceeds held in trust could be
reduced and the per-share liquidation price received by stockholders will be
less than $7.48 per share.
Our
placing of funds in trust may not protect those funds from third party claims
against HAQ. Pursuant to Delaware General Corporation Law Sections 280 and
281,
upon a dissolution we will be required to pay or make reasonable provision
to
pay all claims and obligations of the corporation, including all contingent,
conditional or unmatured claims. Although we will seek to have all vendors,
prospective target businesses or other entities we engage execute agreements
with us waiving any right, title, interest or claim of any kind in or to any
monies held in the trust account for the benefit of our public stockholders,
there is no guarantee that they will execute such agreements. Nor is there
any
guarantee that such entities will agree to waive any claims they may have in
the
future as a result of, or arising out of, any negotiations, contracts or
agreements with us and will not seek recourse against the trust account for
any
reason. Accordingly, the proceeds held in trust could be subject to claims
which
could take priority over the claims of our public stockholders and the IPO
per-share liquidation price could be less than $7.48 per share held in the
trust
account, plus interest, due to claims of such creditors. If we are unable to
complete a business combination and are forced to liquidate, our chairman and
executive officers will be personally liable under certain circumstances (for
example, if a vendor does not waive any rights or claims to the trust account)
to ensure that the proceeds in the trust fund are not reduced by the claims
of
various vendors or other entities that are owed money by us for services
rendered or products sold to us, to the extent necessary to ensure that such
claims do not reduce the amount in the trust fund. However, we cannot assure
you
that our executive officers will be able to satisfy those
obligations.
In
addition, although certain of our Directors and officers have agreed to
indemnify HAQ for claims by any vendor that is owed money by HAQ for services
rendered or products sold to HAQ, to the extent that such claims reduce the
amounts in the trust fund to be distributed to the public stockholders upon
dissolution and liquidation, this indemnification is limited to claims by
vendors that do not execute a valid and enforceable waiver of all rights, title,
interest, and claim of any kind in or to the monies held in the trust account.
The indemnification provided by certain of our Directors and officers would
not
cover claims by target businesses or other entities and vendors that execute
such waivers nor claims related to torts, such as if someone were to be injured
on our premises, securities litigation or franchise and income tax liabilities.
We are not aware of any other claims of the type described above nor any basis
for any such claim and, as of September 30, 2006, there is approximately
$760,000 of cash outside of the trust account. Based on representations made
to
us by certain of our directors and officers, we currently believe that they
are
of substantial means and capable of funding a shortfall in our trust account
to
satisfy their foreseeable indemnification obligations, however, the
indemnification may be limited as we have not asked them to reserve for such
an
eventuality. The indemnification obligations may be substantially higher than
certain of our directors and officers currently foresee or expect and/or their
financial resources may deteriorate in the future which could also act as a
limitation on this indemnification. Hence, we cannot assure you that certain
of
our directors and officers will be able to satisfy those obligations or that
the
proceeds in the trust account will not be reduced by such claims. Furthermore,
creditors may seek to interfere with the distribution of the trust account
pursuant to federal or state creditor and bankruptcy laws, which could delay
the
actual distribution of such funds or reduce the amount ultimately available
for
distribution to our public stockholders. If we are forced to file a bankruptcy
case or an involuntary bankruptcy case is filed against us which is not
dismissed, the funds held in our trust account will be subject to applicable
bankruptcy law and may be included in our bankruptcy estate and subject to
claims of third parties with priority over the claims of our stockholders.
To
the extent bankruptcy claims deplete the trust account, we cannot assure you
that we will be able to return to our stockholders the liquidation amounts
due
to them. Accordingly, the actual per share amount distributed from the trust
account to our public stockholders could be significantly less than
approximately $7.48 per share, without taking into account interest earned
on
the trust account, due to claims of creditors. Any claims by creditors could
cause additional delays in the distribution of trust funds to the public
stockholders beyond the time periods required to comply with Delaware General
Corporation Law procedures and federal securities laws and regulations. As
discussed herein, if the Merger is not consummated, HAQ will be forced to
dissolve and liquidate. In such event, it is more likely than not that the
amount distributed to our stockholders will be less than $7.48 per
share.
Our
stockholders may be held liable for claims against HAQ by third parties to
the
extent of distributions received by them.
We
have
agreed with the trustee to promptly adopt a plan of dissolution and liquidation
and initiate procedures for our dissolution and liquidation if we do not
complete a business combination within 24 months after the consummation of
our
IPO. Under the Delaware General Corporation Law, stockholders may be held liable
for claims by third parties against a corporation to the extent of distributions
received by them in a dissolution. If we complied with certain
procedures
set
forth in Section 280 of the Delaware General Corporation Law intended to ensure
that we make reasonable provision for all claims against us, including a 60-day
notice period during which any third-party claims can be brought against us,
a
90-day period during which we may reject any claims brought, and an additional
150-day waiting period before any liquidating distributions are made to
stockholders, any liability of a stockholder with respect to a liquidating
distribution would be limited to the lesser of such stockholder’s pro rata share
of the claim or the amount distributed to the stockholder, and any liability
of
the stockholder would be barred after the third anniversary of the dissolution.
However, it is our intention to make liquidating distributions to our
stockholders as soon as reasonably possible after dissolution and, therefore,
we
do not intend to comply with those procedures. As such, our stockholders could
potentially be liable for any claims to the extent of distributions received
by
them in a dissolution and any such liability of our stockholders will likely
extend beyond the third anniversary of such dissolution. Accordingly, we cannot
assure you that third parties will not seek to recover from our public
stockholders amounts owed to them by us.
Under
Delaware law, our dissolution requires the approval of the holders of a majority
of our outstanding stock, without which we will not be able to dissolve and
liquidate and distribute our assets to our public
stockholders.
We
have
agreed with the trustee to promptly adopt a plan of dissolution and liquidation
and initiate procedures for our dissolution and liquidation if we do not effect
the Merger by August 3, 2007. However, pursuant to Delaware law, our dissolution
requires the affirmative vote of stockholders owning a majority of our then
outstanding common stock. Soliciting the vote of our stockholders will require
the preparation of preliminary and definitive proxy statements, which will
need
to be filed with the Securities and Exchange Commission and could be subject
to
their review. This process could take a substantial amount of time ranging
from
40 days to several months.
As
a
result, the distribution of our assets to the public stockholders could be
subject to a considerable delay. Furthermore, we may need to postpone the
stockholders meeting, resolicit our stockholders or amend our plan of
dissolution and liquidation to obtain the required stockholder approval, all
of
which would further delay the distribution of our assets and result in increased
costs. If we are not able to obtain approval from a majority of our
stockholders, we will not be able to dissolve and liquidate and we will not
be
able to distribute funds from our trust account to holders of our common stock
sold in our IPO and these funds will not be available for any other corporate
purpose. In the event we seek stockholder approval for a plan of dissolution
and
liquidation and do not obtain such approval, we will nonetheless continue to
pursue stockholder approval for our dissolution. However, we cannot predict
whether our stockholders will approve our dissolution in a timely manner or
will
ever approve our dissolution. As a result, we cannot provide our stockholders
with assurances of a specific timeframe for the dissolution and distribution.
If
our stockholders do not approve a plan of dissolution and liquidation and the
funds remain in the trust account for an indeterminate amount of time, we may
be
considered to be an investment company.
The
financial interests of our officers and directors, which may be different than
the best interests of our stockholders, may have influenced their motivation
in
causing us to enter into and, may influence in the future, their motivation
to
close the Merger Agreement.
Our
officers and directors will not receive reimbursement for any out-of-pocket
expenses incurred by them to the extent that such expenses exceed the amount
of
available proceeds not in the trust account unless the Merger is completed.
If
we do not complete the Merger or other business combination and are forced
to
liquidate, the trust account proceeds may be subject to claims that could take
priority over the claims of our public stockholders. Certain of our officers
and
directors have entered into separate indemnity agreements under which they
will
be personally liable under certain circumstances to ensure that the proceeds
of
the trust account are not reduced by the claims of various vendors that are
owed
money by us for services rendered or contracted for, or claims of other parties
with which we have contracted. The shares of common stock and warrants owned
by
our officers and directors and their affiliates will be worthless if we do
not
consummate a business combination. These financial interests of our officers
and
directors may have influenced their motivation in causing us to enter into
and,
ultimately, may influence their motivation to close the Merger Agreement.
If
third parties bring claims against us or if PharmAthene has breached any of
its
representations, warranties or covenants set forth in the Merger Agreement,
we
may not be adequately indemnified for any losses arising
therefrom.
Although
the Merger Agreement provides that the PharmAthene stockholders will indemnify
us for losses arising from a breach of the representations, warranties and
covenants by PharmAthene set forth in the Merger Agreement, such indemnification
is limited both in the aggregate and the deductible and is subject to other
limitations. In addition, the survival period for any claims under the Merger
Agreement is limited to claims arising within the twelve months immediately
following the effective time of the Merger. Accordingly, we will be prevented
from seeking indemnification for any claims above the aggregate threshold or
arising after the applicable survival period.
If
the Merger’s benefits do not meet the expectations of financial or industry
analysts, the market price of HAQ’s common stock may
decline.
The
market price of HAQ’s common stock may decline as a result of the Merger
if:
· HAQ
does
not achieve the perceived benefits of the Merger as rapidly as, or to the extent
anticipated by, financial or industry analysts; or
· the
effect of the Merger on HAQ’s financial results is not consistent with the
expectations of financial or industry analysts.
Accordingly,
investors may experience a loss as a result of a decreasing stock price and
HAQ
may not be able to raise future capital, if necessary, in the equity
markets.
If
we do not consummate a business combination and dissolve, payments from the
trust account to our public stockholders may be
delayed.
We
currently believe that any plan of dissolution and liquidation subsequent to
the
expiration of the 24 month deadline would proceed in approximately the following
manner:
· our
Board
of Directors will,
consistent with Delaware law and its obligations described in our amended and
restated certificate of incorporation to dissolve, prior to the passing of
such
deadline, convene and adopt a specific plan of dissolution and liquidation,
which it will then vote to recommend to our stockholders; at such time it will
also cause to be prepared a preliminary proxy statement setting out such plan
of
dissolution and liquidation as well as the board’s recommendation of such
plan;
· upon
such
deadline, we would file our preliminary proxy statement with the Securities
and
Exchange Commission;
· if
the
Securities and Exchange Commission does not review the preliminary proxy
statement, then, approximately 10 days following the passing of such deadline,
we will mail the proxy statements to our stockholders, and approximately 30
days
following the passing of such deadline we will convene a meeting of our
stockholders, at which they will either approve or reject our plan of
dissolution and liquidation; and
· if
the
Securities and Exchange Commission does review the preliminary proxy statement,
we currently estimate that we will receive their comments approximately 30
days
following the passing of such deadline. We will mail the proxy statements to
our
stockholders following the conclusion of the comment and review process (the
length of which we cannot predict with any certainty, and which may be
substantial) and we will convene a meeting of our stockholders at which they
will either approve or reject our plan of dissolution and
liquidation.
In
the
event we seek stockholder approval for a plan of dissolution and liquidation
and
do not obtain such approval, we will nonetheless continue to pursue stockholder
approval for our dissolution. Pursuant to the terms of our amended and restated
certificate of incorporation, our powers following the expiration of the
permitted time periods for consummating a business combination will
automatically thereafter be limited to acts and activities relating to
dissolving and winding up our affairs, including liquidation. The funds held
in
our trust account may not be distributed except upon our dissolution and, unless
and until such approval is obtained from our stockholders, the funds held in
our
trust account will not be released. Consequently, holders of a majority of
our
outstanding stock must approve our dissolution in order to receive the funds
held in our trust account and the funds will not be available for any other
corporate purpose.
The
procedures required for us to liquidate under the Delaware law, or a vote to
reject any plan of dissolution and liquidation by our stockholders, may result
in substantial delays in the liquidation of our trust account to our public
stockholders as part of our plan of dissolution and liquidation.
We
will dissolve and liquidate if we do not consummate the
Merger.
If
we do
not complete the Merger on or before August 3, 2007, we will dissolve and
liquidate subject to stockholder approval and Delaware law. We view this
obligation to dissolve and liquidate as an obligation to our public stockholders
and neither we nor our Board
of
Directors will
take
any action to amend or waive any provision of our amended
and restated certificate
of incorporation to allow us to survive for a longer period of time if it does
not appear we will be able to consummate the Merger. Upon approval of our plan
of dissolution, we will distribute, assuming satisfaction of our creditors,
to
all of our public stockholders, in proportion to their respective equity
interest, an aggregate sum equal to the amount in the trust account (net of
taxes payable). Our initial stockholders have waived their rights to participate
in any liquidation distribution with respect to their initial shares and have
agreed to vote in favor of any plan of dissolution and distribution which we
will present to our stockholders for vote. There will be no distribution from
the trust account with respect to our warrants which will expire worthless.
We
will pay the costs of our dissolution and liquidation of the trust account
from
our remaining assets outside of the trust fund, and we estimate such costs
to be
between $50,000 and $75,000.
Because
we entered into a definitive agreement to complete a business combination prior
to the expiration of 18 months after the consummation of our IPO, we have an
additional six months in which to complete the Merger with PharmAthene. If
we
are unable to consummate the Merger before August 3, 2007, our purpose and
powers will be limited to dissolving, liquidating and winding up. Upon notice
from us, the trustee of the trust account will liquidate the investments
constituting the trust account and will turn over the proceeds to our transfer
agent for distribution to our public stockholders as part of our
stockholder-approved plan of dissolution and liquidation. Concurrently, we
shall
pay, or reserve for payment, from funds held outside of the trust account,
if
available, our liabilities and obligations, although we cannot assure you that
there will be sufficient funds for such purpose. The amounts held in the trust
account may be subject to claims by third parties, such as vendors, prospective
target business or other entities, if we do not obtain waivers in advance from
such third parties prior to such parties providing us with services or entering
into arrangements with them.
Our
public stockholders will be entitled to receive funds from the trust account
only in the event of our dissolution and liquidation or if they seek to convert
their respective shares into cash upon a business combination which the
stockholder voted against and which is completed by us. In no other
circumstances will a stockholder have any right or interest of any kind to
or in
the trust account.
FORWARD-LOOKING
STATEMENTS
We
believe that some of the information in this proxy statement constitutes
forward-looking statements. You can identify these statements by forward-looking
words such as “may,” “expect,” “anticipate,” “contemplate,” “believe,”
“estimate,” “intends,” and “continue” or similar words. You should read
statements that contain these words carefully because they:
· |
discuss
future expectations;
|
· |
contain
projections of future results of operations or financial condition;
and
|
· |
state
other “forward-looking”’
information.
|
HAQ
believes it is important to communicate its expectations to its stockholders.
However, there may be events in the future that HAQ or PharmAthene is not able
to accurately predict or over which HAQ or PharmAthene have no control. The
risk
factors and cautionary language discussed in this proxy statement provide
examples of risks, uncertainties and events that may cause actual results to
differ materially from the expectations described by HAQ or PharmAthene in
their
forward-looking statements, including among other things:
· |
changing
interpretations of generally accepted accounting
principles;
|
· |
outcomes
of government reviews, inquiries, investigations and related
litigation;
|
· |
potential
products that appear promising to PharmAthene or its collaborators
cannot
be shown to be efficacious or safe in subsequent pre-clinical or
clinical
trials;
|
· |
PharmAthene
or its collaborators will not obtain appropriate or necessary governmental
approvals to market these or other potential
products;
|
· |
PharmAthene
may not be able to obtain anticipated funding for its development
projects
or other needed funding;
|
· |
PharmAthene
may not be able to secure funding from anticipated government contracts
and grants;
|
· |
PharmAthene
may not be able to secure or enforce adequate legal protection, including
patent protection, for its
products;
|
· |
continued
compliance with government
regulations;
|
· |
legislation
or regulatory environments, requirements or changes adversely affecting
the businesses in which PharmAthene is
engaged;
|
· |
statements
about industry trends;
|
· |
general
economic conditions; and
|
· |
geopolitical
events and regulatory changes.
|
You
are
cautioned not to place undue reliance on these forward-looking statements,
which
speak only as of the date of this proxy statement.
All
forward-looking statements included herein attributable to HAQ, PharmAthene
or
any person acting on either party’s behalf are expressly qualified in their
entirety by the cautionary statements contained or referred to in this section.
Except to the extent required by applicable laws and regulations, HAQ and
PharmAthene undertake no obligation to update these forward-looking statements
to reflect events or circumstances after the date of this proxy statement or
to
reflect the occurrence of unanticipated events.
Before
you grant your proxy or instruct how your vote should be cast or vote on the
approval of the Merger you should be aware that the occurrence of the events
described in the “Risk Factors” section and elsewhere in this proxy statement
could have a material adverse effect on HAQ or PharmAthene upon completion
of
the Merger.
The
HAQ Special Meeting
HAQ
is
furnishing this proxy statement to you as part of the solicitation of proxies
by
the HAQ Board of Directors for use at the Special Meeting in connection with
the
proposed merger, the proposed Certificate of Incorporation Amendment, and the
proposed Incentive Plan. This proxy statement provides you with the information
you need to be able to vote or instruct your vote to be cast at the Special
Meeting.
Date,
Time and Place
The
Special Meeting will be held at ____ __, Eastern Time, on _________, 2007,
at ________________________, to vote on each of the Merger, the Certificate
of
Incorporation Amendment and the Incentive Plan Proposals.
Purpose
of the Special Meeting
At
the
Special Meeting, the holders of HAQ common stock are being asked to consider
and
vote upon the following:
· |
the
Merger Proposal-
the
proposed merger with PharmAthene, Inc. (the “Merger”), a Delaware
corporation, pursuant to the Agreement and Plan of Merger, dated
as of
January 19, 2007, by and among HAQ, Merger Sub and PharmAthene, and
the
transactions contemplated thereby, whereby PharmAthene will become
a
wholly-owned subsidiary of HAQ (“Proposal 1” or the “Merger
Proposal”) and the stockholders, optionholders, warrantholders and
noteholders of PharmAthene shall receive
the following consideration:
|
i. |
an
aggregate of 12,500,000 shares of HAQ common stock;
|
ii. |
$12,500,000
in 8% convertible notes issued by HAQ; and
|
iii. |
up
to $10,000,000 in milestone payments (if certain conditions are
met).
|
· |
the
Amendment Proposal- a proposal to amend HAQ’s amended and restated
certificate of incorporation effective concurrently with the Merger,
to: (i) change HAQ’s name from “Healthcare Acquisition Corp.” to
“PharmAthene, Inc.”, (ii) remove certain provisions containing procedural
and approval requirements applicable to HAQ prior to the consummation
of
the business combination that will no longer be operative after the
consummation of the Merger and (iii) grant to holders of
convertible promissory notes the right to designate three members to
the Board of Directors of HAQ for so long as at least 30% of the
original
face value of such notes remain outstanding (“Proposal 2” or the
“Amendment Proposal”);
|
· |
the
Incentive Plan Proposal-
a
proposal to approve and adopt
the 2007 Long-Term Incentive Plan (the “Incentive Plan”’) pursuant to
which HAQ will reserve 3,500,000 shares of common stock for issuance
pursuant to the Incentive Plan (“Proposal 3” or the “Incentive Plan
Proposal”);
and
|
· |
such
other business as may properly come before the Special Meeting or
any
adjournment or postponement
thereof.
|
The
HAQ
Board of Directors:
· |
has
unanimously determined that the Merger Proposal, the Amendment Proposal
and the Incentive Plan Proposal are fair to, and in the best interests
of,
HAQ and its stockholders;
|
· |
has
determined that the consideration to be paid by HAQ in connection
with the
Merger is fair to our current stockholders from a financial point
of view
and the fair market value of PharmAthene is equal to or greater than
80%
of the value of the net assets of
HAQ;
|
· |
has
unanimously approved and declared it advisable to approve the Merger,
the
Certificate of Incorporation Amendment and the Incentive Plan Proposals;
and
|
· |
unanimously
recommends that the holders of HAQ common stock vote “FOR” the Merger
Proposal, “FOR” the Amendment Proposal and “FOR” the Incentive Plan
Proposal.
|
No
fairness opinion from an independent advisor was sought or obtained by our
board
of directors in reaching its determination to approve the Merger.
Record
Date; Who is Entitled to Vote
The
Record Date for the Special Meeting is __________, 2007. Record holders of
HAQ
common stock at the close of business on the Record Date are entitled to vote
or
have their votes cast at the Special Meeting. On the Record Date, there were
11,650,000 outstanding shares of HAQ common stock.
Each
share of HAQ common stock is entitled to one vote at the Special
Meeting.
Any
shares of HAQ common stock held by our officers and directors will be voted
in
accordance with the majority of the votes cast at the Special Meeting with
respect to the Merger Proposal. The holders of common stock acquired in HAQ’s
IPO or afterwards are free to vote their shares, as they see fit. We have a
total of 11,650,000 shares outstanding, of which 2,250,000 were issued prior
to
the IPO. All of these shares are held by our officers and
directors.
HAQ’s
issued and outstanding warrants do not have voting rights and record holders
of
HAQ warrants will not be entitled to vote at the Special Meeting.
Voting
Your Shares
Each
share of HAQ common stock that you own in your name entitles you to one vote.
Your proxy card shows the number of shares of HAQ common stock that you
own.
There
are
two ways to vote your shares of HAQ common stock:
·
You
can
vote by signing and returning the enclosed proxy card. If you vote by proxy
card, your “proxy,” whose name is listed on the proxy card, will vote your
shares as you instruct on the proxy card. If you sign and return the proxy
card,
but do not give instructions on how to vote your shares, your shares will be
voted, as recommended by the HAQ Board, “FOR” the approval of the Merger
Proposal, “FOR” the approval of the Amendment Proposal and “FOR” the approval of
the Incentive Plan Proposal.
·
You
can
attend the Special Meeting and vote in person. HAQ will give you a ballot when
you arrive. However, if your shares are held in the name of your broker, bank
or
another nominee, you must get a proxy from the broker, bank or other nominee.
That is the only way HAQ can be sure that the broker, bank or nominee has not
already voted your shares.
Who
Can Answer Your Questions About Voting Your Shares
If
you
have any questions about how to vote or direct a vote in respect of your HAQ
common stock, you may call Matthew Kinley at (515) 244-5746.
No
Additional Matters May Be Presented at the Special
Meeting
The
Special Meeting has been called only to consider the approval of the Merger
Proposal, the Amendment Proposal and the Incentive Plan Proposal. Under HAQ’s
bylaws, other than procedural matters incident to the conduct of the meeting,
no
other matters may be considered at the Special Meeting if they are not included
in the notice of the meeting.
Revoking
Your Proxy
If
you
give a proxy, you may revoke it at any time before it is exercised by doing
any
one of the following:
· You
may
send another proxy card with a later date;
· You
may
notify Matthew Kinley, addressed to HAQ, in writing before the Special Meeting
that you have revoked your proxy; and
· You
may
attend the Special Meeting, revoke your proxy, and vote in person.
Quorum;
Vote Required
The
approval and adoption of the Merger Agreement and the transactions contemplated
thereby will require the affirmative vote of a majority of the shares of
HAQ’s common
stock issued in HAQ’s IPO that vote on this proposal at the Special Meeting. A
total of 9,400,000 shares were issued in our IPO. In addition, notwithstanding
the approval of a majority, if the holders of 1,880,000 or more shares of common
stock issued in HAQ’s IPO, an amount equal to 20% or more of the total number of
shares issued in the IPO, vote against the Merger and demand conversion of
their
shares into a pro rata portion of the trust account, then HAQ will not be able
to consummate the Merger. Each HAQ stockholder that holds shares of common
stock
issued in HAQ’s IPO or purchased following such offering in the open market has
the right, assuming such stockholder votes against the Merger Proposal and,
at
the same time, demands that HAQ convert such stockholder’s shares into cash
equal to a pro rata portion of the trust account in which a substantial portion
of the net proceeds of HAQ’s IPO is deposited. These shares will be converted
into cash only if the Merger is consummated and the stockholder requesting
conversion holds such shares until the date the Merger is consummated.
The
approval and adoption of the Amendment Proposal will require the affirmative
vote of a majority of the issued and outstanding shares of HAQ common stock
as
of the Record Date. The approval and adoption of the Incentive Plan Proposal
will require the affirmative vote of a majority of the shares of HAQ’s common
stock that are present in person or by proxy and entitled to vote at the Special
Meeting.
Each
of
the the Amendment Proposal and the Incentive Plan Proposal are conditioned
upon
the approval of the Merger Proposal and, in the event the Merger Proposal does
not receive the necessary vote to approve that proposal, then HAQ will not
complete any of the transactions identified in any of the proposals. If the
Incentive Plan Proposal and/or the Amendment Proposal are not approved but
the
Merger Proposal is approved, we may still consummate the Merger if conditions
in
the Merger Agreement requiring approval of these proposals are waived by
PharmAthene.
A
quorum
is the number of shares that must be represented, in person or by proxy,
in
order for business to be transacted
at the special meeting.
More
than
one-half of the total number of shares of our common stock outstanding as
of the
record date (a quorum) must be represented, either in person or by proxy,
in
order to transact business at the special meeting. Abstentions and broker
non-votes are counted for purposes of determining the presence of a quorum.
If
there is no quorum, a majority of the shares present at the Special Meeting
may
adjourn the Special Meeting to another date.
As
long
as a quorum is established at the Special Meeting, a failure to vote will have
no impact upon the approval of the Merger Proposal or the Incentive Plan
Proposal but as the Amendment Proposal requires a majority of all outstanding
shares of common stock, a failure to vote will have the effect of a vote against
such proposal. Failure to vote will not have the effect of converting your
shares into a pro rata portion of the trust account.
Abstentions
and Broker Non-Votes
If
your
broker holds your shares in its name and you do not give the broker voting
instructions, under the rules of the NASD, your broker may not vote your
shares on the proposals to approve the Merger with PharmAthene pursuant to
the
Merger Agreement and to approve the adoption of the Incentive Plan. If you
do
not give your broker voting instructions and the broker does not vote your
shares, this is referred to as a “broker non-vote.” Abstentions and broker
non-votes are counted for purposes of determining the presence of a
quorum.
Assuming
the presence of a quorum of more than 50% of the shares of our common stock
issued in our IPO, broker non-votes, abstentions or the failure to vote on
the
Merger Proposal will have no effect on the outcome of the vote.
If
you
abstain from voting, it will (i) not be a vote against the Merger Proposal
and will not have the effect of converting your shares into a pro rata portion
of the trust account; (ii) not count as a vote against the Incentive Plan
Proposal; and (iii) be treated as a vote against the approval of the
Amendment Proposal.
Conversion
Rights
Any
stockholder of HAQ holding shares of common stock issued in HAQ’s IPO who votes
against the Merger Proposal may, at the same time, demand that HAQ convert
his
shares into a pro rata portion of the trust account. You must mark the
appropriate box on the proxy card in order to demand the conversion of your
shares. If so demanded, HAQ will convert these shares into a pro rata portion
of
the net proceeds from the IPO that were deposited into the trust account, plus
interest earned thereon after such date, if the Merger is consummated. If the
holders of 20%, or 1,880,000, or more shares of common stock issued in HAQ’s IPO
vote against the Merger Proposal and demand conversion of their shares into
a
pro rata portion of the trust account, HAQ will not be able to consummate the
Merger. Based on the amount of cash held in the trust account as of September
30, 2006, without taking into account any interest accrued after such date,
you
will be entitled to convert each share of common stock that you hold into
approximately $7.48 per share. HAQ will be liquidated if the Merger is not
consummated by August 3, 2007. In any liquidation, the net proceeds of HAQ’s IPO
held in the trust account, plus any interest earned thereon, will be distributed
on a pro rata basis to the holders of HAQ’s common stock other than the
founders, who will not share in any such liquidation proceeds.
If
you
exercise your conversion rights, then you will be exchanging your shares of
HAQ
common stock for cash and will no longer own these shares. You will only be
entitled to receive cash for these shares if you continue to hold these shares
through the closing date of the Merger and then tender your stock certificate
to
HAQ. The closing price of HAQ’s common stock on February 7, 2007, the most
recent trading day practicable before the printing of this proxy statement,
was
$7.34 and the amount of cash held in the trust account is approximately
$7.48 per share as of September 30, 2006, plus interest accrued
thereon after such date. If a HAQ stockholder would have elected to exercise
his
conversion rights on such date, then he would have been entitled to receive
$7.48 per share, plus interest accrued thereon subsequent to such date. Prior
to
exercising conversion rights, HAQ stockholders should verify the market price
of
HAQ’s common stock as they may receive higher proceeds from the sale of their
common stock in the public market than from exercising their conversion rights.
Appraisal
or Dissenters Rights
No
appraisal rights are available under the Delaware General Corporation Law to
the
stockholders of HAQ in connection with the Merger Proposal. The only rights
for
those stockholders voting against the Merger who wish to receive cash for their
shares is to simultaneously demand payment for their shares from the trust
account.
Solicitation
Costs
HAQ
is
soliciting proxies on behalf of the HAQ Board of Directors. This solicitation
is
being made by mail but also may be made by telephone or in person. HAQ and
its
respective directors and officers may also solicit proxies in person, by
telephone or by other electronic means, and in the event of such solicitations,
the information provided will be consistent with this proxy statement and
enclosed proxy card. These persons will not be paid for doing this. HAQ will
ask
banks, brokers and other institutions, nominees and fiduciaries to forward
its
proxy statement materials to their principals and to obtain their authority
to
execute proxies and voting instructions. HAQ will reimburse them for their
reasonable expenses.
Stock
Ownership
Of
the
11,650,000 outstanding shares of HAQ common stock, HAQ’s initial stockholders,
including all of its officers and directors and their affiliates, who purchased
shares of common stock prior to HAQ’s IPO and who own an aggregate of
approximately 19.31% of the outstanding shares of HAQ common stock (2,250,000
shares), have agreed to vote such shares acquired prior to the IPO in accordance
with the vote of the majority in interest of all other HAQ stockholders on
the
Merger Proposal.
Based
solely upon information contained in public filings and the records of our
transfer agent, as of the Record Date, the following stockholders beneficially
own greater than five percent of HAQ’s issued and outstanding common stock, as
such amounts and percentages are reflected in the public filing of such
stockholder:
The
following table sets forth information as of February 7, 2007, based on
information obtained from the persons named below, with respect to the
beneficial ownership of shares of our common stock by (i) each person known
by
us to be the owner of more than 5% of our outstanding shares of common stock,
(ii) each director and (iii) all officers and directors as a group. Except
as
indicated in the footnotes to the table, the persons named in the table have
sole voting and investment power with respect to all shares of common stock
shown as beneficially owned by them.
Name
and Address of
Beneficial
Owner (1)
|
|
Amount
and Nature of Beneficial Ownership
|
|
Percent
of Class
|
|
John
Pappajohn (2)
|
|
|
882,000
|
|
|
7.57
|
%
|
Derace
L. Schaffer, M.D. (3)
|
|
|
882,000
|
|
|
7.57
|
%
|
Matthew
P. Kinley (4)
|
|
|
441,000
|
|
|
3.79
|
%
|
Edward
B. Berger (5)
|
|
|
22,500
|
|
|
*
|
|
Wayne
A. Schellhammer
|
|
|
22,500
|
|
|
*
|
|
Sapling,
LLC (6)
|
|
|
681,815
|
|
|
5.85
|
%
|
Fir
Tree Recovery Master Fund, LP (6)
|
|
|
335,185
|
|
|
2.88
|
%
|
All
directors and executive officers as a group (5) persons
|
|
|
2,250,000
|
|
|
19.31
|
%
|
* Represents
beneficial ownership of less than 1%.
(1)
Does
not include shares of common stock issuable upon exercise of warrants which
are
beneficially owned by certain of the persons named in the above table but which
are not exercisable until the consummation by us of a business combination.
Unless otherwise indicated, the business address of each of the individuals
is
2116 Financial Center, 666 Walnut Street, Des Moines, Iowa 50309.
(2)
Does
not include 141,960 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1, above.
(3)
Does
not include 141,960 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1, above.
(4)
Does
not include 70,980 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1, above.
(5)
Does
not include 12,000 warrants purchased by Mr. Berger in open market purchases.
See footnote 1 above.
(6)
Based
on information contained in a Statement on Schedule 13G filed by Sapling LLC
in
August 2005. Sapling may direct the vote and disposition of the 681,815 shares
of common stock, and Fir Tree Recovery may direct the vote and disposition
of
335,185 shares of common stock. The address of both Sapling LLC and Fir Tree
Recovery is 535 Fifth Avenue, 31st Floor New York, New York
10017.
PROPOSAL
1
THE
MERGER PROPOSAL
The
discussion in this proxy statement of the Merger Proposal and the principal
terms of the Agreement and Plan of Merger, dated January 19, 2007, by and among
HAQ, Merger Sub and PharmAthene (the “Merger Agreement”) is subject to, and is
qualified in its entirety by reference to, the Merger Agreement, which is
attached as “Annex A” to this proxy statement and is incorporated in this proxy
statement by reference.
General
Description of the Merger
Pursuant
to the Merger Agreement, Merger Sub, a wholly-owned subsidiary of HAQ will
merge
with and into PharmAthene and PharmAthene will be the surviving entity and
become a wholly-owned subsidiary of HAQ. At the closing, and subject to certain
adjustments as hereinafter described, the PharmAthene stockholders,
optionholders and warrantholders and noteholders will receive the following
in
the Merger:
(i) |
an
aggregate of 12,500,000 shares of HAQ common stock, subject to adjustments
as described below;
|
(ii) |
$12,500,000
in 8% convertible notes issued by HAQ;
and
|
(iii) |
up
to $10,000,000 in milestone payments (if certain conditions are
met);
|
in
exchange for all of the issued and outstanding capital stock and convertible
notes of PharmAthene (other than the securities being cancelled). HAQ is also
assuming certain outstanding vested and unvested options and warrants, which
shall be exchanged for options and warrants of HAQ on economically equivalent
terms. The 12,500,000 shares of HAQ common stock issued as merger consideration
will not increase due to the vesting, issuance of any options or warrants of
PharmAthene or the assumption of the PharmAthene options and warrants and the
actual number of shares of HAQ common stock ultimately issued may be less to
the
extent options and warrants are not exercised. The number of shares which are
to
be issued may be subject to increase in the event that the
stockholders of HAQ owning more than 5% of the outstanding HAQ common stock
exercise their conversion rights, the number of shares of HAQ common stock
comprising the stock consideration shall be adjusted upward by the product
of
(x) the number (as a percentage) that is the difference between the percentage
of HAQ common stock that is converted and 5% and (y) 2.25 million.
Background
of the Merger
The
terms
of the Merger Agreement are the result of arm’s-length negotiations between
representatives of HAQ and PharmAthene. The following is a brief discussion
of
the background of these negotiations, the Merger and related
transactions.
HAQ
was
incorporated in Delaware on April 25, 2005, as a blank check company formed
to serve as a vehicle for the acquisition, through a merger, capital stock
exchange, asset acquisition or other similar business combination with a then
currently unidentified operating business.
A
registration statement for HAQ’s IPO was declared effective on July 28,
2005. On August 3, 2005, HAQ consummated its IPO of 9,000,000 units, and on
August 16, 2005, HAQ consummated the closing of an additional 400,000 units
that were subject to the underwriters’ over-allotment option. Each unit consists
of one share of common stock and one redeemable common stock purchase warrant.
Each warrant expires on July 27, 2009, or earlier upon redemption, and
entitles the holder to purchase one share of our common stock at an exercise
price of $6.00 per share. The common stock and warrants started trading
separately as of October 6, 2005.
The
net
proceeds from the sale of the HAQ units were approximately $69,450,000. Of
this
amount, $67,928,000 was deposited in trust and, in accordance with HAQ’s amended
and restated certificate of incorporation, will be released either upon the
consummation of a business combination (i.e., the Merger) or upon the
liquidation of HAQ. The remaining $1,522,000 has been held outside of the trust
for use to provide for business, legal and accounting due diligence on
prospective businesses.
During
the period beginning August 3, 2005 through January 19, 2007, HAQ was
involved in investigating and evaluating prospective businesses regarding
potential business combinations. This activity occurred constantly from August
3, 2005 onward until we entered into the Merger Agreement.
In
August
2005, Mr. Kinley created a list of potential contacts that he, Mr. Pappajohn
or
Dr. Schaffer would contact to commence the search for targets for a business
combination. This list of contacts was primarily individuals HAQ management
had
contact or prior business dealings with, and included, but was not limited
to,
the following:
|
·
|
Healthcare
investment bankers;
|
|
·
|
Business
brokers and other “finders”;
|
|
·
|
Venture
capital fund managers;
|
|
·
|
Private
equity fund managers;
|
|
·
|
CEOs
or executives active in the healthcare
industry;
|
|
·
|
Healthcare
consultants; and
|
|
·
|
Physicians
and other healthcare professionals.
|
HAQ
management then communicated to these contacts the desire of HAQ to find
an
attractive healthcare business opportunity. These contacts were made by a
combination of Mr. Pappajohn, Dr. Schaffer and Mr. Kinley. In addition, Mr.
Kinley made a list of healthcare sectors and companies within such sectors
for
possible contact and review by HAQ management. On many occasions Mr. Pappajohn,
Dr. Schaffer and Mr. Kinley met in person or by teleconference to discuss
possible focus sectors of healthcare and specific companies to target. The
result of these meetings was a prioritized a list of potential candidates
for a
business combination. In addition, from August 2005 through January 2007
HAQ
management was contacted by various parties regarding possible targets for
a
business combination. All of these opportunities were either discussed or
the
relevant information was shared by email, primarily between Messrs. Pappajohn
and Kinley and Dr. Schaffer.
Using
this list of contacts and targets as a guide, HAQ management attempted to
initiate conversations (i) directly with third-party companies they believed
could make attractive combination partners, (ii) with professional service
providers (attorneys, accountants, consultants and bankers), (iii) with their
own network of business associates and friends, and (iv) with third-party
intermediaries, including investment bankers and private equity fund managers.
HAQ also responded to inquiries or solicitations from (i) companies looking
for
capital or investment alternatives, and (ii) investment bankers or other
similar professionals who represented companies engaged in sale or fund-raising
processes. From time to time the list of potential candidates was updated
and
supplemented based on additional information derived from these discussions
with
third parties.
As
a
result of these efforts, HAQ initiated contact, either directly or through
a
third party intermediary, with approximately 15 potential targets. In addition
HAQ received business plans, financial summaries or presentation books
of at least 30 additional potential target companies. Of these
contacts, HAQ held detailed discussions with approximately 10 potential target
companies, including PharmAthene. HAQ signed non-disclosure agreements relating
to approximately 20 of these potential business combination
opportunities. HAQ also had extensive discussions with several target companies
with which a non-disclosure agreement was not signed. HAQ was still in
discussions with a potential target company other than PharmAthene as late
as
January 2006, within two weeks of when the Merger agreement was signed. With
respect to each of these business combination opportunities, discussions
included financial disclosures, reviews of potential transaction structures,
preliminary estimates of transaction values and discussions of management
objectives, business plans and projections. Each of the potential target
companies with which HAQ engaged in detailed discussions was either part
of the
initial list created by the HAQ team or was identified through a contacts
described above. One of the discussions with the potential target companies,
in
addition to PharmAthene, resulted in a signed letter of intent. HAQ management
performed extensive due diligence, personal interviews and merger negotiations
with a company but ultimately, HAQ could not reach agreement on valuation
and
other merger related issues. No discussions with the potential target companies,
other than PharmAthene, resulted in a definitive agreement regarding a potential
business combination.
Based
on
their experience in sourcing investment opportunities, the HAQ management
assessed the competition for quality companies that could be a potential
target
for a business combination and determined that a company that HAQ’s management
identified as a suitable potential business combination partner would typically
have several alternatives to any potential business combination with HAQ,
including remaining independent or selling itself to another third party,
as
well as sourcing capital either privately or publicly. Additionally, in many
cases, HAQ management had to spend time educating a prospective business
combination partner about ‘‘blank check” companies and explain, from HAQ
management’s perspective, the benefits HAQ may be able to offer versus other
alternatives they may be considering. The reasons varied for why HAQ did
not
reach agreement with potential business combination partners other than
PharmAthene. For example, after detailed discussions with one potential target,
the HAQ management team could not get comfort with the target company’s
forecasted financial performance and the likelihood management could meet
its
forecasted. Upon HAQ’s requirement for a greater portion of the purchase price
to be contingent on performance, negotiations faltered. In another case,
HAQ
determined that the potential target business was too highly valued and a
competitive bidding situation had reduced the possibility of an attractive
deal
for the HAQ shareholders.
On
June
8, 2006, PharmAthene entered into a Definitive Agreement and Plan of Merger
by
and among PharmAthene, SIGA Technologies Inc.(“SIGA”) and SIGA Acquisition
Corp.
On
October 4, 2006, PharmAthene received from SIGA a notice of termination of
the
Merger Agreement in accordance with the terms thereof.
On
October 5, 2006, Mr. Kinley was contacted by counsel to PharmAthene. The
management of HAQ had previously worked with Counsel to PharmAthene on several
healthcare investments and public companies. During the call, PharmAthenes
counsel inquired if HAQ had committed to an acquisition. Mr. Kinley responded
that HAQ was in negotiations with another healthcare company, but it had
not yet
signed a definitive agreement to merge. PharmAthene’s counsel inquired whether
HAQ would consider discussing a possible business combination with
PharmAthene. There were no pre-existing relationships between any of our
initial stockholders and any insiders of PharmAthene. There are no direct
business relations between any of the officers, directors or principal
stockholders of HAQ and any of the officers, directors or principal stockholders
of PharmAthene. However, counsel to PharmAthene also serves as counsel to
a
company on which John Pappajohn and Derace Schaffer, MD serve as members
of the
Board of Directors and of which Wayne Schellhammer is the President and Chief
Executive Officer.
On
several occasions from October 6, 2006 through the meeting on January 16,
2007,
Mr. Pappajohn, Dr. Schaffer and Mr. Kinley held update discussions with,
and
forwarded information to, Mr. Berger and Mr. Schellhammer so all HAQ directors
were apprised of the progress of the negotiations, due diligence and other
matters related to the merger with PharmAthene.
On
October 6, 2006, at the suggestion of counsel, James Cavanaugh, PhD., a member
of the Board of Directors of PharmAthene, spoke by telephone with John
Pappajohn, Chairman of the Board of HAQ, and Mr. Kinley, to discuss the
status of HAQ and the feasibility of a possible merger between HAQ and
PharmAthene.
From
October 6, 2006 through January 19, 2007, the Investment Committee of
PharmAthene, comprised of Steven. St. Peter, MD, Elizabeth Czerepak and Dr.
Cavanaugh, each a member of PharmAthene’s Board
of
Directors, met via telephone on each Friday to review, among other things,
the status of the discussions of the proposed transaction with HAQ.
On
October 7, 2006, HAQ commenced its due diligence examination of PharmAthene
which continued through January 19, 2007, including reviewing all of
PharmAthene’s significant agreements, conducting interviews with management and
department heads of PharmAthene and visiting each of the PharmAthene facilities.
On
October 12, 2006, at the request of Mr. Pappajohn and Dr. Cavanaugh, Dr.
Schaffer, the Chief Executive Officer and Vice Chairman of HAQ, and Mr. Kinley
met with David P. Wright and Eric Richman, the President and Executive Vice
President, respectively, of PharmAthene, at the offices of PharmAthene’s counsel
in New York City to discuss the possibility of a merger.
On
October 19, 2006, Mr. Pappajohn joined Mr. Kinley and Dr. Schaffer to meet
with Messrs. Wright and Richman at the offices of Bear Stearns in New York.
Following the meeting, all four of the participants met with representatives
of
The Maxim Group, HAQ’s financial advisor, to seek financial counsel as to the
advisability of proceeding with a merger transaction with
PharmAthene.
On
October 25, 2006, HAQ delivered to PharmAthene a draft letter of
intent.
On
November 2, 2006, PharmAthene retained Bear, Stearns &
Co. Inc. to assist and advise PharmAthene in connection with the
proposed
merger.
On
November 4 and 6, 2006, PharmAthene delivered comments to HAQ including
suggested revisions to the initial letter of intent.
On
November 16, 2006, Mr. Pappajohn met with Ms.
Czerepak, a member of PharmAthene’s Board
of
Directors and Investment Committee to discuss the proposed Merger.
On
November 7, 2006, Mr. Pappajohn, Dr. Schaffer and Mr. Kinley met with Messrs.
Wright and Richman and representatives from Bear Stearns and counsel of
PharmAthene at the offices of Bear Stearns in New York, NY.
On
November 9, 2006, Dr. St. Peter met with Mr. Pappajohn in New
York.
On
November 15, 2006, representatives of PharmAthene, including Messrs. Wright
and
Richman and counsel to PharmAthene, met with representatives of HAQ, including
Messrs, Pappajohn, and Kinley and Dr. Schaffer to negotiate the terms of
the letter of intent at the offices of Bear Stearns. Representatives of Bear
Stearns were present at the meeting.
On
November 16, 2006, the Board of Directors of PharmAthene met at the offices
of
Bear Stearns in New York City. At the meeting, the terms of the proposed merger
as embodied in the then current draft letter of intent with HAQ were described
to the Board by counsel. The PharmAthene Board reviewed alternative transactions
that could result in the investment of additional capital into PharmAthene.
The
PharmAthene Board also discussed the affect of the transaction on each class
of
equity of PharmAthene. Representatives of Bear Stearns presented to the Board
their analysis of the transaction from a financial perspective and relative
to
other options that could be explored by PharmAthene. Although the Board
determined that it was favorably disposed to proceed with the transaction,
it
determined not to act with respect to the letter of intent, pending additional
analysis by certain Board members and discussions with certain significant
stockholders of PharmAthene as to whether they would support the proposed
merger.
From
November 4, 2006 through December 12, 2006, representatives of PharmAthene
and
representatives of HAQ continued to negotiate the terms of the proposed
transaction and exchanged various drafts of the letter of intent.
On
December 12, 2006, a meeting was held at PharmAthene’s offices in Annapolis,
Maryland, at which Messrs. Wright and Richman and John Troyer, Jody
Hatch, Jeffrey Jones, Francesca Cook, Wayne Morges, Ph.D., Valerie Riddle,
MD, Richard Schoenfeld and Solomon Langermann were present from PharmAthene
and Mr. Kinley and Dr. Schaffer and Robert Kaufman were present from
HAQ attended.
On
December 12, 2006, the Board of Directors of PharmAthene again held a telephonic
meeting at which the revised terms of the letter of intent were discussed and
a
vote taken to approve the letter of intent. The letter of intent was executed
by
each of PharmAthene and HAQ on December 12, 2006.
From
December 12, 2006 through January 12, 2007, PharmAthene and HAQ negotiated
the
terms of a definitive agreement and plan of merger. During such time,
representatives of HAQ conducted due diligence visits to the facilities of
PharmAthene in Annapolis, Maryland and in Canada.
On
December 19 and 20, 2006, Dr. Schaffer and an outside consultant met with
David Wright and visited the offices of PharmAthene’s Canadian subsidiary
with Messrs. Wright and Schoenfeld.
On
January 12, 2007, copies of the draft Merger Agreement and related documents
were distributed to the Board of Directors of PharmAthene for
consideration.
On
January 14, 2007, copies of the draft Merger Agreement and related documents
were distributed to the Board of Directors of HAQ for review and
comment.
On
January 16, 2007, the Board of Directors of PharmAthene, during a telephonic
board meeting, approved the Merger Agreement and approved the presentation
of
the proposal to merge with HAQ to the stockholders of PharmAthene with its
recommendation that the stockholders approve and adopt the Merger Agreement
and
the transactions contemplated thereby.
On
January 16, 2007, the Board of Directors of HAQ, during a telephonic board
meeting, approved the Merger Agreement and approved the presentation of the
proposal to merge with PharmAthene to the stockholders of HAQ with its
recommendation that the stockholders approve and adopt the Merger Agreement
and
the transactions contemplated thereby.
On
January 19, 2007, the Merger Agreement was executed by David Wright on behalf
of
PharmAthene and John Pappajohn on behalf of HAQ. On January 19, 2007, the
requisite majority of all classes of equity of PharmAthene released their
irrevocable written consent approving and adopting the Merger Agreement and
the
Merger.
Interests
of HAQ Directors and Officers in the Merger
In
considering the recommendation of the Board of Directors of HAQ to vote for
the
proposals to approve and adopt the Merger Agreement and the Merger, you should
be aware that certain members of the HAQ Board have agreements or arrangements
that provide them with interests in the Merger that differ from, or are in
addition to, those of HAQ stockholders generally. In particular:
|
|
·
if
the Merger is not approved, HAQ will be required to adopt a plan
to
liquidate and dissolve, and the shares of common stock and warrants
held
by HAQ’s executive officers and directors will be worthless because HAQ’s
executive officers and directors are not entitled to receive any
of the
net proceeds of HAQ’s IPO that may be distributed upon liquidation of HAQ.
HAQ’s executive officers and directors own a total 2,250,000 shares of
HAQ
common stock that have a market value of $16,515,000 based on HAQ’s
share price of $7.34 as of February 7, 2007. HAQ’s executive officers
and directors also own a total of 366,900 warrants to purchase shares
of
HAQ common stock that have a market value of $498,984 based on HAQ’s
warrant price of $1.36 as of February 7, 2007. Such warrants were
purchased on the open market pursuant to the terms of a 10b5-1 plan.
However, as HAQ’s executive officers, Directors and special advisors are
contractually prohibited from selling their shares of common stock
prior
to July 27, 2008, during which time the value of the shares may
increase or decrease, it is impossible to determine what the financial
impact if the Merger is not approved would be on HAQ’s executive officers
and directors; and
|
|
|
|
|
|
·
it
is currently anticipated that John Pappajohn and Derace M. Schaffer,
M.D.,
both of whom are current Directors of HAQ, will continue as Directors
of
the combined company.
|
HAQ’s
Reasons for the Merger and Recommendation of the HAQ Board
Based
upon its evaluation, our Board of Directors has unanimously approved the Merger
with PharmAthene and determined that it is in the best interests of HAQ and
our
stockholders. No fairness opinion was sought or obtained by our Board of
Directors in reaching its determination.
In
the
prospectus relating to our IPO, we stated our intention to focus our pursuit
of
a business combination on targets in the healthcare industry and in areas where
our management has significant expertise. We believe that the Merger meets
these
investment objectives.
Our
Board
of Directors also considered a wide variety of other factors in connection
with
its evaluation of the Merger. In light of the complexity of those factors,
our
Board of Directors, as a whole, did not consider it practicable to, nor did
it
attempt to, quantify or otherwise assign relative weights to the specific
factors it considered in reaching its decision. Individual members of our Board
of Directors may have given different weight to different factors.
Our
Board
of Directors considered the nature of PharmAthene’s business and assets, its
current capitalization and resulting operating losses, the extent of the
liabilities to be assumed and the factors below, in addition to the various
risks discussed in the section entitled “Risk Factors” beginning on
page 24, in reaching its determination that the Merger is in the best
interests of HAQ’s stockholders and to approve the Merger and enter into the
Merger Agreement.
In
considering the Merger, our Board of Directors gave consideration to the
following positive factors:
· |
PharmAthene
has a strong presence and commitment to the development of products
for
use in the defense against agents of biological warfare. We expect
the
strong development and commercialization capabilities of PharmAthene
together with its research capabilities will create an expanded biodefense
platform with the possibility for multiple procurement stage products
and
near term revenue opportunities;
|
· |
PharmAthene
is a leading company in the biodefense industry. The biodefense industry
is a significant; market in the U.S. and abroad due to the threat
of
biological warfare;
|
· |
the
biodefense industry has been identified by the U.S. government as
a
priority evidenced by the enactment of Project Bioshield with funding
targets of $5.6 billion over 10 years;
|
· |
PharmAthene
has two leading products, Valortim and Protexia that may provide
significant revenues to the combined company;
and
|
· |
PharmAthene
has an experienced management team including David P. Wright,
Pharmathene’s Chief Executive Officer that has participated in the
development and marketing of many successful drug
launches.
|
· |
PharmAthene has
been awarded U.S. government
contracts;
|
· |
PharmAthene’s
business strategy;
|
· |
PharmAthene’s
financial results, including potential for revenue growth and operating
margins;
|
· |
PharmAthene’s
competitive position;
|
· |
the industry dynamics, including barriers
to
entry; |
· |
the
regulatory environment for
PharmAthene;
|
· |
acquisition
opportunities in the industry;
|
· |
the
valuation of comparable companies;
|
· |
the
experience of HAQ’s management, in particular, Mr. Pappajohn and Dr.
Schaffer, in building, consolidating and investing in similar
businesses
in the U.S. including relationships HAQ could introduce to PharmAthene
to
potentially enhance its growth; and
|
· |
the
involvement of certain of the stockholders and noteholders of
PharmAthene,
whom HAQ believes represent strong long term investors with experience
in
venture transactions and growth
companies.
|
We
represented in the prospectus relating to our IPO that the business acquired
by
us in our initial business combination would have a fair market value equal
to
at least 80% of our net assets at the time of the transaction, including the
funds held in the trust account. Based on the financial analysis by our Board
of
Directors generally in evaluating and approving the acquisition, our Board
of
Directors determined that the Merger with PharmAthene meets this requirement.
Our
Board
of Directors has determined that the fair market value of the assets being
purchased is between approximately $110 million and $200 million. This
determination was based on an analysis of PharmAthene’s current and projected
revenue and EBITDA, as compared to other publicly-traded businesses of a similar
nature and the acquisition multiples for other similar transactions in the
biodefense industry that have recently been publicly announced or completed.
In
addition, a leveraged buyout/discounted cash flow analysis was performed to
determine the present economic value of the assets being acquired. The range
of
the fair market value exceeds $53.4 million, which is 80% of our net asset
value of approximately $70.5 million as of September 30, 2006.
The
terms
of the Merger were determined based upon arms-length negotiations between HAQ
and PharmAthene, who had no prior dealings. Under the circumstances, our Board
of Directors believes that the total consideration for the Merger appropriately
reflects the fair market value of PharmAthene. In light of the financial
background and experience of several members of our management and Board of
Directors, our Board also believes it is qualified to determine whether the
Merger meets this requirement. Our Board of Directors did not seek or obtain
an
opinion of an outside fairness or valuation advisor as to whether the 80% test
has been met.
United
States Federal Income Tax Consequences of the Merger
As
the
stockholders of HAQ are not receiving any consideration or exchanging any of
their outstanding securities in connection with the Merger with PharmAthene
and
are simply being asked to vote on the matters, it is not expected that the
stockholders will have any tax related issues as a result of voting on these
matters. However, if you vote against the Merger Proposal and elect a cash
conversion of your shares of HAQ into your pro-rata portion of the trust fund
and as a result receive cash in exchange for your HAQ shares, there may be
certain tax consequences, such as realizing a loss on your investment in HAQ’s
shares.
WE URGE YOU TO CONSULT YOUR OWN TAX ADVISORS REGARDING YOUR PARTICULAR TAX
CONSEQUENCES.
Accounting
Treatment of the
Merger
The
Merger will be accounted for as a reverse
acquisition and equity recapitalization, with HAQ treated as the “acquired”
company for financial reporting purposes. For accounting purposes, the
transaction is being treated as an acquisition of assets and not a business
combination because HAQ did not meet the definition of a business under EITF
98-3, Determination Whether a Nonmonetary Transaction Involves Receipt of
Productive Assets or of a Business. Accordingly, the transaction has been
treated as a capital transaction whereby PharmAthene is issuing stock for the
net monetary assets of HAQ, accompanied by a recapitalization.
Regulatory
Matters
The
Merger and the transactions contemplated by the Merger Agreement are not subject
to any federal or state regulatory requirement or approval, and except for
filings necessary to effectuate the transactions contemplated by the Merger
Proposal and the Certificate of Incorporation Amendment proposal with the
Secretary of State of the State of Delaware.
Consequences
if Merger Proposal is Not Approved
If
the
Merger Proposal is not approved by the stockholders, HAQ will not merge with
PharmAthene. In addition, HAQ would not effect the Certificate of Incorporation
Amendment or adopt the Incentive Plan. In such an event management of HAQ will
not have the time, resources or capital available to find a suitable business
combination partner before (i) the proceeds in the trust account are
liquidated to holders of shares purchased in HAQ’s IPO and (ii) HAQ is
dissolved pursuant to the trust agreement, in accordance with HAQ’s amended and
restated certificate of incorporation and pursuant to stockholder
approval.
If
a
liquidation were to occur by approximately August 2, 2007, HAQ estimates that
approximately $2.0 million in interest would accrue on the amounts that are
held
in trust through such date, which would yield a trust balance of approximately
$72,280,000 or $7.68 per share. This amount, less any liabilities not
indemnified by certain members of HAQ’s Board and not waived by HAQ’s creditors,
would be distributed to the holders of the 9,400,000 shares of common stock
purchased in HAQ’s IPO. HAQ currently estimates that, at the end of January
2007, there would be approximately $250,000 in Delaware franchise tax and state
income tax claims which are not indemnified and not waived by such taxing
authorities. Thus, HAQ estimates that the total amount available for
distribution upon liquidation would be approximately $72,030,000 million or
$7.66 per share.
Separately,
HAQ estimates that the dissolution process would cost approximately $50,000
to
$75,000 and that HAQ would be indemnified for such costs by certain of the
HAQ
executive officers and directors. Such officers and directors have acknowledged
and agreed that such costs are covered by their existing indemnification
agreement. We do not believe there would be any claims or liabilities
against which certain of HAQ’s executive officers and directors have agreed to
indemnify the trust account in the event of such dissolution. In the event
that
such persons indemnifying HAQ are unable to satisfy their indemnification
obligation or in the event that there are subsequent claims such as subsequent
non-vendor claims for which such persons have no indemnification obligation,
the
amount ultimately distributed to stockholders may be reduced even further.
However, HAQ currently has no basis to believe there will be any such
liabilities or to provide an estimate of any such liabilities. The only cost
of
dissolution that HAQ is aware of that would not be indemnified against by such
officers and directors of HAQ is the cost of any associated
litigation.
Required
Vote
Approval
of the merger proposal will require: (1) that a majority of the shares of
our common stock issued in our IPO present in person or by proxy at the special
meeting vote in favor of the proposal; and (2) that holders of 20% or more
of the shares issued in our initial public offering do not vote against the
merger and demand to convert their shares into cash. Assuming the presence
of a
quorum of more than 50% of the shares of our common stock issued in IPO, the
failure to vote, broker non-votes or abstentions will have no effect on the
outcome of the vote.
Recommendation
After
careful consideration, HAQ’s Board of Directors has determined unanimously that
the Merger Proposal is fair to, and in the best interests of, HAQ and its
stockholders. HAQ’s Board of Directors has approved and declared advisable the
Merger Proposal and unanimously recommends that you vote or give instructions
to
vote “FOR” the Merger Proposal.
The
foregoing discussion of the information and factors considered by the HAQ Board
of Directors is not meant to be exhaustive, but includes the material
information and factors considered by the HAQ Board of Directors.
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE
MERGER PROPOSAL.
The
following summary describes the material provisions of the Agreement and Plan
of
Merger. The provisions of the Merger Agreement are complicated and not easily
summarized. This summary may not contain all of the information about the Merger
Agreement that is important to you. The Merger Agreement is attached to this
proxy statement as Annex A and is incorporated by reference into this proxy
statement, and we encourage you to read it carefully in its entirety for a
more
complete understanding of the Agreement and Plan of Merger.
General
The
Agreement and Plan of Merger, sometimes referred to herein as the Merger
Agreement, provides that upon the consummation of the Merger, PharmAthene will
be merged into PAI Acquisition Corp., a newly formed, wholly-owned subsidiary
of
HAQ, sometimes referred to herein sometimes as “Merger Sub”. PharmAthene will
survive the Merger as a wholly-owned subsidiary of HAQ, and stockholders of
PharmAthene will exchange their PharmAthene equity interests for 12,500,000
shares of HAQ common stock thereby becoming equityholders of HAQ and,
potentially, milestone payments not to exceed $10,000,000 in the aggregate,
while noteholders of PharmAthene will exchange currently-outstanding 8%
convertible notes of PharmAthene for new 8% convertible notes of HAQ in the
amount of $12,500,000.
The
closing of the transactions contemplated by the Merger Agreement will occur
promptly after the last of the conditions to the Merger has been satisfied
or
waived, or at such other time as HAQ and PharmAthene agree. Contemporaneously
with or as soon as practicable after that time, HAQ and PharmAthene will file
a
Certificate of Merger with the Secretary of State of the State of Delaware.
The
Merger will become effective upon the filing of the Certificate of Merger or
at
such other time as HAQ and PharmAthene may agree. HAQ and PharmAthene currently
expect that the completion of the Merger will take place in the second calendar
quarter of 2007. However, because the Merger is subject to stockholder approval
and other customary conditions, HAQ and PharmAthene cannot predict exactly
when
or if the Merger will occur.
Stock
Consideration
The
shares of HAQ common stock to be allocated to the holders of PharmAthene capital
stock in the Merger will be distributed to the holders of PharmAthene capital
stock as follows:
· the
holders of PharmAthene common stock will receive, on a pro rata basis
(determined based on the number of shares of PharmAthene common stock held
by
such holder and the number of PharmAthene options and warrants assumed) divided
among the holders thereof, 5.0096% of the total number of shares of HAQ common
stock allocated in the Merger to the holders of PharmAthene capital
stock;
· the
holders of PharmAthene Series A Convertible Preferred Stock will receive, on
a
pro rata basis (determined based on the number of shares of PharmAthene Series
A
Convertible Preferred Stock held by such holder) divided among the holders
thereof, 15.0824% of the total number of shares of HAQ common stock allocated
in
the Merger to the holders of PharmAthene capital stock;
· the
holders of PharmAthene Series B Convertible Preferred Stock will receive, on
a
pro rata basis (determined based on the number of shares of PharmAthene Series
B
Convertible Preferred Stock held by such holder) divided among the holders
thereof, 44.3311% of the total number of shares of HAQ common stock allocated
in
the Merger to the holders of PharmAthene capital stock;
· the
holders of PharmAthene Series C Convertible Preferred Stock will receive, on
a
pro rata basis (determined based on the number of shares of PharmAthene Series
C
Convertible Preferred Stock held by such holder) divided among the holders
thereof, 31.7145% of the total number of shares of HAQ common stock allocated
in
the Merger to the holders of PharmAthene capital stock.
At
the
effective time of the Merger, all options to purchase shares of PharmAthene
stock then outstanding under the PharmAthene, Inc. 2002 Long-Term Incentive
Plan
(as amended, the “PharmAthene Plan”) or issued under any other agreement,
whether vested or unvested, shall be assumed by HAQ. The per-share exercise
price for the shares of HAQ common stock issuable upon exercise of such assumed
outstanding PharmAthene option will be equal to the quotient determined by
dividing the exercise price per share of PharmAthene common stock at which
such
outstanding PharmAthene option was exercisable immediately prior to the closing
of the Merger by the share exchange ratio, and rounding the resulting exercise
price up to the nearest whole cent. PharmAthene has, as of the date hereof,
options and warrants to acquire 9,625,197 shares of its common stock. The
share exchange ratio for the options and warrants is .0502. In summary, HAQ
shall grant 482,800 options and warrants with an average exercise price of
$___
per share in exchange for all of the PharmAthene options and warrants assumed
by
HAQ.
As
of
February 7, 2007, there were 11,650,000 shares of HAQ common stock outstanding.
The fully diluted number of shares of common stock, assuming the exercise of
all
outstanding warrants to purchase HAQ common stock, was 21,050,000 as of February
7, 2007 (but excluding the warrants underlying the unit purchase option).
Assuming no change in HAQ capitalization between the date of the Merger
Agreement and the closing of the Merger, 12,500,000 million shares of HAQ common
stock would be allocated to the PharmAthene equityholders in the manner
described above.
The
holders of more than 80% of the common stock, 100% of the preferred stock and
$11,625,000 principal amount of the 8% convertible noteholders of PharmAthene
have executed an Allocation Agreement evidencing their acceptance of the
foregoing allocations of the Merger. The foregoing allocation may be revised
to
reflect the exercise or termination of warrants or options to purchase
PharmAthene common stock which occurs after the date of the Merger Agreement
and
prior to the closing of the Merger. Additionally, the 12,500,000 shares of
HAQ
common stock issued as merger consideration will be subject to adjustment to
the
extent that the stockholders of HAQ owning more than 5% of the outstanding
HAQ
Common Stock exercise their conversion rights, the number of shares of HAQ
common stock comprising the stock consideration shall be adjusted upward by
the
product of (x) the number (as a percentage) that is the difference between
the
percentage of HAQ common stock that is converted and 5% and (y) 2.25 million.
Other
than warrants to purchase 263,296 shares of common stock of PharmAthene,
all warrants to purchase shares of PharmAthene capital stock will be cancelled
immediately prior to the closing of the Merger. After taking into account this
termination of warrants and assuming that all other currently outstanding
warrants to purchase shares of PharmAthene common stock and all options to
purchase shares of PharmAthene common stock are exercised to the maximum extent
allowable, there would be 22,108,669 shares of PharmAthene common stock
outstanding immediately prior to the Merger. No additional shares of HAQ common
stock will be issued as a result of such conversion and/or exercise.
It
is
expected that, immediately prior to the Merger, there will be 16,442,000 shares
of PharmAthene Series A Convertible Preferred Stock outstanding, 30,448,147
shares of PharmAthene Series B Convertible Preferred Stock outstanding, and
17,538,133 shares of PharmAthene Series C Convertible Preferred Stock
outstanding.
Based
on
the foregoing, and assuming no changes thereto, as a result of the Merger,
the
shares of PharmAthene common stock would convert into approximately 626,200
shares of HAQ common stock, the shares of PharmAthene Series A Convertible
Preferred Stock would convert into approximately 1,885,300 shares of HAQ common
stock, the shares of PharmAthene Series B Convertible Preferred Stock would
convert into approximately 5,541,388 shares of HAQ common stock, and the shares
of PharmAthene Series C Convertible Preferred Stock would convert into
approximately 3,964,313 shares of HAQ common stock. 482,800 shares of common
stock of HAQ will be reserved for issuance upon exercise of PharmAthene options
and warrants that will be assumed in the Merger as described below.
The
actual number of shares of HAQ common stock to be paid to the holders of each
class and series of PharmAthene stock will change only if the 5% contingency
described above occurs between the date of the Merger Agreement and the closing
of the Merger. In addition, the number of outstanding shares of PharmAthene’s
common stock, Series A Convertible Preferred Stock, Series B Convertible
Preferred Stock or Series C Convertible Preferred Stock could change upon the
occurrence of certain events including, but not limited to, (i) the exercise
of
warrants to purchase shares of either common stock or Series C Convertible
Preferred Stock, (ii) the exercise of options to purchase common stock, or
(iii)
the conversion of shares of Series A Convertible Preferred Stock, Series B
Convertible Preferred Stock or Series C Convertible Preferred Stock into
PharmAthene common stock.
At
the
closing, all series of preferred stock of PharmAthene will
be surrendered for conversion, all warrants held by the holders of the
PharmAthene preferred stock will be terminated, and related agreements
previously entered into by the holders of the preferred stock and
PharmAthene will be terminated.
All
of
the noteholders of PharmAthene will surrender their notes for exchange into
the
new 8% notes of HAQ.
All
registration rights, security agreements and any other agreement related to
the
preferred stock and notes of PharmAthene entered into by the holders of the
preferred stock and /or noteholders will be terminated.
No
fractional shares of HAQ common stock will be issued in the Merger. All
fractional shares of HAQ common stock to be distributed to an individual
stockholder of PharmAthene will be aggregated before determining whether a
fractional share remains. Any remaining fractional shares that would otherwise
be issuable in the Merger will be paid in cash.
8%
Convertible Notes to be Issued and Note Exchange Agreement
Pursuant
to the terms of the Merger Agreement, we have agreed to issue new 8% convertible
notes to the holders of PharmAthene’s outstanding 8% convertible notes. The new
notes will be in the aggregate principal amount of $12,500,000 and will replace
the existing PharmAthene notes in the principal amount of $11,800,000 (plus
accured interest). The new notes will be obligations of HAQ, not
PharmAthene.
The
new
notes will be issued, pursuant to the terms of a Note Exchange Agreement and
the
PharmAthene notes will be cancelled, as well as all existing agreements related
to such notes. Unless waived by HAQ, it is a condition to closing that all
of
the existing PharmAthene notes be cancelled at closing.
The
new
8% convertible notes will accrue interest at 8% per annum (based upon a 360
day
year), except, after an event of default, the interest rate will increase to
12%
per annum. Such interest shall only be payable upon repayment of the notes.
Prior to the payment of interest upon repayment, interest shall accrue at the
applicable interest rate and be payable by way of inclusion of the interest
in
the “conversion amount” as defined in the notes. The maturity date for payment
of all principal and interest on the new notes is two years from the date of
closing.
The
principal amount of the notes and any accrued interest are convertible into
shares of HAQ’s common stock at the option of the holders at any time based upon
an initial conversion rate of $10.00 per share. The noteholder is required
to
provide us with a written notice of the amount of his/her/its note to be
converted. If we fail to deliver a share certificate to the holder requesting
conversion within seven business days of the request to convert, we may incur
a
penalty equal to 1.5% per day of the product of the number of shares being
requesting and the closing sale price of our common stock on the day of the
request for conversion.
The
conversion rate is not subject to adjustment except for certain corporate events
such as stock splits, dividends and the like. There are no “price protection”
adjustments which otherwise would require an adjustment in the conversion ratio
as a result of the sale or issuance by us of shares of our common stock.
Upon
a
“change of control” as defined in the notes, noteholders may require HAQ to
redeem all (but not less than all) of their notes for a price equal to the
principal amount then outstanding, together with accrued and unpaid interest
with respect to such principal and any accrued and unpaid late charges with
respect to such principal and interest, provided, however, that at least
two-thirds of the aggregate principal amount of the notes then outstanding
submit optional change of control redemption notices.
A
“change
of control” generally means (1) HAQ shall (a) a consolidate or merge with or
into another person or subsidiary of another person in which the beneficial
owners of HAQ then outstanding voting securities immediately prior to such
transaction beneficially own securities representing 50% or more of the
aggregate voting power of then outstanding voting securities of the resulting
or
acquiring corporation (or any parent thereof), or their equivalent if other
than
a corporation, or (b) sell, assign, transfer, convey or otherwise dispose of
all
or substantially all of the properties or assets of the HAQ to another person,
or (c) be the subject of a purchase, tender or exchange offer that is accepted
by the holders of more than the 50% of the outstanding shares of common stock
(not including any shares of common stock held by the person or persons making
or party to, or associated or affiliated with the persons making or party to,
such purchase, tender or exchange offer), or (d) consummate a stock purchase
agreement or other business combination (including, without limitation, a
reorganization, recapitalization, spin-off or scheme of arrangement) with
another person whereby such other person or parent of such other person acquires
more than the 50% of the outstanding shares of common stock (not including
any
shares of common stock held by the other person or other persons making or
party
to, or associated or affiliated with the other persons making or party to,
such
stock purchase agreement or other business combination), (2) any time the HAQ’s
continuing directors do not constitute a majority of the HAQ’s Board of
Directors (or, if applicable, a successor entity”), or (3) a termination of
trading.
Upon
a
“significant transaction” as defined in the notes, noteholders may require HAQ
to redeem all (but not less than all) of their notes for a price equal to the
principal amount then outstanding, together with accrued and unpaid interest
with respect to such principal and any accrued and unpaid late charges with
respect to such principal and interest. A “significant transaction”
generally means any “fundamental transaction” as defined in the note or
other corporate transaction, or series of transactions, (including but not
limited to, any acquisition, disposition, merger, license or collaboration,
joint venture, financing or securities offering) that would result in either
(x)
the issuance of common stock and/or convertible securities that would exceed
40%
of the Common Stock outstanding prior to the transaction or (y) the payment
or
receipt of cash or other consideration of in excess of $25 million, unless
such
transaction has been approved by the two-thirds of the aggregate principal
amount of the notes then outstanding.
Commencing
upon the 12 month anniversary of issuance, we can prepay the notes, in full
or
in part, on not less than 30 days’ but not more than 60 days’ prior notice after
the one year anniversary of the merger, during which time the note holders
can
convert their notes into our common stock at the then current conversion price.
If we seek to prepay the notes, we are required to pay the principal amount
and
all accrued interest. If we send out a notice to the holders stating that we
are
redeeming the notes, and then fail to pay the redemption price within five
business days of the date set for redemption, the holders can request that
we
re-issue the notes surrendered for redemption or conversion and we will be
required to reduce the conversion price of the note to equal to the lowest
closing bid price of our common stock during the redemption period.
Under
the
terms of these agreements, the noteholders have a right to designate three
persons on our Board of Directors for so long as at least 30% of the original
principal amount of the notes remains outstanding. This is one of the reasons
we
are requesting, as part of Proposal 2, to amend our certificate of
incorporation. See Proposal 2 beginning on page 73 for a further discussion
of this right.
Each
of
the noteholders will be entitled to the rights under the Registration Rights
Agreement, as discussed below. In addition to the rights granted under the
Registration Rights Agreement, we have agreed that the noteholders will be
entitled to certain “penalty” provisions for the failure by us to satisfy the
obligations under the Registration Rights Agreement. If we fail to file a
registration statement within sixty days after closing of the Merger or fail
to
obtain an order of effectiveness within one hundred eighty days of closing,
there will be imposed a penalty of 1% of the aggregate amount of the notes
($125,000) for each such failure. Further, we will incur a further penalty
of 1%
of the principal amount of the notes for every thirty days that such failure
continues or for any period in excess of two days after effectiveness that
the
holders cannot avail themselves of the use of the registration statement.
We
have
agreed to reserve for issuance a number of shares equal to 120% of the total
number of shares issuable upon conversion at the then current conversion rate.
If we fail to maintain the required reserve amount, we are obligated to obtain
stockholder approval to increase our authorized shares within seventy-five
days.
We
agreed
with the noteholders that we would file a listing application with AMEX for
the
listing of the shares of our common stock issuable upon conversion of the notes.
Upon
an
event of default the principal and accrued interest becomes due and payable.
As
defined under the notes, an event of default includes the following
events:
· HAQ’s
failure to pay to the holder any amount of principal when and as
due;
· HAQ’s
failure to pay to the holder any amount of interest, late charges or other
amounts when and as due under the Note if such failure continues for a period
of
at least thirty business days;
· any
acceleration prior to maturity of any indebtedness of the definition thereof
of
HAQ or any of our subsidiaries which individually or in the aggregate is equal
to or greater than $250,000 principal amount of indebtedness;
· HAQ
or
any of our material subsidiaries, (A) commences a voluntary case, (B) consents
to the entry of an order for relief against it in an involuntary case, (C)
consents to the appointment of a receiver, trustee, assignee, liquidator or
similar official, (D) makes a general assignment for the benefit of its
creditors or (E) admits in writing that it is generally unable to pay its debts
as they become due;
· a
court
of competent jurisdiction enters an order or decree under any bankruptcy law
that is not vacated, set aside or reversed within sixty (60) days that (A)
is
for relief against HAQ or any of our material subsidiaries in an involuntary
case, (B) appoints a custodian or any of its material subsidiaries or (C) orders
the liquidation of HAQ or any of our material subsidiaries;
· a
final
judgment or judgments for the payment of money aggregating in excess of
$5,000,000 are rendered against HAQ or any of our Subsidiaries and which
judgments are not, within sixty days after the entry thereof, bonded, discharged
or stayed pending appeal, or are not discharged within sixty days after the
expiration of such stay; provided, however, that any judgment which is covered
by insurance or an indemnity from a credit worthy party shall not be included
in
calculating the $5,000,000 amount set forth above so long as HAQ provides the
holder a written statement from such insurer or indemnity provider (which
written statement shall be reasonably satisfactory to the holder) to the effect
that such judgment is covered by insurance or an indemnity and HAQ will receive
the proceeds of such insurance or indemnity within sixty days of the issuance
of
such judgment;
· HAQ
breaches any covenant or agreement or materially breaches any representation
or
warranty in any of the Notes, the Note Exchange Agreement or Registration Rights
Agreement and such breach continues for a period of at least thirty days after
written notice thereof from one or more Holders to HAQ; or
if
at any
time while at least thirty percent (30%) of the original aggregate principal
amount of the notes outstanding (x) the Board of Directors fails to include
three Directors designated by the noteholders or (y) without the consent of
the
persons then serving as noteholder directors, the Board of Directors exceeds
seven directors, or the compensation committee or nominating committee (or
other
committees serving similar functions) exceeds three members, or (z) the
noteholder directors are not afforded the right to appoint two members of each
of the compensation committee and nominating committee (or committees serving
similar functions). See Proposal 2 beginning on page 73 for a more detailed
description.
Milestone
Payments
Pursuant
to the terms of the Merger Agreement, HAQ has agreed that the PharmAthene
stockholders (including the holders of common stock, options and warrants)
would
be entitled to additional consideration equal to 10% of the actual collections
on gross sales of Valortim to the United States federal government (or a
department thereof) until the earlier of (A) December 31, 2009, or (B) total
aggregate milestone payments to such holders equal $10 million. The Milestone
Payments are conditioned upon receipt by PharmAthene of an award, procurement
or
other contract (x) on or before December 31, 2007; (y) which provides for a
procurement by the U.S. government (or a department thereof) of doses or
treatments equal to or greater than 60,000; and (z) with a total contract value
of $150 million or more. If these conditions are not satisfied, no Milestone
Payments will be paid or due. Any Milestone Payments owed will be
determined, in arrears, by HAQ within forty-five days of the end of each fiscal
quarter based on actual collections from the U.S. government (or a department
thereof) of gross sales, and will be paid within three business days of such
determination.
Effect
of Merger on PharmAthene Options and Warrants
At
the
effective time of the Merger, all options to purchase shares of PharmAthene
stock then outstanding under the PharmAthene, Inc. 2002 Long-Term Incentive
Plan
(as amended, the “PharmAthene Plan”) or issued under any other agreement,
whether vested or unvested, shall be assumed by HAQ. Each such outstanding
PharmAthene option so assumed by HAQ shall continue to have, and be subject
to,
the same terms and conditions set forth in the PharmAthene Plan, option
agreements thereunder and other relevant documentation in existence immediately
prior to the Merger, except that each such outstanding PharmAthene option will
be converted into an option to purchase that number of shares of HAQ common
stock calculated by multiplying the number of PharmAthene shares underlying
such
outstanding PharmAthene option by the share exchange ratio and rounding to
the
nearest whole share of HAQ common stock. The per-share exercise price for the
shares of HAQ common stock issuable upon exercise of such assumed outstanding
PharmAthene option will be equal to the quotient determined by dividing the
exercise price per share of PharmAthene common stock at which such outstanding
PharmAthene option was exercisable immediately prior to the closing of the
Merger by the share exchange ratio, and rounding the resulting exercise price
up
to the nearest whole cent. PharmAthene has, as of the date hereof, options
and
warrants to acquire 9,625,197 shares of its common stock. The share exchange
ratio for the options is .0502. As a consequence, HAQ shall grant 482,800
options and warrants with an average exercise price of $___ per share in
exchange for all of the PharmAthene options assumed by HAQ.
Except
for 263,296 warrants for shares of PharmAthene
common stock, all other warrants will be terminated. These remaining warrants
will be converted into warrants to acquire HAQ common stock and adjusted to
reflect the .0502 ratio.
HAQ
has
agreed to establish a new incentive plan containing terms no less favorable
to
holders of outstanding
PharmAthene options
and HAQ
shall reserve for issuance under such plan a sufficient number of shares of
HAQ
common stock for delivery upon exercise of outstanding
PharmAthene options
assumed
by HAQ under the Merger Agreement, as well as an additional 3,000,000 shares
of
HAQ common stock. See Proposal 3 beginning on page 76 for description of
the Incentive Plan.
Unless
provided for in the option grant or PharmAthene Plan, the vesting of each
outstanding
PharmAthene option
will not
automatically accelerate pursuant to its terms as a result of, or in connection
with, the transactions contemplated hereby.
Representations
and Warranties of the Parties
The
Merger Agreement contains customary representations and warranties made by
each
of HAQ and Merger Sub on the one hand, and PharmAthene on the other, regarding
various aspects of their respective businesses, financial condition and
structure, as well as other facts pertinent to the Merger. These representations
and warranties are subject to materiality, knowledge and other similar
qualifications in many. The representations and warranties of each of the
parties have been made solely for the benefit of the other party and those
representations and warranties should not be relied on by any other person,
except as specifically permitted in the documents relating to the Merger. In
addition, those representations and warranties may be intended not as statements
of actual fact, but rather as a way of allocating risk between the parties,
may
have been modified by the disclosure schedules attached to the Merger Agreement,
are subject to the materiality standard described in the Merger Agreement,
which
may differ from what may be viewed as material by you, and were made only as
of
the date of the Merger Agreement or another date as specified in the Merger
Agreement.
The
representations and warranties made by HAQ and PharmAthene to each other in
the
Merger Agreement include representations and warranties relating to the
following matters (in some cases, made by one party only, and also made in
certain instances with respect to their respective subsidiaries), among
others:
· corporate
organization, existence, good standing and power and authority;
· corporate
authorization to enter into and carry out the obligations contained in the
Merger Agreement and the valid and binding nature of such
obligations;
· absence
of any conflict or violation of the corporate charter and bylaws, any applicable
legal requirements, or any agreements with third parties, as a result of
entering into and carrying out the obligations contained in the Merger
Agreement;
· capital
structure and the absence of restrictions or encumbrances with respect to
capital stock;
· corporate
organization, qualifications to do business and corporate standing of
subsidiaries;
· ownership
of, and absence of restrictions or encumbrances with respect to, the capital
stock of subsidiaries;
· litigation;
· financial
statements;
· internal
accounting controls and disclosure controls and procedures;
· absence
of undisclosed liabilities;
· absence
of certain changes since December 31, 2005;
· intellectual
property;
· taxes
and
tax returns;
· title
to
assets and properties;
· leases
of
intangible or personal property;
· owned
and
leased real property;
· material
contracts and the absence of breaches of material contracts;
· compensation
of employees; absence of collective bargaining arrangements and labor liability
as a result of the Merger;
· benefit
plans;
· labor
relations;
· transactions
with affiliates;
· insurance;
· permits,
licenses, franchise and approvals;
· compliance
with applicable laws;
· environmental
matters;
· governmental
regulatory matters, including FDA rules and regulations;
· entitlements
to any broker’s, finder’s, or other similar fees, commissions or expenses in
connection with the transactions contemplated by the Merger
Agreement;
· absence
of certain business practices;
· restrictions
on business activities;
· inapplicability
of state takeover statutes;
· maintenance
of books and records; and
· disclosure.
Covenants
and Agreements
Operating
Covenants
Under
the
Merger Agreement PharmAthene has agreed, until the closing of the Merger, except
with the prior written consent of HAQ or as scheduled in the Merger Agreement,
to not:
· amend
its
certificate of incorporation or bylaws or equivalent organizational
documents;
· except
for the issuance of stock options under the PharmAthene Plan to employees and
consultants of PharmAthene, issue, deliver, sell, pledge, dispose of or
encumber, or authorize or commit to the issuance, sale, pledge, disposition
or
encumbrance of, any shares of capital stock of any class, or any options,
warrants, convertible securities or other rights of any kind to acquire any
shares of capital stock, or any other ownership interest (including, but not
limited to, stock appreciation rights or phantom stock), of
PharmAthene;
· declare,
set aside, make or pay any dividend or other distribution, payable in cash,
stock, property or otherwise, with respect to any of its capital
stock;
· acquire
(by merger, consolidation or acquisition of stock or assets) any corporation,
partnership or other business organization or division or line of
business;
· modify
its current investment policies or investment practices in any material respect
except to accommodate changes in applicable law;
· except
as
permitted, transfer, sell, lease, mortgage, or otherwise dispose of or subject
to any Lien any of its assets, including capital stock; and (ii) equipment
and property no longer used in the operation of PharmAthene’s business) other
than in the ordinary course of business consistent with past
practice;
· except
as
may be required as a result of a change in law or in generally accepted
accounting or actuarial principles, make any change to the accounting practices
or principles or reserving or underwriting practices or principles used by
it;
· settle
or
compromise any pending or threatened suit, action or claim (other than the
payment of health benefit claims on behalf of customers of PharmAthene)
involving a payment by PharmAthene in excess of $100,000;
· adopt
a
plan of complete or partial liquidation, dissolution, restructuring,
recapitalization or other reorganization of PharmAthene;
· fail
to
use commercially reasonable efforts to maintain in full force and effect the
existing insurance policies covering PharmAthene or its properties, assets
and
businesses or comparable replacement policies;
· authorize
or make capital expenditures in excess of $250,000;
· make
any
material tax election or settle or compromise any material federal, state,
local
or foreign tax liability, change any annual tax accounting period, change any
material method of tax accounting, enter into any closing agreement relating
to
any tax, or surrender any right to claim a tax refund or (ii) consent,
without providing advance notice to HAQ, to any extension or waiver of the
limitations period applicable to any Tax claim or assessment;
· reclassify,
combine, split, subdivide or redeem, purchase or otherwise acquire, directly
or
indirectly, any of its capital stock, stock options or debt
securities;
· repay
or
retire any indebtedness for borrowed money or repurchase or redeem any debt
securities;
· incur
any
indebtedness for borrowed money (including pursuant to any commercial paper
program or credit facility of PharmAthene) or issue any debt securities;
· assume,
guarantee or endorse, or otherwise as an accommodation become responsible for,
the obligations of any person, or make any loans, advances or capital
contributions to, or investments in, any other person, other than providers
of
PharmAthene in the ordinary course of business consistent with past
practice;
· enter
into or renew, extend, materially amend or otherwise materially modify
(i) any material contract of PharmAthene, or (ii) any other contract
or agreement (with “other contract or agreement” being defined for the purposes
of this subsection as a contract or agreement which involves PharmAthene
incurring a liability in excess of $250,000 and which is not terminable by
PharmAthene without penalty upon one year or less notice);
· increase
the compensation or fringe benefits of any of its directors, officers or
employees, except for increases in salary or wages of officers and employees
of
PharmAthene in the ordinary course of business in accordance with past practice,
or grant any severance or termination pay not currently required to be paid
under existing severance plans or enter into, or amend, any employment,
consulting or severance agreement or arrangement with any present or former
director, officer or other employee of PharmAthene, or establish, adopt, enter
into or amend or terminate any collective bargaining, bonus, profit sharing,
thrift, compensation, stock option, restricted stock, pension, retirement,
deferred compensation, employment, termination, welfare, severance or other
plan, agreement, trust, fund, policy or arrangement for the benefit of any
directors, officers or employees, except for any plan amendments to comply
with
Section 409A of the Internal Revenue Internal Revenue Code (provided that
any such amendments shall not materially increase the cost of such plan to
PharmAthene);
· grant
any
license with respect to intellectual property other than non-exclusive licenses
granted in the ordinary course of business;
· take
any
action or omit to take any action that would reasonably be expected to cause
any
intellectual property used or held for use in its business to become
invalidated, abandoned or dedicated to the public domain;
· take
or
fail to take any action that would prevent the Merger from qualifying as
reorganization within the meaning of Section 368(a) of the Internal Revenue
Internal Revenue Code;
· effectuate
a “plant closing” or “mass layoff” as those terms are defined in the Worker
Adjustment and Retraining Notification Act (WARN), affecting in whole or in
part
any site of employment, facility, operating unit or employee of
PharmAthene;
· pay,
discharge or satisfy any claims, liabilities or obligations (absolute accrued,
asserted or unasserted, contingent or otherwise), other than the payment,
discharge or satisfaction, in the ordinary course of business and consistent
with past practice, of liabilities reflected or reserved against in the
financial statements of PharmAthene or incurred in the ordinary course of
business and consistent with past practice;
· enter
into any transaction with, or enter into any agreement, arrangement, or
understanding with any of PharmAthene’s affiliates that would be required to be
disclosed pursuant to Item 404 of SEC Regulation S-K; or
· take,
or
offer or propose to take, or agree to take in writing or otherwise, any of
the
actions described above or any action which would result in any of the
conditions to the Merger not being satisfied or would materially delay the
closing of the Merger.
Also
under the Agreement and Plan of Merger, HAQ has agreed, until the closing of
the
Merger that, except with the prior written consent of PharmAthene, to
not:
· amend
the
HAQ charter or bylaws or equivalent organizational documents;
· issue,
deliver, sell, pledge, dispose of or encumber, or authorize or commit to the
issuance, sale, pledge, disposition or encumbrance of, any shares of capital
stock of any class, or any options, warrants, convertible securities or other
rights of any kind to acquire any shares of capital stock, or any other
ownership interest (including, but not limited to, stock appreciation rights
or
phantom stock), of HAQ;
· declare,
set aside, make or pay any dividend or other distribution, payable in cash,
stock, property or otherwise, with respect to any of its capital
stock;
· acquire
(by merger, consolidation or acquisition of stock or assets) any corporation,
partnership or other business organization or division or line of
business;
· modify
its current investment policies or investment practices in any material respect
except to accommodate changes in applicable law;
· transfer,
sell, lease, mortgage, or otherwise dispose of or subject to any Lien any of
its
assets, including capital stock other than in the ordinary course of business
consistent with past practice;
· except
as
may be required as a result of a change in law or in generally accepted
accounting or actuarial principles, make any change to the accounting practices
or principles or reserving or underwriting practices or principles used by
it;
· settle
or
compromise any pending or threatened suit, action or claim involving a payment
by HAQ in excess of $100,000;
· adopt
a
plan of complete or partial liquidation, dissolution, restructuring,
recapitalization or other reorganization of HAQ;
· fail
to
use commercially reasonable efforts to maintain in full force and effect the
existing insurance policies covering HAQ or its properties, assets and
businesses or comparable replacement policies;
· authorize
or make capital expenditures;
· make
any
material tax election or settle or compromise any material federal, state,
local
or foreign tax liability, change any annual tax accounting period, change any
material method of tax accounting, enter into any closing agreement relating
to
any tax, or surrender any right to claim a tax refund
· consent,
without providing advance notice to PharmAthene, to any extension or waiver
of
the limitations period applicable to any tax claim or assessment;
· reclassify,
combine, split, subdivide or redeem, purchase or otherwise acquire, directly
or
indirectly, any of its capital stock, stock options or debt
securities;
· repay
or
retire any indebtedness for borrowed money or repurchase or redeem any debt
securities;
· incur
any
indebtedness for borrowed money or issue any debt securities;
· assume,
guarantee or endorse, or otherwise as an accommodation become responsible for,
the obligations of any person, or make any loans, advances or capital
contributions to, or investments in, any other person, other than providers
of
HAQ in the ordinary course of business consistent with past
practice;
· enter
into or renew, extend, materially amend or otherwise materially modify
(i) any HAQ material contract, or (ii) any other contract or agreement
incurring a liability in excess of $250,000 and which is not terminable by
HAQ
without penalty upon one year or less notice;
· increase
the compensation or fringe benefits of any of its directors, officers or
employees, except for increases in salary or wages of officers and employees
of
HAQ in the ordinary course of business in accordance with past practice, or
grant any severance or termination pay not currently required to be paid under
existing severance plans or enter into, or amend, any employment, consulting
or
severance agreement or arrangement with any present or former director, officer
or other employee of HAQ, or establish, adopt, enter into or amend or terminate
any collective bargaining, bonus, profit sharing, thrift, compensation, stock
option, restricted stock, pension, retirement, deferred compensation,
employment, termination, welfare, severance or other plan, agreement, trust,
fund, policy or arrangement for the benefit of any directors, officers or
employees, except for any plan amendments to comply with Section 409A of
the Internal Revenue Code (provided that any such amendments shall not
materially increase the cost of such plan to HAQ);
· take
or
fail to take any action that would prevent the Merger from qualifying as
reorganization within the meaning of Section 368(a) of the Internal Revenue
Code;
· pay,
discharge or satisfy any claims, liabilities or obligations (absolute accrued,
asserted or unasserted, contingent or otherwise), other than the payment,
discharge or satisfaction, in the ordinary course of business and consistent
with past practice, of liabilities reflected or reserved against in the
financial statements of HAQ or incurred in the ordinary course of business
and
consistent with past practice;
· enter
into any transaction with, or enter into any agreement, arrangement, or
understanding with any of HAQ’s affiliates that would be required to be
disclosed pursuant to Item 404 of SEC Regulation S-K.
Board
of Directors
Prior
to
the Effective Time, HAQ agreed to take all necessary action so that,
effective
at the closing, the Board of Directors of HAQ shall be reconstituted and
pursuant to the HAQ charter and bylaws, be fixed at a total of seven persons,
and be comprised as follows: (i) PharmAthene shall designate four persons (one
of whom shall be the current Chief Executive Officer of PharmAthene); (ii)
HAQ
shall designate two persons; and (iii) PharmAthene and HAQ shall designate
one
person mutually acceptable to both of them. This is one of the reasons we are
submitting Proposal 2 to our stockholders for a vote. See Proposal 2 beginning
on page 73.
No
Solicitation
Under
the
Merger Agreement, PharmAthene and HAQ have agreed that from the date of the
Merger Agreement until the closing or termination of the Merger Agreement,
neither they nor any of their respective officers and directors shall, and
that
they shall use their respective commercially reasonable efforts to cause their
respective employees, agents and representatives (including any investment
banker, attorney or accountant retained by it) not to, directly or indirectly,
(i) initiate, solicit, encourage or knowingly facilitate any inquiries or the
making of any proposal or offer with respect to, or a transaction to effect,
a
merger, reorganization, share exchange, consolidation, business combination,
recapitalization, liquidation, dissolution or similar transaction involving
it
or any purchase, transfer or sale of the assets of it, or any purchase or sale
of, or tender or exchange offer for, its voting securities that (any such
proposal, offer or transaction (other than a proposal or offer made by the
other
party to the Merger Agreement or an affiliate thereof) being hereinafter
referred to as an “Acquisition Proposal”), (ii) have any discussions with or
provide any confidential information or data to any person relating to an
Acquisition Proposal, or engage in any negotiations concerning an Acquisition
Proposal, or knowingly facilitate any effort or attempt to make or implement
an
Acquisition Proposal, (iii) approve or recommend, or propose publicly to approve
or recommend, any Acquisition Proposal or (iv) approve or recommend, or propose
to approve or recommend, or execute or enter into, any letter of intent,
agreement in principle, merger agreement, asset purchase or share exchange
agreement, option agreement or other similar agreement related to any
Acquisition Proposal or propose or agree to do any of the foregoing.
Access
to Information
Each
of
PharmAthene and HAQ has agreed to give the other, its counsel, accountants
and
other representatives, reasonable access during normal business hours during
the
period prior to the closing, to the properties, books, records and personnel
of
the other to obtain all information concerning the business, including the
status of product development efforts, properties, results of operations and
personnel of the other, as such party may reasonably request.
Public
Announcements
PharmAthene
and HAQ have agreed to a joint communications plan and each party agreed to
(a) ensure that all press releases and other public statements and
communications (including any communications that would require a filing under
Rule 425, Rule 165 and Rule 166 of the Securities Act or
Rule 14a-12 of the Exchange Act) with respect to the Merger Agreement and
the transactions contemplated thereby shall be consistent with such joint
communications plan and (b) unless otherwise required by applicable law or
by obligations pursuant to any listing agreement with or rules of any securities
exchange, PharmAthene will consult with HAQ for a reasonable time before issuing
any press release or otherwise making any public statement or communication
(including any communication that would require a filing under Rule 425,
Rule 165 and Rule 166 of the Securities Act or Rule 14a-12 of the
Exchange Act). HAQ and PharmAthene have also agreed to consult with each other
prior to the release of any press release of PharmAthene or any such public
statement or communication by PharmAthene, with respect to the Merger Agreement
or the transactions contemplated hereby. In addition to the foregoing, except
to
the extent required by applicable law, HAQ and PharmAthene agreed not to issue
any press release or otherwise make any public statement or disclosure
concerning the other party or the other party’s business, financial condition or
results of operations without the consent of the other party.
Other
Agreements
Additionally,
HAQ and PharmAthene have agreed to use commercially reasonable efforts to obtain
necessary consents and approvals in connection with the Merger Agreement, and
to
list the HAQ common stock issued as merger consideration (including shares
issuable upon conversion of the 8% convertible notes) for trading on the AMEX.
The parties believe there are no unordinary consents to be
obtained.
Operations
After the Merger
Following
the Merger, PharmAthene will continue its operations as a wholly owned
subsidiary of HAQ. The stockholders of PharmAthene will become stockholders
of
HAQ, and their rights as stockholders will be governed by the HAQ amended and
restated certificate of incorporation, the HAQ bylaws, and the laws of the
State
of Delaware.
Conditions
to the Completion of the Merger
The
obligations of HAQ and PharmAthene to complete the Merger are subject to the
satisfaction or waiver of specified conditions before completion of the Merger,
including the following:
Conditions
to HAQ’s and PharmAthene’s obligations to consummate the
Merger:
The
respective obligations of each of HAQ and PharmAthene to consummate the Merger
are subject to the satisfaction of, or waiver of, the following
conditions:
· the
receipt of HAQ stockholder approval;
· the
receipt of PharmAthene stockholder approval (which has been obtained and is
irrevocable);
· holders
of the outstanding notes of PharmAthene shall have executed the Note Exchange
Agreement;
· the
outstanding classes of preferred stock of PharmAthene, as well as related
warrants and side agreements are terminated in full; and
· the
absence of any order or injunction preventing consummation of the
merger.
Conditions
to HAQ’s obligations:
The
obligation of HAQ to consummate the Merger is further subject to the following
conditions, among others:
· the
representations and warranties made by PharmAthene must be true and correct
in
all material respects;
· PharmAthene
must have performed in all material respects all obligations required to be
performed by it under the terms of the Merger Agreement;
· there
must not have occurred since the date of the Merger Agreement any material
adverse effect on PharmAthene’s financial condition or business;
and
· PharmAthene
shall have delivered to HAQ executed termination agreements from the holders
of
the PharmAthene preferred stock and noteholders whereby the holders of such
securities terminate all rights under any agreements entered into by PharmAthene
and such preferred stockholders and noteholders.
Conditions
to PharmAthene’s obligations:
The
obligation of PharmAthene to consummate the Merger is further subject to the
following conditions, among others:
· the
representations and warranties made by HAQ and Merger Sub must be true and
correct in all respects;
· HAQ
and
Merger Sub must have performed in all material respects all obligations required
to be performed by it under the terms of the Merger Agreement;
· there
must not have occurred since the date of the Merger Agreement any material
adverse effect on the financial condition or business of HAQ or Merger
Sub;
· the
HAQ
certificate of incorporation shall have been amended and restated to provide
for
board designee rights of the 8% convertible noteholders; and
· the
12,500,000 shares of HAQ common stock issuable in the Merger and the shares
into
which the new 8% convertible notes to be issued in the Merger may be converted
shall have been accepted for listing on the American Stock
Exchange.
Materiality
and Material Adverse Effect
Certain
of the representations and warranties are qualified by materiality or material
adverse effect. For the purposes of the Merger Agreement, a material adverse
effect on an entity means any change, effect, event, occurrence or state of
facts which is, or is reasonably expected to be, materially adverse to the
business, financial condition, results of operations or prospects of such party
and its subsidiaries, taken as a whole, other than any change, effect, event
or
occurrence relating to (i) the economy or securities markets of the U.S. or
any
other region in general or (ii) the Merger Agreement or the transactions
contemplated thereby or the announcement thereof or otherwise as contemplated
by
the Merger Agreement or disclosed thereunder.
Termination
The
Merger Agreement may be terminated at any time prior to the completion of the
Merger, whether before or after receipt of stockholder approval, by mutual
written consent of HAQ, Merger Sub and PharmAthene.
Either
HAQ or PharmAthene may terminate the Merger Agreement if:
|
|
· the
Merger is not consummated on or before August 3, 2007;
or
|
|
|
|
|
|
· any
permanent injunction or other order of a court or other competent
authority preventing the consummation of the Merger shall have become
final and nonappealable; or
|
|
|
|
|
|
· if
during any 15-day trading period following the execution of the Merger
Agreement and before its consummation, the average trading price
of the
publicly-traded warrants of HAQ is below $0.20 per
warrant.
|
PharmAthene
may terminate the Merger Agreement if:
· prior
to
the closing date there shall have been a material breach of any representation,
warranty, covenant or agreement on the part of HAQ or Merger Sub, subject to
certain conditions and a right to cure (within proscribed notice periods);
or
· any
of
the conditions to the consummation of the Merger shall have become incapable
of
fulfillment; or
· HAQ
has
not held its Special Meeting of Stockholders to approve the Merger within
thirty-five (35) days of approval of the proxy statement by the SEC;
or
·
HAQ’s
Board of Directors has withdrawn or changed its recommendation to it
stockholders regarding the Merger; or
· more
than
20% of the holders of the shares issued in HAQ’s IPO entitled to vote on the
Merger elect to convert such shares into cash from the trust fund.
HAQ
may
terminate the Merger Agreement if:
· prior
to
the closing date there shall have been a material breach of any representation,
warranty, covenant or agreement on the part of PharmAthene, subject to certain
conditions and a right to cure, as further described below; or
· any
of
the conditions to the consummation of the Merger shall have become incapable
of
fulfillment; or
· necessary
consents, individually or in the aggregate contain any burdensome terms or
conditions which have a material adverse effect on PharmAthene or
HAQ.
If
permitted under applicable law, either HAQ or PharmAthene may waive conditions
for their own respective benefit and consummate the Merger, even though one
or
more of these conditions have not been met. We cannot assure you that all of
the
conditions will be satisfied or waived or that the Merger will
occur.
If
certain deadlines set forth in the Merger Agreement are not met, and if
prior
to
the closing date there shall have been a material breach of any representation,
warranty, covenant or agreement on the part of either party contained in the
Merger Agreement or any representation or warranty of either party contained
in
the Merger Agreement shall have become untrue after the date of the Merger
Agreement, which breach or untrue representation or warranty cannot be cured
as
described in the Merger Agreement,
then
the non-terminating party may be liable to the other for a termination fee
of
$250,000 which in the case of PharmAthene, is limited to all cash held outside
of HAQ’s trust fund.
Indemnification
of Claims and Escrow of Shares
Under
the
terms of the Merger Agreement the stockholders, optionholders and warrantholders
of PharmAthene agreed to indemnify HAQ for the breach of any representations
or
warranties or covenants by PharmAthene. 1,375,000 shares from the merger
consideration will be placed into escrow which shares will be used to satisfy
any claims. The indemnification is subject to a limitation that we incur damages
of at least $500,000 prior to making any claim. Further, the indemnification
obligation is limited solely and exclusively to the shares held in escrow.
The
shares will be held in escrow until satisfaction of any claims. Any claims
by us
against the shares must be made within 12 months of closing of the Merger.
For
purposes of determining the number of shares required to settle any claim for
which we are entitled to indemnification, the parties have agreed to assign
a
value equal to the average reported last sales price for the ten trading days
ending on the last day prior to the date that the claim for indemnification
is
publicly disclosed (or if there is no public disclosure, the date on which
the
indemnification notice is received) and the ten trading days after such date.
HAQ and the PharmAthene stockholders, optionholders and warrantholders, in
each
case, have agreed to appoint a representative who will have the power and
authority to negotiate and settle claims. Additionally, the representatives
of
the two parties can mutually agree to a different value of the escrowed shares
in order to settle third parties claims, or use the shares to actually settle
any claim. Mr. John Pappajohn has been appointed to serve as HAQ’s
representative and MPM BioVentures III-QP, L.P. has been appointed to serve
as
the representative of the PharmAthene stockholders, optionholders and
warrantholders.
Representative
PharmAthene
designated its representative with authority to make all decisions and
determinations and to take all actions required or permitted under the Merger
Agreement and the Escrow Agreement on behalf of the PharmAthene stockholders,
optionholders and warrantholders. Any such action, decision or determination
so
made or taken shall be deemed the action, decision or determination of the
PharmAthene stockholders, optionholders and warrantholders, and any notice,
document, certificate or information required to be given to any PharmAthene
stockholders, optionholders and warrantholders shall be deemed so given if
given
to the representative. As such representative is also a stockholder of
PharmAthene, it is possible that potential conflicts of interest may arise
with
respect to their obligations as representatives and their interests as
stockholders of PharmAthene. 1,375,000 shares of HAQ Common Stock issued
as merger consideration will be placed into an escrow account, from which the
representative will have the right to withdraw shares necessary to in the
performance of its duties. Any remaining shares held in such account will be
released to the PharmAthene stockholders on the first anniversary of the closing
of the Merger or such time that there are no unresolved claims for
indemnification.
Assignment
The
Merger Agreement and the rights and obligations of the parties thereunder may
not be assigned, transferred or encumbered without the prior written consent
of
the other parties.
Further
Assurances
Each
of
HAQ and PharmAthene agree that it will execute and deliver, or cause to be
executed and delivered, on or after the date of the Merger Agreement, all such
other documents and instruments and will take all reasonable actions as may
be
necessary to transfer and convey the securities of PharmAthene to
HAQ.
OTHER
AGREEMENTS RELATED TO THE MERGER
Registration
Rights Agreement
In
connection with the Merger, we have agreed to grant to the recipients of the
shares of our common stock and the noteholders receiving the new 8% convertible
notes, certain registration rights to allow them to resell their shares in
accordance with the federal securities laws. At the closing of the Merger,
assuming it is approved by our stockholders, we will enter into a registration
rights agreement with each of the recipients of our common stock and the notes.
Under
the
terms of the registration rights agreement, we will agree to file a registration
statement with the Securities and Exchange Commission under the Securities
Act
of 1933, as amended to allow for the resale by the holders of the shares and
the
note conversion shares, which filing will be made within 60 days after the
closing of the Merger. We will further agree to use our best efforts to have
the
registration statement declared effective as soon after filing as
possible.
We
will
also agree that the holders of a majority of the shares and note conversion
shares will have the right to demand that we file a registration statement
on
their behalf at any time commencing 180 days after the closing of the Merger.
Further, if two thirds of the holders so request, we will enter into an
underwriting agreement with an underwriter so that the shares can be offered
on
an underwritten basis. Lastly, if during the five years following the closing
we
file a registration statement to provide for the resale of shares, we will
agree
to notify the holders of the shares and the note conversion shares and if so
requested by a holder, we will include his/her or its shares in the registration
statement being filed.
Lock-Up
Agreements
As
a
condition to the closing of the Merger, substantially all of the holders of
capital stock and all of the noteholders of PharmAthene are required to enter
into lock-up agreements covering the shares of HAQ common stock that they are
to
receive in the Merger or that they may acquire in the future subject to certain
limitations. These agreements provide that, subject to certain exceptions,
the
parties thereto may not offer, pledge, sell, or otherwise dispose of or transfer
any shares of HAQ common stock, or any options or warrants to purchase any
shares of HAQ common stock, or any securities convertible into or exchangeable
or exercisable for HAQ common stock following the closing of the Merger. In
addition, the parties may not enter into any swap or any other agreement or
any
transaction that transfers the economic consequence of ownership of such HAQ
common stock during such period. Fifty percent of the shares of HAQ common
stock
subject to the lock-up agreements shall be released from the lock-up six months
following the Merger, and all shares of HAQ common stock subject to the lock-up
shall be released from the lock-up agreement twelve months following the
closing.
Employment
Agreements
A
condition to HAQ’s obligation to consummate the Merger is that David Wright, the
current Chief Executive Officer of PharmAthene, enter into a mutually acceptable
employment agreement with HAQ. The parties are negotiating the terms of such
agreement.
THE
AMENDMENT PROPOSAL
Pursuant
to the Merger Agreement, HAQ has agreed to amend its amended and restated
certificate of incorporation to change its corporate name from Healthcare
Acquisition Corp. to PharmAthene, Inc. upon consummation of the
Merger.
General
HAQ
also
proposes to amend its amended and restated certificate of incorporation to
(i)
remove the staggered Board provision (ii) remove those provisions of HAQ’S
amended and restated certificate of incorporation that will no longer be
operative upon consummation of the Merger (which constitutes a business
combination for purposes of HAQ’s amended and restated certificate of
incorporation), but which were applicable at the time of HAQ’s formation as a
blank-check company and (iii) grant the right to the 8% convertible note holders
to appoint three members to the Board of Directors. In order to accomplish
this,
the text of Article Sixth will be replaced in its entirety.
Article
Sixth of HAQ’s amended and restated certificate of incorporation currently reads
as follows:
The
following provisions (A) through (E) shall apply during the period commencing
upon the filing of this Certificate of Incorporation and terminating upon the
consummation of any “Business Combination”, and may not be amended prior to the
consummation of any Business Combination. A “Business Combination” shall mean
the acquisition by the Corporation, whether by merger, capital stock exchange,
asset or stock acquisition or other similar type of transaction, of assets
or an
operating business in the healthcare industry (“Target Business”).
A.
Prior
to the consummation of any Business Combination, the Corporation shall submit
such Business Combination to its stockholders for approval regardless of whether
the Business Combination is of a type which normally would require such
stockholder approval under the GCL. In the event that a majority of the IPO
Shares (defined below) cast at the meeting to approve the Business Combination
are voted for the approval of such Business Combination, the Corporation shall
be authorized to consummate the Business Combination; provided that the
Corporation shall not consummate any Business Combination if 20% or more in
interest of the holders of IPO Shares exercise their conversion rights described
in paragraph B below.
B.
In the
event that a Business Combination is approved in accordance with the above
paragraph A and is consummated by the Corporation, any stockholder of the
Corporation holding shares of Common Stock (“IPO Shares”) issued in the
Corporation’s initial public offering (“IPO”) of securities who voted against
the Business Combination may, contemporaneous with such vote, demand that the
Corporation convert his IPO Shares into cash. If so demanded, the Corporation
shall convert such shares at a per share conversion price equal to the quotient
determined by dividing (i) the amount in the Trust Fund (as defined below),
inclusive of any interest thereon, calculated as of two business days prior
to
the proposed consummation of the Business Combination, by (ii) the total number
of IPO Shares. “Trust Fund” shall mean the trust account established by the
Corporation at the consummation of its IPO and into which a certain amount
of
the net proceeds of the IPO are deposited.
C.
In the
event that the Corporation does not consummate a Business Combination by the
later of (i) 18 months after the consummation of the IPO or (ii) 24 months
after
the consummation of the IPO in the event that either a letter of intent, an
agreement in principle or a definitive agreement to complete a Business
Combination was executed but was not consummated within such 18 month period
(such later date being referred to as the “Termination Date”), the officers of
the Corporation shall take all such action necessary to dissolve and liquidate
the Corporation as soon as reasonably practicable. In the event that the
Corporation is so dissolved and liquidated, only the holders of IPO Shares
(at
such time) shall be entitled to receive liquidating distributions and the
Corporation shall pay no liquidating distributions with respect to any other
shares of capital stock of the Corporation.
D.
A
holder of IPO Shares shall be entitled to receive distributions from the Trust
Fund only in the event of a liquidation of the Corporation or in the event
he
demands conversion of his shares in accordance with paragraph B, above. In
no
other circumstances shall a holder of IPO Shares have any right or interest
of
any kind in or to the Trust Fund.
E.
The
Board of Directors shall be divided into two classes: Class A and Class B.
The
number of directors in each class shall be as nearly equal as possible. Prior
to
the IPO, there shall be elected two Class A directors for a term expiring at
the
Corporation’s first Annual Meeting of Stockholders and three Class B directors
for a term expiring at the Corporation’s second Annual Meeting of Stockholders.
Commencing at the first Annual Meeting of Stockholders, and at each annual
meeting thereafter, directors elected to succeed those directors whose terms
expire shall be elected for a term of office to expire at the second succeeding
annual meeting of stockholders after their election. Except as the GCL may
otherwise require, in the interim between annual meetings of stockholders or
special meetings of stockholders called for the election of directors and/or
the
removal of one or more directors and the filling of any vacancy in that
connection, newly created directorships and any vacancies in the Board of
Directors, including unfilled vacancies resulting from the removal of directors
for cause, may be filled by the vote of a majority of the remaining directors
then in office, although less than a quorum (as defined in the Corporation’s
Bylaws), or by the sole remaining director. All directors shall hold office
until the expiration of their respective terms of office and until their
successors shall have been elected and qualified. A director elected to fill
a
vacancy resulting from the death, resignation or removal of a director shall
serve for the remainder of the full term of the director whose death,
resignation or removal shall have created such vacancy and until his successor
shall have been elected and qualified.
If
this
proposal is approved by the stockholders, Article Sixth will read in its
entirety as follows:
For
so
long as at least 30% of the aggregate principal amount of the 8%
convertible notes of the Corporation (the “Notes”) issued on _____, 2007 in the
original aggregate amount of $12,500,000 remains outstanding (and
notwithstanding the existence of less than three (3) noteholders at any given
time), the following provisions shall apply:
A.
the
Corporation shall maintain a Board of Directors consisting of no more than
seven
(7) individuals and each committee of the Board of Directors shall have no
more
than three (3) members;
B.
three
(3) members of the Corporation’s Board of Directors (the “Noteholder Directors”)
shall be elected by the holders of Notes representing two-thirds of the
then outstanding principal amount of all Notes, voting as a separate
class;
C.
subject to applicable law, two (2) Noteholder Directors (in each case chosen
by
majority vote of all of the Noteholder Directors) shall have the right, but
not
the obligation, to serve as members of each committee of the Board of
Directors;
D.
the
Board of Directors of the Corporation shall nominate as Noteholder Directors
only the persons designated as directors pursuant to the Note Exchange
Agreement, dated ____, 2007, by and among HAQ and the holders of the Notes
and
recommend that the holders of the Notes vote to elect such nominees as directors
of the Corporation and shall fill any vacancies that may arise upon the
resignation of any of the Noteholder Directors with a new Noteholder Director
designated in accordance with the foregoing. A Noteholder Director elected
to
fill a vacancy resulting from the death, resignation or removal of a Noteholder
Director shall serve for the remainder of the full term of the Noteholder
Director whose death, resignation or removal shall have created such vacancy
and
until his successor shall have been elected and qualified; and
E.
the
provisions contained in this Article SIXTH shall terminate immediately and
without further action when less than 30% of the aggregate principal amount
of
the Notes remains outstanding.
If
the
Merger Proposal is not approved, this proposal will not be presented at the
meeting. In addition, if the Merger is not subsequently consummated, HAQ’s Board
of Directors will not effect this amendment to HAQ’s amended and restated
certificate of incorporation.
Stockholders
will not be required to exchange outstanding stock certificates for new stock
certificates if the amendment is adopted.
In
the
judgment of HAQ’s Board of Directors, if the Merger is consummated, the
amendment to HAQ’s second amended and restated certificate of incorporation to:
(i) change HAQ’s corporate name, (ii) eliminate the staggered Board and remove
those provisions of HAQ’s second amended and restated certificate of
incorporation that will no longer be operative upon consummation of the Merger
and (iii) to grant the right to the 8% noteholders to appoint three members
to
the Board of Directors, is desirable, among other things, to reflect the fact
that HAQ would then be an operating business. A copy of the amended and restated
certificate of incorporation as it would be filed if the Merger Proposal and
the
proposal to amend HAQ’s amended and restated certificate of incorporation are
approved is attached to this proxy statement as Annex B.
Required
Vote
The
approval of the Amendment Proposal requires the affirmative vote of holders
of
at least a majority of the outstanding shares of our common stock. Abstentions
and broker non-votes, as well as failing to vote by not returning your proxy
card, because they are not affirmative votes, will have the same effect as
a
vote against this proposal.
Recommendation
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE
APPROVAL OF THE AMENDMENT PROPOSAL.
PROPOSAL
3
THE
INCENTIVE PLAN PROPOSAL
HAQ’s
2007 Long-Term Incentive Plan has been approved by HAQ’s Board of Directors
subject to approval and consummation of the Merger and further subject to the
approval of our stockholders. The approval of the Merger Proposal and the
consummation of the Merger are conditions to the effectiveness of the Amendment
Proposal and the Incentive Plan Proposal, assuming such proposals are approved
by the stockholders. If the Merger Proposal is not approved and/or the Merger
is
not consummated, the Incentive Plan will not be adopted.
The
purposes of our Incentive Plan are to create incentives designed to motivate
our
employees to significantly contribute toward our growth and profitability,
to
provide our executives, directors and other employees, and persons who, by
their
position, ability and diligence, are able to make important contributions to
our
growth and profitability, with an incentive to assist us in achieving our
long-term corporate objectives, to attract and retain executives and other
employees of outstanding competence, and to provide such persons with an
opportunity to acquire an equity interest in us.
We
may
grant incentive and non-qualified stock options, stock appreciation rights,
performance units, restricted stock awards and performance bonuses, or
collectively, awards, to our officers and key employees, and those of our
subsidiaries. In addition, the Incentive Plan authorizes the grant of
non-qualified stock options and restricted stock awards to our directors and
to
any independent contractors and consultants who by their position, ability
and
diligence are able to make important contributions to our future growth and
profitability. Generally, all classes of our employees are eligible to
participate in our Incentive Plan. No options, restricted stock or other awards
under the Incentive Plan have been made or committed to be made as of the date
of this proxy statement.
The
following is a summary of the material provisions of our Incentive Plan and
is
qualified in its entirety by reference to the complete text of our Incentive
Plan, a copy of which is attached to this proxy statement as Annex
C.
Stock
Subject to the 2007 Incentive Plan
We
have
reserved a maximum of 3,500,000 shares of our authorized common stock for
issuance upon the exercise of awards to be granted pursuant to our Incentive
Plan. Each share issued under an option or under a restricted stock award will
be counted against this limit. Shares to be delivered at the time a stock option
is exercised or at the time a restricted stock award is made may be available
from authorized but unissued shares or from stock previously issued but which
we
have reacquired and hold in our treasury.
In
the
event of any change in our outstanding common stock by reason of any
reorganization, recapitalization, stock split, stock dividend, combination
of
shares, asset acquisition, consolidation, issuance of rights or other similar
transactions, the number of shares of our common stock which may be issued
upon
exercise of outstanding options, and the exercise price of options previously
granted under our Incentive Plan, will be proportionally adjusted to prevent
any
enlargement or dilution of the rights of holders of previously granted options
as may be appropriate to reflect any such transaction or event.
Administration
Our
Board
will establish a compensation committee that, among other duties, will
administer the Incentive Plan. The compensation committee will be composed
of
three members of the Board, a majority of whom will be “non-employee directors”
within the meaning of Rule 16b-3(b)(3) of the Securities Exchange Act of 1934,
as amended. Under the terms of the Note Exchange Agreement and the Merger
Agreement, HAQ has agreed that two of the three members of the Committee will
be
representatives of the holders of the 8% convertible notes. Members of our
compensation committee will serve at the pleasure of our Board. In connection
with the administration of our Incentive Plan, the compensation committee,
with
respect to awards to be made to any person who is not one of our directors,
will:
·
determine
which employees and other persons will be granted awards under our Incentive
Plan;
·
grant
the
awards to those selected to participate;
·
determine
the exercise price for options; and
·
prescribe
any limitations, restrictions and conditions upon any awards, including the
vesting conditions of awards.
With
respect to stock options or restricted stock awards to be made to any of our
directors, the Compensation Committee will make recommendations to our Board
of
Directors as to:
·
which
of
such persons should be granted stock options, restricted stock awards,
performance units or stock appreciation rights;
·
the
terms
of proposed grants of awards to those selected by our Board of Directors to
participate;
·
the
exercise price for options; and
·
any
limitations, restrictions and conditions upon any awards.
Any
grant
of awards to any of directors under our Incentive Plan must be approved by
our
Board of Directors.
In
addition, the compensation committee will:
·
interpret
our Incentive Plan; and
·
make
all
other determinations and take all other action that may be necessary or
advisable to implement and administer our Incentive Plan.
Types
of Awards
Our
Incentive Plan permits the Compensation Committee to grant the following types
of awards.
Stock
Options.
Stock
options are contractual rights entitling an optionee who has been granted a
stock option to purchase a stated number of shares of our common stock at an
exercise price per share determined at the date of the grant. Options are
evidenced by stock option agreements with the respective optionees. The exercise
price for each stock option granted under our Incentive Plan will be determined
by our Board of Directors or a committee of the Board at the time of the grant,
but will not be less than fair market value on the date of the grant. Our Board
of Directors or a committee of the Board will also determine the duration of
each option; however, no option may be exercisable more than ten years after
the
date the option is granted. Within the foregoing limitations, the Board of
Directors or committee of the Board may, in its discretion, impose limitations
on exercise of all or some options granted under our Incentive Plan, such as
specifying minimum periods of time after grant during which options may not
be
exercised. Options granted under our Incentive Plan will vest at rates specified
in the option agreement at the time of grant; however, all options granted
under
our Incentive Plan will vest upon the occurrence of a change of control, as
defined in the Incentive Plan. Our Incentive Plan also contains provisions
for
our Board of Directors or a committee of the Board to provide in the
participants’ option award agreements for accelerating the right of an
individual employee to exercise his or her stock option or restricted stock
award in the event of retirement or other termination of employment. No cash
consideration is payable to us in exchange for the grant of
options.
Our
Incentive Plan provides that the stock options may either be Incentive Stock
Options within the meaning of Section 422 of the Internal Revenue Code of 1986,
as amended, or Non-Qualified Options, which are stock options other than
Incentive Stock Options within the meaning of Sections 422 of the Code.
Incentive Stock Options may be granted only to our employees or employees of
our
subsidiaries, and must be granted at a per share option price not less than
the
fair market value of our common stock on the date the Incentive Stock Option
is
granted. In the case of an Incentive Stock Option granted to a stockholder
who
owns shares of our outstanding stock of all classes representing more that
10%
of the total combined voting power of all of our outstanding stock of all
classes entitled to vote in the election of directors, the per share option
price must be not less than 110% of the fair market value of one share of our
common stock on the date the Incentive Stock Option is granted and the term
of
such option may not exceed five years. As required by the Code, the aggregate
fair market value, determined at the time an Incentive Stock Option is granted,
of our common stock with respect to which Incentive Stock Options may be
exercised by an optionee for the first time during any calendar year under
all
of our incentive stock option plans may not exceed $100,000.
The
exercise price for Non-Qualified Options may not be less than the fair market
value of our common stock on the date the Non-Qualified Option is granted.
Non-Qualified Options are not subject to any of the restrictions described
above
with respect to Incentive Stock Options. The exercise price of stock options
may
be paid in cash, in whole shares of our common stock, in a combination of cash
and our common stock, or in such other form of consideration as our Board of
Directors or the committee of the Board may determine, equal in value to the
exercise price. However, only shares of our common stock which the option holder
has held for at least six months on the date of the exercise may be surrendered
in payment of the exercise price for the options. In no event may a stock option
be exercised after the expiration of its stated term.
Stock
Appreciation Rights.
A stock
appreciation right permits the grantee to receive an amount (in cash, common
stock, or a combination thereof) equal to the number of stock appreciation
rights exercised by the grantee multiplied by the excess of the fair market
value of our common stock on the exercise date over the stock appreciation
rights’ exercise price. Stock appreciation rights may or may not be granted in
connection with the grant of an option. The exercise price of stock appreciation
rights granted under the Incentive Plan will be determined by the Board of
Directors or a committee of the Board; provided, however, that such exercise
price cannot be less than the fair market value of a share of common stock
on a
date the stock appreciation right is granted (subject to adjustments). A stock
appreciation right may be exercised in whole or in such installments and at
such
times as determined by the Board of Directors or a committee of the
Board.
Restricted
Stock.
Restricted shares of our common stock may be granted under our Incentive Plan
subject to such terms and conditions, including forfeiture and vesting
provisions, and restrictions against sale, transfer or other disposition as
the
Board of Directors or a committee of the Board may determine to be appropriate
at the time of making the award. In addition, the Board of Directors or a
committee of the Board may direct that share certificates representing
restricted stock be inscribed with a legend as to the restrictions on sale,
transfer or other disposition, and may direct that the certificates, along
with
a stock power signed in blank by the grantee, be delivered to and held by us
until such restrictions lapse. The Board of Directors or a committee of the
Board, in its discretion, may provide in the award agreement for a modification
or acceleration of shares of restricted stock in the event of permanent
disability, retirement or other termination of employment or business
relationship with the grantee.
Performance
Units.
The
Incentive Plan permits grants of performance units, which are rights to receive
cash payments equal to the difference (if any) between the fair market value
of
our common stock on the date of grant and its fair market value on the date
of
exercise of the award, except to the extent otherwise provided by the Board
of
Directors or a committee of the Board or required by law. Such awards are
subject to the fulfillment of conditions that may be established by the Board
of
Directors or a committee of the Board including, without limitation, the
achievement of performance targets based upon the factors described above
relating to restricted stock awards.
Performance
Bonus.
The
Incentive Plan permits grants of performance bonuses, which may be paid in
cash,
common stock or combination thereof as determined by the Board of Directors
or a
committee of the Board. The maximum value of performance bonus awards granted
under the Incentive Plan shall be established by the compensation committee
at
the time of the grant. An employee’s receipt of such amount will be contingent
upon achievement of performance targets during the performance period
established by the compensation committee. The performance targets will be
determined by the Board of Directors or a committee of the Board based upon
the
factors described above relating to restricted stock awards. Following the
end
of the performance period, the Board of Directors or a committee of the Board
will determine the achievement of the performance targets for such performance
period. Payment may be made within 60 days of such determination. Any payment
made in shares of common stock will be based upon the fair market value of
the
common stock on the payment date.
Transferability
With
the
exception of Non-Qualified Stock Options, awards are not transferable other
than
by will or by the laws of descent and distribution. Non-Qualified Stock Options
are transferable on a limited basis. Restricted stock awards are not
transferable during the restriction period.
Change
of Control Event
The
Incentive Plan provides for the acceleration of any unvested portion of any
outstanding awards under the Incentive Plan upon a change of control event
unless the terms of a particular award state otherwise.
Termination
of Employment/Relationship
Awards
granted under our Incentive Plan that have not vested will generally terminate
immediately upon the grantee’s termination of employment or business
relationship with us or any of our subsidiaries for any reason other than
retirement with our consent, disability or death. The Board of Directors or
a
committee of the Board may determine at the time of the grant that an award
agreement should contain provisions permitting the grantee to exercise the
stock
options for any stated period after such termination, or for any period the
Board of Directors or a committee of the Board determines to be advisable after
the grantee’s employment or business relationship with us terminates by reason
of retirement, disability, death or termination without cause. Incentive Stock
Options will, however, terminate no more than three months after termination
of
the optionee’s employment, twelve months after termination of the optionee’s
employment due to disability and three years after termination of the optionee’s
employment due to death. The Board of Directors or a committee of the Board
may
permit a deceased optionee’s stock options to be exercised by the optionee’s
executor or heirs during a period acceptable to the Board of Directors or a
committee of the Board following the date of the optionee’s death but such
exercise must occur prior to the expiration date of the stock
option.
Dilution;
Substitution
As
described above, our Incentive Plan will provide protection against substantial
dilution or enlargement of the rights granted to holders of awards in the event
of stock splits, recapitalizations, asset acquisitions, consolidations,
reorganizations or similar transactions. New award rights may, but need not,
be
substituted for the awards granted under our Incentive Plan, or our obligations
with respect to awards outstanding under our Incentive Plan may, but need not,
be assumed by another corporation in connection with any asset acquisition,
consolidation, acquisition, separation, reorganization, sale or distribution
of
assets, liquidation or like occurrence in which we are involved. In the event
that our Incentive Plan is assumed, the stock issuable with respect to awards
previously granted under our Incentive Plan shall thereafter include the stock
of the corporation granting such new option rights or assuming our obligations
under the Incentive Plan.
Amendment
of the Incentive Plan
Our
Board
may amend our Incentive Plan at any time. However, without stockholder approval,
our Incentive Plan may not be amended in a manner that would:
·
increase
the number of shares that may be issued under our Incentive Plan;
·
materially
modify the requirements for eligibility for participation in our Incentive
Plan;
·
materially
increase the benefits to participants provided by our Incentive Plan;
or
·
otherwise
disqualify our Incentive Plan for coverage under Rule 16b-3 promulgated under
the Securities Exchange Act of 1934, as amended.
Awards
previously granted under our Incentive Plan may not be impaired or affected
by
any amendment of our Incentive Plan, without the consent of the affected
grantees.
Accounting
Treatment
Under
generally accepted accounting principles with respect to the financial
accounting treatment of stock options used to compensate employees, upon the
grant of stock options under our Incentive Plan, the fair value of the options
will be measured on the date of grant and this amount will be recognized as
a
compensation expense ratably over the vesting period. Stock appreciation rights
granted under the Incentive Plan must be settled in common stock. Therefore,
stock appreciation rights granted under the Incentive Plan will receive the
same
accounting treatment as options. The cash we receive upon the exercise of stock
options will be reflected as an increase in our capital. No additional
compensation expense will be recognized at the time stock options are exercised,
although the issuance of shares of common stock upon exercise may reduce basic
earnings per share, as more shares of our common stock would then be
outstanding.
When
we
make a grant of restricted stock, the fair value of the restricted stock award
at the date of grant will be determined and this amount will be recognized
over
the vesting period of the award. The fair value of a restricted stock award
is
equal to the fair market value of our common stock on the date of
grant.
Due
to
consideration of the accounting treatment of stock options and restricted stock
awards by various regulatory bodies, it is possible that the present accounting
treatment may change.
Tax
Treatment
The
following is a brief description of the federal income tax consequences, under
existing law, with respect to awards that may be granted under our Incentive
Plan.
Incentive
Stock Options.
An
optionee will not realize any taxable income upon the grant or the exercise
of
an Incentive Stock Option. However, the amount by which the fair market value
of
the shares covered by the Incentive Stock Option (on the date of exercise)
exceeds the option price paid will be an item of tax preference to which the
alternative minimum tax may apply, depending on each optionee’s individual
circumstances. If the optionee does not dispose of the shares of our common
stock acquired by exercising an Incentive Stock Option within two years from
the
date of the grant of the Incentive Stock Option or within one year after the
shares are transferred to the optionee, when the optionee later sells or
otherwise disposes of the stock, any amount realized by the optionee in excess
of the option price will be taxed as a long-term capital gain and any loss
will
be recognized as a long-term capital loss. We generally will not be entitled
to
an income tax deduction with respect to the grant or exercise of an Incentive
Stock Option.
If
any
shares of our common stock acquired upon exercise of an Incentive Stock Option
are resold or disposed of before the expiration of the prescribed holding
periods, the optionee would realize ordinary income, instead of capital gain.
The amount of the ordinary income realized would be equal to the lesser of
(i)
the excess of the fair market value of the stock on the exercise date over
the
option price; or (ii) in the case of a taxable sale or exchange, the amount
of
the gain realized. Any additional gain would be either long-term or short-term
capital gain, depending on whether the applicable capital gain holding period
has been satisfied. In the event of a premature disposition of shares of stock
acquired by exercising an Incentive Stock Option, we would be entitled to a
deduction equal to the amount of ordinary income realized by the
optionee.
Non-Qualified
Options.
An
optionee will not realize any taxable income upon the grant of a Non-Qualified
Option. At the time the optionee exercises the Non-Qualified Option, the amount
by which the fair market value at the time of exercise of the shares covered
by
the Non-Qualified Option exceeds the option price paid upon exercise will
constitute ordinary income to the optionee in the year of such exercise. We
will
be entitled to a corresponding income tax deduction in the year of exercise
equal to the ordinary income recognized by the optionee. If the optionee
thereafter sells such shares, the difference between any amount realized on
the
sale and the fair market value of the shares at the time of exercise will be
taxed to the optionee as capital gain or loss, short- or long-term depending
on
the length of time the stock was held by the optionee before sale.
Stock
Appreciation Rights.
A
participant realizes no taxable income and we are not entitled to a deduction
when a stock appreciation right is granted. Upon exercising a stock appreciation
right, a participant will realize ordinary income in an amount equal to the
fair
market value of the shares received minus any amount paid for the shares, and
we
will be entitled to a corresponding deduction. A participant’s tax basis in the
shares of common stock received upon exercise of a stock appreciation right
will
be equal to the fair market value of such shares on the exercise date, and
the
participant’s holding period for such shares will begin at that time. Upon sale
of the shares of common stock received upon exercise of a stock appreciation
right, the participant will realize short-term or long-term capital gain or
loss, depending upon whether the shares have been held for more than one year.
The amount of such gain or loss will be equal to the difference between the
amount realized in connection with the sale of the shares, and the participant’s
tax basis in such shares.
Restricted
Stock Award.
A
recipient of restricted stock generally will not recognize any taxable income
until the shares of restricted stock become freely transferable or are no longer
subject to a substantial risk of forfeiture. At that time, the excess of the
fair market value of the restricted stock over the amount, if any, paid for
the
restricted stock is taxable to the recipient as ordinary income. If a recipient
of restricted stock subsequently sells the shares, he or she generally will
realize capital gain or loss in the year of such sale in an amount equal to
the
difference between the net proceeds from the sale and the price paid for the
stock, if any, plus the amount previously included in income as ordinary income
with respect to such restricted shares.
A
recipient has the opportunity, within certain limits, to fix the amount and
timing of the taxable income attributable to a grant of restricted stock.
Section 83(b) of the Code permits a recipient of restricted stock, which is
not
yet required to be included in taxable income, to elect, within 30 days of
the
award of restricted stock, to include in income immediately the difference
between the fair market value of the shares of restricted stock at the date
of
the award and the amount paid for the restricted stock, if any. The election
permits the recipient of restricted stock to fix the amount of income that
must
be recognized by virtue of the restricted stock grant. We will be entitled
to a
deduction in the year the recipient is required (or elects) to recognize income
by virtue of receipt of restricted stock, equal to the amount of taxable income
recognized by the recipient.
Performance
Units and Performance Bonuses.
A
participant realizes no taxable income and we are not entitled to a deduction
when performance units or performance bonuses are awarded. When the performance
units or performance bonuses vest and become payable upon the achievement of
the
performance objectives, the participant will realize ordinary income equal
to
the amount of cash received or the fair market value of the shares received
minus any amount paid for the shares, and we will be entitled to a corresponding
deduction. A participant’s tax basis in shares of common stock received upon
payment will be equal to the fair market value of such shares when the
participant receives them. Upon sale of the shares, the participant will realize
short-term or long-term capital gain or loss, depending upon whether the shares
have been held for more than one year at the time of sale. Such gain or loss
will be equal to the difference between the amount realized upon the sale of
the
shares and the tax basis of the shares in the participant’s hands.
Section
162(m) of the Code.
Section
162(m) of the Code precludes a public corporation from taking a deduction for
annual compensation in excess of $1.0 million paid to its chief executive
officer or any of its four other highest-paid officers. However, compensation
that qualifies under Section 162(m) of the Code as “performance-based” is
specifically exempt from the deduction limit. Based on Section 162(m) of the
Code and the regulations thereunder, our ability to deduct compensation income
generated in connection with the exercise of stock options or stock appreciation
rights granted under the Incentive Plan should not be limited by Section 162(m)
of the Code. Further, we believe that compensation income generated in
connection with performance awards granted under the Incentive Plan should
not
be limited by Section 162(m) of the Code. The Incentive Plan has been designed
to provide flexibility with respect to whether restricted stock awards or
performance bonuses will qualify as performance-based compensation under Section
162(m) of the Code and, therefore, be exempt from the deduction limit. If the
vesting restrictions relating to any such award are based solely upon the
satisfaction of one of the performance goals set forth in the Incentive Plan,
then we believe that the compensation expense relating to such an award will
be
deductible by us if the awards become vested. However, compensation expense
deductions relating to such awards will be subject to the Section 162(m)
deduction limitation if such awards become vested based upon any other criteria
set forth in such award (such as the occurrence of a change in control or
vesting based upon continued employment with us).
Certain
Awards Deferring or Accelerating the Receipt of Compensation.
Section
409A of the Internal Revenue Code, enacted as part of the American Jobs Creation
Act of 2004, imposes certain new requirements applicable to “nonqualified
deferred compensation plans.” If a nonqualified deferred compensation plan
subject to Section 409A fails to meet, or is not operated in accordance with,
these new requirements, then all compensation deferred under the plan may become
immediately taxable. Stock appreciation rights and deferred stock awards which
may be granted under the plan may constitute deferred compensation subject
to
the Section 409A requirements. It is our intention that any award agreement
governing awards subject to Section 409A will comply with these new
rules.
Required
Vote
Approval
of our Incentive Plan will require the affirmative vote of the holders of a
majority of the shares of HAQ common stock represented in person or by proxy
and
entitled to vote at the Special Meeting. Assuming the presence of a quorum
of
more than 50% of the shares of our common stock, the failure to vote will have
no effect on the outcome of the vote.
Recommendation
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE
INCENTIVE PLAN PROPOSAL.
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF
PHARMATHENE
The
following discussion should be read in conjunction with the Consolidated
Financial Statements for PharmAthene beginning on page F-24 of this proxy
statement. These Consolidated Financial Statements present the results of
operations for PharmAthene for the fiscal years ended December 31, 2005
(“2005”), 2004 (“2004”) and 2003 (“2003”) and the fiscal quarter ended September
30, 2006 as well as the financial positions at December 31, 2005, December
31,
2004, December 31, 2003 and September 30, 2006. In addition to historical
information, the following discussion may contain forward looking information
that involves risks and uncertainties. All amounts presented, except share
data,
are rounded to the nearest thousand dollars.
Overview
PharmAthene
is a biodefense company engaged in the business of discovery and development
of
novel human therapeutics and prophylactics for the treatment and prevention
of
morbidity and mortality from exposure to biological and chemical weapons.
Additionally, PharmAthene collaborates with other pharmaceutical companies
to
support clinical development of product candidates. PharmAthene has two product
currently under development. Valortim™, a fully monoclonal antibody for the
prevention and treatment of anthrax infection and Protexia®, a bioscavenger for
the treatment of orgarophosphate nerve agent poisoning.
PharmAthene’s
lead product candidate, Valortim, is a fully human monoclonal antibody designed
to protect against and treat inhalation anthrax infection, the most lethal
form
of illness in humans caused by the Bacillus
anthracis
bacterium. PharmAthene is co-developing Valortim with Medarex, Inc., a
biopharmaceutical company that specializes in developing fully human
antibody-based therapeutic products and will share with Medarex any profits
derived from sales of Valortim. Preclinical trials on animal models have
demonstrated that Valortim is highly efficacious as both a prophylaxis and
a
therapeutic for inhalation anthrax infection in some animal models. PharmAthene
and Medarex have completed dosing of healthy volunteers in a Phase I open-label,
dose-escalation clinical trial to evaluate the safety, tolerability,
immunogenicity, and pharmacokinetics of a single dose of Valortim administered
intravenously or intramuscularly. No drug-related serious adverse events have
been reported. Final results from the Phase I trial were presented at the
Infectious Disease Society of America meeting in October 2006. Valortim has
been
granted Fast Track Status by the FDA, which may permit PharmAthene to submit
portions of a Biologics License Application (“BLA”) or efficacy supplement
before the complete BLA is submitted. This may expedite the review process
but
requires that the FDA have sufficient resources to allow early review of the
portions submitted. In addition, Valortim has been granted orphan drug status
for the treatment of inhalational anthrax.
Protexia,
PharmAthene’s second product candidate, is a recombinant form of human
butyrylcholinesterase (“BChE”) for use in the prophylaxis and treatment of
organophosphate chemical nerve agent poisoning. Preclinical trials on animal
models have demonstrated that Protexia is highly efficacious as both a
prophylaxis and a therapeutic for chemical nerve agent poisoning. PharmAthene
plans to continue preclinical animal studies of Protexia throughout 2006 and
2007 and file an Investigational New Drug application (“IND”) with the FDA in
2008. The procurement process for the scale-up development and sale of Protexia
is already underway with the U.S. Department of Defense (“DoD”), the department
tasked with purchasing biodefense countermeasures for military use. The DoD
requested competitive bids in a Request for Proposal (an “RFP”) for a
recombinant form of BChE drug for the prophylaxis treatment of chemical nerve
agent poisoning, which PharmAthene submitted in November 2005. In
September 2006, PharmAthene was awarded a contract with a potential value of
$213 million by the DoD for advanced development of Protexia and procurement
of
an initial 90,000 doses.
PharmAthene
has financed its operations since inception in March 2001 primarily through
the
issuance of equity securities, convertible notes, and proceeds from loans or
other borrowings. Any, or all, of these financing vehicles or others may be
utilized to fund its future capital requirements.
Nexia
Asset Acquisition
In
March
2005, PharmAthene acquired substantially all of the assets and liabilities
of
Nexia Biotechnologies Inc. (‘‘Nexia”) that related to its Protexia® compound for
a purchase price of $19,100,000. PharmAthene delivered to Nexia $11,763,000
in
cash, 7,465,501 shares of Series C Convertible Redeemable Preferred Stock and
2,239,650 warrants to acquire Series C Convertible Preferred Stock and 1,343,790
warrants to purchase common stock. In order to finance the cash portion of
the
acquisition, PharmAthene sold Series C Convertible Redeemable Preferred Stock,
issued warrants to acquire Series C Convertible Preferred Stock and issued
warrants to acquire common stock. The purchased assets and liabilities are
held
by PharmAthene Canada, Inc., PharmAthene’s only subsidiary (‘‘PharmAthene
Canada”), a variable interest entity established in connection with the
acquisition to allow for the investment by certain Canadian stockholders and
consolidated in PharmAthene’s financial statements as of the date of its
inception.
In
conjunction with the issuance of the Series C Preferred Stock, PharmAthene
sold
2,951,654 shares of Class C Shares of PharmAthene Canada (the ‘‘Class C Shares”)
to one investor for net proceeds of $2,364,000. The Class C Shares are, pursuant
to the terms of a Put and Support Agreement, exchangeable for an equal number
of
shares of Series C Preferred Stock. The Class C Shares bear a cumulative
dividend rate of 8% per annum.
The
investor in the Class C Shares also received warrants to purchase 466,498 Class
B Common Shares of PharmAthene Canada at an exercise price of $0.01 per share,
subject to reduction if certain milestones are met by Pharmathene. The investor
in the Class C Shares also received warrants to purchase 777,496 Class C Shares
at an exercise price of $0.91 per share.
Recent
Events
In
May
2006, PharmAthene entered into a Note Purchase Agreement with, among others,
its
three largest principal investors and its Chief Executive Officer, pursuant
to
which it has borrowed approximately $9.8 million due May 5, 2007. In July 2006,
PharmAthene and PharmAthene Canada entered into a Note Purchase Agreement with
PharmAthene Canada’s sole preferred stockholder pursuant to which PharmAthene
Canada has borrowed $2.0 million, which borrowing will convert into an 8%
interest bearing loan. In connection with the proposed Merger, holders of notes
in aggregrate principal amount of approximately $11,625,000 have
entered into an agreement with PharmAthene pursuant to which, among other
things, they have agreed not to demand payment under their notes until the
earlier of: (i) the termination of the Merger Agreement, and (ii) August 3,
2007.
In
June
2006, PharmAthene and SIGA Technologies Inc. (“SIGA”) executed a definitive
Agreement and Plan of Merger (the “SIGA Agreement”). In connection with the SIGA
Agreement, PharmAthene loaned $3.0 million to SIGA pursuant to a Bridge Note
Purchase Agreement, dated March 20, 2006. On October 4, 2006, SIGA terminated
the SIGA Agreement and subsequently repaid the $3.0 million Bridge Notes
including interest. On December 20, 2006, PharmAthene filed a complaint against
SIGA in the Delaware Chancery Court. PharmAthene’s complaint alleges that it has
the right to an exclusive license to develop and market SIGA’s drug
candidate, SIGA-246, pursuant to the terminated SIGA Agreement and other
agreements between the parties and the couse of performance. The complaint
further alleges that SIGA failed to negotiate in good faith the terms of such
a
license pursuant to the terminated SIGA Agreement and other agreements between
the parties and the course of performance. SIGA has filed a Motion to Dismiss
the complaint.
In
September 2006, PharmAthene was awarded a multi-year contract valued at up
to
$213.0 million from the Department of Defense (DoD) U.S. Army Space and Missile
Command for advanced development of PharmAthene’s broad spectrum chemical nerve
agent prophylaxis, Protexia®. Under the contract, PharmAthene will be
responsible for the conduct and oversight of all product development activities.
The initial stage of the development, for which the DoD has allocated $34.7
million, included manufacturing process development, preclinical safety and
toxicity testing, submission of an Investigational New Drug (IND) Application
with the U.S. Food and Drug Administration (FDA), and the initiation of a Phase
I clinical trial.
Results
of Operations
Years
Ended December 31, 2005, 2004 and 2003
Revenue
During
2005, 2004 and 2003, PharmAthene had revenues of $1,098,000, $1,038,000 and
$7,297,000, respectively. All revenue was derived from grant funding from the
U.S. government for the development of pharmaceutical products for biodefense
applications, except for $53,000 of other revenue in fiscal year
2005.
Grant
revenue
Grant
revenues recognized in fiscal years 2005, 2004 and 2003 was derived from U.S.
government funding as follows:
|
·
|
The
U.S. Army Medical Research and Material Command Center awarded PharmAthene
a $16,200,000 grant to fund development of its Dominant Negative
Inhibitor
(‘‘DNI”) program as related to therapeutic countermeasures for anthrax
over a three year period beginning in September of 2002. Development
activity under this grant included manufacturing, bioanalytical
measurement, studies for preclinical assessment and initial human
testing
of DNI. From PharmAthene’s inception through November 2004, its sole
source of income was the cost reimbursement related to research and
development of the DNI program under this grant.
|
|
|
|
|
·
|
With
the March 2005 acquisition of Nexia, PharmAthene was assigned the
rights
to receive the fixed price grant with the U.S. Army Medical Research
and
Material Command Center to fund preclinical studies for the
Protexia®
compound. This grant was awarded for approximately $2,700,000 for
the
period from April 2003 through September 2006. PharmAthene received
$787,000 of this grant during 2005.
|
In
fiscal
year 2005, PharmAthene received approximately $787,000 of grant revenue related
to preclinical development work for Protexia®
and
$258,000 related to the DNI grant program. Revenue related to DNI represented
the agreed upon final reimbursement by the U.S. government for development
activities conducted in 2004 before the program was terminated in November
2004.
Revenue
for fiscal year 2004 was derived from reimbursement of preclinical development
activities, including animal studies, and the initiation of human testing,
related to PharmAthene’s DNI program. Revenue for fiscal year 2003 resulted from
reimbursement for manufacturing and product development activities, research
analysis activities and preclinical activities preparing for and initiating
animal model trials under the DNI program.
Other
revenue
In
connection with the acquisition of the assets of Nexia, PharmAthene acquired
property and equipment, including farm facilities. Other income in fiscal year
2005 includes the leasing of farm facilities that PharmAthene is currently
not
utilizing.
Research
and Development Expenses
PharmAthene’s
research and development expenses were $6,351,000, $7,844,000 and $11,325,000
for fiscal years 2005, 2004 and 2003, respectively. These expenses were incurred
in connection with the PharmAthene research and development programs related
to
each of Valortim™, Protexia®
and DNI,
the last of which was terminated in 2004.
Research
and development expenses in each of the periods ended December 31, 2005, 2004
and 2003 are attributable to research programs as follows:
|
|
Years
Ended December 31,
|
|
|
|
2005
|
|
2004
|
|
2003
|
|
Valortim
|
|
$ |
1,135,000 |
|
$ |
2,793,000 |
|
$ |
— |
|
Protexia
|
|
|
5,070,000 |
|
|
— |
|
|
— |
|
DNI
|
|
|
146,000 |
|
|
5,051,000 |
|
|
11,000,000 |
|
Internal—other
|
|
|
— |
|
|
— |
|
|
325,000 |
|
Total
R&D expenses
|
|
$ |
6,351,000 |
|
$ |
7,844,000 |
|
$ |
11,325,000 |
|
During
the fiscal year ended December 31, 2005, PharmAthene spent approximately $5.1
million on the development of Protexia®, its drug candidate for countermeasure
against nerve gas bio-terrorist attacks, acquired in March 2005. Of this total,
PharmAthene spent approximately $2.6 million on internal human resources and
$2.5 million mainly on pre-clinical testing and manufacturing. From inception
of
the Protexia® development program to date we have expended a total of $5.1
million related to the program.
During
the fiscal years ended December 31, 2005 and 2004, PharmAthene spent
approximately $1.1 million and $2.8 million, respectively, on the development
of
Valortim®,
its
drug candidate for countermeasure against Anthrax associated bio-terrorist
attacks. For the fiscal year ended December 31, 2005, PharmAthene spent
approximately $0.4 million on internal human resources and $0.7 million mainly
on clinical development. For the fiscal year ended December 31, 2004,
PharmAthene spent approximately $41,000 on internal human resources and $2.8
million mainly on pre-clinical testing. From inception of the
Valortim®
development program to date, we have expended a total of $3.9 million related
to
the program. PharmAthene incurred no costs related to this program during the
year ended December 31, 2003.
During
the fiscal years ended December 31, 2005 and 2004, PharmAthene spent
approximately $0.1 million and $5.1 million, respectively, on the development
of
DNI, a drug candidate for countermeasure against Anthrax associated
bio-terrorist attacks. For the fiscal year ended December 31, 2005, PharmAthene
spent approximately $0.1 million on internal human resources. For the fiscal
year ended December 31, 2004, PharmAthene spent approximately $1.1 million
on
internal human resources and $4.0 million mainly on pre-clinical testing. The
DNI program was terminated in late 2004 and costs incurred in 2005 were
primarily related to the termination of the DNI program efforts. During the
fiscal year ended December 31, 2003, PharmAthene incurred $11.0 million in
costs
related to this program and, from inception of the DNI development program
through its termination, PharmAthene expended a total of $16.2 million related
to the program.
Research
and development expenses during fiscal year 2005 resulted entirely from
activities related to the Valortim™ and Protexia®
programs
as compared to research and development expenses incurred in fiscal year 2004,
which included the DNI program activities. Research and development expenses
declined by $1,493,000 from 2004 to 2005 because of different program focuses
and study activity with decreased drug manufacturing of $3,317,000 and lower
preclinical costs of $1,803,000, primarily related to the termination of the
DNI
program at the end of fiscal year 2004. Increased clinical costs of $515,000
from 2004 to 2005 incurred in collaboration with Medarex on the Valortim™
program and development costs related to Protexia®,
acquired in the first quarter of 2005, of $2,897,000 partially offset these
decreases.
Research
and development expenses during 2003 and 2004 related solely to the DNI program.
The decrease of $3,481,000 in research and development expenses from 2003 to
2004 is primarily attributable to reduced contract research organization
expenses of $9,878,000 partially offset by increased product manufacturing
costs
of $3,951,000, preclinical activities of $1,599,000 and increased employee
related costs of $786,000. The contract organization costs incurred in fiscal
year 2003 related to animal model studies and analysis and preparation for
drug
manufacturing. During fiscal year 2004, costs incurred were related to drug
manufacture in preparation for clinical trials, internal expenses related to
preclinical activities, and to the preparation and initiation of a human study
clinical trial. In the fourth quarter of 2004, the DNI program was
terminated.
General
and Administrative Expenses
General
and administrative functions for PharmAthene include the areas of executive
management, finance and administration, government affairs and relations,
corporate development, human resources, legal, and compliance. For each
function, PharmAthene may incur direct expenses such as salaries, supplies
and
third-party consulting and other external costs. Indirect costs such as
facilities, utilities and other administrative overhead are also included in
general and administrative expenses.
Expenses
associated with general and administrative functions for PharmAthene were
$5,009,000, $3,328,000 and $2,510,000 for fiscal years 2005, 2004 and 2003,
respectively. The increase in fiscal year 2005 expenses as compared to fiscal
year 2004 expenses of $1,681,000 resulted primarily from increased employee
related costs of $1,200,000 and increased Canadian operations costs of $764,000,
mostly related to headcount, facility operations and utilities expenses of
PharmAthene Canada, Inc., the operations of which were acquired in the first
quarter of 2005. Consultant and contractor services decreased $505,000, as
PharmAthene began hiring personnel throughout 2005 to perform administrative
functions and proposal work.
The
increase of $818,000 from fiscal year 2003 to fiscal year 2004 resulted from
increased employee related costs of $821,000 and increased consultant and
contractor services of approximately $1,000,000 for administrative functions
throughout the year and proposal review and analysis work related to the Medarex
collaborative agreement for the Valortim™ program which was entered into in the
fourth quarter of 2004. These increases were partially offset by reduced legal
fees in 2004 as compared to 2003 because of the preparation and submission
of
the DNI program grant during 2003 which was awarded in the third quarter of
2003.
Depreciation
and Intangible Amortization
Depreciation
and intangible amortization expense was $661,000 for fiscal year 2005 and
represents a $636,000 increase from fiscal year 2004. For fiscal years 2004
and
2003, depreciation expense was $25,000 and $3,000, respectively. Depreciation
expense for fiscal year 2005 of $560,000 results primarily from building and
leasehold improvements acquired, additionally in fiscal year 2005, $101,000
of
amortization was recorded relating to the acquired patents. The increase in
fiscal year 2005 from fiscal year 2004 results primarily from the Nexia asset
acquisition in March of 2005 in which we acquired $5,021,000 in property and
equipment and $1,407,000 of intangible assets related to patents.
Acquired
In-Process Research and Development
In
connection with the March 2005 acquisition of the Nexia assets and liabilities
related to Protexia®,
PharmAthene engaged a third-party to appraise the value of the assets and
liabilities acquired. Based upon this appraisal, PharmAthene allocated
$12,812,000 of the purchase price of the Nexia asset purchase to acquired
in-process research and development. This allocation represented the estimated
fair value based on projected cash flows that will be generated by the
incomplete research and development of Protexia®.
At the
date of the acquisition, the development of Protexia®
had not
yet reached technological feasibility and had no known alternative future uses.
Accordingly, the acquired in-process research and development was charged to
expense as of the date of the acquisition.
Other
Income and Expenses
Other
income and expenses consists primarily of income on PharmAthene’s investments
and interest expense on our debt and other financial obligations. PharmAthene’s
interest income was $382,000, $72,000 and $13,000 in fiscal years 2005, 2004
and
2003, respectively. The increases in interest income in fiscal years 2005 and
2004 result from higher average investment balances maintained, attributable
to
the issuance of convertible preferred stock each year, as compared to fiscal
years 2004 and 2003, respectively.
PharmAthene
incurred interest expense of $1,000, $33,000 and $20,000 in fiscal years 2005,
2004 and 2003, respectively. Interest expense for fiscal year 2004 results
from
a $1.5 million 8% convertible note payable to one of PharmAthene’s investors,
issued in June 2004, which was subsequently converted into Series B Convertible
Redeemable Preferred Stock in October 2004. Interest expense for fiscal year
2003 resulted from notes payable due to directors and scientific advisory board
members. The outstanding notes and accrued interest related to these notes
were
paid in full in September 2003.
Three
and Nine Months Ended September 30, 2006 and 2005
Revenue
PharmAthene
recorded revenues of $1,600 for the quarter ended September 30, 2006, as
compared to $200,100 of revenues for the quarter ended September 30, 2005.
Revenue for the nine months ended September 30, 2006 and 2005 was $188,000
and
$917,700, respectively, and represented a $729,700, or 80%, decrease from the
period ended September
30,
2005
compared to the period ended September 30, 2006. These revenues consist
primarily of grant revenue funding for the development of pharmaceutical
products for two different bio-defense applications.
During
the first quarter of fiscal year 2006, PharmAthene recognized $178,700 in grant
revenue related to a firm fixed price grant with the U.S. Army Medical Research
and Material Command Center to fund preclinical studies for the
Protexia®
compound. Work under this grant was completed in March 2006, with no additional
grant funding for the remainder of the year. The revenue recognized in the
second quarter of 2005 resulted from preclinical studies for the Protexia®
compound related to this grant. For the nine months ended September 30, 2005,
PharmAthene’s recognized grant revenue includes first quarter revenue of
$248,100 related to its Dominant Negative Inhibitor (‘‘DNI”) program and
represented the agreed upon final reimbursement by the U.S. government for
development activity as this program was terminated in the fourth quarter of
fiscal year 2004.
In
connection with the acquisition of the Nexia assets, PharmAthene acquired
property and equipment, including farm facilities. Other revenue of $9,300
and
$50,600 for the periods ended September 30, 2006 and 2005, respectively,
resulted primarily from the leasing of farm facilities which are currently
not
being utilized.
Research
and Development Expense
PharmAthene’s
research and development expenses were $1,641,800 and $1,131,000 for the
quarters ended September 30, 2006 and 2005, respectively, representing an
increase of $510,800, or 45%. For the nine months ended September 30, 2006
and
2005, research and development expenses were $4,745,600 and $4,076,100,
respectively, and represented a $669,500, or 16% increase from the nine month
period ended September 30, 2005. These expenses resulted from research and
development activities related to programs for ValortimTM,
development activity to protect and treat inhalation anthrax, and
Protexia®,
development activity to fight nerve agent poisoning.
Research
and development expenses for the three and nine month periods ended September
30, 2006 and 2005, respectively, are attributable to research programs as
follows:
|
|
Three
months ended
|
|
Nine
months ended
|
|
|
|
September
30,
2006
|
|
September
30,
2005
|
|
September
30,
2006
|
|
September
30,
2005
|
|
Valortim
|
|
$ |
449,700 |
|
$ |
180,200 |
|
$ |
1,106,600 |
|
$ |
634,300 |
|
Protexia
|
|
|
1,192,100 |
|
|
950,800 |
|
|
3,639,000 |
|
|
3,295,800 |
|
DNI
|
|
|
— |
|
|
— |
|
|
— |
|
|
146,000 |
|
Total
R&D expenses
|
|
$ |
1,641,800 |
|
$ |
1,131,000 |
|
$ |
4,745,600 |
|
$ |
4,076,100 |
|
For
the
three and nine months ended September 30, 2006, PharmAthene spent approximately
$1.2 million and $3.6 million, respectively, on the development of Protexia®. Of
the quarterly total, PharmAthene spent approximately $0.8 million on internal
human resources and $0.4 million mainly on preclinical activities. During the
nine months ended September 30, 2006, spending on internal human resources
and
preclinical activities was approximately $2.3 million and $1.3 million,
respectively. During the third quarter and nine month period ended September
30,
2005, PharmAthene spent approximately $1.0 million and $3.3 million,
respectively, on development of the Protexia® program. Quarterly spending on
internal resources was approximately $0.7 million with the remaining
expenditures on preclinical related activities. For the nine months ended
September 30, 2006, approximately $1.5 million was spent on personnel costs
with
the remaining $1.8 million spent primarily on manufacturing and preclinical
activities.
For
the
three and nine months ended September 30, 2006, PharmAthene spent approximately
$0.4 million and $1.1 million, respectively, on the development of
ValortimTM.
For the
quarter, PharmAthene spent approximately $0.3 million on clinical development
activities and $0.1 million on internal resources. During the nine months ended
September 30, 2006, spending on the ValortimTM
program
of $1.1 million was primarily clinical development and trial related at
approximately $0.9 million. During the third quarter and nine month period
ended
September 30, 2005, PharmAthene spent approximately $0.2 million and $0.6
million, respectively, on development of the ValortimTM
program.
Clinical development activities were $0.1 million and $0.3 million for the
quarter and nine months ended September 30, 2005, respectively. In addition,
PharmAthene incurred approximately $0.1 million and $0.3 million, respectively,
on personnel expenses for the quarter and nine months ended September 30,
2005.
The
research and development expense increase of $510,800 from the quarter ended
September 30, 2005 to the quarter ended September 30, 2006 resulted primarily
from increased preclinical and development costs of $303,800 related to the
Protexia® program and increased employee expenses of $69,000. The increase of
$669,500 in research and development expenses from the nine months ended
September 30, 2005 to the period ended September 30, 2006 resulted primarily
from increased employee related expenses of $673,000 and increased clinical
development costs of $386,000 related to the clinical trial program for the
ValortimTM
program
which was initiated in fiscal year 2005. Theses increases were offset by
decreased development activities of $421,000 related to the Protexia®
program.
PharmAthene
incurs both direct and indirect expenses. Direct expenses include salaries
and
other costs of personnel, raw materials and supplies. PharmAthene may also
incur
third-party costs related to these projects, such as contract research,
consulting and clinical development costs for individual projects.
General
and Administrative Expenses
General
and administrative functions include the areas of executive management, finance
and administration, government affairs and relations, corporate development,
human resources, legal, and compliance. For each function, we may incur direct
expenses such as salaries, supplies and third-party consulting and other
external costs. Indirect costs such as facilities, utilities and other
administrative overhead are also included in general and administrative
expenses.
Expenses
associated with general and administrative functions were $1,655,000 and
$1,267,900 for the quarters ended September 30, 2006 and 2005, respectively.
For
the nine months ended September 30, 2006 and 2005, general and administrative
costs were $4,665,300 and $3,496,100, respectively. The increase of $387,100
quarter over quarter results primarily from increased legal and consulting
fees
of $212,600 for transactional, proposal and compliance related activities,
increased employee expenses of $116,500, and increased stock compensation
expense, of $76,300. The increase of $1,169,200 for the nine months ended
September 30, 2006 as compared to the nine months ended September 30, 2005
is
primarily attributable to increased legal and consulting fees of $607,000
related to transactional, proposal and compliance work, increased employee
expenses of $409,000 and increased stock compensation expense of $254,200 as
PharmAthene adopted Statement of Financial Accounting Standard No. 123 (revised
2004), Share-Based
Payment,
(‘‘FAS
123R”) which requires the measurement and recognition of compensation expense
for all share-based payment awards made to employees and directors including
employee stock options based on estimated fair values.
Depreciation
and Intangible Amortization
Depreciation
and intangible amortization expense was $134,800 for the period ended September
30, 2006 as compared to $199,600 for the period ended September 30, 2005. For
the nine months ended September 30, 2006 and 2005, depreciation and amortization
expense was $390,000 and $455,100, respectively. Depreciation expense results
primarily from building and leasehold improvements with amortization expense
related to the acquired Protexia®
product
patents.
Acquired
In-Process Research and Development
In
connection with the March 2005 acquisition of the Nexia assets and liabilities
related to Protexia®,
PharmAthene engaged an independent third-party to appraise the value of the
assets and liabilities acquired. Based upon this appraisal, PharmAthene
allocated $12,812,000 of the purchase price of the Nexia asset purchase to
acquired in-process research and development. This allocation represented the
estimated fair value based on projected cash flows that will be generated by
the
incomplete research and development of Protexia®.
At the
date of the acquisition, the development of Protexia®
had not
yet reached technological feasibility and had no known alternative future uses.
Accordingly, the acquired in-process research and development was charged to
expense as of the date of the acquisition.
Other
Income and Expenses
Other
income and expenses consists primarily of income on PharmAthene’s investments
and interest expense on PharmAthene’s debt and other financial obligations.
PharmAthene’s interest income was $24,500 and $86,300 for the quarters ended
September 30, 2006 and 2005, respectively, and was $131,200 and $296,100 for
the
nine months ended September 30, 2006 and 2005, respectively. The decrease in
interest income period over period results from lower average investment
balances maintained. Interest expense for the quarter and nine month periods
ended 2005 was minimal. PharmAthene had no significant debt or other financial
obligations until June of 2006. For the quarter and nine months ended September
30, 2006, PharmAthene has recognized interest expense of $229,500 and $298,100
respectively related to the $11.8 million Bridge Notes entered into in the
first
half of fiscal year 2006.
Liquidity
and Capital Resources
Overview
PharmAthene’s
primary cash requirements are to fund its research and development programs
and
to fund general corporate overhead. Its cash requirements could change
materially as a result of changes in its business and strategy. These changes
could arise from PharmAthene’s management team’s evaluation of its business
strategy, the progress of its research and development activities and clinical
programs, licensing activities, acquisitions, divestitures or other corporate
developments.
PharmAthene
has financed its operations since inception in March 2001 primarily through
the
issuance of equity securities in addition to convertible notes, and proceeds
from loans or other borrowings. Any combination of, or all of, these financing
vehicles or others may be utilized to fund its future capital requirements.
In
evaluating alternative sources of financing, PharmAthene considers, among other
things, the dilutive impact, if any, on its stockholders, the ability to
leverage stockholder returns through debt financing, the particular terms and
conditions of each alternative financing arrangement and our ability to service
our obligations under such financing arrangements.
PharmAthene’s
Consolidated Financial Statements have been prepared on a basis which assumes
that it will continue as a going concern and which contemplates the realization
of assets and the satisfaction of liabilities and commitments in the normal
course of business. PharmAthene has incurred cumulative net losses and expects
to incur additional losses to perform further research and development
activities. PharmAthene does not have commercial products and has limited
capital resources. Its plans with regard to these matters include continued
development of its products as well as seeking additional research support
funds
and financial arrangements. Although PharmAthene continues to pursue these
plans, there is no assurance that it will be successful in obtaining sufficient
financing on commercial reasonable terms or that it will be able to secure
financing from anticipated government contracts and grants.
PharmAthene
has developed a plan to reduce its operating expenses in the event that
sufficient funds are not available, or if it is not able to obtain the
anticipated government contracts and grants. If PharmAthene is unable to raise
adequate capital or achieve profitability, future operations will need to be
scaled back or discontinued. Continuance of our going concern is dependent
upon,
among other things, the success of our research and development programs and
our
ability to obtain adequate financing. The financial statements do not include
any adjustments relating to recoverability of the carrying amount of recorded
assets and liabilities that might result from the outcome of these
uncertainties.
Sources
and Uses of Cash
Cash
and
cash equivalents for PharmAthene were $6,505,900 and $7,938,100 at September
30,
2006 and December 31, 2005, respectively. The $1,432,200 decrease in cash and
cash equivalents from December 31, 2005 resulted primarily from the funding
of
operations offset by 8% convertible notes financings in June and July
2006.
Operating
Activities
Net
cash
used in operating activities was $8,667,400 and $7,422,800 for the periods
ended
September 30, 2006 and 2005, respectively. The increase in net cash used in
operations is attributable to an increase in net loss after the effect of
non-cash adjustments and an increase in other assets partially offset by a
decrease in prepaid assets. Non cash adjustments for the nine months ended
September 30, 2006 included $254,200 of non-cash compensation expense which
resulted from PharmAthene’s adoption of FAS 123R which requires all share-based
payments to employees, including grants of employee stock options, to be
recognized in the income statement based on their grant date fair values for
interim or annual periods.
Prepaid
expenses decreased $273,000 as a result of the use of funds for development
activity related to the PharmAthene collaboration with Medarex on the
ValortimTM
program.
Prepaid expenses fluctuate from period to period depending on the timing and
level of preparation and initiation of research and development activity and
clinical trials.
Investing
Activities
Net
cash
used in investing activities was $3,473,285 and $12,400,800 for the nine months
ended September 30, 2006 and 2005, respectively. In March 2005, we acquired
substantially all of the assets and liabilities related to Protexia®
from
Nexia for a net cash outlay of $12,277,000 including cash to Nexia, transaction
costs and the assumption of liabilities. In connection with the SIGA merger
transaction, we entered into a Bridge Note Purchase Agreement providing SIGA
with interim financing of $3.0 million. Remaining investing activities for
the
nine month periods ended September 30, 2006 and 2005 related to the purchase of
property and equipment. We fund capital expenditures primarily through direct
purchases utilizing our existing cash.
Financing
Activities
Net
cash
provided by financing activities was $10,656,700 and $8,858,800 for the periods
ended September 30, 2006 and 2005, respectively. As discussed above,
PharmAthene’s financing activities resulted primarily from the issuance of
convertible redeemable preferred stock and convertible notes of $11.8 million
and $8.9 million, respectively. The $1,357,100 of other asset results from
the
capitalization of professional expenses related to ongoing activities related
to
the proposed SIGA merger transaction and the related private equity offering.
From
April 2006 through July 2006, PharmAthene and PharmAthene Canada, Inc. a
subsidiary of PharmAthene, collectively borrowed an aggregate of $11.8 million
in the form of 8% convertible notes (the 2006 Bridge Notes”). The 2006 Bridge
Notes are convertible upon the occurrence of a number of circumstances,
including (i) the closing of the merger with SIGA and a financing of gross
proceeds exceeding $25.0 million (the ‘‘SIGA Financing”), and (ii) upon any
financing with gross proceeds in excess of $10.0 million, other than as
described in (i) above (an ‘‘Other Financing”). In the case of the SIGA
Financing, the 2006 Bridge Notes are convertible, at a 10% discount, into the
same SIGA securities sold in such financing. In the case of an Other Financing,
the 2006 Bridge Notes are convertible, at a 25% discount, into common stock
of
PharmAthene as well as shares of the same securities sold in such
financing.
In
connection with the SIGA Agreement with SIGA, PharmAthene entered into a Bridge
Note Purchase Agreement with SIGA providing SIGA with interim financing, subject
to the execution of a definitive merger agreement through a bridge loan of
$3,000,000. As of September 30, 2006, PharmAthene had fully funded this
financing. Subsequent to September 30, 2006, SIGA terminated the SIGA Agreement
and repaid the $3.0 million Bridge Notes including interest.
In
March
2005, PharmAthene sold 14,946,479 share of Series C Convertible Redeemable
Preferred Stock (‘‘the Series C Preferred Stock”) at a price of approximately
$0.91 per share for net proceeds of $13,305,000. The Series C Preferred Stock
bears a cumulative dividend rate of 8.0% per annum. Each share of the Series
C
Preferred Stock is convertible into shares of common stock at the
then-applicable conversion rate at any time and at the option of the holder.
The
Series C Preferred Stock will automatically convert to common stock at the
then-applicable conversion rate in the event of an IPO of our stock resulting
in
aggregate proceeds to us of $50 million and a share price of at least $2.74.
Commencing in October 2009, the holders of the Series C Preferred stock may
require us to redeem the Series C Preferred Stock then outstanding for an amount
equal to the original purchase price plus any unpaid dividends. Proceeds from
the equity issuance were used to partially fund the Nexia asset acquisition
and
to fund further research and development programs related to
ValortimTM
and
Protexia®,
working
capital and general corporate purposes.
The
investors in the Series C Preferred Stock also received warrants to purchase
2,690,420 shares of common stock at an exercise price of $0.01 per share,
subject to reduction if certain business milestones were met by us, which expire
in October 2014. Additionally, the investors in the Series C Preferred Stock
also received warrants to acquire 4,483,946 shares of Series C Preferred Stock
at an exercise price of approximately $0.91, which expire in March
2008.
In
conjunction with the issuance of the Series C Preferred Stock, PharmAthene
sold
2,951,654 shares of Class C Shares of PharmAthene Canada, Inc. (the ‘‘Class C
Shares”) in March 2005 for net proceeds of $2,364,000. The Class C Shares are,
pursuant to the terms of a Put and Support Agreement, exchangeable for an equal
number of shares of Series C Preferred Stock. The Class C Shares bear a
cumulative dividend rate of 8% per annum.
The
investors in the Class C Shares also received warrants to purchase 466,498
Class
B Common Shares of PharmAthene Canada at an exercise price of $0.01 per share,
subject to reduction if certain milestones are met by PharmAthene. The investors
in the Class C Shares also received warrants to purchase 777,496 Class C Shares
at an exercise price of $.91 per share.
In
October 2004, PharmAthene sold 30,448,147 shares of Series B Convertible
Redeemable Preferred Stock (the “Series B Preferred Stock”) at a price of
approximately $0.91 per share for net proceeds of $27,570,000. The Series B
Preferred Stock bears a cumulative dividend rate of 8.0% per annum. The Series
B
Preferred Stock will automatically convert to common stock at the
then-applicable conversion rate in the event of an initial public offering
of
PharmAthene’s stock resulting in aggregate proceeds to us of $50 million and a
share price of at least $2.74. Commencing in October 2009, the holders of the
Series B Preferred stock may require PharmAthene to redeem the Series B
Preferred Stock then outstanding for an amount equal to the original purchase
price plus any unpaid dividends. Proceeds from the equity issuance were used
for
further research and development of the DNI program and its clinical trial,
for
the initiation of corporate activities with both Medarex and with the
acquisition of the Protexia®
assets,
as well as working capital and general corporate purposes. The DNI program
was
subsequently terminated in the fourth quarter of 2004.
The
investors in the Series B Preferred Stock also received warrants to purchase
15,400,000 shares of common stock at an exercise price of $0.01 per share,
subject to reduction if certain business milestones, which expire in October
2014, were met by us. In December 2004, PharmAthene met the milestone related
to
1,540,000 shares of common stock underlying the warrants to purchase common
stock thereby reducing the number of outstanding warrants to 13,860,000.
Following the Nexia asset purchase in March 2005, an additional milestone
related to 6,160,001 shares of common stock underlying the warrants was achieved
and total warrants outstanding were further reduced to 7,699,999.
In
June
2004, PharmAthene entered into an agreement to borrow up to $3.0 million in
the
form of 8% convertible notes (the “Bridge Notes”). The Bridge Notes were
repayable upon the earlier of (i) the closing of a financing with gross proceeds
exceeding $10.0 million or (ii) the sale of our company or (iii) December 31,
2004. The Bridge Notes bore an interest rate of 8% per year and were convertible
at the investors’ option during a future financing or on December 31, 2004 into
Series A Convertible Redeemable Preferred Stock (the “Series A Preferred
Stock”). In June 2004, PharmAthene borrowed $1.5 million under the Bridge Notes.
Upon the issuance of Series B Preferred Stock in October 2004, the Bridge Notes
were converted into Series B Preferred Stock at approximately $0.91 per share.
As a result of this financing and in accordance with the terms of the Series
A
Preferred Stock, the conversion price of the Series A Preferred Stock was
adjusted with an additional 2,672,770 shares of Series A Preferred Stock issued
to the investors.
In
September 2003, PharmAthene sold 13,769,230 shares of Series A Preferred Stock
at a price of approximately $1.09 per share for net proceeds of $14,894,000.
The
Series A Preferred Stock bears a cumulative dividend rate of 8.0% per annum.
Each share of the Series A Preferred Stock is convertible into shares of common
stock at the then-applicable conversion rate at any time and at the option
of
the holder. The Series A Preferred Stock will automatically convert to common
stock at the then-applicable conversion rate in the event of an initial public
offering of our stock resulting in aggregate proceeds to us of $50 million
and a
share price of at least $2.74. Commencing in October 2009, the holders of the
Series A Preferred Stock may require PharmAthene to redeem the Series A
Preferred Stock then outstanding for an amount equal to the original purchase
price plus any unpaid dividends. Proceeds from the equity issuance were used
for
research and development of the DNI program, working capital and general
corporate purposes.
From
inception until August 2003, PharmAthene has issued approximately $492,000
in
notes payable to directors and scientific advisory board members. These notes
accrued interest at rates ranging from 4.74% to 8.0%. Subsequent to the issuance
of the Series A Preferred Stock in September 2003, we paid off the outstanding
balance and interest for approximately $521,000.
Future
Cash Needs
PharmAthene
has financed its operations since inception in March 2001 primarily through
the
issuance of equity securities, convertible notes, and proceeds from loans or
other borrowings. Any, or all, of these financing vehicles or others may be
utilized to fund our future capital requirements.
PharmAthene’s
future capital requirements and liquidity will depend on many factors, including
but not limited to: the progress of its research and development programs;
the
progress of pre-clinical and clinical testing; the time and cost involved in
obtaining regulatory approval; the cost of filing, prosecuting, defending and
enforcing any patent claims and other intellectual property rights; the changes
in its existing research relationships, competing technological and marketing
developments; its ability to establish collaborative arrangements and to enter
into licensing agreements and contractual arrangements with others; and any
future change in its business strategy.
PharmAthene
has incurred cumulative net losses and expects to incur additional losses to
perform further research and development activities. It does not have commercial
products and has limited capital resources. PharmAthene’s plans with regard to
these matters include continued development of its product candidates as well
as
seeking additional research support funds and financial arrangements through
a
combination of collaborative agreements, strategic alliances, research grants,
equity and debt financing. Although PharmAthene continues to pursue these plans,
there is no assurance that it will be successful in obtaining sufficient
financing on commercially reasonable terms or that we will be able to secure
financing from anticipated government contracts and grants. PharmAthene has
developed a plan to reduce its operating expenses in the event that sufficient
funds are not available, or if it is not able to obtain anticipated government
contracts and grants. If PharmAthene is unable to raise adequate capital or
achieve profitability, future operations will need to be scaled back or
discontinued.
Off-Balance
Sheet Arrangements
The
only
off-balance sheet arrangements we have entered into are our facility and
equipment operating lease agreements. Our obligations under these agreements
are
presented in this section under ‘‘Contractual Obligations.”
Critical
Accounting Policies and Estimates
The
preparation of financial statements in conformity with U.S. generally accepted
accounting principles requires PharmAthene to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities at the date of the financial statements,
and
the reported amounts of revenues and expenses during the reporting period.
PharmAthene bases its estimates and assumptions on historical experience and
various other factors that are believed to be reasonable under the
circumstances. Actual results could differ from our estimates and assumptions.
PharmAthene believes the following critical accounting policies, among others,
affect our more significant estimates and assumptions and require the use of
complex judgment in their application.
Adoption
of FASB 123R regarding share-based payments
On
December 13, 2004, the FASB issued FAS 123R, which requires that all share-based
payments to employees, including grants of employee stock options, be recognized
in the income statement based on their grant date fair values for interim or
annual periods beginning after June 15, 2005. Costs of all Share-based payments
will be recognized over the requisite service period that an employee must
provide to earn the award (i.e. usually the vesting period) and charged to
the
operating expense associated with that employee. PharmAthene adopted FAS 123R
on
January 1, 2006 using the ‘‘modified prospective” method. Because PharmAthene
does not have history as a publicly held company, it has based such measurements
as volatility on publicly held companies similar to PharmAthene.
Revenue
Recognition
PharmAthene
recognizes revenue when all terms and conditions of the agreements have been
met
including persuasive evidence of an arrangement, services have been rendered,
price is fixed or determinable, and collectibility is reasonably assured. For
reimbursable cost research grants, PharmAthene recognizes revenue as costs
are
incurred and appropriate regulatory approvals have been obtained or approval
criteria are met for invoicing the related government agency. This approval
criteria may be met or obtained on certain factors, such as the achievement
of
milestone objectives or the completion of certain tasks according to agreed
upon
activity terms.
PharmAthene
currently is not engaged in any such reimbursable grants or contracts and all
of
the grant revenue PharmAthene recognized historically was received under a
cost
reimbursement grant from the U.S. government to fund the development of
pharmaceutical products for biodefense applications. Uncertainties exist as
to
the approval of receipts pursuant to such cost reimbursement grants including
the execution risks associated with the successful completion of related tasks
and the funding risks caused by the modifications of contracts at any time
by
the granting agency to accommodate goals or budgetary funding changes. In
addition, reimbursed costs are subject to review and adjustment by the granting
agency. As PharmAthene develops experience with contracting authorities and
as
its incurred cost submissions are reviewed and approved by the responsible
government authorities, estimates of the assumptions related to these
uncertainties may change.
Research
and Development Expenses
Research
and development costs are charged to expense as incurred.
Intangible
Assets
When
PharmAthene acquires development products, we classify the purchase price,
including expenses and assumed liabilities, as tangible and intangible assets.
The portion classified as intangible assets may be allocated to trademarks,
patents and other intangibles using the assistance of valuation experts.
PharmAthene estimates the useful lives of the assets by considering the
remaining life of the patents, estimated future introductions of competing
products, and other related factors.
Because
of the nature of pharmaceutical research, and particularly because of the
difficulties associated with efficacy studies in humans related to the
bioterrorist products with which PharmAthene works and the government’s related
funding provisions, factors that drive the estimate of the life of the asset
are
often more uncertain than other non-bioterrorist pharmaceutical research. On
an
annual basis, PharmAthene assesses recoverability of intangibles from future
operations, using undiscounted future cash flows derived from the intangible
assets.
Any
impairment would be recognized in operating results to the extent the carrying
value exceeds the fair value, which is determined based on the net present
value
of estimated future cash flows; in certain situations, where the carrying value
is dependent upon the outcome of a single study and that study is unsuccessful,
that impairment may be significant in amount and immediate in
timing.
Consolidation
of PharmAthene Canada, Inc.
The
FASB
has issued ASB Interpretation No. 46R, Consolidation of Variable Interest
Entities, (“FIN 46R”), which expands consolidated financial statements to
include variable interest entities. Variable interest entities are to be
consolidated by the company which is considered to be the primary beneficiary
of
the entity, even if such company does not have majority control. Under FIN
46R,
PharmAthene has been deemed the primary beneficiary of PharmAthene Canada,
Inc.,
a variable interest entity. Accordingly, the financial results of PharmAthene
Canada, Inc. have been consolidated with the PharmAthene 2005 financial
statements as of its date of inception.
Contractual
Obligations
The
following are contractual commitments at December 31, 2005 associated with lease
and collaborative development obligations:
|
|
Payments
due by Period
|
|
Contractual
Obligations(1)
|
|
Total
|
|
Less
than
1
Year
|
|
1-3
Years
|
|
3-5
Years
|
|
More
than
5
years
|
|
Capital
lease obligations
|
|
$
|
1,300
|
|
$
|
1,300
|
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
Operating
facility leases
|
|
|
227,100
|
|
|
138,000
|
|
|
89,100
|
|
|
—
|
|
|
—
|
|
Medarex
Inc. collaborative agreement (2)
|
|
|
698,600
|
|
|
130,000
|
|
|
568,600
|
|
|
—
|
|
|
—
|
|
Total
contractual obligations
|
|
$
|
927,000
|
|
$
|
269,300
|
|
$
|
657,700
|
|
$
|
—
|
|
$
|
—
|
|
(1)
|
This
table does not include any royalty payments of future sales of products
subject to license agreements PharmAthene have entered into in relation
to
its in-licensed technology, as the timing and likelihood of such
payments
are not known.
|
|
|
(2)
|
In
November 2004, PharmAthene entered into a collaboration agreement
with
Medarex, Inc. under which the companies plan to develop and commercialize
MDX-1303, a fully monoclonal antibody, for use against human anthrax
infection. In December 2004, PharmAthene paid a $2.0 million deposit
to
Medarex to be used for potential future development activities on
MDX-1303. At December 31, 2005, approximately $1.3 million of this
deposit
remains with current estimates forecasting depletion of this deposit
by
the fourth quarter of fiscal year 2006. The contractual obligations
table
includes PharmAthene’s estimated obligation for funding development
activities under this collaboration agreement subsequent to depleting
the
original deposit.
|
Quantitative
and Qualitative Disclosures About Market Risk
None.
INFORMATION
ABOUT PHARMATHENE
Overview
PharmAthene
is in the business of discovering and developing novel human therapeutics and
prophylactics for the treatment and prevention of morbidity and mortality from
exposure to biological and chemical weapons. PharmAthene has two products
currently in development, Valortim™, a human monoclonal antibody for the
prevention and treatment of anthrax infection, and Protexia®, a bioscavenger for
the treatment of organophosphate nerve agent poisoning.
The
U.S.
government has identified certain indications as priorities for biodefense
funding, including anthrax, nerve agent exposure, smallpox, botulinum toxin
and
radiation. PharmAthene is pursuing the development of products in the areas
of
anthrax and nerve agent exposure. Currently, the FDA has an expedited and
simplified mechanism for regulatory approval of biodefense drugs. Phase I human
clinical trials are required to show reasonable safety, but efficacy only needs
to be demonstrated in two animal species. In addition, the U.S. government
has
enacted laws and established processes to permit the sale of bioterrorism drugs
to government organizations prior to obtaining regulatory approval.
PharmAthene’s
lead product candidate, Valortim, is a fully human monoclonal antibody designed
to protect against and treat inhalation anthrax infection, the most lethal
form
of illness in humans caused by the Bacillus
anthracis
bacterium. PharmAthene is co-developing Valortim with Medarex, Inc., a
biopharmaceutical company that specializes in developing fully human
antibody-based therapeutic products and will share with Medarex any profits
derived from sales of Valortim. Preclinical trials on animal models have
demonstrated that Valortim is highly efficacious as both a prophylaxis and
a
therapeutic for inhalation anthrax infection in some animal models. PharmAthene
and Medarex have completed dosing of healthy volunteers in a Phase I open-label,
dose-escalation clinical trial to evaluate the safety, tolerability,
immunogenicity, and pharmacokinetics of a single dose of Valortim administered
intravenously or intramuscularly. No drug-related serious adverse events have
been reported. Final results from the Phase I trial were presented at the
Infectious Disease Society of America meeting in October 2006. Valortim has
been
granted Fast Track Status by the FDA, which may permit PharmAthene to submit
portions of a Biologics License Application (“BLA”) or efficacy supplement
before the complete BLA is submitted. This may expedite the review process
but
requires that the FDA have sufficient resources to allow early review of the
portions submitted. In addition, Valortim has been granted orphan drug status
for the treatment of inhalational anthrax.
Protexia,
PharmAthene’s second product candidate, is a recombinant form of human
butyrylcholinesterase (“BChE”) for use in the prophylaxis and treatment of
organophosphate chemical nerve agent poisoning. Preclinical trials on animal
models have demonstrated that Protexia is highly efficacious as both a
prophylaxis and a therapeutic for chemical nerve agent poisoning. PharmAthene
plans to continue preclinical animal studies of Protexia throughout 2007 and
file an Investigational New Drug application (“IND”) with the FDA in 2008. The
procurement process for the scale-up development and sale of Protexia is already
underway with the U.S. Department of Defense (“DoD”), the department tasked with
purchasing biodefense countermeasures for military use. The DoD requested
competitive bids in a Request for Proposal (an “RFP”) for a
recombinant form of BChE drug for the prophylaxis treatment of chemical nerve
agent poisoning, which PharmAthene submitted in November 2005. In
September 2006, PharmAthene was awarded a contract with a potential value of
$213 million by the DoD for advanced development of Protexia and procurement
of
an initial 90,000 doses.
Strategy
PharmAthene’s
goal is to become the premier company worldwide specializing in the discovery,
development, and commercialization of therapeutic and prophylactic drugs for
defense against bio-terrorism and to eventually leverage its biodefense
capabilities for non-biodefense products in broader commercial markets.
PharmAthene’s strategy to achieve this objective includes the following
elements:
· In-license
or acquire development-stage product candidates that address other large
biodefense markets.
PharmAthene endeavors to continue to build a portfolio of development-stage
products in the area of biodefense. PharmAthene intends to continue to identify
development-stage product candidates, including therapeutics, diagnostics
and
vaccines, that address the bioterrorism threats given the highest priority
by
the U.S. government, such as smallpox and botulinum toxin.
· Maximize
the value of its product candidates, Valortim and Protexia, by accessing the
resources of PharmAthene’s partners.
PharmAthene intends to maximize the value of its product candidates by
leveraging the substantial clinical, financial, regulatory, and commercial
strengths of its partners. PharmAthene believes that Medarex provides
manufacturing and monoclonal antibody development expertise and other resources
needed to help successfully develop Valortim. In addition, PharmAthene actively
co-developed Protexia with the U.S. Army under a cooperative research and
development agreement. PharmAthene believes the U.S. Army is the leading
institution in the area of chemical nerve agent testing and analysis, including
modified, more toxic forms of organophosphate nerve agents which have not yet
been, but may eventually be, used as weapons.
· Establish
additional collaborations with pharmaceutical and biotechnology
companies.
PharmAthene will seek to enter into additional partnerships to support the
development of existing and future pipeline products, or to more favorably
position its products for government procurement.
· Market
and apply PharmAthene’s capabilities in the procurement of government contracts
to sell other companies’ products.
PharmAthene personnel have significant experience in dealing with all aspects
of
government contract bidding and maintenance. PharmAthene believes that companies
that are not focused on biodefense but that do have products that could be
sold
to the government could benefit from PharmAthene’s capabilities. PharmAthene has
been approached, and anticipates it will continue to be approached, by companies
willing to enter into sales, marketing and distribution agreements for access
to
PharmAthene’s government contracting expertise.
· Expand
into commercial markets by leveraging PharmAthene’s biodefense
capabilities.
To
diversify its risk of dependence on government funding of biodefense products,
PharmAthene intends to apply its drug development expertise and capabilities
for
the development of non-biodefense products for broader commercial markets.
For
example, PharmAthene believes that Protexia, its recombinant human BChE product,
in addition to having utility as a broad-spectrum countermeasure against nerve
agent chemical weapons, may be used to treat cocaine and heroin addiction.
PharmAthene believes that increasing endogenous levels of BChE can help reduce
risks of complications due to cocaine and heroin abuse as well as help prevent
and treat addiction.
Biodefense
Industry
Market
Overview
In
recent
years, the U.S. government has significantly increased spending for development
of measures to counteract biowarfare agents and has established numerous
programs with some budgets extending out for nearly a decade. U.S. government
spending on military and civilian biodefense currently averages nearly $7
billion annually, representing the vast majority of spending on biodefense
countermeasures worldwide. The biodefense market can be divided into three
segments: U.S. civilian, U.S. military, and non-U.S. markets.
The
U.S.
civilian market includes funds allocated to protecting the U.S. population
from
biowarfare agents. The market is largely funded by Project BioShield. The
Project BioShield Act of 2004, the U.S. government’s largest biodefense
initiative, was signed into law for the procurement of biodefense
countermeasures for the Strategic National Stockpile. Project Bioshield provided
for $5.6 billion in biodefense spending for the period from July 2004 through
2013. Procurement awards totaled $1.8 billion through 2006 and $400 million
is
expected to be awarded through 2008. The remaining $2.2 billion is scheduled
to
become available in 2009.
According
to the DoD, U.S. civilian biodefense spending outside of Project BioShield
has
been approximately $5 billion per year since 2003. The Department of Health
and
Human Services and the Department of Homeland Security account for 88% of
civilian biodefense dollars.
The
DoD
is responsible for the development and procurement of countermeasures for the
military segment which focuses on providing biowarfare protection for military
personnel and civilians who are on active duty. The Chemical and Biological
Program was funded with $1.2 billion in 2005, while $1.5 billion was requested
for 2006, according to the DoD. Of such amounts, funds dedicated to the
development and procurement of medical technologies, therapeutics, and vaccines
are approximately $300 million for 2005, while nearly $400 million has been
requested for 2006. Total funding for the Chemical and Biological Program
between 2006 and 2011 is projected by the U.S. government to be $9.9
billion.
Non-U.S.
markets address protection against biowarfare agents for both civilians and
military in foreign countries. PharmAthene believes the recognition by foreign
governments of a need for biodefense programs has been increasing recently.
Foreign biodefense programs would help support a larger market and also further
diversify PharmAthene’s potential sources of funding.
Project
BioShield
Project
BioShield is focused on products with low technology risk that will be available
for purchase in the near term. The U.S. government has identified the following
indications as a priority: anthrax; smallpox; botulinum toxin; radiation; and
nerve agent exposure. To identify the best products for these indications,
HHS
has issued Requests for Information (“RFI”) followed by RFP. The RFP details
requirements including treatment types, number of doses and delivery timeframe.
To qualify for Project BioShield funding, a company is required to demonstrate
product efficacy in an animal model, initial product safety in Phase I clinical
trials and sufficient manufacturing capabilities. To date, 10 awards have been
made under Project BioShield, including those for anthrax vaccines and
therapeutics, radiation, and botulinum. While the largest contract ($877
million) for anthrax vaccine was terminated, HHS has indicated those funds
will
be allocated to a new solicitation and award for anthrax vaccines.
Development
Cycle
The
U.S.
government has acted to facilitate expeditious development of biodefense
countermeasures by shortening the development and approval process relative
to
traditional pharmaceutical products. Development of biodefense products may
be
less expensive and less risky compared to traditional therapeutics and vaccines
because human efficacy trials are not required.
Immediate
Biodefense Focus: Anthrax and Nerve Agent Exposure
Under
Project BioShield, the government has identified certain indications as
priorities for biodefense funding including anthrax, smallpox, botulinum toxin,
radiation, and nerve agent exposure. PharmAthene is pursuing the development
of
products in the areas of anthrax and nerve agent exposure.
Anthrax
The
three
general modes of infection by Bacillus
anthracis
(“B.
anthracis”),
the
bacterium which causes anthrax, are by inhalation, ingestion, and skin contact.
Inhalation is the form of infection most likely to be lethal. Inhalational
anthrax occurs when the anthrax bacterium becomes airborne and enters a person’s
body through the lungs. Persons suffering from inhalation anthrax will
experience a series of symptoms consisting of fever, muscle aches, fatigue,
and
cough, which lasts an average of four days. Following this period, there is
rapid onset of severe respiratory distress, low blood oxygen and low blood
pressure, which generally culminates in death. Inhalation anthrax has a 95%
to
100% mortality rate if left untreated, and at least a 50% mortality rate in
patients treated aggressively with antibiotics. Persons infected by B.
anthracis that
is
ingested will suffer from gastrointestinal anthrax; those whose skin comes
into
contact with the anthrax bacteria will suffer from cutaneous anthrax.
Gastrointestinal anthrax often presents those exposed with serious
gastrointestinal difficulty, vomiting of blood, severe diarrhea, acute
inflammation of the intestinal tract, and loss of appetite. Gastrointestinal
anthrax has a 25% to 65% mortality rate if left untreated. Cutaneous anthrax
generally causes skin infections within a week or two after exposure. Cutaneous
anthrax is the least fatal. Without treatment, approximately 20% of all skin
infection cases are fatal. Treated cutaneous anthrax is rarely
fatal.
B.
anthracis
is a
spore forming bacterium that has potential use as a weapon of bioterror,
especially when delivered in an aerosolized form. Following germination of
the
spores, the bacteria replicates and produces three toxins. The first of these
toxins, Anthrax Protective Antigen initiates the onset of illness by attaching
to the outside of the healthy cells of the infected person, and then facilitates
the entry of the two additional destructive toxins, referred to as Lethal Factor
and Edema Factor, into those cells.
The
DoD
estimates that up to ten countries may possess anthrax weapons and an
undetermined number of individuals and terrorist groups could have access to
anthrax. Anthrax is an effective bioterrorism agent because the spore-forming
bacteria are very stable, can be milled to a very fine powder, and may be
dispersed widely with readily available instruments and machinery. The World
Health Organization estimates that 50 kilograms of B.
anthracis
released
upwind of a city of 500,000 people could result in up to 95,000 fatalities,
with
an additional 125,000 persons being incapacitated.
PharmAthene
believes that currently available treatment for inhalation anthrax is limited
and suboptimal. Following exposure, but prior to the onset of symptoms,
antibiotics like ciprofloxacin, doxycycline, or penicillin can be used as
post-exposure prophylaxis with the goal of preventing progression of the
disease. In order to be fully effective when used in this way, the recommended
antibiotic treatment must be continued for sixty days. PharmAthene believes
that
both compliance and side effects are problematic for anyone asked to take
antibiotics for such an extended period of time. A product like Valortim, with
a
prolonged half-life, might allow for less frequent dosing to achieve adequate
post-exposure prophylaxis.
Once
symptoms have developed following exposure, interventions are aimed at improving
mortality. PharmAthene believes the addition of an anti-toxin like Valortim
has
the potential to significantly improve upon the current therapeutic regimen,
and
it would have the added benefit of acting against the toxins released from
antibiotic-resistant strains.
Chemical
Weapons and Nerve Agents
Chemical
weapons use the toxic properties, as opposed to the explosive properties, of
chemical substances to produce physiological effects on an enemy. Classic
chemical weapons, such as chlorine and phosgene, were employed during World
War
I and consisted primarily of commercial chemicals used as choking and blood
agents, which caused respiratory damage and asphyxiation. Nerve agents, one
of
the most lethal forms of chemical weapons, were developed in the 1930s in the
years leading up to World War II.
Nerve
agents function by binding to acetylcholinesterase, an enzyme that normally
causes the neurotransmitter acetylcholine to relax. By blocking the activity
of
acetylcholinesterase, nerve agents cause nerve impulses to be continually
transmitted, causing muscle contractions that do not stop. This effect is
referred to as a “cholinergic crisis” and consists of a loss of muscle control,
respiratory failure, paralysis and convulsions. Nerve agent exposure that does
not cause death after a short period can lead to permanent brain damage. Nerve
agents are a class of organophosphates, a term which refers to organic chemicals
that contain the element phosphorous.
Nerve
agents, which are all liquids at room temperature, are generally lethal far
more
quickly and in far lower quantities than are classic chemical weapons, and
are
effective both when inhaled and when absorbed through the skin. Nerve gases
can
be classified as either G-agents (such as sarin, soman, tabun) or V-agents
(such
as VX), both of which are volatile and toxic. Chemical agents can be delivered
through explosive devices, spray tanks or most any other liquid or gas
dispersion devices and machinery.
The
current standard of care for post-exposure treatment involves repeated doses
of
a cocktail of drugs, including atropine, oxime reactivators, and
anti-convulsants. PharmAthene believes available treatment options are
inadequate and there is a need for more efficacious countermeasures, especially
as evidence mounts that modified, more toxic forms of organophospates, VX and
G
agents may be used in future attacks.
There
is
currently only one FDA approved product, Pyridostigmine bromide (“PB”), which is
used as a “pre-treatment adjunct” against nerve agent poisoning, and it is only
usable to counteract poisoning by one nerve agent, soman. It confers no
protection on its own but enhances the protection conferred by post-exposure
treatment. The current standard of care for post-exposure treatment involves
repeated doses of a cocktail of drugs including atropine, oxime reactivators
(“2-PAM”) and anti-convulsants. However, this standard of care acts primarily on
the symptoms of nerve agents, not their underlying cause. PharmAthene believes
available pre-and post-treatment options are inadequate and that there is a
need
for more efficacious countermeasures.
PharmAthene’s
Solutions
Based
on
its preclinical and clinical trials to date, PharmAthene believes its two
product candidates will offer tangible benefits over existing treatments for
inhalation anthrax and chemical nerve agent poisoning.
PharmAthene’s
Product Pipeline
|
|
|
|
|
|
Status
|
|
|
|
|
Product
Candidate
|
|
Type
|
|
Disease
|
|
Pre-clinical
|
|
Phase
I
|
|
FDA
Submission
|
|
Next
Milestone
|
|
Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Valortim
|
|
Monoclonal
Antibody
|
|
Inhalation
anthrax
|
|
|
|
NIAID
contract
for advanced
development—
2Q07
|
|
Medarex
|
|
|
|
|
|
|
|
|
|
|
|
Protexia
|
|
Recombinant
Butyrylcholin
esterase
protein
|
|
Toxicity
caused by
nerve agents
|
|
|
|
Complete
process
development—
2Q07
|
|
None
|
Valortim:
Anthrax Monoclonal Antibody
Valortim
is a fully human antibody designed to protect against or treat inhalation
anthrax, the most lethal form of illness in humans caused by B.
anthracis.
Valortim functions by targeting Anthrax Protective Antigen, a protein component
of the lethal toxins produced by the bacterium. Anthrax Protective Antigen
(“Anthrax PA”) initiates the onset of the illness by attaching to and
facilitating the entry of the destructive toxins Lethal Factor (“LF”) and Edema
Factor (“EF”) into healthy cells in the infected person. Valortim is designed to
bind to Anthrax PA and protect the cells from damage by the anthrax toxins.
In
preclinical studies, Valortim both protected against infection, and when
administered some time after exposure, facilitated recovery and survival in
animals exposed to lethal inhalation doses of anthrax spores.
Anthrax
spore challenge studies in animals have demonstrated protection by Valortim
both
when given early following challenge (post-exposure prophylaxis) as well as
when
given up to 48 hours after challenge (therapeutic intervention). Valortim binds
to a novel site of Anthrax PA, permitting protection after toxins have already
attached to the cell. PharmAthene believes Valortim’s potency and unique
mechanism of action differentiate it from competing products, and provides
superior activity in the toxin neutralization assay. PharmAthene believes that,
in the initial Phase I clinical trials in healthy human volunteers, Valortim
was
well-tolerated with no drug-related serious adverse events
reported.
Development
Timeline
Currently,
PharmAthene and Medarex have completed dosing in a Phase I open-label,
dose-escalation clinical trial to evaluate the safety, tolerability,
immunogenicity, and pharmacokinetics of a single dose of Valortim administered
intravenously or intramuscularly in healthy volunteers. Final results from
the
Phase I study were presented at the Infectious Disease Society of America
meeting in October 2006.
Recently,
Valortim received Fast Track designation from the FDA, which generally indicates
that the FDA will facilitate the development and expedite the regulatory review
of the product. However, PharmAthene can provide no assurance that the review
will be successful. Valortim has also been granted Orphan Drug status, a
designation for drugs developed for diseases which affect less than 200,000
persons in the United States and provides for reduced fees to the FDA, market
exclusivity for seven years and other FDA-related privileges.
Clinical
and Preclinical Studies
Valortim
is being developed for two indications: (i) as a post-exposure prophylaxis;
and
(ii) as a post-exposure therapy.
Clinical
Phase I Studies
Valortim
has been tested in a Phase I, single-dose, dose-escalation trial in healthy
human volunteers. PharmAthene found that subjects tolerated Valortim without
drug-related serious adverse events. Minor adverse events reported included
pain
at the intramuscular injection site, headache, muscle aches, and occasionally
bruising at the site of the intravenous catheter inserted for drug dosing and
blood draws. Pharmacokinetic data indicate that Valortim has good
bioavailability following intramuscular injection; additionally, both
intravenous and intramuscular injection result in a half-life of 26 to 30 days.
Preclinical
Studies: Post-exposure Prophylaxis Indication
PharmAthene
has conducted two studies in animals to evaluate the use of Valortim as a
post-exposure prophylaxis, or, in other words, to protect exposed patients
from
developing the symptoms and from dying of inhalational anthrax. Eighty-five
percent of rabbits treated intravenously with doses of Valortim survived
following inhalational exposure to anthrax spores. One hundred percent of
cynomolgus monkeys treated intramuscularly with doses of Valortim were protected
from death following exposure to inhalational anthrax spores. Treatment of
both
of these animal models was initiated within one hour following exposure to
the
anthrax spores.
PharmAthene
has also conducted a study in animals to evaluate the use of Valortim as a
post-exposure therapeutic. This indication for Valortim would be intended to
treat those patients who have already developed symptoms of inhalational
anthrax. In this study, 89% of the animals treated with Valortim intravenously
twenty-four hours following inhalational exposure to anthrax spores survived.
A
second group of animals were not treated with Valortim until forty-eight hours
following exposure; 42% of the animals treated at this timepoint survived.
Lower
doses have not yet been tested in this model. Additional work has begun to
test
Valortim in a second animal model for its effectiveness when given at extended
timepoints following inhalational anthrax spore exposure.
Protexia:
Recombinant Human Butyrylcholinesterase
Protexia
is a recombinant version of human butyrylcholinesterase (“rBChE”), a naturally
occurring protein found in minute quantities in blood. In its natural form,
butyrylcholinesterase, or “BChE” functions as a natural bioscavenger, like a
sponge, to absorb and degrade organophospate poisons (e.g. nerve agents) before
they cause neurological damage. Protexia is being developed as a pre-exposure
and post-exposure therapy for military and civilian targets of a nerve agent
attack.
PharmAthene,
in collaboration with the Institute for Chemical Defense (“ICD”), a U.S.
military organization where the testing of Protexia against traditional and
non-traditional agents is performed, has screened for neutralizing activity
by
rBChE against a number of these classified agents. rBChE continues to be assayed
against such non-traditional agents as they become available. In addition,
newer
more potent forms of rBChE will be screened as second-generation rBChE molecules
(having higher affinity binding characteristics and enhanced catalytic activity)
become available. Because ICD is a U.S. military organization, which treats
the
results of its studies as classified national security information, the results
of these tests are not available to PharmAthene or to the public.
Development
Timeline
Protexia’s
capability as a medical countermeasure has been demonstrated in
vivo
by its
ability to protect animals from multiple lethal doses of nerve agent chemical
weapons. Protexia has also been demonstrated to bind a broad spectrum of agents,
including sarin, soman, tabun and VX. Protexia has several likely advantages,
including providing protection both pre-exposure and post-exposure,
detoxification of organophosphate nerve agents with full spectrum protection
and
an acceptable safety profile.
Protexia
Proof of Concept Studies
Protexia
is being developed for two indications: (i) as a pre-exposure prophylaxis;
and
(ii) as a post-exposure therapy.
Pre-exposure
Prophylaxis Indication:
Pre-treatment
with Protexia not only provided 100% survival against multiple lethal doses
of
the nerve agents VX and soman in animal models but surviving animals also
displayed no nerve agent side effects. In these experiments, one group of
animals was pre-treated with Protexia or a negative control. Eighteen hours
later, they were exposed to multiple lethal doses of nerve agent (VX or soman).
Another group of animals was exposed to approximately 75% less nerve agent
and
then treated immediately with the current standard therapy, a three-drug
cocktail of atropine, 2-PAM and diazepam. Animals were videotaped post-exposure
and evaluated for toxic signs by observers blinded to the treatment groups.
In
addition, a functional observation battery neurological function tests (ability
to balance and memory tests) were formed six hours after exposure.
Results:
None of
the control animals exposed to nerve agents alone survived while 100% of animals
pretreated with Protexia survived with no visible nerve agent side effects
and
no loss of balance or memory relative to negative control animals. In contrast,
the animals exposed to much lower levels of nerve agents and subsequently
treated with the current standard therapy did not respond as well. Survival
in
these animals was mixed with 100% survival in animals exposed to VX but only
50%
survival in animals exposed to soman, although all survivors had significant
side effects including a pronounced loss of balance and loss of
memory.
Post-exposure
Therapeutic Indication:
Based
on
the demonstration of protection when Protexia was administered before nerve
agent exposure, a series of experiments were conducted to determine whether
Protexia was effective as a therapy when administered after exposure to nerve
agent.
The
therapeutic efficacy of Protexia was first evaluated in a domestic pig model
with rapid (intravenous) exposure to nerve agent (VX) followed by treatment
with
Protexia 15 minutes later. All of the control animals receiving nerve agent
alone died with an average time to death of 1.5 hours while 50% of animals
receiving Protexia survived with a prolonged time to death (average of 5.4
hours) in the animals that died.
A
second
study was then conducted to evaluate the therapeutic efficacy of Protexia in
a
different animal model and to increase the time before treatment with Protexia
to one hour. In this study, 90% of the animals exposed to VX on the skin and
then treated with Protexia survived as compared to no survivors among the group
that was not treated.
U.S.
Government Regulatory Pathway
General
Regulation
by governmental authorities in the United States and other countries will be
a
significant factor in the production and marketing of any biopharmaceutical
products that PharmAthene may develop. The nature and the extent to which such
regulations may apply to PharmAthene will vary depending on the nature of any
such products. Virtually all of PharmAthene’s potential biopharmaceutical
products will require regulatory approval by governmental agencies prior to
commercialization. In particular, human therapeutic products are subject to
rigorous pre-clinical and clinical testing and other approval procedures by
the
FDA and similar health authorities in foreign countries. Various federal
statutes and regulations also govern or influence the manufacturing, safety,
labeling, storage, record keeping and marketing of such products. The process
of
obtaining these approvals and the subsequent compliance with appropriate federal
and foreign statutes and regulations requires the expenditure of substantial
resources.
Government
Funding
The
U.S.
Government awarded Medarex, PharmAthene’s partner in the development of
Valortim, two separate grants of up to $7.2 million over the next three years
for the further development of Valortim. In addition, the DoD Appropriations
bills for fiscal year 2006 and 2007 included $2.05 million and $1.0 million
respectively to support PharmAthene’s ongoing development of Valortim. Prior to
PharmAthene’s acquisition of the recombinant butyrylcholinesterase program,
Nexia, the predecessor of PharmAthene Canada, was awarded a $2.6 million
contract by the DoD to support the expression of rBChE in the milk of transgenic
goats and to provide proof of concept data that the product can be produced
in
kilogram quantities. Additionally, PharmAthene was awarded a multi-year contract
which can provide up to $213 million by the DoD U.S. Army Space and Missile
Command for the advanced development of Protexia.
Collaborations
PharmAthene
entered into a collaboration and development agreement with Medarex in November
2004 to co-develop Valortim for the treatment of anthrax infection. Under the
terms of the agreement, Medarex and PharmAthene have agreed jointly to continue
to investigate the potential for Valortim to be used as a therapeutic for
individuals with active disease as well as for prophylactic treatment of
individuals exposed to anthrax. Medarex received an initial payment from
PharmAthene of $2,000,000 used to fund development activities already underway
for Valortim. PharmAthene will be solely responsible for funding all future
research and development activities that are not supported by government funds.
The companies will share profits according to a predetermined allocation
percentage. The percentage of profits that PharmAthene will be entitled to
receive will depend in part upon the amount of funding that it provides in
connection with the collaboration. Additionally, PharmAthene will be responsible
for marketing, selling and distribution of the product.
Additional
animal model development and testing of Valortim for therapeutic efficacy will
be carried out under a recently established Collaborative Research and
Development Agreement with the U.S. Army Medical Research Institute of
Infectious Diseases.
PharmAthene
has actively co-developed Protexia with the U.S. Army Medical Research Institute
of Chemical Defense under a cooperative research and development
agreement.
Non-Biodefense
Products in Development
In
addition to its utility as a broad-spectrum countermeasure against nerve agent
chemical weapons, PharmAthene is evaluating the use of BChE as a potential
clinical candidate for the treatment of cocaine and heroin addiction and the
treatment of initial toxicity from overdose of cocaine and heroin. This is
due
to the unique structure of the enzyme that allows for selective binding to
a
variety of substrates and inhibitors. Increasing endogenous levels of BChE
can
reduce risks of complications due to cocaine and heroin abuse.
Intellectual
Property
PharmAthene’s
success depends in part on its ability to obtain patents, to protect trade
secrets, and to operate without infringing upon the proprietary rights of
others. PharmAthene seeks to protect its proprietary position by, among other
methods, filing U.S. and foreign patent applications related to the proprietary
technology, inventions and improvements that are important to the development
of
its business. Further, all of PharmAthene’s employees have executed agreements
assigning to PharmAthene all rights to any inventions and processes they develop
while they are employed by PharmAthene.
In
addition, PharmAthene intends to use license agreements to access external
products and technologies, as well as to convey its own intellectual property
to
others. PharmAthene will be able to protect its proprietary rights from
unauthorized use by third parties only to the extent that its proprietary rights
are covered by valid and enforceable patents or are effectively maintained
as
trade secrets. Protection of PharmAthene’s intellectual property rights is
subject to a number of risks.
Manufacturing
PharmAthene
has limited manufacturing capabilities and believes that acceptable alternatives
are available through Contract Manufacturing Organizations, “CMOs.” These CMOs
have experience in operating under the current Good Manufacturing Practices
established by the FDA.
For
Protexia, PharmAthene owns and operates a transgenic goat farm for the
production of BChE in Quebec, Canada. PharmAthene is currently producing this
protein in the milk of transgenic goats at commercially feasible concentrations.
This farm will be used for the commercial production of the crude material.
The
large-scale recovery and purification process is currently under development
at
PharmAthene’s research center in Montreal and at a CMO. For commercial
manufacturing, the initial production will be performed at PharmAthene’s farm
and the final purification of the bulk drug substance will be performed at
a
CMO. Final formulation and delivery are still being developed.
For
Valortim, the cell culture process was developed by PharmAthene’s partner for
Valortim, Medarex, and results in a commercially feasible and high purity
product that would be manufactured commercially by a CMO. PharmAthene has
determined that the capital investment and high operating costs of a
manufacturing operation are not justified at this time and several acceptable
CMOs are available to produce this product.
Competition
Anthrax
Therapeutics:
Monoclonal
antibodies (“MAbs”) directed against anthrax PA are being developed for
post-exposure prophylaxis and as symptomatic therapy for anthrax infection.
There are currently a limited number of companies of which PharmAthene is aware
with anti-anthrax MAbs in development. These include: Human Genome Sciences,
Inc., Elusys Therapeutics, Inc., Avanir Pharmaceuticals Inc. and IQ Corporation
BV.
There
are
a number of orally available small molecule drugs approved and/or under
development for the treatment of anthrax. These include both broad spectrum
antibiotics as well as anthrax specific products. Bayer Corporation produces
Ciprofloxacin, or “Cipro,” which has been approved for the post-exposure
prophylaxis of inhalation anthrax. In late 2004, a number of generic versions
of
Cipro were also approved by the FDA.
In
addition to anthrax therapeutics, anthrax vaccines are currently available
or in
development. At present, only one vaccine is approved for use by the FDA for
the
prevention of anthrax which is BioThrax made by BioPort Corporation, a
subsidiary of Emergent Biosolutions Inc. PharmAthene believes that second
generation vaccines consisting of recombinant protective antigen are being
developed by VaxGen Inc. and Avecia Biotechnology. PharmAthene also believes
that third generation vaccines, consisting of improved formulations of the
anthrax protective antigen are being developed by Avant Immunotherapeutics
Inc.,
BioSante Pharmaceuticals, Cerus Corporation Inc., Dynavax Technologies Inc.,
DVC, Vical and LigoCyte Pharmaceuticals Inc.
Organophosphorous
Nerve Agent Therapeutics:
Nerve
agents are considered to be among the most lethal biowarfare agents, yet there
are few antidotes available. Symptoms of intoxication develop within seconds,
and death can result within minutes after exposure by inhalation, absorption
through the skin, or by oral consumption.
The
current medical regimen for organophospate intoxication includes pretreatment
with carbamates (i.e. pyridostigmine)
to
protect acetylcholinesterase (AChE) from irreversible inhibition, followed
by
anticholinergic drugs (i.e. atropine)
to
counteract the effects of excess acetylcholine, quaternary ammonium oximes
(i.e.
2-PAM)
to
reactivate AChE that was inhibited by organophospate binding, and anticonvulsant
drugs (i.e. diazepam)
to
minimize convulsions and permanent brain damage.
However,
these medical countermeasures against nerve agents are not sufficiently
effective, particularly at protecting the central nervous system. PharmAthene
is
aware of several antidotes to other nerve agents being developed by
pharmaceutical companies, including Meridian Medical Technologies, a subsidiary
of King Pharmaceuticals Inc. and DVC, a division of Computer Sciences Corp.,
in
collaboration with Baxter Healthcare Corporation.
PharmAthene’s
Subsidiary: PharmAthene Canada, Inc.
PharmAthene’s
efforts with respect to Protexia are conducted primarily through its facility
in
Canada and through its Canadian subsidiary, PharmAthene Canada, Inc.
(“PharmAthene Canada”) through which it develops and manufactures complex
recombinant proteins in the milk of transgenic goats for medical and industrial
applications. PharmAthene Canada’s strength is producing proteins that cannot be
made commercially using other recombinant systems.
PharmAthene
Management - Directors and Executive Officers
The
following table sets forth the name, position with PharmAthene and principal
occupation of PharmAthene’s executive officers, key employees, directors, and
members of PharmAthene’s scientific advisory board.
Name
|
|
Position
|
|
Principal
Occupation
|
|
|
|
|
|
David
P. Wright
|
|
President,
Chief Executive Officer and Director
|
|
President,
Chief Executive Officer and Director
|
|
|
|
|
|
Christopher
C. Camut
|
|
Chief
Financial Officer, Treasurer and Vice President
|
|
Chief
Financial Officer
|
|
|
|
|
|
Solomon
Langermann, Ph.D.
|
|
Vice
President, Chief Scientific Officer
|
|
Vice
President, Chief Scientific Officer
|
|
|
|
|
|
Valerie
Riddle, MD
|
|
Vice
President, Medical Director
|
|
Vice
President, Medical Director
|
|
|
|
|
|
Eric
I. Richman
|
|
Vice
President, Business Development and Strategic Planning
|
|
Vice
President, Business Development and Strategic Planning
|
|
|
|
|
|
Francesca
Cook
|
|
Vice
President, Policy and Government Affairs
|
|
Vice
President, Policy and Government Affairs
|
|
|
|
|
|
Joel
McCleary
|
|
Chairman
of the Board
|
|
Chairman
of the Board Private Investor
|
|
|
|
|
|
James
Cavanaugh, Ph.D.
|
|
Director
|
|
Managing
Director of HealthCare Ventures LLC
|
|
|
|
|
|
Elizabeth
Czerepak
|
|
Director
|
|
General
Partner, Bear Stearns Health Innoventures Management
LLC
|
Ansbert
Gadicke, MD
|
|
Director
|
|
General
Partner of MPM Capital, L.P.
|
|
|
|
|
|
John
Gill
|
|
Director
|
|
President
and Chief Executive Officer and Director of TetraLogic
Pharmaceuticals
|
|
|
|
|
|
John
Mekalanos, Ph.D.
|
|
Director
|
|
Professor
and Chairman of the Department of Microbiology and Molecular Genetics,
Harvard Medical School
|
|
|
|
|
|
Steven
St. Peter, MD
|
|
Director
|
|
General
Partner of MPM Capital, L.P.
|
|
|
|
|
|
Mrs.
William McCormick Blair
|
|
Advisor
to the Scientific Advisory Board
|
|
Vice
President and Director Emeritus of The Albert and Marcy Lasker
Foundation
|
|
|
|
|
|
Stephen
Calderwood, MD
|
|
Member
Scientific Advisory Board
|
|
Chief,
Division of Infectious Diseases, and Professor of Medicine (Microbiology
and Molecular Genetics) at Harvard Medical School
|
|
|
|
|
|
John
Collier, Ph.D.
|
|
Member
Scientific Advisory Board
|
|
Professor
of Microbiology and Molecular Genetics at Harvard Medical
School
|
|
|
|
|
|
R.
Gordon Douglas, MD
|
|
Member
Scientific Advisory Board
|
|
Consultant
to the Vaccine Research Center at the National Institute of
Health
|
|
|
|
|
|
Stephen
Lory, Ph.D.
|
|
Member
Scientific Advisory Board
|
|
Professor
of Microbiology and Molecular Genetics at Harvard Medical
School
|
|
|
|
|
|
Jerald
C. Sadoff, MD
|
|
Member
Scientific Advisory Board
|
|
President
and Chief Executive Officer of the Aeras Global TB Vaccine
Foundation
|
|
|
|
|
|
John
A.T. Young, Ph.D
|
|
Member
Scientific Advisory Board
|
|
Professor,
The Salk Institute for Biological Studies in LaJolla,
CA
|
Legal
Proceedings
In
June
2006, PharmAthene and SIGA Technologies Inc. (“SIGA”) executed a definitive
Agreement and Plan of Merger (the “SIGA Agreement”). In connection with the SIGA
Agreement, PharmAthene loaned $3.0 million to SIGA pursuant to a Bridge Note
Purchase Agreement, dated March 20, 2006. On October 4, 2006, SIGA terminated
the SIGA Agreement and subsequently repaid the $3.0 million Bridge Notes
including interest. On December 20, 2006, PharmAthene filed a complaint against
SIGA in the Delaware Chancery Court. PharmAthene’s complaint alleges that it has
the right to an exclusive license to develop and market SIGA’s
drug candidate, SIGA-246, pursuant to the terminated SIGA Agreement and other
agreements between the parties and the course of performance. The complaint
further alleges that SIGA failed to negotiate in good faith the terms of such
a
license pursuant to the terminated SIGA Agreement and other agreements between
the parties and the course of performance. SIGA has filed a Motion to Dismiss
the complaint.
PharmAthene
is not a defendant to any material legal proceedings.
Facilities
PharmAthene’s
corporate headquarters are in the Chesapeake Innovation Center (“CIC”) in
Annapolis, Maryland. The CIC is an incubator facility co-sponsored by the State
of Maryland and the National Security Agency.
Employees
As
of
January 31, 2007, PharmAthene had 89 full-time employees. PharmAthene believes
its relations with its employees are good.
INFORMATION
ABOUT HAQ
Business
of HAQ
General
We
were
incorporated in Delaware on April 25, 2005, as a blank check company formed
to
serve as a vehicle for the acquisition, through a merger, capital stock
exchange, asset acquisition or other similar business combination of an
operating business whose fair market value is at least equal to 80% of our
net
assets at the time of such business combination.
A
registration statement for our IPO was declared effective on July 28, 2005.
On August 3, 2005, we consummated our IPO of 9,000,000 units. On
August 16, 2005, we consummated the closing of an additional 400,000 units
that were subject to the underwriters’ over-allotment option. Each unit consists
of one share of common stock and one redeemable common stock purchase warrant.
Each warrant entitles the holder to purchase from us one share of our common
stock at an exercise price of $6.00 per share. Our common stock and warrants
started trading separately as of October 6, 2005.
Our
net
proceeds from the sale of our units were approximately $69,450,000.
Of this
amount, $67,928,000
was
deposited in trust and the remaining $1,522,000 was held outside of the trust.
The proceeds held outside the trust are available to be used by us, and are
being used by us, to provide for business, legal and accounting due diligence
on
prospective acquisitions and continuing general and administrative expenses.
We
evaluated a number of candidates before moving forward with PharmAthene. If
the
Merger with PharmAthene is not consummated, we will not have enough time or
resources to continue searching for an alternative target.
Employees
We
have
three officers, all of whom are also members of our Board of Directors. These
individuals are not obligated to contribute any specific number of hours per
week and intend to devote only as much time as they deem necessary to our
affairs. The amount of time they will devote in any time period will vary based
on the availability of suitable target businesses to investigate. We do not
intend to have any full time employees prior to the consummation of a business
combination.
Properties
We
maintain our executive offices at 2116 Financial Center, 666 Walnut Street,
Des
Moines, Iowa 50309. We have agreed to pay Equity Dynamics, Inc., an affiliated
third party of which Mr. Pappajohn is the President and principal stockholder,
and Mr. Kinley is a Senior Vice President, approximately $7,500 per month for
office space (located at our executive offices) and certain additional general
and administrative services, such as an allocable share of receptionist,
secretarial and general office services. These offices consist of approximately
2,570 square feet of office space. A prior arrangement with an affiliate of
our
Chief Executive Officer, Derace Schaffer, M.D., pursuant to which we paid $1,500
a month for office space and certain general and administrative services, as
a
portion of the $7,500, was terminated on December 31, 2005.
Periodic
Reporting and Audited Financial Statements
HAQ
has
registered its securities under the Securities Exchange Act of 1934 and has
reporting obligations, including the requirement to file annual and quarterly
reports with the SEC. In accordance with the requirements of the Securities
Exchange Act of 1934, HAQ’s annual reports will contain financial statements
audited and reported on by HAQ independent accountants. HAQ has filed an Annual
Report on Form 10-K with SEC covering the fiscal year ended December 31,
2005.
Legal
Proceedings
To
the
knowledge of management, there is no litigation currently pending or
contemplated against us or any of our officers or directors in their capacity
as
such.
AND
RESULTS OF OPERATIONS OF HAQ
The
following discussion should be read in conjunction with the Consolidated
Financial Statements for HAQ beginning on page FS-1 of this proxy statement.
These Consolidated Financial Statements present the results of operations for
HAQ for the fiscal years ended December 31, 2005 (“2005”) and the fiscal quarter
ended September 30, 2006, as well as the financial positions at December 31,
2005 and September 30, 2006. In addition to historical information, the
following discussion may contain forward-looking information that involves
risks
and uncertainties. All amounts presented, except share data, are rounded to
the
nearest thousand dollars.
We
were
formed on April 25, 2005, to serve as a vehicle to acquire, through a merger,
capital stock exchange, asset acquisition or other similar business combination,
one or more domestic or international assets or an operating business in the
healthcare industry. Our initial business combination must be with a target
business or businesses whose fair market value is at least equal to 80% of
our
net assets at the time of such acquisition. We intend to utilize cash derived
from the proceeds of our recently completed IPO, our capital stock, debt or
a
combination of cash, capital stock and debt, in effecting a business
combination.
On
August
3, 2005, we consummated our IPO of 9,000,000 units. On August 16, 2005, we
consummated the closing of an additional 400,000 units that were subject to
the
underwriters’ over-allotment option. Each unit consists of one share of common
stock and one redeemable common stock purchase warrant. Each warrant entitles
the holder to purchase from us one share of our common stock at an exercise
price of $6.00.
As
discussed in greater detail in the section “The Merger Proposal - Background of
the Merger,” prior to entering into the Merger Agreement with PharmAthene, HAQ
was engaged in investigating a suitable business combination candidates. HAQ
had
met with target companies, service professionals and other intermediaries to
discuss with them HAQ, the background of HAQ’s management and HAQ’s combination
preferences. In the course of these discussions, HAQ had also spent time
explaining the capital structure of the IPO, the combination approval process,
and the timeline under which HAQ was operating before the proceeds of the
offering are returned to investors.
Overall,
HAQ has concluded that the environment for target companies has been competitive
and believes that private equity firms and strategic buyers represented its
biggest competition. HAQ ’s management believes that many of the fundamental
drivers of alternative investment vehicles like HAQ are becoming more accepted
by investors and potential business combination targets; these include a
difficult IPO environment, a cash-rich investment community looking for
differentiated opportunities for incremental yield, and business owners seeking
new ways to maximize their stockholder value while remaining invested in the
business.
From
April 2005 (inception) until December 31, 2005, HAQ had net income of
approximately $277,295, derived from dividend and interest income, gain on
derivative liabilities, less operating expenses and taxes.
Our
net
proceeds from the sale of our units, including amounts from exercise of the
underwriters’ over-allotment option, after deducting certain offering expenses
of approximately $1,220,000, including $720,000 evidencing the underwriters’
non-accountable expense allowance of 1% of the gross proceeds (excluding the
proceeds from the underwriters’ over-allotment), and underwriting discounts of
approximately $4,512,000, were approximately $69,468,000. Of this amount,
$67,928,000 is being held in trust and the remaining funds are being held
outside of the trust. The remaining proceeds are available to be used by us
to
provide for business, legal and accounting due diligence on prospective
acquisitions and continuing general and administrative expenses. To the extent
that our capital stock is used in whole or in part as consideration to effect
a
business combination, the proceeds held in the trust fund as well as any other
net proceeds not expended will be used to finance the operations of the target
business. We believe we will have sufficient available funds outside of the
trust fund to operate through August 2007, assuming that a business combination
is not consummated during that time. We do not believe we will need to raise
additional funds in order to meet the expenditures required for operating our
business.
The
table
below compares the use of net proceeds from HAQ’s IPO held outside of the trust
estimated at the time of the public offering (August 3, 2005) versus those
estimated by HAQ as of September 30, 2006.
|
|
S-1
|
|
Currnent
Estimate
|
|
Legal,
Accounting and other expenses attendant to the due diligence
investigations, structuring and negotiation of business
combination
|
|
$
|
200,000
|
|
|
200,000
|
|
Payment
for administrative services and support ($7,500 per month)
|
|
$
|
180,000
|
|
$
|
180,000
|
|
Due
diligence of prospective target businesses
|
|
$
|
600,000
|
|
$
|
402,000
|
|
Legal
and accounting fees relating to SEC reporting obligations
|
|
$
|
50,000
|
|
$
|
52,000
|
|
Income
and Franchise Taxes
|
|
|
— |
|
$
|
300,000
|
|
Working
Capital and Reserves
|
|
$
|
450,000
|
|
$
|
388,000
|
|
Total
|
|
$
|
1,480,000
|
|
$
|
1,522,000
|
|
(1) |
Assumes
the proposed business combination with PharmAthene is consummated
prior to
_______, 2007.
|
(2) |
Existing
available funds are not sufficient to satisfy estimated transaction
costs
prior to the Merger with
PharmAthene.
|
As
of
September 30, 2006, HAQ had (i) $763,931 in cash outside the trust and (ii)
$227,040 in current liabilities including accrued legal fees, due diligence
expenses and related transaction expenses and taxes, but excluding deferred
revenue. Assuming that (a) dissolution is not completed until August 2007,
(b)
that interest earned on the trust between September 30, 2006 and August 2007
is
approximately $2.0 million, HAQ currently estimates the trust amount as of
August 2007 would be approximately $2.0 million higher than the September 30,
2006 balance; management of HAQ believes the $2.0 million of this trust income
would be offset by an estimated $420,000 for franchise and income tax payments
through August 2007. Separately, management of HAQ estimates that the
dissolution process would cost approximately $50,000 to $75,000. This estimated
amount, in addition to the other liabilities currently indemnified by certain
officers and directors, consisting of vendors (list vendor liabilities) would
result in claims or liabilities which certain of HAQ’s officers and directors
have agreed to indemnify the trust account. We do not believe there would
be any claims or liabilities against which certain of HAQ’s executive officers
and directors have agreed to indemnify the trust account in the event of such
dissolution. As of September 30, 2006, HAQ has approximately $760,000
outside of the trust account. The increase in fees versus our original estimates
is due primarily to the length of time and associated expenses that have been
required to complete the Merger Agreement including the time and expense of
preparing various regulatory filings, due diligence costs and the associated
costs therewith relative to what was originally estimated. Such increases are
not necessarily based on the number of months since HAQ’s IPO, but rather the
time and process from the initiation of the drafting of the Merger Agreement
in
February through the expected closing, unanticipated events. Our counsel and
certain of our advisors other than accountants have agreed to alter their fees
or a substantial portion thereof until the consummation of a transaction and
to
forego such fees in the event the Merger is not consummated. Accordingly, HAQ
believes it has adequate funds to complete the proposed merger with PharmAthene.
In the event the Merger is not consummated, HAQ will be forced to liquidate.
See
Risk Factors.
Off-Balance
Sheet Arrangements; Commitments and Contractual
Obligations
As
of
December 31, 2005 and September 30, 2006, HAQ did not have any off-balance
sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and
did not have any commitments or contractual obligations. No unaudited quarterly
operating data is included in this proxy statement as HAQ has conducted no
operations to date.
Dissolution
and Liquidation if No Business Combination
We
have
agreed with the trustee to promptly adopt a plan of dissolution and liquidation
and initiate procedures for our dissolution and liquidation if we do not effect
the Merger before August 3, 2007. The plan of dissolution will provide that
we
liquidate all of our assets, including the trust account, and after reserving
amounts sufficient to cover our liabilities and obligations and the costs of
dissolution and liquidation, distribute those assets solely to our public
stockholders. As discussed below, the plan of dissolution and liquidation will
be subject to stockholder approval.
Upon
the
approval by our stockholders of our plan of dissolution and liquidation, we
will
liquidate our assets, including the trust account, and after reserving amounts
sufficient to cover our liabilities and obligations and the costs of dissolution
and liquidation, distribute those assets solely to our public stockholders.
Our
initial stockholders, including certain of our officers and directors, have
waived their rights to participate in any liquidating distributions occurring
upon our failure to consummate a business combination with respect to those
shares of common stock acquired by them prior to completion of our IPO and
have
agreed to vote all of their shares in favor of any such plan of dissolution
and
liquidation. We estimate that, in the event we liquidate the trust account,
our
public stockholders will receive approximately $7.48 (as of September 30, 2006)
per share. We expect that all costs associated with implementing a plan of
dissolution and liquidation as well as payments to any creditors will not be
able to be funded by the proceeds of our IPO not held in the trust account
and
cannot assure you that any of those funds will be available for such purposes.
Accordingly, if we do not have sufficient or any funds for those purposes,
the
amount distributed to our public stockholders will be less than $7.48 per share
(as of September 30, 2006) as a result of the trust account being reduced to
satisfy the costs associated with a liquidation.
To
mitigate the risk of the amounts in the trust account being reduced by the
claims of creditors:
· Prior
to
completion of the Merger, we will seek to have all vendors, prospective target
businesses and other entities, which we refer to as potential contracted parties
or a potential contracted party, execute valid and enforceable agreements with
us waiving any right, title, interest or claim of any kind in or to any monies
held in the trust account for the benefit of our public stockholders. In the
event that a potential contracted party were to refuse to execute such a waiver,
we will execute an agreement with that entity only if our management first
determines that we would be unable to obtain, on a reasonable basis,
substantially similar services or opportunities from another entity willing
to
execute such a waiver. Examples of instances where we may engage a third party
that has refused to execute a waiver would be the engagement of a third party
consultant whose particular expertise or skills are believed by management
to be
superior to those of other consultants that would agree to execute a waiver
or a
situation in which management does not believe it would be able to find a
provider of required services similar in talent willing to provide the
waiver.
· If
we
enter into an agreement with a potential contracted party that refuses to
execute a valid and enforceable waiver, then our initial directors and officers
will be personally liable to cover the potential claims made by such party
but
only if, and to the extent that, the claims otherwise would reduce the trust
account proceeds payable to our public stockholders in the event of a
dissolution and liquidation and the claims were made by that party for services
rendered or products sold to us.
There
is
no guarantee that vendors, prospective target business, or other entities will
execute such agreements, or even if they execute such agreements that they
would
be prevented from bringing claims against the trust account, including, but
not
limited to, fraudulent inducement, breach of fiduciary responsibility and other
similar claims, as well as claims challenging the enforceability of the waiver,
in each case in order to gain an advantage with a claim against our assets,
including the funds held in the trust account. In addition, the indemnification
provided by certain of our directors and officers is limited to claims by
vendors that do not execute such valid and enforceable agreements. Claims by
target businesses or other entities and vendors that execute such valid and
enforceable agreements would not be indemnified by certain of our directors
and
officers. Based on representations made to us by certain of our directors and
officers, we currently believe they are of substantial means and capable of
funding a shortfall in our trust account to satisfy their foreseeable
indemnification obligations, but we have not asked them to reserve for such
an
eventuality. Despite our belief, we cannot assure you that they will be able
to
satisfy those obligations. The indemnification obligations may be substantially
higher than they currently foresee or expect and/or their financial resources
may deteriorate in the future. As a result, the steps outlined above may not
effectively mitigate the risk of creditors’ claims reducing the amounts in the
trust account.
Furthermore,
creditors may seek to interfere with the distribution of the trust account
pursuant to federal or state creditor and bankruptcy laws which could delay
the
actual distribution of such funds or reduce the amount ultimately available
for
distribution to our public stockholders. If we are forced to file a bankruptcy
case or an involuntary bankruptcy case is filed against us which is not
dismissed, the funds held in our trust account will be subject to applicable
bankruptcy law, and may be included in our bankruptcy estate and subject to
claims of third parties with priority over the claims of our public
stockholders. To the extent bankruptcy claims deplete the trust account, we
cannot assure you we will be able to return to our public stockholders the
liquidation amounts they might otherwise receive.
As
required under Delaware law, we will seek stockholder approval for any plan
of
dissolution and liquidation. We currently believe that any plan of dissolution
and liquidation subsequent to the expiration of the 24 month deadline would
proceed in approximately the following manner (subject to our agreement to
take
earlier action as described below):
· our
Board
will, consistent with its obligations described in our amended
and restated certificate
of incorporation, prior to the passing of such deadline, convene and adopt
a
specific plan of dissolution and liquidation, which it will then vote to
recommend to our stockholders; at such time we will also prepare a preliminary
proxy statement setting out such plan of dissolution and liquidation as well
as
the Board’s recommendation of such plan;
· upon
such
deadline (or earlier as described below), we would file our preliminary proxy
statement with the SEC;
· if
the
SEC does not review the preliminary proxy statement, then, 10 days following
the
filing date, we will file a definitive proxy statement with the SEC and will
mail the definitive proxy statement to our stockholders, and 30 days following
the mailing, we will convene a meeting of our stockholders, at which they will
either approve or reject our plan of dissolution and liquidation;
and
· if
the
SEC does review the preliminary proxy statement, we currently estimate that
we
will receive their comments approximately 30 days following the filing of the
preliminary proxy statement. We will mail a definitive proxy statement to our
stockholders following the conclusion of the comment and review process (the
length of which we cannot predict with any certainty, and which may be
substantial) and we will convene a meeting of our stockholders as soon as
permitted thereafter.
In
the
event that we seek stockholder approval for a plan of dissolution and
liquidation and do not obtain such approval, we will nonetheless continue to
take all reasonable actions to obtain stockholder approval for our dissolution.
Pursuant to the terms of our amended
and restated certificate
of incorporation, our purpose and powers following the expiration of the
permitted time periods for consummating a business combination will
automatically be limited to acts and activities relating to dissolving and
winding up our affairs, including liquidation. Following the expiration of
such
time periods, the funds held in our trust account may not be distributed except
upon our dissolution and, unless and until such approval is obtained from our
stockholders, the funds held in our trust account will not be released.
Consequently, holders of a majority of our outstanding stock must approve our
dissolution in order to receive the funds held in our trust account, and the
funds will not be available for any other corporate purpose. Our initial
stockholders have agreed to vote all the shares of common stock held by them
in
favor of the dissolution. We cannot assure you that our stockholders will
approve our dissolution in a timely manner or will ever approve our dissolution.
As a result, we cannot provide investors with assurances of a specific time
frame for our dissolution and distribution.
We
expect
that our total costs and expenses associated with the implementing and
completing our stockholder-approved plan of dissolution and liquidation will
be
in the range of $50,000 to $75,000. This amount includes all costs and expenses
related to filing our dissolution in the State of Delaware, the winding up
of
our company and the costs of a proxy statement and meeting relating to the
approval by our stockholders of our plan of dissolution and liquidation. We
believe that there should be sufficient funds available from the proceeds not
held in the trust account to fund the $50,000 to $75,000 of expenses, although
we cannot give you assurances that there will be sufficient funds for such
purposes.
Under
the
Delaware General Corporation Law (“DGCL”), stockholders may be held liable for
claims by third parties against a corporation to the extent of distributions
received by them in a dissolution. If we complied with certain procedures set
forth in Section 280 of the DGCL intended to ensure that a corporation makes
reasonable provision for all claims against it, including a 60-day notice period
during which any third-party claims can be brought against the corporation,
a
90-day period during which the corporation may reject any claims brought, and
an
additional 150-day waiting period before any liquidating distributions are
made
to stockholders, any liability of a stockholder with respect to a liquidating
distribution is limited to the lesser of such stockholder’s pro rata share of
the claim or the amount distributed to the stockholder, and any liability of
the
stockholder would be barred after the third anniversary of the dissolution.
However, it is our intention to make liquidating distributions to our public
stockholders as soon as reasonably possible after dissolution and, therefore,
we
do not intend to comply with those procedures. As such, our public stockholders
could potentially be liable for any claims to the extent of distributions
received by them in a dissolution and any such liability of our public
stockholders will likely extend beyond the third anniversary of such
dissolution. Because we will not be complying with Section 280, we will seek
stockholder approval to comply with Section 281(b) of the DGCL, requiring us
to
adopt a plan of dissolution that will provide for our payment, based on facts
known to us at such time, of (i) all existing claims, (ii) all pending claims,
and (iii) all claims that may be potentially
brought against us within the subsequent 10 years. However, because we are
a
blank check company rather than an operating company, and our operations will
be
limited to searching for prospective target businesses to acquire, the only
likely claims to arise would be from our vendors (such as accountants, lawyers,
investment bankers, etc.) or potential target businesses. As described above,
we
seek to have all vendors and prospective target businesses execute valid and
enforceable agreements with us waiving any right, title, interest or claim
of
any kind in or to any monies held in the trust account and to date have entered
into such agreements with PharmAthene. As a result, we believe the claims that
could be made against us will be significantly reduced and the likelihood that
any claim that would result in any liability extending to the trust will be
limited.
FINANCIAL
INFORMATION AS OF SEPTEMER 30, 2006
The
following unaudited pro forma condensed combined consolidated financial
statements combine the historical consolidated balance sheets and statements
of
operations of HAQ and PharmAthene. We are providing the following information
to
aid you in your analysis of the financial aspects of the Merger. We derived
this
information from the audited consolidated financial statements of HAQ for the
fiscal year ended December 31, 2005, from the audited financial statements
of
PharmAthene for the fiscal year ended December 31, 2005, and from the unaudited
financial statements of the two companies for the nine months ended September
30, 2006.
The
unaudited pro forma condensed combined consolidated financial information is
only a summary and you should read it in conjunction with HAQ’s ‘‘Management’s
Discussion and Analysis of Financial Condition and Results of Operations”, the
historical consolidated financial statements and related notes contained in
its
Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and
its
quarterly report on Form 10-Q for the nine months ended September 30, 2006,
incorporated by reference in and accompanying this proxy statement and
PharmAthene’s separate historical financial statements and notes thereto for the
year ended December 31, 2005 and for the nine months ended September 30, 2006,
as included in this proxy statement.
The
unaudited pro forma condensed combined consolidated balance sheet as of
September 30, 2006 gives effect to the Merger. The pro forma condensed combined
consolidated balance sheet is based on the historical balance sheet of HAQ
as of
September 30, 2006 and the historical balance sheet of PharmAthene as of
September 30, 2006. The unaudited pro forma condensed combined the Merger as
if
it had occurred on January 1, 2005 (the first day of year 2005 for PharmAthene).
The pro forma condensed combined consolidated statement of operations for the
fiscal year ended December 31, 2005 is based on historical results of operations
of HAQ and PharmAthene for the year ended December 31, 2005. The unaudited
pro
forma condensed combined consolidated statement of operations for the nine
months ended September 30, 2006 is based on the historical results of operations
of HAQ and PharmAthene for the nine months ended September 30, 2006 and gives
effect to the Merger as if it had occurred on January 1, 2006 (the first day
of
the nine month period ending September 30, 2006 for PharmAthene).
The
unaudited pro forma condensed combined consolidated financial information is
for
illustrative purposes only. The companies may have performed differently had
they always been combined. You should not rely on the pro forma condensed
combined consolidated financial information as being indicative of the
historical results that would have been achieved had the companies always been
combined or the future results that the combined company will experience after
the Merger.
The
following unaudited pro forma condensed consolidated financial statements have
been prepared using two levels of assumptions with respect to the number of
outstanding shares of our common stock, as follows:
(i)
assuming no conversions and maximum approval - this presentation
assumes that none of our stockholders holding shares sold in our IPO vote
against the Merger and convert their shares into a pro rata portion of the
trust
account; and
(ii)
assuming maximum conversions and minimum approval - this presentation
assumes that holders of 19.99% of our stock sold in our IPO vote against the
Merger and convert their shares into a pro rata portion of the trust account.
The
unaudited pro forma condensed consolidated financial statements are based on
the
estimates and assumptions that we believe are reasonable and that are set forth
in the notes to such statements, which are preliminary and have been made solely
for purposes of developing such pro forma information. We are providing this
information to you to aid in your analysis of the financial aspects of the
Merger and related transactions. The unaudited pro forma condensed consolidated
financial statements are not intended to represent or be indicative of our
consolidated results of operations or financial condition that we would have
reported had the Merger, been completed as of the dates presented, and should
not be taken as representative of our future consolidated results of operations
or financial condition.
Unaudited
Pro Forma Condensed Combined Consolidated Balance Sheet
As
of September 30, 2006
|
|
Historical
PharmAthene
|
|
Historical
HAQ
|
|
Pro
Forma
Adjustments
|
|
|
Pro
Forma
Combined
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
6,505,932
|
|
$
|
763,931
|
|
$
|
(2,000,000
|
) |
4c
|
$
|
5,269,863
|
|
Cash
held in trust
|
|
|
|
|
|
70,283,506
|
|
|
(17,031,426
|
) |
4g
|
|
53,252,080
|
|
Accounts
receivable, net
|
|
|
544,251
|
|
|
—
|
|
|
—
|
|
|
|
544,251
|
|
Prepaid
expenses
|
|
|
1,276,687
|
|
|
116,168
|
|
|
—
|
|
|
|
1,392,855
|
|
Note
receivable
|
|
|
3,000,000
|
|
|
—
|
|
|
—
|
|
|
|
3,000,000
|
|
Other
assets
|
|
|
92,150
|
|
|
—
|
|
|
—
|
|
|
|
92,150
|
|
Total
current assets
|
|
|
11,419,020
|
|
|
71,163,605
|
|
|
(19,031,426)
|
) |
|
|
63,551,199
|
|
Property
and equipment, net
|
|
|
5,254,275
|
|
|
—
|
|
|
—
|
|
|
|
5,254,275
|
|
Patents,
net
|
|
|
1,340,869
|
|
|
—
|
|
|
—
|
|
|
|
1,340,869
|
|
Deferred
financing costs
|
|
|
1,357,176
|
|
|
—
|
|
|
—
|
|
|
|
1,357,176
|
|
Total
assets
|
|
$
|
19,371,340
|
|
$
|
71,163,605
|
|
$
|
(19,031,426)
|
) |
|
$
|
71,503,519
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
1,007,790
|
|
$
|
12,477
|
|
$
|
|
|
|
$
|
1,020,267
|
|
Accrued
expenses and other current liabilities
|
|
|
761,765
|
|
|
214,563
|
|
|
306,914
|
|
4e,i
|
|
1,283,242
|
|
Deferred
revenue
|
|
|
—
|
|
|
470,865
|
|
|
|
|
|
|
470,865
|
|
Notes
payable
|
|
|
11,768,088
|
|
|
—
|
|
|
731,912
|
|
4a
|
|
12,500,000
|
|
Total
current liabilities
|
|
|
13,537,643
|
|
|
697,905
|
|
|
1,038,826
|
|
|
|
15,274,374
|
|
Common
stock, subject to possible redemption 1,879,060 shares, at conversion
value
|
|
|
|
|
|
13,578,807
|
|
|
(13,578,807
|
) |
4g
|
|
—
|
|
Minority
Interest — Series C convertible redeemable preferred stock of PHTN Canada,
par value $0.001 per share; unlimited shares authorized
|
|
|
2,507,557
|
|
|
—
|
|
|
(2,507,557
|
) |
4d
|
|
—
|
|
Series
A convertible redeemable preferred stock, par value $0.001 per
share;
authorized 16,442,000 shares
|
|
|
18,736,219
|
|
|
—
|
|
|
(18,736,219
|
) |
4d
|
|
—
|
|
Series
B convertible redeemable preferred stock, par value $0.001 per
share;
authorized 30,448,147 shares
|
|
|
31,051,618
|
|
|
—
|
|
|
(31,051,618
|
) |
4d
|
|
—
|
|
Series
C convertible redeemable preferred stock, par value $0.001 per
share;
authorized 22,799,574 shares
|
|
|
14,259,971
|
|
|
—
|
|
|
(14,259,971
|
) |
4d
|
|
—
|
|
Warrants
to purchase Series C convertible redeemable preferred stock, exercisable
at approx. $0.91 per share
|
|
|
874,270
|
|
|
—
|
|
|
(874,270)
|
|
4b
|
|
—
|
|
Stockholders’
equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock, par value $0.001 per share; authorized 147,089,104 shares,
12,483,472 issued and outstanding
|
|
|
12,483
|
|
|
—
|
|
|
(12,483
|
) |
4d
|
|
—
|
|
Preferred
stock $0.0001 par value; authorized 1,000,000; none issued and
outstanding
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
Common
stock - $0.0001 par value; authorized 100,000,000 shares; 11,650,000
shares issued and outstanding (which includes 1,879,060 subject
to
possible conversion)
|
|
|
—
|
|
|
1,165
|
|
|
970
|
|
4d
|
|
2,135
|
|
Additional
paid-in capital
|
|
|
—
|
|
|
55,818,948
|
|
|
11,621,968
|
|
4f
|
|
67,440,916
|
|
Accumulated
other comprehensive loss
|
|
|
389,720
|
|
|
—
|
|
|
—
|
|
|
|
389,720
|
|
Retained
Earnings (Accumulated deficit)
|
|
|
(61,998,141
|
)
|
|
1,066,780
|
|
|
49,327,735
|
|
4g
|
|
(11,603,626
|
)
|
Total
stockholders’ equity
|
|
|
(61,595,938
|
)
|
|
56,886,893
|
|
|
60,938,189
|
|
|
|
56,229,144
|
|
Total
liabilities, convertible redeemable preferred stock and stockholders’
deficit
|
|
$
|
19,371,340
|
|
$
|
71,163,605
|
|
$
|
(19,031,426
|
) |
|
$
|
71,503,519
|
|
See
accompanying notes to unaudited pro forma condensed combined consolidated
financial statements.
With
Maximum Approval
Unaudited
Pro Forma Condensed Combined Consolidated Balance Sheet
As
of September 30, 2006
|
|
Historical
PharmAthene
|
|
Historical
HAQ
|
|
Pro
Forma
Adjustments
|
|
|
Pro
Forma
Combined
|
|
Cash
and cash equivalents
|
|
$
|
6,505,932
|
|
$
|
763,931
|
|
$
|
(2,000,000
|
) |
4c
|
$
|
5,269,863
|
|
Cash
held in trust
|
|
|
|
|
|
70,283,506
|
|
|
|
|
|
|
70,283,506
|
|
Accounts
receivable, net
|
|
|
544,251
|
|
|
—
|
|
|
—
|
|
|
|
544,251
|
|
Prepaid
expenses
|
|
|
1,276,687
|
|
|
116,168
|
|
|
—
|
|
|
|
1,392,855
|
|
Note
receivable
|
|
|
3,000,000
|
|
|
—
|
|
|
—
|
|
|
|
3,000,000
|
|
Other
assets
|
|
|
92,150
|
|
|
—
|
|
|
—
|
|
|
|
92,150
|
|
Total
current assets
|
|
|
11,419,020
|
|
|
71,163,605
|
|
|
(2,000,000
|
) |
|
|
80,582,625
|
|
Property
and equipment, net
|
|
|
5,254,275
|
|
|
—
|
|
|
—
|
|
|
|
5,254,275
|
|
Patents,
net
|
|
|
1,340,869
|
|
|
—
|
|
|
—
|
|
|
|
1,340,869
|
|
Deferred
financing costs
|
|
|
1,357,176
|
|
|
—
|
|
|
—
|
|
|
|
1,357,176
|
|
Total
assets
|
|
$
|
19,371,340
|
|
$
|
71,163,605
|
|
$
|
(2,000,000
|
) |
|
$
|
88,534,945
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
1,007,790
|
|
$
|
12,477
|
|
$
|
—
|
|
|
$
|
1,020,267
|
|
Accrued
expenses and other current liabilities
|
|
|
761,765
|
|
|
214,563
|
|
|
306,914
|
|
4e,i
|
|
1,283,242
|
|
Deferred
revenue
|
|
|
—
|
|
|
470,865
|
|
|
|
|
|
|
470,865
|
|
Notes
payable
|
|
|
11,768,088
|
|
|
—
|
|
|
731,912
|
|
4a |
|
12,500,000
|
|
Total
current liabilities
|
|
|
13,537,643
|
|
|
697,905
|
|
|
1,038,826
|
|
|
|
15,274,374
|
|
Common
stock, subject to possible redemption 1,879,060 shares, at conversion
value
|
|
|
|
|
|
13,578,807
|
|
|
(13,578,807
|
) |
4g
|
|
—
|
|
Minority
Interest — Series C convertible redeemable preferred stock of PharmAthene
Canada, par value $0.001 per share; unlimited shares
authorized
|
|
|
2,507,557
|
|
|
—
|
|
|
(2,507,557
|
) |
4d
|
|
—
|
|
Series
A convertible redeemable preferred stock, par value $0.001 per share;
authorized 16,442,000 shares
|
|
|
18,736,219
|
|
|
—
|
|
|
(18,736,219
|
) |
4d
|
|
—
|
|
Series
B convertible redeemable preferred stock, par value $0.001 per share;
authorized 30,448,147 shares
|
|
|
31,051,618
|
|
|
—
|
|
|
(31,051,618
|
) |
4d
|
|
—
|
|
Series
C convertible redeemable preferred stock, par value $0.001 per share;
authorized 22,799,574 shares
|
|
|
14,259,971
|
|
|
—
|
|
|
(14,259,971
|
) |
4d
|
|
—
|
|
Warrants
to purchase Series C convertible redeemable preferred stock, exercisable
at approx. $0.91 per share
|
|
|
874,270
|
|
|
—
|
|
|
(874,270
|
) |
4b
|
|
—
|
|
Stockholders’
equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock, par value $0.001 per share; authorized 147,089,104 shares,
12,483,472 issued and outstanding
|
|
|
12,483
|
|
|
—
|
|
|
(12,483
|
) |
4d
|
|
—
|
|
Preferred
stock $0.0001 par value; authorized 1,000,000; none issued and
outstanding
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
Common
stock - $0.0001 par value; authorized 100,000,000 shares; 11,650,000
shares issued and outstanding (which includes 1,879,060 subject to
possible conversion)
|
|
|
—
|
|
|
1,165
|
|
|
1,202
|
|
4d
|
|
2,367
|
|
Additional
paid-in capital
|
|
|
—
|
|
|
55,818,948
|
|
|
11,621,968
|
|
4f
|
|
67,440,916
|
|
Accumulated
other comprehensive loss
|
|
|
389,720
|
|
|
—
|
|
|
—
|
|
|
|
389,720
|
|
Retained
Earnings (Accumulated deficit)
|
|
|
(61,998,141
|
)
|
|
1,066,780
|
|
|
66,358,929
|
|
4g
|
|
5,427,568
|
|
Total
stockholders’ equity
|
|
|
(61,595,938
|
)
|
|
56,886,893
|
|
|
77,969,616
|
|
|
|
73,260,571
|
|
Total
liabilities, convertible redeemable preferred stock and stockholders’
deficit
|
|
$
|
19,371,340
|
|
$
|
71,163,605
|
|
$
|
(2,000,000
|
) |
|
$
|
88,534,945
|
|
See
accompanying notes to unaudited pro forma condensed combined consolidated
financial statements.
Unaudited
Pro Forma Condensed Consolidated Statement of Operations
For
the Nine Months Ended September 30, 2006
|
|
Historical
PharmAthene
|
|
Historical
HAQ
|
|
Pro
Forma Adjustments
|
|
Pro
Forma
Combined
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant
Revenue
|
|
$
|
178,701
|
|
$
|
—
|
|
$
|
|
|
$
|
178,701
|
|
Other
Revenue
|
|
|
9,331
|
|
|
—
|
|
|
|
|
|
9,331
|
|
Total
revenues
|
|
|
188,032
|
|
|
—
|
|
|
—
|
|
|
188,032
|
|
Costs
and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and Development
|
|
|
4,745,628
|
|
|
—
|
|
|
|
|
|
4,745,628
|
|
General
and Administrative
|
|
|
4,665,292
|
|
|
421,071
|
|
|
|
|
|
5,086,363
|
|
Depreciation
& Amortization
|
|
|
389,975
|
|
|
—
|
|
|
|
|
|
389,975
|
|
Acquired
In-Process Research & Development
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
Total
costs and expenses
|
|
|
9,800,895
|
|
|
421,071
|
|
|
—
|
|
|
10,221,966
|
|
Operating
loss
|
|
|
(9,612,863
|
)
|
|
(421,071
|
)
|
|
|
|
|
(10,033,934
|
)
|
Other
income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
Income
|
|
|
131,245
|
|
|
1,355,556
|
|
|
|
|
|
1,486,801
|
|
Interest
Expense
|
|
|
(298,157
|
)
|
|
—
|
|
|
(451,914
|
)4e
|
|
(750,071
|
)
|
Total
other income (loss)
|
|
|
(166,912
|
)
|
|
1,355,556
|
|
|
(451,914
|
)
|
|
736,730
|
|
Income
(loss) before taxes
|
|
|
(9,779,775
|
)
|
|
934,485
|
|
|
(451,914
|
) |
|
(9,297,204)
|
|
Provision
for taxes
|
|
|
—
|
|
|
(145,000
|
)
|
|
145,000
|
4i
|
|
—
|
|
Net
income (loss)
|
|
|
(9,779,775
|
)
|
|
789,485
|
|
|
(306,914
|
) |
|
(9,297,204
|
)
|
Accretion
of redeemable convertible preferred stock to redemptive
value
|
|
|
(4,931,125
|
)
|
|
—
|
|
|
4,931,125
|
4j
|
|
—
|
|
Net
income (loss) attributable to common shareholders
|
|
$
|
(14,710,900
|
)
|
$
|
789,485
|
|
$
|
4,624,211
|
|
$
|
(9,297,204)
|
|
Weighted
average shares outstanding
|
|
|
11,123,241
|
|
|
11,650,000
|
|
|
12,017,200
|
4d
|
|
23,667,200
|
*
|
Net
income (loss) per share
|
|
$
|
(1.32
|
)
|
$
|
0.07
|
|
|
|
|
$
|
(0.39)
|
*
|
*
With
minimum approval, pro forma weighted average shares outstanding would be
21,348,850 resulting in a pro forma net loss per share of ($0.44).
See
accompanying notes to unaudited pro forma condensed combined consolidated
financial statements.
Unaudited
Pro Forma Condensed Consolidated Statement of Operations
For
the Year Ended December 31, 2005
|
|
Historical
PharmAthene
|
|
Historical
HAQ
|
|
Pro
Forma
Adjustments
|
|
Pro Forma
Combined
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant
Revenue
|
|
$
|
1,045,751
|
|
$
|
—
|
|
$
|
|
|
$
|
1,045,751
|
|
Other
Revenue
|
|
|
52,649
|
|
|
—
|
|
|
|
|
|
52,649
|
|
Total
revenues
|
|
|
1,098,400
|
|
|
—
|
|
|
—
|
|
|
1,098,400
|
|
Costs
and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and Development
|
|
|
6,351,157
|
|
|
—
|
|
|
|
|
|
6,351,157
|
|
General
and Administrative
|
|
|
5,009,267
|
|
|
260,779
|
|
|
242,340
|
4h
|
|
5,512,386
|
|
Depreciation
& Amortization
|
|
|
660,567
|
|
|
—
|
|
|
|
|
|
660,567
|
|
Acquired
In-Process Research & Development
|
|
|
12,812,000
|
|
|
—
|
|
|
|
|
|
12,812,000
|
|
Total
costs and expenses
|
|
|
24,832,991
|
|
|
260,779
|
|
|
242,340
|
|
|
25,336,110
|
|
Operating
loss
|
|
|
(23,734,591
|
)
|
|
(260,779
|
)
|
|
(242,340
|
)
|
|
(24,237,710
|
)
|
Other
income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
Income
|
|
|
381,840
|
|
|
586,074
|
|
|
|
|
|
967,914
|
|
Interest
Expense
|
|
|
(988
|
)
|
|
—
|
|
|
(1,000,000)
|
4e
|
|
(1,000,988
|
)
|
Total
other income (loss)
|
|
|
380,852
|
|
|
586,074
|
|
|
(1,000,000)
|
|
|
(33,074)
|
|
Income
(loss) before taxes
|
|
|
(23,353,739
|
)
|
|
325,295
|
|
|
(1,242,340
|
)
|
|
(24,270,784
|
) |
Provision
for taxes
|
|
|
—
|
|
|
(48,000
|
)
|
|
48,000
|
4i
|
|
—
|
|
Net
income (loss)
|
|
|
(23,353,739
|
)
|
|
277,295
|
|
|
(1,194,340
|
)
|
|
(24,270,784)
|
|
Accretion
of redeemable convertible preferred stock to redemptive
value
|
|
|
(5,698,630
|
)
|
|
—
|
|
|
5,698,630
|
4i
|
|
—
|
|
Net
loss attributable to common shareholders
|
|
$
|
(29,052,369
|
)
|
$
|
277,295
|
|
$
|
4,504,290
|
|
$
|
(24,270,784)
|
|
Weighted
average shares outstanding
|
|
|
10,817,949
|
|
|
7,869,200
|
|
|
12,017,200
|
4d
|
|
19,886,400
|
*
|
Net
loss per share
|
|
$
|
(2.69
|
)
|
$
|
0.04
|
|
|
|
|
$
|
(1.22
|
)*
|
*
With
minimum approval, pro forma weighted average shares outstanding would be
18,320,429 resulting in a pro forma net loss per share of
($1.32).
See
accompanying notes to unaudited pro forma condensed combined consolidated
financial statements.
Notes
to Unaudited Pro Forma Condensed Combined Consolidated Financial
Information
|
(1)
|
Description
of Transactions and Basis of Pro Forma
Presentation
|
On
January 19, 2007, PharmAthene and HAQ entered into an Agreement and Plan of
Merger (the “Merger Agreement”). In connection with the proposed merger (the
“Merger”), HAQ will issue 12,500,000 shares of its common stock for all of
PharmAthene’s outstanding shares of preferred stock and common stock, with
482,800 shares reserved for the purpose of issuance upon the exercise of
PharmAthene’s common stock options. For accounting purposes, the transaction is
considered a ‘‘reverse merger” under which PharmAthene is considered to be
acquiring HAQ. The 11,650,000 shares of HAQ common stock outstanding are
considered as the basis for determining the consideration in the reverse merger
transaction. Based on the outstanding shares of PharmAthene capital stock on
September 30, 2006, common stockholders of PharmAthene will exchange their
shares for 626,200 shares of HAQ common stock and preferred stockholders of
PharmAthene will exchange their shares for 11,391,000 shares of HAQ common
stock.
In
addition, each PharmAthene stock option that is outstanding on the closing
date
will be converted to HAQ options by multiplying the PharmAthene options in
accordance with agreed upon amounts. The new exercise price will also be
determined by multiplying the old exercise price by the same ratio. Each of
these options will be subject to the same terms and conditions that were in
effect for the related PharmAthene option.
At
the
effective time of the Merger, all options to purchase shares of PharmAthene
stock then outstanding under the PharmAthene, Inc. 2002 Long-Term Incentive
Plan
(as amended, the “PharmAthene Plan”) or issued under any other agreement,
whether vested or unvested, shall be assumed by HAQ. The per-share exercise
price for the shares of HAQ common stock issuable upon exercise of such assumed
outstanding PharmAthene option will be equal to the quotient determined by
dividing the exercise price per share of PharmAthene common stock at which
such
outstanding PharmAthene option was exercisable immediately prior to the closing
of the Merger by the share exchange ratio, and rounding the resulting exercise
price up to the nearest whole cent. PharmAthene has, as of the date hereof,
options and warrants to acquire 9,625,197 shares of its common stock. The share
exchange ratio for the options is .0502 to one. As a consequence, HAQ shall
grant 482,800 options with an average exercise price of $___ per share in
exchange for all of the PharmAthene options assumed by HAQ.
The
unaudited pro forma condensed consolidated financial statements have been
prepared using two levels of assumptions with respect to the number of
outstanding shares of our common stock, as follows:
(i)
assuming no conversions and maximum approval - this presentation assumes that
none of our stockholders holding shares sold in our IPO vote against the Merger
and convert their shares into a pro rata portion of the trust account; and
(ii)
assuming maximum conversions and minimum approval - this presentation assumes
that holders of 19.99% of our stock sold in our IPO vote against the Merger
and
convert their shares into a pro rata portion of the trust account.
|
(2)
|
Preliminary
Merger Purchase Price
|
The
unaudited pro forma condensed combined consolidated financial statements reflect
the Merger of PharmAthene with HAQ as a reverse merger wherein PharmAthene
is
deemed to be the acquiring entity from an accounting perspective. For accounting
purposes, the transaction is being treated as an acquisition of assets and
not a
business combination because HAQ did not meet the definition of a business
under
EITF 98-3, Determination Whether a Nonmonetary Transaction Involves Receipt
of
Productive Assets or of a Business. Accordingly, the transaction has been
treated as a capital transaction whereby PharmAthene is issuing stock for the
net monetary assets of HAQ, accompanied by a recapitalization. PharmAthene
has
recorded the purchase price as the net assets acquired with the offsetting
credit to equity.
|
(3)
|
Preliminary
Merger Purchase Allocation
|
Based
on
PharmAthene’s preliminary valuation of the fair value of the net assets
acquired, the preliminary purchase price is as follows:
|
|
Initial
Fair
Value
|
|
Tangible
assets acquired
|
|
$
|
71,163,605
|
|
Liabilities
assumed
|
|
|
(697,905
|
)
|
Net
assets acquired
|
|
$
|
70,465,700
|
|
The
final
determination of the purchase price allocation will be based on the fair values
of the assets and the fair value of the liabilities assumed at the effective
date of the Merger. The purchase price will remain preliminary until PharmAthene
is able to finalize its valuation of the fair value of the assets and
liabilities acquired. The final determination of purchase price allocation
will
be completed as soon as practical after the effective date of the Merger. The
final amounts allocated to assets and liabilities could differ significantly
from the amounts presented in the unaudited pro forma condensed combined
consolidated balance sheet and related notes.
(4)
Pro Forma Adjustments
(a)
|
To
record the conversion of the PharmAthene $11.8 million 8%
convertible
notes to the newly issued HAQ $12.5 million in 8% convertible
notes with a
24 month maturity
|
(b)
|
To
record the write-off of PharmAthene warrants convertible
into Series C
convertible redeemable preferred
stock
|
(c)
|
To
record merger-related transaction fees of approximately $2.0
million
|
(d)
|
To
record the elimination of PharmAthene classes of equity in
exchange for
HAQ common stock (See Note 1) and to record issuance of shares
to
HAQ
|
Shares
|
|
Prior
to merger
|
|
Common
Stock
|
|
PharmAthene
common stock
|
|
|
12,483,472
shares
|
|
|
626,200
shares
|
|
PharmAthene
Preferred stock
|
|
|
61,836,626
shares
|
|
|
10,805,286
shares
|
|
Series
C Exchangeable stock
|
|
|
2,591,654
shares
|
|
|
585,714
shares
|
|
Total
|
|
|
76,911,752
shares
|
|
|
12,017,200
shares
|
|
|
|
For
the nine
months
ended
September
30, 2006
|
For
the twelve months
ended December
31, 2005
|
|
HAQ
weighted average shares outstanding
|
|
|
11,650,000
|
|
|
7,869,200
|
|
Issuance
of shares in exchange for PharmAthene preferred and common
stock
|
|
|
12,017,200
|
|
|
12,017,200
|
|
Total
weighted average shares outstanding
|
|
|
23,667,200
|
|
|
19,886,400
|
|
(e)
|
To
record interest expense on the $12.5 million 8% convertible
notes payable
assuming a 24 month maturity and additional $451,914 for
the nine months
ended September 30, 2006 and $1,000,000 for the twelve
months needed
December 31, 2005
|
(f)
|
Pro
forma adjustments to additional paid in capital are an aggregate
of the
following
|
To
transfer HAQ paid in capital to retained earnings
|
|
|
(55,818,948
|
)
|
|
|
|
|
|
To
record the exchange of PharmAthene preferred and common stock for
HAQ
common stock
|
|
|
67,440,916
|
|
|
|
$
|
11,621,968
|
|
(g)
|
Pro
forma adjustments to accumulated deficit are an aggregate of
the
following
|
To
record the transfer of HAQ capital to retained earnings
|
|
$
|
55,818,948
|
|
To
record the transfer of redeemable common stock to retained
earnings
|
|
|
13,578,807
|
|
To
record transaction costs
|
|
|
(2,000,000
|
)
|
To
record additional debt placement with the issuance of $12.5 million
8%
convertible notes
|
|
|
(731,912
|
)
|
To
record additional debt interest
|
|
|
(451,914
|
)
|
To
record elimination of HAQ historic tax provision
|
|
|
145,000
|
|
Adjustment
if maximum stockholder approval (no conversions)
|
|
$
|
66,358,929
|
|
To
record purchase of common stock of stockholders not in favor of the
Merger, assumes a $7.23 purchase price, and includes interest income
earned
|
|
|
(17,031,194
|
)
|
Adjustment
if minimum stockholder approval (maximum conversions)
|
|
$
|
49,327,735
|
|
(h)
|
To
record pro forma stock compensation expense of
$242,340 had PharmAthene adopted Statement of Financial Accounting
Standard 123R Share-Based Payment (“FAS 123R”) as of January 1,
2005.
|
(i)
|
To
record the elimination of historical HAQ tax provision of
$145,000 and
$48,000 for the nine months ended September 30, 2006 and
the twelve months
ended December 31, 2005,
respectively
|
(j)
|
To
record the elimination of historic PharmAthene accretion
of redeemable
convertible preferred stock
|
MERGER
WITH PHARMATHENE
Following
the Merger, it is anticipated that the directors and executive officers of
the
combined company will be the individuals indicated below.
Name
|
Age
|
Position
|
John
Pappajohn
|
78
|
Chairman
of the Board
|
David
P. Wright
|
58
|
Chief
Executive Officer, Director
|
James
H. Cavanaugh, Ph.D.
|
69
|
Director
|
Elizabeth
Czerepak
|
51
|
Director
|
Steven
St. Peter, M.D.
|
40
|
Director
|
Joel
McCleary
|
58
|
Director
|
Derace
L. Shaffer, M.D.
|
59
|
Director
|
John
Pappajohn has served as HAQ’s chairman and secretary since April 2005. Since
1969, Mr. Pappajohn has been the President and principal stockholder of Equity
Dynamics, Inc., a financial consulting firm, and the sole owner of Pappajohn
Capital Resources, a venture capital firm. He also serves as a director of
the
following public companies: Allion Healthcare, Inc., American CareSource
Holdings, Inc., CareGuide, Inc. MC Informatics, Inc. and PACE Health
Management Systems, Inc. Mr. Pappajohn has been an active private equity
investor in healthcare companies for more than 30 years and has served as a
director of more than 40 public companies. Mr. Pappajohn has been a founder
in
several public healthcare companies such as Caremark Rx, Inc., Quantum Health
Resources, and Radiologix, Inc. Mr. Pappajohn received his B.S.C. from the
University of Iowa. Mr. Pappajohn will serve as Chairman of the Board of the
combined company.
David
P.
Wright joined PharmAthene as President and Chief Executive Officer in July
2003.
Prior to joining PharmAthene, and during 2003, he served as President and Chief
Operating Officer of GenVec Inc, and previously, from 2001 to 2003, President
and Chief Business Officer of Guilford Pharmaceuticals. Mr. Wright served as
Executive Vice President for MedImmune, Inc. from 1990 to 2000 where he was
responsible for building MedImmune’s commercial operation and growing product
sales from $0 to over $400 million per year. Prior to serving at MedImmune,
he
has held various marketing and sales positions at pharmaceutical companies
including SmithKline and French Laboratories, G.D. Searle, and
Glaxo.
James
H.
Cavanaugh, Ph.D, has been a Managing Director of HealthCare Ventures LLC since
1989. Prior thereto, Dr. Cavanaugh served as President of SmithKline and French
Laboratories U.S., Inc., from March 1985 to February 1989 and as President
of
SmithKline Clinical Laboratories from 1981 to 1985. Prior thereto, Dr. Cavanaugh
was the President of Allergan International, a specialty eye care company.
Dr.
Cavanaugh also serves as a member of the Board of Directors of. Shire
Pharmaceuticals Group PLC (non-executive Chairman), Diversa Corp. (Chairman),
MedImmune, Inc. and Advancis Pharmaceutical Corporation. Prior to his industry
experience, Dr. Cavanaugh was Deputy Assistant to the President for Domestic
Affairs and Deputy Chief of the White House Staff. Before his White House tour,
he served as Deputy Assistant Secretary for Health and Scientific Affairs in
the
U.S. Department of Health, Education and Welfare and as Special Assistant to
the
Surgeon General of the U.S. Public Health Service. In addition to serving on
the
boards of directors of several health care and biotechnology companies, Dr.
Cavanaugh currently serves as Trustee Emeritus of the California College of
Medicine. He has previously served on the Board of Directors of the National
Venture Capital Association, the Pharmaceutical Research and Manufacturers
Association, Unihealth America, the Proprietary Association and on the Board
of
Trustees of the National Center for Genome Resources. He was a Founding Director
of the Marine National Bank in Santa Ana, California. Dr. Cavanaugh holds a
doctorate and a master’s degree from the University of Iowa and a bachelor of
science degree from Fairleigh Dickinson University.
Elizabeth
Czerepak was a founder of Bear Stearns Health Innoventures and has been a member
of Bear Stearns Health Innoventures Management L.L.C., the general partner
of
the funds comprising the Bear Stearns Health Innoventures group, since its
inception in April 2001. She is an employee of Bear Stearns Asset Management
Inc., the managing member of Bear Stearns Health Innoventures Management LLC.
Prior to joining Bear Stearns Health Innoventures, Ms. Czerepak was vice
president of business development and a member of the executive board at BASF
Pharma/Knoll Pharmaceutical Co. From 1987 to 1995, Ms. Czerepak served in
various senior positions at Hoffmann-La Roche, responsible for licensing,
acquisitions, financial analysis and strategic planning. Ms. Czerepak also
established an internal venture vehicle for Hoffmann-La Roche to facilitate
start-up companies. Ms. Czerepak began her pharmaceutical career at Merck in
1982 where she led the development of a simulation-based model for comprehensive
research and development strategic planning. She was an instructor in the MBA
program at Fairleigh Dickinson University, and holds a bachelor of arts degree
magna cum laude from Marshall University and an MBA degree in finance from
Rutgers University. She is NASD registered and currently serves on the Board
of
Directors of Affymax, Inc., Agensys, Inc., and PharmAthene.
Steven
St. Peter, M.D. has served as a member of PharmAthene’s Board of Directors since
October 2004. He joined MPM Asset Management LLC as a principal in 2004 and
became a general partner in 2005. Prior to joining MPM, from 2001 to 2003,
he
was a principal at Apax Partners and from 1999 to 2001, he was a senior
associate at The Carlyle Group. His investment scope has included both venture
and buyout transactions across the medical technology and biopharmaceutical
industries. Dr. St. Peter is board certified in internal medicine and was
previously an assistant clinical professor of Medicine at Columbia University.
He completed his Doctor of Medicine at Washington University. Prior to his
medical training, he was an investment banker at Merrill Lynch. He is also
a
director of Omrix Biopharmaceuticals (Nasdaq: OMRI), Helicos BioSciences
Corporation, Syndex Pharmaceuticals, Inc. and Xanodyne Pharmaceuticals
Inc.
Joel
McCleary has served as Chairman of the Board of PharmAthene since its inception.
He has previously served as a White House Aide, Treasurer of the Democratic
Party, and President of the Sawyer - Miller Group International and President
of
the Institute for Asian Democracy. He has served as a consultant to the
Department of State. He is a co-founder and board member of Raydiance Inc.
and
is also a co-founder of Drinks that Work Inc. He serves on the Harvard Medical
School’s board of advisors and is an advisor to the Center for Biosecurity of
the University of Pittsburgh Medical Center. Mr. McCleary is founding partner
of
Four Seasons Ventures LLC.
Derace
L.
Schaffer, M.D. has served as our Vice Chairman and Chief Executive Officer
since
April 2005. Dr. Schaffer is the founder and Chief Executive Officer of The
Lan
Group, a venture capital firm specializing in healthcare and high technology
investments. He also serves as a director of the following public companies:
Allion Healthcare, Inc., American CareSource Holdings, Inc., and CareGuide,
Inc.
He has served as Chairman of several healthcare companies including, Radiologix,
Inc when it was private. He has been an active co-investor with Mr. Pappajohn
for more than fifteen years on a variety of healthcare companies, and they
co-founded Allion Healthcare and Radiologix, all of which are public companies.
In addition, Mr. Pappajohn and Dr. Schaffer have worked together on many private
healthcare companies, such as Logisticare, Inc. and Source Medical Inc. Dr.
Schaffer served as Chief Executive Officer and Chairman of the Board of Ide
Imaging Group, P.C. from 1980 to 2001. Dr. Schaffer has served as a director
on
many healthcare boards of directors including several health systems and more
than ten healthcare services and technology companies. Dr. Schaffer received
his
postgraduate radiology training at Harvard Medical School and Massachusetts
General Hospital, where he served as Chief Resident. Dr. Schaffer is currently
also a Clinical Professor of Radiology at Weill Cornell Medical
College.
Other
than their respective relationships with HAQ and PharmAthene,
none of
these individuals has been a principal of or affiliated with a public company
or
blank check company that executed a business plan similar to our business plan,
and none of these individuals is currently affiliated with such an
entity.
After
the
Merger, the officers and employee directors will devote their full time and
attention to the ongoing operations of HAQ and the non-employee directors will
devote such time as is necessary and required to satisfy their duties as a
director of a public company. In addition, upon completion of the Merger, the
following individuals, who are current directors of HAQ, will not be continuing
as directors of the public company: Matthew P. Kinley, Edward B. Berger and
Wayne A. Schellhammer.
Board
of Directors and Committees of the Board
After
the
Merger with PharmAthene, our Board of Directors will consist of up to seven
members, and it is anticipated that a majority of which will be considered
“independent.” Under the Merger Agreement, the noteholders will have the right
to have three persons serve on the Board. We expect the Board members to be
John
Pappajohn, Derace M. Schaffer, M.D., James Cavanaugh, Ph.D., Steven St. Peter,
M.D. Elizabeth Czerepak, Joel McCleary and David Wright.
We
do not
currently have a Compensation Committee but we expect to establish a
Compensation Committee as soon as practicable after the consummation of the
Merger. Pursuant to Section 805 of the AMEX Company Guide, compensation of
our Chief Executive Officer, if any, will be determined, or recommended to
the
Board for determination, by a majority of the independent directors on our
Board
of Directors. The Chief Executive Officer will not be present during voting
or
deliberations. Compensation for all other officers, if any, will be determined,
or recommended to the Board for determination, by a majority of the independent
directors on our Board of Directors. None of our officers currently receive
compensation. We do not expect to pay any compensation to any of our officers
until following the consummation of the Merger with PharmAthene.
HAQ’s
Board of Directors has established a Nominating Committee and an Audit Committee
to devote attention to specific subjects and to assist the Board in the
discharge of its responsibilities. The functions of these committees and their
current members, as well as anticipated membership, are set forth
below.
Audit
Committee
Our
Audit
Committee currently consists of Mr. Berger and Mr. Schellhammer. We expect
to
modify the composition of the Audit Committee as soon as practicable after
the
consummation of the Merger. The independent directors we appoint to our Audit
Committee will each be an independent member of our Board of Directors, as
defined by the rules of the AMEX and the SEC. Each member of our audit committee
will be financially literate under the current listing standards of the AMEX,
and our Board of Directors has determined that Mr. Berger qualifies as an “audit
committee financial expert,” as such term is defined by SEC rules. We expect
that the composition of the Audit Committee subsequent to the Merger will meet
the listing standards of the AMEX and applicable SEC rules.
Upon
completion of the Merger, and in connection with the recommendations of the
Board, we expect that the members of the Audit Committee will be ____, _____
and
______.
The
Audit
Committee reviews the professional services and independence of our independent
registered public accounting firm and our accounts, procedures and internal
controls. The audit committee also recommends the firm selected to be our
independent registered public accounting firm, reviews and approves the scope
of
the annual audit, review and evaluates with the independent public accounting
firm our annual audit and annual consolidated financial statements, reviews
with
management the status of internal accounting controls, evaluates problem areas
having a potential financial impact on us that may be brought to the committee’s
attention by management, the independent registered public accounting firm
or
the Board of Directors, and evaluates all of our public financial reporting
documents.
Nominating
Committee
We
have
established a Nominating Committee of the Board of Directors, which currently
is
comprised of Mr. Berger and Mr. Schellhammer, each of whom is an independent
director as defined by the rules of the AMEX and the SEC. We expect to modify
the composition of the Nominating Committee as soon as practicable after the
consummation of the Merger. The Nominating Committee is responsible for
overseeing the selection of persons to be nominated to serve on our Board of
Directors. The Nominating Committee considers persons identified by its members,
management, stockholders, investment bankers and others. We expect that the
composition of the Nominating Committee subsequent to the Merger will meet
the
listing standards of the AMEX and applicable SEC rules.
Upon
completion of the Merger, and in connection with the recommendations of the
Board, we expect that the members of the Nominating Committee will be ____,
_____ and ______.
Under
the
terms of the Note Exchange Agreement and the Merger Agreement, and in accordance
with the amendments to the Certificate of Incorporation as described under
Proposal 2, we have agreed that the holders of the 8% note to be issued under
the Merger Agreement have the right to have two persons out of the three persons
on the Nominating Committee for as long as at least 30% of the original
principal amount of the 8% notes remain outstanding.
The
guidelines for selecting nominees, which are specified in the nominating
committee charter, generally provide that persons to be nominated should be
actively engaged in business endeavors, have an understanding of financial
statements, corporate budgeting and capital structure, be familiar with the
requirements of a publicly traded company, be familiar with industries relevant
to our business endeavors, be willing to devote significant time to the
oversight duties of the Board of Directors of a public company, and be able
to
promote a diversity of views based on the person’s education, experience and
professional employment. The Nominating Committee evaluates each individual
in
the context of the board as a whole, with the objective of recommending a group
of persons that can best implement our business plan, perpetuate our business
and represent stockholder interests. The Nominating Committee may require
certain skills or attributes, such as financial or accounting experience, to
meet specific board needs that arise from time to time. The Nominating Committee
does not distinguish among nominees recommended by stockholders and other
persons.
Compensation
Committee
Effective
at the closing of the Merger, we expect to create a Compensation Committee
of
the Board of Directors. The Compensation Committee will be charged with
reviewing and determining the compensation of our executive officers, including
the negotiation of any employment agreements with such persons. In addition,
the
Compensation Committee will be charged with oversight of the Incentive Plan
and
the grant of options and awards under the Incentive Plan. The Compensation
Committee will be comprised of three (3) persons, at least two of whom shall
be
independent persons.
Upon
completion of the Merger, and in connection with the recommendations of the
Board, we expect that the members of the Compensation Committee will be ____,
_____ and ______.
Under
the
terms of the Note Exchange Agreement and the Merger Agreement, and in accordance
with the amendments to the Certificate of Incorporation as described under
Proposal 2, we have agreed that the holders of the 8% notes to be issued under
the Merger Agreement have the right to have two persons out of the three persons
on the Compensation Committee for as long as 30% of the original principal
amount of the 8% notes remain outstanding.
Code
of Conduct and Ethics
We
have
adopted a code of conduct and ethics applicable to our directors, officers
and
employees in accordance with applicable federal securities laws and the rules
of
the AMEX. You can review this document by accessing our public filings at the
SEC’s web site at www.sec.gov. In addition, a copy of the code of conduct and
ethics will be provided without charge upon request to us. We intend to disclose
any amendments to or waivers of certain provisions of our code of ethics within
5 business days of such amendment or waiver or as otherwise required by the
SEC.
Director
Compensation
It
is
anticipated that at or prior to the closing of the Merger with PharmAthene,
the
compensation to be paid to members of the Board of Directors of HAQ will be
established and such compensation will be reasonable and customary for the
industry.
Executive
Compensation
None
of
HAQ’s executive officers or directors has received any cash compensation for
services rendered. Commencing on the effective date of our IPO through the
consummation of a business combination, we have agreed to pay Equity Dynamics,
Inc., an affiliated third party of which Mr. Pappajohn (our Chairman and
Secretary) is the President and principal stockholder, and Mr. Kinley (our
President and Treasurer) is a Senior Vice President, approximately $7,500 per
month for office space and certain additional general and administrative
services. A prior arrangement with an affiliate of our Chief Executive Officer,
Derace Schaffer, M.D., pursuant to which we paid $1,500 per month for office
space and certain general and administrative services, as a portion of the
$7,500, was terminated on December 31, 2005. During 2005 and 2006, approximately
$37,500 and $90,000 was incurred under these arrangements, respectively. The
current agreement with Equity Dynamics, Inc. is for our benefit and is not
intended to provide Mr. Pappajohn compensation in lieu of a salary. We believe
that such fees are at least as favorable as we could have obtained from an
unaffiliated third party. Other than this $7,500 per-month fee, no compensation
of any kind, including finder’s and consulting fees, will be paid to any of our
initial stockholders, including our officers and directors, or any of their
respective affiliates, for services rendered prior to or in connection with
a
business combination. However, persons who were stockholders prior to our IPO,
including our officers and directors, will receive reimbursement for any
out-of-pocket expenses incurred by them in connection with activities on our
behalf, such as identifying potential target businesses and performing due
diligence on suitable business combinations.
HAQ
has
required as a condition to closing that Mr. David Wright, the current Chief
Executive Officer of PharmAthene enter into a new employment agreement with
HAQ,
upon terms acceptable to both parties. The parties are negotiating the terms
of
the agreement. In the event that an agreement is not reached, HAQ may determine
not to proceed with the Merger. In addition, upon completion of the Merger,
it
is anticipated that other officers of PharmAthene will be continuing their
employment with PharmAthene.
In
April
2005, HAQ issued 1,500,000 shares of our common stock to the individuals set
forth below for an aggregate amount of $25,000 in cash, at an average purchase
price of approximately $0.0167 per share, as follows:
Name
|
Number
of Shares
|
Relationship
to Us
|
|
|
|
John
Pappajohn
|
600,000
|
Chairman
and Secretary
|
Derace
L. Schaffer, M.D.
|
600,000
|
Vice-Chairman
and CEO
|
Matthew
P. Kinley
|
300,000
|
President,
Treasurer and director
|
Further,
in June 2005, Mr. Pappajohn, Dr. Schaffer and Mr. Kinley transferred, for an
aggregate consideration per share which they paid us and pro rata to their
ownership of our common stock, an aggregate of 30,000 shares of our common
stock
equally to Mr. Berger and Mr. Schellhammer.
On
July
8, 2005, our Board of Directors authorized a stock dividend of approximately
.333333 shares of common stock for each outstanding share of common stock,
effectively lowering the initial purchase price to approximately $.0125 per
share.
On
July
22, 2005, our Board of Directors authorized a stock dividend of approximately
.125 shares of common stock for each outstanding share of common stock,
effectively lowering the initial purchase price to approximately $.0111 per
share.
The
holders of the majority of these shares will be entitled to require us, on
up to
two occasions, to register these shares. The holders of the majority of these
shares may elect to exercise these registration rights at any time after the
date on which these shares of common stock are released from the escrow entered
into in connection with our IPO. In addition, these stockholders have certain
“piggy-back” registration rights on registration statements filed subsequent to
the date on which these shares of common stock are released from escrow. We
will
bear the expenses incurred in connection with the filing of any such
registration statements.
In
connection with our IPO, Mr. Pappajohn, Dr. Schaffer and Mr. Kinley loaned
HAQ a
total of $250,000 which was used to pay a portion of the expenses of our IPO,
such as SEC registration fees, NASD registration fees, AMEX listing fees and
legal and accounting fees and expenses. These loans were repaid out of the
net
proceeds of our IPO not placed in trust.
In
accordance with their agreement with the representative of the underwriters
in
our IPO, Mr. Pappajohn, Dr. Schaffer and Mr. Kinley purchased, pursuant to
the
guidelines set forth in SEC Rule 10b5-1, an aggregate of 354,900 of our
warrants, for aggregate consideration of $386,070, on the open market at prices
up to $1.20 per warrant under established Rule 10b5-1 plans. The Rule 10b5-1
plans terminated on January 6, 2006.
We
agreed
to pay Equity Dynamics, Inc., an affiliated third party of which Mr. Pappajohn
is the President and principal stockholder, and Mr. Kinley a Senior Vice
President, approximately $7,500 per month for office space and certain
additional general and administrative services. A prior arrangement with an
affiliate of our Chief Executive Officer, Derace Schaffer, M.D., pursuant to
which we paid $1,500 a month for office space and certain general and
administrative services, as a portion of the $7,500, was terminated on December
31, 2005. As of December 31, 2005 and 2006, we have paid approximately $37,500
and $90,000, respectively, under these arrangements.
We
will
reimburse our officers and directors for any reasonable out-of- pocket business
expenses incurred by them in connection with certain activities on our behalf
such as identifying and investigating possible target businesses and business
combinations. There is no limit on the amount of accountable out-of-pocket
expenses reimbursable by us, which will be reviewed only by our Board or a
court
of competent jurisdiction if such reimbursement is challenged. As of December
31, 2005 and 2006, we have reimbursed such persons an aggregate of $67,642
and
94,314, respectively, in connection with these activities.
Persons
who were stockholders prior to our IPO, including our officers and directors,
will not receive reimbursement for any out-of- pocket expenses incurred by
them
to the extent that such expenses exceed the amount in the trust fund unless
the
business combination is consummated and there are sufficient funds available
for
reimbursement after such consummation. The financial interest of such persons
could influence their motivation in selecting a target business and thus, there
may be a conflict of interest when determining whether a particular business
combination is in the stockholders’ best interest.
Other
than the reimbursable out-of-pocket expenses payable to our officers and
directors, no compensation or fees of any kind, including finders and consulting
fees, will be paid to any persons who were stockholders prior to our IPO,
officers or directors who owned our common stock prior to our IPO, or to any
of
their respective affiliates for services rendered to us prior to or with respect
to the business combination.
All
ongoing and future transactions between us and any of our officers and directors
or their respective affiliates, including loans by our officers and directors,
will be on terms believed by us to be no less favorable than are available
from
unaffiliated third parties and such transactions or loans, including any
forgiveness of loans, will require prior approval in each instance by a majority
of our uninterested “independent” directors (to the extent we have any) or the
members of our board who do not have an interest in the transaction, in either
case who had access, at our expense, to our attorneys or independent legal
counsel.
Advisors
Maxim
Group LLC
HAQ
has
retained Maxim Group LLC, a registered broker dealer firm, to act as its advisor
in connection with the Merger with PharmAthene. In consideration for its
services, we will pay Maxim Group the sum of $500,000 if and only if the Merger
is completed.
Maxim
Group served as the lead underwriter in HAQ’s IPO. As part of the IPO, Maxim
agreed to defer 1% of its underwriting commission ($720,000) until consummation
of a business combination. If the Merger with PharmAthene is completed, Maxim
will be entitled to its deferred underwriting commission. In addition, Maxim
Group holds an underwriter’s unit purchase option to purchase up to 225,000
units from our IPO (comprised of a total of 225,000 shares and 225,000
warrants), which option will expire without value if we do not complete a
business combination before July 28, 2007. As a result, Maxim Group may have
an
interest in having the Merger completed.
Bear,
Stearns & Co. Inc.
PharmAthene
entered into an agreement with Bear, Stearns & Co. Inc. on November 2, 2006
whereby PharmAthene retained Bear Stearns as its financial advisor in connection
with the proposed transaction with HAQ. As
an
initial payment against its total fee, Bear Stearns received an initial payment
of $500,000, and if the transaction is completed, the remainder of the total
$1,750,000 fee will be due and payable.
The
Bear
Stearns Companies Inc. is the parent company of Bear, Stearns & Co. Inc. and
Bear Stearns Asset Management, Inc., which is the sole manager of Bear Stearns
Health Innoventures Management, LLC. Funds affiliated with Bear Stearns Health
Innoventures Management, LLC will beneficially own approximately ___% of the
outstanding voting shares of the combined company (and __% of the HAQ 8%
convertible notes) following the Merger. In addition, Elizabeth Czerepak
is a general partner of Bear Stearns Health Innoventures Management, LLC,
and is expected to be a member of the Board of Directors of HAQ following the
Merger.
BENEFICIAL
OWNERSHIP OF SECURITIES
The
following table sets forth information as of January 15, 2007, based on
information obtained from the persons named below, with respect to the
beneficial ownership of shares of HAQ common stock by (i) each person known
by
us to be the owner of more than 5% of our outstanding shares of HAQ common
stock, (ii) each director and (iii) all officers and directors as a group.
Except as indicated in the footnotes to the table, the persons named in the
table have sole voting and investment power with respect to all shares of common
stock shown as beneficially owned by them.
Name
and Address of
Beneficial
Owner (1)
|
|
Amount
and Nature of Beneficial Ownership
|
|
Percent
of Class
|
|
John
Pappajohn (2)
|
|
|
882,000
|
|
|
7.57
|
%
|
Derace
L. Schaffer, M.D. (3)
|
|
|
882,000
|
|
|
7.57
|
%
|
Matthew
P. Kinley (4)
|
|
|
441,000
|
|
|
3.79
|
%
|
Edward
B. Berger (5)
|
|
|
22,500
|
|
|
*
|
|
Wayne
A. Schellhammer
|
|
|
22,500
|
|
|
*
|
|
Sapling,
LLC (6)
|
|
|
681,815
|
|
|
5.85
|
%
|
Fir
Tree Recovery Master Fund, LP (6)
|
|
|
335,185
|
|
|
2.88
|
%
|
All
directors and executive officers as a group (5) persons
|
|
|
2,250,000
|
|
|
19.31
|
%
|
* Represents
beneficial ownership of less than 1%.
(1)
Does
not include shares of HAQ common stock issuable upon exercise of warrants which
are beneficially owned by certain of the persons named in the above table but
which are not exercisable until the consummation by us of a business
combination. Unless otherwise indicated, the business address of each of the
individuals is 2116 Financial Center, 666 Walnut Street, Des Moines, Iowa
50309.
(2)
Does
not include 141,960 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1, above.
(3)
Does
not include 141,960 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under with a Rule 10b5-1 Plan. See
footnote 1, above.
(4)
Does
not include 70,980 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1, above.
(5)
Does
not include 12,000 warrants purchased by Mr. Berger in open market purchases.
See footnote 1 above.
(6)
Based
on information contained in a Statement on Schedule 13G filed by Sapling LLC
in
August 2005. Sapling may direct the vote and disposition of the 681,815 shares
of HAQ common stock, and Fir Tree Recovery may direct the vote and disposition
of 335,185 shares of HAQ common stock. The address of both Sapling LLC and
Fir
Tree Recovery is 535 Fifth Avenue, 31st Floor, New York, New York
10017
Beneficial
Ownership following the Merger:
Solely
for illustrative purposes, the following table is designed to set forth
information regarding the beneficial ownership of HAQ common stock of each
person who is anticipated to own greater than 5% of HAQ’s outstanding common
stock and each person who will act in the capacity of officer or director
following the Merger with PharmAthene, based on the following
assumptions:
|
·
|
the
current ownership of the entities and individuals identified above
remains
unchanged;
|
|
· |
the
capital structure of HAQ remains as prior to the Merger such that
only the
pre-Merger number of shares remains 11,650,000 shares of common
stock and
has not increased as a result of any HAQ warrant
exercises.
|
|
· |
The columns reflecting the beneficial
ownership after consummation of the Merger assume the issuance of
all
12,500,000 shares but no conversion of any 8% convertible
notes. |
|
|
Beneficial
Ownership Of
Healthcare
Acquisition Corp. Common Stock
On
February 6, 2007
|
|
Beneficial
Ownership Of
Healthcare
Acquisition Corp. Common Stock After Consummation of the
Merger
|
|
Name
and Address of
Beneficial
Owner (1)
|
|
Amount
and Nature of Beneficial Ownership
|
|
Percent
of Class
|
|
Amount
and Nature of Beneficial Ownership
|
|
Percent
of Class
|
|
John
Pappajohn (2)
|
|
|
882,000
|
|
|
7.57
|
%
|
|
|
|
|
|
|
Derace
L. Schaffer, M.D. (3)
|
|
|
882,000
|
|
|
7.57
|
%
|
|
|
|
|
|
|
Matthew
P. Kinley (4)
|
|
|
441,000
|
|
|
3.79
|
%
|
|
|
|
|
|
|
Edward
Berger
(5) |
|
|
-
|
|
|
-
|
|
|
|
|
|
|
|
Wayne
A. Schellhammer
|
|
|
22,500
|
|
|
*
|
|
|
|
|
|
|
|
Sapling,
LLC (6)
|
|
|
681,815
|
|
|
5.85
|
%
|
|
|
|
|
|
|
Fir
Tree Recovery Master Fund, LP (6)
|
|
|
335,185
|
|
|
2.88
|
%
|
|
|
|
|
|
|
James
Cavanaugh, Ph.D (7)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Steven
St. Peter, M.D.
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Elizabeth
Czerepak (8)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Joel
McCleary
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
David
Wright
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Funds
affiliated with Bear Stearns Health Innoventures Management LLC
(9)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Funds
affiliated with MPM Capital L.P. (10)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
HealthCare
Ventures VII, L.P. (11)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
All
current directors and executive officers as a group (5)
persons
|
|
|
2,250,000
|
|
|
19.31
|
%
|
|
|
|
|
|
|
All
post-merger directors and executive officers as a group (7) persons
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
Does
not include shares of HAQ common stock issuable upon exercise of warrants which
are beneficially owned by certain of the persons named in the above table but
which are not exercisable until the later of (i) July 28, 2006 or (ii) the
consummation by us of a business combination. Unless otherwise indicated, the
business address of each of the individuals is 175 Admiral Cochrane Drive,
Suite
#101, Annapolis, MD 21401.
(2)
Does
not include 141,960 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1, above.
(3)
Does
not include 141,960 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under with a Rule 10b5-1 Plan. See
footnote 1, above.
(4)
Does
not include 70,980 warrants purchased on behalf of such person pursuant to
the
guidelines set forth in SEC Rule 10b5-1 under a Rule 10b5-1 Plan. See footnote
1, above.
(5)
Does not include 12,000 warrants purchased by Mr.
Berger in open market purchases. See footnote 1.
(6)
Based
on information contained in a Statement on Schedule 13G filed by Sapling LLC
in
August 2005. Sapling may direct the vote and disposition of the 681,815 shares
of HAQ common stock, and Fir Tree Recovery may direct the vote and disposition
of 335,185 shares of HAQ common stock. The address of both Sapling LLC and
Fir
Tree Recovery is 535 Fifth Avenue, 31st Floor, New York, New York
10017.
(7) Dr.
Cavanaugh is a general partner of HealthCare Partners VII, L.P., which is the
general partner of HealthCare Ventures VII, L.P. In such capacity he may be
deemed to share voting and investment power with respect to __________ shares
of
HAQ common stock to be held by HealthCare Ventures VII, L.P. following the
Merger. Dr. Cavanaugh disclaims beneficial ownership of the shares reported
except to the extent of his proportionate pecuniary interest
therein.
(8) Elizabeth
Czerepak is a general partner of Bear Stearns Health Innoventures Management,
LLC, which is the sole general partner of Bear Stearns Health Innoventures,
L.P., Bear Stearns Health Innoventures Offshore, L.P., BX, L.P. and Bear Stearns
Health Innoventures Employee Fund, L.P., and BSHI Members, LLC co-invests with
these funds. The shares reported are directly owned by Bear Stearns Health
Innoventures, L.P., Bear Stearns Health Innoventures Offshore, L.P., BX, L.P.,
Bear Stearns Health Innoventures Employee Fund, L.P. and BSHI Members, LLC.
Elizabeth Czerepak disclaims beneficial ownership of these shares except to
the
extent of her proportionate pecuniary interest therein.
(9) Consists
of ___________ shares of HAQ common stock to be held by Bear Stearns Health
Innoventures, L.P. following the Merger, ___________ shares of HAQ common stock
to be held by Bear Stearns Health Innoventures Offshore, L.P. following the
Merger, ___________ shares of HAQ common stock to be held by BX, L.P. following
the Merger, ___________ shares of HAQ common stock to be held by Bear Stearns
Health Innoventures Employee Fund, L.P. following the Merger and ___________
shares of HAQ common stock to be held by BSHI Members, LLC following the Merger.
Elizabeth Czerepak is a general partner of Bear Stearns Health Innoventures
Management, LLC, which is the sole general partner of Bear Stearns Health
Innoventures, L.P., Bear Stearns Health Innoventures Offshore, L.P., BX, L.P.
and Bear Stearns Health Innoventures Employee Fund, L.P., and BSHI Members,
LLC
co-invests with these funds. Elizabeth Czerepak disclaims beneficial ownership
of these shares except to the extent of her proportionate pecuniary interest
therein.
(10) Consists
of ___________ shares of HAQ common stock to be held by MPM
BioVentures III-QP, L.P. following the Merger, ___________ shares of HAQ
common stock to be held by MPM BioVentures III GmbH & Co.
Beteiligungs KG following the Merger, ___________ shares of HAQ common stock
to
be held by MPM BioVentures III, L.P. following the Merger, ___________
shares of HAQ common stock to be held by MPM BioVentures III Parallel Fund,
L.P. following the Merger and ___________ shares of HAQ common stock to be
held
by MPM Asset Management Investors 2004 BVIII LLC following the Merger. MPM
BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect
general partners of MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH
&
Co. Beteiligungs KG, MPM BioVentures III, L.P. and MPM BioVentures III Parallel
Fund, L.P. The members of MPM BioVentures III LLC and MPM Asset Management
Investors 2004 BVIII LLC are Luke Evnin, Ansbert Gadicke, Nicholas Galakatos,
Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler, who
disclaim beneficial ownership of these shares except to the extent of their
proportionate pecuniary interest therein.
(11)
Consists
of __________ shares of HAQ common stock to be held by HealthCare Ventures
VII,
L.P. following the Merger. Dr. Cavanaugh is a general partner of HealthCare
Partners VII, L.P., which is the general partner of HealthCare Ventures VII,
L.P. In such capacity he may be deemed to share voting and investment power
with
respect to these shares. Dr. Cavanaugh disclaims beneficial ownership of these
shares except to the extent of his proportionate pecuniary interest
therein.
All
of
the shares of HAQ common stock outstanding prior to the effective date of its
IPO (all of which are owned by our directors and officers) were placed in escrow
with Continental Stock Transfer & Trust Company, as escrow agent, and
shall remain in escrow until the earliest of:
|
|
July 28,
2008;
|
|
|
|
|
|
HAQ’s
liquidation; or
|
|
|
|
|
|
the
consummation of a liquidation, merger, stock exchange or other similar
transaction which results in all of HAQ’s stockholders having the right to
exchange their shares of common stock for cash, securities or other
property.
|
The
certificates representing shares currently in escrow may be replaced by
certificates representing the shares of the renamed entity.
During
the escrow period, the holders of these shares will not be able to sell or
transfer their securities, except to their spouses and children or trusts
established for their benefit, but will retain all other rights as HAQ
stockholders, including, without limitation, the right to vote their shares
of
common stock and the right to receive cash dividends, if declared. If dividends
are declared and payable in shares of common stock, such dividends will also
be
placed in escrow. If the Merger is not consummated and HAQ is liquidated, none
of HAQ’s existing stockholders owning shares of HAQ’s common stock prior to its
IPO will receive any portion of the liquidation proceeds with respect to common
stock owned by them prior to the date of the IPO.
PRICE
RANGE OF SECURITIES AND DIVIDENDS
PharmAthene
Historical
market price information regarding the PharmAthene common stock is not provided
because there is no public market for PharmAthene stock. On January 15, 2007,
there were approximately 23 record holders of PharmAthene common stock, 1 record
holder of PharmAthene Series A Preferred Stock, 13 record holders of PharmAthene
Series B Preferred Stock, and 15 record holders of PharmAthene Series C
Preferred Stock.
To
date,
PharmAthene has not paid cash dividends on its stock and does not intend to
pay
any cash dividends in the foreseeable future.
Dividends
Upon Completion of the Merger
Upon
completion of the Merger with PharmAthene, HAQ does not intend to pay any
dividends on its shares of common stock. Rather, it intends to reinvest any
earnings back into the combined company. At this time, the combined company
anticipates that it will retain any earnings and will not pay dividends in
the
foreseeable future. The combined company also expects that any loan or credit
facilities that it enters into will limit its ability to pay
dividends.
DESCRIPTION
OF SECURITIES
General
HAQ
is
currently authorized to issue 100,000,000 shares of common stock, par value
$.0001, and 1,000,000 shares of preferred stock, par value $.0001. As of January
15, 2007, 11,650,000 shares of common stock are outstanding, held by 6 record
holders. No shares of preferred stock are currently outstanding.
Common
stock
HAQ’s
stockholders are entitled to one vote for each share held of record on all
matters to be voted on by stockholders. In connection with the vote required
for
any business combination, all of HAQ’s existing stockholders, including all of
its officers and directors, have agreed to vote their respective shares of
common stock owned by them immediately prior to HAQ’s IPO in accordance with the
majority of the votes cast by the public stockholders. This voting arrangement
shall not apply to shares included in units purchased in HAQ’s IPO or purchased
following the offering in the open market by any of HAQ’s initial stockholders,
officers and directors. Additionally, HAQ’s initial stockholders, officers and
directors will vote all of their shares in any manner they determine, in their
sole discretion, with respect to any other items that come before a vote of
HAQ’s stockholders.
HAQ
will
proceed with a business combination only if: (i) HAQ obtains the
affirmative vote of a majority of the shares of HAQ’s common stock issued
in its IPO that vote on the Merger Proposal at the Special Meeting and
(ii) public stockholders owning less than 20% of the shares sold in HAQ’s
IPO exercise their conversion rights discussed below.
If
HAQ is
forced to liquidate prior to a business combination, holders of HAQ’s shares of
common stock purchased in its IPO are entitled to share ratably in the trust
fund, inclusive of any interest, and any net assets remaining available for
distribution to them after payment of liabilities. HAQ’s initial stockholders
have agreed to waive their rights to share in any distribution with respect
to
common stock owned by them prior to the IPO if HAQ is forced to
liquidate.
HAQ’s
stockholders have no conversion, preemptive or other subscription rights and
there are no sinking fund or redemption provisions applicable to the common
stock, except that public stockholders have the right to have their shares
of
common stock converted to cash equal to their pro rata share of the trust fund
if they vote against the business combination and the business combination
is
approved and completed. Public stockholders who convert their stock into their
share of the trust fund still have the right to exercise the warrants that
they
received as part of the units.
Holders
of 2,250,000 shares of common stock that were outstanding prior to HAQ’s IPO are
entitled to registration rights. The holders of the majority of these shares
are
entitled to make up to two demands that HAQ register the resale of these shares.
The holders of the majority of these shares can elect to exercise these
registration rights at any time after the date on which these shares of common
stock are released from escrow. In addition, these stockholders have certain
“piggy-back” registration rights on registration statements filed subsequent to
the date on which these shares of common stock are released from escrow. HAQ
will bear the expenses incurred in connection with the filing of any such
registration statements.
Preferred
stock
HAQ’s
amended
and restated certificate
of incorporation authorizes the issuance of 1,000,000 shares of blank check
preferred stock with such designation, rights and preferences as may be
determined from time to time by HAQ’s Board of Directors. Accordingly, HAQ’s
Board of Directors is empowered, without stockholder approval, to issue
preferred stock with dividend, liquidation, conversion, voting or other rights
which could adversely affect the voting power or other rights of the holders
of
common stock, although the underwriting agreement prohibits HAQ, prior to a
business combination, from issuing preferred stock which participates in any
manner in the proceeds of the trust fund, or which votes as a class with the
common stock on a business combination. HAQ may issue some or all of the
preferred
stock to
effect a business combination, although HAQ will not issue any preferred stock
in the Merger with PharmAthene. In addition, the preferred stock could be
utilized as a method of discouraging, delaying or preventing a change in control
of HAQ. Although HAQ does not currently intend to issue any shares of preferred
stock, HAQ cannot assure you that it will not do so in the
future.
Warrants
HAQ
currently has warrants outstanding to purchase 9,400,000 shares of HAQ common
stock. Each warrant entitles the registered holder to purchase one share of
HAQ’s common stock at a price of $6.00 per share, subject to adjustment as
discussed below, at any time commencing on the later of:
|
·
|
the
completion of a business combination; or
|
The
warrants will expire on July 28, 2009, at 5:00 p.m., New York City time.
HAQ may call the warrants for redemption, in whole and not in part, at a price
of $.01 per warrant at any time after the warrants become exercisable, upon
not
less than 30 days’ prior written notice of redemption to each warrant holder,
if, and only if, the last reported sale price of the common stock equals or
exceeds $11.50 per share, for any 20 trading days within a 30 trading day period
ending on the third business day prior to the notice of redemption to warrant
holders.
The
warrants are issued in registered form under a warrant agreement between
Continental Stock Transfer & Trust Company, as warrant agent, and
HAQ.
The
exercise price and number of shares of common stock issuable on exercise of
the
warrants may be adjusted in certain circumstances including in the event of
a
stock dividend, or HAQ’s recapitalization, reorganization, merger or
consolidation. However, the warrants will not be adjusted for issuances of
common stock at a price below their respective exercise prices.
The
warrants may be exercised upon surrender of the warrant certificate on or prior
to the expiration date at the offices of the warrant agent, with the exercise
form on the reverse side of the warrant certificate completed and executed
as
indicated, accompanied by full payment of the exercise price, by certified
check
payable to HAQ, for the number of warrants being exercised. The warrant holders
do not have the rights or privileges of holders of common stock or any voting
rights until they exercise their warrants and receive shares of common stock.
After the issuance of shares of common stock upon exercise of the warrants,
each
holder will be entitled to one vote for each share held of record on all matters
to be voted on by stockholders.
No
fractional shares will be issued upon exercise of the warrants. If, upon
exercise of the warrants, a holder would be entitled to receive a fractional
interest in a share, HAQ will, upon exercise, round up to the nearest whole
number the number of shares of common stock to be issued to the warrant
holder.
On
January 23, 2007, HAQ entered into a warrant clarification agreement to clarify
the terms of the warrant agreement between HAQ and Continental Stock Transfer
& Trust Company, as warrant agent. The warrant clarification agreement
clarifies that (i) if a registration statement covering the securities issuable
upon the exercise of a warrant was not effective at the time a holder desired
to
exercise the instrument, then the warrant could expire unexercised, and (ii)
in
no event would HAQ be obligated to pay cash or other consideration to the
holders of the warrants or “net-cash settle” the obligations of HAQ under the
warrants.
Unit
Purchase Option
In
connection with its IPO, HAQ agreed to sell to Maxim Group LLC, the
underwriter in HAQ’s IPO, for $100, an option to purchase up to a total of
225,000 units. The units issuable upon exercise of this option are identical
to
those offered in HAQ’s IPO except that the warrants included in the option
have an exercise price of $7.50 (125% of the exercise price of the warrants
included in the units sold in the IPO). This option is exercisable at
$10.00 per unit commencing on the later of the consummation of a business
combination and July 28, 2007 and expiring July 28, 2010. The
exercise price and number of units issuable upon exercise of the option may
be
adjusted in certain circumstances including in the event of a stock dividend,
or HAQ’s recapitalization, reorganization, merger or consolidation.
However, the option will not be adjusted for issuances of common stock at a
price below its exercise price or for any issuances in connection with the
Merger.
On
January 23, 2007, HAQ and Maxim Partners, LLC entered into an amendment to
the
unit purchase option. Such amendment clarifies that (i) if a registration
statement covering the securities issuable upon the exercise of the unit
purchase option was not effective at the time Maxim desired to exercise it,
then
the unit purchase option could expire unexercised, and (ii) in no event would
HAQ be obligated to pay cash or other consideration to the holders of the unit
purchase option or “net-cash settle” the obligations of HAQ under the unit
purchase option.
Transfer
Agent and Warrant Agent
The
transfer agent for HAQ’s common stock and warrant agent for HAQ’s warrants is
Continental Stock Transfer & Trust Company, 17 Battery Place, New York,
New York 10004.
STOCKHOLDER
PROPOSALS
We
are
not anticipating holding any meeting of stockholders during 2007 other than
the
Special Meeting. Assuming that the Merger with PharmAthene is consummated,
the
HAQ 2008 annual meeting of stockholders will be held on or about April 30,
2008,
unless the date is changed by the Board of Directors. If you are a stockholder
and you want to include a proposal in the proxy statement for the 2007 annual
meeting, you need to provide it to us by no later than December 31,
2007.
WHERE
YOU CAN FIND MORE INFORMATION
HAQ
files
reports, proxy statements and other information with the SEC as required by
the
Securities Exchange Act of 1934, as amended.
You
may
read and copy reports, proxy statements and other information filed by HAQ
with
the SEC at the Securities and Exchange Commission public reference room located
at 100 F Street, N.E., Washington, D.C. 20549.
You
may
obtain information on the operation of the Public Reference Room by calling
the SEC at 1-800-SEC-0330. You may also obtain copies of the materials described
above at prescribed rates by writing to SEC, Public Reference Section, 100
F
Street, N.E., Washington, D.C. 20549.
HAQ
files
its reports, proxy statements and other information electronically with the
SEC.
You may access information on HAQ at the SEC web site containing reports, proxy
statements and other information at: http://www.sec.gov.
Information
and statements contained in this proxy statement, or any annex to this proxy
statement, are qualified in all respects by reference to the copy of the
relevant contract or other annex filed as an exhibit to this proxy
statement.
All
information contained in this proxy statement relating to HAQ has been supplied
by HAQ, and all such information relating to PharmAthene has been supplied
by
PharmAthene. Information provided by either of HAQ or PharmAthene does not
constitute any representation, estimate or projection of the other.
If
you
would like additional copies of this proxy statement, or if you have questions
about the acquisition or the financing, you should contact:
Healthcare
Acquisition Corp.
Attn:
Matthew Kinley
2116
Financial Center
666
Walnut Street, Des Moines, Iowa 50309
(515)
244-5746.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
|
|
Page
|
Healthcare
Acquisition Corp.: Financial Statements
|
|
|
|
|
|
Balance
Sheets as of September 30, 2006 (unaudited) and December 31,
2005
|
|
FS-1
|
Statements
of Operations for the three months ended September 30, 2006, for
the three
months ended September 30, 2005, for the nine months ended September
30,
2006 and for the period from April 25, 2005 (inception) to September
30,
2006 (unaudited)
|
|
FS-2
|
Statement
in Stockholders’ Equity for the period from April 25, 2005 (inception) to
September 30, 2006
|
|
FS-3
|
Statement
of Cash Flows for the period from April 25, 2005 (inception) to
September
30, 2006
|
|
FS-4
|
Notes
to Unaudited Condensed Financial Statements
|
|
FS-5
|
|
|
|
Report
of Independent Registered Public Accounting Firm
|
|
FS-10
|
Balance
Sheet as of December 31, 2005
|
|
FS-11
|
Statements
of Operations from April 25, 2005 (inception) to December 31,
2005
|
|
FS-12
|
Statement
of Changes in Stockholders’ Equity from April 25, 2005 (inception) to
December 31, 2005
|
|
FS-13
|
Statement
of Cash Flows from April 25, 2005 (inception) to December 31,
2005
|
|
FS-14
|
Notes
to Financial Statements
|
|
FS-15
|
|
|
|
PharmAthene,
Inc. Consolidated Financial Statements
|
|
|
|
|
|
Condensed
Consolidated Statements of Operations as of September 30, 2005
and
September 30, 2006 (unaudited)
|
|
FS-22
|
Condensed
Consolidated Balance Sheets as of September 30, 2006 (unaudited)
and
December 31, 2005
|
|
FS-23
|
Condensed
Consolidated Statement of Cash Flow
for the nine month periods ended September 30, 2006 and September
30, 2005
(unaudited)
|
|
FS-24
|
Notes
to Unaudited Condensed Consolidated Financial Statements
|
|
FS-25
|
Independent
Auditor’s Report
|
|
FS-43
|
Consolidated
Balance Sheet as of December 31, 2005
|
|
FS-44
|
Consolidated
Statement of Operations for the years ended December 31, 2003,
December 31, 2004, and December 31, 2005
|
|
FS-45
|
Consolidated
Statement of Convertible Redeemable Preferred Stock and Stockholders’
Deficit
|
|
FS-46
|
Consolidated
Statement of Cash Flows for the years ended December 31, 2003,
December
31, 2004, December 31, 2005
|
|
FS-47
|
Notes
to Consolidated Financial Statements
|
|
FS-48
|
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Balance
Sheets
|
|
September
30, 2006
|
|
December
31, 2005
|
|
|
|
|
|
|
|
(audited)
|
|
Assets |
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
763,931.00
|
|
$
|
1,398,181.32
|
|
Cash
held in trust
|
|
|
70,283,506.00
|
|
|
68,636,069.00
|
|
Prepaid
expense
|
|
|
116,168.00
|
|
|
52,500.00
|
|
Total
current assets
|
|
$
|
71,163,605.00
|
|
$
|
70,086,750.32
|
|
|
|
|
|
|
|
|
|
Liabilities
and stockholders’ equity
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
12,477.00
|
|
$
|
6,996.00
|
|
Accrued
expenses
|
|
|
82,996.00
|
|
|
98,996.00
|
|
State
income tax payable
|
|
|
108,874.00
|
|
|
48,000.00
|
|
Capital
based taxes payable
|
|
|
22,693.00
|
|
|
115,000.00
|
|
Deferred
revenue
|
|
|
470,865.00
|
|
|
141,543.00
|
|
Total
current liabilities
|
|
|
697,905.00
|
|
|
410,535.00
|
|
|
|
|
|
|
|
|
|
Common
stock, subject to possible redemption
|
|
|
|
|
|
|
|
1,879,060
shares, at conversion value
|
|
|
13,578,807.00
|
|
|
13,578,807.00
|
|
|
|
|
|
|
|
|
|
Stockholders’
equity
|
|
|
|
|
|
|
|
Preferred
stock, $.0001 par value, 1,000,000 shares authorized; none
|
|
|
|
|
|
|
|
issued
and outstanding
|
|
|
0.00
|
|
|
0.00
|
|
Common
stock, $.0001 par value, 100,000,000 shares authorized;
|
|
|
|
|
|
|
|
11,650,000
shares issued and outstanding (which includes 1,879,060
|
|
|
|
|
|
|
|
subject
to possible conversion)
|
|
|
1,165.00
|
|
|
1,165.00
|
|
Common
stock warrants (9,400,000 outstanding)
|
|
|
0.00
|
|
|
0.00
|
|
Paid-in
capital in excess of par
|
|
|
55,818,948.00
|
|
|
55,818,948.00
|
|
Equity
accumulated during the development stage
|
|
|
1,066,780.00
|
|
|
277,295.00
|
|
Total
stockholders’ equity
|
|
|
56,886,893.00
|
|
|
56,097,408.00
|
|
Total
liabilities and stockholders’ equity
|
|
$
|
71,163,605.00
|
|
$
|
70,086,750.00
|
|
See
accompanying notes to the financial statements
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Statements
of Operations
For
the
period from April 25, 2005 (inception) to September 30,
2006
|
|
For
the Three Months Ended September 30, 2006
|
|
For
the Three Months Ended September 30, 2005
|
|
For
the Nine Months Ended September 30, 2006
|
|
For
the Period from April 25, 2005 (inception) to September 30,
2006
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
|
$
|
10,827.00
|
|
$
|
8,120.00
|
|
$
|
37,442.00
|
|
$
|
56,990.00
|
|
Interest
and dividend income from Trust Fund
|
|
|
473,658.00
|
|
|
198,141.00
|
|
|
1,318,114.00
|
|
|
1,884,640.00
|
|
Total
revenues
|
|
|
484,485.00
|
|
|
206,261.00
|
|
|
1,355,556.00
|
|
|
1,941,630.00
|
|
Costs
and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital
based taxes
|
|
|
22,693.00
|
|
|
0.00
|
|
|
89,238.00
|
|
|
204,238.00
|
|
Management
fees
|
|
|
22,500.00
|
|
|
15,486.00
|
|
|
67,500.00
|
|
|
105,486.00
|
|
Insurance
|
|
|
23,985.00
|
|
|
15,000.00
|
|
|
71,788.00
|
|
|
109,288.00
|
|
Legal
fees
|
|
|
6,501.00
|
|
|
0.00
|
|
|
66,705.00
|
|
|
76,241.00
|
|
Travel
|
|
|
29,799.00
|
|
|
13,902.00
|
|
|
68,958.00
|
|
|
96,699.00
|
|
General
and administrative
|
|
|
19,866.00
|
|
|
5,397.00
|
|
|
56,882.00
|
|
|
87,398.00
|
|
Formation
costs
|
|
|
0.00
|
|
|
|
|
|
0.00
|
|
|
2,500.00
|
|
Total
expenses
|
|
|
125,344.00
|
|
|
49,785.00
|
|
|
421,071.00
|
|
|
681,850.00
|
|
Income
before taxes
|
|
|
359,141.00
|
|
|
156,476.00
|
|
|
934,485.00
|
|
|
1,259,780.00
|
|
Provision
for income taxes
|
|
|
58,000.00
|
|
|
10,000.00
|
|
|
145,000.00
|
|
|
193,000.00
|
|
Net
income
|
|
$
|
301,141.00
|
|
$
|
146,476.00
|
|
$
|
789,485.00
|
|
$
|
1,066,780.00
|
|
Basic
earnings per share
|
|
$
|
0.03
|
|
$
|
0.02
|
|
$
|
0.07
|
|
|
|
|
Diluted
earnings per share
|
|
$
|
0.02
|
|
$
|
0.02
|
|
$
|
0.06
|
|
|
|
|
Weighted
average basic shares outstanding
|
|
|
11,650,000
|
|
|
8,184,066
|
|
|
11,650,000
|
|
|
|
|
Weighted
average diluted shares outstanding
|
|
|
13,614,272
|
|
|
8,184,066
|
|
|
13,758,715
|
|
|
|
|
See
accompanying notes to the financial statements
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Statement
of Stockholders’ Equity
For
the
period from April 25, 2005 (inception) to September 30,
2006
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
Common
|
|
Common
|
|
Common
|
|
Additional
|
|
During
the
|
|
|
|
|
|
Stock
|
|
Par
|
|
Stock
|
|
Paid
in
|
|
Development
|
|
Stockholders’
|
|
|
|
Shares
|
|
Amount
|
|
Warrants
|
|
Capital
|
|
Stage
|
|
Equity
|
|
Common
shares issued to initial
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
stockholders
at $.0111 per share
|
|
|
2,250,000
|
|
$
|
150
|
|
|
-
|
|
$
|
24,850
|
|
$
|
-
|
|
$
|
25,000
|
|
Stock
dividend - July 8, 2005
|
|
|
-
|
|
|
50
|
|
|
-
|
|
|
(50
|
)
|
|
-
|
|
|
-
|
|
Stock
dividend - July 22, 2005
|
|
|
-
|
|
|
25
|
|
|
-
|
|
|
(25
|
)
|
|
-
|
|
|
-
|
|
Sale
of 9,000,000 units, net of
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
underwriters’
discount and offering
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
expenses
(includes 1,799,100 shares
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
subject
to possible conversion)
|
|
|
9,000,000
|
|
|
900
|
|
|
-
|
|
|
66,364,920
|
|
|
-
|
|
|
66,365,820
|
|
Proceeds
of exercise of underwriters’
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
over-allotment
option for 400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
units,
net of commissions. (includes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
79,960
shares subject to possible
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
conversion).
|
|
|
400,000
|
|
|
40
|
|
|
-
|
|
|
3,007,960
|
|
|
-
|
|
|
3,008,000
|
|
Proceeds
subject to possible
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
conversion
of 1,879,060 shares
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(13,578,807
|
)
|
|
-
|
|
|
(13,578,807
|
)
|
Proceeds
from issuance of unit options
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
100
|
|
|
-
|
|
|
100
|
|
Net
income
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
277,295
|
|
|
277,295
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at December 31, 2005
|
|
|
11,650,000
|
|
$
|
1,165
|
|
|
-
|
|
$
|
55,818,948
|
|
$
|
277,295
|
|
$
|
56,097,408
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
789,485
|
|
|
789,485
|
|
Balance
at September 30, 2006
|
|
|
11,650,000
|
|
$
|
1,165
|
|
|
-
|
|
$
|
55,818,948
|
|
$
|
1,066,780
|
|
$
|
56,886,893
|
|
See
accompanying notes to the financial statements
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Statements
of Cash Flows
For
the
period from April 25, 2005 (inception) to September 30, 2006
|
|
For
the Three Months Ended September 30, 2006
|
|
For
the Three Months Ended September 30, 2005
|
|
For
the Nine Months Ended September 30, 2006
|
|
For
the Period from April 25, 2005 (inception) to September 30,
2006
|
|
Operating
activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income
|
|
$
|
301,141
|
|
$
|
146,476
|
|
$
|
789,485
|
|
$
|
1,066,780
|
|
Adjustments
to reconcile net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
to
net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease
(increase) in prepaid expenses
|
|
|
(70,116
|
)
|
|
(75,000
|
)
|
|
(63,669
|
)
|
|
(116,168
|
)
|
Increase
(decrease) in accounts payable and accrued expenses
|
|
|
(30,247
|
)
|
|
9,132
|
|
|
(10,519
|
)
|
|
12,477
|
|
Increase
in deferred revenue
|
|
|
118,340
|
|
|
49,504
|
|
|
329,323
|
|
|
470,865
|
|
Increase
in income tax payable
|
|
|
33,874
|
|
|
10,000
|
|
|
60,874
|
|
|
108,874
|
|
Increase
(decrease) in capital based taxes payable
|
|
|
-
|
|
|
-
|
|
|
(92,307
|
)
|
|
22,693
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
cash provided by operating activities
|
|
|
350,993
|
|
|
140,112
|
|
|
1,013,187
|
|
|
1,565,521
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing
activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase
in cash held in Trust Fund
|
|
|
(591,999
|
)
|
|
(68,175,644
|
)
|
|
(1,647,437
|
)
|
|
(70,283,506
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
proceeds from Initial Public Offering
|
|
|
-
|
|
|
75,200,000
|
|
|
-
|
|
|
75,200,000
|
|
Proceeds
from issuance of unit option
|
|
|
-
|
|
|
100
|
|
|
-
|
|
|
100
|
|
Proceeds
from notes payable, stockholders
|
|
|
-
|
|
|
75,000
|
|
|
-
|
|
|
250,000
|
|
Proceeds
from issuance of common stock
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
25,000
|
|
Payments
made on notes payable, stockholders
|
|
|
-
|
|
|
(250,000
|
)
|
|
-
|
|
|
(250,000
|
)
|
Payments
made for costs of Initial Public Offering
|
|
|
-
|
|
|
(5,523,959
|
)
|
|
-
|
|
|
(5,745,184
|
)
|
Net
cash provided by financing activities
|
|
|
-
|
|
|
69,501,141
|
|
|
-
|
|
|
69,479,916
|
|
Net
increase in cash
|
|
|
(239,006
|
)
|
|
1,465,609
|
|
|
(636,250
|
)
|
|
763,931
|
|
Cash,
beginning of period
|
|
|
1,002,937
|
|
|
5,760
|
|
|
1,398,181
|
|
|
-
|
|
Cash,
end of period
|
|
$
|
763,931
|
|
$
|
1,471,369
|
|
$
|
763,931
|
|
$
|
763,931
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental
schedule of non-cash financing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrual
of deferred offering costs
|
|
$
|
-
|
|
$
|
105,996
|
|
$
|
-
|
|
$
|
80,996
|
|
See
accompanying notes to the financial statements
1.
Basis of Presentation
The
financial statements at September 30, 2006 and for the three months and nine
months ended September 30, 2006, and period from April 25, 2005 (inception)
to
September 30, 2006 are unaudited. In the opinion of management, all adjustments
(consisting of normal accruals) have been made that are necessary to present
fairly the financial position of Healthcare Acquisition Corp. (the “Company”) as
of September 30, 2006 and the results of its operations and its cash flow
for
the three and nine months ended September 30, 2006 and the period from April
25,
2005 (inception) to September 30, 2006. Operating results for the interim
period
are not necessarily indicative of the results to be expected for the full
year.
2.
Nature
of Operations and Summary of Significant Accounting
Policies
Nature
of Operations
Healthcare
Acquisition Corp. (the “Company”) was incorporated in Delaware on April 25,
2005, as a blank check company whose objective is to acquire, through a merger,
capital stock exchange, asset acquisition or other similar business combination,
a currently unidentified operating business.
Primarily
all activity through September 30, 2006 relates to the Company’s formation, the
public offering described below and evaluation of prospective target businesses.
The Company has selected December 31 as its fiscal year-end. The registration
statement for the Company’s initial public offering (“Offering”) was declared
effective July 28, 2005. The Company consummated the Offering on August 3,
2005
(and further consummated the sale of 400,000 units subject to the underwriters’
over-allotment option on August 16, 2005) and received net proceeds of
approximately $69,450,000 (Note 3). The Company’s management has broad
discretion with respect to the specific application of the net proceeds of
this
Offering, although substantially all of the net proceeds of the Offering
are
intended to be generally applied toward consummating a business combination
with
an operating domestic or international company in the healthcare industry,
a
“target business”.
In
evaluating a prospective target business, the Company will consider, among
other
factors, the financial condition and results of operation; growth potential;
experience and skill of management; availability of additional personnel;
capital requirements; competitive position; barriers to entry into other
industries; stage of development of the products, processes or services;
degree
of current or potential market acceptance of the products, processes or
services; proprietary features and degree of intellectual property or other
protection of the products, processes or services; regulatory environment
of the
industry; and costs associated with effecting the business combination. These
criteria are not intended to be exhaustive. Any evaluation relating to the
merits of a particular business combination will be based, to the extent
relevant, on the above factors, as well as other considerations deemed relevant
by the Company in effecting a business combination consistent with its business
objective.
There
are
no assurances the Company will be able to successfully effect a business
combination. An amount of $67,928,000 or approximately 90.3% of the gross
proceeds of this offering (approximately $7.23 per unit) are being held in
an
interest bearing trust account at JP Morgan Chase NY Bank maintained by
Continental Stock Transfer & Trust Company (“Trust Fund”) and invested in
United States Treasury Bills or short-term securities having a maturity of
one
hundred eighty (180) days or less, until the earlier of (i) the consummation
of
the Company’s first business combination or (ii) the liquidation of the Company.
In October 2005, the Company entered into an amendment to its trust agreement
which permits it to invest the funds held in trust not only in treasury bills
having a maturity of 180 days or less, but also in any money market fund
meeting
the requirements of a “cash item” as set forth in Section 3(a)(1)(C) of the
Investment Company Act of 1940, as amended, and any regulations, no-action
letters, exemptive orders or interpretations promulgated thereunder. The
Company
believes that the amendment will allow it greater flexibility in investing
the
funds held in trust from its initial public offering, as well as reducing
its
tax liability, by allowing the Company to invest in tax-free money market
funds.
The placing of funds in the Trust Fund may not protect those funds from third
party claims against the Company. Although the Company will seek to have
all
vendors, prospective target businesses or other entities it engages, execute
agreements with the Company waiving any right, title, interest or claim of
any
kind in or to any monies held in the Trust Fund, there is no guarantee that
they
will execute such agreements. The Company’s officers have severally agreed that
they will be personally liable to ensure that the proceeds in the Trust Fund
are
not reduced by the claims of target businesses or vendors or other entities
that
are owed money by the Company for services rendered or contracted for or
products sold to the Company. However, there can be no assurance that the
officers will be able to satisfy those obligations. The remaining proceeds,
not
held in trust, may be used to pay for business, legal and accounting expenses,
expenses which may be incurred related to the investigation and selection
of a
target business, and the negotiation of an agreement to acquire a target
business, and for continuing general and administrative
expenses.
The
Company’s first business combination must be with a business with a fair market
value of at least 80% of the Company’s net asset value at the time of
acquisition. The Company, after signing a definitive agreement for the
acquisition of a target business, will submit such transaction for stockholder
approval. In the event that stockholders owning 20% or more of the outstanding
stock excluding, for this purpose, those persons who were stockholders prior
to
the Offering, vote against the business combination or request their conversion
right as described below, the business combination will not be consummated.
All
of the Company’s stockholders prior to the Offering, including all of the
officers and directors of the Company (“Initial Stockholders”), have agreed to
vote their 2,250,000 founding shares of common stock in accordance with the
vote
of the majority in interest of all other stockholders of the Company (“Public
Stockholders”) with respect to any business combination. After consummation of
the Company’s first business combination, all of these voting safeguards will no
longer be applicable.
With
respect to the first business combination which is approved and consummated,
any
Public Stockholder who voted against the business combination may demand
that
the Company redeem his or her shares. The per share redemption price will
equal
the amount in the Trust Fund as of the record date for determination of
stockholders entitled to vote on the business combination divided by the
number
of shares of common stock held by Public Stockholders at the consummation
of the
Offering. Accordingly, Public Stockholders holding 19.99% of the aggregate
number of shares owned by all Public Stockholders may seek redemption of
their
shares in the event of a business combination. Such Public Stockholders are
entitled to receive their per share interest in the Trust Fund computed,
without
regard to the shares held by Initial Stockholders. Accordingly, a portion
of the
net proceeds from the Offering (19.99% of the amount held in the Trust Fund)
has
been classified as common stock subject to possible conversion in the
accompanying September 30, 2006 balance sheet and 19.99% of the related interest
earned on cash held in the Trust Fund has been recorded as deferred
revenue.
The
Company’s Amended and Restated Certificate of Incorporation provides for
mandatory liquidation of the Company, without stockholder approval, in the
event
that the Company does not consummate a business combination within eighteen
(18)
months from the date of the consummation of the Offering, or twenty-four
(24)
months from the consummation of the Offering if certain extension criteria
have
been satisfied. In the event of liquidation, it is likely that the per share
value of the residual assets remaining available for distribution (including
Trust Fund assets) will be less than the initial public offering price per
share
in the Offering (assuming no value is attributed to the Warrants contained
in
the Units to be offered in the Offering discussed in Note 3.)
Net
Income Per Common Share
Net
income per share is computed by dividing net income by the weighted-average
number of shares of common stock outstanding during the period.
Derivative
Financial Instruments
Derivative
financial instruments consist of Warrants issued as part of the Offering,
as
described in Note 3, and a Purchase Option that was sold to an underwriter
as
described in Note 5. Based on Emerging Issues Task Force 00-19, Accounting
for
Derivative Financial Instruments Indexed to, and Potentially Settle in, a
Company’s Own Stock, the issuance of the Warrants and sale of the Purchase
Option were reported in permanent equity and accordingly, there is no impact
on
the Company’s financial position and results of operation, except for the $100
in proceeds from sale of the Purchase Option. Subsequent changes in fair
value
will not be recognized as long as the Warrants and Purchase Option continue
to
be classified as equity instruments.
At
date
of issuance the Company had determined the Purchase Option had a fair market
value of approximately $850,000 using a Black-Scholes pricing
model.
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to
make
estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts
of
expenses during the reporting period. Actual results could differ from those
estimates.
Income
Taxes
Deferred
income taxes are provided for the differences between the basis of assets
and
liabilities for financial reporting and income tax purposes. A valuation
allowance is established, when necessary, to reduce deferred tax assets to
the
amount expected to be realized.
The
effective tax rate differs from the statutory rate of 34% due to primarily
all
interest income being generated from tax-exempt securities .
Recent
Accounting Pronouncements
The
Company does not believe that any recently issued, but not yet effective,
accounting standards, if currently adopted, would have a material effect
on the
accompanying financial statements.
3.
Initial Public Offering
On
July
28, 2005, the Company sold 9,000,000 units (“Units”) in the Offering. On August
16, 2005 an additional 400,000 Units were sold. Each Unit consists of one
share
of the Company’s common stock, $.0001 par value and one Redeemable Common Stock
Purchase Warrant (“Warrant”). Each Warrant entitles the holder to purchase from
the Company one share of common stock at an exercise price of $6.00 commencing
the later of the completion of a business combination with a target business
or
one (1) year from the effective date of the Offering and expiring four (4)
years
from the effective date of the Offering. The Warrants will be redeemable
by the
Company at a price of $.01 per Warrant, upon thirty (30) days notice after
the
Warrants become exercisable, only in the event that the last sales price
of the
common stock is at least $11.50 per share for any twenty (20) trading days
within a thirty (30) trading-day period ending on the third day prior to
date on
which notice of redemption is given. The Warrants began trading separately
from
the Company’s common stock on October 6, 2005. In connection with the Offering,
the Company paid the underwriter a discount of 6% of the gross proceeds of
the
Offering and a non-accountable expense allowance of 1% of the gross proceeds
of
the Offering.
4.
Notes Payable, Stockholders
The
Company issued unsecured promissory notes to three Initial Stockholders,
amounting to $250,000, who are also officers. These notes were non-interest
bearing and were repaid from the proceeds of the Offering.
5
.
Unit
Option
In
connection with the Offering, the Company issued to the representative of
the
underwriters for $100, an option to purchase up to a total of 225,000 units,
exercisable at $10 per unit (“Purchase Option”). In lieu of payment of the
exercise price in cash, the holder of the Purchase Option has the right (but
not
the obligation) to convert any exercisable portion of the Purchase Option
into
units using a cashless exercise based on the difference between current market
value of the units and its exercise price. The Warrants issued in conjunction
with these units are identical to those offered by the prospectus, except
that
they have an exercise price of $7.50 (125% of the exercise price of the Warrants
included in the Units sold in the Offering). This option commences on the
later
of the consummation of a business combination and one (1) year from the date
of
the prospectus and expiring five (5) years from the date of the
prospectus.
Additionally,
the option may not be sold, transferred, assigned, pledged or hypothecated
for a
one-year period (including the foregoing 180-day period) following July 28,
2005. However, the option may be transferred to any underwriter and selected
dealer participating in the Offering and their bona fide officers or partners.
The Purchase Option grants to holders demand and “piggy back” rights for periods
of five (5) and seven (7) years, respectively, from July 28, 2005 with respect
to the registration under the Securities Act of the securities directly and
indirectly issuable upon exercise of the option. The Company will bear all
fees
and expenses attendant to registering the securities, other than underwriting
commissions, which will be paid for by the holders themselves. The exercise
price and number of units issuable upon exercise of the option may be adjusted
in certain circumstances, including in the event of a stock dividend,
recapitalization, reorganization, merger or consolidation. However, the option
will not be adjusted for issuances of common stock at a price below its exercise
price.
6.
Commitments and Contingencies
The
Company presently occupies office space in one location, provided by an
affiliate of an Initial Stockholder. This affiliate has agreed that, until
the
Company consummates a business combination, it will make such office space,
as
well as certain office and secretarial services, available to the Company,
as
may be required by the Company from time to time. The Company currently pays
this affiliate $7,500 per month for such services under an office services
agreement. Upon completion of a business combination or liquidation, the
Company
will no longer be required to pay this monthly fee.
The
Company has engaged a representative of the underwriters, on a non-exclusive
basis, as its agent for the solicitation of the exercise of the Warrants.
To the
extent not inconsistent with the guidelines of the NASD and the rules and
regulations of the Securities and Exchange Commission, the Company has agreed
to
pay the representative for bona fide services rendered, a commission equal
to 4%
of the exercise price for each Warrant exercised more than one (1) year after
July 28, 2005 if the exercise was solicited by the underwriters. In addition
to
soliciting, either orally or in writing, the exercise of the Warrants, the
representative’s services may also include disseminating information, either
orally or in writing, to Warrant holders about the Company or the market
for its
securities, and assisting in the processing of the exercise of the Warrants.
No
compensation will be paid to the representative upon the exercise of the
Warrants if:
·
|
the
market price of the underlying shares of common stock is lower
than the
exercise price;
|
|
|
·
|
the
holder of the Warrants has not confirmed in writing that the underwriters
solicited the exercise;
|
|
|
·
|
the
Warrants are held in a discretionary account;
|
|
|
·
|
the
Warrants are exercised in an unsolicited transaction;
or
|
|
|
|
the
arrangement to pay the commission is not disclosed in the prospectus
provided to Warrant holders at the time of
exercise.
|
The
Initial Stockholders, who are holders of 2,250,000 issued and outstanding
shares
of common stock, are entitled to registration rights pursuant to an agreement
signed on the effective date of the Offering. The holders of the majority
of
these shares are entitled to request the Company, on up to two (2) occasions,
to
register these shares. The holders of the majority of these shares can elect
to
exercise these registration rights at any time after the date on which these
shares of common stock are released from escrow. In addition, these stockholders
have certain “piggy-back” registration rights on registration statements filed
subsequent to the date on which these shares of common stock are released
from
escrow. The Company will bear the expenses incurred in connection with the
filing of any such registration statements.
7.
Preferred Stock
The
Company is authorized to issue 1,000,000 shares of preferred stock with such
designations, voting and other rights and preferences, as may be determined
from
time to time by the Board of Directors.
8.
Common Stock
On
July
8, 2005, the Company’s Board of Directors authorized a .333333 to 1 stock
dividend. On July 22, 2005, the Company’s Board of Directors authorized a .125
to 1 stock dividend. All references in the accompanying financial statements
to
the number of shares of stock have been retroactively restated to reflect
these
transactions.
9.
Common Stock Warrants
Each
Warrant entitles the holder to purchase from the Company one share of common
stock at an exercise price of $6.00 commencing the later of the completion
of a
business combination with a target business or one (1) year from the effective
date of the Offering and expiring four (4) years from the effective date
of the
Offering. The Warrants will be redeemable by the Company at a price of $.01
per
Warrant, upon thirty (30) days notice after the Warrants become exercisable,
only in the event that the last sales price of the common stock is at least
$11.50 per share for any twenty (20) trading days within a thirty (30)
trading-day period ending on the third day prior to date on which notice
of
redemption is given. The warrants began trading separately from the Company’s
common stock on October 6, 2005.
Report
of Independent Registered Public Accounting Firm
The
Board
of Directors and Stockholders
Healthcare
Acquisition Corp.
We
have
audited the accompanying balance sheets of Healthcare Acquisition Corp.
(a
corporation in the development stage) as of December 31, 2005, and the
related
statements of operations, stockholders’ equity, and cash flows for the period
from April 25, 2005 (inception) to December 31, 2005. These financial statements
are the responsibility of the Company’s management. Our responsibility is to
express an opinion on these financial statements based on our audits.
We
conducted our audits in accordance with auditing standards of the Public
Company
Accounting Oversight Board (United States). Those standards require that
we plan
and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures
in
the financial statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In
our
opinion, the financial statements referred to above present fairly, in
all
material respects, the financial position of Healthcare Acquisition Corp.
(a
corporation in the development stage) as of December 31, 2005, and the
results
of its operations and its cash flows for the period from April 25, 2005
(inception) to December 31, 2005, in conformity with accounting principles
generally accepted in the United States of America.
|
|
|
/s/
LWBJ, LLP
|
|
|
LWBJ,
LLP
|
|
|
West
Des Moines, Iowa
|
|
March
14, 2006
|
|
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Balance
Sheet
December
31, 2005
Assets
|
|
|
|
Current
assets:
|
|
|
|
Cash
|
|
$
|
1,398,181
|
|
Cash
held in Trust Fund
|
|
|
68,636,069
|
|
Prepaid
expense
|
|
|
52,500
|
|
Total
current assets
|
|
|
70,086,750
|
|
Total
assets
|
|
$
|
70,086,750
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
and stockholders’ equity
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
Accounts
payable
|
|
$
|
6,996
|
|
Accrued
expenses
|
|
|
98,996
|
|
State
income tax payable
|
|
|
48,000
|
|
Capital
based tax payable
|
|
|
115,000
|
|
Deferred
interest
|
|
|
141,543
|
|
Total
current liabilities
|
|
|
410,535
|
|
|
|
|
|
|
Common
stock, subject to possible redemption,
|
|
|
|
|
1,879,060
shares, at conversion value
|
|
|
13,578,807
|
|
|
|
|
|
|
Stockholders’
equity:
|
|
|
|
|
Preferred
stock, $.0001par value, 1,000,000 shares authorized;
|
|
|
|
|
none
issued
|
|
|
-
|
|
Common
stock, $.0001 par value, 100,000,000 shares authorized;
|
|
|
|
|
11,650,000
(which includes 1,879,060 subject to possible conversion)
|
|
|
|
|
issued
and outstanding
|
|
|
1,165
|
|
Common
stock warrants (9,400,000 outstanding)
|
|
|
-
|
|
Additional
paid-in capital
|
|
|
55,818,948
|
|
Equity
accumulated during the development stage
|
|
|
277,295
|
|
Total
stockholders’ equity
|
|
|
56,097,408
|
|
Total
liabilities and stockholders’ equity
|
|
$
|
70,086,750
|
|
See
accompanying notes to the financial statements.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Statement
of Operations
For
the
period from April 25, 2005 (inception) to December 31, 2005
Revenues
|
|
|
|
Interest
income
|
|
$
|
19,548
|
|
Interest
and dividend income from Trust Fund
|
|
|
566,526
|
|
Total
revenues
|
|
|
586,074
|
|
|
|
|
|
|
Costs
and expenses
|
|
|
|
|
Capital
based taxes
|
|
|
115,000
|
|
Management
fees
|
|
|
37,986
|
|
Insurance
|
|
|
37,500
|
|
Travel
|
|
|
27,741
|
|
General
and administrative
|
|
|
40,052
|
|
Formation
costs
|
|
|
2,500
|
|
Total
expenses
|
|
|
260,779
|
|
|
|
|
|
|
Income
before taxes
|
|
|
325,295
|
|
Provision
for income taxes
|
|
|
48,000
|
|
|
|
|
|
|
Net
income
|
|
$
|
277,295
|
|
|
|
|
|
|
Basic
earnings per share
|
|
$
|
0.04
|
|
|
|
|
|
|
Diluted
earnings per share
|
|
$
|
0.03
|
|
|
|
|
|
|
Weighted-average
basic shares outstanding
|
|
|
7,869,200
|
|
|
|
|
|
|
Weighted-average
diluted shares outstanding
|
|
|
8,323,201
|
|
See
accompanying notes to the financial statements.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Statements
of Stockholders’ Equity
For
the
period from April 25, 2005 (inception) to December 31, 2005
|
|
Common
Stock
|
|
|
|
Additional
Paid
in
|
|
Equity
Accumulated During
the Development
|
|
Stockholders’
|
|
|
|
Shares
|
|
Amount
|
|
Warrants
|
|
Capital
|
|
Stage
|
|
Equity
|
|
Common
shares issued to Initial
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders
at $.0111 per share
|
|
|
2,250,000
|
|
$
|
150
|
|
|
|
|
$
|
24,850
|
|
|
|
|
$
|
$25,000
|
|
Stock
dividend - July 8, 2005
|
|
|
|
|
|
50
|
|
|
|
|
|
(50
|
)
|
|
|
|
|
|
|
Stock
dividend - July 22, 2005
|
|
|
|
|
|
25
|
|
|
|
|
|
(25
|
)
|
|
|
|
|
|
|
Sale
of 9,000,000 units, net of
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
underwriters’
discount and offering
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
expenses
(includes 1,799,100 shares
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
subject
to possible conversion)
|
|
|
9,000,000
|
|
|
900
|
|
|
|
|
|
66,364,920
|
|
|
|
|
|
66,365,820
|
|
Proceeds
of exercise of underwriters’
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
over-allotment
option for 400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
units,
net of commissions (includes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
79,960
shares subject to possible
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
conversion.)
|
|
|
400,000
|
|
|
40
|
|
|
|
|
|
3,007,960
|
|
|
|
|
|
3,008,000
|
|
Proceeds
subject to possible
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
conversion
of 1,879,060 shares
|
|
|
|
|
|
|
|
|
|
|
|
(13,578,807
|
)
|
|
|
|
|
(13,578,807
|
)
|
Proceeds
from issuance of unit options
|
|
|
|
|
|
|
|
|
|
|
|
100
|
|
|
|
|
|
100
|
|
Net
income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
277,295
|
|
|
277,295
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at December 31, 2005
|
|
|
11,650,000
|
|
$
|
1,165
|
|
$
|
-
|
|
$
|
55,818,948
|
|
$
|
277,295
|
|
$
|
56,097,408
|
|
See
accompanying notes to the financial statements.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Statement
of Cash Flows
For
the
period from April 25, 2005 (inception) to December 31, 2005
Operating
activities
|
|
|
|
Net
income
|
|
$
|
277,295
|
|
Increase
in prepaid expense
|
|
|
(52,500
|
)
|
Increase
in accounts payable and accrued expenses
|
|
|
24,996
|
|
Increase
in state income tax payable
|
|
|
48,000
|
|
Increase
in capital based tax payable
|
|
|
115,000
|
|
Increase
in deferred interest
|
|
|
141,543
|
|
Net
cash provided by operating activities
|
|
|
554,334
|
|
|
|
|
|
|
Investing
activities
|
|
|
|
|
Cash
held in Trust Fund
|
|
|
(68,636,069
|
)
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
Gross
proceeds from initial public offering
|
|
|
75,200,000
|
|
Proceeds
from issuance of unit option
|
|
|
100
|
|
Proceeds
from note payable, stockholders
|
|
|
250,000
|
|
Payments
received from note payable, stockholders
|
|
|
(250,000
|
)
|
Proceeds
from sale of common stock
|
|
|
25,000
|
|
Payments
made for costs of initial public offering
|
|
|
(5,745,184
|
)
|
Net
cash provided by financing activities
|
|
|
69,479,916
|
|
Net
increase in cash
|
|
|
1,398,181
|
|
|
|
|
|
|
Cash
at beginning of period
|
|
|
-
|
|
Cash
at end of period
|
|
$
|
1,398,181
|
|
|
|
|
|
|
Supplemental
schedule of non-cash financing activities
|
|
|
|
|
Accrual
of deferred offering costs
|
|
$
|
80,996
|
|
See
accompanying notes to the financial statements.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements
December
31, 2005
1. Nature
of Operations and Summary of Significant Accounting
Policies
Nature
of Operations
Healthcare
Acquisition Corp. (the “Company”) was incorporated in Delaware on April 25,
2005, as a blank check company whose objective is to acquire, through a
merger,
capital stock exchange, asset acquisition or other similar business combination,
a currently unidentified operating business.
Primarily
all activity through December 31, 2005 relates to the Company’s formation and
the public offering described below. The Company has selected December
31 as its
fiscal year-end. The registration statement for the Company’s initial public
offering (“Offering”) was declared effective July 28, 2005. The Company
consummated the Offering on August 3, 2005 (and 400,000 units subject to
the
underwriters’ over-allotment option on August 16, 2005) and received net
proceeds of approximately $69,450,000 (Note 2). The Company’s management has
broad discretion with respect to the specific application of the net proceeds
of
this Offering, although substantially all of the net proceeds of the Offering
are intended to be generally applied toward consummating a business combination
with an operating domestic or international company in the healthcare industry,
a “target business”.
In
evaluating a prospective target business, the Company will consider, among
other
factors, the financial condition and results of operation; growth potential;
experience and skill of management; availability of additional personnel;
capital requirements; competitive position; barriers to entry into other
industries; stage of development of the products, processes or services;
degree
of current or potential market acceptance of the products, processes or
services; proprietary features and degree of intellectual property or other
protection of the products, processes or services; regulatory environment
of the
industry; and costs associated with effecting the business combination.
These
criteria are not intended to be exhaustive. Any evaluation relating to
the
merits of a particular business combination will be based, to the extent
relevant, on the above factors, as well as other considerations deemed
relevant
by the Company in effecting a business combination consistent with its
business
objective.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
1. |
Nature
of Operations and Summary of Significant Accounting Policies
(continued)
|
Nature
of Operations (continued)
There
are
no assurances the Company will be able to successfully effect a business
combination. An amount of $67,928,000 or approximately 90.3% of the gross
proceeds of this offering (approximately $7.23 per unit) are being held
in an
interest bearing trust account at JP Morgan Chase NY Bank maintained by
Continental Stock Transfer & Trust Company (“Trust Fund”) and invested in
United States Treasury Bills or short-term securities having a maturity
of one
hundred eighty (180) days or less, until the earlier of (i) the consummation
of
the Company’s first business combination or (ii) the liquidation of the Company.
In October 2005, the Company entered into Amendment No. 1 (the “Amendment”) to
the Investment Management Trust Agreement by and among the Company, Continental
Stock Transfer and Trust Company and Maxim Group, LLC. Pursuant to the
terms of
the Amendment, the Company is permitted to invest the funds held in trust
not
only in treasury bills having a maturity of 180 days or less, but also
in any
money market fund meeting the requirements of a “cash item” as set forth in
Section 3(a)(1)(C) of the Investment Company Act of 1940, as amended, and
any
regulations, no-action letters, exemptive orders or interpretations promulgated
thereunder. The Company believes that the Amendment will allow it greater
flexibility in investing the funds held in trust from its initial public
offering, as well as reducing its tax liability, by allowing the Company
to
invest in tax-free money market funds. The placing of funds in the Trust
Fund
may not protect those funds from third party claims against the Company.
Although the Company will seek to have all vendors, prospective target
businesses or other entities it engages, execute agreements with the Company
waiving any right, title, interest or claim of any kind in or to any monies
held
in the Trust Fund, there is no guarantee that they will execute such agreements.
The Company’s officers have severally agreed that they will be personally liable
to ensure that the proceeds in the Trust Fund are not reduced by the claims
of
target businesses or vendors or other entities that are owed money by the
Company for services rendered or contracted for or products sold to the
Company.
However,
there can be no assurance that the officers will be able to satisfy those
obligations. The remaining proceeds, not held in trust, may be used to
pay for
business, legal and accounting expenses, expenses which may be incurred
related
to the investigation and selection of a target business, and the negotiation
of
an agreement to acquire a target business, and for continuing general and
administrative expenses.
The
Company’s first business combination must be with a business with a fair market
value of at least 80% of the Company’s net asset value at the time of
acquisition. The Company, after signing a definitive agreement for the
acquisition of a target business, will submit such transaction for stockholder
approval. In the event that stockholders owning 20% or more of the outstanding
stock excluding, for this purpose, those persons who were stockholders
prior to
the Offering, vote against the business combination or request their conversion
right as described below, the business combination will not be consummated.
All
of the Company’s stockholders prior to the Offering, including all of the
officers and directors of the Company (“Initial Stockholders”), have agreed to
vote their 2,250,000 founding shares of common stock in accordance with
the vote
of the majority in interest of all other stockholders of the Company (“Public
Stockholders”) with respect to any business combination. After consummation of
the Company’s first business combination, all of these voting safeguards will no
longer be applicable.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
1. |
Nature
of Operations and Summary of Significant Accounting Policies
(continued)
|
Nature
of Operations (continued)
With
respect to the first business combination which is approved and consummated,
any
Public Stockholder who voted against the business combination may demand
that
the Company redeem his or her shares. The per share redemption price will
equal
the amount in the Trust Fund as of the record date for determination of
stockholders entitled to vote on the business combination divided by the
number
of shares of common stock held by Public Stockholders at the consummation
of the
Offering. Accordingly, Public Stockholders holding 19.99% of the aggregate
number of shares owned by all Public Stockholders may seek redemption of
their
shares in the event of a business combination. Such Public Stockholders
are
entitled to receive their per share interest in the Trust Fund computed,
without
regard to the shares held by Initial Stockholders. Accordingly, a portion
of the
net proceeds from the Offering (19.99% of the amount held in the Trust
Fund) has
been classified as common stock subject to possible conversion in the
accompanying December 31, 2005 balance sheet and 19.99% of the related
interest
earned on cash held in the Trust Fund has been recorded as deferred
revenue.
The
Company’s Amended and Restated Certificate of Incorporation provides for
mandatory liquidation of the Company, without stockholder approval, in
the event
that the Company does not consummate a business combination within eighteen
(18)
months from the date of the consummation of the Offering, or twenty-four
(24)
months from the consummation of the Offering if certain extension criteria
have
been satisfied. In the event of liquidation, it is likely that the per
share
value of the residual assets remaining available for distribution (including
Trust Fund assets) will be less than the initial public offering price
per share
in the Offering (assuming no value is attributed to the Warrants contained
in
the Units to be offered in the Offering discussed in Note 2.)
Earnings
Per Share
Basic
earnings per share is computed by dividing income available to common
stockholders (the numerator) by the weighted-average number of common shares
(the denominator) for the period. The computation of diluted earnings per
share
is similar to basic earnings per share, except that the denominator is
increased
to include the number of additional common shares that would have been
outstanding if the potentially dilutive common shares had been issued.
The
denominator in the calculation is based on the following weighted-average
number
of common shares at December 31, 2005:
Basic
|
|
$
|
7,869,200
|
|
Add:
|
|
|
|
|
Shares
issuable pursuant to
|
|
|
|
|
Common
Stock Warrants
|
|
|
454,001
|
|
Diluted
|
|
$
|
8,323,201
|
|
As
stated
in Note 8, Warrants began trading separately from the Company’s stock on October
6, 2005.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
1. Nature
of Operations and Summary of Significant Accounting Policies
(continued)
Derivative
Financial Instruments
As
described in Note 4, the Company has granted a Purchase Option to a
representative of its underwriters. Based on Emerging Issues Task Force
00-19,
Accounting for Derivative Financial Instruments Indexed to, and Potentially
Settle in, a Company’s Own Stock, the sale of the Purchase Option was reported
in permanent equity and accordingly, there is no impact on the Company’s
financial position and results of operation, except for the $100 in proceeds
from sale. Subsequent changes in fair value will not be recognized as long
as
the Purchase Option continues to be classified as an equity instrument.
The
Company has determined, based on the Black-Scholes option pricing formula,
the
fair value of the Purchase Option at date of issuance, was $3.79 per share
or
approximately $852,750 total, using a risk free interest rate of 4.0%,
expected
life of five years and estimated volatility of 60.0%.
The
volatility calculation of 60.0% is based on the 365-day average volatility
of a
representative sample of eight (8) healthcare companies in the information
technology and services niches with market capitalizations between $200
million
and $910 million (“Representative Sample”). Because the Company did not have a
trading history, the Company needed to estimate the potential volatility
of its
common stock price, which depends on a number of factors which could not
be
ascertained at this time. The Company referred to the 365-day volatility
of the
Representative Sample because its management believed that the volatility
of
these representative companies was a reasonable benchmark to use in estimating
the expected volatility for the Company’s common stock post-business
combination.
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management
to make
estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts
of
expenses during the reporting period. Actual results could differ from
those
estimates.
Income
Taxes
Current
tax expense related entirely to state taxes, amounted to $48,000 for the
year
ended December 31, 2005.
At
December 31, 2005, the Company had a net operating loss carryforward for
federal
income tax purposes of approximately $274,000, which is available to offset
future federal taxable income.
Deferred
income taxes are provided for the differences between the basis of assets
and
liabilities for financial reporting and income tax purposes. A valuation
allowance is established to reduce deferred tax assets to the amount expected
to
be realized.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
1. Nature
of Operations and Summary of Significant Accounting Policies
(continued)
Income
Taxes (continued)
The
Company recorded a deferred income tax asset for the tax effect of net
operating
loss carryforwards and temporary differences related to revenue recognition
aggregating to approximately $145,000 at December 31, 2005. In recognition
of
the uncertainty regarding the ultimate amount of income tax benefits to
be
derived, the Company has recorded a full valuation allowance at December
31,
2005.
The
effective tax rate differs from the statutory rate of 34% primarily due
to
substantially all interest being tax exempt for federal tax purposes and
the
valuation allowance.
Recent
Accounting Pronouncements
The
Company does not believe that any recently issued, but not yet effective,
accounting standards, if currently adopted, would have a material effect
on the
accompanying financial statements.
2. Initial
Public Offering
On
July
28, 2005, the Company sold 9,000,000 units (“Units”) in the Offering. On August
16, 2005 an additional 400,000 Units were sold. Each Unit consists of one
share
of the Company’s common stock, $.0001 par value and one Redeemable Common Stock
Purchase Warrant (“Warrant”). In connection with the Offering, the Company paid
the underwriter a discount of 6% of the gross proceeds of the Offering
and a
non-accountable expense allowance of 1% of the gross proceeds of the
Offering.
3. Notes
Payable, Stockholders
The
Company issued unsecured promissory notes to three Initial Stockholders,
amounting to $250,000, who are also officers. These notes were non-interest
bearing and were repaid from the proceeds of this Offering.
4.
Unit
Option
In
connection with the Offering, the Company issued to the representative
of the
underwriters for $100, an option to purchase up to a total of 225,000 units,
exercisable at $10 per unit (“Purchase Option”). In lieu of payment of the
exercise price in cash, the holder of the Purchase Option has the right
(but not
the obligation) to convert any exercisable portion of the Purchase Option
into
units using a cashless exercise based on the difference between current
market
value of the units and its exercise price. The Warrants issued in conjunction
with these units are identical to those offered by the prospectus, except
that
they have an exercise price of $7.50 (125% of the exercise price of the
warrants
included in the Units sold in the offering). This option commences on the
later
of the consummation of a business combination and one (1) year from the
date of
the prospectus and expiring five (5) years from the date of the prospectus.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
4.
Unit
Option (continued)
Additionally,
the option may not be sold, transferred, assigned, pledged or hypothecated
for a
one-year period (including the foregoing 180-day period) following July
28,
2005. However, the option may be transferred to any underwriter and selected
dealer participating in the offering and their bona fide officers or partners.
The purchase option grants to holders demand and “piggy back” rights for periods
of five (5) and seven (7) years, respectively, from July 28, 2005 with
respect
to the registration under the Securities Act of the securities directly
and
indirectly issuable upon exercise of the option. The Company will bear
all fees
and expenses attendant to registering the securities, other than underwriting
commissions, which will be paid for by the holders themselves. The exercise
price and number of units issuable upon exercise of the option may be adjusted
in certain circumstances, including in the event of a stock dividend, or
our
recapitalization, reorganization, merger or consolidation. However, the
option
will not be adjusted for issuances of common stock at a price below its
exercise
price.
5.
Commitments and Contingencies
The
Company presently occupies office space in two locations, provided by two
affiliates of the Initial Stockholders. Such affiliates have agreed that,
until
the Company consummates a business combination, they will make such office
space, as well as certain office and secretarial services, available to
the
Company, as may be required by the Company from time to time. The Company
has
agreed to pay such affiliates $7,500 per month for such services commencing
on
the effective date of the Offering. Upon completion of a business combination
or
liquidation, the Company will no longer be required to pay these monthly
fees.
Subsequent to December 31, 2005, the entire monthly fee of $7,500 shall
be paid
to one affiliate of the Initial Stockholders.
The
Company has engaged a third party to act as the representative of the
underwriters, on a non-exclusive basis, as its agent for the solicitation
of the
exercise of the Warrants. To the extent not inconsistent with the guidelines
of
the NASD and the rules and regulations of the Securities and Exchange
Commission, the Company has agreed to pay the representative for bona fide
services rendered, a commission equal to 4% of the exercise price for each
Warrant exercised more than one (1) year after July 28, 2005 if the exercise
was
solicited by the underwriters. In addition to soliciting, either orally
or in
writing, the exercise of the Warrants, the representative’s services may also
include disseminating information, either orally or in writing, to Warrant
holders about the Company or the market for its securities, and assisting
in the
processing of the exercise of the Warrants. No compensation will be paid
to the
representative upon the exercise of the Warrants if:
· |
the
market price of the underlying shares of common stock is lower
than the
exercise price;
|
· |
the
holder of the Warrants has not confirmed in writing that the
underwriters
solicited the exercise;
|
· |
the
Warrants are held in a discretionary
account;
|
· |
the
Warrants are exercised in an unsolicited transaction;
or
|
· |
the
arrangement to pay the commission is not disclosed in the prospectus
provided to Warrant holders at the time of
exercise.
|
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
5.
Commitments and Contingencies (continued)
The
Initial Stockholders who are holders of 2,250,000 issued and outstanding
shares
of common stock are entitled to registration rights pursuant to an agreement
signed on the effective date of the Offering. The holders of the majority
of
these shares are entitled to request the Company, on up to two (2) occasions,
to
register these shares. The holders of the majority of these shares can
elect to
exercise these registration rights at any time after the date on which
these
shares of common stock are released from escrow. In addition, these stockholders
have certain “piggy-back” registration rights on registration statements filed
subsequent to the date on which these shares of common stock are released
from
escrow. The Company will bear the expenses incurred in connection with
the
filing of any such registration statements.
6.
Preferred Stock
The
Company is authorized to issue 1,000,000 shares of preferred stock with
such
designations, voting and other rights and preferences, as may be determined
from
time to time by the Board of Directors.
On
July
8, 2005, the Company’s Board of Directors authorized a .333333 to 1 stock
dividend. On July 22, 2005, the Company’s Board of Directors authorized a .125
to 1 stock dividend. All references in the accompanying financial statements
to
the number of shares of stock have been retroactively restated to reflect
these
transactions, assuming they occurred at the beginning of the
period.
Each
Warrant entitles the holder to purchase from the Company one share of common
stock at an exercise price of $6.00 commencing the later of the completion
of a
business combination with a target business or one (1) year from the effective
date of the Offering and expiring four (4) years from the effective date
of the
Offering. The Warrants will be redeemable by the Company at a price of
$.01 per
Warrant, upon thirty (30) days notice after the Warrants become exercisable,
only in the event that the last sales price of the common stock is at least
$11.50 per share for any twenty (20) trading days within a thirty (30)
trading-day period ending on the third day prior to date on which notice
of
redemption is given. The warrants began trading separately from the Company’s
common stock on October 6, 2005.
9. Summarized
Quarterly Data (unaudited)
Financial
information for each quarter for the period from April 25, 2005 (inception)
to
December 31, 2005 is as follows:
|
|
June
30,
2005
|
|
September
30,
2005
|
|
December
31,
2005
|
|
April
25, 2005
(inception)
to
December 31, 2005
|
|
Total
revenue
|
|
$
|
—
|
|
$
|
206,261
|
|
$
|
379,813
|
|
$
|
586,074
|
|
Income
(loss) from operations
|
|
|
(2,500
|
)
|
|
156,476
|
|
|
171,319
|
|
|
325,295
|
|
Net
income (loss)
|
|
|
(2,500
|
)
|
|
146,476
|
|
|
133,319
|
|
|
277,295
|
|
Basic
earnings per share
|
|
|
|
|
|
.02
|
|
|
.01
|
|
|
.04
|
|
Diluted
earnings per share
|
|
|
|
|
|
.02
|
|
|
.01
|
|
|
.03
|
|
PHARMATHENE,
INC.
UNAUDITED
FINANCIAL STATEMENTS
PharmAthene,
Inc.
Condensed
Consolidated Statements of Operations (Unaudited)
|
|
Three
Months Ended September 30,
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
2006
|
|
2005
|
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant
Revenue
|
|
$
|
-
|
|
$
|
178,701
|
|
$
|
178,701
|
|
$
|
867,050
|
|
Other
revenue
|
|
|
1,590
|
|
|
21,360
|
|
|
9,331
|
|
|
50,610
|
|
Total
revenues
|
|
|
1,590
|
|
|
200,061
|
|
|
188,032
|
|
|
917,661
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs
and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
1,641,826
|
|
|
1,130,954
|
|
|
4,745,628
|
|
|
4,076,147
|
|
General
and administrative
|
|
|
1,654,963
|
|
|
1,267,935
|
|
|
4,665,292
|
|
|
3,496,130
|
|
Depreciation
and amortization
|
|
|
134,813
|
|
|
199,568
|
|
|
389,975
|
|
|
455,075
|
|
Acquired
In-Process Research and Development
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
12,812,000
|
|
Total
costs and expenses
|
|
|
3,431,602
|
|
|
2,598,457
|
|
|
9,800,895
|
|
|
20,839,352
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(3,430,012
|
)
|
|
(2,398,396
|
)
|
|
(9,612,863
|
)
|
|
(19,921,691
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
Income
|
|
|
24,519
|
|
|
86,271
|
|
|
131,245
|
|
|
296,124
|
|
Interest
Expense
|
|
|
(229,483
|
)
|
|
(699
|
)
|
|
(298,157
|
)
|
|
(929
|
)
|
Total
other income
|
|
|
(204,964
|
)
|
|
85,572
|
|
|
(166,912
|
)
|
|
295,195
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(3,634,976
|
)
|
$
|
(2,312,824
|
)
|
$
|
(9,779,775
|
)
|
$
|
(19,626,496
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accretion
of redeemable convertible preferred stock to redemptive
value
|
|
|
(1,658,546
|
)
|
|
(1,559,306
|
)
|
|
(4,931,125
|
)
|
|
(4,250,410
|
)
|
Net
loss attributable to common shareholders
|
|
$
|
(5,293,522
|
)
|
$
|
(3,872,130
|
)
|
$
|
(14,710,900
|
)
|
$
|
(23,876,906
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss available to common stockholders per share of common stock
- basic
and diluted
|
|
$
|
(0.46
|
)
|
$
|
(0.36
|
)
|
$
|
(1.32
|
)
|
$
|
(2.22
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares of common stock - basic and
diluted
|
|
|
11,478,031
|
|
|
10,847,502
|
|
|
11,123,241
|
|
|
10,776,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro
forma net loss attributable to common stockholders
|
|
|
(5,293,522
|
)
|
|
|
|
|
(14,710,900
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro
forma net loss available to common stockholders per share of common
stock
- basic and diluted
|
|
$
|
(0.50
|
)
|
|
|
|
$
|
(1.39
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro
forma weighted average number of shares of common stock - basic
and
diluted
|
|
|
10,607,009
|
|
|
|
|
|
10,607,009
|
|
|
|
|
See
Notes
to Condensed Consolidated Financial Statements.
PharmAthene,
Inc.
Condensed
Consolidated Balance Sheets
|
|
September
30, 2006
|
|
December
31, 2005
|
|
|
|
(Unaudited)
|
|
|
|
Cash
and cash equivalents
|
|
$
|
6,505,932
|
|
$
|
7,938,116
|
|
Accounts
receivable, net
|
|
|
544,251
|
|
|
494,652
|
|
Prepaid
expenses
|
|
|
1,276,687
|
|
|
1,549,711
|
|
Note
receivable
|
|
|
3,000,000
|
|
|
-
|
|
Other
assets
|
|
|
92,150
|
|
|
8,657
|
|
Total
current assets
|
|
|
11,419,020
|
|
|
9,991,136
|
|
|
|
|
|
|
|
|
|
Property
and equipment, net
|
|
|
5,254,275
|
|
|
4,906,467
|
|
Patents,
net
|
|
|
1,340,869
|
|
|
1,382,631
|
|
Deferred
financing costs
|
|
|
1,357,176
|
|
|
-
|
|
Total
assets
|
|
$
|
19,371,340
|
|
$
|
16,280,234
|
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
Accounts
payable
|
|
|
1,007,790
|
|
|
783,070
|
|
Notes
payable
|
|
|
11,768,088
|
|
|
-
|
|
Accrued
expenses and other current liabilities
|
|
|
761,765
|
|
|
658,257
|
|
Total
current liabilities
|
|
|
13,537,643
|
|
|
1,441,327
|
|
|
|
|
|
|
|
|
|
Minority
Interest - Series C convertible redeemable preferred stock of PHTN
Canada,
par value $0.001 per share; unlimited shares authorized
|
|
|
2,507,557
|
|
|
2,281,360
|
|
Series
A convertible redeemable preferred stock, par value $0.001 per
share;
authorized 16,442,000 shares
|
|
|
18,736,219
|
|
|
17,564,998
|
|
Series
B convertible redeemable preferred stock, par value $0.001 per
share;
authorized 30,448,147 shares
|
|
|
31,051,618
|
|
|
28,886,718
|
|
Series
C convertible redeemable preferred stock, par value $0.001 per
share;
authorized 22,799,574 shares
|
|
|
14,259,971
|
|
|
12,891,164
|
|
Warrants
to purchase Series C convertible redeemable preferred stock, exercisable
at approx. $0.91 per share
|
|
|
874,270
|
|
|
1,323,051
|
|
Stockholders’
equity:
|
|
|
|
|
|
|
|
Common
stock, par value $0.001 per share; authorized 147,089,104 shares,
12,483,472 outstanding
|
|
|
12,483
|
|
|
10,943
|
|
Additional
paid-in capital
|
|
|
-
|
|
|
-
|
|
Accumulated
other comprehensive loss
|
|
|
389,720
|
|
|
115,160
|
|
Accumulated
deficit
|
|
|
(61,998,141
|
)
|
|
(48,234,487
|
)
|
Total
stockholders’ equity
|
|
|
(61,595,938
|
)
|
|
(48,108,384
|
)
|
|
|
|
|
|
|
|
|
Total
liabilities, convertible redeemable preferred stock and stockholders’
deficit
|
|
$
|
19,371,340
|
|
$
|
16,280,234
|
|
See
Notes
to Condensed Consolidated Financial Statements.
PharmAthene,
Inc.
Condensed
Consolidated Statements of Cash Flows (Unaudited)
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
Operating
activities |
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(9,779,775
|
)
|
$
|
(19,626,496
|
)
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
Write-off
of acquired in-process research and development
|
|
|
-
|
|
|
12,812,000
|
|
Depreciation
and amortization
|
|
|
389,975
|
|
|
455,075
|
|
Non-cash
compensation expense
|
|
|
254,215
|
|
|
2,640
|
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(49,599
|
)
|
|
(581,984
|
)
|
Prepaid
expenses and other current assets
|
|
|
189,531
|
|
|
514,663
|
|
Accounts
payable
|
|
|
224,719
|
|
|
(724,871
|
)
|
Accrued
expenses
|
|
|
103,509
|
|
|
(273,821
|
)
|
Net
cash used in operating activities
|
|
|
(8,667,425
|
)
|
|
(7,422,794
|
)
|
|
|
|
|
|
|
|
|
Investing
activities
|
|
|
|
|
|
|
|
Purchase
of property and equipment
|
|
|
(473,285
|
)
|
|
(123,827
|
)
|
Issuance
of note receivable
|
|
|
(3,000,000
|
)
|
|
-
|
|
Purchase
of Nexia assets
|
|
|
-
|
|
|
(12,277,005
|
)
|
Net
cash used in investing activities
|
|
|
(3,473,285
|
)
|
|
(12,400,832
|
)
|
|
|
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
|
|
|
Net
proceeds from exercise of warrants and employee options
|
|
|
245,790
|
|
|
8,858,766
|
|
Proceeds
from issuance of note payable
|
|
|
11,768,089
|
|
|
|
|
Deferred
financing costs
|
|
|
(1,357,176
|
)
|
|
|
|
Net
cash provided by financing activities
|
|
|
10,656,703
|
|
|
8,858,766
|
|
|
|
|
|
|
|
|
|
Effects
of exchange rates on cash
|
|
|
51,824
|
|
|
22,431
|
|
|
|
|
|
|
|
|
|
Decrease
in cash and cash equivalents
|
|
|
(1,432,184
|
)
|
|
(10,964,747
|
)
|
Cash
and cash equivalents at beginning of year
|
|
|
7,938,116
|
|
|
21,662,117
|
|
Cash
and cash equivalents at end of year
|
|
$
|
6,505,932
|
|
$
|
10,719,801
|
|
|
|
|
|
|
|
|
|
Non-cash
financing activities
|
|
|
|
|
|
|
|
Issuance
of Series C redeemable preferred stock and warrants for
assets
|
|
$
|
-
|
|
$
|
(1,212,622
|
)
|
See
Notes
to Condensed Consolidated Financial Statements.
PharmAthene,
Inc.
Notes
to
Condensed Consolidated Financial Statements (Unaudited)
1. General
The
condensed consolidated financial statements do not include footnotes and
certain
financial information normally presented annually under accounting principles
generally accepted in the United States, and, therefore, should be read in
conjunction with the Consolidated Financial Statements for the year ended
December 31, 2005. Accounting measurements at interim dates inherently involve
greater reliance on estimates than at year-end. The results of operations
for
the three and nine months ended September 30, 2006 are not necessarily
indicative of results that can be expected for the fiscal year ending December
31, 2006.
The
condensed consolidated financial statements included herein are unaudited;
however, they contain all adjustments (consisting of normal recurring accruals),
which, in the opinion of the Company, are necessary to present fairly its
consolidated financial position at September 30, 2006 and December 31, 2005,
and
its consolidated results of operations and cash flows for the three and nine
months ended September 30, 2006 and 2005, in conformity with accounting
principles generally accepted in the United States.
PharmAthene,
Inc. (the Company) was incorporated on March 13, 2001 (inception), under
the
laws of the State of Delaware. The Company is a biopharmaceutical company
focused on developing anti-infectives for biodefense applications. The Company
has generated an accumulated deficit of $61,998,141 since inception. The
Company
anticipates incurring additional losses until such time, if ever, as it can
generate significant sales of its products currently in development. Substantial
additional financing will be needed by the Company to fund its operations
and to
commercially develop its products. There is no assurance that such financing
will be available when needed.
The
Company is subject to those risks associated with any biopharmaceutical company
that has substantial expenditures for research and development. There can
be no
assurance that the Company’s research and development projects will be
successful, that products developed will obtain necessary regulatory approval,
or that any approved product will be commercially viable. In addition, the
Company operates in an environment of rapid technological change and is largely
dependent on the services of its employees and consultants.
2. Nexia
Asset Purchase
On
March
10, 2005, the Company acquired substantially all of the assets and liabilities
of Nexia Biotechnologies Inc. (Nexia) that relate to its Protexia®
(recombinant human butyrylcholinesterase) compound. The Company paid
approximately $19.1 million in cash, Series C Convertible Redeemable Preferred
Stock (the Series C Preferred Stock), and warrants. Specifically, the Company
delivered to Nexia (i) 7,465,501 shares of Series C Preferred Stock valued
at
approximately $0.91 per share; (ii) warrants to acquire 2,239,650 shares
of
Series C Preferred Stock, which are exercisable at approximately $0.91 per
share
and which expire on March 10, 2008; and (iii) warrants to acquire 1,343,790
common shares, which are exercisable at $0.01 per share, subject to reduction
if
certain business milestones are met by the Company, as specified in the warrants
and which expire in October 2014. In addition, the Company delivered to Nexia
$11,763,176 in cash. The purchased assets and liabilities are held by
PharmAthene Canada Inc., a variable interest entity consolidated by the Company,
which was established by PharmAthene in connection with the purchase to allow
for the holding of the assets and the investment of certain shareholders
as
further described in Note 8.
The
purchase price of the Nexia assets was allocated to the tangible and
identifiable intangible assets acquired and liabilities assumed based on
their
estimated fair values at the acquisition date. The results of Nexia’s operations
have been included in the financial statement since the acquisition
date.
The
following table summarizes the purchase price allocation to estimated fair
values of the assets acquired and liabilities assumed as of the acquisition
date:
Prepaid
expenses and other current assets
|
|
$
|
248,000
|
|
Property
and equipment, net
|
|
|
5,021,000
|
|
In-process
research and development
|
|
|
12,812,000
|
|
Acquired
identifiable intangibles
|
|
|
1,407,000
|
|
Accounts
payable
|
|
|
(371,000
|
)
|
Total
assets acquired
|
|
$
|
19,117,000
|
|
In
connection with the acquisition and as calculated by a third party appraiser,
the Company recorded $12.8 million of the purchase price of the Nexia Asset
Purchase as acquired in-process research and development. The fair value
was
determined utilizing a present value technique involving a discounted cash
flow
analysis. Under this approach, fair value reflects the present value of the
projected free cash flow that will be generated by the in-process research
and
development.
At
the
date of the acquisition, the development of Protexia®
was not
complete, had not reached technological feasibility and had no known alternative
uses. Consequently, there is considerable uncertainty as to the technological
feasibility of this product at the date of the acquisition. The Company does
not
foresee any alternative future benefit from the acquired in-process research
and
development. Significant technological and regulatory approval risks are
associated with the development of the product. Development of a product
will
require significant amounts of future time, effort, and substantial development
costs, which will be incurred by the Company. The efforts required to develop
the acquired in-process research and development into commercially viable
products include the development of the compound for use in intended subjects
and the reformulation of an alternate purification process for the compound,
as
well as the conducting of applicable clinical-trial testing, regulatory approval
and the development of a product suitable for commercialization. The principal
risks relating to achieving an indication under development are the outcomes
of
clinical studies of the alternatively purified compound and receiving positive
results regulatory filings and approval. Since pharmaceutical products cannot
be
marketed without regulatory approvals, the Company will not receive any benefits
unless regulatory approval is obtained. Accordingly, the portion of the purchase
price related to these products under development was allocated to acquired
in-process research and development and was expensed at the date of
acquisition.
3. Management’s
Plans as to Continuing as a Going Concern
The
Consolidated Financial Statements has been prepared on a basis which assumed
that the Company will continue as a going concern and which contemplates
the
realization of assets and the satisfaction of liabilities and commitments
in the
normal course of business. The Company has incurred cumulative net losses
and
expects to incur additional losses to perform further research and development
activities. The Company does not have commercial products and has limited
capital resources. Management’s plans with regard to these matters include
continued development of its products as well as seeking additional research
support funds and financial arrangements. Although management continues to
pursue these plans, there is no assurance that the Company will be successful
in
obtaining sufficient financing on commercial reasonable terms or that the
Company will be able to secure financing from anticipated government contracts
and grants.
Management
has developed a plan to reduce the Company’s operating expenses in the event
that sufficient funds are not available, or if the Company is not able to
obtain
the anticipated government contracts and grants. If the company is unable
to
raise adequate capital or achieve profitability, future operations will need
to
be scaled back or discontinued. Continuance of the Company’s going concern is
dependent upon, among other things, the success of the Company’s research and
development programs and the Company’s ability to obtain adequate financing. The
financial statements do not include any adjustments relating to recoverability
of the carrying amount of recorded assets and liabilities that might result
from
the outcome of these uncertainties.
4. Summary
of Significant Accounting Policies
Principles
of Consolidation
The
Consolidated Financial Statements include the accounts of the Company and
its
subsidiary, PharmAthene Canada Inc., which was formed in March of 2005. All
significant intercompany transactions and balances have been
eliminated.
The
FASB
has issued FASB Interpretation (FIN) No. 46 (revised December 2003),
Consolidation
of Variable Interest Entities,
(FIN
46R). FIN 46R expands consolidated financial statements to include certain
variable interest entities (VIEs). VIEs are to be consolidated by the company
which is considered to be the primary beneficiary of that entity, even if
the
company does not have majority control. FIN 46R is immediately effective
for
VIEs created after January 31, 2003, and is effective for the Company in
2005
for VIEs created prior to February 1, 2003. The Company’s subsidiary,
PharmAthene Canada, Inc., is a VIE and the Company is the primary beneficiary.
Therefore, the Company has consolidated PharmAthene, Canada Inc. as of its
date
of inception.
Use
of Estimates
The
preparation of financial statements in conformity with generally accepted
accounting principles in the United States requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Comprehensive
Loss and Foreign Currency Translation
The
financial statements of subsidiaries located outside of the United States
are
measured using the local currency as the functional currency. Assets and
liabilities of these subsidiaries are translated at the rates of exchange
at the
balance sheet date. The resultant translation adjustments are included in
accumulated other comprehensive income (loss), a separate component of
stockholders’ equity. Comprehensive loss for each of the nine month periods
ended September 30, 2006 and 2005 was approximately $9,207,131 and $19,468,417,
respectively. Income and expense items are translated at average monthly
rates
of exchange. Gains and losses from foreign currency transactions of these
subsidiaries are included in net earnings.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments with maturities of three
months
or less when purchased to be cash equivalents. Cash equivalents consist of
a
short-term money market account with a bank.
Accounts
Receivable
Through
its inception to date, substantially all of PharmAthene’s accounts receivable
have been associated with US Government contracts and grants or with the
receipt
of Quebec provincial or Canadian Federal credits for internally and externally
generated research and development expenditures. Amounts invoiced or recorded
as
billed under these programs but not yet collected are reported as outstanding
accounts receivable. While the Company has a policy to provide an allowance
for
any amount of accounts receivable which it determines to be uncollectible
and
the Company would write off any uncollectible account when the likelihood
of
collection that the account’s collection is determined to be remote, the Company
has not historically found it necessary to record any write-offs of accounts
receivable or to record an allowance for uncollectible accounts.
Property
and Equipment
Property
and equipment consist of land, building and leasehold improvements, laboratory,
computer, farm and office equipment and furniture and are recorded at cost.
Property and equipment are depreciated using the straight-line method over
the
estimated useful lives of the respective assets as follows:
Asset
Category
|
|
Estimated
Useful Life
(in
years)
|
|
Building
and leasehold improvements
|
|
|
4
-20
|
|
Laboratory
equipment
|
|
|
7
|
|
Furniture,
farm and office equipment
|
|
|
5
-7
|
|
Computer
equipment
|
|
|
3
|
|
Intangible
Assets
Intangible
assets consist of patents and are being amortized using the straight-line
method
over an 11 year period. The intangible assets are reviewed for impairment
when
circumstances indicate that the carrying amount of an asset may not be
recoverable. Impairment is considered to have occurred if expected future
undiscounted cash flows are insufficient to recover the carrying value of
the
asset. If impaired, the asset’s carrying value is reduced to fair
value.
Impairment
of Long-Lived Assets
In
accordance with Statement of Financial Accounting Standards (SFAS) No. 144,
Accounting
for the Impairment or Disposal of Long-Lived Assets,
long-lived assets such as property, plant, and equipment, and purchased
intangibles subject to amortization, are reviewed for impairment whenever
events
or changes in circumstances indicate that the carrying amount of an asset
may
not be recoverable. Recoverability of assets to be held and used is measured
by
a comparison of the carrying amount of an asset to estimated undiscounted
future
cash flows expected to be generated by the asset. If the carrying amount
of an
asset exceeds its estimated future cash flows, then an impairment charge
is
recognized by the amount by which the carrying amount of the asset exceeds
the
fair value of the asset. Assets to be disposed of would be separately presented
in the balance sheets and reported at the lower of the carrying amount or
fair
value, less costs to sell, and are no longer depreciated. The assets and
liabilities of a disposed group classified as held-for-sale would be presented
separately in the appropriate asset and liability sections of the balance
sheets. As of September 30, 2006 and 2005, management believes that no revision
of the remaining useful lives or write-down of long-lived assets is
required.
Revenue
Recognition
Grant
Revenue
The
Company recognizes revenue when all terms and conditions of the agreements
have
been met including persuasive evidence of an arrangement, services have been
rendered, price is fixed or determinable, and collectibility is reasonably
assured. For reimbursable cost research grants, the Company recognizes revenue
as costs are incurred and appropriate regulatory approvals have been obtained
or
approval criteria are met for invoicing the related government
agency.
All
of
the grant revenue the Company recognized was received under a cost reimbursement
grant from the U.S. government to fund the development of pharmaceutical
products for biodefense applications. Receipts pursuant to such cost
reimbursement grants are contingent upon the successful completion of related
tasks, the granting agency may modify the contract at any time, and reimbursed
costs are subject to review and adjustment by the granting agency.
In
September 2006, the Company was awarded a multi-year cost reimbursement contract
valued at up to $213 million from the Department of Defense Army Space and
Missile Command for advanced development of the Company’s broad spectrum
chemical nerve agent prophylaxis, Protexia®. The Department of Defense has
allocated $34.7 million for the initial stage of development, including
manufacturing process development, preclinical and toxicity testing activities,
of this contract. No revenue was recognized on this contract for the period
ended September 30, 2006.
Research
and Development and In-Process Research and Development
Research
and development costs are charged to expense as incurred.
Basic
and Diluted Net Loss Per Share
Basic
net
loss per share of common stock excludes dilution for potential common stock
issuances and is computed by dividing net loss by the weighted-average number
of
shares outstanding for the period. Diluted net loss per share reflects the
potential dilution that could occur if securities were exercised into common
stock. However, for all periods presented, diluted net loss per share is
the
same as basic net loss attributable to common shareholders per share as the
inclusion of weighted average shares of common stock issuable upon the
conversion of mandatorily redeemable convertible preferred stock and exercise
of
stock options and warrants would be anti-dilutive. Securities outstanding
in the
amount of 118,098,900 and 109,098,800 shares for the three and nine month
periods ended September 30, 2006 and 2005, respectively, were excluded from
the
calculation of diluted net loss per share since their inclusion would be
anti-dilutive.
The
following table provides a reconciliation of the numerators and denominators
used in computing basic and diluted net loss per share:
|
|
Three
months ended
September
30,
|
|
Nine
months ended
September
30,
|
|
|
|
2006
|
|
2005
|
|
2006
|
|
2005
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(3,634,976
|
)
|
$
|
(2,312,824
|
)
|
$
|
(9,779,775
|
)
|
$
|
(19,626,496
|
)
|
Dividends
on and accretion of convertible
preferred stock
|
|
|
(1,658,546 |
) |
|
(1,559,306 |
) |
|
(4,931,125 |
) |
|
(4,250,410 |
) |
Net
loss available to common stockholders
|
|
$
|
(5,293,522
|
)
|
$
|
(3,872,130
|
)
|
$
|
(14,710,900
|
)
|
$
|
(23,876,906
|
)
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average
shares of common stock outstanding - basic and diluted
|
|
|
11,478,031 |
|
|
10,847,502 |
|
|
11,123,241 |
|
|
10,776,228 |
|
Net
loss available to common stockholders per share of common stock
- basic
and diluted
|
|
$
|
(0.46
|
)
|
$
|
(0.36
|
)
|
$
|
(1.32
|
)
|
$
|
(2.22
|
)
|
Income
Taxes
The
Company accounts for income taxes in accordance with Statement of Financial
Accounting Standards (SFAS) No. 109, Accounting
for Income Taxes
(SFAS
109), which requires that deferred tax assets and liabilities be recognized
using enacted tax rates for the effect of temporary differences between the
book
and tax bases of recorded assets and liabilities. SFAS 109 also requires
that
deferred tax assets be reduced by a valuation allowance if it is more likely
than not that some portion of the deferred tax asset will not be realized.
In
evaluating the need for a valuation allowance, the Company takes into account
various factors, including the expected level of future taxable income and
available tax planning strategies. If actual results differ from the assumptions
made in the evaluation of the Company’s valuation allowance, the Company records
a change in valuation allowance through income tax expense in the period
such
determination is made.
Fair
Value of Financial Instruments and Concentration of Credit
Risk
The
carrying amounts of the Company’s financial instruments, which include cash
equivalents, accounts receivable, accounts payable, and accrued expenses,
approximate their fair values because of their short maturities at September
30,
2006 and 2005.
Share-Based
Compensation
On
January 1, 2006, the Company adopted SFAS No. 123 (revised 2004), Share-Based
Payment,
(“SFAS
123(R)”) which requires the measurement and recognition of compensation expense
for all share-based payment awards made to employees and directors including
employee stock options based on estimated fair values. SFAS 123(R) supersedes
the Company’s previous accounting under Accounting Principles Board Opinion No.
25, Accounting
for Stock Issued to Employees,
(“APB
25”) for periods beginning on January 1, 2006.
The
Company adopted SFAS 123(R) using the modified prospective method, which
requires the application of the accounting standard as of January 1, 2006,
the
first day of the Company’s fiscal year 2006. The Company’s Consolidated
Financial Statements as of and for the three and six months ended September
30,
2006 reflect the impact of SFAS 123(R). In accordance with the modified
prospective method, the Company’s Consolidated Financial Statements for prior
periods have not been restated to reflect, and do not include, the impact
of
SFAS 123(R). Share-based compensation related to stock options expense
recognized under SFAS 123(R) for the three and nine months ended September
30,
2006 was $76,295 and $254,215, respectively. No share-based compensation
expense
related to employee stock options was recognized during the three and six
month
periods ended September 30, 2005.
SFAS
123(R) requires companies to estimate the fair value of share-based payment
awards on the grant-date using an option-pricing model. The value of the
portion
of the award that is ultimately expected to vest is recognized as expense
over
the requisite service periods in the Company’s Statements of Operations. Prior
to the adoption of SFAS 123(R), the Company accounted for share-based awards
to
employees and directors using the intrinsic value method in accordance with
APB
25 as allowed under Statement of Financial Accounting Standards No. 123,
Accounting
for Stock-Based Compensation
(“SFAS
123”). Under the intrinsic value method, no share-based compensation expense
related to stock options had been recognized in the Company’s Statements of
Operations when the exercise price of the Company’s stock options granted to
employees and directors equaled the fair market value of the underlying stock
at
the grant-date.
Share-based
compensation expense recognized during the current period is based on the
value
of the portion of share-based payment awards that is ultimately expected
to
vest. SFAS 123(R) requires forfeitures to be estimated at the time of grant
in
order to estimate the amount of share-based awards that will ultimately vest.
The forfeiture rate is based on historical rates. Share-based compensation
expense recognized in the Company’s Statements of Operations for the first
quarter of 2006 includes (i) compensation expense for share-based payment
awards
granted prior to, but not yet vested as of December 31, 2005, based on the
grant-date fair value estimated in accordance with the pro forma provisions
of
SFAS 123 and (ii) compensation expense for the share-based payment awards
granted subsequent to December 31, 2005, based on the grant-date fair value
estimated in accordance with the provisions of SFAS 123(R). The Company utilizes
the Black-Scholes option pricing model for the valuation of share-based awards.
Share-based
compensation expense reduced the Company’s results of operations for the three
and nine months ended September 30, 2006 by $76,295, or $0.01 per share,
and
$254,215, or $0.02 per share, and had no impact on the Company’s cash flow.
The
fair
value for the 2006 awards was estimated at the date of grant using the
Black-Scholes option-pricing model assuming a weighted-average volatility
of
approximately 72%, a risk-free interest rate of 4.8%, a dividend yield of
0%,
and a weighted-average expected life of the option of 9.7 years.
The
following table illustrates the effect on net loss and net loss per share
as if
the Company had applied the fair value recognition provisions of SFAS No.
123,
as amended by SFAS No. 148, Accounting
for Stock-Based Compensation - Transition and Disclosures.
|
|
Three
months
ended
September 30,
|
|
Nine
months
ended
September 30,
|
|
|
|
2005
|
|
2005
|
|
Net
loss available to common shareholders, as reported
|
|
$
|
(3,872,130
|
)
|
$
|
(23,876,906
|
)
|
Deduct:
Total stock-based employee compensation expense determined under
the fair
value-based method for all awards
|
|
|
(48,109
|
)
|
|
(164,818
|
)
|
Pro
forma net loss available to common shareholders
|
|
$
|
(3,920,239
|
)
|
$
|
(24,041,724
|
)
|
Basic
and diluted net loss per share:
|
|
|
|
|
|
|
|
As
reported
|
|
$
|
(0.36
|
)
|
$
|
(2.22
|
)
|
Pro
forma
|
|
$
|
(0.36
|
)
|
$
|
(2.23
|
)
|
The
fair
value for the 2005 awards was estimated at the date of grant using the
Black-Scholes option-pricing model assuming a weighted-average volatility
of
approximately 60%, a risk-free interest rate of 3.9%, a dividend yield of
0%,
and a weighted-average expected life of the option of 8.7 years.
5. Property
and Equipment
Property
and equipment, adjusted based on current foreign currency rates, consisted
of
the following:
|
|
September
30,
2006
|
|
December
31,
2005
|
|
Land
|
|
$
|
493,628
|
|
$
|
471,860
|
|
Building
and leasehold improvements
|
|
|
4,343,198 |
|
|
4,014,717 |
|
Furniture,
farm and office equipment
|
|
|
292,857 |
|
|
281,907 |
|
Laboratory
equipment
|
|
|
581,468 |
|
|
325,398 |
|
Computer
equipment
|
|
|
194,276 |
|
|
151,844 |
|
|
|
|
5,905,427 |
|
|
5,245,726 |
|
Less
accumulated depreciation
|
|
|
(651,152 |
) |
|
(339,259 |
) |
Property
and equipment, net
|
|
$
|
5,254,275
|
|
$
|
4,906,467
|
|
6. Patents
In
conjunction with the Nexia Asset Purchase described in Note 2, the Company
recorded intangible assets related to patents of $1,407,000 with a useful
life
of 11 years. The gross carrying value and accumulated amortization, adjusted
based on current foreign currency rates, was:
|
|
September
30,
2006
|
|
December
31,
2005
|
|
Intangible
assets
|
|
$
|
1,552,347
|
|
$
|
1,483,892
|
|
Less
accumulated amortization
|
|
|
(211,478 |
) |
|
(101,261 |
) |
Intangible
assets, net
|
|
$
|
1,340,869
|
|
$
|
1,382,631
|
|
7. Convertible
Redeemable Preferred Stock
Series
A Convertible Redeemable Preferred Stock
The
Series A Convertible Redeemable Preferred Stock (the ‘‘Series A Preferred
Stock”) bears a cumulative dividend rate of 8% per annum. Accrued and unpaid
dividends for Series A Preferred Stock at September 30, 2006 and December
31,
2005 totaled $3,944,276 and $2,921,923, respectively.
Each
share of the Series A Preferred Stock is convertible into shares of common
stock
at the then-applicable conversion rate, as defined, at any time and at the
option of the holder. The shares of Series A Preferred Stock are currently
convertible into 16,442,000 common shares. The conversion rate is subject
to
adjustment for certain defined equity transactions. At September 30, 2006
and
December 31, 2005, the Company has reserved 16,442,000 shares of common stock
for the potential conversion. The Series A Preferred Stock will automatically
convert into common stock at the then-applicable conversion rate in the event
of
an initial public offering of the Company’s common stock resulting in aggregate
proceeds to the Company of $50 million and a price per share of at least
$2.74.
The
Series A Preferred Stock has a liquidation preference in an amount equal
to the
redefined original purchase price of $0.91 per share plus accumulated but
unpaid
dividends, whether or not declared, in the event of a liquidation, dissolution,
winding-up, sale, or merger. This liquidation preference is junior to the
Series
B Preferred Stock and the Series C Preferred Stock, and senior to the common
stock.
The
Company recorded the Series A Preferred Stock at its fair value on the date
of
issuance of approximately $15,000,000 less issuance costs of $105,502. The
issuance costs are accreted to the carrying value of the preferred stock
up to
the earliest redemption period using the effective interest method. The Company
had classified the Series A Preferred Stock outside of permanent equity as
a
result of certain redemption features. Because the Series A Preferred Stock
contains contingently adjustable conversion ratios, the Company evaluated
the
Series A Preferred Stock for potential beneficial conversion features under
EITF
98-5, Accounting
for Convertible Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratios, and
EITF
00-27, Application
of Issue No. 98-5 to Certain Convertible Instruments. The
contingently adjustable conversion ratio changed with the issuance of Series
B
Preferred Stock. Based on the fact that the adjusted implied conversion price
of
the Series A Preferred Stock exceeded the fair value of the common stock
into
which the Series A Preferred Stock converts, no beneficial conversion feature
was deemed to exist. The implied conversion price was calculated by dividing
the
fair value of the Series A Preferred Stock, net of the fair value allocated
to
the warrants issued to the holders of Series A in conjunction with the Series
B
Preferred Stock offering, by the adjusted number of common shares into which
the
Series A Preferred Stock converts.
In
conjunction with the Series B financing, the Series A Preferred stockholders
were granted contingent 5,400,000 warrants to purchase common stock for $0.01.
The Company deemed 1,620,000 warrants to be probable of issuance. Accordingly,
1,620,000 warrants were valued using the Black-Scholes model and were recorded
as a $201,746 discount to the Series A Preferred Stock. This discount is
being
accreted through the period up to the first redemption date using the effective
interest method. The fair value of the warrants were estimated at the date
of
grant using the Black-Scholes model assuming a weighted-average volatility
of
approximately 60%, a risk free interest rate of 4.3%, a dividend yield of
0% and
a weighted-average expected life of the warrant of 8.8 years.
Commencing
October 7, 2009, the holder of the Series A Preferred Stock may require the
Company to redeem the Series A Preferred Stock then outstanding for an amount
equal to the original purchase price plus any unpaid dividends, whether or
not
declared. The right of redemption is junior to the Series B Preferred Stock
and
Series C Preferred Stock redemption rights.
The
holder of the Series A Preferred Stock is entitled to the number of votes
equal
to the number of common shares into which its shares are
convertible.
Series
B Convertible Redeemable Preferred Stock
The
Series B Convertible Redeemable Preferred Stock (‘‘Series B Preferred Stock”)
bears a cumulative dividend rate of 8% per annum. Accrued and unpaid dividends
for Series B Preferred Stock at September 30, 2006 and December 31, 2005
total
$4,616,009 and $2,787,101, respectively.
Each
share of the Series B Preferred Stock is convertible into shares of common
stock
at the then-applicable conversion rate, as defined, at any time and at the
option of the holder. The initial conversion rate is one common share for
each
preferred share, which is subject to adjustment for certain defined equity
transactions. At September 30, 2006 and December 31, 2005, the Company has
reserved 65,768,001 shares of common stock for the potential conversion.
The
Series B Preferred Stock will automatically convert into common stock at
the
then-applicable conversion rate in the event of an initial public offering
of
the Company’s common stock resulting in aggregate proceeds to the Company of $50
million and a price per share of at least $2.74.
The
Series B Preferred Stock has a liquidation preference in an amount equal
to the
original purchase price per share plus accumulated but unpaid dividends,
whether
or not declared, in the event of a liquidation, dissolution, winding-up,
sale,
or merger. This liquidation preference is senior to the Series A Preferred
Stock
and the common stock and equal to the liquidation preference of the Series
C
Preferred Stock.
The
Company recorded the Series B Preferred Stock at its fair value on the date
of
issuance of approximately $27,777,778, less the fair value assigned to warrants
of $3,332,589, less issuance costs of $207,288. The issuance costs are accreted
to the carrying value of the preferred stock up to the earliest redemption
period using the effective interest method. The Company had classified the
Series B Preferred Stock outside of permanent equity as a result of certain
redemption features. Because detachable warrants were granted with the financing
and the Series B Preferred Stock contains contingently adjustable conversion
ratios, the Company evaluated the Series B Preferred Stock for potential
beneficial conversion features under EITF 98-5, Accounting
for Convertible Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratios, and
EITF
00-27, Application
of Issue No. 98-5 to Certain Convertible Instruments. Based
on
the fact that the adjusted implied conversion price of the Series B Preferred
Stock exceeded the fair value of the common stock into which the Series B
Preferred Stock converts, no beneficial conversion feature was deemed to
exist.
The implied conversion price was calculated by dividing the fair value of
the
Series B Preferred Stock, net of the fair value of the warrants, by the number
of common shares into which the Series B Preferred Stock converts.
In
conjunction with the Series B financing, the Series B Preferred stockholders
were granted 15,400,000 contingent warrants to purchase common stock for
$0.01.
The Company deemed 10,780,000 warrants to be probable of issuance. Accordingly,
10,780,000 warrants were valued using the Black-Scholes model and were recorded
as a $2,034,335 discount to the Series B Preferred Stock. This discount is
being
accreted through the period up to the first redemption date using the effective
interest method. The fair value of the warrants were estimated at the date
of
grant using the Black-Scholes model assuming a weighted-average volatility
of
approximately 60%, a risk free interest rate of 4.3%, a dividend yield of
0% and
a weighted-average expected life of the warrant of 8.8 years.
Commencing
October 7, 2009, the holders of the Series B Preferred Stock may require
the
Company to redeem the Series B Preferred Stock then outstanding for an amount
equal to the original purchase price plus any unpaid dividends, whether or
not
declared, and in preference to the Series A Preferred Stock liquidation
rights.
The
holders of the Series B Preferred Stock are entitled to the number of votes
equal to the number of common shares into which its shares are
convertible.
Series
C Convertible Redeemable Preferred Stock
Contemporaneously
with the consummation of the Nexia asset acquisition transaction (as described
in Note 2), the Company sold 7,480,978 shares of Series C Preferred Stock
to
investors at a price of approximately $0.91 per share for net proceeds of
$6,824,896. Included in these proceeds were two Canadian investors, who
previously invested in Nexia, who purchased an aggregate of 3,370,479 shares
of
Series C Preferred Stock for net proceeds of $3,074,880. Those proceeds were
used to partially fund the acquisition of the Nexia assets. In addition,
the
Company issued to such investors (i) warrants to acquire 2,244,296 shares
of
Series C Preferred Stock, which are exercisable at approximately $0.91 per
share
and which expire on March 10, 2008, and (ii) warrants to acquire 1,346,630
common shares, which are exercisable at $0.01 per share, subject to reduction
if
certain business milestones are met by the Company, as specified in the warrants
and which expire in October 2014.
The
Series C Preferred Stock bears a cumulative dividend rate of 8% per annum.
Accrued and unpaid dividends for Series C Preferred Stock at September 30,
2006
and December 31, 2005 total $1,753,464 and $884,635, respectively.
Each
share of the Series C Preferred Stock is convertible into shares of common
stock
at the then-applicable conversion rate, as defined, at any time and at the
option of the holder. The initial conversion rate is one common share for
each
preferred share, which is subject to adjustment for certain defined equity
transactions. At September 30, 2006 and December 31, 2005, the Company has
reserved 22,799,574 shares of common stock for the potential conversion.
The
Series C Preferred Stock will automatically convert into common stock at
the
then-applicable conversion rate in the event of an initial public offering
of
the Company’s common stock resulting in aggregate proceeds to the Company of $50
million and a price per share of at least $2.74.
The
Series C Preferred Stock has a liquidation preference in an amount equal
to the
original purchase price per share plus accumulated but unpaid dividends,
whether
or not declared, in the event of a liquidation, dissolution, winding-up,
sale,
or merger. This liquidation preference is senior to the Series A Preferred
Stock
and the common stock and equal to the liquidation preference of the Series
B
Preferred Stock.
The
Company recorded the Series C Preferred Stock at its fair value on the date
of
issuance of approximately $13,635,534 less the fair value assigned to warrants
of $1,816,799 and issuance costs of $330,495. The discount on the Series
C
Preferred Stock from the value assigned to the warrants and issuance costs
is
accreted to the carrying value of the preferred stock up to the earliest
redemption period using the effective interest method. The Company had
classified the Series C Preferred Stock outside of permanent equity as a
result
of certain redemption features. Because detachable warrants were granted
with
the financing and the Series C Preferred Stock contains contingently adjustable
conversion ratios, the Company evaluated the Series C Preferred Stock for
potential beneficial conversion features under EITF 98-5, Accounting
for Convertible Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratios,
and
EITF 00-27, Application
of Issue No. 98-5 to Certain Convertible Instruments.
Based
on the fact that the adjusted implied conversion price of the Series C Preferred
Stock exceeded the fair value of the common stock into which the Series C
Preferred Stock converts, no beneficial conversion feature was deemed to
exist.
The implied conversion price was calculated by dividing the fair value of
the
Series C Preferred Stock, net of the fair value of the warrants, by the number
of common shares into which the Series C Preferred Stock converts.
In
conjunction with the Series C financing, the Series C Preferred stockholders
were granted 4,483,946 warrants to purchase preferred stock for $0.91. These
warrants were valued using the Black-Scholes model and were recorded as a
$1,531,253 discount to the Series C Preferred Stock. This discount is being
accreted through the period up to the first redemption date using the effective
interest method. The fair value of the warrants were estimated at the date
of
grant using the Black-Scholes model assuming a weighted-average volatility
of
approximately 60%, a risk free interest rate of 3.9%, a dividend yield of
0% and
a weighted-average expected life of the warrant of 3.0 years.
In
conjunction with the Series C financing, the Series C Preferred stockholders
were granted 2,690,420 contingent warrants to purchase common stock for $0.01.
The Company deemed 1,614,225 warrants to be probable of issuance. Accordingly,
1,614,225 warrants were valued using the Black-Scholes model and were recorded
as a $285,546 discount to the Series C Preferred Stock. This discount is
being
accreted through the period up to the first redemption date using the effective
interest method. The fair value of the warrants were estimated at the date
of
grant using the Black-Scholes model assuming a weighted-average volatility
of
approximately 60%, a risk free interest rate of 4.5%, a dividend yield of
0% and
a weighted-average expected life of the warrant of 9.6 years.
Commencing
October 7, 2009, the holders of the Series C Preferred Stock may require
the
Company to redeem the Series C Preferred Stock then outstanding for an amount
equal to the original purchase price plus any unpaid dividends, whether or
not
declared, and in preference to the Series A Preferred Stock liquidation
rights.
The
holders of the Series C Preferred Stock are entitled to the number of votes
equal to the number of common shares into which its shares are
convertible.
8.
Minority
Interest - Series C Convertible Redeemable Preferred Stock of PharmAthene
Canada, Inc.
Through
its ownership of 100% of the common stock of PharmAthene Canada, Inc., the
Company controls all of the voting stock of PharmAthene Canada, Inc., and
considers itself to be the majority interest primary beneficiary of PharmAthene
Canada, Inc., a variable interest entity. In March 2005, a Canadian investor
purchased 2,591,654 shares of Series C Convertible Preferred Stock of
PharmAthene Canada, Inc. for net proceeds of $2,364,366. The shares of Series
C
Convertible Preferred Stock of PharmAthene Canada, Inc. are convertible at
the
discretion of the investors into an equal number of shares of Series C Preferred
Stock of the Company. In addition, the Company issued to such investors (i)
warrants to acquire 777,496 Series C Preferred Stock of PharmAthene Canada,
Inc.
(also convertible into Series C Preferred Stock of the Company) exercisable
at
approximately $0.91 per share, which expire on March 10, 2008, and (ii) warrants
to acquire 466,498 common shares of PharmAthene Canada, Inc. exercisable
at
$0.01 per share, convertible into shares of common stock of the Company on
a
1-for-1 basis, subject to reduction if certain business milestones are met
by
the Company, as specified in the warrants and which expire in October
2014.
In
conjunction with the Series C financing, the Series C Preferred Stock of
PharmAthene Canada, Inc. stockholders were granted 777,496 warrants to purchase
preferred stock for $0.91. These warrants were valued using the Black-Scholes
model and were recorded as a $265,513 discount to the Series C Preferred
Stock
of PharmAthene Canada, Inc. This discount is being accreted through the period
up to the first redemption date using the effective interest method. The
fair
value of the warrants were estimated at the date of grant using the
Black-Scholes model assuming a weighted-average volatility of approximately
60%,
a risk free interest rate of 3.9%, a dividend yield of 0% and a weighted-average
expected life of the warrant of 3.0 years.
In
conjunction with the Series C financing, the Series C Preferred Stock of
PharmAthene Canada, Inc. stockholders were granted 466,498 contingent warrants
to purchase common stock for $0.01. The Company deemed 279,894 warrants to
be
probable of issuance. Accordingly, 279,894 warrants were valued using the
Black-Scholes model and were recorded as a $49,512 discount to the Series
C
Preferred Stock of PharmAthene Canada, Inc. This discount is being accreted
through the period up to the first redemption date using the effective interest
method. The fair value of the warrants were estimated at the date of grant
using
the Black-Scholes model assuming a weighted-average volatility of approximately
60%, a risk free interest rate of 4.5%, a dividend yield of 0% and a
weighted-average expected life of the warrant of 9.6 years.
The
Series C Convertible Preferred Stock of PharmAthene Canada, Inc. bears a
cumulative dividend rate of 8% per annum. Accrued and unpaid dividend for
the
Series C Convertible Preferred Stock of PharmAthene Canada, Inc. at September
30, 2006 and December 31, 2005 total $304,043 and $153,392,
respectively.
The
holders of Series C Convertible Preferred Stock of PharmAthene Canada, Inc.
have
no voting rights.
9. Stockholders’
Deficit
Common
Stock
In
conjunction with the Series A Preferred Stock closing, the common stockholders
agreed to certain limitations on their rights to sell their stock. Further,
the
common stockholders agreed that 5,370,000 shares of common stock would be
subject to a right of repurchase by the Company and the Series A Preferred
Stock
investor in the event of a termination of the relationship between the Company
and the Series A Preferred Stock investor. The repurchase price will be either
cost or fair market value, depending on the termination event. The number
of
shares subject to the repurchase right decreased by 41.67% on December 11,
2004,
and further decreases by 8.33% quarterly thereafter until September 11, 2006.
As
of September 30, 2006, no shares remained subject to the right of repurchase.
2002
Long-Term Incentive Plan
The
Company adopted the 2002 Long-Term Incentive Plan (the Plan) to provide an
incentive to eligible employees, consultants, and officers. The Plan provides
for the granting of stock options, restricted common stock, and stock
appreciation rights. As of September 30, 2006, the Company had reserved
10,919,372 shares of common stock for distribution under the Plan, of which
1,627,351 remain available for future grants. Stock options granted under
the
Plan may be either incentive stock options, as defined by the Internal Revenue
Code, or non-qualified stock options. The Board of Directors determines who
will
receive options, the vesting period which is generally four years, and the
exercise price. Options may have a maximum term of no more than 10
years.
The
following table summarizes the activity of the Company’s stock option plan for
the nine months ended September 30, 2006:
|
|
Shares
|
|
Weighted-
Average
Exercise
Price
|
|
Outstanding,
December 31, 2005
|
|
|
7,986,003 |
|
$
|
0.19
|
|
Granted
|
|
|
1,181,176 |
|
|
0.21 |
|
Exercised
|
|
|
(1,340,566 |
) |
|
0.18 |
|
Forfeited
|
|
|
(92,064 |
) |
|
0.21 |
|
Outstanding,
September 30, 2006
|
|
|
7,734,549 |
|
$
|
0.20
|
|
Exercisable,
September 30, 2006
|
|
|
3,345,076 |
|
$
|
0.19
|
|
Exercise
prices for options granted during 2006 were $0.21 per share. The
weighted-average remaining contractual life of those options is approximately
9.4 years. As of the date of grant, the weighted-average fair value of the
options granted in 2006 was $0.17. The weighted-average expected life of
options
outstanding at September 30, 2006 is approximately 8.2 years.
In
2004
and March 2005, the Company granted options to non-employees to purchase
up to
125,000 and 18,000 shares, respectively, of the Company’s common stock at
exercise prices of $0.1634 and $0.21 per share, respectively. In August 2005,
an
additional 20,000 options were granted at an exercise price of $0.21. The
options vest over four years with stock-based compensation expense recorded
for
the three months ended September 30, 2006 and 2005 were $1,162 and $1,098,
respectively. For the nine months ended September 30, 2006 and 2005, stock
compensation related to the non-employee option of $3,485 and $2,914,
respectively, were recorded.
Warrants
In
conjunction with the Series B Preferred Stock issuance in October 2004, the
Company issued warrants to purchase 15,400,000 shares of common stock at
an
exercise price of $0.01 per share, subject to reduction if certain business
milestones are met by the Company, as specified in the warrants and expiring
in
October 2014. As of December 31, 2004, milestones related to 1,540,000 shares
of
common stock underlying of the warrants to purchase common stock were attained,
with the outstanding total of warrants reduced to 13,860,000. Following the
Nexia asset purchase in March 2005 (as described in Note 2), an additional
milestone related to 6,160,001 shares of common stock underlying of the warrants
was achieved, and the total warrants outstanding were further reduced to
7,699,999.
In
conjunction with the Series C Preferred Stock issuance in March 2005 and
as
further described in notes 2, 7 and 8, the Company issued warrants to purchase
3,156,918 shares of common stock at an exercise price of $0.01 per share.
The
Company also issued warrants to purchase 5,261,442 shares of preferred stock
at
an exercise price of $0.91 per share.
In
January 2006, the Company licensed certain patent rights from a research
company. In connection with this agreement, the Company issued warrants to
purchase 200,000 shares of common stock at an exercise price of $0.01 per
share
in connection with a licensing agreement entered into in January 2006.
Subsequent to June 30, 2006, the research company elected to exercise their
warrants to purchase all 200,000 shares of common stock.
The
following table summarizes the activity of the Company’s warrants outstanding
for the nine months ended September 30, 2006:
|
|
Warrants
for Shares of Common Stock
|
|
Weighted-
Average
Exercise
Price
|
|
Warrants
for Shares of Preferred Stock
|
|
Weighted-Average
Exercise
Price
|
|
Outstanding,
December 31, 2005
|
|
|
11,120,213 |
|
$
|
0.01
|
|
|
5,261,442
|
|
$
|
0.91
|
|
Granted
|
|
|
200,000 |
|
|
0.01 |
|
|
-
|
|
|
- |
|
Exercised
|
|
|
(200,000 |
) |
|
|
|
|
-
|
|
|
- |
|
Forfeited
|
|
|
- |
|
|
|
|
|
-
|
|
|
- |
|
Outstanding,
September 30, 2006
|
|
|
11,120,213 |
|
$
|
0.01
|
|
|
5,261,442
|
|
$
|
0.91
|
|
10. Commitments
and Contingencies
Leases
The
Company leases offices in the United States under a month-to-month operating
lease agreement. In September 2006, the Company entered into a 10 year office
lease, which is anticipated to commence on April 1, 2007. Additionally,
following the Nexia asset purchase in March 2005, the Company entered into
a two
year renewable lease agreement for office space in Canada. This lease is
renewable for an additional two years and provides for expansion into additional
facility space if available. Annual minimum payments are as
follows:
2006
|
|
$
|
49,900
|
|
2007
|
|
|
347,600
|
|
2008
|
|
|
313,600
|
|
2009
|
|
|
323,000
|
|
2010
|
|
|
332,700
|
|
2011
and thereafter
|
|
|
2,316,500
|
|
|
|
$
|
3,683,300
|
|
Total
rent expense under operating lease agreements approximated $98,600 and $163,300
for the three months ended September 30, 2006 and 2005, respectively. For
the
nine month periods ended September 30, 2006 and 2005, total rent expense
under
operating lease agreements was approximately $250,000 and $380,600,
respectively.
License
Agreements
In
June
2002, the Company licensed certain patent rights from a university. The license
agreement required a $125,000 up-front payment and a $125,000 payment upon
closing of the Series A Preferred Stock. Amounts paid to the university upon
the
closing of the Series A Preferred Stock are included in research and development
expense in the accompanying statements of operations. Upon commercialization,
the license agreement requires royalty payments equal to a specified percentage
of future sales of products subject to the license through the expiration
of the
licensed patents, as well as a percentage of any non royalty sublicense
income.
In
November 2004, the Company licensed certain patent rights from two universities.
The license agreements required a $50,000 up-front payment to be paid over
two
years. Additionally, payments within the agreement included a sublicense
fee of
12.5% until Investigational New Drug Application (IND) filing, a minimum
royalty
of $10,000 a year beginning in 2009, and a milestone payment of $100,000
upon
Biologics License Application (BLA) approval. Upon commercialization, the
license agreements require royalty payments equal to a specified percentage
of
future sales of products subject to the license through the expiration of
the
licensed patents.
In
2005,
the Company determined that the program for which these license agreements
were
entered into was not a viable product. Accordingly, the Company terminated
these
agreements and agreed to pay $7,756 and $37,364 to terminate the June 2002
and
November 2004 license agreements, respectively. Of these amounts, $37,364
was
accrued for at December 31, 2005, and no additional future payments are
required.
In
March
2005, the Company licensed certain patent rights from a company. The license
agreement required a $75,000 up front payment. Additionally, the license
agreement requires royalties payments equal to specific percentages of future
sales of products subject to the license through the expiration of the licensed
patent. In the event that the minimum annual royalty amount of $75,000 has
not
been met by either the earliest of obtaining a biologics license application
or
three years upon execution of the license agreement, the Company will pay
the
difference between the minimum royalty payment and those royalties actually
paid.
In
January 2006, the Company licensed certain patent rights from a research
company. The license agreement required a $50,000 up-front payment.
Additionally, payments within the agreement included a sublicense fee of
20% and
milestone payments of $25,000 upon the granting of a U.S. patent, $200,000
upon
the initiation of certain studies or trials, and $250,000 upon BLA approval.
Upon commercialization, the license agreement requires royalty payments equal
to
a specified percentage of future sales of products for both government
procurement and commercial market sales subject to the license through the
expiration of the licensed patents.
In
August
2006, the Company entered into a research and licensing agreement allowing
for
the licensing of certain patent rights. The agreement includes research expense
reimbursement payments and certain development milestone payments. Upon
commercialization, the license agreement requires royalty payments equal
to a
specified percentage of future sales of products for both government procurement
and commercial market sales subject to the license through the expiration
of the
licensed patents.
11. Related
Party Transactions
The
Company leases its office space from an entity that is affiliated with the
organization to which the Company issued warrants for 263,296 shares of common
stock in August 2003 (see Note 9). The Company paid $30,500 and $23,200 in
rent
expense related to this operating lease for the three months ended September
30,
2006 and 2005, respectively. For the nine months ended September 30, 2006
and
2005, the Company paid rent expense related to this operating lease of $86,200
and $62,100, respectively.
12. Medarex
Collaboration
In
November 2004, the Company and Medarex, Inc. entered into a collaboration
agreement under which the companies plan to develop and commercialize MDX-1303,
a fully human monoclonal antibody targeting the Bacillus
anthracis
protective antigen. MDX-1303 was developed by Medarex using its UltiMAb Human
Antibody Development System®,
and
this antibody is currently in preclinical development by Medarex for use
against
human anthrax infection.
In
December 2004, Medarex received a $2.0 million deposit from PharmAthene against
potential future development activities for MDX-1303, against which Medarex
must
submit reports the use of costs as they are incurred in order to take draw
downs
against the deposit. If the project is terminated or if development activities
for MDX-1303 by Medarex are completed prior to exhaustion of the deposit,
amounts remaining under the deposit are to be returned to PharmAthene. For
the
three and nine months ended September 30, 2006, PharmAthene recorded the
use of
these funds for development activities for MDX-1303 as Research and Development
operating expenses of $0.1 million and $0.7 million, respectively. At September
30, 2006, approximately $0.6 million of the deposit remains as compared to
a
December 31, 2005 deposit of approximately $1.3 million. For the three and
nine
months periods ended September 30, 2005, PharmAthene recorded the use of
approximately $0.1 million and $0.4 million, respectively, for the use of
these
funds for development activities of MDX-1031. PharmAthene is fully responsible
for funding all future research and development activities that are not
supported by government funds. The companies will share profits according
to a
pre-agreed allocation percentage.
13. Merger
Agreement
On
March
9, 2006, the Company entered into a term sheet for the merger of the Company
with SIGA Technologies Inc. (SIGA). On September 9, 2006, the boards of
directors of both companies approved the merger in a definitive agreement.
In
conjunction with the transaction, the Company agreed to enter into a Bridge
Note
Purchase Agreement providing SIGA with interim financing, subject to the
execution of a definitive merger agreement, of up to $3.0 million. The Company
paid $3.0 million of this interim financing to SIGA.
On
October 4, 2006, SIGA terminated the merger agreement and subsequently repaid
the $3.0 million Bridge Notes including interest. Additionally, the Company
expensed approximately $1.5 million in merger related costs which had been
recorded on the balance sheet as of September 30, 2006.
In
June 2006, PharmAthene and SIGA Technologies Inc.
(“SIGA”) executed a definitive Agreement and Plan of Merger (the “SIGA
Agreement”). In connection with the SIGA Agreement, PharmAthene loaned $3.0
million to SIGA pursuant to a Bridge Note Purchase Agreement, dated March
20,
2006. On October 4, 2006, SIGA terminated the SIGA Agreement and subsequently
repaid the $3.0 million Bridge Notes including interest. On December 20,
2006,
PharmAthene filed a complaint against SIGA in the Delaware Chancery Court.
PharmAthene’s complaint alleges that it has the right to an
exclusive license to develop and market SIGA’s drug candidate,
SIGA-246, pursuant to the terminated SIGA Agreement and other agreements
between
the parties and the course of performance. The complaint further alleges
that
SIGA failed to negotiate in good faith the terms of such a license pursuant
to
the terminated SIGA Agreement and other agreements between the parties and
the
course of performance SIGA has filed a Motion to Dismiss the
compalint.
14.
Convertible
8% Notes
In
June
2006, certain of the Company’s investors in the Series B Preferred Stock and the
Series C Preferred Stock among others and the Company entered into an agreement
providing for the issuance of $9.8 million in convertible notes (the ‘‘Bridge
Notes”). The Bridge Notes are convertible (i) if the closing of the merger does
not occur, into Series B redeemable convertible preferred stock at $0.91
per
share plus an equal number of common shares (ii) upon the closing of the
merger
with SIGA and a contingent financing with gross proceeds in excess of $25
million, into the same securities sold in such financing, at a 10% price
discount, or (iii) upon a separate financing into such financing securities
at a
25% price discount and an equal number of common shares. The Company may
have a
future beneficial conversion feature based upon the pricing of future
financings. Accordingly, the Company will assess whether a beneficial conversion
feature exists when the contingent event occurs and record the amount, if
any,
at that time.
In
August
2006, the investor in Series C Convertible Preferred Stock of PharmAthene
Canada, Inc. and the Company purchased an additional $2.0 million of Bridge
Notes.
The
Company has recognized interest expense related to the Bridge Notes of
approximately $298,100 through September 30, 2006.
15. Subsequent
Events
On
January 19, 2007 the Company signed a definitive merger agreement with
Healthcare Acquisition Corp. (“HAQ”). Pursuant to the terms of the agreement,
HAQ will issue 12.5 million new shares to the Company’s shareholders. It is
anticipated that shareholders of the Company will own at least 52% of the
outstanding basic shares of the combined company, which is anticipated to
remain
listed on the American Stock Exchange. Additionally, it is anticipated
that the Company’s $11.8 million of outstanding secured convertible notes
will be exchanged for $12.5 million of new unsecured 8% convertible notes
maturing in 24 months. These convertible notes will be convertible at the
option
of the holder into common stock at $10.00 per share and may be redeemed by
the
Company without penalty after 12 months. In the event that the Company enters
into a contract prior to December 31, 2007 for the sale of Valortim™ with the
U.S. government for more than $150,000,000 in anticipated revenue, the Company’s
current shareholders will be eligible for additional cash payments, not to
exceed $10 million, equal to 10% of the actual collections from the sale
of
Valortim™. Subject to certain approvals required of the HAQ and PharmAthene
shareholder by applicable state law and the rules and regulations of the
American Stock Exchange, as well as other regulatory approvals and other
customary closing conditions, the Company expects the merger to close in
the
second or third quarter of 2007.
Report
of
Independent Auditors
Board
of
Directors
PharmAthene, Inc.
We
have
audited the accompanying consolidated balance sheets of PharmAthene, Inc.
as of
December 31, 2005 and 2004, and the related consolidated statements of
operations, convertible redeemable preferred stock and stockholders’ deficit,
and cash flows for each of the three years in the period ended December 31,
2005. These financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on these financial
statements based on our audit.
We
conducted our audits in accordance with auditing standards generally accepted
in
the United States. Those standards require that we plan and perform the audit
to
obtain reasonable assurance about whether the financial statements are free
of
material misstatement. We were not engaged to perform an audit of the Company’s
internal control over financial reporting. Our audits included consideration
of
internal control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for the purpose
of
expressing an opinion on the effectiveness of the Company’s internal control
over financial reporting. Accordingly, we express no such opinion. An audit
also
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In
our
opinion, the financial statements referred to above present fairly, in all
material respects, the consolidated financial position of PharmAthene, Inc.
at
December 31, 2005 and 2004, and the consolidated results of its operations
and its cash flows for each of the three years in the period ended
December 31, 2005 in conformity with accounting principles generally
accepted in the United States.
As
discussed in Note 3 to the financial statements, the Company’s recurring
losses from operations and net capital deficiency raise substantial doubt
about
its ability to continue as a going concern. Management’s plans as to these
matters are also described in Note 3. The 2005 financial statements do not
include any adjustments that might result from the outcome of this uncertainty.
April 19,
2006
PharmAthene, Inc.
Consolidated
Balance Sheets
|
|
December 31
|
|
|
|
2005
|
|
2004
|
|
Assets
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
7,938,116
|
|
$
|
21,662,117
|
|
Accounts
receivable
|
|
|
494,652
|
|
|
-
|
|
Prepaid
expenses
|
|
|
1,549,711
|
|
|
2,287,023
|
|
Other
current assets
|
|
|
8,657
|
|
|
3,150
|
|
Total
current assets
|
|
|
9,991,136
|
|
|
23,952,290
|
|
Property
and equipment, net
|
|
|
4,906,467
|
|
|
64,593
|
|
Patents,
net
|
|
|
1,382,631
|
|
|
-
|
|
Total
assets
|
|
$
|
16,280,234
|
|
$
|
24,016,883
|
|
Liabilities,
convertible redeemable preferred stock, and stockholders’
deficit
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
783,070
|
|
$
|
601,286
|
|
Accrued
expenses and other liabilities
|
|
|
658,257
|
|
|
1,038,403
|
|
Total
current liabilities
|
|
|
1,441,327
|
|
|
1,639,689
|
|
|
|
|
|
|
|
|
|
Warrants
to purchase Series C convertible redeemable preferred stock, exercisable
at approximately $0.91 per share
|
|
|
1,323,051
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Minority
interest - Series C convertible redeemable preferred stock of PharmAthene
Canada, Inc., $0.001 par value; unlimited shares authorized; 2,591,654
issued and outstanding; liquidation preference in the aggregate
of
$2,517,758
|
|
|
2,281,360
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Series
A convertible redeemable preferred stock, $0.001 par value; 16,442,000
shares authorized, issued and outstanding; liquidation preference
in the
aggregate of $17,921,922
|
|
|
17,564,998
|
|
|
16,105,015
|
|
Series
B convertible redeemable preferred stock, $0.001 par value; 65,768,001
shares authorized; 30,448,147 issued and outstanding; liquidation
preference in the aggregate of $30,564,879
|
|
|
28,886,718
|
|
|
26,171,829
|
|
Series
C convertible redeemable preferred stock, $0.001 par value; 22,799,574
shares authorized; 14,946,479 issued and outstanding; liquidation
preference in the aggregate of $14,520,308
|
|
|
12,891,164
|
|
|
-
|
|
Stockholders’
deficit:
|
|
|
|
|
|
|
|
Common
stock, $0.001 par value; 147,089,104 shares authorized; 10,942,906
at
December 31, 2005 and 10,740,000 at December 31, 2004 shares
issued and outstanding
|
|
|
10,943
|
|
|
10,740
|
|
Additional
paid-in capital
|
|
|
-
|
|
|
561,677
|
|
Accumulated
other comprehensive income
|
|
|
115,160
|
|
|
-
|
|
Accumulated
deficit
|
|
|
(48,234,487
|
)
|
|
(20,472,067
|
)
|
Total
stockholders’ deficit
|
|
|
(48,108,384
|
)
|
|
(19,899,650
|
)
|
Total
liabilities, convertible redeemable preferred stock, and stockholders’
deficit
|
|
$
|
16,280,234
|
|
$
|
24,016,883
|
|
See
accompanying notes.
PharmAthene, Inc.
Consolidated
Statements of Operations
|
|
Year
ended December 31
|
|
|
|
2005
|
|
2004
|
|
2003
|
|
|
|
|
|
|
|
|
|
Grant
revenue
|
|
$
|
1,045,751
|
|
$
|
1,037,979
|
|
$
|
7,297,332
|
|
Other
revenue
|
|
|
52,649
|
|
|
-
|
|
|
-
|
|
|
|
|
1,098,400
|
|
|
1,037,979
|
|
|
7,297,332
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
6,351,157
|
|
|
7,843,863
|
|
|
11,324,559
|
|
General
and administrative
|
|
|
5,009,267
|
|
|
3,327,571
|
|
|
2,510,112
|
|
Acquired
in-process research and development
|
|
|
12,812,000
|
|
|
-
|
|
|
-
|
|
Depreciation
and amortization
|
|
|
660,567
|
|
|
25,198
|
|
|
3,074
|
|
Total
operating expenses
|
|
|
24,832,991
|
|
|
11,196,632
|
|
|
13,837,745
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
from operations
|
|
|
(23,734,591
|
)
|
|
(10,158,653
|
)
|
|
(6,540,413
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Other
income (expense):
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
381,840
|
|
|
72,374
|
|
|
12,718
|
|
Interest
expense
|
|
|
(988
|
)
|
|
(32,666
|
)
|
|
(20,349
|
)
|
Total
other income (expense)
|
|
|
380,852
|
|
|
39,708
|
|
|
(7,631
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
(23,353,739
|
)
|
|
(10,118,945
|
)
|
|
(6,548,044
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Accretion
of redeemable convertible preferred stock to redemptive
value
|
|
|
(5,698,630
|
)
|
|
(2,322,699
|
)
|
|
(371,085
|
)
|
Net
loss attributable to common shareholders
|
|
$
|
(29,052,369
|
)
|
$
|
(12,441,644
|
)
|
$
|
(6,919,129
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Basic
and diluted net loss per share
|
|
$
|
(2.69
|
)
|
$
|
(1.16
|
)
|
$
|
(2.03
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average shares used in calculation of basic and diluted net loss
per
share
|
|
|
10,817,949
|
|
|
10,740,000
|
|
|
3,401,212
|
|
See
accompanying notes.
PharmAthene, Inc.
Consolidated
Statements of Convertible Redeemable Preferred Stock and Stockholders’
Deficit
|
|
|
|
|
|
|
|
Stockholders’
Deficit
|
|
|
|
Convertible
Redeemable Preferred Stock
|
|
|
|
Additional
|
|
Accumulated
Other
|
|
|
|
|
|
|
|
Series
A
|
|
Series
B
|
|
Series
C
|
|
Common
Stock
|
|
Paid-In
|
|
Comprehensive
|
|
Accumulated
|
|
Stockholders’
|
|
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
Income
|
|
Deficit
|
|
Deficit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at 12/31/2002
|
|
|
-
|
|
$
|
-
|
|
|
-
|
|
$
|
-
|
|
|
-
|
|
$
|
-
|
|
|
9,340,000
|
|
$
|
9,340
|
|
$
|
167,268
|
|
$
|
-
|
|
$
|
(372,474
|
)
|
$
|
(195,866
|
)
|
Net
loss
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(6,548,044
|
)
|
|
(6,548,044
|
)
|
Exercise
of common stock options
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
1,400,000
|
|
|
1,400
|
|
|
56,529
|
|
|
-
|
|
|
-
|
|
|
57,929
|
|
Issuance
of Series A convertible redeemable preferred stock and warrants
at
approximately $1.09 per share, net of issuance costs of
$105,502
|
|
|
13,769,230
|
|
|
14,894,498
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
10,683
|
|
|
-
|
|
|
-
|
|
|
10,683
|
|
Dividends
to common stockholders
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(3,299,999
|
)
|
|
(3,299,999
|
)
|
Stock
compensation
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
4,000
|
|
|
-
|
|
|
-
|
|
|
4,000
|
|
Accrual
of Series A dividends
|
|
|
-
|
|
|
364,931
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(238,480
|
)
|
|
-
|
|
|
(126,451
|
)
|
|
(364,931
|
)
|
Accretion
of Series A issuance costs
|
|
|
-
|
|
|
6,154
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(6,154
|
)
|
|
(6,154
|
)
|
Balance
as of 12/31/2003
|
|
|
13,769,230
|
|
|
15,265,583
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
10,740,000
|
|
|
10,740
|
|
|
-
|
|
|
-
|
|
|
(10,353,122
|
)
|
|
(10,342,382
|
)
|
Net
loss
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(10,118,945
|
)
|
|
(10,118,945
|
)
|
Accrual
of Series A dividends
|
|
|
-
|
|
|
1,229,194
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(1,229,194
|
)
|
|
-
|
|
|
-
|
|
|
(1,229,194
|
)
|
Accretion
of Series A issuance costs
|
|
|
-
|
|
|
21,100
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(21,100
|
)
|
|
-
|
|
|
-
|
|
|
(21,100
|
)
|
Issuance
of Series B convertible redeemable preferred stock and warrants
at
approximately $0.9123 per share, net of issuance costs of
$207,288
|
|
|
-
|
|
|
-
|
|
|
28,803,951
|
|
|
24,237,901
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
1,832,589
|
|
|
-
|
|
|
-
|
|
|
1,832,589
|
|
Conversion
of bridge loan
|
|
|
-
|
|
|
-
|
|
|
1,644,196
|
|
|
1,298,254
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
201,746
|
|
|
-
|
|
|
-
|
|
|
201,746
|
|
Issuance
of Series A Convertible Redeemable Preferred Stock as deemed
dividend
|
|
|
2,672,770
|
|
|
(436,731
|
)
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
436,731
|
|
|
-
|
|
|
-
|
|
|
436,731
|
|
Accretion
of Series A deemed dividend
|
|
|
-
|
|
|
25,869
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(25,869
|
)
|
|
-
|
|
|
-
|
|
|
(25,869
|
)
|
Accrual
of Series B dividends
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
523,592
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(523,592
|
)
|
|
-
|
|
|
-
|
|
|
(523,592
|
)
|
Accretion
of Series B issuance costs
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
10,364
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(10,364
|
)
|
|
-
|
|
|
-
|
|
|
(10,364
|
)
|
Accretion
of common stock purchase warrants
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
101,718
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(101,718
|
)
|
|
-
|
|
|
-
|
|
|
(101,718
|
)
|
Stock
compensation
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
2,448
|
|
|
-
|
|
|
-
|
|
|
2,448
|
|
Balance
as of 12/31/2004
|
|
|
16,442,000
|
|
|
16,105,015
|
|
|
30,448,147
|
|
|
26,171,829
|
|
|
-
|
|
|
-
|
|
|
10,740,000
|
|
|
10,740
|
|
|
561,677
|
|
|
-
|
|
|
(20,472,067
|
)
|
|
(19,899,650
|
)
|
Net
loss
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(23,353,739
|
)
|
|
(23,353,739
|
)
|
Foreign
currency translation adjustment
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
115,160
|
|
|
-
|
|
|
115,160
|
|
Comprehensive
loss
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(23,238,579
|
)
|
Exercise
of common stock options
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
202,906
|
|
|
203
|
|
|
27,067
|
|
|
-
|
|
|
-
|
|
|
27,270
|
|
Accrual
of Series A dividends
|
|
|
-
|
|
|
1,327,798
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(927,320
|
)
|
|
-
|
|
|
(400,478
|
)
|
|
(1,327,798
|
)
|
Accretion
of Series A issuance costs
|
|
|
-
|
|
|
21,100
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(21,100
|
)
|
|
(21,100
|
)
|
Accretion
of Series A deemed dividend
|
|
|
-
|
|
|
111,085
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(111,085
|
)
|
|
(111,085
|
)
|
Accrual
of Series B dividends
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
2,263,509
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(2,263,509
|
)
|
|
(2,263,509
|
)
|
Accretion
of Series B issuance costs
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
44,508
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(44,508
|
)
|
|
(44,508
|
)
|
Accretion
of common stock purchase warrants
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
406,872
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(406,872
|
)
|
|
(406,872
|
)
|
Issuance
of Series C convertible redeemable preferred stock and warrants
at
approximately $0.9123 per share, net of issuance costs of
$330,495
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
14,946,479
|
|
|
11,488,346
|
|
|
-
|
|
|
-
|
|
|
335,059
|
|
|
-
|
|
|
-
|
|
|
335,059
|
|
Accrual
of Series C dividends
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
884,635
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(1,038,027
|
)
|
|
(1,038,027
|
)
|
Accretion
of Series C issuance costs
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
64,697
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(64,697
|
)
|
|
(64,697
|
)
|
Accretion
of common stock purchase warrants
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
49,774
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(58,405
|
)
|
|
(58,405
|
)
|
Accretion
of preferred stock purchase warrants
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
403,712
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
Stock
compensation
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
3,517
|
|
|
-
|
|
|
-
|
|
|
3,517
|
|
Balance
as of 12/31/2005
|
|
|
16,442,000
|
|
$
|
17,564,998
|
|
|
30,448,147
|
|
$
|
28,886,718
|
|
|
14,946,479
|
|
$
|
12,891,164
|
|
|
10,942,906
|
|
$
|
10,943
|
|
$
|
-
|
|
$
|
115,160
|
|
$
|
(48,234,487
|
)
|
$
|
(48,108,384
|
)
|
See
accompanying notes.
PharmAthene, Inc.
Consolidated
Statements of Cash Flows
|
|
Year
ended December 31
|
|
|
|
2005
|
|
2004
|
|
2003
|
|
Operating
activities
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(23,353,739
|
)
|
$
|
(10,118,945
|
)
|
$
|
(6,548,044
|
)
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
|
|
Write-off
of acquired in-process research and development
|
|
|
12,812,000
|
|
|
-
|
|
|
-
|
|
Depreciation
and amortization
|
|
|
660,567
|
|
|
25,198
|
|
|
3,074
|
|
Compensatory
option expense
|
|
|
3,517
|
|
|
2,448
|
|
|
4,000
|
|
Non-cash
rent expense
|
|
|
-
|
|
|
-
|
|
|
10,683
|
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(494,652
|
)
|
|
355,355
|
|
|
363,719
|
|
Prepaid
expenses and other current assets
|
|
|
979,805
|
|
|
(2,037,023
|
)
|
|
(253,150
|
)
|
Accounts
payable
|
|
|
(218,216
|
)
|
|
(2,076,181
|
)
|
|
2,125,058
|
|
Accrued
expenses
|
|
|
(380,146
|
)
|
|
1,016,056
|
|
|
(19,854
|
)
|
Net
cash used in operating activities
|
|
|
(9,990,864
|
)
|
|
(12,833,092
|
)
|
|
(4,314,514
|
)
|
Investing
activities
|
|
|
|
|
|
|
|
|
|
|
Purchase
of property and equipment
|
|
|
(329,594
|
)
|
|
(46,574
|
)
|
|
(46,291
|
)
|
Purchase
of Nexia assets
|
|
|
(12,277,005
|
)
|
|
-
|
|
|
-
|
|
Net
cash used in investing activities
|
|
|
(12,606,599
|
)
|
|
(46,574
|
)
|
|
(46,291
|
)
|
Financing
activities
|
|
|
|
|
|
|
|
|
|
|
Net
proceeds from the issuance of redeemable preferred stock
|
|
|
8,858,766
|
|
|
26,070,490
|
|
|
14,894,498
|
|
Proceeds
from stock options exercised
|
|
|
27,270
|
|
|
-
|
|
|
-
|
|
Proceeds
from issuance of bridge loan
|
|
|
-
|
|
|
1,500,000
|
|
|
-
|
|
Proceeds
from the issuance of common stock
|
|
|
-
|
|
|
-
|
|
|
57,929
|
|
Dividends
paid to common stockholders
|
|
|
-
|
|
|
-
|
|
|
(3,299,999
|
)
|
Proceeds
from issuance of notes payable to directors
|
|
|
-
|
|
|
-
|
|
|
45,000
|
|
Payments
on notes payable to directors
|
|
|
-
|
|
|
-
|
|
|
(491,858
|
)
|
Net
cash provided by financing activities
|
|
|
8,886,036
|
|
|
27,570,490
|
|
|
11,205,570
|
|
|
|
|
|
|
|
|
|
|
|
|
Effects
of exchange rates on cash
|
|
|
(12,574
|
)
|
|
-
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
(Decrease)
increase in cash and cash equivalents
|
|
|
(13,724,001
|
)
|
|
14,690,824
|
|
|
6,844,765
|
|
Cash
and cash equivalents, at beginning of year
|
|
|
21,662,117
|
|
|
6,971,293
|
|
|
126,528
|
|
Cash
and cash equivalents, at end of year
|
|
$
|
7,938,116
|
|
$
|
21,662,117
|
|
$
|
6,971,293
|
|
Non-cash
financing activities
|
|
|
|
|
|
|
|
|
|
|
Issuance
of Series C redeemable preferred stock and warrants for
assets
|
|
$
|
(1,212,622
|
)
|
$
|
-
|
|
$
|
-
|
|
See
accompanying notes.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements
December 31,
2005, 2004 and 2003
1. Organization
and Business
PharmAthene, Inc.
(the Company) was incorporated on March 13, 2001 (inception), under the
laws of the State of Delaware. The Company is a biopharmaceutical company
focused on developing anti-infectives for biodefense applications. The Company
has generated an accumulated deficit of $48,970,995 since inception. The
Company
anticipates incurring additional losses until such time, if ever, as it can
generate significant sales of its products currently in development. Substantial
additional financing will be needed by the Company to fund its operations
and to
commercially develop its products. There is no assurance that such financing
will be available when needed.
The
Company is subject to those risks associated with any biopharmaceutical company
that has substantial expenditures for research and development. There can
be no
assurance that the Company’s research and development projects will be
successful, that products developed will obtain necessary regulatory approval,
or that any approved product will be commercially viable. In addition, the
Company operates in an environment of rapid technological change and is largely
dependent on the services of its employees and consultants.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
2. Nexia
Asset Purchase
On
March 10, 2005, the Company acquired substantially all of the assets and
liabilities of Nexia Biotechnologies Inc. (Nexia) that relate to its
Protexia®
(recombinant human butyrylcholinesterase) compound. The Company paid
approximately $19.1 million in cash, Series C Convertible Redeemable
Preferred Stock (the Series C Preferred Stock), and warrants. Specifically,
the
Company delivered to Nexia (i) 7,465,501 shares of Series C Preferred Stock
valued at approximately $0.91 per share; (ii) warrants to acquire 2,239,650
shares of Series C Preferred Stock, which are exercisable at approximately
$0.91
per share and which expire on March 10, 2008; and (iii) warrants to acquire
1,343,790 common shares, which are exercisable at $0.01 per share, subject
to
reduction if certain business milestones are met by the Company, as specified
in
the warrants and which expire in October 2014. In addition, the Company
delivered to Nexia $11,763,176 in cash. The purchased assets and liabilities
are
held by PharmAthene Canada, Inc., a variable interest entity consolidated
by the
Company, which was established by PharmAthene in connection with the purchase
to
allow for the holding of the assets and the investment of certain shareholders
as further described in Note 8.
The
purchase price of the Nexia assets was allocated to the tangible and
identifiable intangible assets acquired and liabilities assumed based on
their
estimated fair values at the acquisition date. The results of Nexia’s operations
have been included in the financial statement since the acquisition date.
The
following table summarizes the purchase price allocation to estimated fair
values of the assets acquired and liabilities assumed as of the acquisition
date:
Prepaid
expenses and other current assets
|
|
$
|
248,000
|
|
Property
and equipment, net
|
|
|
5,021,000
|
|
In-process
research and development
|
|
|
12,812,000
|
|
Acquired
identifiable intangibles
|
|
|
1,407,000
|
|
Accounts
payable
|
|
|
(371,000
|
)
|
Total
assets acquired
|
|
$
|
19,117,000
|
|
In
connection with the acquisition and as calculated by a third party appraiser,
the Company recorded $12.8 million of the purchase price of the Nexia Asset
Purchase as acquired in-process research and development. The fair value
was
determined utilizing a present value technique involving a discounted cash
flow
analysis. Under this approach, fair value reflects the present value of the
projected free cash flow that will be generated by the in-process research
and
development.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
2. Nexia
Asset Purchase (continued)
At
the
date of the acquisition, the development of Protexia®
was not
complete, had not reached technological feasibility and had no known alternative
uses. Consequently, there is considerable uncertainty as to the technological
feasibility of this product at the date of the acquisition. The Company does
not
foresee any alternative future benefit from the acquired in-process research
and
development. Significant technological and regulatory approval risks are
associated with the development of the product. Development of a product
will
require significant amounts of future time, effort, and substantial development
costs, which will be incurred by the Company. The efforts required to develop
the acquired in-process research and development into commercially viable
products include the development of the compound for use in intended subjects
and the reformulation of an alternate purification process for the compound,
as
well as the conducting of applicable clinical-trial testing, regulatory approval
and the development of a product suitable for commercialization. The principal
risks relating to achieving an indication under development are the outcomes
of
clinical studies of the alternatively purified compound and receiving positive
results regulatory filings and approval. Since pharmaceutical products cannot
be
marketed without regulatory approvals, the Company will not receive any benefits
unless regulatory approval is obtained. Accordingly, the portion of the purchase
price related to these products under development was allocated to acquired
in-process research and development and was expensed at the date of acquisition.
3. Management’s
Plans as to Continuing as a Going Concern
The
Consolidated Financial Statements has been prepared on a basis which assumed
that the Company will continue as a going concern and which contemplates
the
realization of assets and the satisfaction of liabilities and commitments
in the
normal course of business. The Company has incurred cumulative net losses
and
expects to incur additional losses to perform further research and development
activities. The Company does not have commercial products and has limited
capital resources. Management’s plans with regard to these matters include
continued development of its products as well as seeking additional research
support funds and financial arrangements. Although management continues to
pursue these plans, there is no assurance that the Company will be successful
in
obtaining sufficient financing on commercial reasonable terms or that the
Company will be able to secure financing from anticipated government contracts
and grants.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
3. Management’s
Plans as to Continuing as a Going Concern (continued)
Management
has developed a plan to reduce the Company’s operating expenses in the event
that sufficient funds are not available, or if the Company is not able to
obtain
the anticipated government contracts and grants. If the company is unable
to
raise adequate capital or achieve profitability, future operations will need
to
be scaled back or discontinued. Continuance of the Company’s going concern is
dependent upon, among other things, the success of the Company’s research and
development programs and the Company’s ability to obtain adequate financing. The
financial statements do not include any adjustments relating to recoverability
of the carrying amount of recorded assets and liabilities that might result
from
the outcome of these uncertainties.
4. Summary
of Significant Accounting Policies
Principles
of Consolidation
The
Consolidated Financial Statements include the accounts of the Company and
its
subsidiary, PharmAthene Canada, Inc., which was formed in March of 2005.
All significant intercompany transactions and balances have been
eliminated.
The
FASB
has issued FASB Interpretation (FIN) No. 46 (revised December 2003),
Consolidation
of Variable Interest Entities,
(FIN
46R). FIN 46R expands consolidated financial statements to include certain
variable interest entities (VIEs). VIEs are to be consolidated by the company
which is considered to be the primary beneficiary of that entity, even if
the
company does not have majority control. FIN 46R is immediately effective
for
VIEs created after January 31, 2003, and is effective for the Company in
2005 for VIEs created prior to February 1, 2003. The Company’s subsidiary,
PharmAthene Canada, Inc., is a VIE and the Company is the primary beneficiary.
Therefore, the Company has consolidated PharmAthene Canada, Inc. as of its
date
of inception.
Use
of Estimates
The
preparation of financial statements in conformity with generally accepted
accounting principles in the United States requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those
estimates.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
4. Summary
of Significant Accounting Policies (continued)
Comprehensive
Loss and Foreign Currency Translation
The
financial statements of subsidiaries located outside of the United States
are
measured using the local currency as the functional currency. Assets and
liabilities of these subsidiaries are translated at the rates of exchange
at the
balance sheet date. The resultant translation adjustments are included in
accumulated other comprehensive income (loss), a separate component of
stockholders’ equity. Income and expense items are translated at average monthly
rates of exchange. Gains and losses from foreign currency transactions of
these
subsidiaries are included in net earnings.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments with maturities of three
months
or less when purchased to be cash equivalents. Cash equivalents consist of
a
short-term money market account with a bank.
Accounts
Receivable
Through
its inception to date, substantially all of PharmAthene’s accounts receivable
have been associated with U.S. government contracts and grants or with the
receipt of Quebec provincial or Canadian Federal credits for internally and
externally generated research and development expenditures. Amounts invoiced
or
recorded as billed under these programs but not yet collected are reported
as
outstanding accounts receivable. While the Company has a policy to provide
an
allowance for any amount of accounts receivable which it determines to be
uncollectible and the Company will write off any uncollectible account when
the
likelihood of that account’s collection is determined to be not probable, the
Company has not historically found it necessary to record any write-offs
of
accounts receivable or to record an allowance for uncollectible
accounts.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
4. Summary
of Significant Accounting Policies (continued)
Property
and Equipment
Property
and equipment consist of land, building and leasehold improvements, laboratory,
computer, farm and office equipment and furniture and are recorded at cost.
Property and equipment are depreciated using the straight-line method over
the
estimated useful lives of the respective assets as follows:
Asset
Category
|
|
Estimated
Useful Life
(
in years)
|
|
|
|
|
|
Building
and leasehold improvements
|
|
|
4
- 20
|
|
Laboratory
equipment
|
|
|
7
|
|
Furniture,
farm and office equipment
|
|
|
5
- 7
|
|
Computer
equipment
|
|
|
3
|
|
Intangible
Assets
Intangible
assets consist of patents and are being amortized using the straight-line
method
over an 11 year period. The intangible assets are reviewed for impairment
when
circumstances indicate that the carrying amount of an asset may not be
recoverable. Impairment is considered to have occurred if expected future
undiscounted cash flows are insufficient to recover the carrying value of
the
asset. If impaired, the asset’s carrying value is reduced to fair
value.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
4. Summary
of Significant Accounting Policies (continued)
Impairment
of Long-Lived Assets
In
accordance with Statement of Financial Accounting Standards (SFAS) No. 144,
Accounting
for the Impairment or Disposal of Long-Lived Assets,
long-lived assets such as property, plant, and equipment, and purchased
intangibles subject to amortization, are reviewed for impairment whenever
events
or changes in circumstances indicate that the carrying amount of an asset
may
not be recoverable. Recoverability of assets to be held and used is measured
by
a comparison of the carrying amount of an asset to estimated undiscounted
future
cash flows expected to be generated by the asset. If the carrying amount
of an
asset exceeds its estimated future cash flows, then an impairment charge
is
recognized by the amount by which the carrying amount of the asset exceeds
the
fair value of the asset. Assets to be disposed of would be separately presented
in the balance sheets and reported at the lower of the carrying amount or
fair
value, less costs to sell, and are no longer depreciated. The assets and
liabilities of a disposed group classified as held-for-sale would be presented
separately in the appropriate asset and liability sections of the balance
sheets. As of December 31, 2005, management believes that no revision of
the remaining useful lives or write-down of long-lived assets is
required.
Revenue
Recognition
Grant
Revenue
The
Company recognizes revenue when all terms and conditions of the agreements
have
been met including persuasive evidence of an arrangement, services have been
rendered, price is fixed or determinable, and collectibility is reasonably
assured. For reimbursable cost research grants, the Company recognizes revenue
as costs are incurred and appropriate regulatory approvals have been obtained
or
approval criteria are met for invoicing the related government
agency.
All
of
the grant revenue the Company recognized was received under a cost reimbursement
grant from the U.S. government to fund the development of pharmaceutical
products for biodefense applications. Receipts pursuant to such cost
reimbursement grants are contingent upon the successful completion of related
tasks, the granting agency may modify the contract at any time, and reimbursed
costs are subject to review and adjustment by the granting agency.
Research
and Development and In-Process Research and Development
Research
and development costs are charged to expense as incurred.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
4. Summary
of Significant Accounting Policies (continued)
Stock
Compensation
The
Company accounts for stock-based employee compensation arrangements using
the
intrinsic value method in accordance with Accounting Principles Board Opinion
No. 25, Accounting
for Stock Issued to Employees
(APB
25), and related interpretations and complies with the disclosure provisions
of
SFAS No. 123, Accounting
for Stock-Based Compensation
(SFAS
123). Under APB 25, compensation expense is based on the difference, if any,
on
the date of the grant between the fair value of the Company’s stock and the
exercise price of the option.
The
Company accounts for equity instruments issued to non-employees in accordance
with SFAS 123 and Emerging Issues Task Force (EITF) 96-18, Accounting
for Equity Instruments That Are Issued to Other Than Employees for Acquiring,
or
in Conjunction with Selling, Goods or Services.
Accordingly, the estimated fair value of the equity instrument is recorded
on
the earlier of the performance commitment date or the date the services required
are completed.
In
accordance with SFAS No. 148, Accounting
for Stock-Based Compensation—Transition and Disclosure (SFAS
148), the effect on net loss if the Company had applied the fair value
recognition provisions of SFAS 123 to stock-based employee compensation is
as
follows:
|
|
Year
ended December 31
|
|
|
|
2005
|
|
2004
|
|
2003
|
|
|
|
|
|
|
|
|
|
Net
loss attributable to common shareholders, as reported
|
|
$
|
(29,052,369
|
)
|
$
|
(12,441,644
|
)
|
$
|
(6,919,129
|
)
|
Deduct:
Total stock-based employee compensation expense determined under
fair
value-based method for all awards
|
|
|
(242,340
|
)
|
|
(81,413
|
)
|
|
(45,999
|
)
|
Pro
forma net loss attributable to common shareholders
|
|
$
|
(29,294,709
|
)
|
$
|
(12,523,057
|
)
|
$
|
(6,965,128
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Basic
and diluted net loss per share:
|
|
|
|
|
|
|
|
|
|
|
As
reported
|
|
|
(2.69
|
)
|
|
(1.16
|
)
|
|
(2.03
|
)
|
Pro
forma
|
|
|
(2.71
|
)
|
|
(1.17
|
)
|
|
(2.05
|
)
|
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
4. Summary
of Significant Accounting Policies (continued)
Stock
Compensation (continued)
The
fair
value for the 2005 awards was estimated at the date of grant using the
Black-Scholes option-pricing model assuming a weighted-average volatility
of
approximately 60%, a risk-free interest rate of 3.9%, a dividend yield of
0%,
and a weighted-average expected life of the option of 8.7 years.
The
fair
value for the 2004 awards was estimated at the date of grant using the
Black-Scholes option-pricing model assuming a weighted-average volatility
of
approximately 60%, a risk-free interest rate of 4.1%, a dividend yield of
0%,
and a weighted-average expected life of the option of 7 years.
The
fair
value for the 2003 awards was estimated at the date of grant using the
Black-Scholes option-pricing model assuming a weighted-average volatility
of
approximately 56%, a risk-free interest rate of 3.2%, a dividend yield of
0%,
and a weighted-average expected life of the option of 7 years.
These
pro
forma amounts are not necessarily indicative of future effects of applying
the
fair value-based method because of, among other things, the vesting period
of
the stock options and the fair value of the additional stock options issued
in
future years.
Basic
and Diluted Net Loss Per Share
Basic
net
loss per share of common stock excludes dilution for potential common stock
issuances and is computed by dividing net loss by the weighted-average number
of
shares outstanding for the period. Diluted net loss per share reflects the
potential dilution that could occur if securities were exercised into common
stock. However, for all periods presented, diluted net loss per share is
the
same as basic net loss attributable to common shareholders per share as the
inclusion of weighted average shares of common stock issuable upon the exercise
of stock options and warrants would be anti-dilutive. Securities outstanding
in
the amount of 118,374,000, 31,964,000 and 6,478,000 shares for the years
ended
December 31, 2005, 2004 and 2003, respectively, were excluded from the
calculation of diluted net loss per share since their inclusion would be
anti-dilutive.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
4. Summary
of Significant Accounting Policies (continued)
Basic
and Diluted Net Loss Per Share (continued)
The
following table provides a reconciliation of the numerators and denominators
used in computing basic and diluted net loss per share:
|
|
Year
ended December 31
|
|
|
|
2005
|
|
2004
|
|
2003
|
|
|
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(23,353,739
|
)
|
$
|
(10,118,945
|
)
|
$
|
(6,548,044
|
)
|
Dividends
on and accretion of convertible preferred stock
|
|
|
(5,698,630
|
)
|
|
(2,322,699
|
)
|
|
(371,085
|
)
|
Net
loss available to common stockholders
|
|
$
|
(29,052,369
|
)
|
$
|
(12,441,644
|
)
|
$
|
(6,919,129
|
)
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
Weighted-average
shares of common stock outstanding - basic and diluted
|
|
|
10,817,949
|
|
|
10,740,000
|
|
|
3,401,212
|
|
Income
Taxes
The
Company accounts for income taxes in accordance with Statement of Financial
Accounting Standards (SFAS) No. 109, Accounting
for Income Taxes
(SFAS
109), which requires that deferred tax assets and liabilities be recognized
using enacted tax rates for the effect of temporary differences between the
book
and tax bases of recorded assets and liabilities. SFAS 109 also requires
that
deferred tax assets be reduced by a valuation allowance if it is more likely
than not that some portion of the deferred tax asset will not be realized.
In
evaluating the need for a valuation allowance, the Company takes into account
various factors, including the expected level of future taxable income and
available tax planning strategies. If actual results differ from the assumptions
made in the evaluation of the Company’s valuation allowance, the Company records
a change in valuation allowance through income tax expense in the period
such
determination is made.
Fair
Value of Financial Instruments and Concentration of Credit
Risk
The
carrying amounts of the Company’s financial instruments, which include cash
equivalents, accounts receivable, accounts payable, and accrued expenses,
approximate their fair values because of their short maturities at
December 31, 2005 and 2004.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
4. Summary
of Significant Accounting Policies (continued)
New
Accounting Standards
On
December 16, 2004, the FASB issued SFAS No. 123 (revised 2004),
Share-Based
Payment
(SFAS
123R) which requires all share-based payments to employees, including grants
of
employee stock options, be recognized in the income statement based on their
grant date fair values for interim or annual periods beginning after
June 15, 2005. Pro forma disclosure of stock option expense will no longer
be permitted. The cost will be recognized over the requisite service period
that
an employee must provide to earn the award (i.e., usually the vesting period).
The Company adopted SFAS 123R on January 1, 2006 using the “modified
prospective” method. The Company is still evaluating the impact of SFAS 123R on
its financial statements, however, stock-based employee compensation expense
is
expected to be similar to disclosed pro-forma amounts.
Reclassifications
Certain
prior year amounts in the consolidated financial statements have been
reclassified to conform to the current year presentation.
5. Property
and Equipment
Property
and equipment consisted of the following:
|
|
December 31
|
|
|
|
2005
|
|
2004
|
|
|
|
|
|
|
|
Land
|
|
$
|
471,860
|
|
$
|
-
|
|
Building
and leasehold improvements
|
|
|
4,014,717
|
|
|
-
|
|
Furniture,
farm and office equipment
|
|
|
281,907
|
|
|
22,953
|
|
Laboratory
equipment
|
|
|
325,398
|
|
|
-
|
|
Computer
equipment
|
|
|
151,844
|
|
|
69,910
|
|
|
|
|
5,245,726
|
|
|
92,863
|
|
Less
accumulated depreciation
|
|
|
(339,259
|
)
|
|
(28,270
|
)
|
Property
and equipment, net
|
|
$
|
4,906,467
|
|
$
|
64,593
|
|
Depreciation
expense for the years ended December 31, 2005, 2004 and 2003 was $559,306,
$25,198 and $3,074, respectively. Depreciation expense in 2005 includes the
write off of leasehold improvements of approximately $245,000, adjusted based
on
current foreign currency rates.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
6. Patents
In
conjunction with the Nexia Asset Purchase described in Note 2, the Company
recorded intangible assets related to patents of $1,407,000 with a useful
life
of 11 years. The gross carrying value and accumulated amortization, adjusted
based on current foreign currency rates, was $1,483,892 and $101,261,
respectively, at December 31, 2005. For the year ended December 31,
2005, the Company has recorded amortization expense of $101,261. Amortization
expense related to the above intellectual property is expected to be
approximately $127,910 per year for the next five years.
7. Preferred
Stock
Series
A Convertible Redeemable Preferred Stock
On
October 6, 2003, the Company’s Board of Directors approved a 2-for-1 stock
split to be effected in the form of a stock dividend payable to common and
preferred stockholders of record as of October 6, 2003. On October 15,
2003, the Company affected the 2-for-1 stock split.
All
share
and per share information presented in the consolidated financial statements
and
related footnotes for all periods presented have been restated to reflect
this
2-for-1 stock split.
In
September 2003, the Company sold 13,769,230 shares of Series A convertible
redeemable preferred stock (the Series A Preferred Stock) to an investor
at a
price of approximately $1.09 per share for net proceeds of
$14,894,498.
The
Series A Preferred Stock bears a cumulative dividend rate of 8% per annum.
Accrued and unpaid dividends for Series A Preferred Stock at December 31,
2005 and 2004 totaled $2,921,923 and $1,594,125, respectively.
Each
share of the Series A Preferred Stock is convertible into shares of common
stock
at the then-applicable conversion rate, as defined, at any time and at the
option of the holder. The shares of Series A Preferred Stock are currently
convertible into 16,442,000 common shares. The conversion rate is subject
to
adjustment for certain defined equity transactions. At December 31, 2005
and 2004, the Company has reserved 16,442,000 shares of common stock for
the
potential conversion. The Series A Preferred Stock will automatically convert
into common stock at the then-applicable conversion rate in the event of
an
initial public offering of the Company’s common stock resulting in aggregate
proceeds to the Company of $50 million and a price per share of at least
$2.74.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
7. Preferred
Stock (continued)
Series
A Convertible Redeemable Preferred Stock (continued)
The
Series A Preferred Stock has a liquidation preference in an amount equal
to the
redefined original purchase price of $0.91 per share plus accumulated but
unpaid
dividends, whether or not declared, in the event of a liquidation, dissolution,
winding-up, sale, or merger. This liquidation preference is junior to the
Series
B Convertible Redeemable Preferred Stock (the Series B Preferred Stock) and
the
Series C Preferred Stock, and senior to the common stock.
The
Company recorded the Series A Preferred Stock at its fair value on the date
of
issuance of approximately $15,000,000, less issuance costs of $105,502. The
issuance costs are accreted to the carrying value of the preferred stock
up to
the earliest redemption period using the effective interest method. The Company
had classified the Series A Preferred Stock outside of permanent equity as
a
result of certain redemption features. Because the Series A Preferred Stock
contains contingently adjustable conversion ratios, the Company evaluated
the
Series A Preferred Stock for potential beneficial conversion features under
EITF
98-5, Accounting
for Convertible Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratios,
and
EITF 00-27, Application
of Issue No. 98-5 to Certain Convertible Instruments.
The
contingently adjustable conversion ratio changed with the issuance of Series
B
Preferred Stock. Based on the fact that the adjusted implied conversion price
of
the Series A Preferred Stock exceeded the fair value of the common stock
into
which the Series A Preferred Stock converts, no beneficial conversion feature
was deemed to exist. The implied conversion price was calculated by dividing
the
fair value of the Series A Preferred Stock, net of the fair value allocated
to
the warrants issued to the holders of Series A Preferred Stock in conjunction
with the Series B Preferred Stock offering, by the adjusted number of common
shares into which the Series A Preferred Stock converts.
In
conjunction with the Series B Preferred Stock financing, the Series A Preferred
stockholders were granted 5,400,000 contingent warrants to purchase common
stock
for $0.01. The Company deemed 1,620,000 warrants to be probable of issuance.
Accordingly, 1,620,000 warrants were valued using the Black-Scholes model
and
were recorded as a $201,746 discount to the Series A Preferred Stock. This
discount is being accreted through the period up to the first redemption
date
using the effective interest method. The fair value of the warrants were
estimated at the date of grant using the Black-Scholes model assuming a
weighted-average volatility of approximately 60%, a risk free interest rate
of
4.3%, a dividend yield of 0% and a weighted-average expected life of the
warrant
of 8.8 years.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
7. Preferred
Stock (continued)
Series
A Convertible Redeemable Preferred Stock (continued)
Commencing
September 11, 2008, the holder of the Series A Preferred Stock may require
the Company to redeem the Series A Preferred Stock then outstanding for an
amount equal to the original purchase price plus any unpaid dividends, whether
or not declared. The right of redemption is junior to the Series B Preferred
Stock and Series C Preferred Stock redemption rights.
The
holder of the Series A Preferred Stock is entitled to the number of votes
equal
to the number of common shares into which its shares are
convertible.
Series
B Convertible Redeemable Preferred Stock
In
October 2004, the Company sold 30,448,147 shares of Series B Preferred
Stock to the Series A Preferred Stock investor and four additional investors
at
a price of approximately $0.91 per share for net proceeds of $27,570,490.
Purchasers of the Series B Preferred Stock also received warrants to purchase
common stock as described in Note 9.
The
Series B Preferred Stock bears a cumulative dividend rate of 8% per annum.
Accrued and unpaid dividends for Series B Preferred Stock at December 31,
2005 and 2004 total $2,787,101 and $523,592, respectively.
Each
share of the Series B Preferred Stock is convertible into shares of common
stock
at the then-applicable conversion rate, as defined, at any time and at the
option of the holder. The initial conversion rate is one common share for
each
preferred share, which is subject to adjustment for certain defined equity
transactions. At December 31, 2005, the Company has reserved 65,768,001
shares of common stock for the potential conversion. The Series B Preferred
Stock will automatically convert into common stock at the then-applicable
conversion rate in the event of an initial public offering of the Company’s
common stock resulting in aggregate proceeds to the Company of $50 million
and a price per share of at least $2.74.
The
Series B Preferred Stock has a liquidation preference in an amount equal
to the
original purchase price per share plus accumulated but unpaid dividends,
whether
or not declared, in the event of a liquidation, dissolution, winding-up,
sale,
or merger. This liquidation preference is senior to the Series A Preferred
Stock
and the common stock and equal to the liquidation preference of the Series
C
Preferred Stock.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
7. Preferred
Stock (continued)
Series
B Convertible Redeemable Preferred Stock (continued)
The
Company recorded the Series B Preferred Stock at its fair value on the date
of
issuance of approximately $27,777,778, less the fair value assigned to warrants
of $3,332,589, less issuance costs of $207,288. The issuance costs are accreted
to the carrying value of the preferred stock up to the earliest redemption
period using the effective interest method. The Company had classified the
Series B Preferred Stock outside of permanent equity as a result of certain
redemption features. Because detachable warrants were granted with the financing
and the Series B Preferred Stock contains contingently adjustable conversion
ratios, the Company evaluated the Series B Preferred Stock for potential
beneficial conversion features under EITF 98-5, Accounting
for Convertible Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratios,
and
EITF 00-27, Application
of Issue No. 98-5 to Certain Convertible Instruments.
Based
on the fact that the adjusted implied conversion price of the Series B Preferred
Stock exceeded the fair value of the common stock into which the Series B
Preferred Stock converts, no beneficial conversion feature was deemed to
exist.
The implied conversion price was calculated by dividing the fair value of
the
Series B Preferred Stock, net of the fair value of the warrants, by the number
of common shares into which the Series B Preferred Stock converts.
In
conjunction with the Series B financing, the Series B Preferred stockholders
were granted 15,400,000 contingent warrants to purchase common stock for
$0.01.
The Company deemed 10,780,000 warrants to be probable of issuance. Accordingly,
10,780,000 warrants were valued using the Black-Scholes model and were recorded
as a $2,034,335 discount to the Series B Preferred Stock. This discount is
being
accreted through the period up to the first redemption date using the effective
interest method. The fair value of the warrants were estimated at the date
of
grant using the Black-Scholes model assuming a weighted-average volatility
of
approximately 60%, a risk free interest rate of 4.3%, a dividend yield of
0% and
a weighted-average expected life of the warrant of 8.8 years.
Commencing
October 7, 2009, the holders of the Series B Preferred Stock may require
the Company to redeem the Series B Preferred Stock then outstanding for an
amount equal to the original purchase price plus any unpaid dividends, whether
or not declared, and in preference to the Series A Preferred Stock liquidation
rights.
The
holders of the Series B Preferred Stock are entitled to the number of votes
equal to the number of common shares into which its shares are
convertible.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
7. Preferred
Stock (continued)
Series
B Convertible Redeemable Preferred Stock (continued)
In
conjunction with this financing, the conversion price of the investor’s Series A
Preferred Stock was adjusted in accordance with the terms of the Series A
Preferred Stock, which resulted in the Series A Preferred Stock being
convertible into an additional 2,672,770 shares, or a total of 16,442,000
shares, of the Company’s common stock.
Series
C Convertible Redeemable Preferred Stock
Contemporaneously
with the consummation of the Nexia asset acquisition transaction (as described
in Note 2), the Company sold 7,480,978 shares of Series C Preferred Stock
to investors at a price of approximately $0.91 per share for net proceeds
of
$6,824,896. Included in these proceeds were two Canadian investors, who
previously invested in Nexia, who purchased an aggregate of 3,370,479 shares
of
Series C Preferred Stock for net proceeds of $3,074,880. Those proceeds were
used to partially fund the acquisition of the Nexia assets. In addition,
the
Company issued to such investors (i) warrants to acquire 2,244,296 shares
of
Series C Preferred Stock, which are exercisable at approximately $0.91 per
share
and which expire on March 10, 2008, and (ii) warrants to acquire 1,346,630
common shares, which are exercisable at $0.01 per share, subject to reduction
if
certain business milestones are met by the Company, as specified in the warrants
and which expire in October 2014.
The
Series C Preferred Stock bears a cumulative dividend rate of 8% per annum.
Accrued and unpaid dividends for Series C Preferred Stock at December 31,
2005 total $884,635.
Each
share of the Series C Preferred Stock is convertible into shares of common
stock
at the then-applicable conversion rate, as defined, at any time and at the
option of the holder. The initial conversion rate is one common share for
each
preferred share, which is subject to adjustment for certain defined equity
transactions. At December 31, 2005, the Company has reserved 22,799,574
shares of common stock for the potential conversion. The Series C Preferred
Stock will automatically convert into common stock at the then-applicable
conversion rate in the event of an initial public offering of the Company’s
common stock resulting in aggregate proceeds to the Company of $50 million
and a price per share of at least $2.74.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
7. Preferred
Stock (continued)
Series
C Convertible Redeemable Preferred Stock (continued)
The
Series C Preferred Stock has a liquidation preference in an amount equal
to the
original purchase price per share plus accumulated but unpaid dividends,
whether
or not declared, in the event of a liquidation, dissolution, winding-up,
sale,
or merger. This liquidation preference is senior to the Series A Preferred
Stock
and the common stock and equal to the liquidation preference of the Series
B
Preferred Stock.
The
Company recorded the Series C Preferred Stock at its fair value on the date
of
issuance of approximately $13,635,534, less the fair value assigned to warrants
of $1,816,799 and issuance costs of $330,495. The discount on the Series
C
Preferred Stock from the value assigned to the warrants and issuance costs
is
accreted to the carrying value of the preferred stock up to the earliest
redemption period using the effective interest method. The Company had
classified the Series C Preferred Stock outside of permanent equity as a
result
of certain redemption features. Because detachable warrants were granted
with
the financing and the Series C Preferred Stock contains contingently adjustable
conversion ratios, the Company evaluated the Series C Preferred Stock for
potential beneficial conversion features under EITF 98-5, Accounting
for Convertible Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratios,
and
EITF 00-27, Application
of Issue No. 98-5 to Certain Convertible Instruments.
Based
on the fact that the adjusted implied conversion price of the Series C Preferred
Stock exceeded the fair value of the common stock into which the Series C
Preferred Stock converts, no beneficial conversion feature was deemed to
exist.
The implied conversion price was calculated by dividing the fair value of
the
Series C Preferred Stock, net of the fair value of the warrants, by the number
of common shares into which the Series C Preferred Stock converts.
In
conjunction with the Series C Preferred Stock financing, the Series C Preferred
stockholders were granted 4,483,946 warrants to purchase preferred stock
for
$0.91. These warrants were valued using the Black-Scholes model and were
recorded as a $1,531,253 discount to the Series C Preferred Stock. This discount
is being accreted through the period up to the first redemption date using
the
effective interest method. The fair value of the warrants were estimated
at the
date of grant using the Black-Scholes model assuming a weighted-average
volatility of approximately 60%, a risk free interest rate of 3.9%, a dividend
yield of 0% and a weighted-average expected life of the warrant of 3.0
years.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
7. Preferred
Stock (continued)
Series
C Convertible Redeemable Preferred Stock (continued)
In
conjunction with the Series C Preferred Stock financing, the Series C Preferred
stockholders were granted 2,690,420 contingent warrants to purchase common
stock
for $0.01. The Company deemed 1,614,225 warrants to be probably of issuance.
Accordingly, 1,614,225 warrants were valued using the Black-Scholes model
and
were recorded as a $285,546 discount to the Series C Preferred Stock. This
discount is being accreted through the period up to the first redemption
date
using the effective interest method. The fair value of the warrants were
estimated at the date of grant using the Black-Scholes model assuming a
weighted-average volatility of approximately 60%, a risk free interest rate
of
4.5%, a dividend yield of 0% and a weighted-average expected life of the
warrant
of 9.6 years.
Commencing
October 7, 2009, the holders of the Series C Preferred Stock may require
the Company to redeem the Series C Preferred Stock then outstanding for an
amount equal to the original purchase price plus any unpaid dividends, whether
or not declared, and in preference to the Series A Preferred Stock liquidation
rights.
The
holders of the Series C Preferred Stock are entitled to the number of votes
equal to the number of common shares into which its shares are convertible.
8. Minority
Interest - Series C Convertible Redeemable Preferred Stock of PharmAthene
Canada, Inc.
Through
its ownership of 100% of the common stock in PharmAthene Canada, Inc., the
Company controls all of the voting stock of PharmAthene Canada, Inc. and
considers itself to be the majority interest primary beneficiary of PharmAthene
Canada, Inc., a variable interest entity. In March 2005, a Canadian
investor purchased 2,591,654 shares of Series C Convertible Preferred Stock
of
PharmAthene Canada, Inc. for net proceeds of $2,364,366. The shares of Series
C
Convertible Preferred Stock of PharmAthene Canada, Inc. are convertible at
the
discretion of the investors into an equal number of shares of Series C Preferred
Stock of the Company. In addition, the Company issued to such investors (i)
warrants to acquire 777,496 Series C Preferred Stock of PharmAthene Canada,
Inc.
(also convertible into Series C Preferred Stock of the Company) exercisable
at
approximately $0.91 per share, which expire on March 10, 2008, and (ii)
warrants to acquire 466,498 common shares of PharmAthene Canada, Inc.
exercisable at $0.01 per share, convertible into shares of common stock of
the
Company on a 1-for-1 basis, subject to reduction if certain business milestones
are met by the Company, as specified in the warrants and which expire in
October 2014.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
8. Minority
Interest - Series C Convertible Redeemable Preferred Stock of PharmAthene
Canada, Inc. (continued)
In
conjunction with the Series C financing, the Series C Preferred Stock of
PharmAthene Canada, Inc. stockholders were granted 777,496 warrants to purchase
preferred stock for $0.91. These warrants were valued using the Black-Scholes
model and were recorded as a $265,513 discount to the Series C Preferred
Stock
of PharmAthene Canada, Inc. This discount is being accreted through the period
up to the first redemption date using the effective interest method. The
fair
value of the warrants were estimated at the date of grant using the
Black-Scholes model assuming a weighted-average volatility of approximately
60%,
a risk free interest rate of 3.9%, a dividend yield of 0% and a weighted-average
expected life of the warrant of 3.0 years.
In
conjunction with the Series C financing, the Series C Preferred Stock of
PharmAthene Canada, Inc. stockholders were granted 466,498 contingent warrants
to purchase common stock for $0.01. The Company deemed 279,894 warrants to
be
probable of issuance. Accordingly, 279,894 warrants were valued using the
Black-Scholes model and were recorded as a $49,512 discount to the Series
C
Preferred Stock of PharmAthene Canada, Inc. This discount is being accreted
through the period up to the first redemption date using the effective interest
method. The fair value of the warrants were estimated at the date of grant
using
the Black-Scholes model assuming a weighted-average volatility of approximately
60%, a risk free interest rate of 4.5%, a dividend yield of 0% and a
weighted-average expected life of the warrant of 9.6 years.
The
Series C Convertible Preferred Stock of PharmAthene Canada, Inc. bears a
cumulative dividend rate of 8% per annum. Accrued and unpaid dividend for
the
Series C Convertible Preferred Stock of PharmAthene Canada, Inc. at
December 31, 2005 total $153,392.
The
holders of Series C Convertible Preferred Stock of PharmAthene Canada, Inc.
have
no voting rights.
9. Stockholders’
Deficit
Common
Stock
On
August 28, 2003, the Company’s Board of Directors approved a 50-for-1 stock
split to be effected in the form of a stock dividend payable to stockholders
of
record as of August 28, 2003. On September 11, 2003, the Company
effected the 50-for-1 stock split.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
9. Stockholders’
Deficit (continued)
Common
Stock (continued)
On
October 6, 2003, the Company’s Board of Directors approved a 2-for-1 stock
split to be effected in the form of a stock dividend payable to stockholders
of
record as of October 6, 2003. On October 15, 2003, the Company
effected the 2-for-1 stock split.
All
common stock shares and amounts presented in the consolidated financial
statements and related footnotes for all periods presented have been restated
to
reflect the 50-for-1 and 2-for-1 stock splits.
In
conjunction with the Series A Preferred Stock closing, the common stockholders
agreed to certain limitations on their rights to sell their stock. Further,
the
common stockholders agreed that 5,370,000 shares of common stock would be
subject to a right of repurchase by the Company and the Series A Preferred
Stock
investor in the event of a termination of the relationship between the Company
and the Series A Preferred Stock investor. The repurchase price will be either
cost or fair market value, depending on the termination event. The number
of
shares subject to the repurchase right decreased by 41.67% on December 11,
2004, and further decreases by 8.33% quarterly thereafter until
September 11, 2006. As of December 31, 2005, 2,214,846 shares remained
subject to the right of repurchase.
Cash
Dividends
Upon
the
closing of the Series A Preferred Stock financing, the Company declared and
paid
a cash dividend of $0.614525 per share ($3,299,999 in aggregate) to all common
stockholders of record as of September 12, 2003.
2002
Long-Term Incentive Plan
The
Company adopted the 2002 Long-Term Incentive Plan (the Plan) to provide an
incentive to eligible employees, consultants, and officers. The Plan provides
for the granting of stock options, restricted common stock, and stock
appreciation rights. As of December 31, 2005, the Company had reserved
10,919,372 shares of common stock for distribution under the Plan, of which
1,330,463 remain available for future grants. Stock options granted under
the
Plan may be either incentive stock options, as defined by the Internal Revenue
Code, or non-qualified stock options. The Board of Directors determines who
will
receive options, the vesting period which is generally four years, and the
exercise price. Options may have a maximum term of no more than 10
years.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
9. Stockholders’
Deficit (continued)
2002
Long-Term Incentive Plan (continued)
The
following table summarizes the activity of the Company’s stock option
plan:
|
|
Shares
|
|
Weighted-Average
Exercise Price
|
|
|
|
|
|
|
|
Outstanding,
January 1, 2003
|
|
|
-
|
|
$
|
-
|
|
Granted
|
|
|
4,320,296
|
|
|
0.12
|
|
Exercised
|
|
|
1,400,000
|
|
|
0.04
|
|
Outstanding,
December 31, 2003
|
|
|
2,920,296
|
|
|
0.16
|
|
Exercisable,
December 31, 2003
|
|
|
-
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Outstanding,
January 1, 2004
|
|
|
2,920,296
|
|
$
|
0.16
|
|
Granted
|
|
|
514,330
|
|
|
0.17
|
|
Exercised
|
|
|
-
|
|
|
-
|
|
Outstanding,
December 31, 2004
|
|
|
3,434,626
|
|
$
|
0.16
|
|
Exercisable,
December 31, 2004
|
|
|
650,603
|
|
$
|
0.16
|
|
|
|
|
|
|
|
|
|
Outstanding,
January 1, 2005
|
|
|
3,434,626
|
|
$
|
0.16
|
|
Granted
|
|
|
5,497,677
|
|
|
0.21
|
|
Exercised
|
|
|
202,906
|
|
|
0.13
|
|
Forfeited
|
|
|
743,394
|
|
|
0.19
|
|
Outstanding,
December 31, 2005
|
|
|
7,986,003
|
|
$
|
0.19
|
|
Exercisable,
December 31, 2005
|
|
|
2,405,369
|
|
$
|
0.18
|
|
Exercise
prices for options granted during 2005 were $0.21 per share. The
weighted-average remaining contractual life of those options is approximately
9.2 years. As of the date of grant, the weighted-average fair value of the
options granted in 2005 was $0.14.
Exercise
prices for options granted during 2004 ranged from $0.16 to $0.21 per share.
The
weighted-average remaining contractual life of those options is approximately
8.7 years. As of the date of grant, the weighted-average fair value of the
options granted in 2004 was $0.10.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
9. Stockholders’
Deficit (continued)
2002
Long-Term Incentive Plan (continued)
Exercise
prices for options granted during 2003 ranged from $0.04 to $0.16 per share.
The
weighted-average remaining contractual life of those options is approximately
9.6 years. As of the date of grant, the weighted-average fair value of the
options granted in 2003 was $0.07.
The
weighted-average expected life of options outstanding at December 31, 2005
is approximately 8.7 years.
In
2003,
2004 and 2005, the Company granted options to non-employees to purchase up
to
200,000, 125,000 and 38,000 shares, respectively, of the Company’s common stock
at exercise prices of $0.04, $0.16 and $0.21 per share, respectively. The
2003
options vested immediately, and the fair value measurement of these options
at
the grant date was recorded as compensation expense. The 2004 and 2005 options
vest over four years. Stock-based compensation expense recorded during the
years
ended December 31, 2005, 2004 and 2003 was $3,517, $2,448 and $4,000,
respectively.
Warrants
In
August 2003 in connection with entering into an operating lease for office
space, the Company issued a warrant to an affiliate of its landlord to purchase
up to 263,296 shares of common stock at an exercise price of $0.01 per share.
The warrant is exercisable at any time until August 2013. The Company
recorded the aggregate fair value of the warrant of $10,683 as rent expense
in
2003.
In
conjunction with the Series B Preferred Stock issuance in October 2004, the
Company issued warrants to purchase 15,400,000 shares of common stock at
an
exercise price of $0.01 per share, subject to reduction if certain business
milestones are met by the Company, as specified in the warrants and expiring
in
October 2014. As of December 31, 2004, milestones related to 1,540,000
shares of common stock underlying of the warrants to purchase common stock
were
attained, with the outstanding total of warrants reduced to 13,860,000.
Following the Nexia asset purchase in March 2005 (as described in
Note 2), an additional milestone related to 6,160,001 shares of common
stock underlying of the warrants was achieved, and the total warrants
outstanding were further reduced to 7,699,999.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
9. Stockholders’
Deficit (continued)
Warrants
(continued)
The
following table summarizes the activity of the Company’s warrants:
|
|
Warrants
for Shares of Common Stock
|
|
Weighted-Average
Exercise Price
|
|
Warrants
for Shares of Preferred Stock
|
|
Weighted-Average
Exercise Price
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
at January 1, 2003
|
|
|
-
|
|
$
|
-
|
|
|
-
|
|
$
|
-
|
|
Granted
|
|
|
263,296
|
|
|
0.01
|
|
|
-
|
|
|
-
|
|
Forfeited
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
Outstanding
at December 31, 2003
|
|
|
263,296
|
|
|
0.01
|
|
|
-
|
|
|
-
|
|
Granted
|
|
|
15,400,000
|
|
|
0.01
|
|
|
-
|
|
|
-
|
|
Forfeited
|
|
|
(1,540,000
|
)
|
|
0.01
|
|
|
-
|
|
|
-
|
|
Outstanding
at December 31, 2004
|
|
|
14,123,296
|
|
|
0.01
|
|
|
-
|
|
|
-
|
|
Granted
|
|
|
3,156,918
|
|
|
0.01
|
|
|
5,261,442
|
|
|
0.91
|
|
Forfeited
|
|
|
(6,160,001
|
)
|
|
0.01
|
|
|
-
|
|
|
-
|
|
Outstanding
at December 31, 2005
|
|
|
11,120,213
|
|
$
|
0.01
|
|
|
5,261,442
|
|
$
|
0.91
|
|
10. Income
Taxes
For
the
years ended December 31, 2005, 2004 and 2003, there is no current provision
for income taxes, and the deferred tax provision has been entirely offset
by a
valuation allowance. Actual income tax benefit differs from the expected
income
tax benefit computed at the federal statutory rate as follows:
|
|
December 31
|
|
|
|
2005
|
|
2004
|
|
2003
|
|
|
|
|
|
|
|
|
|
Statutory
federal tax benefit
|
|
$
|
(7,654,035
|
)
|
$
|
(3,351,673
|
)
|
$
|
(2,226,335
|
)
|
State
income tax, net of federal benefit
|
|
|
(326,400
|
)
|
|
(453,900
|
)
|
|
(299,900
|
)
|
Other
permanent differences
|
|
|
16,700
|
|
|
7,300
|
|
|
1,500
|
|
Other,
net
|
|
|
(96,331
|
)
|
|
(616
|
)
|
|
6,289
|
|
Increase
in valuation allowance
|
|
|
8,060,066
|
|
|
3,798,889
|
|
|
2,518,446
|
|
|
|
$ |
-
|
|
$
|
-
|
|
$
|
-
|
|
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
10. Income
Taxes (continued)
The
Company’s net deferred tax assets consisted of the following:
|
|
December 31
|
|
|
|
2005
|
|
2004
|
|
|
|
|
|
|
|
Deferred
tax assets:
|
|
|
|
|
|
Net
operating loss carryforwards
|
|
$
|
10,188,453
|
|
$
|
6,418,954
|
|
Depreciation/amortization
|
|
|
3,967,637
|
|
|
-
|
|
Research
and development credits
|
|
|
267,764
|
|
|
-
|
|
Accrued
expenses and other
|
|
|
54,680
|
|
|
3,012
|
|
|
|
|
14,478,534
|
|
|
6,421,966
|
|
Deferred
tax liabilities:
|
|
|
|
|
|
|
|
Depreciation/amortization
|
|
|
-
|
|
|
(3,498
|
)
|
|
|
|
-
|
|
|
(3,498
|
)
|
Gross
deferred tax assets
|
|
|
14,478,534
|
|
|
6,418,468
|
|
Less:
valuation allowance
|
|
|
(14,478,534
|
)
|
|
(6,418,468
|
)
|
Net
deferred tax assets
|
|
$
|
-
|
|
$
|
-
|
|
The
deferred tax amounts discussed above are classified as follows:
|
|
December 31
|
|
|
|
2005
|
|
2004
|
|
|
|
|
|
|
|
Current
deferred tax assets
|
|
$
|
322,444
|
|
$
|
3,012
|
|
Non-current
deferred tax assets
|
|
|
14,156,090
|
|
|
6,415,456
|
|
|
|
|
14,478,534
|
|
|
6,418,468
|
|
Less:
valuation allowance
|
|
|
(14,478,534
|
)
|
|
(6,418,468
|
)
|
Net
deferred tax assets
|
|
$
|
-
|
|
$
|
-
|
|
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
10. Income
Taxes (continued)
In
assessing the realizability of deferred tax assets, management considers
whether
it is more likely than not that some or all of the deferred tax asset will
not
be realized. The ultimate realization of the deferred tax asset is dependent
upon the generation of future taxable income during the periods in which
the net
operating loss carryforwards are available. Management considers projected
future taxable income, the scheduled reversal of deferred tax liabilities
and
available tax planning strategies that can be implemented by the Company
in
making this assessment. Based upon the level of historical taxable income
and
projections for future taxable income over the periods in which the net
operating loss carryforwards are available to reduce income taxes payable,
management has established a full valuation allowance.
The
U.S. federal net operating loss carryforwards of approximately
$23.8 million will begin to expire in various years beginning 2022. The use
of the Company’s net operating loss carryforwards may be restricted because of
changes in company ownership in accordance with I.R.C. Section 382. The
Canadian net operating loss carryforwards of approximately $3.3 million
will expire in 2015. Additionally, despite the net operating loss carryforwards,
the Company may have a future tax liability due to alternative minimum tax
or
state tax requirements.
The
Company intends to permanently reinvest foreign earnings within the foreign
country.
11. Commitments
and Contingencies
Leases
The
Company leases offices in the United States under a month-to-month operating
lease agreement. Additionally, following the Nexia asset purchase in
March 2005, the Company entered into a two year renewable lease agreement
for office space in Canada. This lease is renewable for an additional two
years
and provides for expansion into additional facility space if available. Annual
minimum payments are as follows:
2006
|
|
$
|
138,026
|
|
2007
|
|
|
89,138
|
|
|
|
$
|
227,164
|
|
Total
rent expense under operating lease agreements approximated $520,365, $69,333
and
$14,870 for the years ended December 31, 2005, 2004 and 2003, respectively.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
11. Commitments
and Contingencies (continued)
License
Agreements
In
June 2002, the Company licensed certain patent rights from a university.
The license agreement required a $125,000 up-front payment and a $125,000
payment upon closing of the Series A Preferred Stock. Amounts paid to the
university upon the closing of the Series A Preferred Stock are included
in
research and development expense in the accompanying statements of operations.
Upon
commercialization, the license agreement requires royalty payments equal
to a
specified percentage of future sales of products subject to the license through
the expiration of the licensed patents, as well as a percentage of any
nonroyalty sublicense income.
In
November 2004, the Company licensed certain patent rights from two
universities. The license agreements required a $50,000 up-front payment
to be
paid over two years. Additionally, payments within the agreement included
a
sublicense fee of 12.5% until Investigational New Drug Application (IND)
filing,
a minimum royalty of $10,000 a year beginning in 2009, and a milestone payment
of $100,000 upon Biologics License Application (BLA) approval. Upon
commercialization, the license agreements require royalty payments equal
to a
specified percentage of future sales of products subject to the license through
the expiration of the licensed patents.
In
2005,
the Company determined that the program for which these license agreements
were
entered into was not a viable product. Accordingly, the Company terminated
these
agreements and agreed to pay $7,756 and $37,364 to terminate the June 2002
and November 2004 license agreements, respectively. Of these amounts,
$37,364 was accrued for at year end, and no additional future payments are
required.
In
March 2005, the Company licensed certain patent rights from a company. The
license agreement required a $75,000 up front payment. Additionally, the
license
agreement requires royalties payments equal to specific percentages of future
sales of products subject to the license through the expiration of the licensed
patent. In the event that the minimum annual royalty amount of $75,000 has
not
been met by either the earliest of obtaining a biologics license application
or
three years upon execution of the license agreement, the Company will pay
the
difference between the minimum royalty payment and those royalties actually
paid.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
12. Related
Party Transactions
Upon
the
closing of the Series A Preferred Stock financing, legal fees totaling
$1.0 million were paid to an affiliate of a shareholder. No additional fees
were paid to that shareholder or its affiliate during 2003.
The
Company leases its office space from an entity that is affiliated with the
organization to which the Company issued warrants for 263,296 shares of common
stock in August 2003 (see Note 10). The Company paid $78,448, $69,333
and $14,870 in rent expense related to this operating lease for the years
ended
December 31, 2005, 2004 and 2003, respectively.
13. Medarex
Collaboration
In
November 2004, the Company and Medarex, Inc. entered into a collaboration
agreement under which the companies plan to develop and commercialize MDX-1303,
a fully human monoclonal antibody targeting the Bacillus
anthracis protective
antigen. MDX-1303 was developed by Medarex using its UltiMAb Human Antibody
Development System®,
and
this antibody is currently in preclinical development by Medarex for use
against
human anthrax infection.
Under
the
terms of the agreement, Medarex and PharmAthene have agreed jointly to continue
to investigate the potential for MDX-1303 to be used as a therapeutic for
individuals with active disease as well as for prophylactic treatment of
individuals exposed to anthrax. In December 2004, Medarex received a
deposit from PharmAthene against potential future development activities
for
MDX-1303, against which Medarex must submit reports of the use of costs as
they
are incurred in order to take draw downs against the deposit. If the project
is
terminated or if development activities for MDX-1303 by Medarex are completed
prior to exhaustion of the deposit, amounts remaining under the deposit are
to
be returned to PharmAthene. For the twelve months ended December 31, 2005
and 2004, PharmAthene recorded the use of these funds for development activities
for MDX-1303 as Research and Development operating expenses of $577,000 and
$87,000, respectively, and, as of December 31, 2005 and December 31,
2004, approximately $1.3 million and $1.9 million, respectively, of
this deposit remained. PharmAthene is fully responsible for funding all future
research and development activities that are not supported by government
funds.
The companies will share profits according to a pre-agreed allocation
percentage.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
14. 8%
Convertible Notes
In
June 2004, the Series A Preferred Stock investor and the Company entered
into an agreement for up to $3.0 million in the form of convertible notes
(the Bridge Notes). The Bridge Notes were repayable upon the earlier of (i)
the
closing of a financing with gross proceeds in excess of $10.0 million, (ii)
the sale of the Company, or (iii) December 31, 2004. The Bridge Notes bear
interest at a rate of 8% per annum and are convertible at the investor’s option
into the next round of financing or, if no financing has occurred by
December 31, 2004, into Series A Preferred Stock.
The
Company drew down $1.5 million under the Bridge Notes in June 2004. In
October 2004, the bridge loan was converted to Series B Preferred Stock at
approximately $0.91 per share. In conjunction with this financing, the
conversion price of the investor’s Series A Preferred Stock was adjusted in
accordance with the terms of the Series A Preferred Stock, which resulted
in the Series A Preferred Stock being convertible into an additional 2,672,770
shares, or a total of 16,442,000 shares, of the Company’s common
stock.
15. Subsequent
Events
Merger
Agreement
On
March 9, 2006, the Company entered into a term sheet for the merger of the
Company with SIGA Technologies Inc. (SIGA). Pursuant to this agreement,
shareholders of the Company will receive shares of SIGA common stock and
warrants will be converted into options and warrants to purchase common stock
of
the combined company. It is expected that shareholders of the Company will
own
approximately 68% of the combined company, which is anticipated to remain
listed
on the NASDAQ stock market. Subject to the execution of a definitive merger
agreement, shareholder of both the Company and SIGA approvals, regulatory
approval and other customary closing conditions, the Company expects the
merger
to close in the second or third quarter of 2006. The Company is entitled
to
certain fees in the event that the merger is not completed and SIGA completes
an
alternative financing within a certain time period.
In
conjunction with the transaction, the Company has agreed to enter into a
Bridge
Note Purchase Agreement providing SIGA with interim financing up to
$3.0 million, of which the Company has already paid $2.0 million. This
interim financing is subject to the execution of a definitive merger
agreement.
PharmAthene, Inc.
Notes
to
Consolidated Financial Statements (continued)
16. Quarterly
Information (Unaudited)
Set
forth
below is the Company’s quarterly financial information for the previous two
fiscal years:
|
|
Three
months ended
|
|
|
|
March 31,
20051
|
|
June 30,
2005
|
|
September 30,
2005
|
|
December 31,
2005
|
|
|
|
|
|
|
|
|
|
|
|
Total
revenue
|
|
$
|
277,389
|
|
$
|
440,210
|
|
$
|
200,061
|
|
$
|
180,740
|
|
Loss
from operations
|
|
|
(15,175,457
|
)
|
|
(2,347,838
|
)
|
|
(2,398,396
|
)
|
|
(3,812,900
|
)
|
Net
loss attributable to common shareholders
|
|
|
(16,171,737
|
)
|
|
(3,777,955
|
)
|
|
(3,844,129
|
)
|
|
(5,258,548
|
)
|
Net
loss attributable to common shareholders per share - basic and
diluted
|
|
|
(1.51
|
)
|
|
(0.35
|
)
|
|
(0.35
|
)
|
|
(0.48
|
)
|
|
|
Three
months ended
|
|
|
|
March 31,
2004
|
|
June 30,
2004
|
|
September 30,
2004
|
|
December 31,
2004
|
|
|
|
|
|
|
|
|
|
|
|
Total
revenue
|
|
$
|
-
|
|
$
|
585,854
|
|
$
|
(157,852
|
)
|
$
|
609,977
|
|
Loss
from operations
|
|
|
(2,672,019
|
)
|
|
(1,469,719
|
)
|
|
(3,099,777
|
)
|
|
(2,917,138
|
)
|
Net
loss attributable to common shareholders
|
|
|
(2,972,513
|
)
|
|
(1,778,235
|
)
|
|
(3,440,478
|
)
|
|
(4,250,054
|
)
|
Net
loss attributable to common shareholders per share - basic and
diluted
|
|
|
(0.28
|
)
|
|
(0.17
|
)
|
|
(0.32
|
)
|
|
(0.40
|
)
|
1
As
described in Note 2, loss from operations for the three months ended
March 31, 2005 includes a $12,812,000 charge to acquired in-process
research and development related to the Nexia asset acquisition.
ANNEX
A
execution
document
AGREEMENT
AND PLAN OF MERGER
DATED
AS OF
JANUARY
19,
2007
BY
AND AMONG
HEALTHCARE
ACQUISITION CORP.,
PAI
ACQUISITION CORP.
AND
PHARMATHENE,
INC.
TABLE
OF
CONTENTS
|
|
page |
ARTICLE
I
|
THE
MERGER
|
1
|
|
|
|
1.1.
|
Defined
Terms
|
1
|
1.2.
|
The
Merger
|
1
|
1.3.
|
Closing
|
2
|
1.4.
|
Effective
Time
|
2
|
1.5.
|
Effects
of the Merger
|
2
|
1.6.
|
Certificate
of Incorporation
|
2
|
1.7.
|
Bylaws
|
2
|
1.8.
|
Directors
and Officers.
|
2
|
1.9.
|
Effect
of Merger on Company Capital Stock and Options; Merger
Consideration
|
2
|
1.10.
|
Merger
Sub Stock
|
2
|
1.11.
|
Dissenters’
Rights
|
2
|
1.12.
|
Certain
Other Adjustments
|
2
|
1.13.
|
Distributions
with Respect to Unexchanged Shares
|
2
|
1.14.
|
No
Further Ownership Rights in Company Capital Stock
|
2
|
1.15.
|
No
Fractional Shares of Parent Common Stock.
|
2
|
1.16.
|
No
Liability
|
2
|
1.17.
|
Surrender
of Certificates
|
2
|
1.18.
|
Lost,
Stolen or Destroyed Certificates
|
2
|
1.19.
|
Withholding
Rights
|
2
|
1.20.
|
Further
Assurances
|
2
|
1.21.
|
Stock
Transfer Books
|
2
|
1.22.
|
Tax
Consequences
|
2
|
1.23.
|
Escrow
|
2
|
1.24.
|
Rule
145
|
2
|
|
|
|
ARTICLE
II
|
REPRESENTATIONS
AND WARRANTIES
|
2
|
|
|
|
2.1.
|
Representations
and Warranties of Parent
|
2
|
2.2.
|
Representations
and Warranties of Parent with Respect to Merger Sub
|
2
|
2.3.
|
Representations
and Warranties of Company
|
2
|
|
|
|
ARTICLE
III
|
COVENANTS
RELATING TO CONDUCT OF BUSINESS
|
2
|
|
|
|
3.1.
|
Conduct
of Business of Company Pending the Merger
|
2
|
3.2.
|
Conduct
of Business of Parent Pending the Merger
|
2
|
3.3.
|
Operational
Matters
|
2
|
|
|
|
ARTICLE
IV
|
ADDITIONAL
AGREEMENTS
|
2
|
TABLE
OF CONTENTS (Continued)
|
|
page |
4.1.
|
Preparation
of Proxy Statement.
|
2
|
4.2.
|
Access
to Information
|
2
|
4.3.
|
Commercially
Reasonable Efforts.
|
2
|
4.4.
|
No
Solicitation of Transactions
|
2
|
4.5.
|
Employee
Benefits Matters
|
2
|
4.6.
|
Notification
of Certain Matters
|
2
|
4.7.
|
Public
Announcements
|
2
|
4.8.
|
Affiliates
|
2
|
4.9.
|
[reserved]
|
2
|
4.10.
|
Takeover
Statutes
|
2
|
4.11.
|
Transfer
Taxes
|
2
|
4.12.
|
AMEX
Listing; Symbol
|
2
|
4.13.
|
Trust
Fund Closing Confirmation.
|
2
|
4.14.
|
Directors
and Officers of Parent After the Merger
|
2
|
|
|
|
ARTICLE
V
|
Post
Closing Covenants
|
2
|
|
|
|
5.1.
|
General
|
2
|
5.2.
|
Litigation
Support
|
2
|
5.3.
|
Transition
|
2
|
5.4.
|
Tax-Free
Reorganization Treatment
|
2
|
5.5.
|
Headquarters
of Surviving Corporation
|
2
|
5.6.
|
Indemnification
of Directors and Officers of Company
|
2
|
5.7.
|
Continuity
of Business Enterprise
|
2
|
5.8.
|
Substantially
All Requirement
|
2
|
5.9.
|
Composition
of the Board of Directors of Parent
|
2
|
|
|
|
ARTICLE
VI
|
CONDITIONS
PRECEDENT
|
2
|
|
|
|
6.1.
|
Conditions
to Each Party’s Obligation to Effect the Merger
|
2
|
6.2.
|
Additional
Conditions to Obligations of Parent and Merger Sub
|
2
|
6.3.
|
Additional
Conditions to Obligations of Company
|
2
|
|
|
|
ARTICLE
VII
|
TERMINATION
AND AMENDMENT
|
2
|
|
|
|
7.1.
|
Termination
|
2
|
7.2.
|
Effect
of Termination.
|
2
|
7.3.
|
Trust
Fund Waiver
|
2
|
7.4.
|
Fees
and Expenses
|
2
|
|
|
|
ARTICLE
VIII
|
REMEDIES
FOR BREACH OF AGREEMENT
|
2
|
TABLE
OF CONTENTS (Continued)
|
|
page |
8.1.
|
Survival
of Representations and Warranties
|
2
|
8.2.
|
Indemnification
Provisions for Benefit of Parent
|
2
|
8.3.
|
Matters
Involving Third Parties.
|
2
|
8.4.
|
Determination
of Adverse Consequences
|
2
|
8.5.
|
Escrow
of Shares by Indemnifying Stockholders
|
2
|
8.6.
|
Determination/Resolution
of Claims.
|
2
|
8.7.
|
Indemnification
Threshold
|
2
|
8.8.
|
Other
Indemnification Provisions.
|
2
|
|
|
|
ARTICLE
IX
|
GENERAL
PROVISIONS
|
2
|
|
|
|
9.1.
|
Survival
|
2
|
9.2.
|
Notices
|
2
|
9.3.
|
Interpretation
|
2
|
9.4.
|
Counterparts
|
2
|
9.5.
|
Entire
Agreement; No Third-Party Beneficiaries.
|
2
|
9.6.
|
Governing
Law; Waiver of Jury Trial.
|
2
|
9.7.
|
Severability
|
2
|
9.8.
|
Amendment
|
2
|
9.9.
|
Extension;
Waiver
|
2
|
9.10.
|
Assignment
|
2
|
9.11.
|
Submission
to Jurisdiction; Waivers.
|
2
|
9.12.
|
Enforcement;
Specific Performance
|
2
|
|
|
|
ARTICLE
X
|
DEFINITIONS
|
2
|
|
|
|
Schedule
1.9(b)(i)
|
Exchange
Ratio
|
2
|
|
|
|
Schedule
1.24
|
Company
Affiliates
|
2
|
|
|
|
Schedule
X(o)
|
PA
Management Team
|
2
|
Exhibit
A
|
Form
of 8% of Convertible Note
|
Exhibit
B
|
Form
of Stock Escrow Agreement
|
Exhibit
C
|
Form
of Lockup Agreement
|
Exhibit
D
|
Form
of Registration Rights Agreement
|
Exhibit
E
|
Form
of Note Exchange Agreement
|
AGREEMENT
AND PLAN OF MERGER,
dated
as of January 19, 2007 (this “Agreement”),
by
and among Healthcare Acquisition Corp., a Delaware corporation (“Parent”),
PAI
Acquisition Corp., a Delaware corporation and a direct, wholly-owned subsidiary
of Parent (“Merger
Sub”),
and
PharmAthene, Inc., a Delaware corporation (“Company”).
WITNESSETH:
WHEREAS,
the
respective Boards of Directors of Parent and Company have determined that
it is
advisable and in the best interests of each corporation and its stockholders
that Parent and Company engage in a business combination in order to advance
the
long-term strategic business interests of Parent and Company; and
WHEREAS,
in
furtherance of such determination, Parent and Company desire to engage in
a
business combination transaction by means of a merger pursuant to which Merger
Sub, a direct, wholly-owned subsidiary of Parent formed solely for the purpose
of effecting the merger, will merge with and into Company as a result of
which
Company will be the surviving corporation and a direct, wholly-owned subsidiary
of Parent; and
WHEREAS,
in
furtherance of such desire, the respective Boards of Directors of Parent,
Merger
Sub and Company have adopted or approved this Agreement, pursuant to which,
subject to the terms and conditions hereof and in accordance with the General
Corporation Law of the State of Delaware, Merger Sub will be merged with
and
into Company with Company being the surviving corporation (the “Merger”);
and
WHEREAS,
prior
to
or concurrently with the execution of this Agreement, the holders of a Requisite
Majority of the Company Capital Stock (each as defined herein) have executed
or
are executing an Allocation Agreement (as defined herein), pursuant to which
they, among other things, are agreeing to the allocation of the Merger
Consideration (as defined herein) as set forth therein;
NOW,
THEREFORE,
in
consideration of the foregoing and the respective representations, warranties,
covenants and agreements of the parties set forth in this Agreement, and
intending to be legally bound hereby, the parties hereto agree as
follows:
ARTICLE
I
THE
MERGER
1.1. Defined
Terms.
All
terms not otherwise defined throughout this Agreement shall have the meanings
ascribed to such terms in Article X of this Agreement.
1.2. The
Merger.
Upon
the terms and subject to the conditions set forth in this Agreement, and
in
accordance with the Delaware General Corporation Law (the “DGCL”),
Merger Sub shall be merged with and into Company at the Effective Time (as
defined in Section 1.4). Upon consummation of the Merger, the separate corporate
existence of Merger Sub shall cease and Company shall continue as the surviving
corporation (the “Surviving
Corporation”).
1.3. Closing.
Subject
to the terms and conditions hereof, the closing of the Merger and the
transactions contemplated by this Agreement (the “Closing”)
will
take place on or before the third Business Day after the satisfaction or
waiver
(subject to applicable law) of the conditions set forth in Article VI (other
than any such conditions which by their terms cannot be satisfied until the
Closing, which shall be required to be so satisfied or waived (subject to
applicable law) on the Closing Date) unless another time or date is agreed
to in
writing by the parties hereto (the actual time and date of the Closing being
referred to herein as the “Closing
Date”).
The
Closing shall be held at the offices of Ellenoff Grossman & Schole, LLP, 370
Lexington Avenue, New York, New York, unless another place is agreed to in
writing by the parties hereto.
1.4. Effective
Time.
At the
Closing, the parties shall file a certificate of merger (the “Certificate
of Merger”)
in
such form as is required by and executed in accordance with the relevant
provisions of the DGCL. The Merger shall become effective at such time as
the
Certificate of Merger is duly filed with the Secretary of State of the State
of
Delaware, or at such subsequent time as Parent and Company shall agree and
as
shall be specified in the Certificate of Merger (the date and time that the
Merger becomes effective being referred to herein as the “Effective
Time”).
1.5. Effects
of the Merger.
At and
after the Effective Time, the effect of the Merger shall be as provided in
this
Agreement and the applicable provisions of the DGCL. Without limiting the
generality of the foregoing, and subject thereto, at the Effective Time all
of
the property, rights, privileges, powers and franchises of Company and Merger
Sub shall be vested in the Surviving Corporation, and all debts, liabilities
and
duties of Company and Merger Sub shall be the debts, liabilities and duties
of
the Surviving Corporation.
1.6. Certificate
of Incorporation.
At the
Effective Time and without any further action on the part of Company or Merger
Sub, the certificate of incorporation of Company, as in effect immediately
prior
to the Effective Time, shall be the certificate of incorporation of the
Surviving Corporation, and thereafter shall continue to be the certificate
of
incorporation until changed or amended as provided therein and under applicable
law. Notwithstanding the foregoing, the certificate of incorporation of Company
shall be amended and restated as of the Effective Time to provide for the
changing of the name of Company and to eliminate all classes of equity
securities other than common stock.
1.7. Bylaws.
At the
Effective Time and without any further action on the part of Company and
Merger
Sub, the bylaws of Company, as in effect immediately prior to the Effective
Time, shall be the bylaws of the Surviving Corporation, and thereafter shall
continue to be the bylaws until changed or amended or repealed as provided
therein, in the certificate of incorporation of the Surviving Corporation
and
under applicable law.
1.8. Directors
and Officers.
(a) Members
of Board of Directors.
From
and after the Effective Time, the members of the Board of Directors of both
the
Parent and the Surviving Corporation shall consist of John Pappajohn, Derace
M.
Schaffer, M.D., James Cavanaugh, Steven St. Peter, Elizabeth Czerepak, Joel
McCleary and David Wright, each to serve until his or her successor is elected
and qualified or until his or her earlier death, resignation or removal.
If at
or after the Effective Time a vacancy shall exist in the Board of Directors
of
Parent and the Surviving Corporation, such vacancy may thereafter be filled
in
the manner provided by law, the certificate of incorporation and bylaws of
Parent and the Surviving Corporation, as the case may be.
(b) Officers
of Parent and Surviving Corporation.
From
and after the Effective Time, the officers of Parent and of the Surviving
Corporation shall be elected by the Board of Directors of each entity provided,
however, that David Wright shall be elected Chief Executive Officer of each
such
entity to serve until his successor is elected and qualified or until his
earlier death, resignation or termination.
1.9. Effect
of Merger on Company Capital Stock and Options; Merger
Consideration.
Subject
to the terms and conditions of this Agreement, at the Effective Time, by
virtue
of the Merger and this Agreement and without any action on the part of Merger
Sub, Company or the holder of any shares of Company Capital Stock (as defined
in
clause (b)(i) below) the following shall occur:
(a) Company
Treasury Shares. All
shares of Company Common Stock (as defined in clause (b)(i) below) that are
held
by Company as treasury stock (the “Company
Treasury Shares”)
or
owned by Merger Sub, Parent or any direct, or indirect, wholly-owned subsidiary
of Parent immediately prior to the Effective Time shall be canceled and shall
cease to exist and no cash, Parent Common Stock (as defined in clause (b)(i)
below) or other consideration shall be delivered in exchange
therefor.
(b) Company
Capital Stock.
(i) The
shares of common stock of Company, $.001 par value (the ‘‘Company
Common Stock”),
Series
A Convertible Preferred Stock of Company, $.001 par value (the “Company
Series A Preferred Stock”‘),
Series B Convertible Preferred Stock of Company, $.001 par value (the
“Company
Series B Preferred Stock”),
and
Series C Convertible Preferred Stock of Company, $.001 par value (the
“Company
Series C Preferred Stock”
and
together with the Company Series A Preferred Stock, and the Company Series
B
Preferred Stock, the “Company
Preferred Stock” and
together with the Company Common Stock collectively referred to as“Company
Capital Stock”,
outstanding immediately prior to the Effective Time, shall be deemed canceled
and converted into the right to receive the merger consideration comprised
of:
(y) 12,500,000 shares of Common Stock of Parent, $.0001 par value (“Parent
Common Stock”),
subject to upward adjustment pursuant to clause (c) below (the “Stock
Consideration”)
and (z)
to the extent applicable, the Milestone Payments (as defined in Article
X).
(ii) The
specific ratio of exchange for the Company Common Stock for shares of Parent
Common Stock (“Share
Exchange Ratio”)
as
well as the specific Merger Consideration to be received by the holders of
other
classes of Company Capital Stock have been prepared by Company in accordance
with the Recapitalization and Proceeds Allocation Agreement, dated the date
of
this Agreement, entered into by and among Company and the holders of a Requisite
Majority of the Company Common Stock and Company Preferred Stock and the
holders
of the PharmAthene Notes (as defined below) (the “Allocation
Agreement”),
and
are set forth on Schedule 1.9(b)(i) and will be confirmed or adjusted by
the
Company, as applicable, at Closing. The holders of Company’s issued and
outstanding secured 8% convertible notes and the Subsidiary’s issued and
outstanding secured 8% convertible note, collectively with an aggregate
principal amount of $11,800,000 (collectively the “PharmAthene
Notes”)
shall
exchange such notes for 8% Convertible Notes of Parent in the aggregate
principal amount of $12.5 million (the “Note
Consideration”)
in
substantially the form of Exhibit A attached hereto, pursuant to the Note
Exchange Agreement, as further described in Section 6.3(j)(viii) below. Parent
shall issue the Merger Consideration (as defined in the next sentence) in
accordance with the Allocation Agreement. For purposes of this Agreement,
the
term “Merger
Consideration”
shall be
deemed to include (a) the Stock Consideration; (b) the Milestone Payments
and
(c) the Note Consideration.
(c) Adjustments
to the Merger Consideration.
The
Merger Consideration shall be subject to the following adjustments:
(i) To
the
extent that the stockholders of Parent owning more than 5% of the outstanding
Parent Common Stock exercise their conversion rights as set forth in Section
6.1(b), the number of shares of Parent Common Stock comprising the Stock
Consideration shall be adjusted upward by the product of (x) the number (as
a
percentage) that is the difference between the percentage of Parent Common
Stock
that is converted and 5% and (y) 2.25 million.
(ii) To
the
extent that there are Outstanding Employee Options (as defined in clause
(d)
below) there shall be no increase in the number of shares of Stock Consideration
being issued, but the number of shares of Parent Common Stock issued at the
Closing as part of the Stock Consideration shall be adjusted downward by
an
amount equal to the number of shares necessary to reserve for issuances under
any Outstanding Employee Options in accordance with the Allocation
Agreement.
(iii) Except
for any warrants issued pursuant to a Company Subsequent Issuance (as defined
in
clause (c)(iv) below), the terms of which shall be subject to the provisions
of
clause (c)(iv) below, to the extent that there are outstanding warrants to
purchase shares of Company Common Stock (“Company
Warrants”),
there
shall be no increase in the number of shares of Stock Consideration being
issued, but the number of shares of Parent Common Stock issued at the Closing
as
part of the Stock Consideration shall be adjusted downward by an amount equal
to
the number of shares necessary to reserve for issuances under any outstanding
Company Warrants in accordance with the Allocation Agreement.
(iv) If,
prior
to the date that the Proxy Statement (as defined in Section 4.1) to be filed
by
Parent pursuant to Article IV hereof is approved by the SEC, Company issues
additional shares of its Common Stock (or any equity or debt securities
convertible into Common Stock) for cash consideration of up to $5 million
(subject to the limitation that the securities of the Company issued to the
purchasers (the “Subsequent
Issuance Securities”)
thereof
will not convert into more than 625,000 shares of Parent Common Stock in
the
Merger, which number of shares would be proportionately reduced to reflect
the
sale of less than $5 million) (a “Company
Subsequent Issuance”),
then
the number of shares of Parent Common Stock comprising the Stock Consideration
shall be increased by the number of shares of Parent Common Stock into which
the
Subsequent Issuance Securities will be converted in the Merger.
(d) Options.
(i) Immediately
after the Effective Time, all options to purchase Company Common Stock then
outstanding (individually, an “Outstanding
Employee Option,”
and
collectively, the “Outstanding
Employee Options”)
under
the PharmAthene, Inc. 2002 Long-Term Incentive Plan (as amended, the
“Option
Plan”)
or
issued under any other agreement shall, whether vested or unvested, be assumed
by Parent. Each such Outstanding Employee Option so assumed by Parent under
this
Agreement shall continue to have, and be subject to, the same terms and
conditions set forth in the Option Plan, option agreements thereunder and
other
relevant documentation in existence immediately prior to the Effective Time,
except that each such Outstanding Employee Option will be converted into
an
option to purchase that number of shares of Parent Common Stock calculated
by
multiplying such Outstanding Employee Option by the Share Exchange Ratio
and
rounding down to the nearest whole share of Parent Common Stock. The per-share
exercise price for the shares of Parent Common Stock issuable upon exercise
of
such assumed Outstanding Employee Option will be equal to the quotient
determined by dividing the exercise price per share of Company Common Stock
at
which such Outstanding Employee Option was exercisable immediately prior
to the
Effective Time by the Share Exchange Ratio, and rounding the resulting exercise
price up to the nearest whole cent.
(ii) Parent
shall establish a new option plan containing terms no less favorable to holders
of Outstanding Employee Options as applicable to the Outstanding Employee
Options and Parent shall reserve for issuance under such plan a sufficient
number of shares of Parent Common Stock for delivery upon exercise of
Outstanding Employee Options assumed by Parent under this Agreement plus
an
additional 3,000,000 shares.
(iii) Unless
provided for in the option grant or Option Plan of Company, the vesting of
each
Outstanding Employee Option will not automatically accelerate pursuant to
its
terms as a result of, or in connection with, the transactions contemplated
hereby. Company shall ensure that none of its Board of Directors nor any
committee thereof nor any other body or person within its control shall take
any
discretionary action so as to cause the vesting of any Outstanding Employee
Option which does not vest by its terms prior to the Effective
Time.
1.10. Merger
Sub Stock.
Each
share of common stock, par value $.0001, of Merger Sub outstanding immediately
prior to the Effective Time shall be deemed canceled and converted into and
shall represent the right to receive one share of common stock, $.01 par
value,
of the Surviving Corporation (the “Surviving
Common Stock”).
1.11. Dissenters’
Rights.
Notwithstanding Section 1.9(b)(i) and (ii), any shares of Company Common
Stock
outstanding immediately prior to the Effective Time and held by a person
who has
not voted in favor of the Merger and who has properly demanded in writing
appraisal for such shares in accordance with Section 262 of the DGCL (the
“Dissenting
Shares”)
shall
not be converted into the right to receive the Merger Consideration or be
entitled to cash in lieu of fractional shares of Parent Common Stock or any
dividends or other distributions pursuant to this Article I unless and until
the
holder thereof (“Dissenting
Stockholder”)
shall
have failed to perfect or shall have effectively withdrawn or lost such holder’s
right to appraisal of such shares of Company Common Stock held by such holder
under Section 262 of the DGCL, and any Dissenting Stockholder shall be entitled
to receive only the payment provided by Section 262 of the DGCL with respect
to
shares of Company Common Stock owned by such Dissenting Stockholder. If any
person who otherwise would be deemed a Dissenting Stockholder shall have
failed
to properly perfect or shall have effectively withdrawn or lost the right
to
dissent with respect to any shares of Company Common Stock, such shares of
Company Common Stock shall thereupon be treated as though such shares of
Company
Common Stock had been converted into the right to receive the Merger
Consideration pursuant to Section 1.9 hereof. Company shall give Parent (i)
prompt notice of any written demands for appraisal, attempted withdrawals
of
such demands and any other instruments served pursuant to applicable law
received by Company relating to stockholders’ rights of appraisal and (ii) the
opportunity to participate in and direct all negotiations and proceedings
with
respect to any such demands for appraisal under the DGCL. Company shall not,
except with the prior written consent of Parent, make any payment with respect
to any demands for appraisals of Dissenting Shares, offer to settle or settle
any such demands or approve any withdrawal of any such demands.
1.12. Certain
Other Adjustments.
If,
between the date of this Agreement and the Effective Time, the outstanding
Parent Common Stock or Company Common Stock shall have been changed into
a
different number of shares or different class by reason of any reclassification,
recapitalization, stock split, split-up, combination or exchange of shares
or a
stock dividend or dividend payable in any other securities shall be declared
with a record date within such period, or any similar event shall have occurred,
the Merger Consideration shall be appropriately adjusted to provide to the
holders of Company Common Stock the same economic effect as contemplated
by this
Agreement prior to such event.
1.13. Distributions
with Respect to Unexchanged Shares.
No
dividends or other distributions declared or made with respect to shares
of
Parent Common Stock with a record date after the Effective Time shall be
paid to
the holder of any unsurrendered certificate for Company Capital Stock (a
“Company
Certificate”)
with
respect to the shares of Parent Common Stock that such holder would be entitled
to receive upon surrender of such Company Certificate until such holder shall
surrender such Company Certificate. Subject to the effect of applicable laws,
following surrender of any such Company Certificate, there shall be paid
to such
holder of shares of Parent Common Stock issuable in exchange therefor, without
interest, (a) promptly after the time of such surrender, the amount of dividends
or other distributions with a record date after the Effective Time but prior
to
such surrender and a payment date prior to such surrender payable with respect
to such shares of Parent Common Stock and (b) at the appropriate payment
date,
the amount of dividends or other distributions with a record date after the
Effective Time but prior to such surrender and a payment date subsequent
to such
surrender payable with respect to such shares of Parent Common
Stock.
1.14. No
Further Ownership Rights in Company Capital Stock.
The
Merger Consideration delivered or deliverable to the holders of Company Capital
Stock in accordance with the terms of this Article I shall be deemed to have
been issued or paid in full satisfaction of all rights pertaining to the
shares
of Company Capital Stock. Until surrendered as contemplated by this Agreement,
each Company Certificate representing Company Capital Stock shall be deemed
at
any time after the Effective Time to represent only the right to receive
upon
such surrender solely the Merger Consideration (and any cash to be paid pursuant
hereto for fractional shares). In addition, until surrendered as contemplated
by
this Agreement, each PharmAthene Note shall be deemed at any time after the
Effective Time to represent only the right to receive upon such surrender
solely
an 8% Convertible Note hereunder and no further interest shall accrue on
the
PharmAthene Notes after the Effective Time.
1.15. No
Fractional Shares of Parent Common Stock.
(a) Fractional
Shares. No
certificates or scrip representing fractional shares of Parent Common Stock
or
book-entry credit of the same shall be issued upon the surrender for exchange
of
Company Certificates and such fractional share interests will not entitle
the
owner thereof to vote or to have any rights of a stockholder of
Parent.
(b) Cash
for Fractional Shares. Notwithstanding
any other provision of this Agreement, each holder of shares of Company Common
Stock exchanged pursuant to the Merger who would otherwise have been entitled
to
receive a fraction of a share of Parent Common Stock (after taking into account
all Company Certificates delivered by such holder) shall receive, in lieu
thereof, cash (without interest) in an amount equal to the product of (i)
such
fractional part of a share of Parent Common Stock multiplied by (ii) the
closing
price for a share of Parent Common Stock on The American Stock Exchange LLC
(the
“AMEX”)
on the
date of the Effective Time or, if such date is not a Business Day, the Business
Day immediately before the date on which the Effective Time occurs.
1.16. No
Liability.
None of
Parent, Merger Sub, Company or the Surviving Corporation shall be liable
to any
Person (as defined in Section 2.3(z)) in respect of any Merger Consideration
delivered to a public official pursuant to any applicable abandoned property,
escheat or similar law.
1.17. Surrender
of Certificates.
Upon
surrender of Company Certificates at Closing, the holders of such Company
Certificates shall receive in exchange therefor Merger Consideration in
accordance with Schedule 1.9(b)(i) attached hereto, as amended if applicable,
and the Company Certificates surrendered shall be canceled. Until so
surrendered, outstanding Company Certificates shall be deemed, from and after
the Effective Time, to evidence only the right to receive the applicable
Merger
Consideration issuable pursuant hereto and the Allocation
Agreement.
1.18. Lost,
Stolen or Destroyed Certificates.
If any
Company Certificate shall have been lost, stolen or destroyed, upon the making
of an affidavit of that fact by the Person claiming such Company Certificate
to
be lost, stolen or destroyed, Parent shall issue in exchange for such lost,
stolen or destroyed certificate the Merger Consideration payable in exchange
therefor; provided, however, that as a condition precedent to the issuance
of
such Merger Consideration, the holder of such lost, stolen or destroyed Company
Certificates shall indemnify Parent against any claim that may be made against
Parent or the Surviving Corporation with respect to the Company Certificates
alleged to have been lost, stolen or destroyed.
1.19. Withholding
Rights.
Each of
the Surviving Corporation and Parent shall be entitled to deduct and withhold
from the Merger Consideration payable pursuant to this Agreement to any holder
of shares of Company Common Stock such amounts as are required to be deducted
and withheld with respect to the making of such payment under the Code and
the
rules and Treasury Regulations promulgated thereunder, or any provision of
state, local or foreign tax law. To the extent that amounts are so withheld
by
the Surviving Corporation or Parent, as the case may be, such withheld amounts
shall be treated for all purposes under this Agreement as having been paid
to
the holder of the shares of Company Common Stock in respect of which such
deduction and withholding was made by the Surviving Corporation or Parent,
as
the case may be, and such amounts shall be delivered by the Surviving
Corporation or Parent, as the case may be, to the applicable taxing
authority.
1.20. Further
Assurances.
If at
any time after the Effective Time the Surviving Corporation shall consider
or be
advised that any deeds, bills of sale, assignments or assurances or any other
acts or things are necessary, desirable or proper (a) to vest, perfect or
confirm, of record of otherwise, in the Surviving Corporation its right,
title
or interest in, to or under any of the rights, privileges, powers, franchises,
properties or assets of either Company or Merger Sub or (b) otherwise to
carry
out the purposes of this Agreement, the Surviving Corporation and its proper
officers and directors or their designees shall be authorized to execute
and
deliver, in the name and on behalf of either Company or Merger Sub, all such
deeds, bills of sale, assignments and assurances and do, in the name and
on
behalf of Company or Merger Sub, all such other acts and things necessary,
desirable or proper to vest, perfect or confirm its rights, title or interest
in, to or under any of the rights, privileges, powers, franchises, properties
or
assets of Company or Merger Sub, as applicable, and otherwise to carry out
the
purposes of this Agreement.
1.21. Stock
Transfer Books.
The
stock transfer books of Company shall be closed immediately upon the Effective
Time and there shall be no further registration of transfers of shares of
Company Capital Stock thereafter on the records of Company. On or after the
Effective Time, any Company Certificate presented to Parent for any reason
shall
be converted into the Merger Consideration with respect to the shares of
Company
Capital Stock formerly represented thereby, any cash in lieu of fractional
shares of Parent Common Stock to which the holders thereof are entitled and
any
dividends or other distributions to which the holders thereof are
entitled.
1.22. Tax
Consequences.
For
U.S.
federal income tax purposes, the parties intend that the Merger be treated
as a
reorganization within the meaning of Sections 368(a)(1)(A) and 368(a)(2)(E)
of
the Code, and that this Agreement shall be, and is hereby, adopted as a plan
of
reorganization for purposes of Section 368 of the Code. Accordingly, unless
otherwise required by Law (as defined in Section 2.3(z)), no party shall
take
any action that reasonably could be expected to jeopardize the treatment
of the
Merger as a reorganization within the meaning of Sections 368(a)(1)(A) and
368(a)(2)(E) of the Code, and the parties shall not take any position on
any Tax
Return (as defined herein) or in any proceeding relating to the Tax consequences
of the Merger inconsistent with this Section 1.22. Notwithstanding the forgoing,
the parties understand and agree that only the Stock Consideration portion
of
the Merger Consideration shall be deemed eligible for a “tax free” exchange
under Section 368 of the Code.
1.23. Escrow.
As the
sole remedy for the indemnity obligations set forth in Article VIII hereof,
at
the Closing, an aggregate of 1,375,000 shares of Parent Common Stock issued
or
issuable as a result of the Merger (the “Escrow
Shares”)
shall
be deposited into escrow to be held during the period commencing on the Closing
Date and ending on the one year anniversary thereof, which shares shall be
allocated among the holders of Company Capital Stock and of Company Options
and
Company Warrants in accordance with the terms and conditions of the Allocation
Agreement and the Escrow Agreement to be entered into between Parent,
Stockholders’ Representative (as defined in Article VIII) and Continental Stock
Transfer & Trust Company, as escrow agent, in substantially the form of
Exhibit B (the “Escrow
Agreement”).
1.24. Rule
145.
All
shares of Parent Common Stock issued pursuant to this Agreement to “affiliates”
of Company identified on Schedule 1.24 attached hereto will be subject to
certain resale restrictions under Rule 145 promulgated under the Securities
Act
(as defined herein) and all certificates representing such shares shall bear
an
appropriate restrictive legend.
ARTICLE
II
REPRESENTATIONS
AND WARRANTIES
2.1. Representations
and Warranties of Parent.
Parent
represents and warrants to Company, that the statements contained in this
Section 2.1 are correct and complete as of the date of this Agreement and
will
be correct and complete as of the Closing Date (as though made then and as
though the Closing Date were substituted for the date of this Agreement
throughout this Section 2.1), except as set forth in the disclosure schedule
to
be delivered to Company by Parent on the date hereof and initialed by the
parties (the “Parent
Disclosure Schedule”).
Disclosures made in the Parent Disclosure Schedule shall not be deemed to
constitute additional representations or warranties of Parent but set forth
disclosures, exceptions and exclusions called for under this Agreement provided
they are set forth with reasonable particularity and describe the relevant
facts
in reasonable detail. The Parent Disclosure Schedule will be arranged in
paragraphs corresponding to the numbered and lettered paragraphs contained
in
this Section 2.1.
(a) Organization,
Standing and Power. Parent
is
a corporation duly organized, validly existing and in good standing (as defined
in Article X) under the laws of the State of Delaware, has the requisite
power
and authority to own, lease and operate its properties and to carry on its
business as now being conducted. Parent is duly qualified or licensed as
a
foreign corporation to do business, and is in good standing, in each
jurisdiction where the character of the properties owned, leased or operated
by
it or the nature of its activities makes such qualification or licensing
necessary, except for such failures to be so duly qualified or licensed and
in
good standing that could not reasonably be expected to have a Material Adverse
Effect (as defined in Article X). Complete and correct copies of the certificate
of incorporation and bylaws of Parent, as amended and currently in effect,
have
been provided to Company and Parent is not in violation of any of the provisions
of such organization documents. Merger Sub is a newly-formed single purpose
entity which has been formed solely for the purposes of the Merger and has
not
carried on, and prior to the Closing will not carry on, any business or engaged
in any activities other than those reasonably related to the Merger. Except
for
Merger Sub, which is a direct, wholly-owned subsidiary of Parent, Parent
has no
subsidiaries and does not own, directly or indirectly, any equity, profit
or
voting interest in any person or has any agreement or commitment to purchase
any
such interest and Parent has not agreed and is not obligation to make nor
is
bound by any written, oral or other agreement, contract, subcontract, lease,
binding understanding, instrument, note, option, warranty, purchase order,
license, sublicense, insurance policy, benefit plan, commitment or undertaking
of any nature, as of the date hereof or as may hereafter be in effect under
which it may become obligated.
(b) Capital
Structure.
The
authorized capital stock of Parent consists of (i) 100,000,000 shares of
Parent
Common Stock, of which 11,650,000 shares were outstanding as of September
30,
2006 and (ii) 1,000,000 shares of preferred stock, $.0001 par value, none
of
which are outstanding. No shares of Parent Common Stock have been issued
between
August 16, 2005 and the date hereof. All issued and outstanding shares of
the
capital stock of Parent are duly authorized, validly issued, fully paid and
nonassessable, and no class of capital stock is entitled to (or has been
issued
in violation of) preemptive rights. As of the date hereof, there are (i)
options
with an exercise price of $10.00 per unit to purchase up to 225,000 units
issued
to the underwriter in Parent’s initial public offering completed pursuant to a
final prospectus of Parent, dated July 28, 2006, as filed under the Securities
Act (the “IPO”),
each
unit consisting of a single share of Parent Common Stock and a single warrant
to
purchase a single share of Parent Common Stock, and (ii) 9,400,000 outstanding
warrants with an exercise price of $6.00 per share issued in the IPO (the
“Parent
Warrants”)
and no
other issued or outstanding rights to acquire capital stock from Parent.
All
outstanding shares of Parent Common Stock and all outstanding Parent Warrants
have been issued and granted in compliance with (x) all applicable securities
laws and (in all material respects, other applicable laws and regulations,
and
(y) all requirements set forth in any applicable Parent contract. Parent
has
delivered to Company complete and correct copies of the Parent Warrants
including all documents relating thereto. All shares of Parent Common Stock
to
be issued in connection with the Merger and the other transactions contemplated
hereby will, when issued in accordance with the terms hereof, have been duly
authorized, be validly issued, fully paid and non-assessable, free and clear
of
all Liens (as defined in Article X). Except as set forth in Section 2.1(b)
of
the Parent Disclosure Schedule, or as contemplated by this Agreement, there
are
no registration rights and there is no voting trust, proxy, rights plan,
anti-takeover plan or other agreements or understandings to which Parent
is a
party or by which the Parent is bound with respect to any equity securities
of
any class of Parent.
(c) Authority;
No Conflicts.
(i) Parent
has all requisite corporate power and authority to enter into this Agreement
and
to consummate the transactions contemplated hereby, including, without
limitation, the issuance of the shares of Parent Common Stock to be issued
in
the Merger (the “Share
Issuance”).
The
execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized by
all
necessary corporate action on the part of Parent and no other corporate
proceedings on the part of Parent are necessary to authorize this Agreement
or
to consummate the transactions contemplated hereby other than the Parent
Stockholder Approval (as defined in Section 6.1(b)). This Agreement has been
duly and validly executed and delivered by Parent and, assuming that this
Agreement constitutes a valid and binding agreement of Company, constitutes
a
valid and binding agreement of Parent, enforceable against Parent in accordance
with its terms, except as such enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium and similar laws relating to or affecting
creditors generally or by general equity principles (regardless of whether
such
enforceability is considered in a proceeding in equity or at law) or by an
implied covenant of good faith and fair dealing.
(ii) The
execution and delivery of this Agreement by Parent do not, and the consummation
by Parent of the Merger and the other transactions contemplated hereby will
not,
conflict with, or result in any violation of, or constitute a default (with
or
without notice or lapse of time, or both) under, or give rise to a right
of
termination, amendment, cancellation or acceleration of any obligation or
the
loss of a material benefit under, or the creation of a Lien on any assets
(any
such conflict, violation, default, right of termination, amendment, cancellation
or acceleration, loss or creation, is hereinafter referred to as a “Violation”)
pursuant to:
(A) any
provision of the certificate of incorporation or bylaws of Parent;
or
(B) except
as
would not reasonably be expected to have, individually or in the aggregate,
a
Material Adverse Effect on Parent, and subject to obtaining or making the
consents, approvals, orders, authorizations, registrations, declarations
and
filings referred to in paragraph (iii) below, any loan or credit agreement,
note, mortgage, bond, indenture, lease, benefit plan or other agreement,
obligation, instrument, permit, concession, franchise, license, judgment,
order,
decree, statute, law, ordinance, rule or regulation applicable to Parent
or its
properties or assets.
(iii) No
consent, approval, order or authorization of, or registration, declaration
or
filing with, any supranational, national, state, municipal, local or foreign
government, any instrumentality, subdivision, tribunal, court, arbitrator,
administrative agency or commission or other authority or instrumentality
thereof, or any quasi-governmental or private body exercising any regulatory,
taxing, importing or other governmental or quasi-governmental authority (a
“Governmental
Entity”)
or
expiry of any related waiting period is required by or with respect to Parent
in
connection with the execution and delivery of this Agreement by Parent or
Merger
Sub or the consummation of the Merger and the other transactions contemplated
hereby, except for those required under or in relation to:
(A) state
securities or “blue sky” laws;
(B) the
Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder (the “Securities
Act”);
(C) the
Securities and Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder (the “Exchange
Act”);
(D) the
DGCL
with respect to the filing of the Certificate of Merger;
(E) Canadian
provincial securities laws relating to the resale of the Parent Common Stock
issued to security holders of the Company resident in Canada; and
(F) such
consents, approvals, orders, authorizations, registrations, declarations
and
filings and expiry of waiting periods the failure of which to make or obtain
or
expire would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect on Parent.
For
purposes of this Agreement, consents, approvals, orders, authorizations,
registrations, declarations and filings required under or in relation to
any of
the foregoing clauses (A) through (E) are hereinafter referred to as
“Necessary
Consents.”
(iv) The
Board
of Directors of Parent, at a meeting duly called and held, duly and unanimously
adopted resolutions (A) approving and declaring advisable this Agreement
and the
transactions contemplated hereby, (B) determining that the terms of the Merger
and the transactions contemplated thereby are fair to and in the best interests
of Parent and its stockholders, (C) determining that the fair market value
of
Company is equal to at least 80% of Parent’s net assets and (D) recommending
that Parent’s stockholders approve the Merger and the transactions contemplated
thereby.
(v) The
only
vote of holders of any class or series of Parent capital stock necessary
to
approve this Agreement and the transactions contemplated hereby is the approval
and adoption by the holders of a majority of the outstanding publicly-held
shares of Parent Common Stock; provided,
however,
that
the Parent may not consummate the Merger if the holders of 20% or more in
interest of the Parent Common Stock issued in the IPO (“IPO
Shares”)
shall
have demanded that Parent convert such shares into cash pursuant to the Parent’s
amended and restated certificate of incorporation (“Parent
Charter”).
(d) Reports
and Financial Statements.
(i) Parent
has filed all required registration statements, reports, schedules, forms,
statements and other documents required to be filed by it with the SEC since
July 28, 2005 (collectively, as they have been amended since the time of
their
filing and including all exhibits thereto, the “Parent
SEC Reports”).
None
of the Parent SEC Reports, as of their respective dates (and, if amended
or
superseded by a filing prior to the date of this Agreement or the Closing
Date,
then on the date of such filing), contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading. Except as set forth on Section 2.1(d)
of
the Parent Disclosure Schedule, each of the financial statements (including
the
related notes) included in the Parent SEC Reports presents fairly, in all
material respects, the consolidated financial position and consolidated results
of operations and cash flows of Parent as of the respective dates or for
the
respective periods set forth therein, all in conformity with generally accepted
accounting principles in the United States (“GAAP”)
applied on a consistent basis throughout the periods involved except as
otherwise noted therein, and subject, in the case of the unaudited interim
financial statements, to normal and recurring adjustments that were not or
are
not expected to be material in amount, and lack footnote disclosure. All
of such
Parent SEC Reports (including any financial statements included or incorporated
by reference therein), as of their respective dates (and as of the date of
any
amendment to the respective Parent SEC Report), complied as to form in all
material respects with the applicable requirements of the Securities Act
and the
Exchange Act and the rules and regulations promulgated thereunder.
(ii) Except
(A) to the extent reflected in the balance sheet of Parent included in the
Parent SEC Report last filed prior to the date hereof or (B) incurred in
the
ordinary course of business since the date of the balance sheet referred
to in
the preceding clause (A), Parent does not have any liabilities or obligations
of
any nature, whether known or unknown, absolute, accrued, contingent or otherwise
and whether due or to become due, that have or would reasonably be expected
to
have, individually or in the aggregate, a Material Adverse Effect on
Parent.
(e) Information
Supplied.
(i) None
of
the information supplied or to be supplied by Parent for inclusion or
incorporation by reference in the Proxy Statement to be filed with the SEC
by
Parent in connection with the Merger, or any of the amendments or supplements
thereto (as defined below) will, at the time such documents are filed with
the
SEC, or at any time they are amended or supplemented, contain any untrue
statement of a material fact or omit to state any material fact required
to be
stated therein or necessary to make the statements therein not misleading.
Such
documents will each comply as to form in all material respects with the
requirements of the Exchange Act and the Securities Act and the rules and
regulations of the SEC thereunder.
(ii) Notwithstanding
the foregoing provisions of this Section 2.1(e), no representation or warranty
is made by Parent with respect to statements made or incorporated by reference
in the Proxy Statement based on information not supplied by it or Merger
Sub.
(f) Trust
Funds; Liquidation.
(i) Since
August 16, 2005, Parent has had at least $67,928,000, plus accrued interest
(the
“Trust
Fund”),
invested in U.S. government securities in a trust account at a New York branch
of JP Morgan Chase (the “Trust
Account”),
held
in trust by Continental Stock Transfer & Trust Company (the “Trustee”)
pursuant to the Investment Management Trust Agreement dated as of July 28,
2005,
between Parent and the Trustee (the “Trust
Agreement”).
Upon
consummation of the Merger and notice thereof to the Trustee, the Trust Account
will terminate and the Trustee shall thereupon be obligated to release as
promptly as practicable to Parent the Trust Fund held in the Trust Account,
which Trust Fund will be free of any Lien whatsoever and, after taking into
account any funds paid to holders of IPO Shares who shall have demanded that
Parent convert their IPO Shares into cash pursuant to the Parent Charter
shall
be an amount at least equal to $54,342,400.
(ii) Effective
as of the Effective Time, the obligations of Parent to dissolve or liquidate
within the specified time period contained in the Parent Charter will terminate,
and effective as of the Effective Time Parent shall have no obligation
whatsoever to dissolve and liquidate the assets of Parent by reason of the
consummation of the Merger or the transactions contemplated thereby, and
following the Effective Time no Parent stockholder shall be entitled to receive
any amount from the Trust Account except to the extent such stockholder votes
against the approval of this Agreement and the transactions contemplated
thereby
and demands, contemporaneous with such vote, that Parent convert such
stockholder’s shares of Parent Common Stock into cash pursuant to the Parent
Charter.
(g) Absence
of Certain Changes or Events. Except
for liabilities incurred in connection with this Agreement or the transactions
contemplated hereby, since December 31, 2005, there has not been any change,
circumstance or event which has had, or would reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect on Parent, nor
has
there by (i) any declaration, setting aside or payment of any dividend on,
or
other distribution (whether in cash, stock or property) in respect of any
class
or series of its capital stock or any purchase, redemption or other acquisition
by Parent of any class or series of its capital stock or any other securities
of
Parent, (ii) any split, combination or reclassification of any capital stock,
(iii) any granting by Parent of any increase in compensation or fringe benefits
and any granting by Parent of any increase in severance or termination pay
or
any entry by Parent into any currently effective employment, severance,
termination or indemnification agreement, (iv) any material change by Parent
in
its accounting methods, principles or practices except as required by concurrent
changes in U.S. GAAP, (v) any change in auditors of Parent, or (vi) any issuance
of Parent capital stock.
(h) Investment
Company Act.
Parent
is not, and will not be after the Effective Time, an “investment
company”
or
a
person directly or indirectly “controlled”
by
or
acting on behalf of an “investment
company”,
in
each case within the meaning of the Investment Company Act of 1940, as
amended.
(i) Litigation.
There
are
no claims, suits, actions or proceedings pending or to Parent’s Knowledge (as
defined in Article X), threatened against Parent, before any court, governmental
department, commission, agency, instrumentality or authority, or any arbitrator
that seeks to restrain or enjoin the consummation of the transactions
contemplated by this Agreement or which could reasonably be expected, either
singularly or in the aggregate with all such claims, actions or proceedings,
to
have a Material Adverse Effect on Parent or have a Material Adverse Effect
on
the ability of the parties hereto to consummate the Merger.
(j) Employees;
Employee Benefit Plans. Parent
currently does not have and never has had any employees in Canada. Parent
does
not maintain, and has no liability under, any plan, and neither the execution
and delivery of this Agreement nor the consummation of the transactions
contemplated hereby will (i) result in any payment (including severance,
unemployment compensation, golden parachute, bonus or otherwise) becoming
due to
any stockholder, director or employee of Parent, or (ii) result in the
acceleration of the time of payment or vesting of any such
benefits.
(k) No
Undisclosed Liabilities. Except
as
set forth in Section 2.1(k) of the Parent Disclosure Schedule, Parent has
no
liabilities (absolute, accrued, contingent or otherwise) of a nature required
to
be disclosed on a balance sheet or in the related notes to the financial
statements included in Parent SEC Reports which are, individually or in the
aggregate, material to the business, results of operations or financial
condition of Parent, except (i) liabilities provided for in or otherwise
disclosed in Parent SEC Reports filed prior to the date hereof, and (ii)
liabilities incurred since September 30, 2006 in the ordinary course of
business, none of which would have a Material Adverse Effect on Parent. Merger
Sub has no assets or properties of any kind, does not now conduct and has
never
conducted any business, and does not now have and will not have at the Closing
any obligations or liabilities of any nature whatsoever except such obligations
and liabilities as are imposed under this Agreement.
(l) Title
to Property. Except
as
set forth in Section 2.1(l) of the Parent Disclosure Schedule, Parent does
not
own or lease any real property or personal property. Except as set forth
in
Section 2.1(l) of the Parent Disclosure Schedule, there are no options or
other
contracts under which Parent has a right or obligation to acquire or lease
any
interest in real property or personal property.
(m) Taxes.
(i) Parent
has timely filed all Tax Returns required to be filed by Parent with any
Tax
authority prior to the date hereof. All such Tax Returns are true, correct
and
complete in all material respects. Parent has paid all Taxes shown to be
due on
such Tax Returns.
(ii) All
Taxes
that Parent is required by law to withhold or collect have been duly withheld
or
collected, and have been timely paid over to the proper governmental authorities
to the extent due and payable.
(iii) Parent
has not been delinquent in the payment of any material Tax nor is there any
material Tax deficiency outstanding, proposed or assessed against Parent,
nor
has Parent executed any unexpired waiver of any statute of limitations on
or
extending the period for the assessment or collection of any Tax (as defined
in
Section 2.3(k)).
(iv) No
audit
or other examination of any Tax Return of Parent by any Tax authority is
presently in progress, nor has Parent been notified of any request for such
an
audit or other examination.
(v) No
adjustment relating to any Returns filed by Parent has been proposed in writing,
formally or informally, by any Tax authority to Parent or any representative
thereof.
(vi) Parent
has no liability for any material unpaid Taxes which have not been accrued
for
or reserved on Parent’s balance sheets included in the audited financial
statements for the most recent fiscal year ended, whether asserted or
unasserted, contingent or otherwise, which is material to Parent, other than
any
liability for unpaid Taxes that may have accrued since the end of the most
recent fiscal year in connection with the operation of the business of Parent
in
the ordinary course of business, none of which is material to the business,
results of operations or financial condition of Parent.
(vii) Parent
has not taken any action and does not know of any fact, agreement, plan or
other
circumstance that is reasonably likely to prevent the Merger from qualifying
as
a reorganization within the meaning of Section 368(a) of the Code.
(n) Environmental
Matters. Except
for such matters that, individually or in the aggregate, are not reasonably
likely to have a Material Adverse Effect: (i) Parent has, to Parent’s Knowledge,
complied with all applicable Environmental Laws (as defined in Section 2.3(s);
(ii) Parent has not received any notice, demand, letter, claim or request
for
information alleging that Parent may be in violation of or liable under any
Environmental Law; and (iii) Parent is not subject to any orders, decrees,
injunctions or other arrangements with any governmental entity or subject
to any
indemnity or other agreement with any third party relating to liability under
any Environmental Law.
(o) Brokers.
Except
as
set forth in Section 2.1(o) of the Parent Disclosure Schedule, Parent has
not
incurred, nor will it incur, directly or indirectly, any liability for brokerage
or finders’ fees or agent’s commissions or any similar charges in connection
with this Agreement or any transactions contemplated hereby.
(p) Intellectual
Property. Parent
does not own, license or otherwise have any right, title or interest in any
Intellectual Property Rights (as defined in Section 2.3(t)).
(q) Agreements,
Contracts and Commitments.
(i) Except
as
set forth in the Parent SEC Reports filed prior to the date of this Agreement,
there are no contracts, agreements, leases, mortgages, indentures, notes,
bonds,
liens, license, permit, franchise, purchase orders, sales orders or other
understandings, commitments or obligations (including without limitation
outstanding offers or proposals) of any kind, whether written or oral, to
which
Parent is a party or by or to which any of the properties or assets of Parent
may be bound, subject or affected, which either (x) creates or imposes a
liability greater than $25,000, or (y) may not be cancelled by Parent on
less
than thirty (30) days’ or less prior notice (“Parent
Contracts”).
All
Parent Contracts are set forth in Section 2.1(q) of the Parent Disclosure
Schedule, other than those that are exhibits to the Parent SEC
Reports.
(ii) Other
than as set forth in Section 2.1(q) of the Parent Disclosure Schedule, each
Parent Contract was entered into at arms’ length and in the ordinary course, is
in full force and effect and is valid and binding upon and enforceable against
each of the parties thereto. Correct and complete copies of all Parent Contracts
(or written summaries in the case of oral Parent Contracts) and of all
outstanding offers or proposals of Parent have been heretofore delivered
to
Company.
(iii) Neither
Parent nor, to Parent’s Knowledge, any other party thereto is in breach of or in
default under, and no event has occurred which with notice or lapse of time
or
both would become a breach of or default under, any Parent Contract, and
no
party to any Parent Contract has given any written notice of any claim of
any
such breach, default or event, which, individually or in the aggregate, are
reasonably likely to have a Material Adverse Effect on Parent. Each agreement,
contract or commitment to which Parent is a party or by which it is bound
that
has not expired by its terms is in full force and effect, except where such
failure to be in full force and effect is not reasonably likely to have a
Material Adverse Effect on Parent.
(r) Insurance.
Set
forth
in Section 2.1(r) of the Parent Disclosure Schedule, is a complete list of
all
liability insurance coverage maintained by Parent which coverage is in full
force and effect.
(s) Interested
Party Transactions. Except
as
set forth in the Parent SEC Reports filed prior to the date of this Agreement,
no employee, officer, director or stockholder of Parent or a member of his
or
her immediate family is indebted to Parent nor is Parent indebted (or committed
to make loans or extend or guarantee credit) to any of them, other than
reimbursement for reasonable expenses incurred on behalf of Parent. To Parent’s
Knowledge, none of such individuals has any direct or indirect ownership
interest in any Person with whom Parent is affiliated or with whom Parent
has a
material contractual relationship, or any Person that competes with Parent,
except that each employee, stockholder, officer or director of Parent and
members of their respective immediate families may own less than 5% of the
outstanding stock in publicly traded companies that may compete with Parent.
To
Parent’s Knowledge, no officer, director or stockholder or any member of their
immediate families is, directly or indirectly, interested in any material
contract with Parent (other than such contracts as relate to any such individual
ownership of capital stock or other securities of Parent).
(t) Indebtedness.
Parent
has no indebtedness for borrowed money.
2.2. Representations
and Warranties of Parent with Respect to Merger Sub. Parent and Merger Sub
represent and warrant to Company as follows:
(a) Organization;
Reporting. Merger
Sub is a corporation duly incorporated, validly existing and in good standing
under the laws of the State of Delaware. Merger Sub is a direct, wholly-
owned
subsidiary of Parent. Merger Sub has never been subject to the reporting
requirements of Sections 13(a) and 15(d) of the Exchange Act.
(b) Corporate
Authorization. Merger
Sub has all requisite corporate power and authority to enter into this Agreement
and to consummate the transactions contemplated hereby. The execution, delivery
and performance by Merger Sub of this Agreement and the consummation by Merger
Sub of the transactions contemplated hereby have been duly authorized by
all
necessary corporate action on the part of Merger Sub. Parent, in its capacity
as
sole stockholder of Merger Sub, has approved this Agreement and the other
transactions contemplated hereby as required by the DGCL. This Agreement
has
been duly executed and delivered by Merger Sub and, assuming that this Agreement
constitutes the valid and binding agreement of Company, constitutes a valid
and
binding agreement of Merger Sub, enforceable against it in accordance with
its
terms, except as such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium and other similar laws relating to or affecting
creditors generally or by general equity principles (regardless of whether
such
enforceability is considered in a proceeding in equity or at law) or by an
implied covenant of good faith and fair dealing.
(c) Non-Contravention.
The
execution, delivery and performance by Merger Sub of this Agreement and the
consummation by Merger Sub of the transactions contemplated hereby do not
and
will not contravene or conflict with the certificate of incorporation or
the
bylaws of Merger Sub.
(d) No
Business Activities. Merger
Sub has not conducted any activities other than in connection with the
organization of Merger Sub, the negotiation and execution of this Agreement
and
the consummation of the transactions contemplated hereby. Merger Sub has
no
subsidiaries.
2.3. Representations
and Warranties of Company.
Company
represents and warrants to Parent and Merger Sub that the statements contained
in this Section 2.3 are correct and complete as of the date of this Agreement
and will be correct and complete as of the Closing Date (as though made then
and
as though the Closing Date were substituted for the date of this Agreement
throughout this Section 2.3), except as set forth in the disclosure schedule
to
be delivered by Company to Parent on the date hereof and initialed by the
parties (the “Company
Disclosure Schedule”).
Disclosures made in the Company Disclosure Schedule shall not be deemed to
constitute additional representations or warranties of Company but set forth
disclosures, exceptions and exclusions called for under this Agreement provided
that they are set forth with reasonable particularity and describe the relevant
facts in reasonable detail. The Company Disclosure Schedule will be arranged
in
paragraphs corresponding to the lettered and numbered paragraphs contained
in
this Section 2.3 and Company shall make reasonable effort to specifically
cross
reference all sections where a particular disclosure qualifies or
applies.
(a) Organization,
Standing and Power.
(i) Company
is duly organized, validly existing and in good standing under the laws of
the
State of Delaware and has full corporate power and authority to own or hold
under lease the assets and properties which it owns or holds under lease,
to
conduct its business as currently conducted, to perform all of its obligations
under the agreements to which it is a party, including, without limitation,
this
Agreement, and upon the receipt of authorization of the holders of Company
Capital Stock in accordance with the DGCL, to consummate the Merger. Company
is
in good standing in each other jurisdiction wherein the failure so to qualify,
individually or in the aggregate, would have a Material Adverse Effect. The
copies of the certificate of incorporation and by-laws of Company which have
been delivered to Parent by Company are complete and correct. Company
has made available to Parent correct and complete copies of the minutes of
all
meetings of (w) Company stockholders, (x) the Board of Directors of Company
and
(y) each committee of the Board of Directors of Company held since
inception.
(ii) Company
has only one subsidiary, PharmAthene Canada, Inc. (the “Subsidiary”).
Company does not, directly or indirectly, beneficially or legally own or
hold
any capital stock or other proprietary interest of an other corporation,
partnership, joint venture, business trust or other legal entity. Section
2.3(a)
of the Company Disclosure Schedule indicates the jurisdiction of the
Subsidiary’s incorporation or formation, and Company’s direct or indirect
ownership thereof. The Subsidiary is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
incorporation, and has full corporate power and authority to own or hold
under
lease the assets and properties which it owns or holds under lease and to
perform all its obligations under the agreements to which it is a party and
to
conduct the Subsidiary’s business. The Subsidiary is in good standing in each
other jurisdiction wherein the failure so to qualify would, individually
or in
the aggregate, would have a Material Adverse Effect. Except as set forth
on
Section 2.3(a) of the Company Disclosure Schedule, all of the outstanding
shares
of the capital stock of the Subsidiary is owned by Company and is duly
authorized and validly issued, fully paid and non-assessable, issued without
violation of the preemptive rights of any person, and are owned free and
clear
of any mortgages, deeds of trust, pledges, liens, security interests or any
charges or encumbrances of any nature. Except as set forth on Section 2.3(a)
of
the Company Disclosure Schedule, no shares of capital stock or other proprietary
interest of the Subsidiary is subject to any option, call, commitment or
other
agreement of any nature, and except as set forth on Section 2.3(a) of the
Company Disclosure Schedule, there are no subscriptions, warrants, options,
calls, commitments by agreements to which Company or the Subsidiary is bound
relating to the issuance or purchase of any shares of capital stock of the
Subsidiary. Except as set forth on Section 2.3(a) of the Company Disclosure
Schedule, neither Company nor the Subsidiary is party to any agreement or
arrangement relating to the voting or control of any capital stock of the
Subsidiary, or obligating Company or the Subsidiary to sell any assets of
the
Subsidiary, which is material to Company’s business or condition. The copies of
the certificate of incorporation and by-laws, or other instruments of formation,
of the Subsidiary, which have been delivered or made available to Parent
by
Company are complete and correct. Company has made available to Parent correct
and complete copies of the minutes of all meetings of (w) stockholders of
the
Subsidiary, (x) the Board of Directors of the Subsidiary and (y) each committee
of the Board of Directors of the Subsidiary held since inception. Each reference
to a “subsidiary”
or
“subsidiaries”
of
any
person means any corporation, partnership, joint venture or other legal entity
of which such person (either above or through or together with any other
subsidiary), owns, directly or indirectly, more than 50% of the stock or
other
equity interests the holder of which are generally entitled to vote for the
election of the board of directors or other governing body of such corporation
or other legal entity.
(b) Capital Structure.
(i) The
authorized capital stock of Company consists of (i) 147,089,105 shares of
Company Common Stock, of which 10,942,906 shares are issued and outstanding
and
(ii) 105,009,575 shares of Company Preferred Stock, of which (A) 16,442,000
shares have been designated as Series A Convertible Preferred Stock, 16,442,000
of which are issued or outstanding, (B) 65,768,001 shares have been designated
as Series B Convertible Preferred Stock, 30,448,147 of which are issued or
outstanding, and (C) 22,799,574 shares have been designated as Series C
Convertible Preferred Stock, of which 14,946,479 shares are issued and
outstanding. There are no other classes of capital stock of Company authorized,
issued or outstanding. All of the outstanding shares of Company Capital Stock
are, and all outstanding shares of Company Capital Stock issuable upon exercise
of Company Options and Company Warrants will be, duly authorized, validly
issued
and fully paid and non-assessable, issued without violation of the preemptive
rights of any person. Except as set forth on Section 2.3(b) of the Company
Disclosure Schedule, there are no subscriptions, warrants, options, calls,
commitments by or agreements to which Company is bound relating to the issuance,
conversion, or purchase of any shares of Company Common Stock, or any other
Company Capital Stock. Except as set forth on Section 2.3(b) of the Company
Disclosure Schedule, Company is not a party to any agreement or arrangement
relating to the voting or control of any of the Company Capital Stock, or
obligating Company, directly or indirectly, to sell any asset which is material
to the businesses, financial condition, results of operations or prospects
of
Company and its Subsidiary, taken as a whole (hereinafter referred to as
“Company’s
business or condition”).
Except as set forth in Section 2.3(b) of the Company Disclosure Schedule,
Company has not agreed to register any securities under the Securities Act
under
any arrangements that would require any such registration as a result of
this
Agreement or the transactions contemplated hereby or otherwise. All outstanding
shares of Company Capital Stock, all outstanding Company Options, and all
outstanding Company Warrants have been issued or granted in compliance with
all
applicable securities laws.
(ii) The
authorized capital stock of the Subsidiary (the “Subsidiary Capital Stock”)
consists of an unlimited number of Class A common shares of which 1,000 shares
are issued and outstanding, an unlimited number of Class B common shares
of
which none are outstanding (of which 466,498 shares issuable upon exercise
of
warrants), an unlimited number of Class B non-voting preferred shares of
which
none are issued and outstanding and an unlimited number of Class C non-voting
preferred shares of which 2,591,654 are issued and outstanding (and of which
777,496 are issuable upon exercise of warrants). There are no other classes
of
capital stock of the Subsidiary authorized, issued or outstanding. All of
the
outstanding shares of Subsidiary Capital Stock are, and all outstanding shares
of Subsidiary Capital Stock issuable upon exercise Subsidiary Warrants (as
defined below) will be, duly authorized, validly issued and fully paid and
non-assessable, issued without violation of the preemptive rights of any
person.
Except as set forth on Section 2.3(b) of the Company Disclosure Schedule,
there
are no subscriptions, warrants, options, calls, commitments by or agreements
to
which the Subsidiary is bound relating to the issuance, conversion, or purchase
of any shares of Subsidiary Capital Stock. The Warrants described on Section
2.3(b) of the Company Disclosure Schedule are referred to herein as the
“Subsidiary
Warrants.”
Except
as set forth on Section 2.3(b) of the Company Disclosure Schedule, Subsidiary
is
not a party to any agreement or arrangement relating to the voting or control
of
any of the Subsidiary Capital Stock, or obligating Subsidiary, directly or
indirectly, to sell any asset which is material to Company’s business or
condition. Except as set forth in Section 2.3(b) of the Company Disclosure
Schedule, Subsidiary has not agreed to register any securities under the
Securities Act or like foreign statute, rule or regulation under any
arrangements that would require any such registration as a result of this
Agreement or the transactions contemplated hereby or otherwise. All outstanding
shares of Subsidiary Capital Stock and all outstanding Subsidiary Warrants
have
been issued or granted in compliance with all applicable securities laws
or like
foreign statutes, rules or regulations. Upon completion of the Merger, at
the
Effective Time, Company shall own all of the Subsidiary Capital Stock and
there
shall not be outstanding any options, warrants or other convertible securities
or any other rights to acquire any Subsidiary Capital Stock.
(c) Authority;
No Conflicts.
(i) Company
has all requisite corporate power and authority to enter into this Agreement
and
to consummate the transactions contemplated hereby. The execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby
have been duly authorized by all necessary corporate action on the part of
Company. This Agreement has been duly executed and delivered by Company and,
assuming that this Agreement constitutes a valid and binding agreement of
Parent
and Merger Sub, constitutes a valid and binding agreement of Company,
enforceable against it in accordance with its terms, except as such
enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium and similar laws relating to or affecting creditors generally
or by
general equity principles (regardless of whether such enforceability is
considered in a proceeding in equity or at law) or by an implied covenant
of
good faith and fair dealing.
(ii) The
execution and delivery of this Agreement by Company does not, and the
consummation by Company of the Merger and the other transactions contemplated
hereby will not, conflict with, or result in a Violation pursuant to: (A)
any
provision of the certificate of incorporation or bylaws of Company or (B)
except
as set forth in Section 2.3(c) of the Company Disclosure Schedule or as would
not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect on Company, and subject to obtaining or making the consents,
approvals, orders, authorizations, registrations, declarations and filings
referred to in paragraph (iii) below, any loan or credit agreement, note,
mortgage, bond, indenture, lease, benefit plan or other agreement, obligation,
instrument, permit, concession, franchise, license, judgment, order, decree,
statute, law, ordinance, rule or regulation applicable to Company or its
properties or assets.
(iii) No
consent, approval, order or authorization of, or registration, declaration
or
filing with, any Governmental Entity or expiry of any related waiting period
is
required by or with respect to Company in connection with the execution and
delivery of this Agreement by Company or the consummation of the Merger and
the
other transactions contemplated hereby, except the Necessary Consents, the
approvals set forth in Section 2.3(c) of the Company Disclosure Schedule
and
such consents, approvals, orders, authorizations, registrations, declarations
and filings and expiry of waiting periods the failure of which to make or
obtain
or expire would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect on Company.
(iv) The
Board
of Directors of Company has taken all actions so that the restrictions contained
in Section 203 of the DGCL applicable to a “business
combination”
(as
defined in Section 203 of the DGCL) will not apply to the execution, delivery
or
performance of this Agreement or to the consummation of the transactions
contemplated by this Agreement.
(v) The
Allocation Agreement has been duly and validly executed by Company, and to
its
Knowledge, each of the other signatories thereto, and constitutes the valid
and
binding obligation of the parties thereto. There have been no amendments
or
modifications, written or otherwise, to the Allocation Agreement. Company
has
delivered to Parent a true and correct copy of the Allocation
Agreement.
(d) Financial
Statements.
(i) Company
has heretofore furnished Parent with copies of the following consolidated
financial statements of Company and its Subsidiary: (a) consolidated balance
sheet as at September 30, 2006; (b) consolidated statements of operations
for
the year ended on December 31, 2005; (c) a balance sheet (the “Reference
Balance Sheet”)
as at
September 30, 2006 (the “Reference
Balance Sheet Date”);
(d) a
consolidated statement of operations (the “Reference
Income Statement”)
for
the 9 months ended September 30, 2006 and (e) consolidated audited financial
statements for the fiscal years ending December 31, 2005 and December 31,
2004.
Company will furnish consolidated audited financial statements for the fiscal
years ending December 31, 2006 as soon as they become available and in no
event
later that February 14, 2007. Except as set forth on Section 2.3(d) to the
Company Disclosure Schedule, all such consolidated financial statements are
or
will be complete and correct, were or will be prepared in accordance with
generally accepted accounting principles of the United States (“GAAP”),
consistently applied throughout the periods indicated, and have been or will
be
prepared in accordance with the books and records of Company and its Subsidiary,
and present or will present fairly the financial position of Company and
its
Subsidiary at such dates and the results of its consolidated operations and
cash
flows for the periods then ended, subject to such inaccuracies, if any, which
are not material in nature or amount. The consolidated financial statements
of
Company and its Subsidiary provided or to be provided to Parent pursuant
to this
Section 2.3(d) are referred to herein as the “Company
Financial Statements.”
(ii) There
are
no liabilities of or against Company or its Subsidiary of any nature (accrued,
absolute or contingent, unasserted, known or unknown, or otherwise), except:
(a)
as and to the extent reflected or reserved against on the Reference Balance
Sheet; (b) as set forth on Section 2.3(d) to the Company Disclosure Schedule;
(c) those that are individually, or in the aggregate, not material and were
incurred since the Reference Balance Sheet Date in the ordinary course of
business consistent with prior practice; or (d) open purchase or sales orders
or
agreements for delivery of goods and services in the ordinary course of business
consistent with prior practice.
(iii) Each
of
Company and its Subsidiary: maintains a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed
in
accordance with management’s general or specific authorizations; (ii)
transactions are recorded timely as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and
to
maintain asset accountability; (iii) access to assets is permitted only in
accordance with management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with the existing assets at
reasonable intervals and appropriate action is taken with respect to any
differences. Since December 31, 2004, there have been no changes in the internal
accounting controls or in other factors that could affect Company’s internal
accounting controls.
(e) Information
Supplied.
None of
the information supplied or to be supplied by Company for inclusion or
incorporation by reference in the Proxy Statement (as defined below), at
the
time such document is filed with the SEC, or at any time it is amended or
supplemented, contain any untrue statement of a material fact or omit to
state
any material fact required to be stated therein or necessary to make the
statements therein not misleading. Notwithstanding the foregoing, no
representation or warranty is made by Company with respect to statements
made or
incorporated by reference in such documents based on information supplied
by
Parent or Merger Sub.
(f) Approval. i)
The
Board of Directors of Company, by resolutions duly adopted at a meeting duly
called and held and not subsequently rescinded or modified in any way, has
unanimously (1) declared that this Agreement, the Merger and the other
transactions contemplated hereby are advisable and in the best interests
of
Company and the stockholders of Company, and (2) approved this Agreement,
the
Merger and the transactions contemplated hereby. The Board of Directors of
Company has approved this Agreement, the Merger, and the transactions
contemplated hereby and thereby for purposes of Section 203 of the DGCL,
and,
except for Section 203 of the DGCL (which does not apply as a result of such
approval of the Board of Directors of Company), no other “moratorium,” “control
share,” “fair price,” or other state takeover statute applies to this Agreement,
the Merger or the transactions contemplated hereby and thereby.
(ii) The
affirmative vote or consent of a Requisite Majority of the Company Capital
Stock
(the “Required
Company Vote”)
is the
only vote of the holders of any class or series of Company Capital Stock
necessary to approve the transactions contemplated hereby.
(g) Brokers
or Finders. Except
as set forth in Section 2.3(g) of the Company Disclosure Schedule, neither
Company, nor its Subsidiary, nor any director, officer, agent or employee
thereof has employed any broker or finder or has incurred or will incur any
broker’s, finder’s or similar fees, commissions or expenses, in each case in
connection with the transactions contemplated by this Agreement.
(h) Litigation;
Permits.
(i) Except
as set forth in Section 2.3(h) of the Company Disclosure Schedule, there
is
no action, suit, proceeding, or claim, pending or to Company’s Knowledge,
threatened, and no investigation by any court or government or governmental
agency or instrumentality, domestic or foreign, pending or to Company’s
Knowledge, threatened, against Company or its Subsidiary, before any court,
government or governmental agency or instrumentality, domestic or foreign,
nor
is there any outstanding order, writ, judgment, stipulation, injunction,
decree,
determination, award, or other order of any court or government or governmental
agency or instrumentality, domestic or foreign, against Company or its
Subsidiary.
(ii) Except
as
would not reasonably be expected to have, individually or in the aggregate,
a
Material Adverse Effect on Company, Company holds all permits, licenses,
variances, exemptions, orders and approvals of all Governmental Entities
necessary for the operation of the businesses of Company (the “Company
Permits”).
Company is in compliance with the terms of the Company Permits, except where
the
failure to so comply would not reasonably be expected to have, individually
or
in the aggregate, a Material Adverse Effect on Company. The business of Company
is not being conducted in violation of, and Company has not received any
notices
of violations with respect to, any Law, ordinance or regulation of any
Governmental Entity, except for actual or possible violations which would
not
reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect on Company. Since January 1, 2004, Company has timely filed
all
material regulatory reports, schedules, statements, documents, filings,
submissions, forms, registrations and other documents, together with any
amendments required to be made with respect thereto, that each was required
to
file with any Governmental Entity, including state health and regulatory
authorities (“Company
Regulatory Filings”)
and
any applicable Federal regulatory authorities, and have timely paid all Taxes,
fees and assessments due and payable in connection therewith, except where
the
failure to make such filings on a timely basis or payments would not be material
to Company. All such Company Regulatory Filings complied in all material
respects with applicable Law. All rates, plans, policy forms and terms
established or used by Company or its Subsidiary that are required to be
filed
with and/or approved by Governmental Entities have been so filed and/or
approved, the rates charged conform in all material respects to the rates
so
filed and/or approved and comply in all material respects with the Laws
applicable thereto, and to Company’s Knowledge, no such premiums are subject to
any investigation by any Governmental Entity.
(iii) Persons
employed or otherwise contracted with by Company to provide healthcare services
hold all material permits, licenses, exemptions, orders and approvals of
all
Governmental Entities necessary for such Persons to function in the capacity
for
which they were employed or contracted.
(i) Absence
of Certain Changes or Events. Since
December 31, 2005, Company and its Subsidiary have operated their respective
businesses in the ordinary course consistent with past practice. Without
limiting the generality of the immediately preceding sentence, except as
set
forth in Section 2.3(i) of the Company Disclosure Schedule, since December
31,
2005, neither Company nor its Subsidiary has:
(i) amended
or otherwise modified its constituting documents or by-laws (or similar
organizational documents);
(ii) altered
any term of any of its outstanding securities or made any change in its
outstanding shares of capital stock or other ownership interests or its
capitalization, whether by reason of a reclassification, recapitalization,
stock
split or combination, exchange or readjustment of shares, stock dividend
or
otherwise;
(iii) with
respect to, any shares of its capital stock or any other of its securities,
granted, encumbered, issued or sold, or authorized for grant or encumbrance,
issuance or sale, or granted, encumbered, issued or sold any options, warrants,
purchase agreements, put agreement, call agreements, participation agreements,
subscription rights, conversion rights, exchange rights or other securities,
contracts, arrangements, understanding or commitments fixed or contingent
that
could directly or indirectly, require Company or its Subsidiary to issue,
sell,
pledge, dispose of or otherwise cause to become outstanding, any of its
authorized but unissued shares of capital stock or ownership interests, as
appropriate, or any securities convertible into, exchangeable for or carrying
a
right or option to purchase shares of capital stock, or to create, authorize,
issue, sell or otherwise cause to become outstanding any new class of capital
stock or ownership interests, as appropriate or entered into any agreement,
commitment or understanding calling for any of the above;
(iv) declared,
set aside or made any payment, dividend or other distribution upon any capital
stock or, directly or indirectly, purchased, redeemed or otherwise acquired
or
disposed of any shares of capital stock or other securities of or other
ownership interests in Company or its Subsidiary;
(v) incurred
any liability or obligation under agreements or otherwise, except current
liabilities entered into or incurred in the ordinary course of business
consistent with past practice; issued any notes or other corporate debt
securities or paid or discharged any outstanding indebtedness, except in
the
ordinary course of business consistent with past practice; or waived any
of its
respective rights;
(vi) mortgaged,
pledged, subjected to any Lien (as hereinafter defined) or granted any security
interest in any of its assets or properties; entered into any lease of real
property or buildings; or, except in the ordinary course of business consistent
with past practice, entered into any lease of machinery or equipment, or
sold,
transferred, leased to others or otherwise disposed of any tangible or
intangible asset or property;
(vii) effected
any increase in salary, wages or other compensation of any kind, whether
current
or deferred, to any employee or agent, other than routine increases in the
ordinary course of business consistent with past practice or as was required
from time to time by governmental legislation affecting wages (provided,
however, that in no event was any such increase in compensation made with
respect to any employee or agent earning in excess of $100,000 per annum);
made
any bonus, pension, option, deferred compensation, or retirement payment,
severance, profit sharing, or like payment to any employee or agent, except
as
required by the terms of plans or arrangements existing prior to such date
(provided, however, that in no event was any such payment made with respect
to
any employee or agent earning in excess of $100,000 per annum); or entered
into
any salary, wage, severance, or other compensation agreement with a term
of one
year or longer with any employee or agent or made any contribution to any
trust
or plan for the benefit of any employee or agent, except as required by the
terms of plans or arrangements existing prior to such date; or lost the
employment services of any employee whose annual salary exceeded
$100,000;
(viii) adopted
or, except as required by law, amended, any employee benefit plan other than
as
necessary in connection with the transactions contemplated hereby;
(ix) entered
into any transaction other than in the ordinary course of business consistent
with past practice, except in connection with the execution and performance
of
this Agreement and the transactions contemplated hereby;
(x) terminated
or modified any Company Material Contract (as defined below), or received
any
written notice of termination of any Company Material Contract, except for
terminations of Company Material Contracts upon their expiration during such
period in accordance with their terms;
(xi) incurred
or assumed any indebtedness for borrowed money or guaranteed any obligation
or
the net worth of any entity or person;
(xii) discharged
or satisfied any Lien other than those then required to be discharged or
satisfied during such period in accordance with their original
terms;
(xiii) paid
any
material obligation or liability (absolute, accrued, contingent or otherwise),
whether due or to become due, except for any current liabilities, and the
current portion of any long term liabilities, shown on the Company Financial
Statements or incurred since December 31, 2005 in the ordinary course of
business consistent with past practice;
(xiv) cancelled,
waived or compromised any material debt or claim;
(xv) suffered
any damage, destruction, or loss to any of its assets or properties (whether
or
not covered by insurance) except for damage, destruction or loss occurring
in
the ordinary course of business which, individually or in the aggregate,
would
not have a Material Adverse Effect;
(xvi) made
any
loan or advance to any entity or person other than travel and other similar
routine advances to employees in the ordinary course of business consistent
with
past practice;
(xvii) made
any
capital expenditures or capital additions or betterments in amounts which
exceed
$50,000 in the aggregate;
(xviii) purchased
or acquired any capital stock or other securities of any other corporation
or
any ownership interest in any other business enterprise;
(xix) changed
its method of accounting or its accounting principles or practices, including
any policies or practices with respect to the establishment of reserves for
work-in-process and accounts receivable, utilized in the preparation of the
Company Financial Statements, other than as required by GAAP;
(xx) instituted
or settled any litigation or any legal, administrative or arbitration action
or
proceeding before any court, government or governmental agency or
instrumentality, domestic or foreign, relating to it or any of its properties
or
assets;
(xxi) made
any
new elections, changed any current elections or settled or compromised any
liability with respect to its Taxes;
(xxii) entered
into any agreement or commitment to do any of the foregoing;
(xxiii) suffered
any Material Adverse Effect; or
(xxiv) since
December 31, 2005, there has been no condition, development or contingency
which, so far as reasonably may be foreseen, may, individually or in the
aggregate, have a Material Adverse Effect.
(j) Compliance
with Laws and Regulations.
(i) Company
and its Subsidiary have complied with all applicable Laws (including rules,
regulations, codes, plans, injunctions, judgments, orders, decrees, rulings,
and
charges thereunder) of Governmental Entities (and all agencies thereof) except
where such non-compliance has not and would not have a Material Adverse Effect
on their businesses or operations, and no action, suit, proceeding, hearing,
investigation, charge, complaint, claim, demand, or notice has been filed
or
commenced against any of them alleging any failure so to comply. Company
and its
Subsidiary hold all licenses and permits, required to be held by them under
the
laws all jurisdictions in which they operate in order to operate their
businesses as currently operated and Company has not received any notice,
written or otherwise, of the initiation of proceedings to revoke any such
license or permit, except where such failure to hold any such licenses or
permits would not have a Material Adverse Effect. Section 2.3(j) of the Company
Disclosure Schedule sets forth the names of those states in which Company
operates.
(ii) Neither
Company nor its Subsidiary has, since its incorporation, entered into a
memorandum of understanding, consent decree or similar instrument with any
governmental agency or has been the subject of any investigation or legal
proceeding, which could have a Material Adverse Effect on its business or
operations.
(iii) Neither
Company nor any of its respective officers, directors, employees or agents,
has
directly or indirectly: (A) offered or paid any amount to, or made any financial
arrangement with, any of its accounts in order to promote business from such
accounts, other than standard pricing or discount arrangements consistent
with
proper business practices; (B) given, or agreed to give, or is aware that
there
has been made, or that there is an agreement to make, any gift or gratuitous
payment of any kind, nature or description (whether in money, property or
services) to any current account or supplier, source of financing, landlord,
sub-tenant, licensee or anyone else; or (C) made, or has agreed to make,
any
payments to any person with the intention or understanding that any part
of such
payment was to be used directly or indirectly for the benefit of any current
account or employee, supplier or landlord of such current account, or for
any
purpose other than that reflected in the documents supporting the
payments.
(iv) Company
and its Subsidiary are in compliance with, and are not in default or violation
of, (A) its respective certificate of incorporation and bylaws, (B) any Law
or
order by which any of its respective assets or properties are bound or affected
and (C) the terms of all notes, bonds, mortgages, indentures, contracts,
permits, franchises and other instruments or obligations to which it is a
party
or by which it is or any of its assets or properties are bound or affected,
except, in the case of clauses (B) and (C), for any such failures of compliance,
defaults and violations which could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. Company is in
compliance with the terms of all approvals, except where the failure to so
comply could not, individually or in the aggregate, reasonably be expected
to
have a Material Adverse Effect. Except as set forth in the Company Disclosure
Schedule or as could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect, neither Company nor its Subsidiary
has received notice of any revocation or modification of any Approval of
any
Governmental Entity that is material to Company.
(v) The
operations of Company and its Subsidiary are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as
amended, the money laundering statutes of all jurisdictions, the rules and
regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any Governmental Entity
(collectively, the “Money
Laundering Law”)
and no
action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving Company with respect to the
Money
Laundering Laws is pending or, to Company’s Knowledge, threatened, except, in
each case, as would not reasonably be expected to materially and adversely
affect the condition, financial or otherwise, or the earnings, business or
operations of Company and its Subsidiary, taken as a whole.
(vi) Company
and its Subsidiary are in material compliance with all statutory and regulatory
requirements under the Arms Export Control Act (22 U.S.C. 2778), the
International Traffic in Arms Regulations (22 C.F.R. § 120 et seq.), the Export
Administration Regulations (15 C.F.R. §730 et seq.) and associated executive
orders, the laws implemented by the Office of Foreign Assets Controls, United
States Department of Treasury and all other domestic or foreign laws relating
to
export control (collectively, the “Export
Control Laws”)
except
as would not individually or in the aggregate be material to Company taken
as a
whole. Company has not received any written communication that alleges that
Company is not, or may not be, in compliance with, or has, or may have, any
liability under Export Control Laws. Company has all necessary authority
under
the Export Control Laws to conduct its business substantially in the manner
conducted prior to the date hereof and substantially as it is being conducted
on
the date hereof except as would not, individually or in the aggregate, be
material to Company.
(vii) Company
is in compliance with all national security obligations, including, without
limitation, those specified in the National Industrial Security Program
Operating Manual, DOD 5220.22-M (January 1995). To Company’s Knowledge, it has
not, within the last five (5) years, received any invalidation of a facility
clearance or other adverse action of a Governmental Entity with respect to
any
facility clearance or any adverse determination with respect to personal
security clearances for officers, directors or employees of
Company.
(k) Taxes.
Except
as
set forth in Section 2.3(k) of the Company Disclosure Schedule:
(i) Company
and its Subsidiary has timely and accurately filed, or caused to be timely
and
accurately filed, all Tax Returns required to be filed by it, and has paid,
collected or withheld, or caused to be paid, collected or withheld, all amounts
of Taxes required to be paid, collected or withheld, other than such Taxes
for
which adequate reserves have been established and which are being contested
in
good faith. There are no claims or assessments pending against Company or
its
Subsidiary for any alleged deficiency in any Tax, there are no pending or,
to
Company’s Knowledge, threatened audits or investigations for or relating to any
liability in respect of any Taxes, and Company has not been notified in writing
of any proposed Tax claims or assessments against Company or its Subsidiary
(other than in each case, claims or assessments for which adequate reserves
have
been established and which are being contested in good faith). Neither Company
nor its Subsidiary has executed any waivers or extensions of any applicable
statute of limitations to assess any amount of Taxes. There are no outstanding
requests by Company or its Subsidiary for any extension of time within which
to
file any Tax Return or within which to pay any amounts of Taxes shown to
be due
on any Tax Return. To the Company’s Knowledge, there are no liens for Taxes on
the assets of Company or its Subsidiary except for statutory liens for current
Taxes not yet due and payable. There are no outstanding powers of attorney
enabling any party to represent Company or its Subsidiary with respect to
Taxes.
Other than with respect to Company or its Subsidiary, neither Company nor
its
Subsidiary is liable for Taxes of any other Person, or is currently under
any
contractual obligation to indemnify any person with respect to any amounts
of
Taxes (except for customary agreements to indemnify lenders or security holders
in respect of Taxes), or is a party to any tax sharing agreement or any other
agreement providing for payments by Company or its Subsidiary with respect
to
any amounts of Taxes. Neither Company nor its Subsidiary has engaged in any
transaction which requires its participation to be disclosed under Treas.
Reg.
Sec. 1.6011-4.
(ii) For
purposes of this Agreement, the term “Tax”
shall
mean any United States or Canadian federal, national, state, provincial,
territorial, local or other jurisdictional income, gross receipts, property,
sales, goods and services, use, license, excise, franchise, employment, payroll
(including employee withholding taxes), estimated, alternative, or add-on
minimum, ad valorem, transfer or excise tax, goods and services or any other
tax, custom, duty, governmental fee or other like assessment or charge imposed
by any governmental authority, together with any interest or penalty imposed
thereon. The term “Tax
Return”
shall
mean a report, return or other information (including any attached schedules
or
any amendments to such report, return or other information) required to be
supplied to or filed with a governmental authority with respect to any Tax,
including an information return, claim for refund, amended return or declaration
or estimated Tax.
(l) Accounting
and Financial Matters. Since
January 1, 2004, except as set forth in Section 2.3(l) of the Company Disclosure
Schedule, Company has not received written notice from any Governmental Entity
that any of its accounting policies or practices are or may be the subject
of
any review, inquiry, investigation or challenge by a Governmental Entity.
Since
January 1, 2004, Company’s independent public accounting firm has not informed
Company that it has any material questions, challenges or disagreements
regarding or pertaining to Company’s accounting policies or practices. Since
January 1, 2004, no officer or director of Company has received, or is entitled
to receive, any material compensation from any entity that has engaged in
or is
engaging in any material transaction with Company or its Subsidiary. Set
forth
in Section 2.3(l) of the Company Disclosure Schedule is a list of all
off-balance sheet special purpose entities and financing arrangements of
Company
and its Subsidiary.
(m) Third-Party
Payors.
All
contracts with third-party payors were entered into by Company or its Subsidiary
in the ordinary course of business. Company and its Subsidiary have properly
charged and billed in accordance with the terms of those contracts in all
material respects, including, where applicable, billing and collection of
all
deductibles and co-payments.
(n) Government
Contracts.
(i) Except
as set forth in Section 2.3(n) of the Company Disclosure Schedule, with
respect to each contract, agreement, bid or proposal between Company, its
Subsidiary and any (A) Governmental Entity, including any facilities contract
for the use of government-owned facilities or (B) third party relating to
a
contract between such third party and any Governmental Entity (each a
“Government
Contract”),
(1)
Company and its Subsidiary have complied in all material respects with all
requirements of all applicable laws, or agreements pertaining to such Government
Contract; (2) all representations and certifications executed, acknowledged
or
set forth in or pertaining to such Government Contract were complete and
correct
as of their effective dates and Company has complied with all such
representations and certifications; (3) neither the United States government
nor
any prime contractor, subcontractor or other Person has notified Company,
in
writing or orally, that Company has breached or violated any Law, certification,
representation, clause, provision or requirement pertaining to such Government
Contract; (4) neither Company nor its Subsidiary has received any notice
of
termination for convenience, notice of termination for default, cure notice
or
show cause notice pertaining to such Government Contract; (5) other than
in the
ordinary course of business, no cost incurred by Company or its Subsidiary
pertaining to such Government Contract has been questioned or challenged,
is the
subject of any audit or investigation or has been disallowed by any Governmental
Entity; and (6) no payments due to Company or its Subsidiary pertaining to
such
Government Contract have been withheld or set off, nor has any claim been
made
to withhold or set off money, and Company is entitled to all progress or
other
payments received with respect thereto, except, in the case of (1) through
(6)
above, as would not be material to Company, taken as a whole.
(ii) Company
or to Company’s Knowledge, any of its directors, officers, employees or
authorized agents is not, or since January 1, 2004 has not been under (A)
any
civil or criminal investigation or indictment by any Governmental Entity
or
under investigation by Company or its Subsidiary or (B) administrative
investigation or audit by any Governmental Entity in either case with respect
to
any alleged improper act or omission arising under or relating to any Government
Contract.
(iii) There
exist (A) no outstanding material claims against Company or its Subsidiary,
either by any Governmental Entity or by any prime contractor, subcontractor,
vendor or other Person, arising under or relating to any Government Contract,
and (B) no material disputes between Company and the United States government
under the Contract Disputes Act, as amended, or any other federal statute,
or
between Company or its Subsidiary, on the one hand, and any prime contractor,
subcontractor or vendor on the other, arising under or relating to any
Government Contract. Company does not have any interest in any material pending
claim against any prime contractor, subcontractor, vendor or other Person
arising under or relating to any Government Contract.
(iv) Since
January 1, 2004, neither Company nor its Subsidiary has been debarred or
suspended from participation in the award of Contracts with the United States
government or any other Governmental Entity. To Company’s Knowledge, there exist
no facts or circumstances that would warrant the institution of suspension
or
debarment proceedings or the finding of non-responsibility or ineligibility
on
the part of Company or any of its directors, officers or employees. Company
has
no Knowledge of any claim, potential claim or potential liability for defective
pricing, false statements or false claims with respect to any of their
Government Contracts.
(o) Property
Interests.
(i) Set
forth
in Section 2.3(o) of the Company Disclosure Schedule attached hereto is a
list
of every parcel of real estate owned by Company or its Subsidiary and a list
of
each lease agreement under which Company or its Subsidiary is lessee of,
or
holds or operates, any real estate owned by any third party (collectively
hereinafter referred to as the “Company
Real Properties”).
Company or its Subsidiary has good and marketable title to the properties
owned
by Company or its Subsidiary set forth on Section 2.3(o) of the Company
Disclosure Schedule and all fixtures thereon in fee simple absolute, subject
to
no Liens. There is no option or right held by any third party to purchase
any
such properties or any part thereof, or any of the fixtures and equipment
thereon. All buildings, driveways and other improvements on such properties,
respectively, are within its boundary lines, and no improvements on adjoining
properties extend across the boundary lines onto such properties. Each lease
agreement described in Section 2.3(o) of the Company Disclosure Schedule
is in
full force and effect and constitutes a legal, valid and binding obligation
of
the respective parties thereto. Neither Company nor its Subsidiary is in
a
default under any such lease agreement, nor to the Company’s Knowledge is any
other party to any such lease agreement in default thereunder, and no event
has
occurred, or is alleged to have occurred, which constitutes, or with lapse
of
time or giving of notice or both would constitute, a default by any party
to any
such lease agreement or a basis for a claim of force majeure or other claim
of
excusable delay or non-performance thereunder, other than with respect to
any
default, event or claim which, individually or in the aggregate, would not
have
a Material Adverse Effect;
(ii) Except
as
set forth in Section 2.3(o) of the Company Disclosure Schedule, Company and
its
Subsidiary have good and marketable title to all of their respective assets
and
properties, in each case free and clear of all Liens. Company and its Subsidiary
lease or own all properties and assets necessary for the operation of their
respective businesses as presently conducted, and the assets and properties
of
Company and its Subsidiary include all of the assets, of every kind and nature,
whether tangible or intangible, and wherever located, which are utilized
by
Company or its Subsidiary in the conduct of their respective businesses.
Neither
Company nor its Subsidiary have received notice of any violation of, or default
under, any Law, ordinance, order, regulation, or governmental or contractual
requirement relating to the assets and properties of Company or its Subsidiary
which remains uncured or has not been dismissed, other than with respect
to any
violation which, individually or in the aggregate, would not have a Material
Adverse Effect. All leases and licenses pursuant to which Company or its
Subsidiary lease or license personal and intangible property from others,
are in
good standing, valid and effective in accordance with their respective terms,
and there is not, under any of such leases or licenses, any existing default
or
event of default (or event which with notice or lapse of time, or both, would
constitute a default, or would constitute a basis for a claim of force majeure
or other claim of excusable delay or non-performance) which would result
in a
Material Adverse Effect. All the tangible personal property owned or leased
by
Company or its Subsidiary is in good operating condition and repair, subject
only to ordinary wear and tear, and conforms in all respects to all applicable
Laws, ordinances, orders, regulations or governmental or contractual
requirements relating to their operations.
(p) Affiliate
Transactions.
Except
(i) for employment relationships between Company or its Subsidiary and employees
of Company or its Subsidiary otherwise disclosed pursuant to this Agreement,
(ii) for remuneration by Company or its Subsidiary for services rendered
as a
director, officer or employee of Company or its Subsidiary otherwise disclosed
pursuant to this Agreement, or (iii) as set forth in Section 2.3(p) of the
Company Disclosure Schedule, (A) neither Company nor its Subsidiary has,
and has
not since its inception, in the ordinary course of business or otherwise,
directly or indirectly, purchased, leased or otherwise acquired any property
or
obtained any services from, or sold, leased or otherwise disposed of any
property or furnished any services to any affiliate of Company or its
Subsidiary; (B) neither Company nor its Subsidiary owes any amount to any
affiliate of Company or its Subsidiary; (C) no affiliate of Company or its
Subsidiary owes any amount to any of Company or its Subsidiary; and (D) no
part
of the property or assets of any affiliate of Company or its Subsidiary is
used
by either of Company or its Subsidiary in the conduct or operation of their
businesses. No affiliate of Company or its Subsidiary owns any business which
is
a significant competitor of Company or its Subsidiary.
(q) Health
Insurance Portability and Accountability Act of 1996. Company
is, and Company’s business is being conducted, in compliance in all material
respects with the Health Insurance Portability and Accountability Act of
1996.
(r) Off-Balance
Sheet Arrangements. Section
2.3(r) of the Company Disclosure Schedule describes, and Company has delivered
to Parent copies of the documentation creating or governing, all securitization
transactions and other “off-balance sheet arrangements” (as defined in Item
303(c) of Regulation S-K of the SEC) that existed or were effected by Company
since January 1, 2004 in effect on the date hereof.
(s) Environmental
Matters.
Definitions. For
the
purposes of this Agreement, the following terms shall have the meanings set
forth below:
“Environment”
shall
mean air, land, surface soil, subsurface soil, sediment, surface water,
groundwater, wetlands and all flora and fauna present therein or
thereon.
“Environmental
Conditions”
shall
mean any pollution or contamination or threatened pollution or contamination
of,
or the Release or threatened Release of Hazardous Materials into, the
Environment.
“Environmental
Laws”
means
all federal, regional, state, county or local Laws, statutes, ordinances,
decisional law, rules, regulations, codes, orders, decrees, directives and
judgments relating to public health or safety, pollution, damage to or
protection of the Environment, Environmental Conditions, Releases or threatened
Releases of Hazardous Materials into the Environment or the use, manufacture,
processing, distribution, treatment, storage, generation, disposal, transport
or
handling of Hazardous Materials, including but not limited to, the Federal
Water
Pollution Control Act, 33 U.S.C. §§ 1231-1387; the Resource Conservation and
Recovery Act, 42 U.S.C. §§ 6901-6991 (“RCRA”);
the
Clean Air Act, 42 U.S.C. §§7401-7642; the Comprehensive Environmental Response
Compensation and Liability Act, 42 U.S.C. §§ 9601-9675 (“CERCLA”);
the
Toxic Substances Control Act, 15 U.S.C. §§ 2601-2629; the Federal Occupational
Safety and Health Act, 29 U.S.C. § 657 et seq.
(“OSHA”);
comparable state laws; and any and all rules and regulations promulgated
thereunder.
“Hazardous
Materials”
shall
mean any substances, materials or wastes, whether liquid, gaseous or solid,
or
any pollutant or contaminant, that is infectious, toxic, hazardous, explosive,
corrosive, flammable or radioactive, including without limitation, petroleum,
polychlorinated biphenyls, asbestos and asbestos containing materials and
urea
formaldehyde, or that is regulated under, defined, listed or included in
any
Environmental Laws, including without limitation, CERCLA, RCRA and
OSHA.
“Release”
shall
mean any intentional or unintentional release, discharge, burial, spill,
leaking, pumping, pouring, emitting, emptying, injection, disposal or dumping
into the Environment.
Except
as
set forth in Section 2.3(s) of the Company Disclosure Schedule:
(i) The
respective businesses of Company and its Subsidiary, and the Company Real
Properties, are, and at all times have been, in compliance with all applicable
Environmental Laws, except for such non-compliance which, individually or
in the
aggregate, would not have a Material Adverse Effect.
(ii) Company
possesses all permits, authorizations, licenses, approvals and consents required
under Environmental Laws (“Environmental
Permits”)
in
order to conduct its business as it is now being conducted. Company is in
compliance with all requirements, terms and provisions of such Environmental
Permits, except for such non-compliance which, individually or in the aggregate,
would not have a Material Adverse Effect.
(iii) Company
and its Subsidiary have filed on a timely basis (and updated as required)
all
reports, disclosures, notifications, applications, pollution prevention,
storm
water prevention or discharge prevention or response plans or other emergency
or
contingency plans required to be filed under Environmental Laws with respect
to
their business and the Company Real Properties.
(iv) Neither
Company nor, to Company’s Knowledge, its Subsidiary have received any notice
that Company, its Subsidiary or any of the Company Real Properties: (1) is
in
violation of the requirements of any Environmental Permit or Environmental
Laws;
(2) is the subject of any suit, claim, proceeding, demand, order, investigation
or request or demand for information arising under any Environmental Permit
or
Environmental Laws; or (3) has actual or potential liability under any
Environmental Laws, including without limitation, CERCLA, RCRA or any comparable
state or local Environmental Laws.
(v) To
Company’s Knowledge, there are no Environmental Conditions or other facts,
circumstances or activities arising out of or relating to the business of
Company or its Subsidiary or the use, operation or occupancy by Company or
its
Subsidiary of any of the Company Real Properties that result or reasonably
could
be expected to result in (1) any obligation of Company or its Subsidiary
to file
any report or notice, to conduct any investigation, sampling or monitoring
or to
effect any environmental cleanup or remediation, whether on-site or offsite;
or
(2) liability, either to governmental agencies or third parties, for damages
(whether to person, property or natural resources), cleanup costs or remedial
costs of any kind or nature whatsoever.
(vi) Neither
Company nor, to Company’s Knowledge, its Subsidiary has transported for storage,
treatment or disposal, by contract, agreement or otherwise, or arranged for
the
transportation, storage, treatment or disposal, of any Hazardous Material
at or
to any location including, without limitation, any location used for the
treatment, storage or disposal of Hazardous Materials.
(t) Intellectual
Property.
(i) As
used
in this Agreement, the term “Intellectual
Property Rights”
means
all: (i) patents, patent applications, foreign patents and foreign patent
applications, inventions and designs, and any registrations thereof with
any
agency or authority, (ii) trademarks, service marks, trade names, domain
names,
copyrights and mask works and all registrations and applications to register
any
of the foregoing with any agency or authority; (iii) trade secrets and
confidential business information, whether patentable or unpatentable and
whether or not reduced to practice, including all formulae, processes, know-how,
technical and clinical data, shop rights, financial, marketing and business
data, pricing and cost information, business and marketing plans and customer
and supplier lists and information and any media or other tangible embodiment
thereof and all descriptions thereof; (iv) all other technology and intangible
property, including without limitation computer software and programs in
object
code or source code form, databases, and documentation and flow charts; and
(v)
all licenses, grants or other rights running to or from a person relating
to any
of the foregoing, including material transfer agreements.
(ii) Set
forth
on Section 2.3(t) of the Company Disclosure Schedule is a true, accurate
and
complete list of all Intellectual Property Rights owned, licensed or used
by
Company or its Subsidiary and that are material to the business of Company
as
presently conducted or as contemplated to be conducted (hereinafter referred
to
as the “Company
Intellectual Property Rights”),
specifying whether such Intellectual Property Rights are exclusive or
non-exclusive to Company or its Subsidiary and including identifying information
of all federal, state and foreign registrations of such Intellectual Property
Rights or applications for registration thereof (but excluding software licenses
that are generally commercially available).
(iii) Company
or its Subsidiary owns, is licensed to use, or otherwise has the full legal
right to use all of the Company Intellectual Property Rights, free and clear
of
any Lien. To Company’s Knowledge, such Company Intellectual Property Rights are
sufficient for the conduct of Company’s business as presently conducted and to
Company’s Knowledge, as contemplated to be conducted, and constitute all of the
Intellectual Property Rights owned, licensed or used by Company. Except for
the
licenses disclosed in Section 2.3(t) of the Company Disclosure Schedule
(hereinafter referred to as the “Company
Licenses”),
(A)
Company is not bound by or a party to any rights or options (whether or not
currently exercisable), licenses or agreements of any kind (other than software
licenses that are generally commercially available) with respect to the Company
Intellectual Property Rights and (B) to Company’s Knowledge, there are no other
outstanding rights or options (whether or not currently exercisable), licenses
or agreements of any kind relating to Company Intellectual Property Rights.
Except under the Company Licenses identified in Section 2.3(t) of the Company
Disclosure Schedule, Company is not obligated to pay any royalties or other
compensation or expenses (other than fees for software licenses that are
generally commercially available), to any third party in respect of its
ownership, use or license of any of the Company Intellectual Property Rights.
There has been no breach or violation by Company, and to Company’s Knowledge
there is no breach or violation by any other party to, any Company License
that
is reasonably likely to give rise to any termination or any loss of rights
thereunder.
(iv) Except
as
set forth in Section 2.3(t) of the Company Disclosure Schedule, to the Company’s
Knowledge, neither Company’s business, as presently conducted or as contemplated
to be conducted, nor the current and contemplated products or services of
Company infringe, constitute the misappropriation of, or conflict with, any
Intellectual Property Rights of any third party. Company is not aware of
any
claim, and has not received any notice or other communication (in writing
or
otherwise) of any claim from, any person asserting that Company’s business, as
presently conducted or as contemplated to be conducted, or any of the current
or
contemplated products or services of Company infringe or may infringe,
constitute the misappropriation of, or conflict with, any Intellectual Property
Rights of another person. Company is not aware of any existing or threatened
infringement, misappropriation, or competing claim by any third party on
the
right to use or own any of, the Company Intellectual Property
Rights.
(v) Company
has taken commercially reasonable measures and precautions to establish and
preserve the confidentiality, secrecy and ownership of all Company Intellectual
Property Rights with respect to its products and services. Without limiting
the
generality of the foregoing employees who have had access to confidential
or
proprietary information of Company have executed and delivered to Company
confidentiality agreements in a form customary in the industry in which Company
operates. Copies of such agreements have been delivered to Parent, and all
of
such agreements are in full force and effect. Company is not aware of any
violation of the confidentiality of any non-public Company Intellectual Property
Rights. Company is not making unlawful use of any confidential information
or
trade secrets of any third party. To Company’s Knowledge, the activities of
Company’s employees, consultants, or independent contractors on behalf of
Company’s business, as presently conducted and contemplated to be conducted, do
not violate any agreements or arrangements which such employees have with
former
employers or any other third person. To Company’s Knowledge, no current or
former employee, officer, director, stockholder, consultant or independent
contractor has any right, claim or interest in or with respect to any of
the
Company Intellectual Property Rights.
(vi) Except
as
set forth in Section 2.3(t) of the Company Disclosure Schedule, to Company’s
Knowledge, no third party has infringed, misappropriated or otherwise conflicted
with any of the Company Intellectual Property Rights. To Company’s Knowledge,
there are no third party challenges to the Company Intellectual Property
Rights
including interferences, reexaminations, oppositions and appeals.
(vii) Except
as
set forth in Section 2.3(t) of the Company Disclosure Schedule, (i) there
is no
action, suit, order, claim, or to Company’s Knowledge, governmental
investigation pending, or, to Company’s Knowledge, threatened in writing against
Company or affecting Company, relating to the Company Intellectual Property
Rights and reasonably likely so as to cause a Material Adverse Effect (or
to
Company’s Knowledge, pending or threatened in writing against any of the
officers, directors or employees of Company with respect to Company’s business
or proposed business activities) at law or in equity, or before or by any
governmental department, commission, board, bureau, agency or instrumentality
(including, without limitation, any actions, suits, proceedings or
investigations with respect to the transactions contemplated by this Agreement);
(ii) nor has there been any such actions, suits, orders, claims, or to Company’s
Knowledge, governmental investigations or claims pending against Company
at any
time; (iii) to Company’s Knowledge, there is no valid basis for any of the
foregoing; (v) Company is not subject to any judgment, order or decree of
any
court or other governmental agency; and (vi) there is no action, suit,
proceeding, or investigation by Company currently pending or which Company
presently intends to initiate with respect to the transactions contemplated
by
the Agreement.
(u) Certain
Agreements. Section
2.3(u) of the Company Disclosure Schedule lists, as of the date hereof, each
of
the following contracts, agreements or arrangements, whether written or oral,
to
which Company is a party or by which it is bound (collectively, the
“Company
Material Contracts”):
(i) any
“material contract” (as such term is defined in Item 601(b)(10) of Regulation
S-K of the SEC);
(ii) all
healthcare and clinical testing contracts measured in terms of payments
received;
(iii) all
Government Contracts;
(iv) promissory
notes, loans, agreements, indentures, evidences of indebtedness or other
instruments providing for the lending of money, whether as borrower, lender
or
guarantor, in amounts greater than $100,000 (it being understood that trade
payables, ordinary course business funding mechanisms between Company and
its
customers and providers shall not be considered indebtedness for purposes
of
this provision);
(v) any
contract or other agreement expressly restricting the payment of dividends
or
the repurchase of stock or other equity;
(vi) collective
bargaining contracts;
(vii) material
joint venture, partnership agreements or other similar agreements;
(viii) any
contract for the pending acquisition, directly or indirectly (by merger or
otherwise), of any entity or business;
(ix) any
contract, agreement or policy for reinsurance involving ceded insurance premiums
of greater than $100,000;
(x) leases
for real or personal property involving annual expense in excess of $500,000
and
not cancelable by Company (without premium or penalty) within twelve (12)
months;
(xi) all
contracts to which Company is a party granting any license to intellectual
property (other than trade and service marks) and any other license (other
than
real estate or computer software) having an aggregate value per license,
or
involving payments to Company, of more than $100,000 on an annual
basis;
(xii) all
confidentiality agreements (other than in the ordinary course of business),
agreements by Company not to acquire assets or securities of a third party
or
agreements by a third party not to acquire assets or securities of
Company;
(xiii) any
contract, other than any insured customer contracts or equipment lease, having
an aggregate value per contract, or involving payments by or to Company,
of more
than $100,000 on an annual basis that requires consent of a third party in
the
event of or with respect to the Merger, including in order to avoid termination
or loss of benefits under any such contract;
(xiv) any
non-competition agreement or any other agreement or arrangement that by its
terms (A) limits or otherwise restricts Company or any successor thereto
or (B)
would, after the Effective Time, limit or otherwise restrict Company or Parent
including the Surviving Corporation or any successor thereto, from engaging
or
competing in any line of business or in any geographic area;
(xv) any
contract or order with or from a Governmental Entity; and
(xvi) all
employment contracts, consulting agreements, representative agreements and
service contracts to which Company is a party.
Company
has previously made available to Parent complete and accurate copies of each
Company Material Contract listed, or required to be listed, in Section 2.3(u)
of
the Company Disclosure Schedule (including all amendments, modifications,
extensions, renewals, guarantees or other contracts with respect thereto,
but
excluding certain names, terms and conditions that have been redacted in
compliance with applicable laws governing the sharing of information or
otherwise). All of the Company Material Contracts are valid and binding and
in
full force and effect (except those which are cancelled, rescinded or terminated
after the date hereof in accordance with their terms), except where the failure
to be in full force and effect, individually or in the aggregate would not
reasonably be expected to have a Material Adverse Effect on Company. To
Company’s Knowledge, no Person is challenging the validity or enforceability of
any Company Material Contract, except such challenges which, individually
or in
the aggregate, would not reasonably be expected to have a Material Adverse
Effect on Company. Company has not, and to Company’s Knowledge, as of the date
hereof, none of the other parties thereto, have violated any provision of,
or
committed or failed to perform any act which (with or without notice, lapse
of
time or both) would constitute a default under the provisions of, any Company
Material Contract, except for those violations and defaults which, individually
or in the aggregate, would not reasonably be expected to have a Material
Adverse
Effect on Company.
(v) FDA
Matters.
(i) For
purposes of this Agreement: (i)”FDA”
means
the United States Food and Drug Administration and corresponding regulatory
agencies in other countries and in states of the United States, (ii)
“FDA
Clearance and Approval”
means
any pre-market notification or pre-market approval application, consent,
certificate, registration, permit, license or other authorization, and the
filing of any notification, application, report or information, required
by the
FDA or any other government entity pursuant to any FDA Law, (iii) “FDA
Company Contractor”
means
any person with which Company or its Subsidiary formerly or presently had
or has
any agreement or arrangement (whether oral or written) under which that person
has or had physical possession of, or was or is obligated to develop, test,
process, investigate, manufacture or produce, any FDA Regulated Product on
behalf of Company, (iv) “FDA
Law”
means
any statute, regulation, judicial or administrative interpretation, guideline,
point-to-consider, recommendation or standard international guidance relating
to
any FDA Regulated Product, including, without limitation, the Federal Food,
Drug, and Cosmetic Act, 21 U.S.C. sec. 301 et seq., the FDA Modernization
Act of
1997, Stand Alone Provisions, Pub. L. No. 105-115, 111 Stat. 2295 (1997),
and
equivalent statutes, regulations and guidance’s adopted by countries,
international bodies and other jurisdictions, in addition to the United States,
where Company has facilities, does business, or directly or through others
sells
or offers for sale any FDA Regulated Product, and (v) “FDA
Regulated Product”
means
any product or component including, without limitation, any medical device,
that
is studied, used, held or offered for sale for human research or investigation
or clinical use.
(ii) Company
has not obtained any clearances or approvals from the FDA to conduct its
current
businesses, to manufacture, hold or sell FDA Regulated Products, and to use
and
occupy the Company Real Properties.
(iii) Company
has no obligations to submit reports and filings to the FDA.
(iv) Except
as
set forth in Section 2.3(v) to the Company Disclosure Schedule, there is
no
civil, criminal or administrative action, suit, demand, claim, complaint,
hearing, notice of violation, investigation, notice, demand letter, proceeding
or request for information pending or any liability (whether actual or
contingent) to comply with any FDA Laws. There is no act, omission, event
or
circumstance of which Company has Knowledge that may give rise to any such
action, suit, demand, claim, complaint, hearing, notice of violation,
investigations, notice, demand letter, proceeding or request, or any such
liability:
against,
involving or of Company, or
against,
involving or of any other person (including, without limitation, any FDA
Company
Contractor) that could be imputed or attributed to Company.
(v) There
has
not been any violation of any FDA Laws by Company in their prior product
developmental efforts, or any other Governmental Entity (or any failure to
make
any such submission or report) that could reasonably be expected to require
investigation, corrective action or enforcement action.
(w) Employee Benefit Plans.
(i) Except
as
set forth on Section
2.3(w) of the Company Disclosure Schedule, neither Company nor its Subsidiary
maintains, sponsors, contributes to, is required to contribute to, is a party
to, or otherwise has or is reasonably expected to have any liability (contingent
or otherwise) with respect to (1) any “employee
welfare benefit plan,”
as
defined in Section 3(1) of the Employee Retirement Income Security Act of
1974,
as amended (“ERISA”),
(2)
any “employee
pension benefit plan,”
as
defined in Section 3(2) of ERISA, (3) any plan or
agreement providing for bonuses, stock options, stock appreciation rights,
stock
purchase plans or other forms of equity-based compensation, (4) any other
plan
or agreement involving direct or indirect compensation (including any deferred
compensation) other than workers’ compensation, unemployment compensation and
other government programs, (5) any employment, severance, separation, change
of
control or other similar contract, arrangement or policy providing for insurance
coverage,
salary continuation,
non-statutory workers’ compensation, disability benefits, supplemental
unemployment benefits, vacation benefits, retirement benefits, pension,
supplemental pension, savings, retirement savings,
fringe
benefits, deferred compensation, profit-sharing, bonuses, other forms of
incentive compensation or post-retirement insurance, compensation or benefits,
(6) any other
employee benefit plan, arrangement, program, agreement, policy or practice,
formal or informal, funded or unfunded, insured or self-insured, that covers
any
current or former employee of Company or its Subsidiary,
or (7)
any multiemployer plan (within the meaning of Section 3(37) of ERISA)
(hereinafter “Multiemployer
Plan”).
Each
plan or agreement required to be set forth on Section 2.3(w) of the Company
Disclosure Schedule, other than a Multiemployer Plan, pursuant to the foregoing
is referred to herein as a “Company
Benefit Plan.”
(ii) Company
has delivered or made available to Parent the following documents with respect
to each Company Benefit Plan: (1) correct and complete copies of all documents
embodying such Company Benefit Plan, including (without limitation) all
amendments thereto and all related trust documents, (2) a written description
of
any Company Benefit Plan that is not set forth in a written document, (3)
the
most recent summary plan description, summary of material modifications and
other similar descriptive materials distributed to plan participants and
beneficiaries, (4) the most recent Internal Revenue Service (“IRS”)
determination letter or similar forms of any applicable foreign jurisdiction,
if
any, (5) the three most recent annual reports (Form Series 5500 and all
schedules and financial statements attached thereto), if any, and (6) all
material written agreements and contracts currently in effect, including
(without limitation) administrative service agreements, group annuity contracts
and group insurance contracts.
(iii) Each
Company Benefit Plan materially complies, and has been maintained and
administered in all material respects in compliance with, its terms and with
the
requirements prescribed by any and all applicable law, including (without
limitation) ERISA and the Code. All material contributions, reserves or premium
payments required to be made or accrued as of the date hereof to the Company
Benefit Plans have been timely made or accrued. Neither Company nor its
Subsidiary has taken or failed to take any action with respect to any Company
Benefit Plan which might create any material liability on the part of Company
or
its Subsidiary.
(iv) Neither
Company nor its Subsidiary maintains, participates in or contributes to,
nor
have they ever maintained, participated in, or contributed to, any Multiemployer
Plan, a plan described in Section 413 of the Code, or any plan subject to
Title
IV of ERISA or Section 302 of ERISA. Neither Company nor its Subsidiary has
any
outstanding or contingent obligations or liabilities (including, without
limitation, any withdrawal liability) with respect to a Multiemployer Plan
providing pension or other benefits, a plan described in Section 413 of the
Code, or any plan subject to Title IV of ERISA or Section 302 of
ERISA.
(v) Neither
Company nor its Subsidiary is subject to any material liability or penalty
under
Sections 4975 through 4980B of the Code or Title I of ERISA. With respect
to
each Benefit Plan which is a “group
health plan”
as
defined in Section 5000(b)(1) of the Code and Section 607(l) of ERISA, Company
and its Subsidiary have complied in all material respects with the applicable
health care continuation requirements in Section 4980B of the Code and in
ERISA.
Company, and its Subsidiary, and each Company Benefit Plan which is a group
health plan has, as of the date hereof, complied in all material respects
with
the Family and Medical Leave Act of 1993, the Health Insurance Portability
and
Accountability Act of 1996, the Women’s Health and Cancer Rights Act of 1998,
the Newborns’ and Mothers’ Health Protection Act of 1996, and any similar
provisions of state law applicable to employees of Company and its Subsidiary.
No “prohibited
transaction,”
within
the meaning of Section 4975(c) of the Code or Sections 406 or 407 of ERISA
and
not otherwise exempt under Section 408 of ERISA, has occurred with respect
to
any Company Benefit Plan.
(vi) Except
as
set forth on Section 2.3(w) of the Company Disclosure Schedule, there is
no
contract, plan or arrangement covering any employee or former employee of
Company or its Subsidiary that, individually or collectively, would give
rise to
the payment as a result of the transactions contemplated by this Agreement
of
any amount that would not be deductible by Company or its Subsidiary by reason
of Section 280G or 162(m) of the Code.
(vii) No
material action, suit or claim (excluding claims for benefits incurred in
the
ordinary course) has been brought or is pending or, to Company’s Knowledge,
threatened against or with respect to any Company Benefit Plan, or the assets
or
any fiduciary thereof (in that person’s capacity as a fiduciary of such Company
Benefit Plan) and to Company’s Knowledge, there are no facts likely to give rise
to any such action, suit or claim. There are no audits, inquiries or proceedings
pending or, to Company’s Knowledge, threatened by the IRS or the United States
Department of Labor or corresponding authority in Canada with respect to
any
Company Benefit Plan, and no Company Benefit Plan has been the subject of
any
application for relief under the Internal Revenue Service Employee Plans
Compliance Resolution System or the Closing Agreement Program, nor has any
Company Benefit Plan been the subject of any application for relief under
the
United States Department of Labor Voluntary Fiduciary Correction Program
or
Delinquent Filer Voluntary Compliance Program.
(viii) All
Company Benefit Plans that are intended to be qualified and exempt from United
States federal income taxes under Section 401(a) and Section 501(a),
respectively, of the Code, have been the subject of favorable determination
letters or in the case of prototype plans, opinion letters, from the IRS
which
consider the effect of the series of laws commonly known as GUST, and no
such
determination letter has been revoked nor has revocation been
threatened.
(ix) Except
for Company Benefit Plans for employees working in Canada, each “fiduciary”
(within
the meaning of Section 3(21)(A) of ERISA) as to each Company Benefit Plan
has
complied in all material respects with the requirements of ERISA and all
other
applicable law in respect of each such Company Benefit Plan.
(x) Except
as
set forth in Section 2.3(w) of the Company Disclosure Schedule, all required
employer and employee contributions and premiums under the Company Benefit
Plans
to the date hereof have been paid or duly accrued, the respective fund or
funds
established under the Company Benefit Plans are, in all material respects,
funded in accordance with all applicable law and such plans, and no material
past service funding liabilities exist thereunder.
(xi) Other
than any pension benefits payable under the Company Benefit Plans, neither
Company nor its Subsidiary is under any obligation to provide benefits or
coverage under a Company Benefit Plan to retirees of Company or its Subsidiary
or other former employees of Company or its Subsidiary (or the beneficiaries
of
such retirees or former employees), including, but not limited to, retiree
health care coverage (except to the extent mandated by the Consolidated Omnibus
Budget Reconciliation Act of 1985).
(xii) Neither
Company nor its Subsidiary maintains any voluntary employees’ beneficiary
association within the meaning of Sections 501(c)(9) and 505 of the Code
(a
VEBA) with respect to any Company Benefit Plan.
(xiii) No
commitments have been made by Company or its Subsidiary to amend any Company
Benefit Plan, to provide increased benefits thereunder or to establish any
new
benefit plan, except as required by applicable laws or as disclosed in Section
2.3(w) of the Company Disclosure Schedule. None of the Company Benefit Plans
require or permit retroactive increases or assessments in premiums or payments.
Except as set forth in Section 2.3(w) of the Company Disclosure Schedule,
all
Company Benefit Plans can be amended or terminated without any restrictions
and
Company or its Subsidiary has the unrestricted power to amend or terminate
any
of the Company Benefit Plans.
(x) Labor
Matters. There
are
no disputes pending or to Company’s Knowledge, threatened between Company or its
Subsidiary on the one hand and any of their respective employees on the other,
and, to Company’s Knowledge, there are no organizational efforts currently being
made or threatened involving any of such employees. Company has materially
complied with all laws relating to the employment of labor, including without
limitation, any provisions thereof relating to wages, hours, collective
bargaining and the payment of social security and similar taxes, and is not
liable for any material arrearage of wages or any taxes or penalties for
failure
to comply with any of the foregoing.
(y) Insurance.
As
of the
date of this Agreement, Company and its Subsidiary maintain insurance policies,
and bonding arrangements, covering all of their respective assets and
properties, and in each case the various occurrences which may arise in
connection with the operation of their respective businesses. Section 2.3(y)
of
the Company Disclosure Schedule attached hereto sets forth all such policies
and
bonding arrangements. Such policies and bonding arrangements are in full
force
and effect, all premiums and other amounts due thereon have been paid, and
Company and its Subsidiary have complied with the provisions of such policies
and bonding arrangements. There are no notices of any pending or threatened
terminations or premium increases with respect to any such policies or bonding
arrangements, and such policies and bonding arrangements will not be modified
as
a result of or terminate or lapse by reason of, the transactions contemplated
by
this Agreement.
(z) Absence
of Sensitive Payments.
Neither
Company nor its Subsidiary, nor any of their respective directors or officers,
nor, to Company’s Knowledge, any of the employees or agents of Company or its
Subsidiary, has directly or indirectly (a) made any contribution or gift
which
contribution or gift is in violation of any applicable Law, (b) made any
bribe,
rebate, payoff, influence payment, kickback or other payment to any Person,
private or public, regardless of form, whether in money, property or services
(i) to obtain favorable treatment in securing business, (ii) to pay for
favorable treatment for business secured, (iii) to obtain special concessions
or
for special concessions already obtained for or in respect of Company or
its
Subsidiary, or any affiliate of Company or its Subsidiary, or (iv) in violation
of any Law or legal requirement, or (c) established or maintained any fund
or
asset of Company or its Subsidiary, that has not been recorded in the books
and
records of Company or its Subsidiary. For purposes of this Agreement, the
term
“Person”
shall
mean an individual, partnership, venture, unincorporated association,
organization, syndicate, corporation, limited liability company, or other
entity, trust, trustee, executor, administrator or other legal or personal
representative or any government or any agency or political subdivision thereto,
and the term “Law”
shall
mean any law in any jurisdiction (including common law), statute, code,
ordinance, rule, regulation, permit, order, decree or other requirement or
guideline.
(aa) Books
and Records.
The
books
and records of Company and its Subsidiary with respect to Company and its
Subsidiary, their operations, employees and properties have been maintained
in
the usual, regular and ordinary manner, all entries with respect thereto
have
been accurately made, and all transactions involving Company and its Subsidiary,
have been accurately accounted for.
(bb) Compensation.
Except
as
disclosed in Section 2.3(cc) of the Company Disclosure Schedule attached
hereto,
neither Company nor its Subsidiary has any agreement with any employee with
regard to compensation, whether individually or collectively, that, with
respect
to employees located in Canada can be terminated by providing the notice
or
indemnity required by applicable Canadian federal or provincial law, and
set
forth in Section 2.3(bb) of the Company Disclosure Schedule attached hereto
is a
list of all employees of Company and its Subsidiary entitled to receive annual
compensation in excess of $100,000 and their respective positions and salaries.
No union or other collective bargaining unit has been certified or recognized
by
Company or its Subsidiary as representing any of their respective employees.
Neither Company nor Parent will incur any liability with respect to any payment
due or damage suffered by any employee of Company or its Subsidiary, including,
but not limited to, any claims for severance, termination benefits or similar
claims, by virtue of the operation of the transactions contemplated
hereby.
ARTICLE
III
COVENANTS
RELATING TO CONDUCT OF BUSINESS
3.1. Conduct
of Business of Company Pending the Merger.
Company
covenants and agrees that, during the period from the date hereof to the
Effective Time and except as otherwise agreed to in writing by Parent or
as
expressly contemplated by this Agreement, the business of Company shall be
conducted only in, and Company shall not take any action except in, the ordinary
course of business and in a manner consistent with past practice and in
compliance with applicable laws; and Company, except as expressly contemplated
by this Agreement, shall use its commercially reasonable efforts to preserve
substantially intact the business organization of Company, to keep available
the
services of the present officers and employees and to preserve the present
relationships of Company with such of the customers, suppliers, licensors,
licensees, or distributors with which Company has significant business
relations. By way of amplification and not limitation, without the prior
written
consent of Parent (which shall not be unreasonably withheld or delayed),
Company
shall not, between the date of this Agreement and the Effective Time, except
as
set forth in Section 3.1 of the Company Disclosure Schedule, directly or
indirectly do, or propose or commit to do, any of the following:
(a) Amend
its
certificate of incorporation or bylaws or equivalent organizational
documents;
(b) Except
for (i) a Company Subsequent Issuance, (ii) the issuance of stock options
under
the Option Plan to employees and consultants of Company and (iii) the issuance
of warrants in connection with certain contemplated financing as described
in
Section 3.1 of the Company Disclosure Schedule, issue, deliver, sell, pledge,
dispose of or encumber, or authorize or commit to the issuance, sale, pledge,
disposition or encumbrance of, any shares of capital stock of any class,
or any
options, warrants, convertible securities or other rights of any kind to
acquire
any shares of capital stock, or any other ownership interest (including,
but not
limited to, stock appreciation rights or phantom stock), of
Company;
(c) Declare,
set aside, make or pay any dividend or other distribution, payable in cash,
stock, property or otherwise, with respect to any of the Company Capital
Stock;
(d) Acquire
(by merger, consolidation or acquisition of stock or assets) any corporation,
partnership or other business organization or division or line of
business;
(e) Modify
its current investment policies or investment practices in any material respect
except to accommodate changes in applicable Law;
(f) Transfer,
sell, lease, mortgage, or otherwise dispose of or subject to any Lien any
of its
assets, including the Company Capital Stock (except (i) by incurring Permitted
Liens (as defined in Article X); and (ii) equipment and property no longer
used
in the operation of Company’s business) other than in the ordinary course of
business consistent with past practice;
(g) Except
as
may be required as a result of a change in Law or in generally accepted
accounting or actuarial principles, make any change to the accounting practices
or principles or reserving or underwriting practices or principles used by
it;
(h) Settle
or
compromise any pending or threatened suit, action or claim (other than the
payment of health benefit claims on behalf of customers of Company) involving
a
payment by Company in excess of $100,000;
(i) Adopt
a
plan of complete or partial liquidation, dissolution, restructuring,
recapitalization or other reorganization of Company;
(j) Fail
to
use commercially reasonable efforts to maintain in full force and effect
the
existing insurance policies covering Company or its properties, assets and
businesses or comparable replacement policies;
(k) Authorize
or make capital expenditures in excess of $250,000;
(l) (i)
Make
any material Tax election or settle or compromise any material federal, state,
local or foreign Tax liability, change any annual tax accounting period,
change
any material method of Tax accounting, enter into any closing agreement relating
to any Tax, or surrender any right to claim a Tax refund or (ii) consent,
without providing advance notice to Parent, to any extension or waiver of
the
limitations period applicable to any Tax claim or assessment;
(m) Reclassify,
combine, split, subdivide or redeem, purchase or otherwise acquire, directly
or
indirectly, any of the Company Capital Stock or its stock options or debt
securities;
(n) (i)
Repay
or retire any indebtedness for borrowed money or repurchase or redeem any
debt
securities; (ii) except as set forth in Section 3.1 of the Company Disclosure
Schedule incur any indebtedness for borrowed money (including pursuant to
any
commercial paper program or credit facility of Company) or issue any debt
securities; or (iii) assume, guarantee or endorse, or otherwise as an
accommodation become responsible for, the obligations of any Person, or make
any
loans, advances or capital contributions to, or investments in, any other
Person, other than providers of Company in the ordinary course of business
consistent with past practice;
(o) Except
as
set forth in Section 3.1 of the Company Disclosure Schedule, enter into or
renew, extend, materially amend or otherwise materially modify (i) any Company
Material Contract, or (ii) any other contract or agreement (with “other contract
or agreement” being defined for the purposes of this subsection as a contract or
agreement which involves Company incurring a liability in excess of $250,000
and
which is not terminable by Company without penalty upon one year or less
notice);
(p) Except
as
set forth in Section 3.1 of the Company Disclosure Schedule and except to
the
extent required under this Agreement or pursuant to applicable law, increase
the
compensation or fringe benefits of any of its directors, officers or employees,
except for increases in salary or wages of officers and employees of Company
in
the ordinary course of business in accordance with past practice, or grant
any
severance or termination pay not currently required to be paid under existing
severance plans or enter into, or amend, any employment, consulting or severance
agreement or arrangement with any present or former director, officer or
other
employee of Company, or establish, adopt, enter into or amend or terminate
any
collective bargaining, bonus, profit sharing, thrift, compensation, stock
option, restricted stock, pension, retirement, deferred compensation,
employment, termination, welfare, severance or other plan, agreement, trust,
fund, policy or arrangement for the benefit of any directors, officers or
employees, except for any plan amendments to comply with Section 409A of
the
Code (provided that any such amendments shall not materially increase the
cost
of such plan to Company);
(q) Grant
any
license with respect to Intellectual Property Rights other than non-exclusive
licenses granted in the ordinary course of business;
(r) Take
any
action or omit to take any action that would reasonably be expected to cause
any
Intellectual Property Rights used or held for use in its business to become
invalidated, abandoned or dedicated to the public domain;
(s) Take
or
fail to take any action that would prevent the Merger from qualifying as
reorganization within the meaning of Section 368(a) of the Code;
(t) Except
as
set forth in Section 3.1 of the Company Disclosure Schedule, effectuate a
“plant
closing” or “mass layoff” as those terms are defined in the Worker Adjustment
and Retraining Notification Act (WARN), affecting in whole or in part any
site
of employment, facility, operating unit or employee of Company;
(u) Pay,
discharge or satisfy any claims, liabilities or obligations (absolute accrued,
asserted or unasserted, contingent or otherwise), other than the payment,
discharge or satisfaction, in the ordinary course of business and consistent
with past practice, of liabilities reflected or reserved against in the
financial statements of Company or incurred in the ordinary course of business
and consistent with past practice;
(v) Enter
into any transaction with, or enter into any agreement, arrangement, or
understanding with any of Company’s affiliates that would be required to be
disclosed pursuant to Item 404 of SEC Regulation S-K; or
(w) Take,
or
offer or propose to take, or agree to take in writing or otherwise, any of
the
actions described in Sections 3.1(a) through 3.1(v) or any action which would
result in any of the conditions set forth in Article VI not being satisfied
or
would materially delay the Closing.
3.2. Conduct
of Business of Parent Pending the Merger.
Parent
covenants and agrees that, during the period from the date hereof to the
Effective Time and except as otherwise agreed to in writing by Company, Parent
shall not:
(a) Amend
the
Parent Charter or bylaws or equivalent organizational documents;
(b) Issue,
deliver, sell, pledge, dispose of or encumber, or authorize or commit to
the
issuance, sale, pledge, disposition or encumbrance of, any shares of capital
stock of any class, or any options, warrants, convertible securities or other
rights of any kind to acquire any shares of capital stock, or any other
ownership interest (including, but not limited to, stock appreciation rights
or
phantom stock), of Parent;
(c) Declare,
set aside, make or pay any dividend or other distribution, payable in cash,
stock, property or otherwise, with respect to any of its capital
stock;
(d) Acquire
(by merger, consolidation or acquisition of stock or assets) any corporation,
partnership or other business organization or division or line of
business;
(e) Modify
its current investment policies or investment practices in any material respect
except to accommodate changes in applicable Law;
(f) Transfer,
sell, lease, mortgage, or otherwise dispose of or subject to any Lien any
of its
assets, including capital stock other than in the ordinary course of business
consistent with past practice;
(g) Except
as
may be required as a result of a change in Law or in generally accepted
accounting or actuarial principles, make any change to the accounting practices
or principles or reserving or underwriting practices or principles used by
it;
(h) Settle
or
compromise any pending or threatened suit, action or claim involving a payment
by Parent in excess of $100,000;
(i) Adopt
a
plan of complete or partial liquidation, dissolution, restructuring,
recapitalization or other reorganization of Parent;
(j) Fail
to
use commercially reasonable efforts to maintain in full force and effect
the
existing insurance policies covering Parent or its properties, assets and
businesses or comparable replacement policies;
(k) Authorize
or make capital expenditures;
(l) (i)
Make
any material Tax election or settle or compromise any material federal, state,
local or foreign Tax liability, change any annual tax accounting period,
change
any material method of Tax accounting, enter into any closing agreement relating
to any Tax, or surrender any right to claim a Tax refund or (ii) consent,
without providing advance notice to Company, to any extension or waiver of
the
limitations period applicable to any Tax claim or assessment;
(m) Reclassify,
combine, split, subdivide or redeem, purchase or otherwise acquire, directly
or
indirectly, any of its capital stock, stock options or debt
securities;
(n) (i)
Repay
or retire any indebtedness for borrowed money or repurchase or redeem any
debt
securities; (ii) incur any indebtedness for borrowed money or issue any debt
securities; or (iii) assume, guarantee or endorse, or otherwise as an
accommodation become responsible for, the obligations of any Person, or make
any
loans, advances or capital contributions to, or investments in, any other
Person, other than providers of Parent in the ordinary course of business
consistent with past practice;
(o) Except
as
set forth in Section 3.2 of the Parent Disclosure Schedule, enter into or
renew,
extend, materially amend or otherwise materially modify (i) any material
contract, or (ii) any other contract or agreement (with “other
contract or agreement”
being
defined for the purposes of this subsection as a contract or agreement which
involves Parent incurring a liability in excess of $250,000 and which is
not
terminable by Parent without penalty upon one year or less notice);
(p) Except
as
set forth in Section 3.2 of the Parent Disclosure Schedule and except to
the
extent required under this Agreement or pursuant to applicable law, increase
the
compensation or fringe benefits of any of its directors, officers or employees,
except for increases in salary or wages of officers and employees of Parent
in
the ordinary course of business in accordance with past practice, or grant
any
severance or termination pay not currently required to be paid under existing
severance plans or enter into, or amend, any employment, consulting or severance
agreement or arrangement with any present or former director, officer or
other
employee of Parent, or establish, adopt, enter into or amend or terminate
any
collective bargaining, bonus, profit sharing, thrift, compensation, stock
option, restricted stock, pension, retirement, deferred compensation,
employment, termination, welfare, severance or other plan, agreement, trust,
fund, policy or arrangement for the benefit of any directors, officers or
employees, except for any plan amendments to comply with Section 409A of
the
Code (provided that any such amendments shall not materially increase the
cost
of such plan to Parent);
(q) Take
or
fail to take any action that would prevent the Merger from qualifying as
reorganization within the meaning of Section 368(a) of the Code;
(r) Pay,
discharge or satisfy any claims, liabilities or obligations (absolute accrued,
asserted or unasserted, contingent or otherwise), other than the payment,
discharge or satisfaction, in the ordinary course of business and consistent
with past practice, of liabilities reflected or reserved against in the
financial statements of Parent or incurred in the ordinary course of business
and consistent with past practice;
(s) Enter
into any transaction with, or enter into any agreement, arrangement, or
understanding with any of Parent’s affiliates that would be required to be
disclosed pursuant to Item 404 of SEC Regulation S-K; or
(t) Take,
or
offer or propose to take, or agree to take in writing or otherwise, any of
the
actions described in Sections 3.1(a) through 3.1(s) or any action which would
result in any of the conditions set forth in Article VI not being satisfied
or
would materially delay the Closing.
3.3. Operational
Matters.
From
the date of this Agreement until the Effective Time, at the request of Parent,
senior management of Company shall (a) confer on a regular and frequent basis
with Parent and (b) report (to the extent permitted by law or regulation
or any
applicable confidentiality agreement) to Parent on operational matters. Company
shall file or furnish all reports, communications, announcements, publications
and other documents required to be filed or furnished by it with all
Governmental Entities between the date of this Agreement and the Effective
Time
and Company shall (to the extent any report, communication, announcement,
publication or other document contains any statement relating to this Agreement
or the Merger, and to the extent permitted by law or regulation or applicable
confidentiality agreement) consult with Parent for a reasonable time before
filing or furnishing any such report, communication, announcement, publication
or other document and mutually agree upon any such statement and deliver
to
Parent copies of all such reports, communications, announcements, publications
and other documents promptly after the same are filed or furnished. Nothing
contained in this Agreement shall give Parent, directly or indirectly, the
right
to control or direct the operations of Company prior to the Effective Time.
Prior to the Effective Time, each of Company and Parent shall exercise,
consistent with the terms and conditions of this Agreement, complete control
and
supervision over respective businesses and operations.
ARTICLE
IV
ADDITIONAL
AGREEMENTS
4.1. Preparation
of Proxy Statement.
(a) As
soon
as practicable following the date of this Agreement, Parent shall, with the
cooperation of Company and the PA Management Team (as defined in Article
X),
prepare and file with the SEC under the Exchange Act, and with all other
applicable regulatory bodies, a proxy statement (the “Proxy
Statement”)
in
preliminary form. The Proxy Statement shall:
(i) request
approval from Parent’s stockholders of the Merger and this Agreement upon the
terms set forth herein;
(ii) request
approval for the amendment of the Parent Charter to, among other things,
(A)
effect the change of the name of the Parent from its current name to
PharmAthene, Inc., (B) delete the preamble and SPAC-specific portions of
the
Parent Charter from and after the Closing and (C) provide that, for so long
as
at least 30% of the 8% Convertible Notes remain outstanding, the number of
directors constituting the Board of Directors of Parent shall not exceed
7, the
number of directors constituting each committee of the Board of Directors
of
Parent shall not exceed 3, and the holders of the 8% Convertible Notes shall
have the right, as a separate class (and notwithstanding the existence of
less
than three such holders at any given time), to (x) elect 3 members to the
Board
of Directors of Parent and, (y) to the extent they elect to fill such committee
positions, appoint 2 of the 3 members of each Committee of the Board of
Directors (including the nominating and corporate governance committee and
the
compensation committee and committees performing similar functions);
and
(iii) request
approval from the Parent’s stockholders for an incentive stock option plan in
form and substance acceptable to the PA Management Team, Parent and Company
(“Stock
Option Plan”)
to
provide for, among other things, the reservation of a sufficient number of
shares of Parent Common Stock for issuance thereunder for all outstanding
Company Options plus 3,000,000; and (v) such other approvals as the parties
may
determine are necessary or desirable. Parent shall also take any action required
to be taken under any applicable state securities laws in connection with
the
issuance of Parent Common Stock in the Merger.
The
Proxy
Statement shall be filed in preliminary form in accordance with the Exchange
Act, and each of Company and Parent shall use its commercially reasonable
efforts to respond as promptly as practicable to any comments of the SEC
with
respect thereto. Parent shall use its reasonable best efforts to (1) prepare
and
file with the SEC the definitive Proxy Statement, (2) cause the Proxy Statement,
including any amendment or supplement thereto to be approved by the SEC,
and (3)
to cause the definitive Proxy Statement to be mailed to Parent’s stockholders
and holders of Parent Warrants as promptly as practicable after the SEC has
approved them. Parent shall notify Company promptly of the receipt of any
comments from the SEC or its staff and of any request by the SEC or its staff
for amendments or supplements to the Proxy Statement or for additional
information and each of Parent and Company shall supply each other with copies
of all correspondence between such or any of its representatives, on the
one
hand, and the SEC or its staff, on the other hand, with respect to the Proxy
Statement or the Merger.
(b) The
parties hereto shall use all reasonable efforts to have the Proxy Statement
approved by the SEC as promptly as practicable after such filing. Parent
and its
counsel shall obtain from Company and the PA Management Team such information
required to be included in the Proxy Statement and, after consultation with
Company and its counsel, respond promptly to any comments made by the SEC
with
respect to the Proxy Statement. Parent shall allow Company’s full participation
in the preparation of the Proxy Statement and any amendment or supplement
thereto and shall consult with Company and its advisors concerning any comments
from the SEC with respect thereto. The PA Management Team and Company’s
independent accountants shall assist Parent and its counsel in preparing
the
Proxy Statement and acknowledge that a substantial portion of the Proxy
Statement shall include disclosure regarding Company, its management, operations
and financial condition. Company shall furnish consolidated audited financial
statements for the fiscal years ended December 31, 2006 as soon as they become
available and in no event later that February 14, 2007, for inclusion in
the
Proxy Statement. The PA Management Team shall make itself available to Parent
and its counsel in connection with the drafting of the Proxy Statement and
responding in a timely manner to comments from the SEC and shall cause to
be
delivered opinions of counsel related to FDA and Intellectual Property Rights
matters as described in the Proxy Statement with respect to Company’s business
as Parent may reasonably request opining on such matters as are usual and
customary for underwritten public offerings. All information regarding Company,
its management, operations and financial condition, including any material
contracts required to be filed as part of the Proxy Statement (for purposes
hereof referred to collectively as “Company
Information”)
shall
be true and correct in all material respects and shall not contain any
misstatements of any material information or omit any material information
regarding Company. Prior to the filing of the Proxy Statement with the SEC
and
each amendment thereto, the PA Management shall confirm in writing to Parent
and
its counsel that it has reviewed the Proxy Statement (and each amendment
thereto) and approved the Company Information contained therein.
(c) If,
prior
to the Effective Time, any event occurs with respect to Company, or any change
occurs with respect to other information supplied by Company for inclusion
in
the Proxy Statement, which is required to be described in an amendment of,
or a
supplement to, the Proxy Statement, Company shall promptly notify Parent
of such
event, and Company and Parent shall cooperate in the prompt filing with the
SEC
of any necessary amendment or supplement to the Proxy Statement and, as required
by Law, in disseminating the information contained in such amendment or
supplement to Parent’s stockholders.
(d) If,
prior
to the Effective Time, any event occurs with respect to Parent or Merger
Sub, or
any change occurs with respect to other information supplied by Parent for
inclusion in the Proxy Statement, which is required to be described in an
amendment of, or a supplement to, the Proxy Statement, Parent shall promptly
notify Company of such event, and Parent and Company shall cooperate in the
prompt filing with the SEC of any necessary amendment or supplement to the
Proxy
Statement and, as required by Law, in disseminating the information contained
in
such amendment or supplement to Parent’s stockholders.
(e) Parent
shall, promptly after the date hereof, take all action necessary to duly
call,
give notice of, convene and hold a meeting of its stockholders (the
“Parent
Stockholders Meeting”)
as
soon as practicable after the Proxy Statement is approved by the SEC. Parent
shall consult with Company on the date for Parent Stockholders Meeting. Parent
shall use its commercially reasonable efforts to cause the Proxy Statement
to be
mailed to Parent’s stockholders as soon as practicable after the Proxy Statement
is approved. Parent shall, through Parent’s Board of Directors, recommend to its
stockholders that they give the Parent Stockholder Approval, except to the
extent that Parent’s Board of Directors shall have withdrawn its approval or
recommendation of this Agreement and the Merger, which withdrawal may be
made
only if deemed by Parent’s Board of Directors to be necessary in order to comply
with its fiduciary duties. Notwithstanding any other provision thereof, Parent
shall not be restricted from complying with any of its obligations under
the
Exchange Act.
(f) During
the term of this Agreement, Company shall not take any actions to exempt
any
Person other than Parent and Merger Sub from the threshold restrictions on
Company Common Stock ownership or any other anti-takeover provision in Company’s
certificate of incorporation, or make any state takeover statute (including
any
Delaware state takeover statute) or similar statute inapplicable to any
Alternative Transaction (as defined in Article X).
(g) Parent
shall comply with all applicable federal and state securities laws in all
material respects.
4.2. Access
to Information.
Upon
reasonable notice, Company shall afford to the officers, employees, accountants,
counsel, financial advisors and other representatives of Parent reasonable
access during normal business hours, during the period prior to the Effective
Time, to such of its properties, books, contracts, commitments, records,
officers and employees as Parent may reasonably request and, during such
period,
Company shall furnish promptly to Parent (a) a copy of each report, schedule
and
other document filed, published, announced or received by it during such
period
pursuant to the requirements of Federal or state laws, as applicable (other
than
documents which Company is not permitted to disclose under applicable Law),
and
(b) consistent with its legal obligations, all other information concerning
it
and its business, properties and personnel as Parent may reasonably
request;
provided, however,
that
Company may restrict the foregoing access to the extent that any Law, treaty,
rule or regulation of any Governmental Entity applicable to Company requires
Company to restrict access to any properties or information. Parent will
hold
any such information that is non-public in confidence. Any investigation
by
Parent shall not affect the representations and warranties of
Company.
4.3. Commercially
Reasonable Efforts.
(a) Subject
to the terms and conditions of this Agreement, each party will use its
commercially reasonable efforts to prepare and file as promptly as practicable
all documentation to effect all necessary applications, notices, petitions,
filings, and other documents and to obtain as promptly as practicable all
consents, waivers, licenses, orders, registrations, approvals, permits, tax
rulings and authorizations necessary or advisable to be obtained from any
third
party and/or any Governmental Entity in order to consummate the Merger and
the
other transactions contemplated by this Agreement. Upon the terms and subject
to
the conditions hereof, each party will use its commercially reasonable efforts
to take, or cause to be taken, all actions, to do, or cause to be done, all
things reasonably necessary to satisfy the conditions to Closing set forth
herein and to consummate the Merger and the other transactions contemplated
by
this Agreement. Company shall provide Parent with the opportunity to participate
in any meeting or substantive telephone call with any Governmental Entity
in
respect of any filings, investigations or other inquiry in connection with
the
transactions contemplated hereby.
(b) Nothing
contained in this Section 4.3 or in any other provision of this Agreement
shall
be construed as requiring Parent to agree to any terms or conditions as a
condition to, or in connection with, obtaining any Necessary Consents or
any
required approval of the health care or other applicable special license
requirements that would:
(i) impose
any limitations on Parent’s ownership or operation of all or any portion of its
or Company’s businesses or assets, or compel Parent or any of its Subsidiaries
to dispose of or hold separate all or any portion of its or Company’s, or any of
their respective Subsidiaries’, businesses or assets,
(ii) impose
any limitations on the ability of Parent to acquire or hold or to exercise
full
rights of ownership of the Company Common Stock,
(iii) impose
any obligations on Parent or Company in respect of or relating to Parent’s or
Company’s facilities, operations, places of business, employment levels,
products or businesses,
(iv) require
Parent or Company to make any payments, or
(v) impose
any other obligation, restriction, limitation, qualification or other condition
on Parent or Company (other than, with respect to clauses (iii), (iv) and
(v),
such terms or conditions as are reasonable and relate to the ordinary course
of
business of Company and that are imposed by a Governmental Entity with power
and
authority to grant the Necessary Consents, and which individually or in the
aggregate (A) could have been imposed on Company as of January 1, 2006 by
such
Governmental Entity in the ordinary course of regulating the business of
Company
and (B) do not competitively disadvantage Parent or Company) (any such term
or
condition in (i) through (v) being referred to herein as a “Burdensome
Term or Condition”).
4.4. No
Solicitation of Transactions.
Each of
Parent and Company agrees that neither Parent nor Company nor any of their
respective officers and directors shall, and that they shall use their
respective commercially reasonable efforts to cause their respective employees,
agents and representatives (including any investment banker, attorney or
accountant retained by it) not to, directly or indirectly, except as set
forth
in Section 3.1 of the Company Disclosure Schedule, (A) initiate, solicit,
encourage or knowingly facilitate any inquiries or the making of any proposal
or
offer with respect to, or a transaction to effect, a merger, reorganization,
share exchange, consolidation, business combination, recapitalization,
liquidation, dissolution or similar transaction involving it or any purchase,
transfer or sale of the assets of it, or any purchase or sale of, or tender
or
exchange offer for, its voting securities (any such proposal, offer or
transaction (other than a proposal or offer made by one party to this Agreement
to the other party to this Agreement or an affiliate thereof) being hereinafter
referred to as an “Acquisition
Proposal”),
(B)
have any discussions with or provide any confidential information or data
to any
person relating to an Acquisition Proposal, or engage in any negotiations
concerning an Acquisition Proposal, or knowingly facilitate any effort or
attempt to make or implement an Acquisition Proposal, (C) approve or recommend,
or propose publicly to approve or recommend, any Acquisition Proposal or
(D)
approve or recommend, or propose to approve or recommend, or execute or enter
into, any letter of intent, agreement in principle, merger agreement, asset
purchase or share exchange agreement, option agreement or other similar
agreement related to any Acquisition Proposal or propose or agree to do any
of
the foregoing.
4.5. Employee
Benefits Matters.
From
the date hereof until the Effective Time, Company shall provide compensation
and
benefits to the current and former employees of Company (other than those
current and former employees whose terms and conditions of employment are
subject to a collective bargaining agreement) upon the same terms as have
been
provided to such employees prior to the date of this Agreement, subject to
termination of such compensation or benefits in accordance with their terms
and
any adjustment required by applicable law, the terms and conditions of any
contract or agreement or the provisions of any Company Benefit
Plan.
4.6. Notification
of Certain Matters.
Company
shall use commercially reasonable efforts to give prompt notice to Parent,
and
Parent shall use commercially reasonable efforts to give prompt notice to
Company, to the extent that either acquires actual knowledge of (a) the
occurrence or non-occurrence of any event the occurrence or non-occurrence
of
which would be reasonably likely to cause any representation or warranty
contained in this Agreement to be untrue or inaccurate and (b) any failure
of
Parent, Merger Sub or Company, as the case may be, to comply with or satisfy
any
covenant, condition or agreement to be complied with or satisfied by it
hereunder;
provided, however,
that the
delivery of any notice pursuant to this Section 4.6 shall not limit or otherwise
affect the remedies available hereunder to the party receiving such
notice.
4.7. Public
Announcements.
Parent
and Company shall develop a joint communications plan and each party shall
(a)
ensure that all press releases and other public statements and communications
(including any communications that would require a filing under Rule 425,
Rule
165 and Rule 166 of the Securities Act or Rule 14a-12 of the Exchange Act)
with
respect to this Agreement and the transactions contemplated hereby shall
be
consistent with such joint communications plan and (b) unless otherwise required
by applicable law or by obligations pursuant to any listing agreement with
or
rules of any securities exchange, Company shall consult with Parent for a
reasonable time before issuing any press release or otherwise making any
public
statement or communication (including any communication that would require
a
filing under Rule 425, Rule 165 and Rule 166 of the Securities Act or Rule
14a-12 of the Exchange Act), and Parent and Company shall mutually agree
upon
any such press release of Company or any such public statement or communication
by Company, with respect to this Agreement or the transactions contemplated
hereby. In addition to the foregoing, except to the extent required by
applicable Law, neither Parent nor Company shall issue any press release
or
otherwise make any public statement or disclosure concerning the other party
or
the other party’s business, financial condition or results of operations without
the consent of the other party.
4.8. Affiliates.
Promptly after execution and delivery of this Agreement, Company shall deliver
to Parent a letter identifying all persons who, to the best of Company’s
Knowledge, may be deemed as of the date hereof “affiliates” of Company for
purposes of Rule 145 under the Securities Act, and such list shall be updated
as
necessary to reflect changes from the date thereof until the Effective
Time.
4.9. [reserved]
4.10. Takeover
Statutes.
Company
and its Board of Directors shall, if any takeover statute or similar statute
or
regulation of any state becomes or may become applicable to this Agreement,
the
Merger or any other transactions contemplated by this Agreement, grant such
approvals and take such actions as are necessary to ensure that the Merger
and
the other transactions contemplated by this Agreement may be consummated
as
promptly as practicable on the terms contemplated hereby and otherwise to
minimize the effect of such statute or regulation on this Agreement, the
Merger
and the other transactions contemplated by this Agreement.
4.11. Transfer
Taxes.
Each of
Parent, Merger Sub and Company shall pay any sales, use, ad valorem, property,
transfer (including real property transfer) and similar Taxes imposed on
such
Person as a result of or in connection with the Merger and the other
transactions contemplated hereby.
4.12. AMEX
Listing; Symbol.
Parent
shall cause the shares of Stock Consideration and the Note Conversion Shares
to
be issued in the Merger to be approved for listing on the AMEX, subject to
official notice of issuance, prior to the Effective Time. After the Effective
Time, Parent shall cause the symbol under which the Parent Common Stock and
Parent Warrants are traded on the AMEX to change to a symbol that, if available,
is reasonably representative of the corporate name or business of the Surviving
Corporation.
4.13. Trust
Fund Closing Confirmation.
(a) Promptly
after the date hereof, Parent shall give to the Trustee the notice attached
as
Exhibit A to the Trust Agreement.
(b) Not
later
than 48 hours prior to the Effective Time, Parent shall (i) give the Trustee
advance notice of the Effective Time, and (ii) cause the Trustee to provide
a
written confirmation to Parent confirming the dollar amount of the Trust
Fund
balance held by the Trustee in the Trust Account that will be released to
Parent
upon consummation of the Merger.
4.14. Directors
and Officers of Parent After the Merger.
Prior
to the Effective Time, Parent shall take all necessary action so that,
effective
at the Closing, the Board of Directors of Parent shall be reconstituted and
pursuant to the Parent Charter and bylaws, shall be fixed at a total of seven
(7) persons, and be comprised as follows: (A) the holders of the 8% Convertible
Notes shall designate three (3) persons (the “Noteholder
Designees”),
(B) Company shall designate one (1) person who shall be the current Chief
Executive Officer of Company; (C) Parent shall designate two (2) persons;
and
(D) Company and Parent shall designate one (1) person mutually acceptable
to
both of them. At least fifteen (15) days prior to the filing of the Proxy
Statement, the parties shall notify each other of the names and backgrounds
of
the persons nominated by them to serve on the Board of Directors of Parent.
All
such directors, once appointed as of the Effective Time, shall continue to
serve
in accordance with the Parent Charter and bylaws until their successors are
duly
elected and qualified; provided, however, that as to the Noteholder Designees,
such persons shall continue to serve on the Board of Directors for so long
as at
least 30% of the principal amount of the 8% Convertible Notes issued as a
part
of the Merger Consideration remain outstanding (and
notwithstanding the existence of less than three such holders at any given
time)
and provided further, that two (2) of such designees shall be appointed as
two
(2) of the three (3) members of each committee of the Board of Directors
of
Parent including the nominating and corporate governance committee and
compensation committee of Parent assuming such composition is in compliance
with
applicable regulations of the AMEX. In the event that any nominee of the
holders
of the 8% Convertible Notes, Company or Parent, as the case may be, is unable
or
determines not to complete his initial term, then a replacement nominee of
the
holders of the 8% Convertible Notes, Company or Parent, as the case may be,
shall fill such vacancy, subject to approval of the Board of Directors
nominating and governance committee, which approval shall not be unreasonably
withheld or delayed. Notwithstanding anything to the contrary contained herein,
as of the Closing Date, the Board shall include such number of directors
deemed
“independent” within the rules of the AMEX as such rules may require, but in no
event shall the Board include less than two (2) such “independent”
directors.
ARTICLE
V
Post
Closing Covenants
5.1. General.
In case
at any time after the Closing any further action is necessary to carry out
the
purposes of this Agreement, each of the parties will take such further action
(including the execution and delivery of such further instruments and documents)
as any other party reasonably may request, all at the sole cost and expense
of
the requesting party (unless the requesting party is entitled to indemnification
therefor under section 5.6 below). Company acknowledges and agrees that from
and
after the Closing, Parent will be entitled to possession of all documents,
books, records (including tax records), agreements, and financial data of
any
sort relating to Company; provided, however, that after Closing, Parent shall
provide to Company stockholders reasonable access to and the right to copy
such
documents, books, records (including tax records), agreements, and financia1
data where Company stockholders have a legitimate purpose, including without
limitation, in the event of an internal revenue service audit.
5.2. Litigation
Support.
In the
event and for so long as any party actively is contesting or defending against
any action, suit, proceeding, hearing, investigation, charge, complaint,
claim,
or demand in connection with (a) any transaction contemplated under this
agreement or (b) any fact, situation, circumstance, status, condition, activity,
practice, plan, occurrence, event, incident, action, failure to act, or
transaction on or prior to the Closing Date involving Company, each of the
other
parties will cooperate with him or it and his or its counsel in the contest
or
defense, make available their personnel, and provide such testimony and access
to their books and records as shall be necessary in connection with the contest
or defense, all at the sole cost and expense of the contesting or defending
party (unless the contesting or defending party is entitled to indemnification
therefor under Article VIII below).
5.3. Transition.
Company
will exercise reasonable commercial efforts to assure that none of Company
stockholders will take any action that is designed or intended to have the
effect of discouraging any lessor, licensor, customer, supplier, or other
business associate of Company from maintaining the same business relationships
with Company after the Closing as it maintained with Company prior to the
Closing. Company will refer all customer inquiries relating to the businesses
of
Company to Parent or the Surviving Corporation from and after the
Closing.
5.4. Tax-Free
Reorganization Treatment.
The
parties hereto shall use their commercially reasonable efforts to cause the
Merger to be treated as a reorganization within the meaning of Section 368(a)
of
the Code and shall not knowingly take or fail to take any action which action
or
failure to act would jeopardize the qualification of the Merger as a
reorganization within the meaning of Section 368(a) of the Code. Unless required
by law each of Parent, Merger Sub and Company shall not file any Tax Return
or
take any position inconsistent with the treatment of the Merger as a
reorganization described in Section 368(a) of the Code.
5.5. Headquarters
of Surviving Corporation.
Following the Effective Time, the headquarters and the principal executive
offices of the Surviving Corporation shall be in Annapolis,
Maryland.
5.6. Indemnification
of Directors and Officers of Company.
From
and after the Effective Time, Parent will cause the Surviving Corporation
to
fulfill and honor in all respects the obligations of Company pursuant to
any
indemnification agreements between Company and its directors and officers
as of
the Effective Time (the “Indemnified
Directors and Officers”)
and any
indemnification or expense advancement provisions under Company’s certificate of
incorporation or bylaws as in effect on the date hereof. The certificate
of
incorporation and bylaws of the Surviving Corporation will contain provisions
with respect to exculpation and indemnification and expense advancement that
are
at least as favorable to the Indemnified Directors and Officers as those
contained in the certificate of incorporation and bylaws of Company as in
effect
on the date hereof, which provisions will not be amended, repealed or otherwise
modified for a period of six years from the Effective Time in any manner
that
would adversely affect the rights thereunder of individuals who, immediately
prior to the Effective Time, were directors, officers, employees or agents
of
Company, unless such modification is required by Law.
5.7. Continuity
of Business Enterprise.
Parent
will continue at least one significant historic business line of Company,
or use
at least a significant portion of Company’s historic business assets in a
business, in each case within the meaning of Reg. §1.368-1(d), except that
Parent may transfer Company’s historic business assets (i) to a corporation that
is a member of Parent’s “qualified group,” within the meaning of Reg.
§1.368-1(d)(4)(ii), or (ii) to a partnership if (A) one or more members of
Parent’s “qualified group” have active and substantial management functions as a
partner with respect to Company’s historic business or (B) members of Parent’s
“qualified group” in the aggregate own an interest in the partnership
representing a significant interest in Company’s historic business, in each case
within the meaning of Reg. §1.368-1(d)(r)(ii).
5.8. Substantially
All Requirement.
Following the Merger, to the Knowledge of Parent, Surviving Corporation will
hold at least 90% of the fair market value of the net assets and at least
70% of
the fair market value of the gross assets that were held by Company immediately
prior to the Effective Time, and at least 90% of the fair market value of
the
net assets and at least 70% of the fair market value of the gross assets
that
were held by Merger Sub immediately prior to the Effective Time. Insofar
as this
representation is dependent upon actions of Company prior to the Merger,
Parent
and Merger Sub have assumed that Company will take no action prior to the
Merger
that will cause Company not to hold at least 90% of the fair market value
of its
net assets and at least 70% of the fair market value of its gross assets
immediately prior to the Effective Time. For purposes of this Section 5.8,
cash
or other property paid by Company or Merger Sub to stockholders, or used
by
Company or Merger Sub to pay reorganization expenses, or distributed by Company
or Merger Sub with respect to or in redemption of its outstanding stock,
other
than regular dividends paid in the ordinary course and other than cash or
other
property transferred by Parent to Merger Sub in pursuance of the plan of
Merger
immediately preceding, or in contemplation of, the Merger are included as
assets
held by Company and Merger Sub immediately prior to the Effective Time.
Additionally, Parent has not participated in any plan of Company to effect
(i)
any distribution with respect to any Company stock (other than regular dividend
distributions made in the ordinary course), or (ii) any redemption or
acquisition of any Company stock (other than in the Merger).
5.9. Composition
of the Board of Directors of Parent.
Notwithstanding anything to the contrary contained herein, for so long as
at
least 30% of the principal amount of 8% Convertible Notes issued as part
of the
Merger Consideration remains outstanding, the number of directors constituting
the Board of Directors of Parent shall be fixed at seven (7) and the holders
of
the 8% Convertible Notes shall have the right, as a separate class (and
notwithstanding the existence of less than three (3) such holders at any
given
time), to elect three (3) members to the Board of Directors of Parent and,
to
the extent that the holders elect to fill committee positions, they shall
have
the right, subject to applicable Law and the regulations of the AMEX, to
appoint
two (2) of the three (3) members of each committee of the Board of Directors
including the nominating and corporate governance committee and the compensation
committee of Parent. The Parent Charter shall reflect such right of the holders
of the 8% Convertible Notes. Parent and its Board of Directors shall include
the
names of the three (3) nominees of the holders of the 8% Convertible Notes
in
every proxy statement delivered to stockholders of Parent for any special
or
annual meeting of Parent’s stockholders at which directors are to be elected
during the period commencing on the Closing Date and ending upon the date
that
less than 30% of the principal amount of the 8% Convertible Notes issued
as
Merger Consideration remains outstanding, at which time the rights of such
holders under this Section 5.9 shall terminate.
ARTICLE
VI
CONDITIONS
PRECEDENT
6.1. Conditions
to Each Party’s Obligation to Effect the Merger.
The
respective obligations of Parent, Merger Sub and Company to effect the Merger
are subject to the satisfaction or waiver on or prior to the Closing Date
of the
following conditions:
(a) No
Injunctions or Restraints, Illegality. (i)
No
Governmental Entity or federal or state court of competent jurisdiction shall
have enacted, issued, promulgated, enforced or entered any statute, rule,
regulation, executive order, decree, judgment, injunction or other order
(whether temporary, preliminary or permanent), in any case which is in effect
and which prevents or prohibits consummation of the Merger or any of the
other
transactions contemplated in this Agreement and (ii) no Governmental Entity
shall have instituted any action or proceeding (which remains pending at
what
would otherwise be the Closing Date) before any United States court or other
Governmental Entity of competent jurisdiction seeking to enjoin, restrain
or
otherwise prohibit consummation of the transactions contemplated by this
Agreement.
(b) Parent
Stockholder Approval.
The
Parent shall have obtained from its stockholders in accordance with the DGCL,
(i) approval of this Agreement, the Merger and the transactions contemplated
hereby; provided, however, that stockholders of Parent holding not more than
19.99% of the IPO Shares shall have voted against the Merger and exercised
their
conversion rights under the Parent Charter to convert their shares of Common
Stock into a cash payment from the Trust Fund (iii) approval of the amendment
of
the Parent Charter as set forth in Section 4.1(ii) and (iii) approval of
the
Stock Option Plan (together, the “Parent Stockholder Approval”).
(c) Company
Stockholder Approval. This
Agreement and the transactions contemplated hereby shall have been adopted
by
the Requisite Majority of the Company Capital Stock. At least the Requisite
Majority of the holders of the Company Capital Stock and all of the holders
of
then outstanding PharmAthene Notes shall have executed and delivered the
Allocation Agreement and the Note Exchange Agreement, as applicable, and
such
agreements shall be in full force and effect.
6.2. Additional
Conditions to Obligations of Parent and Merger Sub.
The
obligations of Parent and Merger Sub to effect the Merger are subject to
the
satisfaction or waiver by Parent, on or prior to the Closing Date, of the
following conditions:
(a) Representations
and Warranties. The
representations and warranties of Company shall be true and correct as of
the
date of this Agreement and as of the Closing Date as though made on and as
of
the Closing Date (except to the extent that such representations and warranties
speak as of another date), other than such failures to be true and correct
that
would not reasonably be expected to have, individually or in the aggregate,
a
Material Adverse Effect on Company. Parent shall have received a certificate
of
the chief executive officer and the chief financial officer of Company to
such
effect.
(b) Performance
of Obligations of Company. Company
shall have performed or complied in all respects with all agreements and
covenants required to be performed by it under this Agreement at or prior
to the
Closing Date. Parent shall have received a certificate of the chief executive
officer and the chief financial officer of Company to such effect.
(c) Required
Governmental Consents. The
Necessary Consents shall have been obtained and shall be in full force and
effect, and the Necessary Consents shall not, individually or in the aggregate,
impose any Burdensome Term or Condition.
(d) No
Proceedings. There
shall not be pending or threatened any suit, litigation, action or other
proceeding relating to the transactions contemplated by this Agreement except
as
disclosed to Parent.
(e) No
Material Adverse Change.
At any
time on or after the date of this Agreement there shall not have occurred
any
change, circumstance or event that, individually or in the aggregate, has
had or
would reasonably be expected to have a Material Adverse Effect on
Company.
(f) Termination
of Side Agreements related to Company Preferred Stock and Subsidiary Capital
Stock.
Company
shall have delivered to Parent executed termination agreements in form and
substance reasonably satisfactory to Parent from the holders of the Company
Preferred Stock whereby the holders of such securities terminate all rights
under any agreements entered into by Company in connection with the issuance
and
sale of the Company Series A Preferred Stock, Company Series B Preferred
Stock
and Company Series C Preferred Stock, including, without limitation, all
registration rights agreements, management or stockholder agreements and
tag
along agreements. Company shall have delivered to Parent executed termination
agreements in form and substance reasonably satisfactory to Parent from the
signatories to the Amended and Restated Put and Support Agreement, dated
July
24, 2006, by and among Company, Canadian Medical Discoveries Fund Inc. and
Subsidiary and the Amended and Restated Shareholders’ Agreement, dated July 24,
2006, by and among Company, Canadian Medical Discoveries Fund Inc. and
Subsidiary, in each case relating to the Subsidiary Capital Stock.
(g) Deliverables.
(i) Company
Officer’s Certificate.
Parent
shall have been provided with a certificate executed on behalf of Company
by an
authorized officer to the effect set forth in Sections 6.2(a) and
6.2(b).
(ii) Company
Secretary Certificate.
Parent
shall have received a duly executed certificate from the Secretary of Company
with respect to: (A) the certificate of incorporation, as certified by the
Secretary of State of Delaware as of a recent date, and bylaws of Company,
(B)
resolutions of the board of directors of Company with respect to the
authorizations of this Agreement and the other agreements contemplated hereby,
(C) a certificate of existence and good standing as of a recent date from
the
Secretary of State of the State of Delaware and (iv) the incumbency of the
executing officers of Company.
(iii) Legal
Opinion.
Parent
shall have been furnished with the favorable opinion of McCarter & English,
LLP, dated as of the Closing Date, counsel to Company, in form and substance
reasonably acceptable to Parent.
(iv) Company
Stockholders Lock-Up Agreement. Each
of
the Company stockholders and holders of PharmAthene Notes and the holders
of
Company Options and Company Warrants to purchase not less than 100,000 shares
of
Company Common Stock and all officers and directors of the Company shall
have
executed a Lockup Agreement in substantially the form attached hereto as
Exhibit
C (the “Lockup
Agreement”),
that
such person shall not sell, pledge, transfer, assign or engage in any hedging
transaction with respect to Parent Common Stock issued to such stockholders
as
part of the Merger Consideration except in accordance with the following
schedule: 50% of the Stock Consideration shall be released from the Lock-Up
Agreement commencing six (6) months following the Effective Time, and all
Stock
Consideration shall be released from the Lock-Up Agreement twelve (12) months
following the Effective Time.
(v) Employment
Agreements. (a)
David
Wright shall have duly executed and delivered to Parent an employment agreement
in form and substance mutually acceptable to such parties and (b) all other
Company employment agreements currently in effect shall have been assumed
by
Parent or otherwise continued by Company.
(vi) Escrow
Agreement. The
Stockholders’ Representative and Parent Representative (as defined in Article
VIII) shall have duly executed and delivered to Parent the Escrow
Agreement.
(vii) Resignations.
All
current officers and directors of Company shall have executed and delivered
to
Parent their resignations unless it is contemplated pursuant to the terms
of
this Agreement that such officer or director shall continued in office following
the Closing.
(viii) FIRPTA.
Company
shall have delivered to Parent a properly executed FIRPTA Notification Letter,
in form and substance reasonably acceptable to Parent, which states that
shares
of Company Capital Stock do not constitute “United States real property
interests” under Section 897(c) of the Code, for purposes of satisfying Parent’s
obligations under Treasury Regulation Section 1.1445-2(c)(3). In addition,
simultaneously with delivery of such Notification Letter, Company shall have
provided to Parent, as agent for Company, a form of notice to the Internal
Revenue Service in accordance with the requirements of Treasury Regulation
Section 1.897-2(h)(2) and in form and substance reasonably acceptable to
Parent,
along with written authorization for Parent to deliver such notice form to
the
Internal Revenue Service on behalf of Company upon the Closing.
(ix) Third
Party Consents.
Company
shall have obtained all necessary consents from third parties, including,
without limitation, the Necessary Consents.
(x) Instruments
and Possessions.
In
order to effect the Merger, Company shall have executed and/or delivered
to
Parent:
(A) all
Books
and Records of Company;
(B) such
keys, lock and safe combinations and other similar items as Parent shall
require, to obtain, full occupation, possession and control of Company’s
facilities;
(C) such
changes relating to the bank accounts and safe deposit boxes of Company as
are
being transferred to the Surviving Corporation;
(D) such
other certificates, documents, instruments and agreements as Parent shall
deem
necessary in its reasonable discretion in order to effectuate the Merger
and the
other transactions contemplated herein, in form and substance reasonably
satisfactory to Parent.
6.3. Additional
Conditions to Obligations of Company.
The
obligations of Company to effect the Merger are subject to the satisfaction
or
waiver by Company, on or prior to the Closing Date, of the following additional
conditions:
(a) Representations
and Warranties. The
representations and warranties of Parent and Merger Sub shall be true and
correct as of the date of this Agreement and as of the Closing Date as though
made on and as of the Closing Date (except to the extent that such
representations and warranties speak as of another date), other than such
failures to be true and correct that would not reasonably be expected to
have,
individually or in the aggregate, a Material Adverse Effect on Parent or
Merger
Sub. Company shall have received a certificate of the chief executive officer
and the chief financial officer of Parent to such effect.
(b) Performance
of Obligations of Parent and Merger Sub. Parent
and Merger Sub shall have performed or complied in all material respects
with
all agreements and covenants required to be performed by them under this
Agreement at or prior to the Closing Date. Company shall have received a
certificate of the chief executive officer and the chief financial officer
of
Parent to such effect.
(c) Required
Governmental Consents. The
Necessary Consents shall have been obtained and shall be in full force and
effect, and the Necessary Consents shall not, individually or in the aggregate,
impose any Burdensome Term or Condition.
(d) No
Proceedings. There
shall not be pending or threatened any suit, litigation, action or other
proceeding relating to the transactions contemplated by this Agreement except
as
disclosed to Company.
(e) No
Material Adverse Change.
At any
time on or after the date of this Agreement there shall not have occurred
any
change, circumstance or event that, individually or in the aggregate, has
had or
would reasonably be expected to have a Material Adverse Effect on
Parent.
(f) Third
Party Consents.
Parent
shall have obtained all necessary consents from third parties including,
without
limitation, the Necessary Consents.
(g) Parent
Charter Amendment; Board of Directors. The
Parent Charter shall have been amended to provide for the structure and election
of the Board of Directors as provided herein (including as set forth in Section
4.1(ii)) and all necessary actions on the part of Parent shall have been
taken
to elect the new slate of directors to the Board of Directors of Parent as
of
the Effective Time.
(h) AMEX
Listing. Parent
shall have caused the shares of Stock Consideration to be issued in the Merger
to be approved for listing on the AMEX, subject to official notice of issuance,
prior to the Effective Time.
(i) Tax
Consequences. For
U.S.
federal income tax purposes, the Merger shall be treated as a reorganization
within the meaning of Sections 368(a)(1)(A) and 368(a)(2)(E) of the
Code.
(j) Deliverables.
(i) Parent
Officer’s Certificate.
At the
Closing, Company shall have received a duly executed certificate on behalf
of
Parent by an authorized officer to the effect set forth in Sections 6.3(a)
and
6.3(b).
(ii) Parent
Secretary Certificate.
At the
Closing, Company shall have received a duly executed certificate from the
Secretary of Parent and Merger Sub with respect to: (a) the certificate of
incorporation, as certified by the Secretary of State of Delaware as of a
recent
date, and bylaws of such entities, (b) resolutions of the board of directors
of
such entities with respect to the authorizations of this Agreement and the
other
agreements contemplated hereby, (c) a certificate of existence and good standing
of such entities as of a recent date from the Secretary of State of Delaware
and
(d) the incumbency of the executing officers of such entities.
(iii) Employment
Agreements.
Parent
shall have (a) duly executed and delivered to David Wright an employment
agreement in form and substance mutually acceptable to such parties and (b)
all
other Company employment agreements currently in effect shall have been assumed
by Parent or otherwise continued by Company.
(iv) Note
Exchange Agreement. Parent
shall have entered into a Note Exchange Agreement in substantially the form
of
Exhibit E (the“Note
Exchange Agreement”)
with
each of the holders of PharmAthene Notes or with the Stockholders’
Representative on their behalf.
(v) 8%
Convertible Notes.
The 8%
Convertible Notes, in substantially the form attached hereto as Exhibit A,
shall
have been duly executed and delivered to the holders of the PharmAthene Notes
pursuant to such Note Exchange Agreement.
(vi) Legal
Opinion.
Company
and its stockholders shall have been furnished with the favorable opinion
of
Ellenoff Grossman & Schole LLP, counsel to the Parent, dated as of the
Closing Date, in form and substance reasonably acceptable to
Company.
(vii) Registration
Rights Agreement with respect to Parent Common Stock.
Parent
shall have entered into a Registration Rights Agreement in substantially
the
form of Exhibit D (the“Registration
Rights Agreement”)
with
each of Company’s stockholders receiving Parent Common Stock and the holders of
the 8% Convertible Notes or the Stockholders’ Representative on their
behalf.
(viii) Instruments
and Possessions.
In
order to effect the Merger, Parent and Merger Sub shall have executed and/or
delivered to Company such other certificates, documents, instruments and
agreements as Parent shall deem necessary in its reasonable discretion in
order
to effectuate the Merger and the other transactions contemplated herein,
in form
and substance reasonably satisfactory to Company.
ARTICLE
VII
TERMINATION
AND AMENDMENT
7.1. Termination.
This
Agreement may be terminated and the Merger contemplated hereby may be abandoned
at any time prior to the Effective Time:
(a) By
mutual
written consent of Parent, Merger Sub and Company;
(b) By
Parent
or Company, if (i) the Merger shall not have been consummated on or before
August 3, 2007;
provided, however,
that the
right to terminate this Agreement pursuant to this Section 7.1(b)(i) shall
not
be available to any party if such party’s action or failure to act has been the
principal cause of or resulted in the failure of the Merger to be consummated
on
or before such date; if (ii) any permanent injunction or other order of a
court
or other competent authority preventing the consummation of the Merger shall
have become final and nonappealable; or, (iii) during any 15-day trading
period
following the execution of this Agreement and before the Effective Time,
the
average trading price of the publicly-traded warrants of the Parent is below
$0.20 per warrant.
(c) By
Company, if (i) prior to the Closing Date there shall have been a material
breach of any representation, warranty, covenant or agreement on the part
of
Parent or Merger Sub contained in this Agreement or any representation or
warranty of Parent or Merger Sub shall have become untrue after the date
of this
Agreement, which breach or untrue representation or warranty (A) would,
individually or in the aggregate with all other such breaches and untrue
representations and warranties, give rise to the failure of a condition and
(B)
is incapable of being cured prior to the Closing Date by Parent or is not
cured
within thirty (30) days of notice of such breach, (ii) any of the conditions
set
forth in Sections 6.1 (other than 6.1(c) which shall not be grounds for
termination by Company) or 6.3 shall have become incapable of fulfillment;
(iii)
Parent has not filed its preliminary Proxy Statement with the SEC by February
14, 2007 through no fault of Company or such Proxy Statement has not been
approved by the SEC by July 10, 2007; (iv) Parent has not held its Parent
Stockholders Meeting to approve the Merger within thirty-five (35) days of
approval of the Proxy Statement by the SEC; (v) Parent’s Board of Directors has
withdrawn or changed its recommendation to its stockholders regarding the
Merger; or (vi) more than 19.99% of the holders of the IPO Shares entitled
to
vote on the Merger elect to convert their IPO Shares into cash from the Trust
Fund.
(d) By
Parent, if (i) prior to the Closing Date there shall have been a material
breach
of any representation, warranty, covenant or agreement on the part of Company
contained in this Agreement or any representation or warranty of Company
shall
have become untrue after the date of this Agreement, which breach or untrue
representation or warranty (A) would, individually or in the aggregate with
all
other such breaches and untrue representations and warranties, give rise
to the
failure of a condition and (B) is incapable of being cured prior to the Closing
Date by Company or is not cured within thirty (30) days of notice of such
breach; (ii) any of the conditions set forth in Sections 6.1 (other than
6.1(c)
which shall not be grounds for termination by Parent) or 6.2 shall have become
incapable of fulfillment; (iii) the Necessary Consents, individually or in
the
aggregate contain any Burdensome Terms or Conditions which have a Material
Adverse Effect on Company or Parent.
7.2. Effect
of Termination.
(a) In
the
event of the termination of this Agreement pursuant to Section 7.1, the
obligations of the parties under this Agreement shall terminate and there
shall
be no liability on the part of any party hereto, except for the obligations
in
the confidentiality provisions hereof, and all of the provisions of this
Section
7.2, Section 7.3, Section 7.4 and Section 9.11;
provided, however,
that no
party hereto shall be relieved or released from any liabilities or damages
arising out of its willful breach of any provision of this
Agreement.
(b) In
the
event that this Agreement is terminated by Parent pursuant to Section 7.1(d)(i)
and 7.1(d)(ii)(and, in the case of the failure to fulfill conditions, such
failure is within Company’s control which shall be deemed to include a failure
of the Company, its stockholders or holders of PharmAthene Notes to agree
upon
the terms of any re-allocation of the Merger Consideration which may be made
necessary as a result of a Company Subsequent Issuance or an issuance in
connection with any financing transaction with General Electric Capital Corp.),
then Company shall be obligated to pay to Parent, within five (5) business
days
of such termination, the sum of $250,000 (the “Termination
Fee”)
in
cash.
(c) In
the
event that this Agreement is terminated by Company pursuant to Section 7.1(c)(i)
through (v)(and, in the case of the failure to fulfill conditions, such failure
is within Parent’s control), then Parent shall be obligated to pay to Company,
within five (5) business days of such termination, the Termination Fee, in
cash,
or such lesser amount (in the event that Parent does not have $250,000 in
available funds outside of the Trust Fund) as shall equal all remaining
available funds of Parent which are not a part of the Trust Fund.
7.3. Trust
Fund Waiver.
Reference is made to the final prospectus of Parent, dated July 28, 2005
(the
“Prospectus”),
Company understands that, except for a portion of the interest earned on the
amounts held in the Trust Fund, Parent may disburse monies from the Trust
Fund
only: (a) to its public stockholders in the event of the redemption of their
shares or the dissolution and liquidation of Parent, (b) to Parent and Maxim
Group LLC (with respect to Maxim Group LLC’s deferred underwriting compensation
only) after Parent consummates a business combination (as described in the
Prospectus) or (c) as consideration to the sellers of a target business with
which Parent completes a business combination.
Company
agrees that, notwithstanding any other provision contained in this Agreement
(including the termination provisions of this Article VII), Company does
not now
have, and shall not at any time prior to the Closing have, any claim to,
or make
any claim against, the Trust Fund, regardless of whether such claim arises
as a
result of, in connection with or relating in any way to, the business
relationship between Company, on the one hand, and Parent, on the other hand,
this Agreement, or any other agreement or any other matter, and regardless
of
whether such claim arises based on contract, tort, equity or any other theory
of
legal liability (any and all such claims are collectively referred to in
this
Section 7.3 as the “Claims”).
Notwithstanding any other provision contained in this Agreement, Company
hereby
irrevocably waives any Claim they may have, now or in the future (in each
case,
however, prior to the consummation of a business combination), and will not
seek
recourse against, the Trust Fund for any reason whatsoever in respect thereof.
In the event that Company commences any action or proceeding based upon,
in
connection with, relating to or arising out of any matter relating to Parent,
which proceeding seeks, in whole or in part, relief against the Trust Fund
or
the public stockholders of Parent, whether in the form of money damages or
injunctive relief, Parent shall be entitled to recover from Company the
associated legal fees and costs in connection with any such action, in the
event
Parent prevails in such action or proceeding.
7.4. Fees
and Expenses.
Each
party shall bear its own expenses in connection with this Agreement and the
transactions contemplated hereby, including any expenses incurred with regard
to
the Engagement Letter in the event that this Agreement is terminated; in
the
event that the Merger is consummated, all liabilities of Company shall continue
as liabilities of Company as the Surviving Corporation and as a direct,
wholly-owned subsidiary of Parent.
ARTICLE
VIII
REMEDIES
FOR BREACH OF AGREEMENT
8.1. Survival
of Representations and Warranties.
All of
the representations and warranties of the parties contained in this Agreement
shall survive the Closing hereunder (unless the non-breaching party had received
from the breaching party written notice of any misrepresentation or breach
of
warranty prior to the time of Closing and expressly waived in writing such
breach or misrepresentation) and continue in full force and effect until
a
period of twelve (12) months from the Closing Date (“Survival
Period”).
8.2. Indemnification
Provisions for Benefit of Parent.
In the
event that Company violates, misrepresents or breaches (or in the event any
third party alleges facts that are ultimately proven or conceded to represent
a
Company violation, misrepresentation or breach) any of its representations,
warranties, and covenants contained herein including, without limitation,
the
covenants and agreements of Company and PA Management Team to provide Company
Information contained in Section 4.1(b) hereof and, if there is an applicable
Survival Period pursuant to Section 8.1 above, provided that the Parent
Representative makes a written claim for indemnification against Company
pursuant to Section 8.6 below within the Survival Period, then the Indemnifying
Stockholders (as defined in Article X) agree to indemnify Parent from and
against the entirety of any Adverse Consequences (as defined in Article X)
that
Parent may suffer through and after the date of the claim for indemnification
(including any Adverse Consequences Parent may suffer after the end of any
applicable Survival Period) resulting from, arising out of, relating to,
in the
nature of, or caused by the violation, misrepresentation or breach. Any
liability incurred by the Indemnifying Stockholders pursuant to the terms
of
this Article VIII shall be limited to, and paid by, the Indemnifying
Stockholders to Parent by return for cancellation of the Escrow Shares in
accordance with Section 8.6 hereof which shall represent the sole and exclusive
source for payment of any indemnification obligations of the Indemnifying
Stockholders. All determinations relating to the submission of claims for
the
benefit of Parent hereunder shall be determined, in good faith, solely by
the
nominees of Parent to the Board of Directors.
Notwithstanding Company’s disclosure in Item 2 of Section 2.3(h)(i) of the
Company Disclosure Schedule (the “Section
2.3(h) disclosure”),
Parent
shall have the right to indemnification under this Article VIII, subject
to all
of the terms and conditions of this Article VIII (including, without limitation,
meeting the indemnification threshold set forth in Section 8.7 and the
limitations set forth in Section 8.5), with respect to any Adverse Consequences
suffered by Parent as a result of any claims relating to such Section 2.3(h)
disclosure which claims are not resolved prior to Closing. For the avoidance
of
doubt, the parties expressly acknowledge and agree that the resolution of
any
claims relating to the Section 2.3(h) disclosure occurring prior to Closing
shall be within the sole discretion of Company and shall in no way effect
the
Merger Consideration or be applicable towards the indemnification threshold
or
otherwise be subject to indemnification.
8.3. Matters
Involving Third Parties.
(a) If
any
third party shall notify any party (the “Indemnified
Party”)
with
respect to any matter (a “Third
Party Claim”)
which
may give rise to a claim for indemnification against any other party (the
“Indemnifying
Party”)
under
this Article VIII, then the Indemnified Party shall promptly (and in any
event
within ten (10) business days after receiving notice of the Third Party Claim)
notify each Indemnifying Party and the Escrow Agent thereof in writing (an
“Indemnification
Notice”);
provided, however, that no delay on the part of the Indemnified Party in
notifying any Indemnifying Party shall relieve the Indemnifying Party from
any
obligation hereunder unless (and then solely to the extent) the Indemnifying
Party thereby is prejudiced.
(b) Any
Indemnifying Party will have the right to defend the Indemnified Party against
the Third Party Claim with counsel of its choice reasonably satisfactory
to the
Indemnified Party so long as (i) the Indemnifying Party notifies the Indemnified
Party in writing within thirty (30) business days (or earlier in the event
the
underlying Third Party claim requires action) after the Indemnified Party
has
given notice of the Third Party Claim that the Indemnifying Party will indemnify
the Indemnified Party from and against the entirety of any Adverse Consequences
the Indemnified Party may suffer resulting from, arising out of, relating
to, in
the nature of, or caused by the Third Party Claim, (ii) the Indemnifying
Party
provides the Indemnified Party with evidence reasonably acceptable to the
Indemnified Party that the Indemnifying Party will have the financial resources
to defend against the Third Party Claim and fulfill its indemnification
obligations hereunder, (iii) the Third Party Claim involves only money damages
and does not seek an injunction or other equitable relief, (iv) settlement
of,
or an adverse judgment with respect to, the Third Party Claim is not, in
the
good faith judgment of the Indemnified Party, likely to establish a precedent
or
practice materially adverse to the continuing business interests of the
Indemnified Party, and (v) the Indemnifying Party conducts the defense of
the
Third Party Claim actively and diligently.
(c) So
long
as the Indemnifying Party is conducting the defense of the Third Party Claim
in
accordance with Section 8.3(b) above, (i) the Indemnified Party may retain
separate co-counsel at its sole cost and expense and participate in the defense
of the Third Party Claim, (ii) the Indemnified Party will not consent to
the
entry of any judgment or enter into any settlement with respect to the Third
Party Claim without the prior written consent of the Indemnifying Party (not
to
be withheld unreasonably) and (iii) the Indemnifying Party will not consent
to
the entry of any judgment or enter into any settlement with respect to the
Third
Party Claim without the prior written consent of the Indemnified Party (not
to
be withheld unreasonably).
(d) In
the
event that any of the conditions in Section 8.3(b) above fail to be complied
with, however, (i) the Indemnified Party may defend against, and consent
to the
entry of any judgment or enter into any settlement with respect to, the Third
Party Claim in any manner it reasonably may deem appropriate (and the
Indemnified Party need not consult with, or obtain any consent from, any
Indemnifying Party in connection therewith), (ii) the Indemnifying Parties
will
reimburse the Indemnified Party promptly and periodically for the costs of
defending against the Third Party Claim (including reasonable attorneys’ fees
and expenses), and (iii) the Indemnifying Parties will remain responsible
for
any Adverse Consequences the Indemnified Party may suffer resulting from,
arising out of, relating to, in the nature of, or caused by the Third Party
Claim to the fullest extent provided in this Article VIII.
(e) Notwithstanding
anything to the contrary contained in this Article VIII, Parent, Company
and
Merger Sub shall not settle and pay any Third Party Claim unless and until
Parent shall have obtained the prior written consent of the Stockholders’
Representative to such settlement which consent the Stockholders’ Representative
shall not unreasonably withhold or delay.
8.4. Determination
of Adverse Consequences.
All
claims for indemnification payments under this Article VIII shall be made
in
good faith and although a claim may be made hereunder, no payments shall
be made
for the benefit of the Indemnified Party until the Indemnified Party has
incurred actual out-of pocket expenses. In the event that Parent has made
a
claim for indemnification prior to the termination of any applicable Survival
Period, no Escrow Shares held in escrow pursuant to this Article VIII and
the
Escrow Agreement shall be released from the escrow until such time as the
claim
has been resolved unless the Survival Period shall have expired after the
making
of such claim but before such claim is fully resolved, in which case the
Escrow
Shares in excess of the Fair Market Value of the amount of Adverse Consequence
shall be released from Escrow.
8.5. Escrow
of Shares by Indemnifying Stockholders.
As the
sole and exclusive source for the payment of the indemnification obligations
of
the Indemnifying Stockholders under this Article VIII, Company and the
Indemnifying Stockholders hereby authorize Parent to withhold, from the delivery
of the Stock Consideration otherwise deliverable to the Indemnifying
Stockholders as part of the Merger Consideration, for delivery into escrow,
pursuant to the Escrow Agreement, 1,375,000 shares of Parent Common Stock
which
shall be allocated among the Indemnifying Stockholders in accordance with
the
relative proportions established by the Allocation Agreement as provided
to
Parent in a certificate executed and delivered by Company at Closing (the
“Company
Closing Certificate”).
(a) Escrow
Shares.
The
Escrow Shares shall be withheld from delivery to the Indemnifying Stockholders
and segregated from shares issuable upon the exercise of Company Options
and
Company Warrants at Closing and placed in escrow pursuant to the terms of
the
Escrow Agreement. The Escrow Shares shall be registered in the name of each
Indemnifying Stockholder in the amounts set forth on the Company Closing
Certificate, and shall be held by Continental Stock Transfer & Trust Company
(the “Escrow
Agent”),
and
shall constitute the escrow fund (the “Escrow
Fund”)
governed by the terms of the Escrow Agreement. In the event that Parent issues
any additional shares of Parent Common Stock to the Indemnifying Stockholders
for any reason, such additional shares shall be issued in the name of such
Indemnifying Stockholders as applicable and shall not be subject to escrow.
Once
released from the Escrow Fund, shares of Parent Common Stock shall cease
to be
Escrow Shares.
(b) Payment
of Dividends; Voting. Any
cash
dividends, dividends payable in securities, or other distributions of any
kind
made in respect of the Escrow Shares will be delivered promptly to the
Indemnifying Stockholders. The Indemnifying Stockholders (other than the
holders
of Company Options and Company Warrants) shall be entitled to vote the Escrow
Shares on any matters to come before the stockholders of Parent, with each
Indemnifying Stockholder being entitled to direct the voting of its or his
Escrow Shares listed on the Company Closing Certificate.
(c) Distribution
of Escrow Shares. At
the
times provided for in Section 8.5(e), the Escrow Shares shall be released
to the
Indemnifying Stockholders (and to Parent on behalf of holders of Company
Options
and Company Warrants) in accordance with the Company Closing Certificate
unless
the Stockholders’ Representative shall have instructed the Escrow Agent
otherwise in writing, in which case the Escrow Agent and the Parent shall
be
entitled to rely upon such instructions. Parent will take such action as
may be
necessary to cause such certificates to be issued in the names of the
appropriate persons. Certificates representing Escrow Shares so issued that
are
subject to resale restrictions under applicable securities laws will bear
a
legend to that effect. No fractional shares shall be released and delivered
from
the Escrow Fund to the Indemnifying Stockholders and all fractional shares
shall
be rounded to the nearest whole share.
(d) Assignability.
No
Escrow Shares or any beneficial interest therein may be pledged, sold, assigned
or transferred, including by operation of law, by any Indemnifying Stockholders
or be taken or reached by any legal or equitable process in satisfaction
of any
debt or other liability of any such stockholder, prior to the delivery to
such
Indemnifying Stockholders of its or his pro rata portion of the Escrow Fund
by
the Escrow Agent as provided herein.
(e) Release
from Escrow Fund.
Within
five (5) business days following expiration of the Survival Period (the
“Release
Date”),
the
Escrow Shares will be released from the Escrow Fund to the Indemnifying
Stockholders less
the
number of Escrow Shares, if any, with a Fair Market Value equal to the amount
of
Adverse Consequences set forth in any Indemnification Notice from Parent
with
respect to any pending but unresolved claim for indemnification. Prior to
the
Release Date, the Parent Representative and the Stockholder Representative
shall
issue to the Escrow Agent a certificate executed by each of them instructing
the
Escrow Agent to release such number of Escrow Shares determined in accordance
with this Section 8.5(e). Any Escrow Shares retained in the Escrow Fund as
a
result of the immediately preceding sentence shall be released to the
Indemnifying Stockholders or Parent, as appropriate, promptly upon resolution
of
the related claim for indemnification in accordance with the provisions of
this
Article VIII. For purposes of this Article VIII, the “Fair
Market Value”
shall
be the average reported last sales price for the ten (10) trading days ending
on
the last day prior to the date that the claim for indemnification is publicly
disclosed (or if there is no public disclosure, the date on which the
Indemnification Notice is received) and the ten (10) trading days after such
date; provided, however, the Stockholders’ Representative and the Parent
Representative acting together shall have the right to assign a different
value
to the Escrow Shares in order to settle or pay any Third Party Claim in the
event the third party claimant is willing to accept the Escrow Shares in
full or
partial settlement therefor.
(f) Stockholders’
Representative and Parent Representative.
(i) MPM
BioVentures III-QP, L.P. is hereby constituted and appointed jointly as the
Stockholders’ Representative for and on behalf of the Indemnifying Stockholders
to give and receive notices and communications, to authorize delivery to
Parent
of shares of Parent Common Stock from the Escrow Fund in satisfaction of
indemnification claims by Parent, to object to such deliveries, negotiate,
enter
into settlements and compromises of, and comply with orders of courts with
respect to such claims (including Third Party Claims), and to take all actions
necessary or appropriate in the judgment of the Stockholders’ Representative for
the accomplishment of the foregoing. Such agency may be changed by from time
to
time upon not less than ten (10) days’ prior written notice, executed by the
Stockholders’ Representative, to the Parent Representative. No bond shall be
required of the Stockholders’ Representative, and the Stockholders’
Representative shall receive no compensation for his services. Notices or
communications to or from the Stockholders’ Representative shall constitute
notice to or from Company and each of the Indemnifying
Stockholders.
(ii) The
Stockholders’ Representative shall not be liable for any act done or omitted
hereunder as Stockholders’ Representative while acting in good faith and any act
done or omitted pursuant to the advice of counsel shall be conclusive evidence
of such good faith. The Indemnifying Stockholders shall severally indemnify
the
Stockholders’ Representative and hold him harmless against any loss, liability,
or expense (including legal and accounting fees) incurred without gross
negligence or bad faith on the part of the Stockholders’ Representative and
arising out of or in connection with the acceptance or administration of
his
duties hereunder.
(iii) A
decision, act, consent or instruction of the Stockholders’ Representative shall
constitute a decision of all Indemnifying Stockholders for whom Escrow Shares
otherwise issuable to them are deposited in escrow and shall be final, binding,
and conclusive upon each such Indemnifying Stockholder, and Parent may rely
upon
any decision, act, consent, or instruction of the Stockholders’ Representative
as being the decision, act, consent or instruction of each and every such
Indemnifying Stockholder. The Stockholders’ Representative shall have the right
to consent to the use of the Escrow Shares to settle any claims made hereunder.
For purposes of clarification, in connection with the settlement or payment
of
any claims for indemnification hereunder, the “Fair
Market Value”
of
the
Escrow Shares as defined under this Article VIII, shall not be binding upon
the
Parent or Stockholders’ Representative if they mutually agree upon any value
other than Fair Market Value and shall also have the discretion to mutually
agree to use the Escrow Shares to settle or pay any Third Party
Claims.
(iv) John
Pappajohn is hereby constituted and appointed jointly as the Parent
Representative for and on behalf of the Parent to give and receive notices
and
communications, to negotiate, enter into settlements and compromises of,
and
comply with orders of courts with respect to such claims (including Third
Party
Claims), and to take all actions necessary or appropriate in the judgment
of the
Parent Representative for the accomplishment of the foregoing. Such agency
may
be changed by from time to time upon not less than ten (10) days’ prior written
notice, executed by the Parent Representative, to the Stockholders’
Representative. No bond shall be required of the Parent Representative, and
the
Parent Representative shall receive no compensation for his services. Notices
or
communications to or from the Parent Representative shall constitute notice
to
or from Parent.
(v) The
Parent Representative shall not be liable for any act done or omitted hereunder
while acting in good faith and any act done or omitted pursuant to the advice
of
counsel shall be conclusive evidence of such good faith. The Parent shall
indemnify the Parent Representative and hold him harmless against any loss,
liability, or expense incurred without gross negligence or bad faith on the
part
of the Parent Representative and arising out of or in connection with the
acceptance or administration of his duties hereunder.
(vi) A
decision, act, consent or instruction of the Parent Representative shall
constitute a decision of Parent under this Article VIII and shall be final,
binding, and conclusive upon Parent. The Stockholders’ Representative and the
Indemnifying Stockholders may rely upon any decision, act, consent, or
instruction of the Parent Representative as being the decision, act, consent
or
instruction of the Parent. The Parent Representative shall have the right
to
consent to the use of the Escrow Shares to settle any claim for which Parent
is
entitled to indemnification under this Article VIII. For purposes of
clarification, in connection with the settlement or payment of any claims
for
indemnification hereunder, the “Fair
Market Value”
of
the
Escrow Shares as defined under this Article VIII, shall not be binding upon
the
Parent Representative or Stockholders’ Representative if they mutually agree
upon any value other than Fair Market Value and shall also have the discretion
to mutually agree to use the Escrow Shares to settle or pay any Third Party
Claims.
8.6. Determination/Resolution
of Claims.
(a) If
an
Indemnified Party wishes to make a claim for indemnification against an
Indemnifying Party, such Indemnified Party shall deliver the Indemnification
Notice to the Indemnifying Party and to the Escrow Agent on or before the
expiration of the Survival Period. Such Indemnification Notice shall contain
the
amount of Adverse Consequences for which the Indemnified Party is seeking
indemnification and shall set forth the reasons therefore in reasonable
detail.
(b) If
Parent
asserts a claim upon the Escrow Fund by delivering an Indemnification Notice
to
the Stockholders’ Representative and the Escrow Agent on or before the end of
the Survival Period, the Escrow Agent shall retain in the Escrow Fund such
number of shares of Parent Common Stock as shall be determined in accordance
with Section 8.5(e) above.
(c) Unless
the Stockholders’ Representative shall notify Parent in writing within thirty
(30) days after receipt of an Indemnification Notice that the Stockholders’
Representative objects to any claim for indemnification set forth therein,
which
notice shall include a reasonable explanation of the basis for such objection,
then such indemnification claim shall be deemed to be accepted by the
Stockholders’ Representative and the parties shall issue to the Escrow Agent a
certificate executed by the Parent Representative and the Stockholders’
Representative indicating what number of Escrow Shares are to be released
to
Parent. If the Stockholders’ Representative shall timely notify Parent in
writing that it objects to any claim for indemnification made in such an
Indemnification Notice, Parent shall have fifteen (15) days from receipt
of such
notice to respond in a written statement to such objection. If after thirty
(30)
days following receipt of Parent’s written statement, there remains a dispute as
to any indemnification claims set forth in the Indemnification Notice, the
Stockholders’ Representative and the Parent Representative shall attempt in good
faith for sixty (60) days to agree upon the rights of the respective parties
with respect to each of such claims. If the Stockholders’ Representative and the
Parent Representative should so agree, a memorandum setting forth such agreement
shall be prepared and signed by both parties. Based upon the memorandum,
the
parties shall issue to the Escrow Agent a certificate executed by the Parent
Representative and the Stockholders’ Representative indicating what number of
Escrow Shares are to be released to Parent. The Escrow Agent shall be entitled
to rely on any such certificate and disburse Escrow Shares from the Escrow
Fund
in accordance with the terms thereof.
(d) If
the
Stockholders’ Representative and the Parent Representative cannot resolve a
dispute during the sixty-day period (or such longer period as the parties
may
agree to in writing), then such dispute shall be submitted (and either party
may
submit such dispute) for arbitration before a single arbitrator in Wilmington,
Delaware, in accordance with the commercial arbitration rules of the American
Arbitration Association then in effect. The Stockholders’ Representative and the
Parent Representative shall attempt to agree upon an arbitrator. In the event
that the Stockholders’ Representative and the Parent Representative are unable
to agree upon an arbitrator within ten (10) days after the date on which
the
disputed matter may, under this Agreement, be submitted to arbitration, then
either the Stockholders’ Representative or the Parent Representative, upon
written notice to the other, may apply for appointment of such arbitrator
by the
American Arbitration Association. Each party shall pay the fees and expenses
of
counsel used by it and 50% of the fees and expenses of the arbitrator and
of the
other expenses associated with the arbitration. The arbitrator shall render
his
decision within ninety (90) days after his appointment, such decision shall
be
in writing and shall be final and conclusive on the parties. The decision
shall
be submitted to the Escrow Agent which shall act in accordance
therewith.
8.7. Indemnification
Threshold.
Notwithstanding anything to the contrary contained herein, no Person or Party
shall have any obligation to indemnify Parent or Company, as the case may
be,
from and against any Adverse Consequences caused proximately by the breach
of
any representation or warranty of Parent or Company hereunder, as the case
may
be, until Parent or Company, as the case may be, has suffered Adverse
Consequences by reason of all such breaches (or alleged breaches) in excess
of
$500,000 in the aggregate, with no single Adverse Consequence being valued
at
less than $50,000.
8.8. Other
Indemnification Provisions.
(a) Any
Indemnified Party seeking indemnification under this Article VIII shall be
required to take all reasonable actions to mitigate the damages associated
with
the Adverse Consequences.
(b) Notwithstanding
any provision contained in this Agreement, no indemnification claim shall
be
maintained by any party for breach of representations or warranties of the
other
party if such claiming party had knowledge of the breach of the representations
and warranties on or before the Closing.
(c) No
recovery for indemnification shall include recovery for special, incidental,
punitive or consequential damages. All claims for indemnification shall be
subject to reduction or offset for any tax benefits associated with or insurance
proceeds applicable to the claim.
ARTICLE
IX
GENERAL
PROVISIONS
9.1. Survival.
The
agreements and covenants contained in this Agreement shall survive the Closing
Date without limitation. The representations and warranties contained in
this
Agreement shall survive the Closing Date for a period of twelve (12)
months.
9.2. Notices.
All
notices and other communications hereunder shall be in writing and shall
be
deemed duly given (a) on the date of delivery if delivered personally, or
by
telecopy upon confirmation of receipt; (b) on the first Business Day following
the date of dispatch if delivered by a recognized next-day courier service;
or
(c) on the third Business Day following the date of mailing if delivered
by
registered or certified mail, return receipt requested, postage prepaid.
All
notices hereunder shall be delivered as set forth below, or pursuant to such
other instructions as may be designated in writing by the party to receive
such
notice:
if
to
Parent or Merger Sub, to:
Healthcare
Acquisition Corp.
666
Walnut Street, Suite 2116
Des
Moines, Iowa 50309
Attn:
Matthew P. Kinley
Phone:
(515) 244-5746
Fax:
with
a
copy to:
Ellenoff
Grossman & Schole LLP
370
Lexington Ave.
New
York,
New York 10017
Attn:
Barry I. Grossman, Esq.
Phone:
(212) 370-1300
Fax:
(212) 370-7889
if
to
Company or Stockholders, to
PharmAthene,
Inc.
175
Admiral Cochrane Drive, Suite #101
Annapolis,
MD 21401
Attn:
David P. Wright
President
& Chief Executive Officer
Phone:
(410) 571-8920
Fax:
(410) 571-8927
with
a
copy to:
McCarter
& English, LLP
Four
Gateway Center
100
Mulberry Street
Newark,
New Jersey 07102
Attn:
Jeffrey A. Baumel, Esq.
Phone:
(973) 639-5904
Fax:
(973) 624-7070
If
to
Stockholders’ Representative:
MPM
BioVentures
III-QP, LP
The
John
Hancock Tower
200
Clarendon Street
54th
Floor
Boston,
MA 02116
Attn:
Steven St. Peter, M.D.
Phone:
(617) 425-9200
Fax:
(617) 425-9201
If
to
Parent Representative:
John
Pappajohn
2116
Financial Center
Des
Moines, Iowa 50309
Phone:
Fax:
(515) 244-2346
9.3. Interpretation.
When a
reference is made in this Agreement to Sections, Exhibits or Schedules, such
reference shall be to a Section of or Exhibit or Schedule to this Agreement
unless otherwise indicated. The headings contained in this Agreement are
for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. Whenever the words “include,” “includes” or
“including” are used in this Agreement, they shall be deemed to be followed by
the words “without limitation.” The parties have participated jointly in the
negotiating and drafting of this Agreement. In the event that an ambiguity
or a
question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the parties, and no presumption or burden of proof
shall arise favoring or disfavoring any party by virtue of the authorship
of any
provisions of this Agreement.
9.4. Counterparts.
This
Agreement may be executed in one or more counterparts, all of which shall
be
considered one and the same agreement and shall become effective when one
or
more counterparts have been signed by each of the parties and delivered to
the
other party, it being understood that both parties need not sign the same
counterpart.
9.5. Entire
Agreement; No Third-Party Beneficiaries.
(a) This
Agreement, including the schedules hereto, and the Confidentiality Agreement,
dated January 12, 2007 between Company and Parent, constitute the entire
agreement and supersede all prior agreements and understandings, both written
and oral, among the parties with respect to the subject matter hereof and
thereof.
(b) This
Agreement shall be binding upon and inure solely to the benefit of each party
hereto, and nothing in this Agreement, express or implied, is intended to
or
shall confer upon any other Person any right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement.
9.6. Governing
Law; Waiver of Jury Trial.
(a) This
Agreement and the transactions contemplated hereby, and all disputes between
the
parties under or related to this Agreement or the facts and circumstances
leading to its execution, whether in contract, tort or otherwise, shall be
governed by and construed in accordance with the internal laws of the State
of
Delaware, applicable to contracts executed in and to be performed entirely
within the State of Delaware.
(b) EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER
THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE
EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH
PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR
INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT
(i)
NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH PARTY UNDERSTANDS
AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii) EACH PARTY MAKES
THIS
WAIVER VOLUNTARILY, AND (iv) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS
AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN
THIS
SECTION 9.6.
9.7. Severability.
The
provisions of this Agreement shall be deemed severable and the invalidity
or
unenforceability of any provision shall not affect the validity or
enforceability or the other provisions hereof. If any provision of this
Agreement, or the application thereof to any person or any circumstance,
is
invalid or unenforceable, (a) a suitable and equitable provision shall be
substituted therefor in order to carry out, so far as may be valid and
enforceable, the intent and purpose of such invalid or unenforceable provision
and (b) the remainder of this Agreement and the application of such provision
to
other persons or circumstances shall not be affected by such invalidity or
unenforceability, nor shall such invalidity or unenforceability affect the
validity or enforceability of such provision, or the application thereof,
in any
other jurisdiction.
9.8. Amendment.
This
Agreement may not be amended except by an instrument in writing signed on
behalf
of each of the parties hereto.
9.9. Extension;
Waiver.
At any
time prior to the Effective Time, the parties hereto, by action taken or
authorized by their respective Boards of Directors, may, to the extent legally
allowed, (i) extend the time for the performance of any of the obligations
or
other acts of the other parties hereto, (ii) waive any inaccuracies in the
representations and warranties contained herein or in any document delivered
pursuant hereto or (iii) waive compliance with any of the agreements or
conditions contained herein. Any agreement on the part of a party hereto
to any
such extension or waiver shall be valid only if set forth in a written
instrument signed on behalf of the party against which such waiver or extension
is to be enforced. The failure of any party to this Agreement to assert any
of
its rights under this Agreement or otherwise shall not constitute a waiver
of
those rights.
9.10. Assignment.
Neither
this Agreement nor any of the rights, interests or obligations hereunder
shall
be assigned by any of the parties hereto, in whole or in part (whether by
operation of law or otherwise), without the prior written consent of the
other
parties, and any attempt to make any such assignment without such consent
shall
be null and void. This Agreement will be binding upon, inure to the benefit
of
and be enforceable by the parties and their respective successors and
assigns.
9.11. Submission
to Jurisdiction; Waivers.
(a) Each
of
Company, Parent and Merger Sub hereby irrevocably agrees that any legal action
or proceeding with respect to this Agreement or for recognition and enforcement
of any judgment in respect hereof brought by another party hereto or its
successors or assigns shall be brought and determined exclusively in any
federal
or state court of competent jurisdiction located in the State of Delaware
and in
the courts hearing appeals therefrom. Each party hereto hereby irrevocably
waives, and agrees not to assert, by way of motion, as a defense, counterclaim
or otherwise, in any action or proceeding with respect to this Agreement,
any
claim that it is not personally subject to the jurisdiction of the above-named
courts for any reason other than the failure to serve process in accordance
with
Section (b) below, that its property is exempt or immune from jurisdiction
of
any such court or from any legal process commenced in such courts (whether
through service of notice, attachment prior to judgment, attachment in aid
of
execution of judgment, execution of judgment or otherwise), and to the fullest
extent permitted by applicable law, that the suit, action or proceeding in
any
such court is brought in an inconvenient forum, or that this Agreement, or
the
subject matter hereof, may not be enforced in or by such courts and further
irrevocably waives, to the fullest extent permitted by applicable law, the
benefit of any defense that would hinder, fetter or delay the levy, execution
or
collection of any amount to which the party is entitled pursuant to the final
judgment of any court having jurisdiction. Each party irrevocably consents
to
the service of process out of any of the aforementioned courts in any such
action or proceeding by the mailing of copies thereof by registered airmail,
postage prepaid, to such party at its address set forth in this Agreement,
such
service of process to be effective upon acknowledgement of receipt of such
registered mail. Nothing herein shall affect the right of any party to serve
process in any other manner permitted by law or to commence legal proceedings
or
otherwise proceed against the other party in any other jurisdiction in which
the
other party in any other jurisdiction in which the other party may be subject
to
suit.
(b) Each
of
Company, Parent and Merger Sub hereby agrees that mailing of process or other
papers in connection with any such action or proceeding in the manner provided
in Section 9.2 or in such other manner as may be permitted by applicable
law
shall be valid and sufficient service thereof.
9.12. Enforcement;
Specific Performance.
The
parties agree that irreparable damage would occur in the event that any of
the
provisions of this Agreement were not performed in accordance with their
specific terms. It is accordingly agreed that the parties shall be entitled
to
an injunction or injunctions to prevent breaches of this Agreement and to
specific performance of the terms hereof, this being in addition to any other
remedy to which they are entitled at law or in equity.
ARTICLE
X
DEFINITIONS
As
used
in this Agreement terms not otherwise defined herein:
(a) “8%
Convertible Notes”
means
the unsecured notes to be issued to certain noteholders of Company as Note
Consideration in accordance with the Note Exchange Agreement which shall
mature
twenty four (24) months from the Effective Time, accrue interest at 8.00%
per
annum, and be convertible into shares of Parent Common Stock at $10.00 per
share
and be in substantially the form of Exhibit A attached hereto.
(b) “Adverse
Consequences”
means
all actions, suits, proceedings, hearings, investigations, charges, complaints,
claims, demands, injunctions, judgments, orders, decrees, rulings, damages,
dues, penalties, fines, costs, amounts paid in settlement, Liabilities,
obligations, Taxes, Liens, losses, expenses, and fees, including court costs
and
attorneys’ fees and expenses.
(c) “Alternative
Transaction”
means
any of the following events: (i) any tender or exchange offer, merger,
consolidation, share exchange, business combination, reorganization,
recapitalization, liquidation, dissolution or other similar transaction
involving Company (any of the above, a “Business
Combination Transaction”),
with
any Person other than Parent, Merger Sub or any affiliate (as such term is
defined in Rule 12b-2 promulgated under the Exchange Act) thereof (a
“Third
Party”)
or
(ii) the acquisition by a Third Party of 10% or more of the outstanding shares
of Company Common Stock, or of 10% or more of the assets or operations of
Company, taken as a whole, in a single transaction or a series of related
transactions, provided,
however,
that
the following shall not be deemed Alternative Transactions: (x) the issuance
by
the Company of equity securities valued in the aggregate at no more than
$5
million (subject to the limitation that the securities of the Company issued
to
the purchasers thereof will not convert into more than 625,000 shares of
Parent
Common Stock in the Merger); and, (y) licensing transactions or other strategic
alliances.
(d) “Board
of Directors”
means
the Board of Directors of any specified Person and any committees
thereof.
(e) “Business
Day”
means
any day on which banks are not required or authorized to close in the City
of
New York.
(f) “Code”
mans the U.S. Internal Revenue Code of 1986, as amended.
(g) “good
standing”
means,
when used with respect to the status of any entity domiciled or doing business
in a particular state, that such entity has filed its most recent required
annual report and (i) if a domestic entity, has not filed articles of
dissolution, and (ii) if a foreign entity, has not applied for a certificate
of
withdrawal and is not the subject of a proceeding to revoke its certificate
of
authority.
(h) “Indemnifying
Stockholders”
means
those holders of Company Capital Stock and outstanding Company Options and
Company Warrants.
(i) “Knowledge”
or
any
phrase of similar import shall mean the actual knowledge after reasonable
investigation of any person holding the office or position, or fulfilling
the
function of a director or officer of Company.
(j) “Liability”
means
any liability (whether known or unknown, whether asserted or unasserted,
whether
absolute or contingent, whether accrued or unaccrued, whether liquidated
or
unliquidated, and whether due or to become due), including any liability
for
Taxes.
(k) “Liens”
means any
mortgage, deed of trust, security interest, pledge, lien, or other charge
or
encumbrance of any nature whatsoever except: (a) liens disclosed in the Company
Financial Statements; (b) liens for taxes, assessments, or governmental charges
or levies not yet due and delinquent; and (c) liens consisting of zoning
or
planning restrictions, easements, permits, any other restrictions or limitations
on the use of real property or irregularities in title thereto which do not
materially detract from the value of, or impair the use of, such property
by
Company, Parent or any of their respective subsidiaries).
(l) “Material
Adverse Effect”
with
respect to a party shall mean any change, effect, event, occurrence or state
of
facts which is, or is reasonably expected to be, materially adverse to the
business, financial condition, results of operations or prospects of such
party
and its subsidiaries, taken as a whole, other than any change, effect, event
or
occurrence relating to (i) the economy or securities markets of the United
States or any other region in general or (ii) this Agreement or the transactions
contemplated hereby or the announcement thereof or otherwise as contemplated
by
this Agreement or disclosed hereunder.
(m) “Milestone
Payment” means
payments made to the stockholders of Company as part of the Merger Consideration
equal to 10% of the actual collections on gross sales of Valortim to the
United
States federal government (or a department thereof) until the earlier of
(A)
December 31, 2009, or (B) total aggregate milestone payments to the Stockholders
equal $10 million. These payments shall be conditioned upon receipt by Company
of an award, procurement or other contract (x) on or before December 31,
2007;
(y) which provides for a procurement by the U.S. government (or a department
thereof) of doses or treatments equal to or greater than 60,000; and (z)
with a
total contract value of $150 million or more, and otherwise no Milestone
Payments shall be paid or due. Any Milestone Payments owed shall be determined,
in arrears, by Parent within forty-five (45) days of the end of each fiscal
quarter based on actual collections from the U.S. government (or a department
thereof) of gross sales, and shall be paid within three (3) business days
of
such determination. Subject to the limitations set forth above, the Stockholders
shall be entitled to Milestone Payments related to collections prior to and
including December 31, 2009.
(n) “Note
Conversion Shares” means
the
shares of Parent Common Stock issuable upon conversion of the 8% Convertible
Notes.
(o) “the
other party”
means,
with respect to Company, Parent and means, with respect to Parent,
Company
(p) “PA
Management Team”
means
and refers to those persons identified on Schedule X(o).
(q) “Parent
Representative” means
John Pappajohn.
(r) “Permitted
Liens”
means
(i) any liens for Taxes not yet due or which are being contested in good
faith
by appropriate proceedings; (ii) carriers’, warehousemen’s, mechanics’,
materialmen’s, repairmen’s or other similar liens; (iii) pledges or deposits in
connection with workers’ compensation, unemployment insurance, and other social
security legislation; and (iv) easements, rights-of-way, restrictions and
other
similar encumbrances incurred in the ordinary course of business which, in
the
aggregate, are not substantial in amount and which do not in any case materially
detract from the value of the property subject thereto.
(s) “Requisite
Majority”
means
(i) with respect to the Company Common Stock, the vote of the holders of
80% of
the issued and outstanding shares of Common Stock and (ii) with respect to
the
Company Preferred Stock, the vote of holders of at least 66.66% of each
outstanding series acting separately.
(t) “SEC”
means
the Securities and Exchange Commission.
(u) “Valortim”
means a high affinity, fully
human monoclonal antibody to bacillus
anthracis
protective antigen (PA) which fights the invading organism. It is designed
to
target and bind to PA cells and protect healthy human cells from infiltration
by
the certain toxins produced by the anthrax bacteria.
IN
WITNESS WHEREOF, Parent, Merger Sub and Company have caused this Agreement
to be
signed by their respective officers thereunto duly authorized, all as of
the
date first written above.
|
HEALTHCARE
ACQUISITION CORP.
|
|
|
|
|
By:
|
/s/
John Pappajohn |
|
Name:
|
John
Pappajohn |
|
Title:
|
Chairman |
|
|
|
|
PAI
ACQUISITION CORP.
|
|
|
|
|
By:
|
/s/
John Pappajohn |
|
Name:
|
John
Pappajohn |
|
Title:
|
Chairman |
|
|
|
|
PHARMATHENE,
INC.
|
|
|
|
|
By:
|
/s/
David P. Wright |
|
|
Name:
David P. Wright
|
|
|
Title:
President and Chief Executive Officer
|
|
|
|
Soley
as to Article VIII and Article IX:
|
|
|
|
|
John
Pappajohn, as Parent Representative
|
|
|
|
/s/
John Pappajohn |
|
|
|
|
Soley
as to Article VIII and Article IX:
|
|
|
|
|
MPM
BioVentures III-QP, L.P., as Stockholder
Representative
|
|
|
|
|
By:
|
/s/
Ansbert Gadicke |
|
Name:
|
Ansbert
Gadicke |
|
Title:
|
Stockholder
Representative |
ANNEX
B
AMENDED
AND RESTATED
CERTIFICATE
OF INCORPORATION
OF
HEALTHCARE
ACQUISITION CORP.
ADOPTED
IN ACCORDANCE WITH SECTION 242 AND 245
OF
THE DELAWARE GENERAL CORPORATION LAW
*
* * * *
* * * * * * * * * *
Healthcare
Acquisition Corp., a Delaware corporation (the “Corporation”) does hereby
certify that:
FIRST:
The name of the corporation is Healthcare Acquisition Corp. The date of
filing
of the original Certificate of Incorporation with the Delaware Secretary
of
State was April 25, 2005; an Amended and Restated Certificate of Incorporation
with the Delaware Secretary of State was filed on April 28, 2005; a further
Amended and Restated Certificate of Incorporation with the Delaware Secretary
of
State was filed on July 26, 2005. The name under which the Corporation
was
originally incorporated was Healthcare Acquisition Corp.
SECOND:
This Amended and Restated Certificate of Incorporation (the “Certificate”)
amends, restates and integrates the provisions of the Amended and Restated
Certificate of Incorporation of the Corporation and has been duly adopted
in
accordance with the provisions of Section 242 and 245 of the General Corporation
Law of the State of Delaware (the “GCL”) in a special meeting of the holders of
the outstanding stock entitled to vote thereon in accordance with the provisions
of Section 228 of the GCL.
THIRD:
This Certificate shall become effective immediately upon its filing with
the
Secretary of State of the State of Delaware.
FOURTH:
Upon the filing with the Secretary of State of the State of Delaware of
this
Certificate, the Certificate of Incorporation shall be amended and restated
in
its entirety to be and read as set forth on Exhibit A attached
hereto.
IN
WITNESS WHEREOF, the Corporation has caused this Certificate to be executed
by a
duly authorized officer __________, 2007.
|
HEALTHCARE
ACQUISITION CORP.
|
|
|
|
By:
/s/
Matthew P. Kinley
|
|
Name: Matthew P. Kinley
|
|
Title: President
|
EXHIBIT
A
AMENDED
AND RESTATED
CERTIFICATE
OF INCORPORATION
OF
PHARMATHENE,
INC.
FIRST:
The name of the corporation is PharmAthene, Inc. (hereinafter sometimes referred
to as the “Corporation”).
SECOND:
The address of the Corporation’s registered office in the State of Delaware is
National Registered Agents, Inc., 160 Greentree Drive, Suite 101, Dover,
Delaware 19904, County of Kent. The name of the Corporation’s registered agent
at such address is National Registered Agents, Inc.
THIRD:
The purpose of the Corporation shall be to engage in any lawful act or activity
for which corporations may be organized under the General Corporation Law
(“GCL”).
FOURTH:
The total number of shares of all classes of capital stock which the Corporation
shall have authority to issue is 101,000,000 of which 100,000,000 shares
shall
be Common Stock of the par value of $.0001 per share and 1,000,000 shares
shall
be Preferred Stock of the par value of $.0001 per share.
A.
Preferred Stock. The Board of Directors is expressly granted authority to
issue
shares of the Preferred Stock, in one or more series, and to fix for each
such
series such voting powers, full or limited, and such designations, preferences
and relative, participating, optional or other special rights and such
qualifications, limitations or restrictions thereof as shall be stated and
expressed in the resolution or resolutions adopted by the Board of Directors
providing for the issue of such series (a “Preferred Stock Designation”) and as
may be permitted by the GCL. The number of authorized shares of Preferred
Stock
may be increased or decreased (but not below the number of shares thereof
then
outstanding) by the affirmative vote of the holders of a majority of the
voting
power of all of the then outstanding shares of the capital stock of the
Corporation entitled to vote generally in the election of directors, voting
together as a single class, without a separate vote of the holders of the
Preferred Stock, or any series thereof, unless a vote of any such holders
is
required pursuant to any Preferred Stock Designation.
B.
Common
Stock. Except as otherwise required by law or as otherwise provided in any
Preferred Stock Designation, the holders of the Common Stock shall exclusively
possess all voting power and each share of Common Stock shall have one
vote.
FIFTH:
The name and mailing address of the sole incorporator of the Corporation
are as
follows:
Address: |
c/o Equity Dynamics, Inc.
|
2116 Financial Center
Des Moines, Iowa, 50309
SIXTH:
For so long as at least 30% of the aggregate principal amount of the 8%
convertible notes (the “Notes”) issued on ____________,
2007
in the original aggregate principal amount of $12,500,000) remains
outstanding (and notwithstanding the existence of less than three (3) note
holders at any given time), the following provisions shall apply:
A.
the
Corporation shall maintain a Board of Directors consisting of no more than
seven
(7) individuals and the Compensation Committee and Nominating Committee (or
other committees serving similar functions) all shall have no more than three
(3) members;
B.
three (3) members of the Corporation’s Board of Directors (the “Noteholder
Directors”) shall be elected by the holders of Notes representing two-thirds of
the then outstanding principal amount of all Notes, voting as a separate
class;
C.
two
(2) Noteholder Directors (in each case chosen by a majority vote of all the
Noteholder Directors) shall have the right, but not the obligation,
to serve as members of each of the committees of the Corporation’s
Board of Directors;
D.
The
Board of Directors of the Corporation shall nominate as Noteholder
Directors only the persons designated as director pursuant to the Note Exchange
Agreement, dated _________, 2007, by and among the Corporation and the holders
of the Notes and recommend that the holders vote to elect
such nominees as directors of the Corporation and shall fill any vacancies
that may arise upon the resignation of any of the Noteholder Directors with
a
new Noteholder Director designated in accordance with the foregoing. A
Noteholder Director elected to fill a vacancy resulting from the death,
resignation or removal of a Noteholder Director shall serve for the remainder
of
the full term of the Noteholder Director whose death, resignation or removal
shall have created such vacancy and until his successor shall have been elected
and qualified; and
E.
The
provisions contained in this Article Sixth shall terminate immediately
and without further action when less than 30% of the aggregate principal
original amount of the Notes as of the date of this Amendment remains
outstanding.
SEVENTH:
The following provisions are inserted for the management of the business
and for
the conduct of the affairs of the Corporation, and for further definition,
limitation and regulation of the powers of the Corporation and of its directors
and stockholders:
A.
Election of directors need not be by ballot unless the by-laws of the
Corporation so provide.
B.
The
Board of Directors shall have the power, without the assent or vote of the
stockholders, to make, alter, amend, change, add to or repeal the by-laws
of the
Corporation as provided in the by-laws of the Corporation.
C.
The
directors in their discretion may submit any contract or act for approval
or
ratification at any annual meeting of the stockholders or at any meeting
of the
stockholders called for the purpose of considering any such act or contract,
and
any contract or act that shall be approved or be ratified by the vote of
the
holders of a majority of the stock of the Corporation which is represented
in
person or by proxy at such meeting and entitled to vote thereat (provided
that a
lawful quorum of stockholders be there represented in person or by proxy)
shall
be as valid and binding upon the Corporation and upon all the stockholders
as
though it had been approved or ratified by every stockholder of the Corporation,
whether or not the contract or act would otherwise be open to legal attack
because of directors’ interests, or for any other reason.
D.
In
addition to the powers and authorities hereinbefore or by statute expressly
conferred upon them, the directors are hereby empowered to exercise all such
powers and do all such acts and things as may be exercised or done by the
Corporation; subject, nevertheless, to the provisions of the statutes of
Delaware, of this Certificate of Incorporation, and to any by-laws from time
to
time made by the stockholders; provided, however, that no by-law so made
shall
invalidate any prior act of the directors which would have been valid if
such
by-law had not been made.
EIGHTH:
A. A director of the Corporation shall not be personally liable to the
Corporation or its stockholders for monetary damages for any breach of fiduciary
duty by such director as a director, except for liability (i) for any breach
of
the director’s duty of loyalty to the Corporation or its stockholders, (ii) for
acts or omissions not in good faith or which involve intentional misconduct
or a
knowing violation of law, (iii) under Section 174 of the GCL, or (iv) for
any
transaction from which the director derived an improper personal benefit.
If the
GCL is amended to authorize corporate action further eliminating or limiting
the
personal liability of directors, then the liability of a director of the
Corporation shall be eliminated or limited to the fullest extent permitted
by
the GCL, as so amended. Any repeal or modification of this paragraph A by
the
stockholders of the Corporation shall not adversely affect any right or
protection of a director of the Corporation with respect to events occurring
prior to the time of such repeal or modification.
B.
The
Corporation, to the full extent permitted by Section 145 of the GCL, as amended
from time to time, shall indemnify all persons whom it may indemnify pursuant
thereto. Expenses (including attorneys’ fees) incurred by an officer or director
in defending any civil, criminal, administrative, or investigative action,
suit
or proceeding for which such officer or director may be entitled to
indemnification hereunder shall be paid by the Corporation in advance of
the
final disposition of such action, suit or proceeding upon receipt of an
undertaking by or on behalf of such director or officer to repay such amount
if
it shall ultimately be determined that he is not entitled to be indemnified
by
the Corporation as authorized hereby.
NINTH:
Whenever a compromise or arrangement is proposed between this Corporation
and
its creditors or any class of them and/or between this Corporation and its
stockholders or any class of them, any court of equitable jurisdiction within
the State of Delaware may, on the application in a summary way of this
Corporation or of any creditor or stockholder thereof or on the application
of
any receiver or receivers appointed for this Corporation under Section 291
of
Title 8 of the Delaware Code or on the application of trustees in dissolution
or
of any receiver or receivers appointed for this Corporation under Section
279 of
Title 8 of the Delaware Code order a meeting of the creditors or class of
creditors, and/or of the stockholders or class of stockholders of this
Corporation, as the case may be, to be summoned in such manner as the said
court
directs. If a majority in number representing three fourths in value of the
creditors or class of creditors, and/or of the stockholders or class of
stockholders of this Corporation, as the case may be, agree to any compromise
or
arrangement and to any reorganization of this Corporation as a consequence
of
such compromise or arrangement, the said compromise or arrangement and the
said
reorganization shall, if sanctioned by the court to which the said application
has been made, be binding on all the creditors or class of creditors, and/or
on
all the stockholders or class of stockholders, of this Corporation, as the
case
may be, and also on this Corporation.
TENTH:
The Corporation hereby elects not to be governed by Section 203 of the
GCL.
ANNEX
C
HEALTHCARE
ACQUISITION CORP.
2007
LONG-TERM INCENTIVE COMPENSATION PLAN
ARTICLE
I
PURPOSE
Section
1.1 Purpose.
This
2007 Long-Term Incentive Compensation Plan (the “Plan”) is established by
Healthcare Acquisition Corp., a Delaware corporation (the “Company”), to create
incentives which are designed to motivate Participants to put forth maximum
effort toward the success and growth of the Company and to enable the Company
to
attract and retain experienced individuals who by their position, ability
and
diligence are able to make important contributions to the Company’s success.
Toward these objectives, the Plan provides for the grant of Options, Restricted
Stock Awards, Stock Appreciation Rights (“SARs”), Performance Units and
Performance Bonuses to Eligible Employees and the grant of Nonqualified
Stock
Options, Restricted Stock Awards, SARs and Performance Units to Consultants
and
Eligible Directors, subject to the conditions set forth in the
Plan.
Section
1.2 Establishment.
The Plan
is effective as of [___________], 2007 and for a period of ten years thereafter.
The Plan shall continue in effect until all matters relating to the payment
of
Awards and administration of the Plan have been settled. The Plan is subject
to
approval by the Company’s stockholders in accordance with applicable law which
approval must occur within the period ending twelve months after the date
the
Plan is adopted by the Board. Pending such approval by the stockholders,
Awards
under the Plan may be granted, but no such Awards may be exercised prior
to
receipt of stockholder approval. In the event stockholder approval is not
obtained within a twelve-month period, all Awards granted shall be
void.
Section
1.3 Shares Subject to the Plan.
Subject
to the limitations set forth in the Plan, Awards may be made under this
Plan for
a total of 3,500,000 shares of the Company’s common stock, par value $.0001 per
share (the “Common Stock”).
ARTICLE
II
DEFINITIONS
Section
2.1 “Account”
means
the recordkeeping account established by the Company to which will be credited
an Award of Performance Units to a Participant.
Section
2.2 “Affiliated Entity”
means
any corporation, partnership, limited liability company or other form of
legal
entity in which a majority of the partnership or other similar interest
thereof
is owned or controlled, directly or indirectly, by the Company or one or
more of
its Subsidiaries or Affiliated Entities or a combination thereof. For purposes
hereof, the Company, a Subsidiary or an Affiliated Entity shall be deemed
to
have a majority ownership interest in a partnership or limited liability
company
if the Company, such Subsidiary or Affiliated Entity shall be allocated
a
majority of partnership or limited liability company gains or losses or
shall be
or control a managing director or a general partner of such partnership
or
limited liability company.
Section
2.3 “Award”
means,
individually or collectively, any Option, Restricted Stock Award, SAR,
Performance Unit or Performance Bonus granted under the Plan to an Eligible
Employee by the Board or any Nonqualified Stock Option, Performance Unit
SAR or
Restricted Stock Award granted under the Plan to a Consultant or an Eligible
Director by the Board pursuant to such terms, conditions, restrictions,
and/or
limitations, if any, as the Board may establish by the Award Agreement
or
otherwise.
Section
2.4 “Award Agreement”
means
any written instrument that establishes the terms, conditions, restrictions,
and/or limitations applicable to an Award in addition to those established
by
this Plan and by the Board’s exercise of its administrative powers.
Section
2.5 “Board”
means
the Board of Directors of the Company and, if the Board has appointed a
Committee as provided in Section 3.1, the term “Board” shall include such
Committee.
Section
2.6 “Change of Control Event” means
each of the following:
(i)
Any
transaction in which shares of voting securities of the Company representing
more than 50% of the total combined voting power of all outstanding voting
securities of the Company are issued by the Company, or sold or transferred
by
the stockholders of the Company as a result of which those persons and
entities
who beneficially owned voting securities of the Company representing more
than
50% of the total combined voting power of all outstanding voting securities
of
the Company immediately prior to such transaction cease to beneficially
own
voting securities of the Company representing more than 50% of the total
combined voting power of all outstanding voting securities of the Company
immediately after such transaction;
(ii)
The
merger or consolidation of the Company with or into another entity as a
result
of which those persons and entities who beneficially owned voting securities
of
the Company representing more than 50% of the total combined voting power
of all
outstanding voting securities of the Company immediately prior to such
merger or
consolidation cease to beneficially own voting securities of the Company
representing more than 50% of the total combined voting power of all outstanding
voting securities of the surviving corporation or resulting entity immediately
after such merger of consolidation; or
(iii)
The
sale of all or substantially all of the Company’s assets to an entity of which
those persons and entities who beneficially owned voting securities of
the
Company representing more than 50% of the total combined voting power of
all
outstanding voting securities of the Company immediately prior to such
asset
sale do not beneficially own voting securities of the purchasing entity
representing more than 50% of the total combined voting power of all outstanding
voting securities of the purchasing entity immediately after such asset
sale.
Section
2.7 “Code”
means
the Internal Revenue Code of 1986, as amended. References in the Plan to
any
section of the Code shall be deemed to include any amendments or successor
provisions to such section and any regulations under such section.
Section
2.8 “Committee”
means
the Committee appointed by the Board as provided in Section 3.1.
Section
2.9 “Common Stock”
means
the common stock, par value $.0001 per share, of the Company, and after
substitution, such other stock as shall be substituted therefore as provided
in
Article X.
Section
2.10 “Consultant”
means
any person who is engaged by the Company, a Subsidiary or an Affiliated
Entity
to render consulting or advisory services.
Section
2.11 “Date of Grant”
means
the date on which the grant of an Award is authorized by the Board or such
later
date as may be specified by the Board in such authorization.
Section
2.12 “Disability”
means
the Participant is unable to continue employment by reason of any medically
determinable physical or mental impairment which can be expected to result
in
death or can be expected to last for a continuous period of not less than
12
months. For purposes of this Plan, the determination of Disability shall
be made
in the sole and absolute discretion of the Board.
Section
2.13 “Eligible Employee”
means
any employee of the Company, a Subsidiary, or an Affiliated Entity as approved
by the Board.
Section
2.14 “Eligible Director”
means
any member of the Board who is not an employee of the Company, a Subsidiary
or
an Affiliated Entity.
Section
2.15 “Exchange Act”
means
the Securities Exchange Act of 1934, as amended.
Section
2.16 “Fair Market Value”
means
(A) during such time as the Common Stock is registered under Section 12
of the
Exchange Act, the closing price of the Common Stock as reported by an
established stock exchange or automated quotation system on the day for
which
such value is to be determined, or, if no sale of the Common Stock shall
have
been made on any such stock exchange or automated quotation system that
day, on
the next preceding day on which there was a sale of such Common Stock,
or (B)
during any such time as the Common Stock is not listed upon an established
stock
exchange or automated quotation system, the mean between dealer “bid” and “ask”
prices of the Common Stock in the over-the-counter market on the day for
which
such value is to be determined, as reported by the National Association
of
Securities Dealers, Inc., or (C) during any such time as the Common Stock
cannot
be valued pursuant to (A) or (B) above, the fair market value shall be
as
determined by the Board considering all relevant information including,
by
example and not by limitation, the services of an independent
appraiser.
Section
2.17 “Incentive Stock Option”
means an
Option within the meaning of Section 422 of the Code.
Section
2.18 “Nonqualified Stock Option”
means an
Option which is not an Incentive Stock Option.
Section
2.19 “Option”
means an
Award granted under Article V of the Plan and includes both Nonqualified
Stock
Options and Incentive Stock Options to purchase shares of Common
Stock.
Section
2.20 “Participant”
means an
Eligible Employee, a Consultant or an Eligible Director to whom an Award
has
been granted by the Board under the Plan.
Section
2.21 “Performance Bonus”
means
the cash bonus which may be granted to Eligible Employees under Article
IX of
the Plan.
Section
2.22 “Performance Units”
means
those monetary units that may be granted to Eligible Employees, Consultants
or
Eligible Directors pursuant to Article VIII hereof.
Section
2.23 “Plan”
means
this Healthcare Acquisition Corp. 2007 Long-Term Incentive Compensation
Plan.
Section
2.24 “Restricted Stock Award”
means an
Award granted to an Eligible Employee, Consultant or Eligible Director
under
Article VI of the Plan.
Section
2.25 “Retirement”
means
the termination of an Eligible Employee’s employment with the Company, a
Subsidiary or an Affiliated Entity on or after attaining age __.
Section
2.26 “SAR”
means a
stock appreciation right granted to an Eligible Employee, Consultant or
Eligible
Director under Article VII of the Plan.
Section
2.27 “Subsidiary”
shall
have the same meaning set forth in Section 424 of the Code.
ARTICLE
III
ADMINISTRATION
Section
3.1 Administration of the Plan by the Board.
The
Board shall administer the Plan. The Board may, by resolution, appoint
the
Compensation Committee to administer the Plan and delegate its powers described
under this Section 3.1 and otherwise under the Plan for purposes of Awards
granted to Eligible Employees and Consultants.
Subject
to the provisions of the Plan, the Board shall have exclusive power
to:
(a)
Select Eligible Employees and Consultants to participate in the
Plan.
(b)
Determine the time or times when Awards will be made to Eligible Employees
or
Consultants.
(c)
Determine the form of an Award, whether an Incentive Stock Option, Nonqualified
Stock Option, Restricted Stock Award, SAR, Performance Unit, or Performance
Bonus, the number of shares of Common Stock or Performance Units subject
to the
Award, the amount and all the terms, conditions (including performance
requirements), restrictions and/or limitations, if any, of an Award, including
the time and conditions of exercise or vesting, and the terms of any Award
Agreement, which may include the waiver or amendment of prior terms and
conditions or acceleration or early vesting or payment of an Award under
certain
circumstances determined by the Board.
(d)
Determine whether Awards will be granted singly or in combination.
(e)
Accelerate the vesting, exercise or payment of an Award or the performance
period of an Award.
(f)
Determine whether and to what extent a Performance Bonus may be deferred,
either
automatically or at the election of the Participant or the Board.
(g)
Take
any and all other action it deems necessary or advisable for the proper
operation or administration of the Plan.
Section
3.2 Administration of Grants to Eligible Directors.
The
Board shall have the exclusive power to select Eligible Directors to participate
in the Plan and to determine the number of Nonqualified Stock Options,
Performance Units, SARs or shares of Restricted Stock awarded to Eligible
Directors selected for participation. If the Board appoints a committee
to
administer the Plan, it may delegate to the committee administration of
all
other aspects of the Awards made to Eligible Directors.
Section
3.3 Board to Make Rules and Interpret Plan.
The
Board in its sole discretion shall have the authority, subject to the provisions
of the Plan, to establish, adopt, or revise such rules and regulations
and to
make all such determinations relating to the Plan, as it may deem necessary
or
advisable for the administration of the Plan. The Board’s interpretation of the
Plan or any Awards and all decisions and determinations by the Board with
respect to the Plan shall be final, binding, and conclusive on all
parties.
Section
3.4 Section 162(m) Provisions.
The
Company intends for the Plan and the Awards made there under to qualify
for the
exception from Section 162(m) of the Code for “qualified performance based
compensation” if it is determined by the Board that such qualification is
necessary for an Award. Accordingly, the Board shall make determinations
as to
performance targets and all other applicable provisions of the Plan as
necessary
in order for the Plan and Awards made there under to satisfy the requirements
of
Section 162(m) of the Code.
ARTICLE
IV
GRANT
OF AWARDS
Section
4.1 Grant of Awards.
Awards
granted under this Plan shall be subject to the following
conditions:
(a)
Any
shares of Common Stock related to Awards which terminate by expiration,
forfeiture, cancellation or otherwise without the issuance of shares of
Common
Stock or are exchanged in the Board’s discretion for Awards not involving Common
Stock, shall be available again for grant under the Plan and shall not
be
counted against the shares authorized under Section 1.3.
(b)
Common Stock delivered by the Company in payment of an Award authorized
under
Articles V and VI of the Plan may be authorized and unissued Common Stock
or
Common Stock held in the treasury of the Company.
(c)
The
Board shall, in its sole discretion, determine the manner in which fractional
shares arising under this Plan shall be treated.
(d)
Separate certificates or a book-entry registration representing Common
Stock
shall be delivered to a Participant upon the exercise of any
Option.
(e)
The
Board shall be prohibited from canceling, reissuing or modifying Awards
if such
action will have the effect of repricing the Participant’s Award.
(f)
Eligible Directors may only be granted Nonqualified Stock Options, Restricted
Stock Awards, SARs or Performance Units under this Plan.
(g)
The
maximum term of any Award shall be ten years.
ARTICLE
V
STOCK
OPTIONS
Section
5.1 Grant of Options.
The
Board may, from time to time, subject to the provisions of the Plan and
such
other terms and conditions as it may determine, grant Options to Eligible
Employees. These Options may be Incentive Stock Options or Nonqualified
Stock
Options, or a combination of both. The Board may, subject to the provisions
of
the Plan and such other terms and conditions as it may determine, grant
Nonqualified Stock Options to Eligible Directors and Consultants. Each
grant of
an Option shall be evidenced by an Award Agreement executed by the Company
and
the Participant, and shall contain such terms and conditions and be in
such form
as the Board may from time to time approve, subject to the requirements
of
Section 5.2.
Section
5.2 Conditions of Options.
Each
Option so granted shall be subject to the following conditions:
(a)
Exercise Price. As limited by Section 5.2(e) below, each Option shall state
the
exercise price which shall be set by the Board at the Date of Grant; provided,
however, no Option shall be granted at an exercise price which is less
than the
Fair Market Value of the Common Stock on the Date of Grant.
(b)
Form
of Payment. The exercise price of an Option may be paid (i) in cash or
by check,
bank draft or money order payable to the order of the Company; (ii) by
delivering shares of Common Stock having a Fair Market Value on the date
of
payment equal to the amount of the exercise price, but only to the extent
such
exercise of an Option would not result in an adverse accounting charge
to the
Company for financial accounting purposes with respect to the shares used
to pay
the exercise price unless otherwise determined by the Board; or (iii) a
combination of the foregoing. In addition to the foregoing, the Board may
permit
an Option granted under the Plan to be exercised by a broker-dealer acting
on
behalf of a Participant through procedures approved by the Board.
(c)
Exercise of Options. Options granted under the Plan shall be exercisable,
in
whole or in such installments and at such times, and shall expire at such
time,
as shall be provided by the Board in the Award Agreement. Exercise of an
Option
shall be by written notice to the Secretary of the Company at least two
business
days in advance of such exercise stating the election to exercise in the
form
and manner determined by the Board. Every share of Common Stock acquired
through
the exercise of an Option shall be deemed to be fully paid at the time
of
exercise and payment of the exercise price.
(d)
Other
Terms and Conditions. Among other conditions that may be imposed by the
Board,
if deemed appropriate, are those relating to (i) the period or periods
and the
conditions of exercisability of any Option; (ii) the minimum periods during
which Participants must be employed by the Company, its Subsidiaries, or
an
Affiliated Entity, or must hold Options before they may be exercised; (iii)
the
minimum periods during which shares acquired upon exercise must be held
before
sale or transfer shall be permitted; (iv) conditions under which such Options
or
shares may be subject to forfeiture; (v) the frequency of exercise or the
minimum or maximum number of shares that may be acquired at any one time;
(vi)
the achievement by the Company of specified performance criteria; and (vii)
non-compete and protection of business matters.
(e)
Special Restrictions Relating to Incentive Stock Options. Options issued
in the
form of Incentive Stock Options shall only be granted to Eligible Employees
of
the Company or a Subsidiary, and not to Eligible Employees of an Affiliated
Entity unless such entity shall be considered as a “disregarded entity” under
the Code and shall not be distinguished for federal tax purposes from the
Company or the applicable Subsidiary.
(f)
Application of Funds. The proceeds received by the Company from the sale
of
Common Stock pursuant to Options will be used for general corporate
purposes.
(g)
Stockholder Rights. No Participant shall have a right as a stockholder
with
respect to any share of Common Stock subject to an Option prior to purchase
of
such shares of Common Stock by exercise of the Option.
ARTICLE
VI
RESTRICTED
STOCK AWARDS
Section
6.1 Grant of Restricted Stock Awards.
The
Board may, from time to time, subject to the provisions of the Plan and
such
other terms and conditions as it may determine, grant a Restricted Stock
Award
to Eligible Employees, Consultants or Eligible Directors. Restricted Stock
Awards shall be awarded in such number and at such times during the term
of the
Plan as the Board shall determine. Each Restricted Stock Award shall be
subject
to an Award Agreement setting forth the terms of such Restricted Stock
Award and
may be evidenced in such manner as the Board deems appropriate, including,
without limitation, a book-entry registration or issuance of a stock certificate
or certificates.
Section
6.2 Conditions of Restricted Stock Awards.
The
grant of a Restricted Stock Award shall be subject to the
following:
(a)
Restriction Period. Restricted Stock Awards granted to an Eligible Employee
shall require the holder to remain in the employment of the Company, a
Subsidiary, or an Affiliated Entity for a prescribed period. Restricted
Stock
Awards granted to Consultants or Eligible Directors shall require the holder
to
provide continued services to the Company for a period of time. These employment
and service requirements are collectively referred to as a “Restriction Period”.
The Board or the Committee, as the case may be, shall determine the Restriction
Period or Periods which shall apply to the shares of Common Stock covered
by
each Restricted Stock Award or portion thereof. In addition to any time
vesting
conditions determined by the Board or the Committee, as the case may be,
Restricted Stock Awards may be subject to the achievement by the Company
of
specified performance criteria based upon the Company’s achievement of all or
any of the operational, financial or stock performance criteria set forth
on
Exhibit A annexed hereto, as may from time to time be established by the
Board
or the Committee, as the case may be. At the end of the Restriction Period,
assuming the fulfillment of any other specified vesting conditions, the
restrictions imposed by the Board or the Committee, as the case may be
shall
lapse with respect to the shares of Common Stock covered by the Restricted
Stock
Award or portion thereof. In addition to acceleration of vesting upon the
occurrence of a Change of Control Event as provided in Section 11.5, the
Board
or the Committee, as the case may be, may, in its discretion, accelerate
the
vesting of a Restricted Stock Award in the case of the death, Disability
or
Retirement of the Participant who is an Eligible Employee or resignation
of a
Participant who is a Consultants or an Eligible Director.
(b)
Restrictions. The holder of a Restricted Stock Award may not sell, transfer,
pledge, exchange, hypothecate, or otherwise dispose of the shares of Common
Stock represented by the Restricted Stock Award during the applicable
Restriction Period. The Board shall impose such other restrictions and
conditions on any shares of Common Stock covered by a Restricted Stock
Award as
it may deem advisable including, without limitation, restrictions under
applicable Federal or state securities laws, and may legend the certificates
representing Restricted Stock to give appropriate notice of such
restrictions.
(c)
Rights as Stockholders. During any Restriction Period, the Board may, in
its
discretion, grant to the holder of a Restricted Stock Award all or any
of the
rights of a stockholder with respect to the shares, including, but not
by way of
limitation, the right to vote such shares and to receive dividends. If
any
dividends or other distributions are paid in shares of Common Stock, all
such
shares shall be subject to the same restrictions on transferability as
the
shares of Restricted Stock with respect to which they were paid.
ARTICLE
VII
STOCK
APPRECIATION RIGHTS
Section
7.1 Grant of SARs.
The
Board may from time to time, in its sole discretion, subject to the provisions
of the Plan and subject to other terms and conditions as the Board may
determine, grant a SAR to any Eligible Employee, Consultant or Eligible
Director. SARs may be granted in tandem with an Option, in which event,
the
Participant has the right to elect to exercise either the SAR or the Option.
Upon the Participant’s election to exercise one of these Awards, the other
tandem Award is automatically terminated. SARs may also be granted as an
independent Award separate from an Option. Each grant of a SAR shall be
evidenced by an Award Agreement executed by the Company and the Participant
and
shall contain such terms and conditions and be in such form as the Board
may
from time to time approve, subject to the requirements of the Plan. The
exercise
price of the SAR shall not be less than the Fair Market Value of a share
of
Common Stock on the Date of Grant of the SAR.
Section
7.2 Exercise and Payment.
SARs
granted under the Plan shall be exercisable in whole or in installments
and at
such times as shall be provided by the Board in the Award Agreement. Exercise
of
a SAR shall be by written notice to the Secretary of the Company at least
two
business days in advance of such exercise. The amount payable with respect
to
each SAR shall be equal in value to the excess, if any, of the Fair Market
Value
of a share of Common Stock on the exercise date over the exercise price
of the
SAR. Payment of amounts attributable to a SAR shall be made in shares of
Common
Stock.
Section
7.3 Restrictions.
In the
event a SAR is granted in tandem with an Incentive Stock Option, the Board
shall
subject the SAR to restrictions necessary to ensure satisfaction of the
requirements under Section 422 of the Code. In the case of a SAR granted
in
tandem with an Incentive Stock Option to an Eligible Employee who owns
more than
10% of the combined voting power of the Company or its Subsidiaries on
the date
of such grant, the amount payable with respect to each SAR shall be equal
in
value to the applicable percentage of the excess, if any, of the Fair Market
Value of a share of Common Stock on the Exercise date over the exercise
price of
the SAR, which exercise price shall not be less than 110% of the Fair Market
Value of a share of Common Stock on the date the SAR is granted.
ARTICLE
VIII
PERFORMANCE
UNITS
Section
8.1 Grant of Awards.
The
Board may, from time to time, subject to the provisions of the Plan and
such
other terms and conditions as it may determine, grant Performance Units
to
Eligible Employees, Consultants and Eligible Directors. Each Award of
Performance Units shall be evidenced by an Award Agreement executed by
the
Company and the Participant, and shall contain such terms and conditions
and be
in such form as the Board may from time to time approve, subject to the
requirements of Section 8.2.
Section
8.2 Conditions of Awards.
Each
Award of Performance Units shall be subject to the following
conditions:
(a)
Establishment of Award Terms. Each Award shall state the target, maximum
and
minimum value of each Performance Unit payable upon the achievement of
performance goals.
(b)
Achievement of Performance Goals. The Board shall establish performance
targets
for each Award for a period of no less than a year based upon some or all
of the
operational, financial or performance criteria listed in Exhibit A attached.
The
Board shall also establish such other terms and conditions as it deems
appropriate to such Award. The Award may be paid out in cash or Common
Stock as
determined in the sole discretion of the Board.
ARTICLE
IX
PERFORMANCE
BONUS
Section
9.1 Grant of Performance Bonus.
The
Board may from time to time, subject to the provisions of the Plan and
such
other terms and conditions as the Board may determine, grant a Performance
Bonus
to certain Eligible Employees selected for participation. The Board will
determine the amount that may be earned as a Performance Bonus in any period
of
one year or more upon the achievement of a performance target established
by the
Board. The Board shall select the applicable performance target(s) for
each
period in which a Performance Bonus is awarded. The performance target
shall be
based upon all or some of the operational, financial or performance criteria
more specifically listed in Exhibit A attached.
Section
9.2 Payment of Performance Bonus.
In order
for any Participant to be entitled to payment of a Performance Bonus, the
applicable performance target(s) established by the Board must first be
obtained
or exceeded. Payment of a Performance Bonus shall be made within 60 days
of the
Board’s certification that the performance target(s) has been achieved unless
the Participant has previously elected to defer payment pursuant to a
nonqualified deferred compensation plan adopted by the Company. Payment
of a
Performance Bonus may be made in either cash or Common Stock as determined
in
the sole discretion of the Board.
ARTICLE
X
STOCK
ADJUSTMENTS
In
the
event that the shares of Common Stock, as constituted on the effective
date of
the Plan, shall be changed into or exchanged for a different number or
kind of
shares of stock or other securities of the Company or of another corporation
(whether by reason of merger, consolidation, recapitalization, reclassification,
stock split, spin-off, combination of shares or otherwise), or if the number
of
such shares of Common Stock shall be increased through the payment of a
stock
dividend, or a dividend on the shares of Common Stock, or if rights or
warrants
to purchase securities of the Company shall be issued to holders of all
outstanding Common Stock, then there shall be substituted for or added
to each
share available under and subject to the Plan, and each share theretofore
appropriated under the Plan, the number and kind of shares of stock or
other
securities into which each outstanding share of Common Stock shall be so
changed
or for which each such share shall be exchanged or to which each such share
shall be entitled, as the case may be, on a fair and equivalent basis in
accordance with the applicable provisions of Section 424 of the Code; provided,
however, with respect to Options, in no such event will such adjustment
result
in a modification of any Option as defined in Section 424(h) of the Code.
In the
event there shall be any other change in the number or kind of the outstanding
shares of Common Stock, or any stock or other securities into which the
Common
Stock shall have been changed or for which it shall have been exchanged,
then if
the Board shall, in its sole discretion, determine that such change equitably
requires an adjustment in the shares available under and subject to the
Plan, or
in any Award, theretofore granted, such adjustments shall be made in accordance
with such determination, except that no adjustment of the number of shares
of
Common Stock available under the Plan or to which any Award relates that
would
otherwise be required shall be made unless and until such adjustment either
by
itself or with other adjustments not previously made would require an increase
or decrease of at least 1% in the number of shares of Common Stock available
under the Plan or to which any Award relates immediately prior to the making
of
such adjustment (the “Minimum Adjustment”). Any adjustment representing a change
of less than such minimum amount shall be carried forward and made as soon
as
such adjustment together with other adjustments required by this Article
X and
not previously made would result in a Minimum Adjustment. Notwithstanding
the
foregoing, any adjustment required by this Article X which otherwise would
not
result in a Minimum Adjustment shall be made with respect to shares of
Common
Stock relating to any Award immediately prior to exercise, payment or settlement
of such Award. No fractional shares of Common Stock or units of other securities
shall be issued pursuant to any such adjustment, and any fractions resulting
from any such adjustment shall be eliminated in each case by rounding downward
to the nearest whole share.
ARTICLE
XI
GENERAL
Section
11.1 Amendment or Termination of Plan.
The
Board may alter, suspend or terminate the Plan at any time provided, however,
that it may not, without stockholder approval, adopt any amendment which
would
(i) increase the aggregate number of shares of Common Stock available under
the
Plan (except by operation of Article X), (ii) materially modify the requirements
as to eligibility for participation in the Plan, or (iii) materially increase
the benefits to Participants provided by the Plan.
Section
11.2 Termination of Employment; Termination of Service.
If an
Eligible Employee’s employment with the Company, a Subsidiary or an Affiliated
Entity terminates as a result of death, Disability or Retirement, the Eligible
Employee (or personal representative in the case of death) shall be entitled
to
purchase all or any part of the shares subject to any (i) vested Incentive
Stock
Option for a period of up to three months from such date of termination
(one
year in the case of death or Disability (as defined above) in lieu of the
three-month period), and (ii) vested Nonqualified Stock Option during the
remaining term of the Option. If an Eligible Employee’s employment terminates
for any other reason, the Eligible Employee shall be entitled to purchase
all or
any part of the shares subject to any vested Option for a period of up
to three
months from such date of termination. In no event shall any Option be
exercisable past the term of the Option. The Board may, in its sole discretion,
accelerate the vesting of unvested Options in the event of termination
of
employment of any Participant.
In
the
event a Consultant ceases to provide services to the Company or an Eligible
Director terminates service as a director of the Company, the unvested
portion
of any Award shall be forfeited unless otherwise accelerated pursuant to
the
terms of the Eligible Director’s Award Agreement or by the Board. The Consultant
or Eligible Director shall have a period of three years following the date
he
ceases to provide consulting services or ceases to be a director, as applicable,
to exercise any Nonqualified Stock Options which are otherwise exercisable
on
his date of termination of service.
Section
11.3 Limited Transferability - Options.
The
Board may, in its discretion, authorize all or a portion of the Nonqualified
Stock Options granted under this Plan to be on terms which permit transfer
by
the Participant to (i) the ex-spouse of the Participant pursuant to the
terms of
a domestic relations order, (ii) the spouse, children or grandchildren
of the
Participant (“Immediate Family Members”), (iii) a trust or trusts for the
exclusive benefit of such Immediate Family Members, or (iv) a partnership
or
limited liability company in which such Immediate Family Members are the
only
partners or members. In addition, there may be no consideration for any
such
transfer. The Award Agreement pursuant to which such Nonqualified Stock
Options
are granted expressly provide for transferability in a manner consistent
with
this paragraph. Subsequent transfers of transferred Nonqualified Stock
Options
shall be prohibited except as set forth below in this Section 11.3. Following
transfer, any such Nonqualified Stock Options shall continue to be subject
to
the same terms and conditions as were applicable immediately prior to transfer,
provided that for purposes of Section 11.2 hereof the term “Participant” shall
be deemed to refer to the transferee. The events of termination of employment
of
Section 11.2 hereof shall continue to be applied with respect to the original
Participant, following which the Nonqualified Stock Options shall be exercisable
by the transferee only to the extent, and for the periods specified in
Section
11.2 hereof. No transfer pursuant to this Section 11.3 shall be effective
to
bind the Company unless the Company shall have been furnished with written
notice of such transfer together with such other documents regarding the
transfer as the Board shall request. With the exception of a transfer in
compliance with the foregoing provisions of this Section 11.3, all other
types
of Awards authorized under this Plan shall be transferable only by will
or the
laws of descent and distribution; however, no such transfer shall be effective
to bind the Company unless the Board has been furnished with written notice
of
such transfer and an authenticated copy of the will and/or such other evidence
as the Board may deem necessary to establish the validity of the transfer
and
the acceptance by the transferee of the terms and conditions of such
Award.
Section
11.4 Withholding Taxes.
Unless
otherwise paid by the Participant, the Company, its Subsidiaries or any
of its
Affiliated Entities shall be entitled to deduct from any payment under
the Plan,
regardless of the form of such payment, the amount of all applicable income
and
employment taxes required by law to be withheld with respect to such payment
or
may require the Participant to pay to it such tax prior to and as a condition
of
the making of such payment. In accordance with any applicable administrative
guidelines it establishes, the Board may allow a Participant to pay the
amount
of taxes required by law to be withheld from an Award by (i) directing
the
Company to withhold from any payment of the Award a number of shares of
Common
Stock having a Fair Market Value on the date of payment equal to the amount
of
the required withholding taxes or (ii) delivering to the Company previously
owned shares of Common Stock having a Fair Market Value on the date of
payment
equal to the amount of the required withholding taxes. However, any payment
made
by the Participant pursuant to either of the foregoing clauses (i) or (ii)
shall
not be permitted if it would result in an adverse accounting charge with
respect
to such shares used to pay such taxes unless otherwise approved by the
Board.
Section
11.5 Change of Control.
Notwithstanding any other provision in this Plan to the contrary, Awards
granted
under the Plan to any Eligible Employee, Consultant or Eligible Director
shall
be immediately vested, fully earned and exercisable upon the occurrence
of a
Change of Control Event unless the terms of the Award state otherwise.
Section
11.6 Amendments to Awards.
Subject
to the limitations of Article IV, such as the prohibition on repricing
of
Options, the Board may at any time unilaterally amend the terms of any
Award
Agreement, whether or not presently exercisable or vested, to the extent
it
deems appropriate. However, amendments which are adverse to the Participant
shall require the Participant’s consent.
Section
11.7 Registration; Regulatory Approval.
Following approval of the Plan by the stockholders of the Company as provided
in
Section 1.2 of the Plan, the Board, in its sole discretion, may determine
to
file with the Securities and Exchange Commission and keep continuously
effective, a Registration Statement on Form S-8 with respect to shares
of Common
Stock subject to Awards hereunder. Notwithstanding anything contained in
this
Plan to the contrary, the Company shall have no obligation to issue shares
of
Common Stock under this Plan prior to the obtaining of any approval from,
or
satisfaction of any waiting period or other condition imposed by, any
governmental agency which the Board shall, in its sole discretion, determine
to
be necessary or advisable.
Section
11.8 Right to Continued Employment.
Participation in the Plan shall not give any Eligible Employee any right
to
remain in the employ of the Company, any Subsidiary, or any Affiliated
Entity.
The Company or, in the case of employment with a Subsidiary or an Affiliated
Entity, the Subsidiary or Affiliated Entity reserves the right to terminate
any
Eligible Employee at any time. Further, the adoption of this Plan shall
not be
deemed to give any Eligible Employee or any other individual any right
to be
selected as a Participant or to be granted an Award.
Section
11.9 Reliance on Reports.
Each
member of the Board and each member of the Board shall be fully justified
in
relying or acting in good faith upon any report made by the independent
public
accountants of the Company and its Subsidiaries and upon any other information
furnished in connection with the Plan by any person or persons other than
himself or herself. In no event shall any person who is or shall have been
a
member of the Board be liable for any determination made or other action
taken
or any omission to act in reliance upon any such report or information
or for
any action taken, including the furnishing of information, or failure to
act, if
in good faith.
Section
11.10 Construction.
Masculine pronouns and other words of masculine gender shall refer to both
men
and women. The titles and headings of the sections in the Plan are for
the
convenience of reference only, and in the event of any conflict, the text
of the
Plan, rather than such titles or headings, shall control.
Section
11.11 Governing Law.
The Plan
shall be governed by and construed in accordance with the laws of the State
of
Delaware except as superseded by applicable Federal law.
Section
11.12 Other Laws.
The
Board may refuse to issue or transfer any shares of Common Stock or other
consideration under an Award if, acting in its sole discretion, it determines
that the issuance or transfer of such shares or such other consideration
might
violate any applicable law or regulation or entitle the Company to recover
the
same under Section 16(b) of the Exchange Act, and any payment tendered
to the
Company by a Participant, other holder or beneficiary in connection with
the
exercise of such Award shall be promptly refunded to the relevant Participant,
holder or beneficiary.
Section
11.13 No Trust or Fund Created.
Neither
the Plan nor an Award shall create or be construed to create a trust or
separate
fund of any kind or a fiduciary relationship between the Company and a
Participant or any other person. To the extent that a Participant acquires
the
right to receive payments from the Company pursuant to an Award, such right
shall be no greater than the right of any general unsecured creditor of
the
Company.
Section
11.14 Conformance to Section 409A of the Code To
the
extent that the Committee determines that any Award granted under the Plan
is
subject to Section 409A of the Code, the Award Agreement evidencing such
Award
shall incorporate the terms and conditions required by Section 409A of
the Code.
To the extent applicable, the Plan and Award Agreements shall be interpreted
in
accordance with Section 409A of the Code and Department of Treasury regulations
and other interpretive guidance issued thereunder, including without limitation
any such regulations or other guidance that may be issued after the Effective
Date. Notwithstanding any provision of the Plan to the contrary, in the
event
that the Committee determines that any Award may be subject to Section
409A of
the Code and related Department of Treasury guidance, the Committee may
adopt
such amendments to the Plan and the applicable Award Agreement or adopt
other
policies and procedures (including amendments, policies and procedures
with
retroactive effect), or take any other actions, that the Committee determines
are necessary or appropriate to (i) exempt the Award from Section 409A
of the
Code or (ii) comply with the requirements of Section 409A of the Code and
related Department of Treasury guidance.
EXHIBIT
A
2007
Long-Term Incentive Compensation Plan
Performance
Criteria
Operational
Criteria may include:
Reserve
additions/replacements
Finding
& development costs
Production
volume
Production
Costs
Financial
Criteria may include:
Earnings(net
income, earnings before interest, taxes, depreciation and amortization
(“EBITDA”)
Earnings
per share:
Cash
flow
Operating
income
General
and Administrative Expenses
Debt
to
equity ratio
Debt
to
cash flow
Debt
to
EBITDA
EBITDA
to
Interest
Return
on
Assets
Return
on
Equity
Return
on
Invested Capital
Profit
returns/margins
Midstream
margins
Stock
Performance Criteria:
Stock
price appreciation
Total
stockholder return
Relative
stock price performance
Preliminary
Copy
HEALTHCARE
ACQUISITION CORP.
THIS
PROXY IS BEING SOLICITED ON BEHALF OF OUR BOARD OF DIRECTORS
The
undersigned hereby appoints John Pappajohn and Matthew Kinley, together as
proxies and each with full power of substitution, to represent and to vote
all
shares of common stock of Healthcare Acquisition Corp. at the special meeting
of
stockholders of HAQ to be held on
[ ],
at 10:00 a.m. Eastern Time, and at any adjournment or postponement thereof,
hereby revoking any and all proxies heretofore given.
|
1.
|
Proposal
1:
to
approve the Merger Proposal- the proposed merger with PharmAthene,
Inc.
(the “Merger”), a Delaware corporation, pursuant to the Agreement and Plan
of Merger, dated as of January 19, 2007, by and among HAQ, Merger
Sub and
PharmAthene, and the transactions contemplated thereby, whereby
PharmAthene will become a wholly-owned subsidiary of HAQ and the
stockholders, optionholders, warrantholders and noteholders of
PharmAthene
shall receive the following consideration:
i. an
aggregate of 12,500,000 shares of HAQ common stock;
ii.
$12,500,000 in 8% convertible notes issued by
HAQ; and
iii. up
to $10,000,000 in milestone payments (if certain conditions are
met).
|
¨ FOR
¨ AGAINST
¨ ABSTAIN
Only
if you vote “AGAINST” Proposal 1 and you hold shares of our common stock
issued in our initial public offering, you may exercise your conversion
rights and demand that we convert your shares of common stock into
cash
equal to a pro rata portion of the funds in the trust account by
marking
the “Exercise Conversion Rights” box below. If you exercise your
conversion rights, then you will be exchanging your shares of our
common
stock for cash and you will no longer own these shares. You will
only be
entitled to receive cash for these shares if the Merger is completed
and
you continue to hold these shares until the date the Merger is
completed.
¨ EXERCISE
CONVERSION RIGHTS
|
|
2.
|
Proposal
2:
to
approve the Amendment Proposal - the amendment to HAQ’s amended and
restated certificate of incorporation (the “Certificate of Incorporation
Amendment”), to: (i) change HAQ’s name from “Healthcare Acquisition
Corp.” to “PharmAthene, Inc.”, (ii) remove certain provisions containing
procedural and approval requirements applicable to HAQ prior to
the
consummation of the business combination that will no longer be
operative
after the consummation of the Merger and (iii) grant to holders of 8%
convertible notes issued in the Merger the right to designate three
members to the Board of Directors of HAQ for so long as at least
30% of
the original face value of such notes remain outstanding.
|
¨
FOR ¨ AGAINST ¨ ABSTAIN
|
3.
|
Proposal
3:
to
approve the Incentive Plan Proposal- the adoption of the 2007 Long-Term
Incentive Plan pursuant to which HAQ will reserve 3,500,000 shares
of
common stock for issuance pursuant to the Plan.
|
¨
FOR ¨ AGAINST ¨ ABSTAIN
This
proxy, when properly executed, will be voted in the manner directed herein
by
the undersigned stockholder. If no direction is made, this proxy will be
voted
“FOR”
Proposals 1, 2 and 3.
Our
Board of Directors believes that the Merger Proposal is fair to, and in the
best
interests of, all of our stockholders, including those who acquired shares
in
our initial public offering. Accordingly, our Board of Directors unanimously
recommends that you vote “FOR” Proposals 1,2, and 3.
In
their
discretion, the proxies are authorized to vote upon such other matters as
may
properly come before the special meeting or any adjournments thereof. If
you
wish to vote in accordance with our Board of Directors’ recommendations, just
sign below. You need not mark any boxes.
Dated
|
|
2007 |
|
|
|
Signature of Stockholder
|
|
|
|
|
|
Signature of Stockholder (if held jointly)
|
|
|
NOTES:
1.
Please
sign your name exactly as your name appears hereon. If the shares are owned
by
more than one person, all owners should sign. Persons signing as executors,
administrators, trustees or in similar capacities should so indicate. If
a
corporation, please sign the full corporate name by the president or other
authorized officer. If a partnership, please sign in the partnership name
by an
authorized person.
2.
To be
valid, the enclosed form of proxy for the special meeting, together with
the
power of attorney or other authority, if any, under which it is signed,
must be received by
[ ],
Eastern Time,
on [ ],
2007 at the offices of our transfer agent, Continental Stock Transfer &
Trust Company, 17 Battery Place, New York, New York 10004.
3.
Returning the enclosed form of proxy will not prevent you from attending
and
voting in person at the special meeting or any adjournment or postponement
thereof.
PLEASE
COMPLETE, SIGN, DATE AND RETURN THIS PROXY CARD
PROMPTLY
TO CONTINENTAL STOCK TRANSFER & TRUST COMPANY